

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM F-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

Zhengye Biotechnology Holding Limited

(Exact name of registrant as specified in its charter)

Cayman Islands	2834	Not Applicable
(State or other jurisdiction of incorporation or organization)	(Primary Standard Industrial Classification Code Number)	(I.R.S. Employer Identification Number)

**No.1 Lianmeng Road, Jilin Economic & Technical Development Zone
Jilin City, Jilin Province, China
+86-0432-63047008**

**Cogency Global Inc.
122 East 42nd Street, 18th Floor
New York, NY 10168
(212) 947-7200**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

With a Copy to:

Ying Li, Esq. Guillaume de Sampigny, Esq. Hunter Taubman Fischer & Li LLC 950 Third Avenue, 19th Floor New York, NY 10022 212-530-2206	Fang Liu, Esq. VCL Law LLP 1945 Old Gallows Road, Suite 260 Vienna, VA 22182 703-919-7285
--	--

Approximate date of commencement of proposed sale to the public: Promptly after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

Emerging growth company

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities Act.

The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act, or until the registration statement shall become effective on such date as the U.S. Securities and Exchange Commission, acting pursuant to such Section 8(a), may determine.

The information in this prospectus is not complete and may be changed. We may not sell the securities until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting any offer to buy these securities in any jurisdiction where such offer or sale is not permitted.

SUBJECT TO COMPLETION

PRELIMINARY PROSPECTUS DATED JANUARY 9, 2024

[*] Ordinary Shares



科技让动物更美好
Empower Animals with Technology

Zhengye Biotechnology Holding Limited

This is an initial public offering on a firm commitment basis of our ordinary shares, par value \$0.0001 per share ("Ordinary Shares"). Prior to this offering, there has been no public market for our Ordinary Shares. We expect the initial public offering price to be in the range of \$[] to \$[] per Ordinary Share. The offering is being made on a "firm commitment" basis by the underwriters. See "Underwriting." We submitted our application to list our Ordinary Shares on the Nasdaq Global Market ("Nasdaq"). At this time, Nasdaq has not yet approved our application to list our Ordinary Shares. The closing of this offering is conditioned upon Nasdaq's final approval of our listing application, and there is no guarantee or assurance that our Ordinary Shares will be approved for listing on Nasdaq.

Investing in our Ordinary Shares involves a high degree of risk, including the risk of losing your entire investment. See "Risk Factors" beginning on page 16 to read about factors you should consider before buying our Ordinary Shares.

Unless otherwise stated, as used in this prospectus and in the context of describing our operations and consolidated financial information, "we," "us," "our," the "Company," "our Company," or "Zhengye Cayman" refers to Zhengye Biotechnology Holding Limited, an exempted company limited by shares incorporated in Cayman Islands, when describing Zhengye Cayman's consolidated financial information for the six months ended June 30, 2023 and the fiscal years ended December 31, 2022 and 2021, also includes Zhengye Cayman's subsidiaries, including subsidiaries in China; "VVAX Skyline" refers to VVAX Skyline Holdings Limited, a British Virgin Islands corporation, which is wholly owned by Zhengye Cayman; "Peg Biotechnology" refers to Peg Biotechnology (HK) Holding Limited, a Hong Kong corporation, which is wholly owned by VVAX Skyline; "Windsor Holdings" refers to Windsor Holdings Co., Ltd., a British Virgin Islands corporation, which is wholly owned by VVAX Skyline; and "Jilin Zhengye" or the "operating entity" refers to Jilin Zhengye Biological Products Co., Ltd., a limited liability company organized under the laws of the PRC, which is held 58.6890% by Hainan Senhan Biotechnology Co., Ltd. ("Hainan Senhan"), 25.1524% by Windsor Holdings, 15.2439% by Jilin Economic and Technological Development Zone Economic and Technological Development General Corporation, 0.9146% by Jilin Jinqiao Investment Co., Ltd., and 0.0001% by Yufeng Liu.

Zhengye Cayman is a holding company incorporated in the Cayman Islands and not a Chinese or Hong Kong operating company. As a holding company with no material operations of its own, Zhengye Cayman conducts its operations through its principal subsidiary incorporated in China. See "Risk Factors — Risks Relating to Doing Business in China — Chinese regulatory authorities could disallow our holding company structure, which may result in a material change in the operating entity's operations and/or a material change in the value of the securities we are registering for sale, including that it could cause the value of such securities to significantly decline or become worthless." The Ordinary Shares offered in this prospectus are shares of the Cayman Islands holding company instead of shares of the operating entity in China. Holders of our Ordinary Shares do not directly own any equity interests in our subsidiaries, including the equity interests in our principal subsidiary based in China, but will instead own shares of a Cayman Islands holding company.

We are subject to certain legal and operational risks associated with being based in and having the majority of the Company's operations in China. These risks may result in material changes in our operations, or a complete hindrance of our ability to offer or continue to offer our securities to investors, and could cause the value of such securities to significantly decline or become worthless. Recently, the PRC government adopted a series of regulatory actions and issued statements to regulate business operations in China with little advance notice, including cracking down on illegal activities in the securities market, adopting new measures to extend the scope of cybersecurity reviews, and expanding the efforts in anti-monopoly enforcement. As of the date of this prospectus, neither we nor the operating entity have been involved in any investigations on cybersecurity review initiated by any PRC regulatory authority, nor has any of them received any inquiry, notice, or sanction. The Cybersecurity Review Measures became effective on February 15, 2022. As confirmed by our PRC counsel, Guantao Law Firm Hangzhou Office ("Guantao"), we do not expect to become subject to cybersecurity review by the CAC for this offering, given that: (i) the data the operating entity handles in its business operations, either by its nature or in scale, do not trigger significant concerns over PRC national security; and (ii) neither we nor the operating entity have processed, or anticipate to process in the foreseeable future, personal information of more than one million users or persons. Based on the above and the information currently available, we believe the impact of the CAC's increasing oversight over data security on the operating entity's business is immaterial as of the date of this prospectus. However, there remains uncertainty as to how the Cybersecurity Review Measures will be interpreted or implemented and whether the PRC regulatory authorities may adopt new laws, regulations, rules, or detailed implementation and interpretation in relation

[Table of Contents](#)

to, or in addition to the Cybersecurity Review Measures. While we intend to closely monitor the evolving laws and regulations in this area and take all reasonable measures to mitigate compliance risks, we cannot guarantee that the operating entity's business and operations will not be adversely affected by the potential impact of the Cybersecurity Review Measures or other laws and regulations related to privacy, data protection, and information security. If the operating entity is subject to cybersecurity review and network data security review in the future, the operating entity must apply for a review conducted by the Cybersecurity Review Office of the PRC, which ranges from 30 to 90 working days. During such review, the operating entity may be required to suspend its operations or experience other disruptions to its operations. Cybersecurity review and network data security review could materially and adversely affect our business, financial conditions, and results of operations, which could cause the value of our securities to significantly decline or in extreme cases, become worthless. If the Office of Cybersecurity Review determines that our or the operating entity's business or operations involve national security during its review, we and the operating entity may probably be banned from accepting foreign investments or listing on a Unites States or other foreign exchange. Furthermore, according to the Anti-Monopoly Law of the People's Republic of China (the "Anti-Monopoly Law"), which took effect on August 1, 2008, where the concentration of business operators reaches the filing threshold stipulated by the State Council of the People's Republic of China (the "State Council"), business operators shall file a declaration with the State Administration for Market Regulation (the "SAMR"), and no concentration shall be implemented until the SAMR clears the anti-monopoly filing. We currently are not subject to the Anti-Monopoly Law because we don't reach the filing threshold stipulated by the State Council. If we will be found to be subject to the Anti-Monopoly Law, we will be required to file a declaration with the SAMR, and no concentration shall be implemented until the SAMR clears the anti-monopoly filing, which ranges from 30 to 150 days. During such reviews, we may be required to suspend the operations or experience other disruptions to the operation, which will also result in negative publicity with respect to our Company and diversion of our managerial and financial resources, which could materially and adversely affect our business, financial conditions, and results of operations. If the SAMR determines that our or the operating entity's business or operations involve national security, we and the operating entity may probably be banned from accepting foreign investments or listing on a Unites States or other foreign exchange. We believe that, based on the advice of Guantao, as of the date of this prospectus, neither we nor the operating entity are subject to the Cybersecurity Review Measures or the Anti-Monopoly Law, because we and the operating entity fall below the review threshold stipulated by the CAC and the filing threshold stipulated by the State Council, and therefore, these laws do not have adverse impact on our ability to accept foreign investments or list on a Unites States or other foreign exchange. However, there are substantial uncertainties regarding the interpretation and application of PRC laws and regulations and future PRC laws and regulations, and there can be no assurance that the relevant government agencies will take a view that is contrary to, or otherwise different from, the conclusions stated above. If the relevant government agencies take a view that is contrary to, or otherwise different from, the foregoing conclusions, it could have a material adverse effect on the PRC subsidiaries' business, operating results and reputation, as well as the trading price of our Ordinary Shares and the Company's ability to accept foreign investments or list on a U.S. or other foreign exchange. See "Risk Factors — Risks Relating to Doing Business in China — Recent greater oversight by the CAC over data security, particularly for companies seeking to list on a foreign exchange, could adversely impact our business and our offering" and "Risk Factors — Risks Relating to Doing Business in China — Uncertainties in the interpretation and enforcement of PRC laws and regulations and changes in policies, rules, and regulations in China, which may be quick with little advance notice, could limit the legal protection available to you and us."

On February 17, 2023, the China Securities Regulatory Commission ("CSRC") promulgated the Trial Administrative Measures of the Overseas Securities Offering and Listing by Domestic Companies (the "Overseas Listing Trial Measures") and relevant five guidelines, which became effective on March 31, 2023. According to the Overseas Listing Trial Measures, PRC domestic companies that seek to offer and list securities in overseas markets, either in direct or indirect means, are required to fulfill the filing procedures with the CSRC and report relevant information. Based on the foregoing, our PRC counsel is of the view that we are required to complete the filing procedures with the CSRC in connection with the offering and listing. Any failure by us to comply with such filing requirements may result in orders to rectify, warnings and fines against us and could materially hinder our ability to offer or continue to offer our securities. We have filed with the CSRC the filing documents and shall complete the filing before the completion of our overseas offering and listing. Given the current PRC regulatory environment, it is uncertain whether we will be required to obtain approvals from the PRC government to offer securities to foreign investors in the future, and whether we would be able to obtain such approvals. If we are unable to obtain such approvals if required in the future, or inadvertently conclude that such approvals are not required then the value of our ordinary shares may depreciate significantly or become worthless.

On February 24, 2023, the CSRC promulgated the Provisions on Strengthening Confidentiality and Archives Administration of Overseas Securities Offering and Listing by Domestic Companies (the "Confidentiality and Archives Administration Provisions"), which also became effective on March 31, 2023. According to the Confidentiality and Archives Administration Provisions, domestic companies that seek overseas offering and listing (either in direct or indirect means) and the securities companies and securities service (either incorporated domestically or overseas) providers that undertake relevant businesses shall institute a sound confidentiality and archives administration system, and take necessary measures to fulfill confidentiality and archives administration obligations. They shall not leak any state secret and working secret of government agencies, or harm national security and public interest. Therefore, a domestic company that plans to, either directly or through its overseas listed entity, publicly disclose or provide to relevant individuals or entities including securities companies, securities service providers and overseas regulators, any documents and materials that

[Table of Contents](#)

contain state secrets or working secrets of government agencies, shall first obtain approval from competent authorities according to law, and file with the secrecy administrative department at the same level. The above-mentioned documents and materials that, if leaked, will be detrimental to national security or public interest, therefore, the domestic company shall strictly fulfill relevant procedures stipulated by applicable regulations. Furthermore, a domestic company that provides accounting archives or copies of accounting archives to any entities including securities companies, securities service providers and overseas regulators and individuals shall fulfill due procedures in compliance with applicable regulations. Working papers produced in Chinese mainland by securities companies and securities service providers in the process of undertaking businesses related to overseas offering and listing by domestic companies shall be retained in Chinese mainland. Where such documents need to be transferred or transmitted to outside Chinese mainland, relevant approval procedures stipulated by regulations shall be followed. We believe that this offering does not involve leaking any state secret and working secret of government agencies, or harming national security and public interest. However, we may be required to perform additional procedures in connection with the provision of accounting archives in accordance with the Confidentiality and Archives Administration Provisions. The specific requirements of the relevant procedures are currently unclear and we cannot be certain whether we will be able to perform the relevant procedures.

As of the date of this prospectus, except for the Supplementary Material Request issued by the CSRC regarding our planned overseas listing on September 26, 2023, to which we responded by submitting supplementary materials on October 16, 2023, we and the operating entity have not received any inquiry, notice, warning, or sanctions regarding our planned overseas listing from the CSRC or any other PRC governmental authorities. Since these statements and regulatory actions are newly published, however, official guidance and related implementation rules have not been issued. It is highly uncertain what the potential impact such modified or new laws and regulations will have on the daily business operations of our subsidiaries and the operating entity, our ability to accept foreign investments, and our listing on an U.S. exchange. The Standing Committee of the National People's Congress (the "SCNPC") or PRC regulatory authorities may in the future promulgate laws, regulations, or implementing rules that require us, or our subsidiaries, or the operating entity to obtain regulatory approval from Chinese authorities before listing in the U.S. If we do not receive or maintain the approval, or inadvertently conclude that such approval is not required, or applicable laws, regulations, or interpretations change such that we are required to obtain approval in the future, we may be subject to an investigation by competent regulators, fines or penalties, or an order prohibiting us from conducting an offering, and these risks could result in a material adverse change in our operations and the value of our Ordinary Shares, significantly limit or completely hinder our ability to offer or continue to offer securities to investors, or cause such securities to significantly decline in value or become worthless.

The same legal and operational risks associated with operations in mainland China also apply to operations in Hong Kong. Hong Kong was established as a special administrative region of the PRC in accordance with Article 31 of the Constitution of the PRC. The Basic Law of the Hong Kong Special Administrative Region of the PRC (the "Basic Law") was adopted and promulgated on April 4, 1990 and became effective on July 1, 1997, when the PRC resumed the exercise of sovereignty over Hong Kong. Pursuant to the Basic Law, Hong Kong is authorized by the National People's Congress of the PRC to exercise a high degree of autonomy and enjoy executive, legislative, and independent judicial power, under the principle of "one country, two systems," and the PRC laws and regulations shall not be applied in Hong Kong except for those listed in Annex III of the Basic Law (which is confined to laws relating to national defense, foreign affairs, and other matters that are not within the scope of autonomy). However, there is no assurance that there will not be any changes in the economic, political, and legal environment in Hong Kong in the future. Due to the uncertainty of the PRC legal system and changes in laws, regulations, or policies, the Basic Law may be revised in the future and thus we may face the same legal and operational risks associated with operating in the PRC. If there is a significant change to current political arrangements between mainland China and Hong Kong, or if the applicable laws, regulations, or interpretations change, our Hong Kong subsidiary, Peg Biotechnology, may become subject to PRC laws or authorities. As a result, our Hong Kong subsidiary could incur material costs to ensure compliance, be subject to fines, experience devaluation of securities or delisting, no longer conduct offerings to foreign investors, and no longer be permitted to continue their current business operations.

In addition, our Ordinary Shares may be prohibited from trading on a national exchange under the Holding Foreign Companies Accountable Act, or the "HFCA Act," if the Public Company Accounting Oversight Board (United States) (the "PCAOB") is unable to inspect our auditors for three consecutive years beginning in 2022. On December 16, 2021, the PCAOB issued a report on its determinations that it is unable to inspect or investigate completely PCAOB-registered public accounting firms headquartered in mainland China or in Hong Kong, a Special Administration Region of the PRC, because of positions taken by PRC authorities in those jurisdictions. Our auditor, WWC, P.C. ("WWC"), is headquartered in San Mateo, California, and has been inspected by the PCAOB on a regular basis, with the last inspection in 2021. The PCAOB currently has access to inspect the working papers of our auditor and our auditor is not subject to the determinations announced by the PCAOB on December 16, 2021, which determinations were vacated on December 15, 2022. If trading in our Ordinary Shares is prohibited under the HFCA Act in the future because the PCAOB determines that it cannot inspect or fully investigate our auditor at such future time, Nasdaq may determine to delist our Ordinary Shares and trading in our Ordinary Shares could be prohibited. On June 22, 2021, the U.S. Senate passed the Accelerating Holding Foreign Companies Accountable Act ("AHFCAA"), and on December 29, 2022, legislation entitled "Consolidated Appropriations Act, 2023" (the "Consolidated Appropriations Act") was

[Table of Contents](#)

signed into law by President Biden, which contained, among other things, an identical provision to the Accelerating Holding Foreign Companies Accountable Act and amended the HFCA Act by requiring the SEC to prohibit an issuer's securities from trading on any U.S. stock exchanges if its auditor is not subject to PCAOB inspections for two consecutive years instead of three, thus reducing the time period for triggering the prohibition on trading. On August 26, 2022, the CSRC, the Ministry of Finance of the PRC (the "MOF"), and the PCAOB signed a Statement of Protocol (the "Protocol") governing inspections and investigations of accounting firms based in mainland China and Hong Kong, taking the first step toward opening access for the PCAOB to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong. Pursuant to the fact sheet with respect to the Protocol disclosed by the U.S. Securities and Exchange Commission (the "SEC"), the PCAOB shall have independent discretion to select any issuer audits for inspection or investigation and has the unfettered ability to transfer information to the SEC. On December 15, 2022, the PCAOB Board determined that the PCAOB was able to secure complete access to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong and voted to vacate its previous determinations to the contrary. However, should PRC authorities obstruct or otherwise fail to facilitate the PCAOB's access in the future, the PCAOB Board will consider the need to issue a new determination. See "Risk Factors — Risks Relating to Doing Business in the PRC — Recent joint statement by the SEC and the PCAOB, rule changed by Nasdaq, and the HFCA Act all call for additional and more stringent criteria to be applied to emerging market companies upon assessing the qualification of their auditors, especially the non-U.S. auditors who are not inspected by the PCAOB. These developments could add uncertainties to our offerings."

As of the date of this prospectus, except for a loan from the operating entity to Hainan Senhan on October 10, 2023, with a principal amount of RMB100,000, no cash transfer or transfer of other assets has occurred among the Company and any of its subsidiaries. See "Prospectus Summary — Asset Transfers Between the Company and its Subsidiaries," "Prospectus Summary — Dividends or Distributions Made to the Company and U.S. Investors and Tax Consequences," and our audited consolidated financial statements for the years ended December 31, 2022 and 2021.

During the six months ended June 30, 2023 and the fiscal years ended December 31, 2022 and 2021, dividends and distributions made by the operating entity to its original shareholders amounted to RMB18,000,000, RMB21,424,500, and RMB11,047,500, respectively. On April 28, 2023, the shareholders of the operating entity passed the resolution of the dividend plan for 2022, with the dividend amount of RMB55,104,000, and the dividend will be distributed before May 2024. Except as disclosed, we intend to keep any future earnings to finance the expansion of our business, and we do not anticipate that any cash dividends will be paid in the foreseeable future. See "Prospectus Summary — Dividends or Distributions Made to the Company and U.S. Investors and Tax Consequences."

We are an "emerging growth company" as defined under the federal securities laws and will be subject to reduced public company reporting requirements. Please read the disclosures beginning on page 13 of this prospectus for more information.

Following the completion of this offering, our director, chairman of the board of directors and largest shareholder, Mr. Zhenfa Han, will beneficially own approximately [%] of the aggregate voting power of our issued and outstanding Ordinary Shares. As such, we may be deemed a "controlled company" under Nasdaq Marketplace Rules 5615(c). However, even if we are deemed a "controlled company," we do not intend to avail ourselves of the corporate governance exemptions afforded to a "controlled company" under the Nasdaq Listing Rules. See "Risk Factors" and "Management — Controlled Company."

	Per Share	Total
Initial public offering price	\$	\$
Underwriters' discounts⁽¹⁾	\$	\$
Proceeds to our company before expenses⁽²⁾	\$	\$

(1) We have agreed to pay US Tiger Securities, Inc., the representative of the underwriters (the "Representative"), a fee equal to 7% of the gross proceeds of the offering. See "Underwriting" starting on page 154 of this prospectus for more information regarding our arrangements with the underwriters.

The underwriters expect to deliver the Ordinary Shares against payment on or about [%], 2024.

Neither the U.S. Securities and Exchange Commission nor any state securities commission nor any other regulatory body has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

US Tiger Securities, Inc.

Prospectus dated [%], 2024

TABLE OF CONTENTS

	Page
PROSPECTUS SUMMARY	1
RISK FACTORS	16
DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS	48
ENFORCEABILITY OF CIVIL LIABILITIES	49
USE OF PROCEEDS	50
DIVIDEND POLICY	52
CAPITALIZATION	53
DILUTION	54
CORPORATE HISTORY AND STRUCTURE	55
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	57
INDUSTRY	74
BUSINESS	87
REGULATIONS	116
MANAGEMENT	127
PRINCIPAL SHAREHOLDERS	132
RELATED PARTY TRANSACTIONS	134
DESCRIPTION OF SHARE CAPITAL	135
SHARES ELIGIBLE FOR FUTURE SALE	146
MATERIAL INCOME TAX CONSIDERATION	147
UNDERWRITING	154
EXPENSES RELATING TO THIS OFFERING	158
LEGAL MATTERS	159
EXPERTS	159
WHERE YOU CAN FIND ADDITIONAL INFORMATION	159
INDEX TO FINANCIAL STATEMENTS	F-1

ABOUT THIS PROSPECTUS

We and the underwriters have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by us or on our behalf or to which we have referred you. We take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the Ordinary Shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted or where the person making the offer or sale is not qualified to do so or to any person to whom it is not permitted to make such offer or sale. For the avoidance of doubt, no offer or invitation to subscribe for Ordinary Shares is made to the public in the Cayman Islands. The information contained in this prospectus is current only as of the date on the front cover of the prospectus. Our business, financial condition, results of operations, and prospects may have changed since that date.

Neither we nor the underwriters have taken any action to permit a public offering of the Ordinary Shares outside the United States or to permit the possession or distribution of this prospectus or any filed free-writing prospectus outside the United States. Persons outside the United States who come into possession of this prospectus or any filed free writing prospectus must inform themselves about, and observe any restrictions relating to, the offering of the Ordinary Shares and the distribution of this prospectus or any filed free-writing prospectus outside the United States.

Conventions that Apply to this Prospectus

Unless otherwise indicated or the context requires otherwise, references in this prospectus to:

- “BVI” are to the British Virgin Islands;
- “China” or the “PRC” are to the People’s Republic of China, excluding Taiwan for the purposes of this prospectus only;
- “GMP” are to Good Manufacturing Practice;
- “GSP” are to Good Supplying Practice;
- “HKD” or “HK\$” are to the legal currency of Hong Kong;
- “Hong Kong” are to the Hong Kong Special Administrative Region of the People’s Republic of China;
- “ODI filings” are to the formalities and filings of overseas direct investment of Chinese enterprises, including but not limited to fulfilling the filing, approval or registration procedures in the development and reform authorities, the competent commercial authorities, and foreign exchange administration authorities and competent banks authorized by such authorities;
- “Renminbi” or “RMB” are to the legal currency of China;
- “shares,” “Shares,” or “Ordinary Shares” are to the ordinary shares of Zhengye Cayman, par value \$0.0001 per share; and
- “\$,” “USD,” “US\$,” or “U.S. dollars” are to the legal currency of the United States.

Our business is conducted by the operating entity in China using RMB. Our consolidated financial statements are presented in U.S. dollars. In this prospectus, we refer to assets, obligations, commitments, and liabilities in our consolidated financial statements in U.S. dollars. These dollar references are based on the exchange rate of RMB to U.S. dollars, determined as of a specific date or for a specific period. Changes in the exchange rate will affect the amount of our obligations and the value of our assets in terms of U.S. dollars which may result in an increase or decrease in the amount of our obligations (expressed in dollars) and the value of our assets, including accounts receivable (expressed in dollars). With respect to amounts not recorded in our consolidated financial statements included elsewhere in this prospectus, the conversion of RMB into U.S. dollars is based on 0.1450 for the fiscal years ended December 31, 2022 and 2021, and the conversion of RMB into U.S. dollars is based on 0.1379 for the six months ended June 30, 2023 and 2022.


PROSPECTUS SUMMARY

The following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information and financial statements appearing elsewhere in this prospectus. In addition to this summary, we urge you to read the entire prospectus carefully, especially the risks of investing in our Ordinary Shares discussed under “Risk Factors,” “Business,” and information contained in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” before deciding whether to invest in our Ordinary Shares. This prospectus contains information from an industry report in March 2023, commissioned by us and prepared by Frost & Sullivan, a third-party independent research firm. We refer to this report as the Frost and Sullivan Report.

Our Corporate Structure

We are a holding company incorporated in the Cayman Islands. Our Ordinary Shares offered in this prospectus are shares of our Cayman Islands holding company. As a holding company with no material operations of our own, we conduct our operations through the operating entity established in the PRC. See “Risk Factors — Risks Relating to Doing Business in China — Chinese regulatory authorities could disallow our holding company structure, which may result in a material change in the operating entity’s operations and/or a material change in the value of the securities we are registering for sale, including that it could cause the value of such securities to significantly decline or become worthless.” The Ordinary Shares offered in this prospectus are shares of the Cayman Islands holding company instead of shares of the operating entity in China. Holders of our Ordinary Shares do not directly own any equity interests in the operating entity, but will instead own shares of a Cayman Islands holding company.

The following diagram illustrates our corporate structure as of the date of this prospectus and upon the completion of this offering, assuming the sales of all of the Ordinary Shares we are offering at an assumed public offering price of \$[] per share. For more details on our corporate history, please refer to “Corporate History and Structure.”



Notes:

- (i) All percentages reflect the equity interests.
- (1) Represents 10,000,000 Ordinary Shares held by Securingium Holding Limited, a BVI company, which is (i) 0.01% owned by Jiahe Developments Limited, which itself is 100% owned by Zhenfa Han, and (ii) 99.99% owned by TSset Holding Limited, which itself is 100% owned by Trident Trust Company (HK) Limited, which acts as the trustee of Generations United Trust, as of the date of this prospectus. The settlor, beneficiary, and protector of Generations United Trust is Zhenfa Han.
- (2) Represents 570,830 Ordinary Shares held by VVAX Holdings Limited, a BVI company, which is 100% owned by Jilin Zhengye Group Co., Ltd., which is 99% owned by Zhenfa Han and 1% owned by Lihua Sun, as of the date of this prospectus.
- (3) Represents 569,688 Ordinary Shares held by Vanguard Skyline Holdings Limited, a BVI company, which is 100% owned by Changchun Feier Investment Center (Limited Partnership), which is 64.81% owned by Zhenfa Han. Changchun Feier Investment Center (Limited Partnership) is ultimately controlled by its managing partner, Zhenfa Han, as of the date of this prospectus.

Table of Contents

- (4) Represents 259,465 Ordinary Shares held by TLjinmao Limited, a BVI company, which is 100% owned by Nanjing Tailong Jinmao Pharmaceutical Industry Investment Enterprise (Limited Partnership), which is a private equity fund established and managed by Tibet Golden Investment Management Co., Ltd., as of the date of this prospectus. Tibet Golden Investment Management Co., Ltd. is a Chinese private equity fund management company focusing on investment management and financial information consulting.
- (5) Represents 16,611 Ordinary Shares held by XZjinyuan Limited, a BVI company, which is 100% owned by Tibet Golden Investment Management Co., Ltd., which is a Chinese private equity fund management company focusing on investment management and financial information consulting, as of the date of this prospectus.
- (6) Jilin Zhengye is held 58.6890% by Hainan Senhan, 25.1524% by Windsor Holdings, 15.2439% by Jilin Economic and Technological Development Zone Economic and Technological Development General Corporation, 0.9146% by Jilin Jinqiao Investment Co., Ltd., and 0.0001% by Yufeng Liu, as of the date of this prospectus.

We are subject to certain legal and operational risks associated with the business operations in mainland China and Hong Kong. PRC laws and regulations governing the current business operations of the operating entity are sometimes vague and uncertain, and as a result, these risks may result in material changes in the operations of the operating entity, significant depreciation of the value of our Ordinary Shares, or a complete hindrance of our ability to offer, or continue to offer, our securities to investors. Recently, the PRC government adopted a series of regulatory actions and issued statements to regulate business operations in China with little advance notice, including cracking down on illegal activities in the securities market, adopting new measures to extend the scope of cybersecurity reviews, and expanding the efforts in anti-monopoly enforcement. The Cybersecurity Review Measures, which became effective on February 15, 2022, provide that, in addition to CIOs that intend to purchase Internet products and services, data processing operators engaging in data processing activities that affect or may affect national security must be subject to cybersecurity review by the Cybersecurity Review Office of the PRC. According to the Cybersecurity Review Measures, a cybersecurity review assesses potential national security risks that may be brought about by any procurement, data processing, or overseas listing. The Cybersecurity Review Measures further require that online platform operators that possess personal data of at least one million users must apply for a review by the Cybersecurity Review Office of the PRC before conducting listings in foreign countries. As of the date of this prospectus, neither we nor the operating entity have been involved in any investigations on cybersecurity review initiated by any PRC regulatory authority, nor has any of them received any inquiry, notice, or sanction. We do not expect to become subject to cybersecurity review by the CAC for this offering, given that: (i) the data the operating entity handles in its business operations, either by its nature or in scale, do not trigger significant concerns over PRC national security; and (ii) neither we nor the operating entity have processed, or anticipate to process in the foreseeable future, personal information of more than one million users or persons. Based on the above and the information currently available, we believe the impact of the CAC's increasing oversight over data security on the operating entity's business is immaterial as of the date of this prospectus. However, there remains uncertainty as to how the Cybersecurity Review Measures will be interpreted or implemented and whether the PRC regulatory authorities may adopt new laws, regulations, rules, or detailed implementation and interpretation in relation to, or in addition to the Cybersecurity Review Measures. While we intend to closely monitor the evolving laws and regulations in this area and take all reasonable measures to mitigate compliance risks, we cannot guarantee that the operating entity's business and operations will not be adversely affected by the potential impact of the Cybersecurity Review Measures or other laws and regulations related to privacy, data protection, and information security. If the operating entity is subject to cybersecurity review and network data security review in the future, the operating entity must apply for a review conducted by the Cybersecurity Review Office of the PRC, which ranges from 30 to 90 working days. During such review, the operating entity may be required to suspend its operations or experience other disruptions to its operations. Cybersecurity review and network data security review could materially and adversely affect our business, financial conditions, and results of operations, which could cause the value of our securities to significantly decline or in extreme cases, become worthless. If the Office of Cybersecurity Review determines that our or the operating entity's business or operations involve national security during its review, we and the operating entity may probably be banned from accepting foreign investments or listing on a Unites States or other foreign exchange. Furthermore, according to the Anti-Monopoly Law of the People's Republic of China (the "Anti-Monopoly Law"), which took effect on August 1, 2008, where the concentration of business operators reaches the filing threshold stipulated by the State Council of the People's Republic of China (the "State Council"), business operators shall file a declaration with the State Administration for Market Regulation (the "SAMR"), and no concentration shall be implemented until the SAMR clears the anti-monopoly filing. We currently are not subject to the Anti-Monopoly Law because we don't reach the filing threshold stipulated by the State Council. If we will be found to be subject to the Anti-Monopoly Law, we will be required to file a declaration with the SAMR, and no concentration shall be implemented until the SAMR clears the anti-monopoly filing, which ranges from 30 to 150 days. During such reviews, we may be required to suspend the operations or experience other disruptions to the operation, which could materially and adversely affect our business,

financial conditions, and results of operations, which could cause the value of our securities to significantly decline or in extreme cases, become worthless. If the SAMR determines that our and the operating entity's business or operations involve national security, we and the operating entity may probably be banned from accepting foreign investments or listing on a Unites States or other foreign exchange. We believe that, based on the advice of Guantao, as of the date of this prospectus, neither we nor the operating entity are subject to the Cybersecurity Review Measures or the Anti-Monopoly Law, because we and the operating entity fall below the review threshold stipulated by the CAC and the filing threshold stipulated by the State Council, and therefore, these laws do not have adverse impact on our ability to accept foreign investments or list on a Unites States or other foreign exchange. However, there are substantial uncertainties regarding the interpretation and application of PRC laws and regulations and future PRC laws and regulations, and there can be no assurance that the relevant government agencies will take a view that is contrary to, or otherwise different from, the conclusions stated above. If the relevant government agencies take a view that is contrary to, or otherwise different from, the foregoing conclusions, it could have a material adverse effect on the PRC subsidiaries' business, operating results and reputation, as well as the trading price of our Ordinary Shares and the Company's ability to accept foreign investments or list on a U.S. or other foreign exchange. See "Risk Factors — Risks Relating to Doing Business in China — Recent greater oversight by the CAC over data security, particularly for companies seeking to list on a foreign exchange, could adversely impact our business and our offering" and "Risk Factors — Risks Relating to Doing Business in China — Uncertainties in the interpretation and enforcement of PRC laws and regulations and changes in policies, rules, and regulations in China, which may be quick with little advance notice, could limit the legal protection available to you and us."

On February 17, 2023, the CSRC promulgated the Overseas Listing Trial Measures and five supporting guidelines, which came into effect on March 31, 2023. We are required to complete the filing procedures with the CSRC in connection with the offering and listing pursuant to the Overseas Listing Trial Measures. See "Risk Factors — Risks Relating to Doing Business in the PRC — The Opinions, the Trial Measures, and the revised Provisions recently issued by PRC authorities may subject us to additional compliance requirements in the future." Other than the foregoing, according to our PRC counsel, no relevant laws or regulations in the PRC explicitly require us to seek approval from the CSRC for our overseas listing. As of the date of this prospectus, neither we nor our subsidiaries have received any inquiry, notice, warning, or sanctions regarding our overseas listing from the CSRC or any other PRC governmental authorities. Since these statements and regulatory actions are newly published, however, related implementation rules have not been issued. It is highly uncertain what the potential impact such modified or new laws and regulations will have on the daily business operations of our subsidiaries, our ability to accept foreign investments, and our listing on a U.S. exchange. The SCNPC or PRC regulatory authorities may in the future promulgate laws, regulations, or implementing rules that require us and our subsidiaries to obtain regulatory approval from Chinese authorities for listing in the U.S. If we do not receive or maintain the approval, or inadvertently conclude that such approval is not required, or applicable laws, regulations, or interpretations change such that we are required to obtain approval in the future, we may be subject to an investigation by competent regulators, fines or penalties, or an order prohibiting us from conducting an offering, and these risks could result in a material adverse change in our operations and the value of our Ordinary Shares, significantly limit or completely hinder our ability to offer or continue to offer securities to investors, or cause such securities to significantly decline in value or become worthless.

The same legal and operational risks associated with operations in China also apply to operations in Hong Kong. Hong Kong was established as a special administrative region of the PRC in accordance with Article 31 of the Constitution of the PRC. The Basic Law was adopted and promulgated on April 4, 1990 and became effective on July 1, 1997, when the PRC resumed the exercise of sovereignty over Hong Kong. Pursuant to the Basic Law, Hong Kong is authorized by the National People's Congress of the PRC to exercise a high degree of autonomy and enjoy executive, legislative, and independent judicial power, under the principle of "one country, two systems," and the PRC laws and regulations shall not be applied in Hong Kong except for those listed in Annex III of the Basic Law (which is confined to laws relating to national defense, foreign affairs, and other matters that are not within the scope of autonomy). However, there is no assurance that there will not be any changes in the economic, political, and legal environment in Hong Kong in the future. Due to the uncertainty of the PRC legal system and changes in laws, regulations, or policies, the Basic Law may be revised in the future and thus we may face the same legal and operational risks associated with operating in the PRC. If there is a significant change to current political arrangements between mainland China and Hong Kong, or if the applicable laws, regulations, or interpretations change, our Hong Kong subsidiary may become subject to PRC laws or authorities. As a result, our Hong Kong subsidiary could incur material costs to ensure compliance, be subject to fines, experience devaluation of securities or delisting, no longer conduct offerings to foreign investors, and no longer be permitted to continue their current business operations.

In addition, our Ordinary Shares may be prohibited from trading on a national exchange under the HFCA Act, if the PCAOB is unable to inspect our auditors for two consecutive years beginning in 2022. On December 16, 2021, the PCAOB issued a report on its determinations that it is unable to inspect or investigate completely PCAOB-registered public accounting firms headquartered in mainland China or in Hong Kong, a Special Administration Region of the PRC, because of positions taken by PRC authorities in those jurisdictions. Our auditor, WWC, is headquartered in San Mateo, California, and has been inspected by the PCAOB on a regular basis, with the last inspection in 2021. The PCAOB currently has access to inspect the working papers of our auditor and our auditor is not subject to the determinations announced by the PCAOB on December 16, 2021, which determinations were vacated on December 15, 2022. If trading in our Ordinary Shares is prohibited under the HFCA Act in the future because the PCAOB determines that it cannot inspect or fully investigate our auditor at such future time, Nasdaq may determine to delist our Ordinary Shares and trading in our Ordinary Shares could be prohibited. On June 22, 2021, the U.S. Senate passed the AHFCAA, and on December 29, 2022, legislation entitled the Consolidated Appropriations Act was signed into law by President Biden, which contained, among other things, an identical provision to the Accelerating Holding Foreign Companies Accountable Act and amended the HFCA Act by requiring the SEC to prohibit an issuer's securities from trading on any U.S. stock exchanges if its auditor is not subject to PCAOB inspections for two consecutive years instead of three, thus reducing the time period for triggering the prohibition on trading. On August 26, 2022, the CSRC, the MOF, and the PCAOB signed the Protocol governing inspections and investigations of accounting firms based in mainland China and Hong Kong, taking the first step toward opening access for the PCAOB to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong. Pursuant to the fact sheet with respect to the Protocol disclosed by the SEC, the PCAOB shall have independent discretion to select any issuer audits for inspection or investigation and has the unfettered ability to transfer information to the SEC. On December 15, 2022, the PCAOB Board determined that the PCAOB was able to secure complete access to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong and voted to vacate its previous determinations to the contrary. However, should PRC authorities obstruct or otherwise fail to facilitate the PCAOB's access in the future, the PCAOB Board will consider the need to issue a new determination. See "Risk Factors — Risks Relating to Doing Business in the PRC — Recent joint statement by the SEC and the PCAOB, rule changes by Nasdaq, and the HFCA Act all call for additional and more stringent criteria to be applied to emerging market companies upon assessing the qualification of their auditors, especially the non-U.S. auditors who are not inspected by the PCAOB. These developments could add uncertainties to our continued listing or future offerings of our securities in the U.S."

Business Overview

We, through the operating entity, focus on the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For nearly 20 years, the operating entity has been committed to enhancing the health of livestock. The operating entity markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity's products are available in 29 provincial regions across China and are exported overseas, to Vietnam, Pakistan, and Egypt.

For the six months ended June 30, 2023 and the fiscal years ended December 31, 2022, and 2021, our revenue was RMB116.9 million (\$16.1 million), RMB260.3 million (\$37.7 million), and RMB214.1 million (\$31.0 million), respectively.

Competitive Strengths

We believe the following competitive strengths are essential for our success and differentiate us from our competitors:

- diversified products;
- high production quality;
- strong research and development capabilities;
- extensive distribution channels; and
- experienced management team and employees.

Growth Strategies

We intend to develop our business and strengthen brand loyalty by implementing the following strategies:

- develop high-demand products and expand the operating entity's business by entering into household animals vaccines industry;
- expand the operating entity's sales and distribution network;
- enhance the operating entity's ability to attract, incentivize and retain talented professionals;
- increase the investment in production lines; and
- increase research and development investment.

Corporate Information

Our principal executive offices are located at No.1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin Province, China and our phone number is +86-0432-63047008. Our registered office in the Cayman Islands is located at 3-212 Governors Square, 23 Lime Tree Bay Avenue, P.O. Box 30746, Seven Mile Beach, Grand Cayman KY1-1203, Cayman Islands. We maintain a corporate website at www.jlzybio.com. The information contained in, or accessible from, our website or any other website does not constitute a part of this prospectus. Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168.

Summary of Risk Factors

Investing in our Ordinary Shares involves significant risks. You should carefully consider all of the information in this prospectus before making an investment in our Ordinary Shares. Below please find a summary of the principal risks we face, organized under relevant headings. These risks are discussed more fully in the section titled "Risk Factors."

Risks Relating to Doing Business in the PRC (for a more detailed discussion, see "Risk Factors — Risks Relating to Doing Business in the PRC")

We face risks and uncertainties relating to doing business in the PRC in general, including, but not limited to, the following:

- changes in China's economic, political, or social conditions or government policies could have a material adverse effect on the operating entity's business and operations (see page 16 of this prospectus);
- uncertainties in the interpretation and enforcement of PRC laws and regulations and changes in policies, rules, and regulations in China, which may be quick with little advance notice, could limit the legal protection available to you and us (see page 16 of this prospectus);
- you may experience difficulties in effecting service of legal process, enforcing foreign judgments, or bringing actions in China against us or our management named in this prospectus based on foreign laws. It may also be difficult for you or overseas regulators to conduct investigations or collect evidence within China (see page 17 of this prospectus);
- given the Chinese government's significant oversight and discretion over the conduct of business of the operating entity, the Chinese government may intervene or influence its operations at any time, which could result in a material change in the operations of the operating entity and/or the value of our Ordinary Shares (see page 18 of this prospectus);
- any actions by the Chinese government, including any decision to intervene or influence the operations of the operating entity or to exert control over any offering of securities conducted overseas and/or foreign investment in China-based issuers, may cause us to make material changes to the operations of the operating entity, may limit or completely hinder our ability to offer or continue to offer securities to investors, and may cause the value of such securities to significantly decline or be worthless (see page 18 of this prospectus);
- recent greater oversight by the CAC over data security, particularly for companies seeking to list on a foreign exchange, could adversely impact our business and our offering (see page 18 of this prospectus);

- the Opinions recently issued by the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council may subject us and the operating entity to additional compliance requirements in the future (see page 19 of this prospectus);
- recent joint statement by the SEC and the PCAOB, rule changes by Nasdaq, and the Holding Foreign Companies Accountable Act all call for additional and more stringent criteria to be applied to emerging market companies upon assessing the qualification of their auditors, especially the non-U.S. auditors who are not inspected by the PCAOB. These developments could add uncertainties to our offerings (see page 20 of this prospectus);
- to the extent cash or assets in the business are in the PRC/Hong Kong or a PRC/Hong Kong entities, the funds or assets may not be available to fund operations or for other use outside of the PRC/Hong Kong due to interventions in or the imposition of restrictions and limitations on the ability of our Company, our subsidiaries, or the operating entity by the PRC government to transfer cash or assets (see page 21 of this prospectus);
- increases in labor costs in the PRC may adversely affect the operating entity's business and profitability (see page 22 of this prospectus);
- PRC regulations relating to offshore investment activities by PRC residents may subject our PRC resident beneficial owners or the PRC subsidiaries to liability or penalties, limit our ability to inject capital into the PRC subsidiaries, limit the PRC subsidiaries' ability to increase their registered capital or distribute profits to us, or may otherwise adversely affect us (see page 22 of this prospectus);
- PRC regulation of parent/subsidiary loans and direct investment by offshore holding companies to PRC entities may delay or prevent us from using the proceeds of offshore offerings to make loans or additional capital contributions to the PRC subsidiaries, which could materially and adversely affect their liquidity and their ability to fund and expand their business (see page 24 of this prospectus);
- fluctuations in exchange rates could have a material and adverse effect on our results of operations and the value of your investment (see page 25 of this prospectus);
- under the PRC Enterprise Income Tax Law, we may be classified as a PRC "resident enterprise" for PRC enterprise income tax purposes. Such classification would likely result in unfavorable tax consequences to us and our non-PRC shareholders and have a material adverse effect on our results of operations and the value of your investment (see page 25 of this prospectus);
- we face uncertainty with respect to indirect transfers of equity interests in PRC resident enterprises by their non-PRC holding companies (see page 26 of this prospectus);
- the PRC subsidiaries are subject to restrictions on paying dividends or making other payments to us, which may have a material adverse effect on our ability to conduct our business (see page 27 of this prospectus);
- governmental control of currency conversion may affect the value of your investment and our payment of dividends (see page 27 of this prospectus);
- there are significant uncertainties under the EIT Law relating to the withholding tax liabilities of the PRC subsidiaries, and dividends payable by our PRC subsidiaries to our offshore subsidiaries may not qualify to enjoy certain treaty benefits (see page 27 of this prospectus);
- if we become directly subject to the scrutiny, criticism, and negative publicity involving U.S.-listed Chinese companies, we may have to expend significant resources to investigate and resolve the matter which could harm our business operations, stock price, and reputation (see page 28 of this prospectus);
- the disclosures in our reports and other filings with the SEC and our other public pronouncements are not subject to the scrutiny of any regulatory bodies in the PRC (see page 28 of this prospectus);
- the approval of the CSRC may be required in connection with this offering under the PRC law (see page 28 of this prospectus);

- the M&A Rules and certain other PRC regulations establish complex procedures for certain acquisitions of Chinese companies by foreign investors, which could make it more difficult for us to pursue growth through acquisitions in China (see page 30 of this prospectus); and
- Chinese regulatory authorities could disallow our holding company structure, which may result in a material change in our operations and/or a material change in the value of the securities we are registering for sale, including that it could cause the value of such securities to significantly decline or become worthless (see page 30 of this prospectus).

Risks Relating to Our Business and Industry (for a more detailed discussion, see “Risk Factors — Risks Related to Our Business and Industry”)

Risks and uncertainties related to our business include, but are not limited to, the following:

- the operating entity operates in a highly-competitive market and our failure to compete effectively could adversely affect its results of operations (see page 31 of this prospectus);
- perceived adverse effects on human health linked to the consumption of food derived from animals that utilize the operating entity’s products could cause a decline in the sales of such products (see page 32 of this prospectus);
- increased regulation relating to the raising, processing or consumption of food-producing animals could reduce demand for the operating entity’s livestock products (see page 32 of this prospectus);
- the operating entity’s business is subject to risk based on customer exposure to rising costs and reduced customer income (see page 32 of this prospectus);
- the operating entity may not successfully acquire and integrate other businesses, license rights to technologies or products, form and manage alliances or divest businesses (see page 32 of this prospectus);
- the operating entity’s research and development, acquisition and licensing efforts may fail to generate new products and brand life-cycle developments (see page 33 of this prospectus);
- advances in veterinary medical practices and animal health technologies could negatively affect the market for the operating entity’s products (see page 33 of this prospectus);
- the operating entity’s research and development relies on evaluations in animals (see page 33 of this prospectus);
- manufacturing problems may cause product launch delays, inventory shortages, recalls or unanticipated costs (see page 33 of this prospectus);
- the operating entity may fail to detect or cure defects of its products (see page 34 of this prospectus);
- the misuse or off-label use of the operating entity’s products may harm the operating entity’s reputation or result in financial or other damages (see page 34 of this prospectus);
- We derive a significant portion of our revenue from swine vaccines and any reduction in demand of swine vaccines could have an adverse effect on our business, financial condition, results of operations, cash flows, and prospects (see page 35 of this prospectus);
- animal health products are subject to unanticipated safety or efficacy concerns, which may harm the operating entity’s reputation (see page 35 of this prospectus);
- operating entity’s historical growth rates and performance may not be sustainable or indicative of our future growth and financial results. We cannot guarantee that we will be able to maintain the growth rate we have experienced to date (see page 35 of this prospectus);
- COVID-19 affects our results of operations (see page 35 of this prospectus);
- the operating entity’s business is subject to inherent risks relating to product liability (see page 36 of this prospectus);

- the operating entity’s business will be materially and adversely affected if its collaborative partners, licensees and other third parties over whom the operating entity is very dependent fail to perform as expected (see page 36 of this prospectus);
- the operating entity’s business requires a number of permits and licenses. We cannot assure you that the operating entity can maintain all required licenses, permits and certifications to carry on its business at all times (see page 36 of this prospectus);
- the operating entity’s ability to generate more revenue would be adversely affected if it needs more clinical trials or take more time to complete its clinical trials than it has planned (see page 37 of this prospectus);
- if we cannot retain, attract, and motivate key personnel, we may be unable to effectively implement our business plan (see page 37 of this prospectus);
- if the operating entity is unable to obtain the regulatory approvals or clearances that are necessary to commercialize its products, we will have less revenue than expected (see page 37 of this prospectus);
- The operating entity sources its raw materials used for manufacturing from a limited number of suppliers. If it loses one or more of the suppliers, its operation may be disrupted, and both the operating entity’s and our results of operations may be adversely and materially impacted (see page 38 of this prospectus);
- high customer concentration exposes the operating entity to all of the risks faced by its major customer and may subject it to significant fluctuations or declines in revenue, which may have a material adverse impact on the operating entity’s business, and its and our financial condition and results of operations (see page 38 of this prospectus);
- damage to our brand image could have a material adverse effect on our growth strategy and our business, financial condition, results of operations and prospects (see page 39 of this prospectus);
- if the operating entity cannot successfully protect its intellectual property and exclusive rights, our brand and business would suffer (see page 39 of this prospectus);
- the operating entity may be accused of infringing, misappropriating or otherwise violating the intellectual property rights of third parties (see page 40 of this prospectus);
- we are subject to legal and regulatory proceedings from time to time in the ordinary course of our business (see page 40 of this prospectus); and
- we could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws (see page 40 of this prospectus).

Risks Relating to this Offering and the Trading Market (for a more detailed discussion, see “Risk Factors — Risks Relating to this Offering and the Trading Market”)

In addition to the risks described above, we are subject to general risks and uncertainties relating to this offering and the trading market, including, but not limited to, the following:

- there has been no public market for our Ordinary Shares prior to this offering, and you may not be able to resell our Ordinary Shares at or above the price you pay for them, or at all (see page 41 of this prospectus);
- the initial public offering price for our Ordinary Shares may not be indicative of prices that will prevail in the trading market and such market prices may be volatile (see page 41 of this prospectus);
- you will experience immediate and substantial dilution in the net tangible book value of Ordinary Shares purchased (see page 41 of this prospectus);
- if we fail to implement and maintain an effective system of internal controls or fail to remediate the material weaknesses in our internal control over financial reporting that have been identified, we may fail to meet our reporting obligations or be unable to accurately report our results of operations or prevent fraud, and investor confidence and the market price of our Ordinary Shares may be materially and adversely affected (see page 41 of this prospectus);

- we will incur substantial increased costs as a result of being a public company (see page 42 of this prospectus);
- substantial future sales of our Ordinary Shares or the anticipation of future sales of our Ordinary Shares in the public market could cause the price of our Ordinary Shares to decline (see page 42 of this prospectus);
- we do not intend to pay dividends in the foreseeable future (see page 43 of this prospectus);
- if securities or industry analysts do not publish research or reports about our business, or if they publish a negative report regarding our Ordinary Shares, the price of our Ordinary Shares and trading volume could decline (see page 43 of this prospectus);
- the market price of our Ordinary Shares may be volatile or may decline regardless of our operating performance, and you may not be able to resell your shares at or above the initial public offering price (see page 43 of this prospectus);
- the price of our Ordinary Shares could be subject to rapid and substantial volatility. Such volatility, including any stock run-ups, may be unrelated to our actual or expected operating performance and financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our Ordinary Shares (see page 44 of this prospectus);
- our management has broad discretion to determine how to use the funds raised in the offering and may use them in ways that may not enhance our results of operations or the price of our Ordinary Shares (see page 44 of this prospectus);
- if we cease to qualify as a foreign private issuer, we would be required to comply fully with the reporting requirements of the Exchange Act applicable to U.S. domestic issuers, and we would incur significant additional legal, accounting and other expenses that we would not incur as a foreign private issuer (see page 44 of this prospectus);
- because we are a foreign private issuer and intend to take advantage of exemptions from certain Nasdaq corporate governance standards applicable to U.S. issuers, you will have less protection than you would have if we were a domestic issuer (see page 44 of this prospectus); and
- if we cannot continue to satisfy the listing requirements and other rules of the Nasdaq, our securities may be delisted, which could negatively impact the price of our securities and your ability to sell them (see page 45 of this prospectus).

Impact of the COVID-19 Pandemic

The COVID-19 pandemic has resulted in the implementation of significant governmental measures, including lockdowns, closures, quarantines, and travel bans, intended to control the spread of the virus. In January 2020, the Chinese government issued a series of policies to prevent the spread of COVID-19. In March 2022, a new wave of COVID-19 outbreak hit Jilin Province, particularly Changchun City and Jilin City. The resulting closure measures lasted for around two months and significantly impacted the social and industrial activities of Jilin City, where the operating entity is situated. Particularly, the area where the operating entity operates was classified as a high-risk zone. As a result, the operating entity's operational performance was affected.

For the fiscal years ended December 31, 2022 and 2021, the Company and the operating entity did not experience a significant negative impact of COVID-19 on their operations, capital, and financial position. Our revenue reached approximately RMB260.3 million (\$37.7 million) for the fiscal year ended December 31, 2022, representing an increase of approximately RMB46.2 million or 21.6% from approximately RMB214.1 million (\$31.0 million) for the fiscal year ended December 31, 2021.

For the six months ended June 30, 2023 and 2022, the Company and the operating entity did not experience a significant negative impact of COVID-19 on their operations, capital, and financial position. Our revenue reached approximately RMB116.9 million (\$16.1 million) for the six months ended June 30, 2023, representing a slight decrease of approximately RMB6.5 million or 5.3% from approximately RMB123.4 million (\$17.0 million) for the six months ended June 30, 2022.

In December 2022, the COVID-19 restriction policies in China were gradually loosened and lifted, both locally and nationally. Starting from January 2023, among other changes, China no longer conducts nucleic acid tests and centralized quarantine for all inbound travelers, and measures to control the number of international passenger flights are lifted.

The extent of the impact of COVID-19 on the Company's future financial results will be dependent on future developments such as the length and severity of the pandemic, the potential resurgence of the pandemic, future government actions in response to the pandemic and the overall impact of the COVID-19 pandemic on the global economy and capital markets, among many other factors, all of which remain highly uncertain and unpredictable. Given this uncertainty, the Company is currently unable to quantify the expected impact of the COVID-19 pandemic on its future operations, financial condition, liquidity and results of operations if the current situation continues. See "Risk Factors — Risks Related to Our Business and Industry — COVID-19 Affects our Results of Operations."

Permissions or Approval Required from the PRC Authorities for the Operating Entity

Our PRC legal counsel, Guantao, has advised us that, as of the date of this prospectus, the operating entity has obtained and currently maintain all approvals, permits, licenses, registrations or filings from PRC authorities needed to engage in the businesses currently conducted in China. Such permits, licenses, registrations and permissions (the "Governmental Permits") include, but are not limited to, the following:

1. Business License, which is a permit issued by Market Supervision and Administration that allows companies to conduct specific businesses within the government's geographical jurisdiction;
2. Certificate of Good Manufacturing Practice for Animal Drugs ("GMP"), which is a quality management standard for veterinary drug production issued by the Animal Husbandry Administration of Jilin Province;
3. Veterinary Drug Production License, which is a permit issued by Jilin Animal Husbandry Bureau that allows companies to produce veterinary drugs;
4. Veterinary Drug Operation License, which is a permit issued by Jilin Animal Husbandry Bureau that allows companies to deal in veterinary drugs;
5. Use License of Experimental Animals, which is a permit issued by Department of Science and Technology of Jilin Province that allows companies to conduct scientific experiments or studies using animals;
6. Registration Certificate of New Veterinary Drugs, which is a permit issued by Ministry of Agriculture and Rural Affairs of the PRC that allows companies to apply for approval document numbers of veterinary drug products, with which companies can manufacture a new veterinary drug; and
7. Pollutant Discharge Permit, which is a permit issued by Jilin City Ecological Environment Bureau in the PRC that allows companies to discharge pollutants in accordance with regulations.

We cannot assure you that the operating entity will always be able to successfully update or renew the Governmental Permits required for the relevant business in a timely manner or that these licenses or permits are sufficient to conduct all of the operating entity's present or future business. The operating entity's operations could be adversely affected, directly or indirectly; our ability to offer, or continue to offer, securities to investors would be potentially hindered; and the value of our securities might significantly decline or be worthless, by existing or future laws and regulations relating to the business of the subsidiaries and the operating entity or our industry, or by intervention or interruption by PRC governmental authorities, if we or the operating entity (1) do not receive or maintain such Governmental Permits, (2) inadvertently conclude that such Governmental Permits are not required, (3) applicable laws, regulations, or interpretations change and the operating entity is required to obtain such Governmental Permits in the future.

Permissions or Approval Required from the PRC Authorities for Overseas Listing

As of the date of this prospectus, our PRC counsel, Guantao, has advised us that neither we nor any of the PRC subsidiaries (1) is required to obtain permission from any of the PRC authorities to operate and issue our Ordinary Shares to foreign investors except for the filing with the CSRC for this offering, and (2) has been denied such permissions by any PRC authorities.

Recently, however, the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued the “Opinions on Severely Cracking Down on Illegal Securities Activities According to Law,” or the “Opinions,” which were made available to the public on July 6, 2021. The Opinions emphasized the need to strengthen the administration over illegal securities activities and the need to strengthen the supervision over overseas listings by Chinese companies. These opinions proposed to take effective measures, such as promoting the construction of relevant regulatory systems, to deal with the risks and incidents facing China-concept overseas-listed companies and the demand for cybersecurity and data privacy protection.

The Cybersecurity Review Measures, which became effective on February 15, 2022, provide that, in addition to CIIOs that intend to purchase Internet products and services, online platform operators engaging in data processing activities that affect or may affect national security must be subject to cybersecurity review by the Cybersecurity Review Office of the PRC. According to the Cybersecurity Review Measures, a cybersecurity review assesses potential national security risks that may be brought about by any procurement, data processing, or overseas listing. The Cybersecurity Review Measures further require that online platform operators that possess personal data of at least one million users must apply for a review by the Cybersecurity Review Office of the PRC before conducting listings in foreign countries.

On November 14, 2021, the CAC published the Regulations on Network Data Security Protection (Draft for Comments), or the Security Administration Draft, for public comments, which reiterated that data processors that process personal information of more than one million users listing in a foreign country should apply for a cybersecurity review. As of the date of this prospectus, the Security Administration Draft has not been enacted.

Based on the description regarding our business operations and our marketplace, neither we or the operating entity are required to go through a cybersecurity review with the CAC, because we and the operating entity are not an operator of CIIOs or an online platform operator that possesses over one million users’ personal information. Based on the foregoing and also the advice of our PRC legal counsel, Guantao, we believe that we and the operating entity are currently not required to go through a cybersecurity review with the CAC as of the date hereof. As of the date of this prospectus, we and the operating entity have also not been involved in any investigations on cybersecurity or data security initiated by related governmental regulatory authorities, and we have not received any inquiry, notice, warning, or sanction in such respect. There remains uncertainty, however, as to how the Cybersecurity Review Measures will be interpreted or implemented and whether the PRC over data security, particularly for companies seeking to list on a foreign exchange, could adversely impact our PRC subsidiaries’ business and our offering.

On February 17, 2023, the CSRC promulgated the Overseas Listing Trial Measures and relevant five guidelines, which became effective on March 31, 2023. According to the Overseas Listing Trial Measures, PRC domestic companies that seek to offer and list securities in overseas markets, either in direct or indirect means, are required to fulfill the filing procedure with the CSRC and report relevant information. Based on the foregoing, our PRC counsel is of the view that we are required to complete the filing procedures with the CSRC in connection with the offering and listing. There is no assurance that we can complete such filing in a timely manner or even at all. Any failure by us to comply with such filing requirements may result in orders to rectify, warnings and fines against us and could materially hinder our ability to offer or continue to offer our securities. We have filed with the CSRC the filing documents and shall complete the filing before the completion of our overseas offering and listing. Given the current PRC regulatory environment, it is uncertain whether we will be required to obtain approvals from the PRC government to offer securities to foreign investors in the future, and whether we would be able to obtain such approvals. If we are unable to obtain such approvals in the future, then the value of our Ordinary Shares may depreciate significantly or become worthless. See “Regulations — Regulations Relating to Overseas Listings” and “Risk Factors — Risks Relating to Doing Business in the PRC — The Opinions recently issued by the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council may subject us and the operating entity to additional compliance requirements in the future.”

Asset Transfers Between Our Company and Our Subsidiaries

As of the date of this prospectus, except for a loan from the operating entity to Hainan Senhan on October 10, 2023, with a principal amount of RMB100,000, no cash transfer or transfer of other assets has occurred between our Company and our subsidiaries. During the six months ended June 30, 2023 and the fiscal years ended December 31, 2022 and 2021, dividends and distributions made by the operating entity to its original shareholders amounted to RMB18,000,000, RMB21,424,500, and RMB11,047,500, respectively. On April 28, 2023, the shareholders of the operating entity passed the resolution of the dividend plan for 2022, with the dividend amount of RMB55,104,000, and

the dividend will be distributed before May 2024. Apart from the aforementioned, there is no other transfers, dividends, or distributions between the Company's subsidiaries as of the date of this prospectus. We have established controls and procedures for cash flows within our organization based on internal cash management policies established by our finance department, discussed, considered, and reviewed by the relevant departments in our Company, and approved by our Chairman of the Board of Directors. Specifically, our finance department supervises cash management, following the instructions of our management. Our finance department is responsible for establishing our cash operation plan and coordinating cash management matters among our subsidiaries and departments. Each subsidiary and department initiate a cash request by putting forward a cash demand plan, which explains the specific amount and timing of cash requested, and submitting it to our finance department. The finance department reviews the cash demand plan and prepares a summary for the management of our Company. Management examines and approves the allocation of cash based on the sources of cash and the priorities of the needs. Other than the above, we currently do not have other cash management policies or procedures that dictate how funds are transferred.

Dividends or Distributions Made to Our Company and U.S. Investors and Tax Consequences

During the six months ended June 30, 2023 and the fiscal years ended December 31, 2022 and 2021, dividends and distributions made by the operating entity to its original shareholders amounted to RMB18,000,000, RMB21,424,500, and RMB11,047,500, respectively. On April 28, 2023, the shareholders of the operating entity passed the resolution of the dividend plan for 2022, with the dividend amount of RMB55,104,000, and the dividend will be distributed before May 2024.

Except as disclosed above, we intend to keep any future earnings to finance the expansion of our business, and we do not anticipate that any cash dividends will be paid in the foreseeable future. Subject to the passive foreign investment company ("PFIC") rules, the gross amount of distributions we make to investors with respect to our Ordinary Shares (including the amount of any taxes withheld therefrom) will be taxable as a dividend, to the extent that the distribution is paid out of our current or accumulated earnings and profits, as determined under U.S. federal income tax principles.

Under the Cayman Islands law, a Cayman Islands company may pay a dividend on its shares out of profit and/or share premium, provided that in no circumstances may a dividend be paid out of share premium if this would result in the company being unable to pay its debts as they fall due in the ordinary course of business.

If we determine to pay dividends on any of our Ordinary Shares in the future, as a holding company, we will be dependent on receipt of funds from our Hong Kong subsidiary. There are currently no restrictions on foreign exchange and our ability to transfer cash among our Cayman Islands holding company and our subsidiary in BVI and Hong Kong. However, as the PRC government imposes control over currency conversion, it has the authority to conduct exchange transfer reviews, which may impose certain limitations on our ability to transfer cash between our Company, our subsidiaries, and our investors, primarily reflected in the following aspects: (i) we are restricted from injecting capital or providing loans to our PRC subsidiaries, which may adversely affect the operations of our PRC subsidiaries; (ii) our PRC subsidiaries may be restricted from paying dividends to us; and (iii) if we are unable to obtain dividends from our PRC subsidiaries, it may adversely impact our dividends distribution to investors. See "Summary of Risk Factors," "Risk Factors — Risks Relating to Doing Business in the PRC — PRC regulations relating to offshore investment activities by PRC residents may subject our PRC resident beneficial owners or our PRC subsidiaries to liability or penalties, limit our ability to inject capital into our PRC subsidiaries, limit our PRC subsidiaries' ability to increase their registered capital or distribute profits to us, or may otherwise adversely affect us," "Risk Factors — Risks Relating to Doing Business in the PRC — PRC regulation of parent/subsidiary loans and direct investment by offshore holding companies to PRC entities may delay or prevent us from using the proceeds of offshore offerings to make loans or additional capital contributions to our PRC subsidiaries, which could materially and adversely affect their liquidity and their ability to fund and expand their business," and "Risk Factors — Risks Relating to Doing Business in the PRC — Governmental control of currency conversion may affect the value of your investment and our payment of Dividends."

Current PRC regulations permit PRC subsidiaries to pay dividends to Peg Biotechnology only out of its accumulated profits, if any, determined in accordance with Chinese accounting standards and regulations. The PRC government also imposes controls on the conversion of RMB into foreign currencies and the remittance of currencies out of the PRC. For instance, the Circular on Promoting the Reform of Foreign Exchange Management and Improving Authenticity and Compliance Review, or "SAFE Circular 3," issued on January 26, 2017, provides that banks shall, when dealing with dividend remittance transactions from a domestic enterprise to its offshore shareholders of more than \$50,000, review the relevant board resolutions, original tax filing form, and audited financial statements of such

domestic enterprise based on the principle of genuine transaction. Furthermore, if our PRC subsidiaries incur debt on their own in the future, the instruments governing the debt may restrict their ability to pay dividends or make other payments. If we or our PRC subsidiaries are unable to receive all of the revenue from its operations, we may be unable to pay dividends on our Ordinary Shares.

Cash dividends, if any, on our Ordinary Shares will be paid in U.S. dollars. Peg Biotechnology may be considered a non-resident enterprise for tax purposes, so that any dividends our PRC subsidiaries pay to Peg Biotechnology may be regarded as China-sourced income and as a result may be subject to PRC withholding tax at a rate of up to 10%. See “Material Income Tax Consideration — People’s Republic of China Enterprise Taxation in Mainland China.”

As a holding company, we may rely on dividends and other distributions on equity paid by our subsidiaries, including those based in mainland China, for our cash and financing requirements. If any of our PRC subsidiaries incurs debt on its own behalf in the future, the instruments governing such debt may restrict its ability to pay dividends to us.

Pursuant to the Arrangement between Mainland China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Tax Evasion on Income (the “Double Tax Avoidance Arrangement”), the 10% withholding tax rate may be lowered to 5% if a Hong Kong resident enterprise owns no less than 25% of a PRC resident enterprise. The 5% withholding tax rate, however, does not automatically apply and certain requirements must be satisfied, including without limitation that (a) the Hong Kong resident enterprise must directly own the required percentage of equity interests and voting rights in the PRC resident enterprise; and (b) the Hong Kong resident enterprise must have directly owned such required percentage in the PRC resident enterprise throughout the 12 months prior to receiving of the dividends. In current practice, a Hong Kong resident enterprise must obtain a tax resident certificate from the Hong Kong tax authority to apply for the 5% lower PRC withholding tax rate. As the Hong Kong tax authority will issue such a tax resident certificate on a case-by-case basis, we cannot assure you that we will be able to obtain the tax resident certificate from the relevant Hong Kong tax authority and enjoy the preferential withholding tax rate of 5% under the Double Tax Avoidance Arrangement with respect to any dividends paid by Hainan Senhan to its immediate holding company, Peg Biotechnology. As of the date of this prospectus, we have not applied for the tax resident certificate from the relevant Hong Kong tax authority. Peg Biotechnology intends to apply for the tax resident certificate if and when Hainan Senhan plans to declare and pay dividends to Peg Biotechnology. See “Risk Factors — Risks Relating to Doing Business in the PRC — There are significant uncertainties under the EIT Law relating to the withholding tax liabilities of our PRC subsidiary, and dividends payable by our PRC subsidiaries to our offshore subsidiaries may not qualify to enjoy certain treaty benefits.”

Implications of Being an “Emerging Growth Company”

As a company with less than \$1.235 billion in revenue during our last fiscal year, we qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the “JOBS Act.” An “emerging growth company” may take advantage of reduced reporting requirements that are otherwise applicable to larger public companies. In particular, as an emerging growth company, we:

- may present only two years of audited financial statements and only two years of related Management’s Discussion and Analysis of Financial Condition and Results of Operations;
- are not required to provide a detailed narrative disclosure discussing our compensation principles, objectives and elements and analyzing how those elements fit with our principles and objectives, which is commonly referred to as “compensation discussion and analysis”;
- are not required to obtain an attestation and report from our auditors on our management’s assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002;
- are not required to obtain a non-binding advisory vote from our shareholders on executive compensation or golden parachute arrangements (commonly referred to as the “say-on-pay,” “say-on-frequency,” and “say-on-golden-parachute” votes);
- are exempt from certain executive compensation disclosure provisions requiring a pay-for-performance graph and CEO pay ratio disclosure;
- are eligible to claim longer phase-in periods for the adoption of new or revised financial accounting standards under §107 of the JOBS Act; and

- will not be required to conduct an evaluation of our internal control over financial reporting until our second annual report on Form 20-F following the effectiveness of our initial public offering.

We intend to take advantage of all of these reduced reporting requirements and exemptions, including the longer phase-in periods for the adoption of new or revised financial accounting standards under §107 of the JOBS Act. Our election to use the phase-in periods may make it difficult to compare our financial statements to those of non-emerging growth companies and other emerging growth companies that have opted out of the phase-in periods under §107 of the JOBS Act.

Under the JOBS Act, we may take advantage of the above-described reduced reporting requirements and exemptions until we no longer meet the definition of an emerging growth company. The JOBS Act provides that we would cease to be an “emerging growth company” at the end of the fiscal year in which the fifth anniversary of our initial sale of common equity pursuant to a registration statement declared effective under the Securities Act occurred, if we have more than \$1.235 billion in annual revenue, have more than \$700 million in market value of our Ordinary Shares held by non-affiliates, or issue more than \$1 billion in principal amount of non-convertible debt over a three-year period.

Foreign Private Issuer Status

We are a foreign private issuer within the meaning of the rules under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). As such, we are exempt from certain provisions applicable to United States domestic public companies. For example:

- we are not required to provide as many Exchange Act reports, or as frequently, as a domestic public company;
- for interim reporting, we are permitted to comply solely with our home country’s requirements, which are less rigorous than the rules that apply to domestic public companies;
- we are not required to provide the same level of disclosure on certain issues, such as executive compensation;
- we are exempt from provisions of Regulation FD aimed at preventing issuers from making selective disclosures of material information;
- we are not required to comply with the sections of the Exchange Act regulating the solicitation of proxies, consents, or authorizations in respect of a security registered under the Exchange Act; and
- we are not required to comply with Section 16 of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities and establishing insider liability for profits realized from any “short-swing” trading transaction.

Controlled Company

Upon completion of this offering, our director, chairman of the board of directors and largest shareholder, Mr. Zhenfa Han, will beneficially own approximately []% of the aggregate voting power of our issued and outstanding Ordinary Shares. As a result, we will be deemed a “controlled company” for the purpose of the Nasdaq listing rules. As a controlled company, we are permitted to elect to rely on certain exemptions from the obligations to comply with certain corporate governance requirements, including the requirements that:

- a majority of our board of directors consist of independent directors;
- our director nominees be selected or recommended solely by independent directors; and
- we have a nominating and corporate governance committee and a compensation committee that are composed entirely of independent directors with a written charter addressing the purposes and responsibilities of the committees.

Although we do not intend to rely on the controlled company exemptions under the Nasdaq listing rules even if we are a controlled company, we could elect to rely on these exemptions in the future, and if so, you would not have the same protection afforded to shareholders of companies that are subject to all of the corporate governance requirements of Nasdaq. See “Risk Factors” and “Management — Controlled Company.”

THE OFFERING	
Ordinary Shares offered by us	[•] Ordinary Shares
Price per Ordinary Share	We currently estimate that the initial public offering price will be in the range of \$[•] to \$[•] per Ordinary Share.
Ordinary Shares outstanding prior to completion of this offering	11,416,594 Ordinary Shares issued and outstanding
Ordinary Shares outstanding immediately after this offering	[•] Ordinary Shares
Listing	We will apply to have our Ordinary Shares listed on the Nasdaq Global Market. The closing of this offering is conditioned upon Nasdaq’s final approval of our listing application, and there is no guarantee or assurance that our Ordinary Shares will be approved for listing on Nasdaq.
Proposed ticker symbol	“ZYBT”
Transfer Agent	Transhare Corporation
Use of proceeds	We intend to use the proceeds from this offering to acquire vaccine production companies, build new workshops, conduct research and development projects, and for working capital and other general corporate purposes. See “Use of Proceeds” on page 50 for more information.
Lock-up	We, and any successors of us, will not, without the prior written consent of the Representative, for one hundred eighty (180) days from the date of commencement of sales of this offering, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any of our Ordinary Shares or any securities that are convertible into or exercisable or exchangeable for our Ordinary Shares, (ii) file or cause to be filed any registration statement with the SEC relating to the offering of any Ordinary Shares or any securities convertible into or exercisable or exchangeable for Ordinary Shares, or (iii) complete any offering of our debt securities, other than entering into a line of credit with a traditional bank, or (iv) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our capital shares, whether any such transaction described in clause (i), (ii), (iii), or (iv) above is to be settled by delivery of shares of our Company or such other securities, in cash or otherwise. Furthermore, all of our directors, officers, 5% or greater shareholders have agreed with the underwriters, subject to certain exceptions, not to offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer, or dispose of, directly or indirectly, any of our Ordinary Shares or securities convertible into or exercisable or exchangeable for our Ordinary Shares for one hundred eighty (180) days from the date of commencement of sales of this offering. See “Underwriting — Lock-Up Agreements” for more information.
Risk factors	The Ordinary Shares offered hereby involve a high degree of risk. You should read “Risk Factors,” beginning on page 16 for a discussion of factors to consider before deciding to invest in our Ordinary Shares.

RISK FACTORS

An investment in our Ordinary Shares involves a high degree of risk. Before deciding whether to invest in our Ordinary Shares, you should consider carefully the risks described below, together with all of the other information set forth in this prospectus, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and related notes. If any of these risks actually occurs, our business, financial condition, results of operations, or cash flow could be materially and adversely affected, which could cause the trading price of our Ordinary Shares to decline, resulting in a loss of all or part of your investment. The risks described below and discussed in other parts of this prospectus are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business. You should only consider investing in our Ordinary Shares if you can bear the risk of loss of your entire investment.

Risks Relating to Doing Business in the PRC

Changes in China’s economic, political, or social conditions or government policies could have a material adverse effect on the operating entity’s business and operations.

All of the operating entity’s assets and our operations are currently located in China. Accordingly, the operating entity’s business, financial condition, results of operations, and prospects may be influenced to a significant degree by political, economic, and social conditions in China generally. The Chinese economy differs from the economies of most developed countries in many respects, including the level of government involvement, level of development, growth rate, control of foreign exchange, and allocation of resources. Although the Chinese government has implemented measures emphasizing the utilization of market forces for economic reform, including the reduction of state ownership of productive assets and the establishment of improved corporate governance in business enterprises, a substantial portion of productive assets in China is still owned by the government. In addition, the Chinese government continues to play a significant role in regulating industry development by imposing industrial policies. The Chinese government also exercises significant control over China’s economic growth by allocating resources, controlling payment of foreign currency-denominated obligations, setting monetary policy, and providing preferential treatment to particular industries or companies.

While the Chinese economy has experienced significant growth over the past decades, growth has been uneven, both geographically and among various sectors of the economy. Any adverse changes in economic conditions in China, in the policies of the Chinese government, or in the laws and regulations in China could have a material adverse effect on the overall economic growth of China. Such developments could adversely affect the operating entity’s business and operating results, reduce demand for its products, and weaken its competitive position. The Chinese government has implemented various measures to encourage economic growth and guide the allocation of resources. Some of these measures may benefit the overall Chinese economy, but may have a negative effect on the operating entity. For example, the operating entity’s financial condition and results of operations may be adversely affected by government control over capital investments or changes in tax regulations. In addition, in the past the Chinese government has implemented certain measures, including interest rate adjustments, to control the pace of economic growth. These measures may cause decreased economic activities in China, which may adversely affect the operating entity’s business and operating results.

Furthermore, our Company, the operating entity, and our investors may face uncertainty about future actions by the government of China that could significantly affect the operating entity’s financial performance and operations. As of the date of this prospectus, neither our Company nor the operating entity has received or was denied permission from Chinese authorities to list on U.S. exchanges. However, there is no guarantee that our Company or the operating entity will receive or not be denied permission from Chinese authorities to list on U.S. exchanges in the future.

Uncertainties in the interpretation and enforcement of PRC laws and regulations and changes in policies, rules, and regulations in China, which may be quick with little advance notice, could limit the legal protection available to you and us.

The PRC legal system is based on written statutes. Unlike common law systems, it is a system in which legal cases have limited value as precedents. In the late 1970s, the PRC government began to promulgate a comprehensive system of laws and regulations governing economic matters in general. The legislation over the past three decades has significantly increased the protection afforded to various forms of foreign or private-sector investment in China.

[Table of Contents](#)

Hainan Senhan and the operating entity are subject to various PRC laws and regulations generally applicable to companies in China. Since these laws and regulations are relatively new and the PRC legal system continues to rapidly evolve, however, the interpretations of many laws, regulations, and rules are not always uniform and enforcement of these laws, regulations, and rules involve uncertainties.

From time to time, we may have to resort to administrative and court proceedings to enforce our legal rights. Since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, however, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy in the PRC legal system than in more developed legal systems. Furthermore, the PRC legal system is based in part on government policies, internal rules, and regulations (some of which are not published in a timely manner or at all) that may have retroactive effect and may change quickly with little advance notice. As a result, we may not be aware of our violation of these policies and rules until sometime after the violation. Such uncertainties, including uncertainties over the scope and effect of our contractual, property (including intellectual property), and procedural rights, and any failure to respond to changes in the regulatory environment in China could materially and adversely affect our business and impede our ability to continue our operations.

You may experience difficulties in effecting service of legal process, enforcing foreign judgments, or bringing actions in China against us or our management named in this prospectus based on foreign laws. It may also be difficult for you or overseas regulators to conduct investigations or collect evidence within China.

As a company incorporated under the laws of the Cayman Islands, we conduct substantially most of our operations in China and substantially most of our assets are located in China. In addition, except for one director, Mrs. Wenhua Sun, who is a resident of the U.S., the rest of our directors and all of our senior executive officers reside within China for a significant portion of the time and are PRC nationals. As a result, it may be difficult for you to effect service of process upon those persons inside mainland China. It may be difficult for you to enforce judgements obtained in U.S. courts based on civil liability provisions of the U.S. federal securities laws against us and our officers and directors who do not currently reside in the U.S. or have substantial assets in the U.S. In addition, there is uncertainty as to whether the courts of the Cayman Islands or the PRC would recognize or enforce judgments of U.S. courts against us or such persons predicated upon the civil liability provisions of the securities laws of the U.S. or any state.

The recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedures Law. PRC courts may recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based either on treaties between China and the country where the judgment is made or on principles of reciprocity between jurisdictions. China does not have any treaties or other forms of written arrangement with the United States that provide for the reciprocal recognition and enforcement of foreign judgments. In addition, according to the PRC Civil Procedures Law, the PRC courts will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment violates the basic principles of PRC laws or national sovereignty, security, or public interest. As a result, it is uncertain whether and on what basis a PRC court would enforce a judgment rendered by a court in the United States.

It may also be difficult for you or overseas regulators to conduct investigations or collect evidence within China. For example, in China, there are significant legal and other obstacles to obtaining information needed for shareholder investigations or litigation outside China or otherwise with respect to foreign entities. Although the authorities in China may establish a regulatory cooperation mechanism with counterparts of another country or region to monitor and oversee cross border securities activities, such regulatory cooperation with the securities regulatory authorities in the United States may not be efficient in the absence of a practical cooperation mechanism. Furthermore, according to Article 177 of the PRC Securities Law, or "Article 177," which became effective in March 2020, no overseas securities regulator is allowed to directly conduct investigations or evidence collection activities within the territory of the PRC. Article 177 further provides that Chinese entities and individuals are not allowed to provide documents or materials related to securities business activities to foreign agencies without prior consent from the securities regulatory authority of the State Council and the competent departments of the State Council. While detailed interpretation of or implementing rules under Article 177 have yet to be promulgated, the inability for an overseas securities regulator to directly conduct investigation or evidence collection activities within China may further increase difficulties faced by you in protecting your interests.

Given the Chinese government's significant oversight and discretion over the conduct of the business of the operating entity, the Chinese government may intervene or influence its operations at any time, which could result in a material change in the operations of the operating entity and/or the value of our Ordinary Shares.

The Chinese government has significant oversight and discretion over the conduct of the operating entity and may intervene or influence its operations at any time as the government deems appropriate to further regulatory, political, and societal goals, which could result in a material change in the operations of the operating entity and/or the value of our Ordinary Shares.

The Chinese government has recently published new policies that significantly affected certain industries, such as education and internet, we cannot rule out the possibility that it will in the future release regulations or policies regarding the veterinary vaccine industry that could adversely affect the business, financial condition, and results of operations of the operating entity. Furthermore, if China adopts more stringent standards with respect to certain areas such as corporate social responsibilities, the operating entity may incur increased compliance costs or become subject to additional restrictions in its operations. Certain areas of the law, including intellectual property rights and confidentiality protections, in China may also not be as effective as in the United States or other countries. In addition, we cannot predict the effects of future developments in the PRC legal system on their business operations of the operating entity, including the promulgation of new laws, or changes to existing laws or the interpretation or enforcement thereof. These uncertainties could limit the legal protections available to us and our investors, including you.

Any actions by the Chinese government, including any decision to intervene or influence the operations of the operating entity or to exert control over any offering of securities conducted overseas and/or foreign investment in China-based issuers, may cause us to make material changes to the operations of the operating entity, may limit or completely hinder our ability to offer or continue to offer securities to investors, and may cause the value of such securities to significantly decline or be worthless.

The Chinese government has exercised and continues to exercise substantial control over virtually every sector of the Chinese economy through regulation and state ownership. The ability of the operating entity to operate in China may be impaired by changes in its laws and regulations, including those relating to taxation, environmental regulations, land use rights, foreign investment limitations, and other matters. The central or local governments of China may impose new, stricter regulations or interpretations of existing regulations that would require additional expenditures and efforts for the operating entity to ensure its compliance with such regulations or interpretations. As such, the operating entity may be subject to various government and regulatory interference in the provinces in which it operates in China. It could be subject to regulation by various political and regulatory entities, including various local and municipal agencies and government sub-divisions. It may incur increased costs necessary to comply with existing and newly adopted laws and regulations or penalties for any failure to comply.

Furthermore, it is uncertain when and whether we will be required to obtain permission from the PRC government to list on U.S. exchanges in the future, and even when such permission is obtained, whether it will be later denied or rescinded. Although we believe our Company and the operating entity are currently not required to obtain permission from any Chinese authorities and have not received any notice of denial of permission to list on the U.S. exchange as of the date of this prospectus, our operations could be adversely affected, directly or indirectly, by existing or future laws and regulations relating to our business or industry, particularly in the event permission to list on U.S. exchanges may be later required, or withheld or rescinded once given.

Accordingly, government actions in the future, including any decision to intervene or influence the operations of the operating entity at any time or to exert control over an offering of securities conducted overseas and/or foreign investment in China-based issuers, may cause us to make material changes to the operations of the operating entity, may limit or completely hinder our ability to offer or continue to offer securities to investors, and/or may cause the value of such securities to significantly decline or be worthless.

Recent greater oversight by the CAC over data security, particularly for companies seeking to list on a foreign exchange, could adversely impact our business and our offering.

On December 28, 2021, 13 governmental departments of the PRC, including the CAC, jointly promulgated the Cybersecurity Review Measures, which became effective on February 15, 2022. The Cybersecurity Review Measures provide that, in addition to CIIO that intend to purchase Internet products and services, net platform operators engaging

[Table of Contents](#)

in data processing activities that affect or may affect national security must be subject to cybersecurity review by the Cybersecurity Review Office of the PRC. According to the Cybersecurity Review Measures, a cybersecurity review assesses potential national security risks that may be brought about by any procurement, data processing, or overseas listing. The Cybersecurity Review Measures require that an online platform operator which possesses the personal information of at least one million users must apply for a cybersecurity review by the CAC if it intends to be listed in foreign countries.

On November 14, 2021, the CAC published the Security Administration Draft. The Security Administration Draft provides that data processors shall apply for a cybersecurity review under certain circumstances, such as mergers, restructurings, and divisions of Internet platform operators that hold large amount of data relating to national security, economic development, or public interest which affects or may affect the national security, overseas listings of data processors that process personal data for more than one million individuals, Hong Kong listings of data processors that affect or may affect national security, and other data processing activities that affect or may affect the national security. The deadline for public comments on the Security Administration Draft was December 13, 2021. As of the date of this prospectus, the Security Administration Draft has not been enacted.

As of the date of this prospectus, neither we nor the operating entity have received any notice from any authorities identifying our PRC subsidiaries as CIIOs or requiring us or the operating entity to go through cybersecurity review or network data security review by the CAC. As confirmed by our PRC counsel, Guantao, neither the operations of the operating entity, nor our listing are expected to be affected, and that we and the operating entity are not subject to cybersecurity review by the CAC under the Cybersecurity Review Measures, nor will any such entity be subject to the Security Administration Draft, if it is enacted as proposed, given that neither we nor the operating entity is a CIIO or online platform operator with personal information of more than one million users. There remains uncertainty, however, as to how the Cybersecurity Review Measures and the Security Administration Draft will be interpreted or implemented and whether the PRC regulatory agencies, including the CAC, may adopt new laws, regulations, rules, or detailed implementation and interpretation related to the Cybersecurity Review Measures and the Security Administration Draft. If any such new laws, regulations, rules, or implementation and interpretation come into effect, we expect to take all reasonable measures and actions to comply and to minimize the adverse effect of such laws on us. We cannot guarantee, however, that the operating entity will not be subject to cybersecurity review and network data security review in the future. During such reviews, the operating entity may be required to suspend its operations or experience other disruptions to its operations. Cybersecurity review and network data security review could also result in negative publicity with respect to our Company and diversion of our managerial and financial resources, which could materially and adversely affect our business, financial conditions, and results of operations.

The Opinions recently issued by the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council may subject us and the operating entity to additional compliance requirements in the future.

Recently, the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued the Opinions, which were made available to the public on July 6, 2021. The Opinions emphasized the need to strengthen the administration over illegal securities activities and the supervision on overseas listings by China-based companies. These opinions proposed to take effective measures, such as promoting the construction of relevant regulatory systems, to deal with the risks and incidents facing China-based overseas-listed companies and the demand for cybersecurity and data privacy protection. On February 17, 2023, the CSRC promulgated the Overseas Listing Trial Measures and relevant five guidelines, which became effective on March 31, 2023. According to the Overseas Listing Trial Measures, PRC domestic companies that seek to offer and list securities in overseas markets, either in direct or indirect means, are required to fulfill the filing procedure with the CSRC and report relevant information. Among other provisions, if a domestic enterprise intends to indirectly offer and list securities in an overseas market, the record-filing obligation is with a major operating entity incorporated in the PRC and such filing obligation shall be completed within three working days after the overseas listing application is submitted. We are required to complete the filing procedures with the CSRC in connection with the offering and listing. Moreover, we could be subject to the filing requirement for future share offerings, major changes in our company, and other scenarios as required under the Overseas Listing Trial Measures. See “Regulations — Regulations Relating to Overseas Listings.” The aforementioned policies and any related implementation rules to be enacted may subject us to additional compliance requirements in the future. As the Opinions and the Overseas Listing Trial Measures were

[Table of Contents](#)

recently issued, their official guidance and interpretation and remain unclear in several respects at this time. Therefore, we cannot assure you that we and the operating entity will remain fully compliant with all new regulatory requirements of the Opinions or the Overseas Listing Trial Measures or any future implementation rules on a timely basis, or at all.

Recent joint statement by the SEC and the PCAOB, rule changes by Nasdaq, and the Holding Foreign Companies Accountable Act all call for additional and more stringent criteria to be applied to emerging market companies upon assessing the qualification of their auditors, especially the non-U.S. auditors who are not inspected by the PCAOB. These developments could add uncertainties to our offerings.

On April 21, 2020, SEC Chairman Jay Clayton and PCAOB Chairman William D. Duhnke III, along with other senior SEC staff, released a joint statement highlighting the risks associated with investing in companies based in or have substantial operations in emerging markets including China. The joint statement emphasized the risks associated with lack of access for the PCAOB to inspect auditors and audit work papers in China and higher risks of fraud in emerging markets.

On May 18, 2020, Nasdaq filed three proposals with the SEC to (i) apply a minimum offering size requirement for companies primarily operating in a “Restrictive Market,” (ii) adopt a new requirement relating to the qualification of management or the board of directors for Restrictive Market companies, and (iii) apply additional and more stringent criteria to an applicant or listed company based on the qualifications of the company’s auditor. On October 4, 2021, the SEC approved Nasdaq’s revised proposal for the rule changes.

On May 20, 2020, the U.S. Senate passed the HFCA Act requiring a foreign company to certify it is not owned or controlled by a foreign government if the PCAOB is unable to audit specified reports because the company uses a foreign auditor not subject to PCAOB inspection. If the PCAOB is unable to inspect the company’s auditors for three consecutive years, the issuer’s securities are prohibited to trade on a national exchange. On December 2, 2020, the U.S. House of Representatives approved the HFCA Act. On December 18, 2020, the HFCA Act was signed into law.

On March 24, 2021, the SEC announced the adoption of interim final amendments to implement the submission and disclosure requirements of the HFCA Act. In the announcement, the SEC clarifies that before any issuer will have to comply with the interim final amendments, the SEC must implement a process for identifying covered issuers. The announcement also states that the SEC staff is actively assessing how best to implement the other requirements of the HFCA Act, including the identification process and the trading prohibition requirements.

On September 22, 2021, the PCAOB adopted a final rule implementing the HFCA Act, which provides a framework for the PCAOB to use when determining, as contemplated under the HFCA Act, whether the board of directors of a company is unable to inspect or investigate completely registered public accounting firms located in a foreign jurisdiction because of a position taken by one or more authorities in that jurisdiction.

On December 2, 2021, the SEC adopted amendments to finalize rules implementing the submission and disclosure requirements in the Holding Foreign Companies Accountable Act, which became effective on January 10, 2022. The rules apply to registrants that the SEC identifies as having filed an annual report with an audit report issued by a registered public accounting firm that is located in a foreign jurisdiction and that the PCAOB is unable to inspect or investigate completely because of a position taken by an authority in foreign jurisdictions. For example, on December 16, 2021, the PCAOB issued a report on its determinations that it is unable to inspect or investigate completely PCAOB-registered public accounting firms headquartered in mainland China and in Hong Kong, because of positions taken by PRC authorities in those jurisdictions.

On December 16, 2021, the PCAOB issued a report on its determinations that the Board is unable to inspect or investigate completely PCAOB-registered public accounting firms headquartered in mainland China and in Hong Kong, because of positions taken by PRC authorities in those jurisdictions. The Board made these determinations pursuant to PCAOB Rule 6100, which provides a framework for how the PCAOB fulfills its responsibilities under the HFCA Act.

Our auditor, WWC, the independent registered public accounting firm that issues the audit report included elsewhere in this prospectus, as an auditor of companies that are traded publicly in the United States and a firm registered with the PCAOB, is subject to laws in the United States pursuant to which the PCAOB conducts regular inspections to assess its compliance with the applicable professional standards. Our auditor, WWC, is headquartered in San Mateo, California, and has been inspected by the PCAOB on a regular basis, with the last inspection in 2021. The PCAOB currently has access to inspect the working papers of our auditor and our auditor is not subject to the determinations announced by

[Table of Contents](#)

the PCAOB on December 16, 2021. However, the recent developments would add uncertainties to our offering and we cannot assure you whether the national securities exchange we apply to for listing or regulatory authorities would apply additional and more stringent criteria to us after considering the effectiveness of our auditors' audit procedures and quality control procedures, adequacy of personnel and training, or sufficiency of resources, geographic reach, or experience as it relates to our audit. In addition, the HFCA Act, which requires that the PCAOB be permitted to inspect an issuer's public accounting firm within three years, may result in the delisting of our Company or prohibition of trading in our Ordinary Shares in the future if the PCAOB is unable to inspect our accounting firm at such future time.

On June 22, 2021, the U.S. Senate passed the AHFCAA, and on December 29, 2022, legislation entitled the Consolidated Appropriations Act was signed into law by President Biden, which contained, among other things, an identical provision to the Accelerating Holding Foreign Companies Accountable Act and amended the HFCA Act by requiring the SEC to prohibit an issuer's securities from trading on any U.S. stock exchanges if its auditor is not subject to PCAOB inspections for two consecutive years instead of three, thus reducing the time period for triggering the prohibition on trading.

On August 26, 2022, the CSRC, the MOF, and the PCAOB signed the Protocol governing inspections and investigations of accounting firms based in mainland China and Hong Kong, taking the first step toward opening access for the PCAOB to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong. Pursuant to the fact sheet with respect to the Protocol disclosed by the SEC, the PCAOB shall have independent discretion to select any issuer audits for inspection or investigation and has the unfettered ability to transfer information to the SEC. On December 15, 2022, the PCAOB Board determined that the PCAOB was able to secure complete access to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong and voted to vacate its previous determinations to the contrary. However, should PRC authorities obstruct or otherwise fail to facilitate the PCAOB's access in the future, the PCAOB Board will consider the need to issue a new determination.

To the extent cash or assets in the business are in the PRC/Hong Kong or a PRC/Hong Kong entity, the funds or assets may not be available to fund operations or for other use outside of the PRC/Hong Kong due to interventions in or the imposition of restrictions and limitations on the ability of our Company, our subsidiaries, or the operating entity by the PRC government to transfer cash or assets.

Relevant PRC laws and regulations permit the companies in the PRC to pay dividends only out of their retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. Additionally, each of the companies in the PRC are required to set aside at least 10% of its after-tax profits each year, if any, to fund a statutory reserve until such reserve reaches 50% of its registered capital. The companies in the PRC are also required to further set aside a portion of their after-tax profits to fund the employee welfare fund, although the amount to be set aside, if any, is determined at their discretion. These reserves are not distributable as cash dividends. Furthermore, in order for us to pay dividends to our shareholders, we will rely on receipt of funds from our Hong Kong subsidiary. Peg Biotechnology will rely on payments made from the operating entity to Hainan Senhan. If Jilin Zhengye incurs debt on its own behalf in the future, the instruments governing the debt may restrict their ability to pay dividends or make other distributions to us.

Our cash dividends, if any, will be paid in U.S. dollars. If we are considered a tax resident enterprise of the PRC for tax purposes, any dividends we pay to our overseas shareholders may be regarded as China-sourced income and as a result may be subject to PRC withholding tax. See “— Risks Relating to Doing Business in the PRC — Under the PRC Enterprise Income Tax Law, we may be classified as a PRC ‘resident enterprise’ for PRC enterprise income tax purposes. Such classification would likely result in unfavorable tax consequences to us and our non-PRC shareholders and have a material adverse effect on our results of operations and the value of your investment.”

The PRC government also imposes controls on the convertibility of RMB into foreign currencies and, in certain cases, the remittance of currency out of the PRC. The majority of our PRC subsidiaries' income is received in RMB and shortages in foreign currencies may restrict our ability to pay dividends or other payments, or otherwise satisfy our foreign currency denominated obligations, if any. Under existing PRC foreign exchange regulations, payments of current account items, including profit distributions, interest payments, and expenditures from trade-related transactions, can be made in foreign currencies without prior approval from the State Administration of Foreign Exchange (“SAFE”) as long as certain procedural requirements are met. Approval from appropriate government authorities is required if RMB is converted into foreign currency and remitted out of the PRC to pay capital expenses such as the repayment of

[Table of Contents](#)

loans denominated in foreign currencies. The PRC government may, at its discretion, impose restrictions on access to foreign currencies for current account transactions and if this occurs in the future, we may not be able to pay dividends in foreign currencies to our shareholders.

As of the date of this prospectus, there are no restrictions or limitations imposed by the Hong Kong government on the transfer of capital within, into, and out of Hong Kong (including funds from Hong Kong to mainland China), except for the transfer of funds involving money laundering and criminal activities. However, there is no guarantee that the Hong Kong government will not promulgate new laws or regulations that may impose such restrictions in the future. There is no assurance the PRC government will not intervene in or impose restrictions on our ability to transfer cash or assets.

As a result of the above, to the extent cash or assets in the business are in the PRC/Hong Kong or a PRC/Hong Kong entity, such funds or assets may not be available to fund operations or for other use outside of the PRC/Hong Kong, due to interventions in or the imposition of restrictions and limitations on the ability of our Company, our subsidiaries, or the operating entity by the competent government to the transfer of cash or assets.

Increases in labor costs in the PRC may adversely affect the operating entity's business and profitability.

China's economy has experienced increases in labor costs in recent years. China's overall economy and the average wage in China are expected to continue to grow. The average wage level for the operating entity's employees has also increased in recent years. We expect that their labor costs, including wages and employee benefits, will continue to increase. Unless the operating entity is able to pass on these increased labor costs to their customers by increasing prices for their products or services, their profitability and results of operations may be materially and adversely affected.

In addition, the operating entity has been subject to stricter regulatory requirements in terms of entering into labor contracts with their employees and paying various statutory employee benefits, including pensions, housing fund, medical insurance, work-related injury insurance, unemployment insurance, and maternity insurance to designated government agencies for the benefit of their employees. Pursuant to the *PRC Labor Contract Law*, or the "Labor Contract Law," that became effective in January 2008 and its amendments that became effective in July 2013 and its implementing rules that became effective in September 2008, employers are subject to stricter requirements in terms of signing labor contracts, minimum wages, paying remuneration, determining the term of employees' probation, and unilaterally terminating labor contracts. In the event that the operating entity decides to terminate some of their employees or otherwise change their employment or labor practices, the Labor Contract Law and its implementation rules may limit their ability to effect those changes in a desirable or cost-effective manner, which could adversely affect their business and results of operations.

As the interpretation and implementation of labor-related laws and regulations are still evolving, we cannot assure you that the operating entity's employment practices do not and will not violate labor-related laws and regulations in China, which may subject the operating entity to labor disputes or government investigations. If the operating entity is deemed to have violated relevant labor laws and regulations, they could be required to provide additional compensation to their employees and their business, and, in such case, our financial condition, and results of operations could be materially and adversely affected.

PRC regulations relating to offshore investment activities by PRC residents may subject our PRC resident beneficial owners or the PRC subsidiaries to liability or penalties, limit our ability to inject capital into the PRC subsidiaries, limit the PRC subsidiaries' ability to increase their registered capital or distribute profits to us, or may otherwise adversely affect us.

On July 4, 2014, SAFE issued the Circular on Issues Concerning Foreign Exchange Control over the Overseas Investment and Financing and Round-trip Investment by Domestic Residents via Special Purpose Vehicles, or "SAFE Circular 37." According to SAFE Circular 37, prior registration with the local SAFE branch is required for PRC residents, (including PRC individuals and PRC corporate entities as well as foreign individuals that are deemed as PRC residents for foreign exchange administration purpose), in connection with their direct or indirect contribution of domestic assets or interests to offshore special purpose vehicles, or "SPVs." SAFE Circular 37 further requires amendments to the SAFE registrations in the event of any changes with respect to the basic information of the offshore SPV, such as change of a PRC individual shareholder, name, and operation term, or any significant changes with respect to the offshore SPV, such as an increase or decrease of capital contribution, share transfer or exchange, or

[Table of Contents](#)

mergers or divisions. SAFE Circular 37 is applicable to our shareholders who are PRC residents and may be applicable to any offshore acquisitions that we make in the future. In February 2015, SAFE promulgated a Circular on Further Simplifying and Improving Foreign Exchange Administration Policy on Direct Investment, or “SAFE Circular 13,” effective in June 2015. Under SAFE Circular 13, applications for foreign exchange registration of inbound foreign direct investments and outbound overseas direct investments, including those required under SAFE Circular 37, will be filed with qualified banks instead of SAFE. The qualified banks will directly examine the applications and accept registrations under the supervision of SAFE.

In addition to SAFE Circular 37 and SAFE Circular 13, our ability to conduct foreign exchange activities in China may be subject to the interpretation and enforcement of the Implementation Rules of the Administrative Measures for Individual Foreign Exchange promulgated by SAFE in January 2007 (as amended and supplemented, the “Individual Foreign Exchange Rules”). Under the Individual Foreign Exchange Rules, any PRC individual seeking to make a direct investment overseas or engage in the issuance or trading of negotiable securities or derivatives overseas must make the appropriate registrations in accordance with SAFE provisions, the failure of which may subject such PRC individual to warnings, fines, or other liabilities.

The Company has used its best efforts to request PRC residents who the Company knows hold direct or indirect interest in the Company to make the necessary applications, filings, and registrations as required under SAFE Circular 37. As of the date of this prospectus, our current shareholder who is subject to SAFE Circular 37 or SAFE Circular 13 have completed the initial registrations with the local SAFE branch or qualified banks as required by SAFE Circular 37.

Furthermore, according to the Administrative Measures on Overseas Investments adopted by the Ministry of Commerce (the “MOFCOM”) and the Measures for the Administration of Overseas Investment of Enterprises (the “Enterprise Overseas Investment Measures”) adopted by the National Development and Reform Commission (the “NDRC”), a PRC enterprise that intends to make overseas investments is required to obtain approvals from provincial commerce authorities and NDRC’s local branches or to make filings with such authorities, depending on the type and the region of their investments. As confirmed by our PRC counsel, our PRC enterprise shareholders are required to file with such provincial commerce authorities and NDRC’s local branches. In addition, according to the SAFE Circular 13 adopted by SAFE, our PRC enterprise shareholders are obliged to register with qualified banks when they make overseas investments or financings. Generally, for an overseas direct investment, the filings with the qualified bank at the request of SAFE, the filings with the provincial commerce authorities, and the filing with the NDRC or its local branches are collectively referred to as the “ODI filings.” Pursuant to the aforementioned laws and regulations, if a PRC enterprise makes such overseas direct investments without obtaining all of the ODI filings, the relevant approval or filing authority has the authority to take corrective measures, such as ordering such enterprise to suspend or cease the implementation of the projects, issuing warnings, or imposing other penalties.

As of the date of this prospectus, the Company believes that its current shareholders who are subject to the Administrative Measures on Overseas Investments, Enterprise Overseas Investment Measures, and other related laws and regulations have completed the ODI filings as required by the aforementioned regulations.

Under relevant laws and regulations regarding the ODI filings, following the submission or approval of filings with the MOFCOM or provincial commerce authorities, the filing entity is required to file for modifications with the MOFCOM or the provincial commerce authorities that processed its original filing or approval, should there be any changes to the overseas direct investments provided in initial filing materials or the original certificates of overseas investments of enterprises. Likewise, for an overseas direct investment project that has been approved and filed with the NDRC, the investor shall file an application for modifications to the relevant authority in advance of certain circumstances, such as changes to the number of investors, project activities, or project scale.

Although it is our understanding that all of our current PRC enterprise shareholders who are subject to the Administrative Measures on Overseas Investments, Enterprise Overseas Investment Measures, and other related laws and regulations have completed the required the ODI filings, we have no control over whether any of our future beneficial owners would complete such ODI filings. Furthermore, we cannot guarantee that all of our enterprise shareholders will renew their ODI filings on a timely basis when required by law, and we cannot assure you that our shareholders’ applications for renewal will be approved. Thus, we cannot provide any assurance that our current or future PRC resident beneficial owners, including PRC residents and enterprises, will comply with our request to make or obtain any applicable registrations or filings, or continue to comply with all registration and filing procedures set forth in the ODI filings. Such failure or inability of our PRC resident beneficial owners to comply with the ODI filings may subject us or our PRC resident beneficial owners to fines and legal sanctions, restrict our cross-border investment activities, limit our

PRC subsidiaries' ability to distribute dividends to or obtain foreign-exchange- dominated loans from us, or prevent us from making distributions or pay dividends, which will materially and adversely affect our business operations and our ability to distribute profits to you.

PRC regulation of parent/subsidiary loans and direct investment by offshore holding companies to PRC entities may delay or prevent us from using the proceeds of offshore offerings to make loans or additional capital contributions to the PRC subsidiaries, which could materially and adversely affect their liquidity and their ability to fund and expand their business.

We are an offshore holding company conducting our operations in China through PRC subsidiaries, to which we can make loans and make additional capital contributions. Most of these loans or contributions are subject to PRC regulations and approvals or registration. For example, any loans to the PRC subsidiaries, which are treated as foreign-invested enterprises under PRC law, are subject to PRC regulations and foreign exchange loan registrations. Furthermore, loans made by us to the PRC subsidiaries to finance their activities cannot exceed statutory limits and must be registered with the local counterpart of SAFE, or filed with SAFE in its information system. Pursuant to relevant PRC regulations, we may provide loans to the operating entity up to the larger amount of (i) the balance between the registered total investment amount and registered capital of these entities, or (ii) twice the amount of the net assets of these entities calculated in accordance with the Circular on Full-Coverage Macro-Prudent Management of Cross-Border Financing, or the "PBOC Circular 9." Moreover, any medium or long-term loan to be provided by us to the PRC subsidiaries, or other domestic PRC entities must also be filed and registered with the National Development and Reform Commission (the "NDRC"). We may also decide to finance the PRC subsidiaries by means of capital contributions. These capital contributions are subject to registration with the State Administration for Market Regulation (the "SAMR") or its local branch, reporting of foreign investment information with the Ministry of Commerce of the PRC (the "MOFCOM"), or registration with other governmental authorities in China.

On March 30, 2015, SAFE issued the Notice of the State Administration of Foreign Exchange on Reforming the Administrative Approach Regarding the Settlement of the Foreign Exchange Capital of Foreign-invested Enterprises, or "SAFE Circular 19," which took effect and replaced previous regulations effective on June 1, 2015, and was amended on December 30, 2019. Pursuant to SAFE Circular 19, up to 100% of foreign currency capital of a foreign-invested enterprise may be converted into RMB capital according to the actual operation, and within the business scope, of the enterprise at its will. Although SAFE Circular 19 allows for the use of RMB converted from the foreign currency-denominated capital for equity investments in the PRC, the restrictions continue to apply as to foreign-invested enterprises' use of the converted RMB for purposes beyond their business scope, for entrusted loans or for inter-company RMB loans. On June 9, 2016, SAFE promulgated the Notice of the State Administration of Foreign Exchange on Reforming and Standardizing the Foreign Exchange Settlement Management Policy of Capital Account, or "SAFE Circular 16," effective on June 9, 2016, which reiterates some rules set forth in SAFE Circular 19, but changes the prohibition against using RMB capital converted from foreign currency-denominated registered capital of a foreign-invested company to issue RMB entrusted loans to a prohibition against using such capital to issue loans to non-affiliated enterprises. SAFE Circular 19 and SAFE Circular 16 may significantly limit our ability to transfer any foreign currency we hold, including the net proceeds from our offshore offerings, to the PRC subsidiaries, which may adversely affect our liquidity and our ability to fund and expand our business in China. On October 23, 2019, SAFE issued the Notice of the State Administration of Foreign Exchange on Further Facilitating Cross-border Trade and Investment, or "SAFE Circular 28," which, among other things, expanded the use of foreign exchange capital to domestic equity investment area. Non-investment foreign-funded enterprises are allowed to lawfully make domestic equity investments by using their capital on the premise without violation to prevailing Special Administrative Measures for Access of Foreign Investments (2021 Edition), or the Negative List (2021)," and the authenticity and compliance with the regulations of domestic investment projects. However, since SAFE Circular 28 is newly promulgated, it is unclear how SAFE and competent banks will carry it out in practice.

In light of the various requirements imposed by PRC regulations on loans to and direct investment in PRC entities by offshore holding companies, including SAFE Circular 19, SAFE Circular 16, and other relevant rules and regulations, we cannot assure you that we will be able to complete the necessary registrations or obtain the necessary government approvals on a timely basis, if at all, with respect to future loans or capital contributions to the PRC subsidiaries. As a result, uncertainties exist as to our ability to provide prompt financial support to the PRC subsidiaries when needed. If we fail to complete such registrations or obtain such approvals, our ability to use the proceeds we received or expect to

[Table of Contents](#)

receive from our offshore offerings and to capitalize or otherwise fund our PRC operations may be negatively affected, which could materially and adversely affect the PRC subsidiaries' business, including their liquidity and their ability to fund and expand their business.

Fluctuations in exchange rates could have a material and adverse effect on our results of operations and the value of your investment.

The value of the RMB against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in political and economic conditions in China and by China's foreign exchange policies. On July 21, 2005, the PRC government changed its decade-old policy of pegging the value of the RMB to the U.S. dollar, and the RMB appreciated more than 20% against the U.S. dollar over the following three years. Between July 2008 and June 2010, this appreciation halted and the exchange rate between the RMB and the U.S. dollar remained within a narrow band. Since June 2010, the RMB has fluctuated against the U.S. dollar, at times significantly and unpredictably. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future.

Our business is conducted in the PRC through the operating entity, and its books and records are maintained in RMB. The financial statements that we file with the SEC and provide to our shareholders are presented in U.S. dollars. Changes in the exchange rates between the RMB and U.S. dollar affect the value of the PRC subsidiaries' assets and results of operations, when presented in U.S. dollars. The value of the RMB against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in the PRC's political and economic conditions and perceived changes in the economy of the PRC and the United States. Any significant revaluation of the RMB may materially and adversely affect our cash flows, revenue, and financial condition. Further, our Ordinary Shares offered in the U.S. are offered in U.S. dollars, we need to convert the net proceeds we receive into RMB in order to use the funds for the PRC subsidiaries' business. Changes in the conversion rate among the U.S. dollar and the RMB will affect the amount of proceeds we will have available for the PRC subsidiaries' business.

Very limited hedging options are available in China to reduce our exposure to exchange rate fluctuations. To date, we have not entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. While we may decide to enter into hedging transactions in the future, the availability and effectiveness of these hedges may be limited and we may not be able to adequately hedge our exposure or at all. In addition, our currency exchange losses may be magnified by PRC exchange control regulations that restrict our ability to convert RMB into foreign currency. As a result, fluctuations in exchange rates may have a material adverse effect on your investment.

Under the PRC Enterprise Income Tax Law, we may be classified as a PRC "resident enterprise" for PRC enterprise income tax purposes. Such classification would likely result in unfavorable tax consequences to us and our non-PRC shareholders and have a material adverse effect on our results of operations and the value of your investment.

Under the PRC Enterprise Income Tax Law (the "EIT Law"), which became effective in January 2008, an enterprise established outside the PRC with "de facto management bodies" within the PRC is considered a "resident enterprise" for PRC enterprise income tax purposes and is generally subject to a uniform 25% enterprise income tax rate on its worldwide income. Under the implementation rules to the EIT Law, a "de facto management body" is defined as a body that has material and overall management and control over the manufacturing and business operations, personnel and human resources, finances, and properties of an enterprise. In April 2009, the State Administration of Taxation (the "SAT") issued the Circular on Issues Concerning the Identification of Chinese-Controlled Overseas Registered Enterprises as Resident Enterprises in Accordance with the Actual Standards of Organizational Management, or "SAT Circular 82," which was amended in December 2017. SAT Circular 82 specifies that certain offshore incorporated enterprises controlled by PRC enterprises or PRC enterprise groups will be classified as PRC resident enterprises if the following are located or resident in the PRC: senior management personnel and departments that are responsible for daily production, operation and management; financial and personnel decision-making bodies; key properties, accounting books, company seal, and minutes of board meetings and shareholders' meetings; and half or more of the senior management or directors having voting rights. In addition to SAT Circular 82, the SAT issued the Measures for the Administration of Enterprise Income Tax of Chinese-Controlled Overseas Registered Enterprises as Resident Enterprises (for Trial Implementation), or "SAT Bulletin 45," which took effect in September 2011 and was amended in April 2015, to provide more guidance on the implementation of SAT Circular 82 and clarify the reporting and filing obligations of such "Chinese-controlled offshore incorporated resident enterprises." SAT Bulletin 45 provides procedures and administrative details for the determination of resident status and administration on post-determination

matters. Although both SAT Circular 82 and SAT Bulletin 45 only apply to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those controlled by PRC individuals or foreign individuals, the determining criteria set forth in SAT Circular 82 and SAT Bulletin 45 may reflect the SAT's general position on how the "de facto management body" test should be applied in determining the tax resident status of offshore enterprises, regardless of whether they are controlled by PRC enterprises, PRC enterprise groups, or by PRC or foreign individuals.

If the PRC tax authorities determine that the actual management organ of Zhengye Cayman is within the territory of China, Zhengye Cayman may be deemed to be a PRC resident enterprise for PRC enterprise income tax purposes and a number of unfavorable PRC tax consequences could follow. First, we will be subject to the uniform 25% enterprise income tax on our world-wide income, which could materially reduce our net income. In addition, we will also be subject to PRC enterprise income tax reporting obligations. Finally, dividends payable by us to our investors and gains on the sale of our shares may become subject to PRC withholding tax, at a rate of 10% in the case of non-PRC enterprises or 20% in the case of non-PRC individuals (in each case, subject to the provisions of any applicable tax treaty), if such gains are deemed to be from PRC sources. It is unclear whether non-PRC shareholders of our Company would be able to claim the benefits of any tax treaties between their country of tax residence and the PRC in the event that we are treated as a PRC resident enterprise. Any such tax may reduce the returns on your investment in our shares. Although up to the date of this prospectus, Zhengye Cayman has not been notified or informed by the PRC tax authorities that it has been deemed to be a resident enterprise for the purpose of the EIT Law, we cannot assure you that it will not be deemed to be a resident enterprise in the future.

We face uncertainty with respect to indirect transfers of equity interests in PRC resident enterprises by their non-PRC holding companies.

In February 2015, SAT issued a Public Notice Regarding Certain Corporate Income Tax Matters on Indirect Transfer of Properties by Non-Tax Resident Enterprises, or "SAT Circular 7." SAT Circular 7 provides comprehensive guidelines relating to indirect transfers of PRC taxable assets (including equity interests and real properties of a PRC resident enterprise) by a non-resident enterprise. In addition, in October 2017, SAT issued an Announcement on Issues Relating to Withholding at Source of Income Tax of Non-resident Enterprises, or "SAT Circular 37," effective in December 2017, which, among others, amended certain provisions in SAT Circular 7 and further clarify the tax payable declaration obligation by non-resident enterprise. Indirect transfer of equity interest and/or real properties in a PRC resident enterprise by their non-PRC holding companies are subject to SAT Circular 7 and SAT Circular 37.

SAT Circular 7 provides clear criteria for an assessment of reasonable commercial purposes and has introduced safe harbors for internal group restructurings and the purchase and sale of equity through a public securities market. As stipulated in SAT Circular 7, indirect transfers of PRC taxable assets are considered as reasonable commercial purposes if the shareholding structure of both transaction parties falls within the following situations: (i) the transferor directly or indirectly owns 80% or above equity interest of the transferee, or vice versa; (ii) the transferor and the transferee are both 80% or above directly or indirectly owned by the same party; and (iii) the percentages in bullet points (i) and (ii) shall be 100% if over 50% the share value of a foreign enterprise is directly or indirectly derived from PRC real properties. Furthermore, SAT Circular 7 also brings challenges to both foreign transferor and transferee (or other person who is obligated to pay for the transfer) of taxable assets. Where a non-resident enterprise transfers PRC taxable assets indirectly by disposing of the equity interests of an overseas holding company, which is an indirect transfer, the non-resident enterprise as either transferor or transferee, or the PRC entity that directly owns the taxable assets, may report such indirect transfer to the relevant tax authority and the PRC tax authority may disregard the existence of the overseas holding company if it lacks a reasonable commercial purpose and was established for the purpose of reducing, avoiding, or deferring PRC tax. As a result, gains derived from such indirect transfer may be subject to PRC enterprise income tax, and the transferee or other person who is obligated to pay for the transfer is obligated to withhold the applicable taxes, currently at a rate of 10% for the transfer of equity interests in a PRC resident enterprise. Both the transferor and the transferee may be subject to penalties under PRC tax laws if the transferee fails to withhold the taxes and the transferor fails to pay the taxes.

According to SAT Circular 37, where the non-resident enterprise fails to declare the tax payable pursuant to Article 39 of the EIT Law, the tax authority may order it to pay the tax due within required time limits, and the non-resident enterprise shall declare and pay the tax payable within such time limits specified by the tax authority. If the non-resident enterprise, however, voluntarily declares and pays the tax payable before the tax authority orders it to do so within required time limits, it shall be deemed that such enterprise has paid the tax in time.

[Table of Contents](#)

We face uncertainties as to the reporting and assessment of reasonable commercial purposes and future transactions where PRC taxable assets are involved, such as offshore restructuring, sale of the shares in our offshore subsidiaries, and investments. In the event of being assessed as having no reasonable commercial purposes in an indirect transfer transaction, we may be subject to filing obligations or taxed if we are a transferor in such transactions, and may be subject to withholding obligations (to be specific, a 10% withholding tax for the transfer of equity interests) if we are a transferee in such transactions, under SAT Circular 7 and SAT Circular 37. For transfer of shares by investors who are non-PRC resident enterprises, the PRC subsidiaries may be requested to assist in the filing under the SAT circulars. As a result, we may be required to expend valuable resources to comply with the SAT circulars or to request the relevant transferors from whom we purchase taxable assets to comply with these circulars, or to establish that we should not be taxed under these circulars, which may have a material adverse effect on our financial condition and results of operations.

The PRC subsidiaries are subject to restrictions on paying dividends or making other payments to us, which may have a material adverse effect on our ability to conduct our business.

We are a holding company incorporated in the Cayman Islands. We may need dividends and other distributions on equity from the PRC subsidiaries to satisfy our liquidity requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders and service any debt we may incur. If the PRC subsidiaries incur debt on their own behalf in the future, the instruments governing the debt may restrict their ability to pay dividends or make other distributions to us.

Current PRC regulations permit the PRC subsidiaries to pay dividends to us only out of their accumulated profits, if any, determined in accordance with PRC accounting standards and regulations. In addition, the PRC subsidiaries are required to set aside at least 10% of their respective accumulated profits each year, if any, to fund certain reserve funds until the total amount set aside reaches 50% of their respective registered capital. The PRC subsidiaries may also allocate a portion of their respective after-tax profits based on PRC accounting standards to employee welfare and bonus funds at their discretion. These reserves are not distributable as cash dividends. These limitations on the ability of the PRC subsidiaries to pay dividends or make other distributions to us could materially and adversely limit our ability to grow, make investments, or acquisitions that could be beneficial to our business, pay dividends, or otherwise fund and conduct our business.

Governmental control of currency conversion may affect the value of your investment and our payment of dividends.

The PRC government imposes controls on the convertibility of the RMB into foreign currencies and, in certain cases, the remittance of currency out of China. We receive substantially most of our revenue in RMB. Under our current corporate structure, Zhengye Cayman may rely on dividend payments from our PRC subsidiaries to fund any cash and financing requirements we may have. Under existing PRC foreign exchange regulations, payments of current account items, such as profit distributions and trade and service-related foreign exchange transactions, can be made in foreign currencies without prior approval from SAFE by complying with certain procedural requirements. Therefore, the PRC subsidiaries are able to pay dividends in foreign currencies to us without prior approval from SAFE, subject to the condition that the remittance of such dividends outside of the PRC complies with certain procedures under PRC foreign exchange regulation, such as the overseas investment registrations by our shareholders or the ultimate shareholders of our corporate shareholders who are PRC residents. Approval from or registration with appropriate government authorities is, however, required where the RMB is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. The PRC government may also at its discretion restrict access in the future to foreign currencies for current account transactions. If the foreign exchange control system prevents us from obtaining sufficient foreign currencies to satisfy our foreign currency demand, we may not be able to pay dividends in foreign currencies to our shareholders.

There are significant uncertainties under the EIT Law relating to the withholding tax liabilities of the PRC subsidiaries, and dividends payable by our PRC subsidiaries to our offshore subsidiaries may not qualify to enjoy certain treaty benefits.

Under the EIT Law and its implementation rules, the profits of a foreign-invested enterprise generated through operations, which are distributed to its immediate holding company outside the PRC, will be subject to a withholding tax rate of 10%. Pursuant to the Double Tax Avoidance Arrangement, a withholding tax rate of 10% may be lowered to

[Table of Contents](#)

5% if the enterprise in mainland China is at least 25% held by a Hong Kong enterprise for at least 12 consecutive months prior to distribution of the dividends and is determined by the relevant PRC tax authority to have satisfied other conditions and requirements under the Double Tax Avoidance Arrangement and other applicable PRC laws.

However, based on the Circular on Certain Issues with Respect to the Enforcement of Dividend Provisions in Tax Treaties, or the “SAT Circular 81,” which became effective on February 20, 2009, if the relevant PRC tax authorities determine, in their discretion, that a company benefits from such reduced income tax rate due to a structure or arrangement that is primarily tax-driven, such PRC tax authorities may adjust the preferential tax treatment. According to Circular on Several Issues regarding the “Beneficial Owner” in Tax Treaties, which became effective as of April 1, 2018, when determining an applicant’s status as the “beneficial owner” regarding tax treatments in connection with dividends, interests, or royalties in the tax treaties, several factors will be taken into account. Such factors include whether the business operated by the applicant constitutes actual business activities, and whether the counterparty country or region to the tax treaties does not levy any tax, grant tax exemption on relevant incomes, or levy tax at an extremely low rate. This circular further requires any applicant who intends to be proved of being the “beneficial owner” to file relevant documents with the relevant tax authorities. Hainan Senhan is wholly owned by Peg Biotechnology. However, we cannot assure you that our determination regarding our qualification to enjoy the preferential tax treatment will not be challenged by the relevant PRC tax authority or we will be able to complete the necessary filings with the relevant PRC tax authority and enjoy the preferential withholding tax rate of 5% under the Double Tax Avoidance Arrangement with respect to dividends to be paid by Hainan Senhan to our Hong Kong subsidiary, Peg Biotechnology, in which case, we would be subject to the higher withdrawing tax rate of 10% on dividends received.

If we become directly subject to the scrutiny, criticism, and negative publicity involving U.S.-listed Chinese companies, we may have to expend significant resources to investigate and resolve the matter which could harm our business operations, stock price, and reputation.

U.S. public companies that have substantially most of their operations in China have been the subject of intense scrutiny, criticism, and negative publicity by investors, financial commentators, and regulatory agencies, such as the SEC. Much of the scrutiny, criticism, and negative publicity has centered on financial and accounting irregularities and mistakes, a lack of effective internal controls over financial accounting, inadequate corporate governance policies or a lack of adherence thereto and, in many cases, allegations of fraud. As a result of the scrutiny, criticism, and negative publicity, the publicly traded stock of many U.S. listed Chinese companies sharply decreased in value and, in some cases, have become virtually worthless. Many of these companies are now subject to shareholder lawsuits and SEC enforcement actions and are conducting internal and external investigations into the allegations. It is not clear what effect this sector-wide scrutiny, criticism, and negative publicity will have on us, our business, and the price of our Ordinary Shares. If we become the subject of any unfavorable allegations, whether such allegations are proven to be true or untrue, we will have to expend significant resources to investigate such allegations and/or defend our Company. This situation will be costly and time-consuming and could distract our management from developing our business. If such allegations are not proven to be groundless, we and our business operations will be severely affected and you could sustain a significant decline in the value of our Ordinary Shares.

The disclosures in our reports and other filings with the SEC and our other public pronouncements are not subject to the scrutiny of any regulatory bodies in the PRC.

We are regulated by the SEC, and our reports and other filings with the SEC are subject to SEC review in accordance with the rules and regulations promulgated by the SEC under the Securities Act and the Exchange Act. Our SEC reports and other disclosure and public pronouncements are not subject to the review or scrutiny of any PRC regulatory authority. For example, the disclosure in our SEC reports and other filings are not subject to the review by the CSRC, a PRC regulator that is responsible for oversight of the capital markets in China. Accordingly, you should review our SEC reports, filings, and our other public pronouncements with the understanding that no local regulator has done any review of us, our SEC reports, other filings, or any of our other public pronouncements.

The approval of the CSRC may be required in connection with this offering under the PRC law.

The Regulations on Mergers and Acquisitions of Domestic Companies by Foreign Investors, or the “M&A Rules,” adopted by six PRC regulatory agencies in 2006 and amended in 2009, requires an overseas SPV formed for listing purposes through acquisitions of PRC domestic companies and controlled by PRC companies or individuals to obtain

[Table of Contents](#)

the approval of the CSRC, prior to the listing and trading of such SPV's securities on an overseas stock exchange. In September 2006, the CSRC published a notice on its official website specifying documents and materials required to be submitted to it by an SPV seeking the CSRC approval of its overseas listings. The application of the M&A Rules remains unclear.

Our PRC legal counsel, Guantao, has advised us, based on their understanding of the current PRC law, rules, and regulations, that the CSRC's approval is not required for the listing and trading of our Ordinary Shares on the Nasdaq Global Market in the context of this offering, given that (i) the CSRC currently has not issued any definitive rule or interpretation concerning whether offerings under this prospectus are subject to the M&A Rule; and (ii) we established the PRC subsidiaries by means of direct investment rather than by merger with or acquisition of PRC domestic companies as defined in the M&A Rules.

Our PRC legal counsel, however, has further advised us that there remains some uncertainty as to how the M&A Rules will be interpreted or implemented in the context of an overseas offering and its opinions summarized above are subject to any new laws, rules and regulations or detailed implementations and interpretations in any form relating to the M&A Rules. We cannot assure you that relevant PRC governmental agencies, including the CSRC, would reach the same conclusion as we have. If it is determined that the CSRC approval is required for our offerings in the U.S., we may face sanctions by the CSRC or other PRC regulatory agencies for failure to seek the CSRC approval for our offerings in the U.S. These sanctions may include fines and penalties on our operations in the PRC, limitations on our operating privileges in the PRC, delays in or restrictions on the repatriation of the proceeds from our offerings in the U.S. into the PRC, restrictions on or prohibition of the payments or remittance of dividends by the PRC subsidiaries, or other actions that could have a material and adverse effect on our business, financial condition, results of operations, reputation, and prospects, as well as the trading price of our Ordinary Shares. The CSRC or other PRC regulatory agencies may also take actions requiring us, or making it advisable for us, to halt our offerings in the U.S. before the settlement and delivery of the Ordinary Shares that we are offering.

Recently, the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued the Opinions on Severe and Lawful Crackdown on Illegal Securities Activities, which was available to the public on July 6, 2021. These opinions emphasized the need to strengthen the administration over illegal securities activities and the supervision on overseas listings by China-based companies. These opinions proposed to take effective measures, such as promoting the construction of relevant regulatory systems, to deal with the risks and incidents facing China-based overseas-listed companies and the demand for cybersecurity and data privacy protection. The aforementioned policies and any related implementation rules to be enacted may subject us to additional compliance requirement in the future. As of the date of this prospectus, we have not received any or been denied of any permission from the PRC authorities to list on U.S. stock exchanges. As these opinions were recently issued, official guidance and interpretation of the opinions remain unclear in several respects at this time. Therefore, we cannot assure you that we will remain fully compliant with all new regulatory requirements of these opinions or any future implementation rules on a timely basis, or at all. We face uncertainty about future actions by the PRC government that could significantly affect the operating entity's financial performance.

Furthermore, on February 17, 2023, the CSRC promulgated the Overseas Listing Trial Measures and relevant five guidelines, which became effective on March 31, 2023. According to the Overseas Listing Trial Measures, PRC domestic companies that seek to offer and list securities in overseas markets, either in direct or indirect means, are required to fulfill the filing procedure with the CSRC and report relevant information. Based on the foregoing, our PRC counsel is of the view that we are required to complete the filing procedures with the CSRC in connection with the offering and listing. There is no assurance that we can complete such filing in a timely manner or even at all. Any failure by us to comply with such filing requirements may result in orders to rectify, warnings and fines against us and could materially hinder our ability to offer or continue to offer our securities. We have filed with the CSRC the filing documents and shall complete the filing before the completion of our overseas offering and listing. Given the current PRC regulatory environment, it is uncertain whether we will be required to obtain approvals from the PRC government to offer securities to foreign investors in the future, and whether we would be able to obtain such approvals. Any failure on our part to fully comply with new regulatory requirements may significantly limit or completely hinder our ability to offer or continue to offer our Ordinary Shares, cause significant disruption to our business operations, and severely damage our reputation, which would materially and adversely affect our financial condition and results of operations and cause our Ordinary Shares to significantly decline in value or become worthless. On December 27, 2021, the MOFCOM and the NDRC promulgated the Special Administrative Measures for Access of Foreign Investment (2021 Edition), or the Negative List (2021). The Negative List (2021) stipulates that if a domestic enterprise engaged in

business in the prohibited investment field issues shares abroad and is listed for trading, it shall be examined and approved by the relevant competent authorities of the state. According to a press release issued by the NDRC in relation to the Negative List (2021), the above provisions are only applicable to the direct overseas listing of domestic enterprises engaged in the prohibited investment field. Besides, we focus our business on the research, development, manufacturing and sales of veterinary vaccines, which is not listed as a prohibited or restricted field under the Negative List (2021). However, if the CSRC or other regulatory agencies later promulgate new rules or explanations requiring that we should obtain such approvals for this offering and any follow-on offering, we may be unable to obtain such approvals which could significantly limit or completely hinder our ability to offer or continue to offer securities to our investors. The CSRC or other PRC regulatory agencies may also take actions requiring us, or making it advisable for us, to halt this offering before the settlement and delivery of the Ordinary Shares that we are offering. Consequently, if you engage in market trading or other activities in anticipation of and prior to the settlement and delivery of the Ordinary Shares we are offering, you would be doing so at the risk that the settlement and delivery may not occur. Any uncertainties or negative publicity regarding such approval requirements could have a material adverse effect on our ability to complete this offering or any follow-on offering of our securities or the market for and market price of our Ordinary Shares.

The M&A Rules and certain other PRC regulations establish complex procedures for certain acquisitions of Chinese companies by foreign investors, which could make it more difficult for us to pursue growth through acquisitions in China.

The M&A Rules and recently adopted PRC regulations and rules concerning mergers and acquisitions established additional procedures and requirements that could make merger and acquisition activities by foreign investors more time consuming and complex. For example, the M&A Rules require that MOFCOM be notified in advance of any change-of-control transaction in which a foreign investor takes control of a PRC domestic enterprise, if (i) any important industry is concerned, (ii) such transaction involves factors that have or may have impact on the national economic security, or (iii) such transaction will lead to a change in control of a domestic enterprise which holds a famous trademark or PRC time-honored brand. Mergers or acquisitions that allow one market player to take control of or to exert decisive impact on another market player must also be notified in advance to MOFCOM when the threshold under the Provisions on Thresholds for Prior Notification of Concentrations of Undertakings, or the “Prior Notification Rules,” issued by the State Council in August 2008 is triggered. In addition, the Provisions of the Ministry of Commerce on the Implementation of the Security Review System for Mergers and Acquisitions of Domestic Enterprises by Foreign Investors (the “Security Review Rules”) issued by MOFCOM that became effective in September 2011 specify that mergers and acquisitions by foreign investors that raise “national defense and security” concerns and mergers and acquisitions through which foreign investors may acquire de facto control over domestic enterprises that raise “national security” concerns are subject to strict review by MOFCOM, and the Security Review Rules prohibit any activities attempting to bypass a security review, including by structuring the transaction through a proxy or contractual control arrangement. In the future, we may grow our business by acquiring complementary businesses. Complying with the requirements of the above-mentioned regulations and other relevant rules to complete such transactions could be time consuming, and any required approval processes, including obtaining approval from MOFCOM or its local counterparts may delay or inhibit our ability to complete such transactions. It is clear that the operating entity’s business would not be deemed to be in an industry that raises “national defense and security” or “national security” concerns. MOFCOM or other government agencies, however, may publish explanations in the future determining that the PRC subsidiaries’ business is in an industry subject to the security review, in which case our future acquisitions in the PRC, including those by way of entering into contractual control arrangements with target entities, may be closely scrutinized or prohibited. The PRC subsidiaries’ ability to expand their business or maintain or expand their market share through future acquisitions would as such be materially and adversely affected.

Chinese regulatory authorities could disallow our holding company structure, which may result in a material change in the operating entity’s operations and/or a material change in the value of the securities we are registering for sale, including that it could cause the value of such securities to significantly decline or become worthless.

We indirectly hold the equity of the operating entity through Hainan Senhan, and thus the operating entity is directly or indirectly foreign-invested enterprises. Although the PRC government has increasingly open attitude towards absorbing foreign investment in general, it still implements the Negative List (2021), which restricts or prohibits overseas enterprises from holding the equity of Chinese companies whose operations are included in the Negative List (2021). As the boundaries stipulated in the Negative List (2021) are relatively vague, they are subject to further

[Table of Contents](#)

determination and clarification by the Chinese government. As of the date of this prospectus, the business operated by the operating entity has not been included in the Negative List (2021), but we cannot fully guarantee that the Chinese government will not make a different interpretation, so as to disallow our holding corporate structure. Moreover, the Chinese government revises the list from time to time; although the scope of the Negative List (2021) is narrowing as a whole, it remains uncertain whether our existing business or future business will be included in future revisions. If the business of the operating entity is deemed as a restricted or prohibited business based on the Negative List (2021), our existing corporate structure may be considered illegal and required to be restructured by the Chinese government, which may adversely affect the operating entity's operations and the value of the securities we are registering for sale.

If any PRC residents intend to directly or indirectly invest in us, they are required to perform foreign exchange registration and ODI filings in accordance with the requirements of the Chinese government, see “— PRC regulations relating to offshore investment activities by PRC residents may subject our PRC resident beneficial owners or the PRC subsidiaries to liability or penalties, limit our ability to inject capital into the PRC subsidiaries, limit the PRC subsidiaries' ability to increase their registered capital or distribute profits to us, or may otherwise adversely affect us.” If any of our PRC resident shareholders did not take relevant actions in accordance with the requirements of the Chinese government, our company structure may be disallowed by the Chinese governments. As of this prospectus, it is our understanding that all of our current PRC resident shareholders have completed the required foreign exchange registration and ODI filings.

If any of our shareholders who is a PRC resident or enterprise fails to fulfill the required foreign exchange registration or ODI filings, it will be deemed illegal for such shareholder to directly or indirectly hold our equity under the PRC laws. Furthermore, if PRC authorities disallow such shareholder to own our equity, the operating entity may be prohibited from distributing dividends to us or from carrying out other subsequent cross-border foreign exchange activities, and we may be restricted in our ability to contribute additional capital to the operating entity, which may adversely affect the operating entity's operations and our values of the securities we are registering for sale.

Furthermore, if future laws, administrative regulations, or provisions mandate further actions to be taken by us or the operating entity with respect to our existing corporate structure, we may face substantial uncertainties as to whether we can complete such actions in a timely manner, or at all. Failure to take timely and appropriate measures to cope with any of these or similar regulatory compliance challenges could materially and adversely affect our current corporate structure, resulting in a material change in the operating entity's operations and/or a material change in the value of our Ordinary Shares, including that it could cause the value of our Ordinary Shares to significantly decline or become worthless.

Risks Relating to Our Business and Industry

The operating entity operates in a highly-competitive market and its failure to compete effectively could adversely affect its results of operations.

The veterinary vaccine industry in China is highly-competitive and rapidly evolving, with many new companies joining the competition in recent years and few leading companies. The operating entity competes or plans to compete with manufacturers of veterinary vaccines. See “Business — Competition.” Some of its competitors and potential competitors have greater product development capabilities and financial, scientific, marketing, and human resources than we do. Technological competition from biopharmaceutical companies and biotechnology companies is intense and is expected to increase. Other companies have developed technologies that could be the basis for competitive products. Some of these products have an entirely different approach or means of accomplishing the desired curative effect than products we are developing. Alternative products may be developed that are more effective, work faster, and are less costly than our products. Competitors may succeed in developing products earlier than us, obtaining approvals and clearances for such products more rapidly than the operating entity, or developing products that are more effective than its. In addition, other forms of treatment may be competitive with its products. Over time, its technology or products may become obsolete or uncompetitive.

Perceived adverse effects on human health linked to the consumption of food derived from animals that utilize the operating entity's products could cause a decline in the sales of such products.

The operating entity's livestock business depends heavily on a healthy and growing livestock industry. If the public perceives a risk to human health from the consumption of the food-producing animals that utilize the operating entity's products, there may be a decline in the production of such food products and, in return, demand for the operating entity's products. For example, livestock producers may experience decreased demand for their products or reputational harm as a result of evolving consumer views of animal rights, nutrition and health-related or other concerns. Any reputational harm to the livestock industry may also extend to companies in related industries, including the operating entity and thus, our company. Adverse consumer views related to the use of one or more of the operating entity's products in livestock also may result in a decrease in the use of such products and could have a material adverse effect on both the operating entity's and our operating results and financial condition.

Increased regulation relating to the raising, processing or consumption of food-producing animals could reduce demand for the operating entity's livestock products.

Companies in the livestock industries are subject to extensive and increasingly stringent regulations. If livestock producers are adversely affected by new regulations or changes to existing regulations, they may reduce herd sizes or become less profitable and, as a result, they may reduce their use of the operating entity's products, which may materially adversely affect both the operating entity's and our operating results and financial condition. Furthermore, adverse regulations related, directly or indirectly, to the use of one or more of the operating entity's products may injure livestock producers' market position. More stringent regulation of the livestock industry or the operating entity's products could have a material adverse effect on both the operating entity's and our operating results and financial condition.

The operating entity's business is subject to risk based on customer exposure to rising costs and reduced customer income.

Feed, fuel and transportation and other key costs for livestock producers may increase or animal protein prices or sales may decrease. Either of these trends could cause deterioration in the financial condition of the operating entity's livestock product customers, potentially inhibiting their ability to purchase the operating entity's products or pay it for products delivered. The operating entity's livestock product customers may offset rising costs by reducing spending on the operating entity's products, including by switching to lower-cost alternatives to the operating entity's products, which could have a material adverse effect on both the operating entity's and our operating results and financial condition.

The operating entity may not successfully acquire and integrate other businesses, license rights to technologies or products, form and manage alliances or divest businesses.

The operating entity may pursue acquisitions, technology licensing arrangements, strategic alliances or divestitures of some of its businesses as part of the business strategy. The operating entity may not complete these transactions in a timely manner, on a cost-effective basis or at all. In addition, it may be subject to regulatory constraints or limitations or other unforeseen factors that prevent it from realizing the expected benefits. Even if it is successful in making an acquisition, the products and technologies that are acquired may not be successful or may require significantly greater resources and investments than originally anticipated. It may be unable to integrate acquisitions successfully into its existing business, and it may be unable to achieve expected gross margin improvements or efficiencies. It also could incur or assume significant debt and unknown or contingent liabilities. Its reported results of operations could be negatively affected by acquisition or disposition-related charges, amortization of expenses related to intangibles and charges for impairment of long-term assets. It may be subject to litigation in connection with, or as a result of, acquisitions, dispositions, licenses or other alliances, including claims from terminated employees, customers or third parties, and it may be liable for future or existing litigation and claims related to the acquired business, disposition, license or other alliance because either it is not indemnified for such claims or the indemnification is insufficient. These effects could cause it to incur significant expenses and could materially adversely affect both its and our operating results and financial condition.

The operating entity's research and development, acquisition and licensing efforts may fail to generate new products and brand life-cycle developments.

Our future success depends on both the existing product portfolio and the pipeline of new products, including new products that the operating entity may develop and products that it is able to obtain through license or acquisition. The operating entity commits substantial effort, funds and other resources to research and development, both through its own dedicated resources and through collaborations with third parties.

The operating entity may be unable to determine with accuracy when or whether any of its products now under development will be approved or launched, or it may be unable to develop, license or otherwise acquire product candidates or products. In addition, it cannot predict whether any products, once launched, will be commercially successful or will achieve sales and revenue that are consistent with its expectations. Furthermore, the timing and cost of its research and development may increase, making the research and development less predictable. For example, changes in regulations applicable to animal health industry may make it more time-consuming and/or costly to research, test and develop products.

The operating entity expects to enter into collaboration or licensing arrangements with third parties to provide it with access to certain technology for purposes of its business. Such agreements are typically complex and require time to negotiate and implement. If it enters into these arrangements, it may not be able to maintain these relationships or establish new ones in the future on acceptable terms or at all. In addition, any collaboration that it enters into may not be successful, and the success may depend on the efforts and actions of its collaborators, which it may not be able to control. If it is unable to access to certain technology to conduct research and development on cost-effective terms, its ability to develop new products could be limited. As a result, both the operating entity's and our operating results and financial condition could be materially and adversely affected.

Advances in veterinary medical practices and animal health technologies could negatively affect the market for the operating entity's products.

The market for the operating entity's products could be impacted negatively by the introduction and/or broad market acceptance of newly-developed or alternative products that address the diseases and conditions for which it sells products, including "green" or "holistic" health products or specially bred disease-resistant animals. In addition, technological breakthroughs by others may obviate the operating entity's technology and reduce or eliminate the market for the operating entity's products. Introduction or acceptance of such products or technologies could materially adversely affect both the operating entity's and our operating results and financial condition.

The operating entity's research and development relies on evaluations in animals.

As a veterinary vaccines business, the evaluation of the operating entity existing and new products in animals is required to register its products. Animal testing in certain industries has been the subject of controversy and adverse publicity. Some organizations and individuals have attempted to ban animal testing or encourage the adoption of additional regulations applicable to animal testing. To the extent that the activities of such organizations and individuals are successful, the operating entity's research and development, and by extension its and our operating results and financial condition, could be materially adversely affected. In addition, negative publicity about the operating entity or the veterinary vaccines industry could harm the operating entity's reputation.

Manufacturing problems may cause product launch delays, inventory shortages, recalls or unanticipated costs.

Minor deviations in the manufacturing processes, such as temperature excursions or improper package sealing, could result in delays, inventory shortages, unanticipated costs, product recalls, product liability and/or regulatory action. In addition, a number of factors could cause production interruptions, including:

- the failure of the operating entity or any of its vendors or suppliers to comply with applicable regulations and quality assurance guidelines;
- construction delays;
- equipment malfunctions;
- shortages of materials;

[Table of Contents](#)

- labor problems;
- natural disasters;
- power outages;
- terrorist activities;
- changes in manufacturing production sites and limits to manufacturing capacity due to regulatory requirements, changes in types of products produced, shipping distributions or physical limitations; and
- the outbreak of any highly contagious diseases near the production sites.

These interruptions could result in launch delays, inventory shortages, recalls, unanticipated costs or issues with the operating entity's agreements under which it supplies third parties, which may adversely affect both the operating entity's and our operating results.

The operating entity may fail to detect or cure defects of its products.

Despite the quality control management system, the operating entity cannot eliminate the risks of errors, defects, or failures. The operating entity may fail to detect or cure defects as a result of a number of factors, many of which are outside its control, including:

- technical or mechanical malfunctions in the production process;
- human error or malfeasance by quality control personnel;
- tampering by third parties; and
- defective raw materials or equipment.

Failure to detect quality defects in the products could result in animal illness, customer dissatisfaction, or other problems that could harm the operating entity's reputation and business, expose it to liability, and adversely affect its revenue and profitability. Relevant PRC laws and regulations were formulated to strengthen the administration of rules pertaining to product quality, as well as to clarify the rules on product liability, protect consumers and maintain social and economic order. Products offered for sale in China must meet the relevant quality and safety standards. Violations of state or industrial standards for health, safety and any other related violations may result in civil liabilities and penalties, such as compensation for damages, fines, suspension, or shutdown of business, as well as confiscation of products illegally produced for sale and the sales proceeds of such products. As a result, it could materially adversely affect both the operating entity's and our operating results and financial condition.

The misuse or off-label use of the operating entity's products may harm the operating entity's reputation or result in financial or other damages.

The operating entity's products have been approved for use under specific circumstances for the treatment of certain diseases and conditions in specific species. There may be increased risk of product liability if veterinarians, livestock producers, pet owners or others attempt to use the products off-label, including the use of the products in species for which they have not been approved. Furthermore, the use of the operating entity's products for indications other than those indications for which its products have been approved may not be effective, which could harm the operating entity's reputation and lead to an increased risk of litigation. If the operating entity is deemed by a governmental or regulatory agency to have engaged in the promotion of any of its products for off-label use, such agency could request that it modifies its training or promotional materials and practices and it could be subject to significant fines and penalties, and the imposition of these sanctions could also affect its reputation and position within the industry. Any of these events could materially adversely affect both the operating entity's and our operating results and financial condition.

We derive a significant portion of our revenue from swine vaccines and any reduction in demand of swine vaccines could have an adverse effect on our business, financial condition, results of operations, cash flows, and prospects.

We derive a significant portion of our revenue from the sale of swine vaccines. For the six months ended June 30, 2023 and the fiscal years ended December 31, 2022 and 2021, our revenue from the sale of swine vaccines amounted to approximately US\$14.3 million, US\$34.2 million and US\$26.6 million, or approximately 88.5%, 90.5% and 85.6% of our revenue, respectively. For details on the swine vaccines sold by our Company, please see the section entitled “Business — Products”. Consequently, any reduction in demand of swine vaccines could have an adverse effect on our business, financial condition, results of operations, cash flows and prospects.

Animal health products are subject to unanticipated safety or efficacy concerns, which may harm the operating entity’s reputation.

Unanticipated safety or efficacy concerns can arise with respect to animal health products, whether or not scientifically or clinically supported, leading to product recalls, withdrawals or suspended or declining sales, as well as product liability, and other claims. In addition, the operating entity depends on positive perceptions of the safety and quality of its products, and animal health products generally, by its customers, veterinarians and end-users, and such concerns may harm its reputation. These concerns and the related harm to its reputation could materially adversely affect the operating entity’s and our operating results and financial condition, regardless of whether such reports are accurate.

Our historical growth rates and performance may not be sustainable or indicative of our future growth and financial results. We cannot guarantee that we will be able to maintain the growth rate we have experienced to date.

We have grown rapidly over the last few years. Our revenue increased from RMB214.1 million (\$31.0 million) in the fiscal year ended December 31, 2021 to RMB260.3 million (\$37.7 million) in the fiscal year ended December 31, 2022. Our revenue decreased slightly from RMB123.4 million (\$18.4 million) for the six months ended June 30, 2022 to RMB116.9 million (\$16.1 million) for the six months ended June 30, 2023. However, our historical performance may not be indicative of our future growth or financial results. We cannot assure you that we will be able to grow at the same rate as we did in the past, or avoid any decline in the future. Our growth may slow or become negative, and revenue may decline for a number of possible reasons, some of which are beyond our control, including decreasing consumer spending, increasing competition, declining growth of our overall market or industry, the emergence of alternative business models and changes in rules, regulations, government policies, or general economic conditions. It is difficult to evaluate our prospects, as we may not have sufficient experience in addressing the risks to which companies operating in rapidly evolving markets may be exposed. If our growth rate declines, our business, financial condition and results of operations may be materially and adversely affected.

COVID-19 Affects our Results of Operations.

The COVID-19 pandemic has resulted in the implementation of significant governmental measures, including lockdowns, closures, quarantines, and travel bans, intended to control the spread of the virus. In January 2020, the Chinese governments issued a series of policies to prevent the spread of COVID-19. In March 2022, a new wave of COVID-19 outbreak hit Jilin Province, particularly Changchun City and Jilin City. The resulting closure measures lasted for around two months and significantly impacted the social and industrial activities of Jilin City where the operating entity is situated. Particularly, the area where the operating entity operates was classified as a high-risk zone. As a result, the operating entity’s operational performance was affected.

For the fiscal years ended December 31, 2022 and 2021, the Company and the operating entity did not experience a significant negative impact of COVID-19 on their operations, capital, and financial position. Our revenue reached approximately RMB260.3 million for the fiscal year ended December 31, 2022, representing an increase of approximately RMB46.2 million or 21.6% from approximately RMB214.1 million for the fiscal year ended December 31, 2021. For the six months ended June 30, 2023 and 2022, the Company and the operating entity did not experience a significant negative impact of COVID-19 on their operations, capital, and financial position. Our revenue reached approximately RMB116.9 million (\$16.1 million) for the six months ended June 30, 2023, representing a slight decrease of approximately RMB6.5 million or 5.3% from approximately RMB123.4 million (\$18.4 million) for the six months ended June 30, 2022.

[Table of Contents](#)

In December 2022, the COVID-19 restriction policies in China were gradually loosened and lifted, both locally and nationally. Starting from January 2023, among other changes, China no longer conducts nucleic acid tests and centralized quarantine for all inbound travelers, and measures to control the number of international passenger flights will be lifted.

The extent of the impact of COVID-19 on the Company's future financial results will be dependent on future developments such as the length and severity of the pandemic, the potential resurgence of the pandemic, future government actions in response to the pandemic and the overall impact of the COVID-19 pandemic on the global economy and capital markets, among many other factors, all of which remain highly uncertain and unpredictable. Given this uncertainty, the Company is currently unable to quantify the expected impact of the COVID-19 pandemic on its future operations, financial condition, liquidity and results of operations if the current situation continues.

The operating entity's business is subject to inherent risks relating to product liability.

At present, the veterinary vaccines produced by the operating entity cover animals such as pigs, chickens, ducks, cattle, sheep, dogs. The quality of the veterinary vaccines is directly related to the prevention effect of animal epidemics. If the operating entity's vaccine products do not meet the quality standard, it will not only fail to achieve the immune effect and cause disease transmission but also may produce serious immune side effects, leading to the death of animals and causing economic losses to farmers, which will adversely affect its brand, reputation, and market influence of the enterprise, and the operating entity will have to pay a certain fee.

In addition, the operating entity may be held liable if any product we develop, or any product which is made using our technologies, causes injury or is found unsuitable during product testing, manufacturing, marketing, sale, or use. These risks are inherent in the development of veterinary vaccines and bio-pharmaceutical products. The operating entity currently does not have sufficient product liability insurance. If it cannot obtain sufficient insurance coverage at an acceptable cost or otherwise protect against potential product liability claims, the commercialization of products that it develops may be prevented or inhibited. If the operating entity is sued for any injury caused by its products, its liability could exceed its total assets, which could materially harm its business, financial condition and results of operations.

The operating entity's business will be materially and adversely affected if its collaborative partners, licensees and other third parties over whom the operating entity is very dependent fail to perform as expected.

Due to the complexity of the process of developing bio-pharmaceuticals, the operating entity's core business depends on arrangements with bio-pharmaceutical institutes, corporate and academic collaborators, licensors, licensees and others for the research, development, clinical testing, technology rights, manufacturing, marketing and commercialization of our products. The operating entity has various research collaborations and outsource other business functions. The operating entity's license agreements could obligate it to diligently bring potential products to market, make substantial milestone payments and royalties and incur the costs of filing and prosecuting patent applications. There are no assurances that the operating entity will be able to establish or maintain collaborations that are important to its business on favorable terms, or at all. The operating entity could enter into collaborative arrangements for the development of particular products that may lead to its relinquishing some or all rights to the related technology or products. A number of risks arise from the operating entity's dependence on collaborative agreements with third parties. Product development and commercialization efforts could be adversely affected if any collaborative partner (i) terminates or suspends its agreement or arrangement with the operating entity; (ii) causes delays; (iii) fails to timely develop or manufacture in adequate quantities a substance needed in order to conduct clinical trials; (iv) fails to adequately perform clinical trials; (v) determines not to develop, manufacture or commercialize a product to which it has rights; or (vi) otherwise fails to meet its contractual obligations. In addition, the operating entity's collaborative partners could pursue other technologies or develop alternative products that could compete with the products the operating entity is developing.

The operating entity's business requires a number of permits and licenses. We cannot assure you that the operating entity can maintain all required licenses, permits and certifications to carry on its business at all times.

Before the operating entity's products can be profitable, they must be produced in commercial quantities in a cost effective manufacturing process that complies with regulatory requirements, such as China's GMP, production and quality control regulations. If the operating entity cannot arrange for or maintain commercial-scale manufacturing on acceptable terms, or if there are delays or difficulties in the manufacturing process, the operating entity may not be able to conduct clinical trials, obtain regulatory approval or meet demand for its products.

[Table of Contents](#)

The operating entity has obtained certificates, permits, and licenses required for the operation of a bio pharmaceutical enterprise and the manufacturing of veterinary vaccines in the PRC. However, we cannot assure you that the operating entity can maintain all the other required licenses, permits and certifications to carry on its business at all times, and in the past from time to time the operating entity may have not been in compliance with all such required licenses, permits and certifications. Moreover, these licenses, permits and certifications are subject to periodic renewal and/or reassessment by the relevant PRC governmental authorities and the standards of such renewal or reassessment may change from time to time. The operating entity intends to apply for the renewal of these licenses, permits and certifications when required by then applicable laws and regulations. Any failure by the operating entity to obtain and maintain all licenses, permits and certifications necessary to carry on its business at any time could have a material adverse effect on its business, financial condition and results of operations. In addition, any inability to renew these licenses, permits and certifications could severely disrupt the operating entity's business and prevent it from continuing to carry on its business. Any changes in the standards used by governmental authorities in considering whether to renew or reassess the operating entity's business licenses, permits and certifications, as well as any enactment of new regulations that may restrict the conduct of its business, may also decrease its revenue and/or increase its costs and materially reduce its profitability and prospects. Furthermore, if the interpretation or implementation of existing laws and regulations changes or if new regulations come into effect requiring the operating entity to obtain any additional licenses, permits or certifications that were previously not required to operate its existing businesses, we cannot assure you that the operating entity will successfully obtain such licenses, permits or certifications.

The operating entity's ability to generate more revenue would be adversely affected if it needs more clinical trials or take more time to complete its clinical trials than it has planned.

Clinical trials vary in design by factors including dosage, end points, length, and controls. The operating entity may need to conduct a series of trials to demonstrate the safety and efficacy of its products. The results of these trials may not demonstrate safety or efficacy sufficiently for regulatory authorities to approve its products. Further, the actual schedules for the operating entity's clinical trials could vary dramatically from the forecasted schedules due to factors including changes in trial design, conflicts with the schedules of participating clinicians and clinical institutions, and changes affecting product supplies for clinical trials. Delays in or failure to commence or complete any planned clinical trials could delay the ultimate timelines for the operating entity's product releases. Such delays could reduce investors' confidence in the operating entity's ability to develop products, likely causing the price of our Ordinary Shares to decrease.

If we cannot retain, attract, and motivate key personnel, we may be unable to effectively implement our business plan.

Our success depends in large part upon our ability to retain, attract, and motivate highly skilled management, research and development, marketing, and sales personnel. The loss of and failure to replace key technical management and personnel could adversely affect multiple development efforts. Recruitment and retention of senior management and skilled technical, sales and other personnel is very competitive, and we may not be successful in either attracting or retaining such personnel. We may lose key personnel to other high technology companies, and many larger companies with significantly greater resources than us may aggressively recruit key personnel. As part of our strategy to attract and retain key personnel, we may offer equity compensation through grants of share options, restricted share awards or restricted share units. Potential employees, however, may not perceive our equity incentives as attractive enough. In addition, due to the intense competition for qualified employees, we may be required to, and have had to, increase the level of compensation paid to existing and new employees, which could materially increase our operating expenses.

If the operating entity is unable to obtain the regulatory approvals or clearances that are necessary to commercialize its products, we will have less revenue than expected.

China and other countries impose significant statutory and regulatory obligations upon the manufacture and sale of bio-pharmaceutical products. Each regulatory authority typically has a lengthy approval process in which it examines pre-clinical and clinical data and the facilities in which the product is manufactured. Regulatory submissions must meet complex criteria to demonstrate the safety and efficacy of the ultimate products. Addressing these criteria requires considerable data collection, verification and analysis. We may spend time and money preparing regulatory submissions or applications without assurances as to whether they will be approved on a timely basis or at all.

[Table of Contents](#)

The operating entity's product candidates, some of which are currently in the early stages of development, will require significant additional development and pre-clinical and clinical testing prior to their commercialization. These steps and the process of obtaining required approvals and clearances can be costly and time-consuming. If the operating entity's potential products are not successfully developed, cannot be proven to be safe and effective through clinical trials, or do not receive applicable regulatory approvals and clearances, or if there are delays in the process, (i) the commercialization of the operating entity's products could be adversely affected; (ii) any competitive advantages of the products could be diminished; and (iii) revenue or collaborative milestones from the products could be reduced or delayed.

Governmental and regulatory authorities may approve a product candidate for fewer indications or narrower circumstances than requested or may condition approval on the performance of post-marketing studies for a product candidate. Even if a product receives regulatory approval and clearance, it may later exhibit adverse side effects that limit or prevent its widespread use or that force us to withdraw the product from the market. Any marketed product and its manufacturer, including the operating entity, will continue to be subject to strict regulation after approval. Results of post-marketing programs may limit or expand the further marketing of products. Unforeseen problems with an approved product or any violation of regulations could result in restrictions on the product, including its withdrawal from the market and possible civil actions.

In manufacturing the operating entity's products, the operating entity are required to comply with applicable GMP regulations, which include requirements relating to quality control and quality assurance, as well as the maintenance of records and documentation. If the operating entity cannot comply with regulatory requirements, including applicable GMP requirements, the operating entity may not be allowed to develop or market the product candidates. If the operating entity or its manufacturers fail to comply with applicable regulatory requirements at any stage during the regulatory process, the operating entity may be subject to sanctions, including fines, product recalls or seizures, injunctions, refusal of regulatory agencies to review pending market approval applications or supplements to approve applications, total or partial suspension of production, civil penalties, withdrawals of previously approved marketing applications and criminal prosecution.

The operating entity sources its raw materials used for manufacturing from a limited number of suppliers. If it loses one or more of the suppliers, its operation may be disrupted, and both the operating entity's and our results of operations may be adversely and materially impacted.

For the six months ended June 30, 2023, three of the operating entity's suppliers accounted for 10.1%, 8.7%, and 7.6% of the total purchases, respectively. For the fiscal year ended December 31, 2022, three of the operating entity's suppliers accounted for 25.3%, 12.9% and 7.4% of the total purchases, respectively. For the year ended December 31, 2021, three of the operating entity's suppliers accounted for 20.5%, 13.0% and 10.1% of the total purchases, respectively. For the fiscal year ended December 31, 2020, three of the operating entity's suppliers accounted for 11.2%, 9.4%, and 4.5% of the total purchases, respectively. If the operating entity loses suppliers and is unable to swiftly engage new suppliers, its operations may be disrupted or suspended, and it may not be able to deliver products to its customers on time. The operating entity may also have to pay a higher price to source from a different supplier on short notice. While the operating entity is actively searching for and negotiating with new suppliers, there is no guarantee that it will be able to locate appropriate new suppliers or supplier merger targets in its desired timeline. As such, both the operating entity's and our results of operations may be adversely and materially impacted.

High customer concentration exposes the operating entity to all of the risks faced by its major customer and may subject it to significant fluctuations or declines in revenue, which may have a material adverse impact on the operating entity's business, and its and our financial condition and results of operations.

For the six months ended June 30, 2023, two customers, Muyuan Foods Co., Ltd. ("MYF") and Shuangbaotai (Group) Corporation Limited, account for more than 10.0% of the Company's total revenue, accounting for 54.6% and 16.9% of total revenue, respectively. For the fiscal years ended December 31, 2022 and 2021, MYF is the only customer that accounts for more than 10.0% of the Company's total revenue, accounting for 74.5% and 55.6% of total revenue, respectively. Although the operating entity continually seeks to diversify its customer base, we cannot assure you that the proportion of the revenue contribution from these customers to the operating entity's total revenue will decrease in the near future. Dependence on these customers will expose the operating entity to the risks of substantial losses. Specifically, any one of the following events, among others, may cause material fluctuations or declines in the operating entity's revenue and have a material and adverse effect on the operating entity's business, and both its and our financial condition, and results of operations:

- an overall decline in the business of these customers;
- the decision by these customers to switch to the operating entity's competitors;

[Table of Contents](#)

- the reduction in the prices of the operating entity's products agreed by these customers; or
- the failure or inability of any of these customers to make timely payment for the operating entity's products.

If the operating entity fails to maintain relationships with these customers, and if it is unable to find replacement customers on commercially desirable terms or in a timely manner or at all, the operating entity business, both its and our financial condition and results of operations may be materially and adversely affected.

Damage to our brand image could have a material adverse effect on our growth strategy and our business, financial condition, results of operations and prospects.

Maintaining and enhancing our brand is critical to expanding our base of customers. Our ability to maintain and enhance our brand depends largely on our ability to maintain customer confidence in our product and service offerings, including by providing after-sales services and technical guidance to customers. If customers do not have a satisfactory experience with our products or services, our customers may seek out alternatives from our competitors and may not return to us in the future, or at all.

In addition, unfavorable publicity regarding, for example, our practices relating to privacy and data protection, product quality, delivery problems, competitive pressures, litigation or regulatory activity, could seriously harm our reputation. Such negative publicity also could have an adverse effect on the size, engagement, and loyalty of our customer base and result in decreased total revenue which could adversely affect our business, financial condition and results of operations. Customer complaints or negative publicity about our marketplace, products, delivery times, company practices, employees, customer data handling and security practices or customer support, especially on social media websites and in our marketplace, could rapidly and severely diminish our customers' confidence in us and result in harm to our brands.

If the operating entity cannot successfully protect its intellectual property and exclusive rights, our brand and business would suffer.

The operating entity relies on a combination of trademark, copyright, domain name and trade secret protection laws in China, as well as confidentiality procedures and contractual provisions, to protect its intellectual property rights and other exclusive rights. The operating entity also enters into agreements containing confidentiality obligations with its employees and any third parties who may access its proprietary technology and information, and the operating entity rigorously controls access to its proprietary technology and information.

Nevertheless, we cannot guarantee that the operating entity can successfully protect its intellectual property and exclusive rights from unauthorized usage by third parties or breach of confidentiality obligations by its counterparties. For example, there could be other competitors imitating or copying the operating entity's self-developed products without the operating entity's prior consent, which may harm its reputation and operations. Furthermore, a third-party may take advantage of the "first-to-file" trademark registration system in China to register the operating entity's brands in bad faith, which will cause the operating entity to incur additional costs for legal actions. Moreover, confidentiality obligations may be breached by counterparties, and there may not be adequate remedies available to the operating entity for any such breach. Accordingly, the operating entity may not be able to effectively protect its intellectual property rights and exclusive rights or to enforce its contractual rights in China or elsewhere. Moreover, although the operating entity sells its products outside of the PRC, it does not have any intellectual property protection in those foreign countries. Failure to protect its intellectual properties in these countries could have a material adverse effect on both our and the operating entity's business, financial condition and results of operations.

In addition, policing any unauthorized use of the operating entity's intellectual property and exclusive rights is difficult, time-consuming and costly. The precaution steps the operating entity has taken for protecting our rights may be inadequate. In the event that the operating entity resorts to litigation to enforce its intellectual property rights and exclusive rights, such litigation could result in substantial costs and a diversion of the operating entity's managerial and financial resources. We can provide no assurance that the operating entity will prevail in such litigation or that the operating entity would be able to halt any unauthorized use of its intellectual property and exclusive rights. In addition, the operating entity's trade secrets may be leaked to, or be independently discovered by, its competitors. Any failure in protecting or enforcing the operating entity's intellectual property rights could have a material adverse effect on our business, financial condition and results of operations.

The operating entity may be accused of infringing, misappropriating or otherwise violating the intellectual property rights of third parties.

We cannot assure you that the operating entity's product design, offerings, or technologies do not or will not infringe upon copyrights or other intellectual property rights (including, but not limited to, trademarks, patents and know-how) held by third parties. For example, the design of third-party products and the operating entity's products may be similar and result in intellectual property disputes. Nor can we assure you that the operating entity's use of software or any other intellectual properties in business and operation will not be alleged by any third party as infringement resulting from lack of licenses. If any third-party infringement claims are brought against the operating entity, the operating entity may be forced to divert management's time and other resources from its business and operations to defend against these claims. The operating entity may also be prohibited from using such intellectual property or relevant content. As a result, the operating entity may incur licensing or usage fees, develop alternatives of its own, or even need to pay damages, legal fees and other costs. Even if such assertions against the operating entity are unsuccessful, they may cause the operating entity to lose existing and future business and incur reputational harm and substantial legal fees. As a result, our reputation may be harmed and our business and financial performance may be materially and adversely affected.

We are subject to legal and regulatory proceedings from time to time in the ordinary course of our business.

We have not been subject to any material allegations or complaints in the past, but we may be involved in legal and other disputes in the ordinary courses of our business, including allegations against us for potential infringement of third-party copyrights or other intellectual property rights, as well as customer complaints in relation to our refund policy, the quality of our services, and other dissatisfaction. We might also be involved in governmental investigations for content posted on our websites or other aspect of our business operation in the future. Any claims against us, with or without merit, could be time-consuming and costly to defend or litigate, divert our management's attention and resources or harm our brand equity. If a lawsuit or governmental proceeding against us is successful, we may be required to pay substantial damages or fines. We may also lose, or be limited in, the rights to offer some of our products and services or be required to make changes to our content offerings or business model. As a result, the scope of our content, product and service offerings could be reduced, which could adversely affect our ability to attract new customers, harm our reputation and have a material adverse effect on our business, financial condition and results of operations.

Moreover, becoming a public company will raise our public profile, which may result in increased litigation as well as increased public awareness of any such litigation. There is substantial uncertainty regarding the scope and application of many of the laws and regulations to which we are subject, which increases the risk that we will be subject to claims alleging violations of those laws and regulations. In the future, we may also be accused of having, or be found to have, infringed, misappropriated or otherwise violated third-party intellectual property rights.

We could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws.

We are facilitating overseas business development. The U.S. Foreign Corrupt Practices Act and similar anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to foreign government officials for the purpose of obtaining or retaining business. Practices in the local business communities of many countries outside the United States have a level of government corruption that is greater than that found in the developed world. Our policies mandate compliance with these anti-bribery laws and we have established policies and procedures designed to monitor compliance with these anti-bribery law requirements; however, we cannot assure you that our policies and procedures will protect us from all potential reckless or criminal acts committed by individual employees or agents. If we are found to be liable for anti-bribery law violations, we could suffer from criminal or civil penalties or other sanctions that could have a material adverse effect on our business.

Risks Relating to this Offering and the Trading Market

There has been no public market for our Ordinary Shares prior to this offering, and you may not be able to resell our Ordinary Shares at or above the price you pay for them, or at all.

Prior to this offering, there has not been a public market for our Ordinary Shares. We submitted our application for the listing of our Ordinary Shares on the Nasdaq Global Market. At this time, Nasdaq has not yet approved our application to list our Ordinary Shares. An active public market for our Ordinary Shares, however, may not develop or be sustained after the offering, in which case the market price and liquidity of our Ordinary Shares will be materially and adversely affected.

The initial public offering price for our Ordinary Shares may not be indicative of prices that will prevail in the trading market and such market prices may be volatile.

The initial public offering price for our Ordinary Shares will be determined by negotiations between us and the underwriters and may not bear a direct relationship to our earnings, book value, or any other indicia of value. We cannot assure you that the market price of our Ordinary Shares will not decline significantly below the initial public offering price. The financial markets in the United States and other countries have experienced significant price and volume fluctuations in the last few years. Volatility in the price of our Ordinary Shares may be caused by factors outside of our control and may be unrelated or disproportionate to changes in our results of operations.

You will experience immediate and substantial dilution in the net tangible book value of Ordinary Shares purchased.

The initial public offering price of our Ordinary Shares is substantially higher than the net tangible book value per share of our Ordinary Shares. Consequently, when you purchase our Ordinary Shares in the offering, upon completion of the offering you will incur immediate dilution of \$[•] per share, assuming an initial public offering price of \$[•]. See “Dilution.” In addition, you may experience further dilution to the extent that additional Ordinary Shares are issued upon exercise of outstanding options we may grant from time to time.

If we fail to implement and maintain an effective system of internal controls or fail to remediate the material weaknesses in our internal control over financial reporting that have been identified, we may fail to meet our reporting obligations or be unable to accurately report our results of operations or prevent fraud, and investor confidence and the market price of our Ordinary Shares may be materially and adversely affected.

Prior to this offering, we have been a private company with limited accounting personnel and other resources with which to address our internal controls and procedures. The material weakness identified relates to (i) the lack of formal internal control policies and internal independent supervision functions to establish formal risk assessment process and internal control framework over financing reporting; (ii) the lack of accounting staff and resources with appropriate knowledge of generally accepted U.S. GAAP and SEC reporting and compliance requirements to design and implement formal period-end financial reporting policies and procedures to address complex U.S. GAAP technical accounting issue in accordance with U.S. GAAP and the SEC requirements.

Following the identification of the material weaknesses and control deficiencies, we have taken the following remedial measures: (i) hiring additional qualified accounting and financial personnel with appropriate knowledge and experience in U.S. GAAP accounting and SEC reporting; and (ii) organizing regular training for our accounting staffs, especially training related to U.S. GAAP and SEC reporting requirements. As of the date of this prospectus, we have hired one Certified Internal Auditor of the Institute of Internal Auditors and one Certified Management Accountant of the Institute of Certified Management Accountants USA. We also plan to adopt additional measures to improve our internal control over financial reporting, including, among others, creating U.S. GAAP accounting policies and procedures manual, which will be maintained, reviewed, and updated, on a regular basis, to the latest U.S. GAAP accounting standards, and establishing an audit committee and strengthening corporate governance.

However, the implementation of these measures may not fully address the material weaknesses in our internal control over financial reporting. Our failure to correct the material weaknesses or our failure to discover and address any other material weaknesses or control deficiencies could result in inaccuracies in our financial statements and could also impair our ability to comply with applicable financial reporting requirements and related regulatory filings on a timely basis. As a result, our business, financial condition, results of operations and prospects, as well as the trading price of our Ordinary Shares, may be materially and adversely affected. Moreover, ineffective internal control over financial reporting significantly hinders our ability to prevent fraud.

[Table of Contents](#)

Upon completion of this offering, we will become a public company in the United States subject to the Sarbanes Oxley Act of 2002. Section 404 of the Sarbanes-Oxley Act of 2002 will require that we include a report of management on our internal control over financial reporting in our annual report on Form 20-F beginning with our second annual report after becoming a public company. In addition, once we cease to be an “emerging growth company,” as such term is defined in the JOBS Act, our independent registered public accounting firm must attest to and report on the effectiveness of our internal control over financial reporting. Our management may conclude that our internal control over financial reporting is not effective. Moreover, even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm, after conducting its own independent testing, may issue a report that is qualified, if it is not satisfied with our internal controls or the level at which our controls are documented, designed, operated, or reviewed, or if it interprets the relevant requirements differently from us. In addition, after we become a public company, our reporting obligations may place a significant strain on our management, operational, and financial resources and systems for the foreseeable future. We may be unable to complete our evaluation testing and any required remediation in a timely manner.

We will incur substantial increased costs as a result of being a public company.

Upon consummation of this offering, we will incur significant legal, accounting, and other expenses as a public company that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, as well as rules subsequently implemented by the SEC and Nasdaq, impose various requirements on the corporate governance practices of public companies.

Compliance with these rules and regulations increases our legal and financial compliance costs and makes some corporate activities more time-consuming and costlier. We have incurred additional costs in obtaining director and officer liability insurance. In addition, we incur additional costs associated with our public company reporting requirements. It may also be more difficult for us to find qualified persons to serve on our board of directors or as executive officers.

We are an “emerging growth company,” as defined in the JOBS Act and will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of this offering, (b) in which we have total annual gross revenue of at least \$1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our Ordinary Shares that is held by non-affiliates exceeds \$700 million as of the prior June 30, and (2) the date on which we have issued more than \$1.0 billion in non-convertible debt during the prior three-year period. An emerging growth company may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies. These provisions include exemption from the auditor attestation requirement under Section 404 in the assessment of the emerging growth company’s internal control over financial reporting and permission to delay adopting new or revised accounting standards until such time as those standards apply to private companies.

After we are no longer an “emerging growth company,” or until five years following the completion of our initial public offering, whichever is earlier, we expect to incur significant additional expenses and devote substantial management effort toward ensuring compliance with the requirements of Section 404 and the other rules and regulations of the SEC. For example, as a public company, we have been required to increase the number of independent directors and adopt policies regarding internal controls and disclosure controls and procedures.

We are currently evaluating and monitoring developments with respect to these rules and regulations, and we cannot predict or estimate with any degree of certainty the amount of additional costs we may incur or the timing of such costs.

Substantial future sales of our Ordinary Shares or the anticipation of future sales of our Ordinary Shares in the public market could cause the price of our Ordinary Shares to decline.

Sales of substantial amounts of our Ordinary Shares in the public market after this offering, or the perception that these sales could occur, could cause the market price of our Ordinary Shares to decline. An aggregate of [•] Ordinary Shares are outstanding before the consummation of this offering. An aggregate of [•] Ordinary Shares will be outstanding immediately after the consummation of this offering. Sales of these shares into the market could cause the market price of our Ordinary Shares to decline.

We do not intend to pay dividends in the foreseeable future.

During the six months ended June 30, 2023 and the fiscal years ended December 31, 2022 and 2021, dividends and distributions made by the operating entity to its original shareholders amounted to RMB18,000,000, RMB21,424,500, and RMB11,047,500, respectively. On April 28, 2023, the shareholders' meeting of the operating entity passed the resolution of the dividend plan for 2022, with the dividend amount of RMB55,104,000, and the dividend will be distributed before May 2024.

Except as disclosed above, we currently intend to retain any future earnings to finance the operation and expansion of our business, and we do not expect to declare or pay any dividends in the foreseeable future. As a result, you may only receive a return on your investment in our Ordinary Shares if the market price of our Ordinary Shares increases.

If securities or industry analysts do not publish research or reports about our business, or if they publish a negative report regarding our Ordinary Shares, the price of our Ordinary Shares and trading volume could decline.

Any trading market for our Ordinary Shares may depend in part on the research and reports that industry or securities analysts publish about us or our business. We do not have any control over these analysts. If one or more of the analysts who cover us downgrade us, the price of our Ordinary Shares would likely decline. If one or more of these analysts cease coverage of our Company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause the price of our Ordinary Shares and the trading volume to decline.

The market price of our Ordinary Shares may be volatile or may decline regardless of our operating performance, and you may not be able to resell your shares at or above the initial public offering price.

The initial public offering price for our Ordinary Shares will be determined through negotiations between the underwriters and us and may vary from the market price of our Ordinary Shares following our initial public offering. If you purchase our Ordinary Shares in our initial public offering, you may not be able to resell those shares at or above the initial public offering price. We cannot assure you that the initial public offering price of our Ordinary Shares, or the market price following our initial public offering, will equal or exceed prices in privately negotiated transactions of our shares that have occurred from time to time prior to our initial public offering. The market price of our Ordinary Shares may fluctuate significantly in response to numerous factors, many of which are beyond our control, including:

- actual or anticipated fluctuations in our revenue and other operating results;
- the financial projections we may provide to the public, any changes in these projections or our failure to meet these projections;
- actions of securities analysts who initiate or maintain coverage of us, changes in financial estimates by any securities analysts who follow our Company, or our failure to meet these estimates or the expectations of investors;
- announcements by us or our competitors of significant products or features, technical innovations, acquisitions, strategic partnerships, joint ventures, or capital commitments;
- price and volume fluctuations in the overall stock market, including as a result of trends in the economy as a whole;
- lawsuits threatened or filed against us; and
- other events or factors, including those resulting from war or incidents of terrorism, or responses to these events.

In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. Stock prices of many companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have filed securities class litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business, and adversely affect our business.

The price of our Ordinary Shares could be subject to rapid and substantial volatility. Such volatility, including any stock run-ups, may be unrelated to our actual or expected operating performance and financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our Ordinary Shares.

There have been instances of extreme stock price run-ups followed by rapid price declines and strong stock price volatility with recent initial public offerings, especially among those with relatively smaller public floats. As a relatively small-capitalization company with a relatively small public float, we may experience greater stock price volatility, extreme price run-ups, lower trading volume, and less liquidity than large-capitalization companies. In particular, our Ordinary Shares may be subject to rapid and substantial price volatility, low volumes of trades, and large spreads in bid and ask prices. Such volatility, including any stock run-ups, may be unrelated to our actual or expected operating performance and financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our Ordinary Shares.

In addition, if the trading volumes of our Ordinary Shares are low, persons buying or selling in relatively small quantities may easily influence the price of our Ordinary Shares. This low volume of trades could also cause the price of our Ordinary Shares to fluctuate greatly, with large percentage changes in price occurring in any trading day session. Holders of our Ordinary Shares may also not be able to readily liquidate their investment or may be forced to sell at depressed prices due to low volume trading. Broad market fluctuations and general economic and political conditions may also adversely affect the market price of our Ordinary Shares. As a result of this volatility, investors may experience losses on their investment in our Ordinary Shares. A decline in the market price of our Ordinary Shares also could adversely affect our ability to issue additional shares of Ordinary Shares or other of our securities and our ability to obtain additional financing in the future. No assurance can be given that an active market in our Ordinary Shares will develop or be sustained. If an active market does not develop, holders of our Ordinary Shares may be unable to readily sell the shares they hold or may not be able to sell their shares at all.

Our management has broad discretion to determine how to use the funds raised in the offering and may use them in ways that may not enhance our results of operations or the price of our Ordinary Shares.

We anticipate that we will use the net proceeds from this offering to build new workshops, conduct research and development (“R&D”) projects, and for working capital and other general corporate purposes. Our management will have significant discretion as to the use of the net proceeds to us from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the market price of our Ordinary Shares.

If we cease to qualify as a foreign private issuer, we would be required to comply fully with the reporting requirements of the Exchange Act applicable to U.S. domestic issuers, and we would incur significant additional legal, accounting and other expenses that we would not incur as a foreign private issuer.

We expect to qualify as a foreign private issuer upon the completion of this offering. As a foreign private issuer, we will be exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as United States domestic issuers, and we will not be required to disclose in our periodic reports all of the information that United States domestic issuers are required to disclose. While we currently expect to qualify as a foreign private issuer immediately following the completion of this offering, we may cease to qualify as a foreign private issuer in the future, in which case we would incur significant additional expenses that could have a material adverse effect on our results of operations.

Because we are a foreign private issuer and are exempt from certain Nasdaq corporate governance standards applicable to U.S. issuers, you will have less protection than you would have if we were a domestic issuer.

Nasdaq listing rules require listed companies to have, among other things, a majority of its board members be independent. As a foreign private issuer, however, we are permitted to, and we may follow home country practice in lieu of the above requirements, or we may choose to comply with the above requirement within one year of listing. The corporate governance practice in our home country, the Cayman Islands, does not require a majority of our board to consist of independent directors. Thus, although a director must act in the best interests of our Company, it is possible that fewer board members will be exercising independent judgment and the level of board oversight on the management of our Company may decrease as a result. In addition, Nasdaq listing rules also require U.S. domestic

[Table of Contents](#)

issuers to have a compensation committee, a nominating/corporate governance committee composed entirely of independent directors, and an audit committee with a minimum of three members. We, as a foreign private issuer, are not subject to these requirements. Nasdaq listing rules may require shareholder approval for certain corporate matters, such as requiring that shareholders be given the opportunity to vote on all equity compensation plans and material revisions to those plans, certain ordinary share issuances. We intend to comply with the requirements of Nasdaq listing rules in determining whether shareholder approval is required on such matters and to appoint a nominating and corporate governance committee. We may, however, consider following home country practice in lieu of the requirements under Nasdaq listing rules with respect to certain corporate governance standards which may afford less protection to investors.

If we cannot continue to satisfy the listing requirements and other rules of the Nasdaq Global Market, our securities may be delisted, which could negatively impact the price of our securities and your ability to sell them.

We plan to apply to have our Ordinary Shares listed on the Nasdaq Global Market upon consummation of this offering. It is a condition to the closing of this offering that our Ordinary Shares qualify for listing on a national securities exchange. Following this offering, in order to maintain our listing on the Nasdaq Global Market, we will be required to comply with certain rules of the Nasdaq Global Market, including those regarding minimum stockholders' equity, minimum share price, minimum market value of publicly held shares, and various additional requirements. Even if we initially meet the listing requirements and other applicable rules of the Nasdaq Global Market, we may not be able to continue to satisfy these requirements and applicable rules. If we are unable to satisfy the Nasdaq Global Market criteria for maintaining our listing, our securities could be subject to delisting.

If the Nasdaq Global Market subsequently delists our securities from trading, we could face significant consequences, including:

- a limited availability for market quotations for our securities;
- reduced liquidity with respect to our securities;
- a determination that our Ordinary Shares are a "penny stock," which will require brokers trading in our Ordinary Shares to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our Ordinary Shares;
- limited amount of news and analyst coverage; and
- a decreased ability to issue additional securities or obtain additional financing in the future.

Anti-takeover provisions in our articles of association may discourage, delay, or prevent a change in control.

Some provisions of our post-offering articles of association, which will become effective on or before the completion of this offering, may discourage, delay, or prevent a change in control of our Company or management that shareholders may consider favorable, including, among other things, the following:

- provisions that authorize our board of directors to issue shares with preferred, deferred, or other special rights or restrictions without any further vote or action by our shareholders; and
- provisions that restrict the ability of our shareholders to call meetings and to propose special matters for consideration at shareholder meetings.

Because we are an "emerging growth company," we may not be subject to requirements that other public companies are subject to, which could affect investor confidence in us and our Ordinary Shares.

For as long as we remain an "emerging growth company," as defined in the JOBS Act, we will elect to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not "emerging growth companies," including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of shareholder approval of any golden parachute payments not previously approved. Because of these lessened regulatory requirements, our shareholders would be left without information or rights available to shareholders of more mature companies.

[Table of Contents](#)

Further, we elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (1) are no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. If some investors find our Ordinary Shares less attractive as a result, there may be a less active trading market for our Ordinary Shares and our share price may be more volatile. See “Implications of Our Being an Emerging Growth Company.”

The laws of the Cayman Islands may not provide our shareholders with benefits comparable to those provided to shareholders of corporations incorporated in the United States.

We are an exempted company incorporated under the laws of the Cayman Islands with limited liability. Our corporate affairs are governed by our memorandum and articles of association, the Companies Act (As Revised) of the Cayman Islands and by the common law of the Cayman Islands. The rights of shareholders to take action against our directors, actions by minority shareholders and the fiduciary responsibilities of our directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law in the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands and from English common law. Decisions of the Privy Council (which is the final Court of Appeal for British Overseas Territories such as the Cayman Islands) are binding on a court in the Cayman Islands. Decisions of the English courts, and particularly the Supreme Court and the Court of Appeal are generally of persuasive authority but are not binding in the courts of the Cayman Islands. Decisions of courts in other Commonwealth jurisdictions are similarly of persuasive but not binding authority. The rights of our shareholders and the fiduciary responsibilities of our directors under Cayman Islands law are not as clearly established as they would be under statutes or judicial precedents in the United States. In particular, the Cayman Islands has a less developed body of securities laws relative to the United States. Therefore, our public shareholders may have more difficulty protecting their interests in the face of actions by our management, directors or controlling shareholders than would shareholders of a corporation incorporated in a jurisdiction in the United States.

Shareholders of Cayman Islands exempted companies like us have no general rights under Cayman Islands law to inspect corporate records or to obtain copies of the register of members of these companies. Our post-offering articles of association have provisions that provide our shareholders the right to inspect our register of members without charge, and to receive our annual audited financial statements. Subject to the foregoing, our directors have discretion under our articles of association to determine whether or not, and under what conditions, our corporate records may be inspected by our shareholders, but are not obliged to make them available to our shareholders. This may make it more difficult for you to obtain the information needed to establish any facts necessary for a shareholder motion or to solicit proxies from other shareholders in connection with a proxy contest.

As a result of all of the above, public shareholders may have more difficulty in protecting their interests in the face of actions taken by our management, members of the board of directors or controlling shareholders than they would as public shareholders of a company incorporated in the United States. For a discussion of significant differences between the company law of the Cayman Islands and the laws applicable to companies incorporated in the United States and their shareholders, see “Description of Share Capital — Differences in Corporate Law.”

You may be unable to present proposals before annual general meetings or extraordinary general meetings not called by shareholders.

Cayman Islands law does not provide shareholders with any right to requisition a general meeting or put any proposal before a general meeting. These rights, however, may be provided in a company’s articles of association. Our post-offering articles of association allow any one or more of our shareholders holding shares representing in aggregate not less than one-third of our voting share capital in issue, to requisition a general meeting of our shareholders, in which case our directors are obliged to call such meeting. Advance notice of at least ten clear days is required for the convening of our annual general shareholders’ meeting and any other general meeting of our shareholders. A quorum required for a meeting of shareholders consists of at least two shareholders present or by proxy, representing not less than one-third of the total issued shares carrying the right to vote at a general meeting of our Company. For these purposes, “clear days” means that period excluding (a) the day when the notice is given or deemed to be given and (b) the day for which it is given or on which it is to take effect.

If we are classified as a PFIC, United States taxpayers who own our Ordinary Shares may have adverse United States federal income tax consequences.

A non-U.S. corporation such as ourselves will be classified as a PFIC for any taxable year if, for such year, either

- At least 75% of our gross income for the year is passive income; or
- The average percentage of our assets (determined at the end of each quarter) during the taxable year which produce passive income or which are held for the production of passive income is at least 50%.

Passive income generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business), and gains from the disposition of passive assets.

If we are determined to be a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S. taxpayer who holds our Ordinary Shares, the U.S. taxpayer may be subject to increased U.S. federal income tax liability and may be subject to additional reporting requirements.

Depending on the amount of cash we raise in this offering, together with any other assets held for the production of passive income, it is possible that, for our 2022 taxable year or for any subsequent year, more than 50% of our assets may be assets which produce passive income, in which case we would be deemed a PFIC, which could have adverse U.S. federal income tax consequences for U.S. taxpayers who are shareholders. We will make this determination following the end of any particular tax year. For purposes of the PFIC analysis, in general, a non-U.S. corporation is deemed to own its pro rata share of the gross income and assets of any entity in which it is considered to own at least 25% of the equity by value.

For a more detailed discussion of the application of the PFIC rules to us and the consequences to U.S. taxpayers if we were or are determined to be a PFIC, see “Material Income Tax Consideration — Material United States Federal Income Tax Consequences — PFIC Consequences.”

Our pre-IPO shareholders will be able to sell their shares upon completion of this offering subject to restrictions under Rule 144 under the Securities Act.

11,416,594 of our Ordinary Shares are issued and outstanding as of the date of this prospectus. Our pre-IPO shareholders may be able to sell their Ordinary Shares under Rule 144 after the completion of this offering. See “Shares Eligible for Future Sale.” Because these shareholders have paid a lower price per Ordinary Share than participants in this offering, when they are able to sell their pre-IPO shares under Rule 144, they may be more willing to accept a lower sales price than the IPO price. This fact could impact the trading price of the Ordinary Shares following the completion of the offering, to the detriment of participants in this offering. Under Rule 144, before our pre-IPO shareholders can sell their shares, in addition to meeting other requirements, they must meet the required holding period. We do not expect any of the Ordinary Shares to be sold pursuant to Rule 144 during the pendency of this offering.

The shareholders who own 5% or more of our Ordinary Shares have agreed not to sell any of their Ordinary Shares for a period of 180 days from the date of this prospectus. See “Underwriting — Lock-Up Agreements” for more information.

DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus contains forward-looking statements that reflect our current expectations and views of future events, all of which are subject to risks and uncertainties. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. You can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this prospectus. These statements are likely to address our growth strategy, financial results and product and development programs. You must carefully consider any such statements and should understand that many factors could cause actual results to differ from our forward-looking statements. These factors may include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially. Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to:

- assumptions about our future financial and operating results, including revenue, income, expenditures, cash balances, and other financial items;
- our ability to execute our growth, and expansion, including our ability to meet our goals;
- current and future economic and political conditions;
- our capital requirements and our ability to raise any additional financing which we may require;
- our ability to attract clients and further enhance our brand recognition;
- our ability to hire and retain qualified management personnel and key employees in order to enable us to develop our business;
- the COVID-19 pandemic;
- trends and competition in the veterinary vaccine industry; and
- other assumptions described in this prospectus underlying or relating to any forward-looking statements.

We describe certain material risks, uncertainties and assumptions that could affect our business, including our financial condition and results of operations, under “Risk Factors.” We base our forward-looking statements on our management’s beliefs and assumptions based on information available to our management at the time the statements are made. We caution you that actual outcomes and results may, and are likely to, differ materially from what is expressed, implied or forecast by our forward-looking statements. Accordingly, you should be careful about relying on any forward-looking statements. Except as required under the federal securities laws, we do not have any intention or obligation to update publicly any forward-looking statements after the distribution of this prospectus, whether as a result of new information, future events, changes in assumptions, or otherwise.

Industry Data and Forecasts

This prospectus contains data related to the veterinary vaccine industry in China that we obtained from various government and private entity publications, including the industry report of Frost & Sullivan Limited (“Frost & Sullivan”) which we commissioned. This industry data includes projections that are based on a number of assumptions which have been derived from industry and government sources which we believe to be reasonable. The veterinary vaccine industry may not grow at the rate projected by industry data, or at all. The failure of the industry to grow as anticipated is likely to have a material adverse effect on our business and the market price of our Ordinary Shares. In addition, the rapidly changing nature of the veterinary vaccine industry subjects any projections or estimates relating to the growth prospects or future condition of our industry to significant uncertainties. Furthermore, if any one or more of the assumptions underlying the industry data turns out to be incorrect, actual results may, and are likely to, differ from the projections based on these assumptions.

ENFORCEABILITY OF CIVIL LIABILITIES

We are incorporated under the laws of the Cayman Islands as an exempted company with limited liability. We are incorporated under the laws of the Cayman Islands because of certain benefits associated with being a Cayman Islands company, such as political and economic stability, an effective judicial system, a favorable tax system, the absence of foreign exchange control or currency restrictions and the availability of professional and support services. The Cayman Islands, however, has a less developed body of securities laws as compared to the United States and provides significantly less protection for investors than the United States. Additionally, Cayman Islands companies may not have standing to sue in the Federal courts of the United States.

Substantially all of our assets are located in China. In addition, except for one director, Mrs. Wenhua Sun, who is a resident of the U.S., the rest of our directors and all of our officers are nationals or residents of the PRC and all or a substantial portion of their assets are located outside the United States. As a result, it may be difficult for investors to effect service of process within the United States upon us or these persons, or to enforce against us or them judgments obtained in United States courts, including judgments predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States.

We have appointed Cogency Global Inc. as our agent to receive service of process with respect to any action brought against us in the United States District Court for the Southern District of New York under the federal securities laws of the United States or of any state in the United States or any action brought against us in the Supreme Court of the State of New York in the County of New York under the securities laws of the State of New York.

Conyers Dill & Pearman (“Conyers”), our counsel with respect to the laws of the Cayman Islands, Guantao, our counsel with respect to PRC law, have advised us that there is uncertainty as to whether the courts of the Cayman Islands or the PRC would (i) recognize or enforce judgments of United States courts obtained against us or our directors or officers predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States or (ii) entertain original actions brought in the Cayman Islands or the PRC against us or our directors or officers predicated upon the securities laws of the United States or any state in the United States.

Conyers has further advised us that although there is no statutory enforcement in the Cayman Islands of judgments obtained in the federal or state courts of the United States, the courts of the Cayman Islands would recognize as a valid judgment, a final and conclusive judgment in personam obtained in the federal or state courts of the United States against us under which a sum of money is payable (other than a sum of money payable in respect of multiple damages, taxes or other charges of a like nature or in respect of a fine or other penalty) or, in certain circumstances, an in personam judgment for non-monetary relief, and would give a judgment based thereon provided that (a) such courts had proper jurisdiction over the parties subject to such judgment; (b) such courts did not contravene the rules of natural justice of the Cayman Islands; (c) such judgment was not obtained by fraud; (d) the enforcement of the judgment would not be contrary to the public policy of the Cayman Islands; (e) no new admissible evidence relevant to the action is submitted prior to the rendering of the judgment by the courts of the Cayman Islands; and (f) there is due compliance with the correct procedures under the laws of the Cayman Islands. However, the Cayman Islands courts are unlikely to enforce a judgment obtained from United States courts under civil liability provisions of the U.S. federal securities law if such judgment is determined by the courts of the Cayman Islands to give rise to obligations to make payments that are penal or punitive in nature. Because such a determination has not yet been made by a court of the Cayman Islands, it is uncertain whether such civil liability judgments from U.S. courts would be enforceable in the Cayman Islands. A Cayman Islands court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere.

Guantao has further advised us that the recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedure Law. PRC courts may recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedure Law based either on treaties between China and the country where the judgment is made or on reciprocity between jurisdictions. There are no treaties or other forms of reciprocity between China and the United States for the mutual recognition and enforcement of court judgments. Guantao has further advised us that under PRC law, PRC courts will not enforce a foreign judgment against us or our officers and directors if the court decides that such judgment violates the basic principles of PRC law or national sovereignty, security or public interest, thus making the recognition and enforcement of a U.S. court judgment in China difficult.

USE OF PROCEEDS

We estimate that the net proceeds from the sale of [•] Ordinary Shares in this offering will be approximately \$[•], after deducting the underwriting discounts, non-accountable expense allowance, and estimated offering expenses payable by us, based on the assumed initial public offering price of \$[•] per Ordinary Share, the midpoint of the estimated price range set forth on the cover page of this prospectus.

A US\$1.0 increase (decrease) in the assumed initial public offering price of US\$[•] per Ordinary Share would increase (decrease) the net proceeds to us from this offering by US\$[•] million, or by US\$[•] million assuming the number of Ordinary Shares offered by us, as set forth on the front cover of this prospectus, remains the same and after deducting the estimated underwriting discounts and estimated expenses payable by us.

We plan to use the net proceeds we receive from this offering for the following purposes:

- approximately 33%, or RMB100 million, or US\$13.8 million, for acquiring vaccine production companies;
- approximately 30%, or RMB90.2 million, or US\$12.6 million, for building a new workshop;
- approximately 30%, or RMB90.2 million, or US\$12.6 million, for conducting R&D projects; and
- the balance, approximately 7%, or RMB20 million, or US\$2.8 million, to fund working capital and for other general corporate purposes.

The new workshop, with an anticipated area of approximately 75,347 square feet, will be located at No.1 Lianmeng Road, Jilin Economic & Technical Development Zone Jilin City, Jilin Province, China, which is expected to be completed within two years. The annual production capacity of the new workshop is expected to include 88 million Pseudorabies Live Vaccines, 2.3 million Canine Four-combination Live Vaccine, 4 million (8 million milliliter) Rabies Inactivated Vaccines, 2 million (4 million milliliter) Feline Triple Inactivated Vaccines, and 40 million milliliter Swine Pseudorabies Inactive Vaccine (Porcine circovirus).

With regard to the Company's intention to use 30% of the net proceeds to conduct R&D projects, please see below table which shows the types of R&D projects the operating entity plans to conduct and pertinent details.

Vaccines the operating entity plans to research and develop	Project Term (year)	Type of Vaccine	Status	Clinical Trial Status	Collaborator	Proceeds Expected to be Paid to Collaborator	Proceeds Expected to be Used by the Operating Entity
Replicate-defective Human Adenovirus Type-5 Recombinant Rabies Glycoprotein Vaccine	2	Dog	Laboratory research completed, undergoing pilot-scale production	Pre-clinical	N/A	N/A	RMB6.3 million or US\$0.9 million
Feline Panleukopenia, FCV, Feline Viral Rhinotracheitis Triple Inactivated Vaccine	3	Cat	A Registration Certificate of New Veterinary Drugs received	Clinical Trial Completed	Changchun Xinuo Biotechnology Co., Ltd.	RMB5.0 million or US\$0.7 million	RMB5.0 million or US\$0.7 million
Feline Rhinotracheitis, Feline Rhinconjunctivitis and Feline Panleukopenia Triple Inactivated vaccine (Strain JK+Strain FM+Strain CY)	3	Cat	laboratory research completed, undergoing pilot-scale production	Pre-clinical	N/A	N/A	RMB6.5 million or US\$0.9 million
Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Genetically Engineered Live Vaccine (Strain rHN-NP49)	2	Swine	Applying for a Registration Certificate of New Veterinary Drugs	Clinical Trial Completed	Shanghai Veterinary Research Institute	RMB2.0 million or US\$0.3 million	RMB2.6 million or US\$0.4 million
Subunit Vaccine of Porcine Circovirus Type 2, Type 3	3	Swine	Undergoing laboratory research	Pre-clinical	N/A	N/A	RMB5.0 million or US\$0.7 million

[Table of Contents](#)

Vaccines the operating entity plans to research and develop	Project Term (year)	Type of Vaccine	Status	Clinical Trial Status	Collaborator	Proceeds Expected to be Paid to Collaborator	Proceeds Expected to be Used by the Operating Entity
Combined Inactivated Vaccine of Porcine Circovirus Based Baculovirus Vector and Mycoplasma Hypermania	2	Swine	Applying for a Registration Certificate of New Veterinary Drugs	Clinical Trial Completed	Zhejiang Sci-Tech University	RMB2.0 million or US\$0.3 million	RMB3.4 million or US\$0.5 million
Newcastle Disease, Avian Influenza (Subtype, H9), Infections Bursal Disease and Fowl Adenovirus Disease (Group I, Type 4) Vaccine, Inactivated	4	Poultry	Applying for clinical trial	Pre-clinical	Shanghai Veterinary Research Institute China Agricultural University	RMB4.0 million or US\$0.6 million	RMB2.4 million or US\$0.3 million
Novel Duck Reovirus Live Vaccine	3	Poultry	Laboratory research and pilot-scale production completed, applying for clinical trial	Pre-clinical	Shanghai Veterinary Research Institute	RMB4.0 million or US\$0.6 million	RMB5.1 million or US\$0.7 million
Combined Heat-resistant Protective Agent Live Vaccine against Newcastle Disease and Infectious Bronchitis (Strain LaSota+Stain SZ160)	2	Poultry	Applying for a Registration Certificate of New Veterinary Drugs	Clinical Trial Completed	China Agricultural University	RMB5.5 million or US\$0.8 million	RMB2.4 million or US\$0.3 million
Gene-deleted Live Vaccine of Contagious Ecthyma Virus	2	Ovine	Undergoing laboratory research	Pre-clinical	Jilin University	RMB2.0 million or US\$0.3 million	RMB7.5 million or US\$1.0 million
Inactivated Bovine Akabane Disease Vaccine	3	Bovine	Undergoing laboratory research	Pre-clinical	N/A	N/A	RMB7.5 million or US\$1.0 million
Porcine Reproductive and Respiratory Syndrome mRNA Vaccine	5	Swine	Undergoing laboratory research	Pre-clinical	To be determined	RMB6.0 million or US\$0.8 million	RMB6.0 million or US\$0.8 million
Total						RMB30.5 million or US\$4.4 million	RMB59.7 million or US\$8.2 million

With the net proceeds from the offering, the Company expects to complete all R&D projects in the above table, including completing the clinical trials and receive Registration Certificates of New Veterinary Drugs for the above 12 vaccines.

The foregoing represents our current intentions based upon our present plans and business conditions to use and allocate the net proceeds of this offering. Our management, however, will have significant flexibility and discretion to apply the net proceeds of this offering, including to the R&D of mRNA vaccines and production capacity expansion. If an unforeseen event occurs or business conditions change, we may use the proceeds of this offering differently than as described in this prospectus. To the extent that the net proceeds we receive from this offering are not immediately used for the above purposes, we intend to invest our net proceeds in short-term, interest-bearing bank deposits or debt instruments.

In using the proceeds of this offering, we are permitted under PRC laws and regulations to utilize the proceeds from this offering to fund our PRC subsidiaries by making loans or additional capital contributions, subject to applicable government registration and approval requirements. We cannot assure you that we will be able to obtain these government registrations or approvals on a timely basis, if at all. See “Risk Factors — Risks Relating to Doing Business in the PRC — PRC regulation of parent/subsidiary loans and direct investment by offshore holding companies to PRC entities may delay or prevent us from using the proceeds of offshore offerings to make loans or additional capital contributions to our PRC subsidiaries, which could materially and adversely affect our liquidity and our ability to fund and expand our business.”

DIVIDEND POLICY

During six months ended June 30, 2023 and the fiscal years ended December 31, 2022 and 2021, dividends and distributions made by the operating entity to its original shareholders amounted to RMB18,000,000, RMB21,424,500, and RMB11,047,500, respectively. On April 28, 2023, the shareholders of the operating entity passed the resolution of the dividend plan for 2022, with the dividend amount of RMB55,104,000, and the dividend will be distributed before May 2024.

We intend to keep any future earnings to finance the expansion of our business, and we do not anticipate that any cash dividends will be paid in the foreseeable future. Subject to the PFIC rules, the gross amount of distributions we make to investors with respect to our Ordinary Shares (including the amount of any taxes withheld therefrom) will be taxable as a dividend, to the extent that the distribution is paid out of our current or accumulated earnings and profits, as determined under U.S. federal income tax principles.

Under Cayman Islands law, a Cayman Islands company may pay a dividend on its shares out of profit and/or share premium, provided that in no circumstances may a dividend be paid out of share premium if this would result in the company being unable to pay its debts as they fall due in the ordinary course of business.

If we determine to pay dividends on any of our Ordinary Shares in the future, as a holding company, we will be dependent on receipt of funds from our PRC subsidiary and from the operating entity to our PRC subsidiary. Dividends distributed by our subsidiaries in certain jurisdictions, such as in China, are subject to local taxes. PRC regulations may restrict the ability of our PRC subsidiaries to pay dividends to us.

Current PRC regulations permit Hainan Senhan, to pay dividends to Peg Biotechnology only out of their accumulated profits, if any, determined in accordance with Chinese accounting standards and regulations. In addition, Hainan Senhan is required to set aside at least 10% of its after-tax profits each year, if any, to fund a statutory reserve until such reserve reaches 50% of its registered capital.

The PRC government also imposes controls on the conversion of RMB into foreign currencies and the remittance of currencies out of the PRC. For instance, SAFE Circular 3 issued on January 26, 2017, provides that banks shall, when dealing with dividend remittance transactions from a domestic enterprise to its offshore shareholders of more than \$50,000, review the relevant board resolutions, original tax filing form, and audited financial statements of such domestic enterprise based on the principle of genuine transaction. Furthermore, if our PRC subsidiaries incur debt on their own in the future, the instruments governing the debt may restrict their ability to pay dividends or make other payments. If we or the PRC subsidiaries are unable to receive all of the revenue from our operations, we may be unable to pay dividends on our Ordinary Shares.

Cash dividends, if any, on our Ordinary Shares will be paid in U.S. dollars. Peg Biotechnology may be considered a non-resident enterprise for tax purposes, so that any dividends Hainan Senhan pays to Peg Biotechnology may be regarded as China-sourced income and as a result may be subject to PRC withholding tax at a rate of up to 10%. See “Material Income Tax Consideration — Enterprise Taxation in Mainland China.”

In order for us to pay dividends to our shareholders, we will rely on payments from our Hong Kong subsidiary, Peg Biotechnology. Peg Biotechnology will rely on payments made from Hainan Senhan. Hainan Senhan relies on payments made from Jilin Zhengye. If the PRC subsidiaries incur debt on their own behalf in the future, the instruments governing the debt may restrict their ability to pay dividends or make other distributions to us.

Pursuant to the Double Tax Avoidance Arrangement, the 10% withholding tax rate may be lowered to 5% if a Hong Kong resident enterprise owns no less than 25% of a PRC resident enterprise. The 5% withholding tax rate, however, does not automatically apply and certain requirements must be satisfied, including without limitation that (a) the Hong Kong resident enterprise must directly own the required percentage of equity interests and voting rights in the PRC resident enterprise; and (b) the Hong Kong resident enterprise must have directly owned such required percentage in the PRC resident enterprise throughout the 12 months prior to receiving the dividends. In current practice, a Hong Kong resident enterprise must obtain a tax resident certificate from the Hong Kong tax authority to apply for the 5% lower PRC withholding tax rate. As the Hong Kong tax authority will issue such a tax resident certificate on a case-by-case basis, we cannot assure you that we will be able to obtain the tax resident certificate from the relevant Hong Kong tax authority and enjoy the preferential withholding tax rate of 5% under the Double Tax Avoidance Arrangement with respect to any dividends paid by Hainan Senhan to its immediate holding company, Peg Biotechnology. As of the date of this prospectus, we have not applied for the tax resident certificate from the relevant Hong Kong tax authority. Peg Biotechnology intends to apply for the tax resident certificate if and when Hainan Senhan plans to declare and pay dividends to Peg Biotechnology. See “Risk Factors — Risks Relating to Doing Business in the PRC — There are significant uncertainties under the EIT Law relating to the withholding tax liabilities of the PRC subsidiaries, and dividends payable by the PRC subsidiaries to our offshore subsidiaries may not qualify to enjoy certain treaty benefits.”

CAPITALIZATION

The following table sets forth our capitalization as of June 30, 2023:

- on an actual basis; and
- on an as adjusted basis to reflect the issuance and sale of the Ordinary Shares by us in this offering at the assumed initial public offering price of \$[*] per Ordinary Share, which is the midpoint of the estimated initial public offering price range set forth on the cover page of this prospectus, after deducting the estimated discounts to the underwriters and the estimated offering expenses payable by us.

You should read this capitalization table in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements and the related notes appearing elsewhere in this prospectus.

	Actual	As adjusted
	RMB	RMB
	(RMB in thousands)	
Noncurrent liability		
Long-term loan	9,990	[•]
Shareholders’ Equity:	—	—
Ordinary shares, (\$0.0001 par value, 500,000,000 Ordinary Shares authorized, 11,416,594 Ordinary Shares issued and outstanding as of June 30, 2023)	8	[•]
Additional paid-in capital ⁽¹⁾	203,150	[•]
Statutory reserve	27,565	[•]
Retained earnings	30,851	[•]
Total Shareholders’ equity	261,574	[•]
Non-controlling-interests	64,259	[•]
Total Capitalization	335,823	[•]

- (1) Reflects the sale of Ordinary Shares in this offering at an assumed initial public offering price of \$[*] per share, and after deducting the estimated underwriting discounts, non-accountable expense allowance, and estimated offering expenses payable by us. The as adjusted information is illustrative only, and we will adjust this information based on the actual initial public offering price and other terms of this offering determined at pricing. Additional paid-in capital reflects the net proceeds we expect to receive, after deducting the underwriting discounts, non-accountable expense allowance, and estimated offering expenses payable by us. We estimate that such net proceeds will be approximately \$[*].

A \$1.00 increase (decrease) in the assumed initial public offering price of \$[*] per Ordinary Share would increase (decrease) each of additional paid-in capital, total shareholders’ equity and total capitalization by \$[*] million, assuming the number of Ordinary Shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and estimated expenses payable by us.

DILUTION

If you invest in our Ordinary Shares, your ownership interest will be diluted to the extent of the difference between the initial public offering price per Ordinary Share and our net tangible book value per Ordinary Share after this offering. Dilution results from the fact that the initial public offering price per Ordinary Share is substantially in excess of the net tangible book value per Ordinary Share attributable to the existing shareholders for our presently outstanding Ordinary Shares.

Our net tangible book value as of June 30, 2023, was \$42.5 million, or \$3.72 per Ordinary Share. Net tangible book value represents the amount of our total consolidated tangible assets, less the amount of our total consolidated liabilities. Dilution is determined by subtracting the net tangible book value per Ordinary Share (as adjusted for the offering) from the initial public offering price per Ordinary Share and after deducting the estimated underwriting discounts and the estimated offering expenses payable by us.

After giving effect to our sale of [•] Ordinary Shares offered in this offering based on the initial public offering price of \$[•] per Ordinary Share after deduction of the estimated underwriting discounts and the estimated offering expenses payable by us, our as adjusted net tangible book value as of June 30, 2023, would have been \$[•], or \$[•] per outstanding Ordinary Share. This represents an immediate increase in net tangible book value of \$[•] per Ordinary Share to the existing shareholders, and an immediate dilution in net tangible book value of \$[•] per Ordinary Share to investors purchasing Ordinary Shares in this offering. The as adjusted information discussed above is illustrative only.

The following table illustrates such dilution:

	Post-Offering
Assumed Initial public offering price per Ordinary Share	\$
Net tangible book value per Ordinary Share as of June 30, 2023	\$
Increase in net tangible book value per Ordinary Share attributable to payments by new investors	\$
As adjusted net tangible book value per Ordinary Share immediately after this offering	\$
Amount of dilution in net tangible book value per Ordinary Share to new investors in the offering	\$

The as adjusted net tangible book value per Ordinary Share after the offering would be \$[•], the increase in net tangible book value per Ordinary Share to existing shareholders would be \$[•], and the immediate dilution in net tangible book value per Ordinary Share to new investors in this offering would be \$[•].

The following tables summarize, on an as adjusted basis as of June 30, 2023, the differences between existing shareholders and the new investors with respect to the number of Ordinary Shares purchased from us, the total consideration paid and the average price per Ordinary Share before deducting the estimated underwriting discounts and the estimated offering expenses payable by us.

	Ordinary Shares purchased		Total consideration		Average price per Ordinary Share
	Number	Percent	Amount	Percent	
(\$ in thousands)					
Existing shareholders		%	\$	%	\$
New investors		%	\$	%	\$
Total		%	\$	%	\$

The as adjusted information as discussed above is illustrative only. Our net tangible book value following the completion of this offering is subject to adjustment based on the actual initial public offering price of our Ordinary Shares and other terms of this offering determined at the pricing.

CORPORATE HISTORY AND STRUCTURE

Our Corporate History

On May 18, 2004, Jilin Zhengye was established as a limited liability company organized under the laws of the PRC.

In connection with this offering, we have undertaken a reorganization of our corporate structure (the “Reorganization”) in the following steps:


- On March 24, 2023, Zhengye Cayman was incorporated as an exempted company with limited liability in the Cayman Islands;
- On April 3, 2023, VVAX Skyline was incorporated in the BVI as a company with limited liability; it is a wholly owned subsidiary of Zhengye Cayman;
- On April 28, 2023, Peg Biotechnology was incorporated in Hong Kong with as a company limited liability; it is a wholly owned subsidiary of VVAX Skyline;
- On May 18, 2023, we repurchased 100% of the equity interests from our original shareholders and issued 10,000,000 Ordinary Shares to Securingium Holding Limited;
- On May 22, 2023, Hainan Senhan was incorporated in the PRC with limited liability; it is a wholly owned subsidiary of Peg Biotechnology;
- On May 22, 2023 and June 20, 2023, Hainan Senhan acquired an aggregate of 58.689% of the equity interests in Jilin Zhengye from its original shareholders;
- On May 30, 2023, VVAX Skyline acquired 100% of the equity interests in Windsor Holdings from its original shareholders; and
- On June 21, 2023, we issued 570,830 Ordinary Shares to VVAX Holdings Limited, 569,688 Ordinary Shares to Vanguard Skyline Holdings Limited, 259,465 Ordinary Shares to TLjinmao Limited, and 16,611 Ordinary Shares to XZjinyuan Limited.

Consequently, Zhengye Cayman, through a restructuring which is accounted for as a reorganization of entities under common control, became the ultimate holding company of all other entities mentioned above.

As a holding company, Zhengye Cayman has no material operations of its own and conducts its operations through Jilin Zhengye. See “Risk Factors — Risks Relating to Doing Business in China — Chinese regulatory authorities could disallow our holding company structure, which may result in a material change in the operating entity’s operations and/or a material change in the value of the securities we are registering for sale, including that it could cause the value of such securities to significantly decline or become worthless.”

Our Corporate Structure

The following diagram illustrates our corporate structure as of the date of this prospectus and as of the closing of this offering:



Notes:

- (i) All percentages reflect the equity interests.
- Represents 10,000,000 Ordinary Shares held by Securingium Holding Limited, a BVI company, which is (i) 0.01% owned by Jiahe Developments Limited, which itself is 100% owned by Zhenfa Han, and (ii) 99.99% owned by TSset Holding Limited, which itself is 100% owned by Trident Trust Company (HK) Limited, which acts as the trustee of Generations United Trust, as of the date of this prospectus. The settlor, beneficiary, and protector of Generations United Trust is Zhenfa Han.
 - Represents 570,830 Ordinary Shares held by VVAX Holdings Limited, a BVI company, which is 100% owned by Jilin Zhengye Group Co., Ltd., which is 99% owned by Zhenfa Han and 1% owned by Lihua Sun, as of the date of this prospectus.
 - Represents 569,688 Ordinary Shares held by Vanguards Skyline Holdings Limited, a BVI company, which is 100% owned by Changchun Feier Investment Center (Limited Partnership), which is 64.81% owned by Zhenfa Han. Changchun Feier Investment Center (Limited Partnership) is ultimately controlled by its managing partner, Zhenfa Han, as of the date of this prospectus.
 - Represents 259,465 Ordinary Shares held by TLjinmao Limited, a BVI company, which is 100% owned by Nanjing Tailong Jinmao Pharmaceutical Industry Investment Enterprise (Limited Partnership), which is a private equity fund established and managed by Tibet Golden Investment Management Co., Ltd., as of the date of this prospectus. Tibet Golden Investment Management Co., Ltd. is a Chinese private equity fund management company focusing on investment management and financial information consulting.
 - Represents 16,611 Ordinary Shares held by XZjinyuan Limited, a BVI company, which is 100% owned by Tibet Golden Investment Management Co., Ltd., which is a Chinese private equity fund management company focusing on investment management and financial information consulting, as of the date of this prospectus.
 - Jilin Zhengye is held 58.6890% by Hainan Senhan, 25.1524% by Windsor Holdings, 15.2439% by Jilin Economic and Technological Development Zone Economic and Technological Development General Corporation, 0.9146% by Jilin Jinqiao Investment Co., Ltd., and 0.0001% by Yufeng Liu, as of the date of this prospectus.

For details of each shareholder's ownership, please refer to the beneficial ownership table in the section captioned "Principal Shareholders."

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our combined financial statements and consolidated financial statements and the related notes included in this prospectus. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under "Risk Factors" and elsewhere in this prospectus.

OVERVIEW

We, through the operating entity, focus on the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For nearly 20 years, the operating entity has been committed to enhancing the health of animals. The operating entity markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity's products are available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt.

We have realized steady growth with healthy financial performance. We recorded net income of RMB55.7 million (US\$8.1 million) in 2022 as compared to net income of RMB46.5 million (\$6.7 million) incurred in 2021. We recorded net income of RMB24.1 million (US\$3.3 million) for the six months ended June 30, 2023 as compared to net income of RMB27.6 million (\$3.8 million) incurred for the same period in 2022.

FACTORS AFFECTING RESULTS OF OPERATIONS

Our results of operations and financial condition are affected by the general factors driving veterinary vaccine market. We have benefited from the China's overall economic growth, increased number of large-scale farms, and national policies of animal epidemic detection and prevention in China, which has been attracting breeders' attention and promoting compulsory immunization to raise breeders' full awareness of the risk of animal epidemics and the necessity of immunization.

While our business is influenced by these general factors, we believe our results of operations are also directly affected by certain company specific factors, including the following major factors:

The operating entity's ability to develop high-demand products and expand its business beyond vaccines for livestock by entering into the household animals vaccines industry.

The operating entity intends to develop high-demand products, for example, Subunit Vaccine of Porcine Circovirus Type 2 (Recombinant Baculovirus Strain OKM), which the operating entity has received a Registration Certificate of New Veterinary Drugs for Subunit Vaccine of Porcine Circovirus Type 2 (Recombinant Baculovirus Strain OKM) on September 26, 2021. In addition to developing high demand products, the operating entity also intends to expand its business by developing and manufacturing vaccines for companion animals. As of the date of this prospectus, the operating entity has completed clinical trials for Feline Panleukopenia, FCV, Feline Viral Rhinotracheitis Triple Inactivated Vaccine and Canine Distemper-Parvovirus Vaccine, Inactivated, and its application for Registration Certificate of New Veterinary Drugs for Feline Panleukopenia, FCV, Feline Viral Rhinotracheitis Triple Inactivated Vaccine has been received by the Ministry of Agriculture and Rural Affairs of the PRC on August 9, 2023.

The operating entity's ability to expand its sales and distribution network.

The operating entity intends to expand its sales and distribution network to enter new geographic markets, gain more market share in existing markets and access a broader range of customers. It will continue leveraging its local resources to quickly enter new markets, while also minimizing requirements for capital outlay.

The operating entity's ability to continue to upgrade its technological capabilities

The operating entity believes that its success greatly depends on its ability to attract, incentivize and retain talented professionals. With a view to maintaining and improving its competitive advantage in the market, it plans to implement a series of initiatives to attract additional and retain mid- to high-level personnel, including formulating a market-oriented employee compensation structure and implementing a standardized multilevel performance review mechanism.

The operating entity's ability to maintain its product quality

Relevant PRC laws and regulations were formulated to strengthen the administration of rules pertaining to product quality, as well as to clarify the rules on product liability, consumer protection and maintaining social and economic order. Products offered for sale in China must meet the relevant quality and safety standards. Violations of national or

[Table of Contents](#)

industrial standards for health, safety and any other related violations may result in civil liabilities and penalties, such as compensation for damages, fines, suspension, or shutdown of business, as well as confiscation of products illegally produced for sale and the sales proceeds of such products.

The operating entity has always strictly followed the requirements of the GMP documents of the Ministry of Agriculture and Rural Affairs, adhering to the business philosophy of “creating products with technology, shaping future with quality.” In terms of production process, strict quality control is carried out from raw material entry to product delivery, and quality improvement is achieved through refined management. In terms of personnel, regular training is provided to personnel from departments related to procurement, production, inspection, logistics, and other production processes, designed to ensure the stability of the operating entity’s product quality.

KEY COMPONENTS OF RESULTS OF OPERATIONS

Net Revenues

We derived revenues from (i) swine vaccines, (ii) poultry vaccines and (iii) other vaccines. The following table sets forth a breakdown of our revenues both in absolute amounts and as a percentage of our total revenues for the years indicated.

For the years ended December 31,						
2021			2022			
	RMB	US\$	%	RMB	US\$	%
(in thousands, except for percentages)						
Revenues						
Swine vaccines	183,203	26,562	85.6	235,610	34,160	90.5
Poultry vaccines	19,027	2,759	8.9	16,370	2,373	6.3
Other vaccines	11,837	1,716	5.5	8,289	1,202	3.2
Total revenues	214,067	31,037	100	260,269	37,735	100

The following table sets forth a breakdown of our revenues both in absolute amounts and as a percentage of our total revenues for the six months ended June 30, 2022 and 2023.

For the six months ended June 30,						
2022			2023			
	RMB	US\$	%	RMB	US\$	%
(in thousands, except for percentages)						
Revenues						
Swine vaccines	112,172	15,469	90.9	103,436	14,264	88.5
Poultry vaccines	7,341	1,012	6.0	8,607	1,188	7.4
Other vaccines	3,838	529	3.1	4,809	663	4.1
Total	123,351	17,010	100	116,852	16,115	100

As our revenues are generated from different distribution channels, the following table sets forth a breakdown of our revenues from different distribution channels for the years ended December 31, 2021 and 2022:

For the years ended December 31,						
2021			2022			
	RMB	US\$	%	RMB	US\$	%
(in thousands, except for percentages)						
Revenues						
Direct sales channel	151,256	21,930	70.7	207,324	30,059	79.6
Distribution network	53,886	7,813	25.2	47,845	6,937	18.4
Government tender and procurement	8,925	1,294	4.1	5,100	739	2.0
Total revenues	214,067	31,037	100	260,269	37,735	100

[Table of Contents](#)

The following table sets forth a breakdown of our revenues from different distribution channels for the six months ended June 30, 2022 and 2023.

For the six months ended June 30,						
	2022			2023		
	RMB	US\$	%	RMB	US\$	%
(in thousands, except for percentages)						
Revenues						
Direct sales channel	101,404	13,984	82.2	88,966	12,269	76.1
Distribution network	19,037	2,625	15.4	26,842	3,702	23.0
Government tender and procurement	2,910	401	2.4	1,044	144	0.9
Total	123,351	17,010	100	116,852	16,115	100

Cost of Revenues

Costs of revenues consist primarily of inventory cost and shipping and handling cost of providing these services or goods. The following table sets forth a breakdown of our cost of revenues by nature both in absolute amounts and as a percentage of our total cost of revenues for the years indicated.

For the years ended December 31,						
	2021			2022		
	RMB	US\$	%	RMB	US\$	%
(in thousands, except for percentages)						
Cost of revenues:						
Swine vaccines	68,302	9,903	77.6	88,645	12,852	83.5
Poultry vaccines	10,631	1,541	12.1	9,865	1,430	9.3
Other vaccines	9,075	1,316	10.3	7,707	1,117	7.2
Total	88,008	12,760	100	106,217	15,399	100

The following table sets forth a breakdown of our cost of revenues by nature both in absolute amounts and as a percentage of our total cost of revenues for the six months ended June 30, 2022 and 2023.

For the six months ended June 30,						
	2022			2023		
	RMB	US\$	%	RMB	US\$	%
(in thousands, except for percentages)						
Cost of revenues:						
Swine vaccines	40,397	5,571	86.8	33,959	4,683	76.5
Poultry vaccines	3,616	499	7.8	5,123	707	11.5
Other vaccines	2,494	344	5.4	5,319	733	12.0
Total	46,507	6,414	100	44,401	6,123	100

Operating Expenses

Our operating expenses consist of sales and marketing expenses, research and development expenses, general and administrative expenses, allowance for credit losses and impairment for inventory and intangible asset.

Sales and marketing expenses

Sales and marketing expenses consist primarily of advertising expenses, salaries and other compensation-related expenses to sales and marketing personnel and warranty expenses. We expense all advertising costs as incurred and classify these costs under sales and marketing expenses.

Research and development expenses

Research and development costs are expensed as incurred. These costs primarily consist of payroll and related expenses for personnel engaged in research and development activities.

General and administrative expenses

General and administrative expenses consist primarily of salaries, bonuses and benefits for employees involved in general corporate functions and those not specifically dedicated to research and development activities, depreciation and amortization of fixed assets which are not used in research and development activities, legal and other professional services fees, rental and other general corporate related expenses.

Allowance for credit losses

The Company considers the past collection experience, current economic conditions, future economic conditions (external data and macroeconomic factors) and changes in the Company's customer collection trends. The allowance for credit losses and corresponding receivables were written off when they are determined to be uncollectible.

Impairment

If the sum of the expected future undiscounted cash flows is less than the carrying value of the assets, the Company recognizes an impairment loss based on the excess of the carrying value of the assets over the fair value of the assets.

For the years ended December 31,						
	2021			2022		
	RMB	US\$	%	RMB	US\$	%
(in thousands, except for percentages)						
Sales and marketing expenses	35,904	5,206	49.2	34,565	5,012	39.4
General and administrative expenses	22,290	3,232	30.5	28,993	4,204	33.1
Research and development expenses	11,370	1,648	15.6	13,424	1,946	15.3
Allowance for credit losses	1,925	279	2.6	9,735	1,411	11.1
Impairment for inventory and intangible asset	1,521	221	2.1	968	140	1.1
Total	73,010	10,586	100	87,685	12,713	100

For the six months ended June 30,						
	2022			2023		
	RMB	US\$	%	RMB	US\$	%
(in thousands, except for percentages)						
Sales and marketing expenses	15,941	2,198	36.0	16,581	2,287	38.5
General and administrative expenses	12,428	1,714	28.1	17,055	2,351	39.5
Research and development expenses	8,967	1,237	20.2	6,154	849	14.3
Allowance for credit losses	6,112	843	13.8	(1,408)	(194)	(3.3)
Impairment for inventory and intangible asset	850	117	1.9	4,747	655	11.0
Total	44,298	6,109	100	43,129	5,948	100

TAXATION

Cayman Islands

Under current laws of the Cayman Islands, the Company is not subject to tax on income or capital gains. Additionally, upon payments of dividends by the Company to their shareholders, no withholding tax will be imposed.

Hong Kong

Our subsidiary in Hong Kong is subject to a two-tiered profits tax rate regime. The first HKD\$2 million of assessable profits earned by a company is subject to be taxed at a profits tax rate of 8.25%, while the remaining profits will continue to be taxed at the profits tax rate of 16.5%. Under the Hong Kong tax law, our subsidiary in Hong Kong is exempted from income tax on its foreign derived income and there are no withholding taxes in Hong Kong on remittance of dividends.

China

Effective from January 1, 2008, the PRC’s statutory Enterprise Income Tax (“EIT”) rate is 25%. If our holding company in the Cayman Islands or any of our subsidiaries outside of China were deemed to be a “resident enterprise” under the PRC Enterprise Income Tax Law, it would be subject to enterprise income tax on its worldwide income at a rate of 25%. See “Risk Factors — Risks Relating to Doing Business in the PRC — Under the PRC Enterprise Income Tax Law, we may be classified as a PRC “resident enterprise” for PRC enterprise income tax purposes. Such classification would likely result in unfavorable tax consequences to us and our non-PRC shareholders and have a material adverse effect on our results of operations and the value of your investment.”

RESULTS OF OPERATIONS

The following table sets forth a summary of our consolidated results of operations for the years indicated, both in absolute amounts and as a percentage of our total revenues. This information should be read together with our consolidated financial statements and related notes included elsewhere in this prospectus. The operating results in any period are not necessarily indicative of the results that may be expected for any future period.

Translations of balances in the consolidated balance sheets, consolidated statements of income and comprehensive income, and consolidated statements of cash flows from RMB into US\$ as of and for the years ended December 31, 2021 and 2022 are solely for the convenience of the readers, and they were calculated at the rate of US\$1.00 to RMB6.8972. Translations of balances in the consolidated balance sheets, consolidated statements of comprehensive income, and consolidated statements of cash flows from RMB into US\$ as of and for the six months ended June 30, 2022 and 2023 are solely for the convenience of the readers, and they were calculated at the rate of US\$1.00 to RMB7.2513.

	For the years ended December 31,			
	2021		2022	
	RMB	US\$	RMB	US\$
	(Amounts in thousands of RMB and US\$, except for number of shares and per share data)			
Net revenues	214,067	31,037	260,269	37,735
Cost of revenues	(88,674)	(12,857)	(106,750)	(15,477)
Gross profit	125,393	18,180	153,519	22,258
Sales and marketing expenses	(35,904)	(5,206)	(34,565)	(5,012)
General and administrative expenses	(22,290)	(3,232)	(28,993)	(4,204)
Research and development expenses	(11,370)	(1,648)	(13,424)	(1,946)
Allowance for credit losses	(1,925)	(279)	(9,735)	(1,411)
Impairment for inventory and intangible asset	(1,521)	(221)	(968)	(140)
Total operating expenses	(73,010)	(10,586)	(87,685)	(12,712)
Operating income	52,383	7,594	65,834	9,545
Other income (expenses):				
Other income	53	8	650	94
Other expenses	(137)	(20)	(100)	(14)
Interest income	112	16	114	17
Interest expense	(1,046)	(152)	(2,839)	(412)
Government subsidy	1,701	247	255	37
Total other income (expense), net	683	99	(1,920)	(278)
Income before income taxes	53,066	7,694	63,914	9,267
Income tax expense	(6,599)	(957)	(8,172)	(1,185)
Net income and total comprehensive income	46,467	6,737	55,742	8,082
Net income and comprehensive income attributable to noncontrolling interests	(7,508)	(1,089)	(9,007)	(1,306)
Net income and comprehensive income attributable to the Zhengye Biotechnology Holding Limited’s shareholders	38,959	5,648	46,735	6,776
Earnings per share:				
Ordinary shares – basic and diluted	4.07	0.59	4.88	0.71
Weighted average shares outstanding used in calculating basic and diluted earnings per share:				
Ordinary shares – basic and diluted	11,416,594	11,416,594	11,416,594	11,416,594

[Table of Contents](#)

The following table sets forth a summary of our consolidated results of operations for the six months ended June 30, 2022 and 2023, both in absolute amounts and as a percentage of our total revenues.

	For the six months ended June 30,			
	2022		2023	
	RMB	US\$	RMB	US\$
	(Amounts in thousands of RMB and US\$, except for number of shares and per share data)			
Net revenues	123,351	17,011	116,852	16,115
Cost of revenues	(46,507)	(6,414)	(44,401)	(6,123)
Gross profit	76,844	10,597	72,451	9,992
Sales and marketing expenses	(15,941)	(2,198)	(16,581)	(2,287)
General and administrative expenses	(12,428)	(1,714)	(17,055)	(2,351)
Research and development expenses	(8,967)	(1,237)	(6,154)	(849)
Allowance for doubtful debt	(6,112)	(843)	1,408	194
Impairment for inventory and intangible asset	(850)	(117)	(4,747)	(655)
Total operating expenses	(44,298)	(6,109)	(43,129)	(5,948)
Operating income	32,546	4,488	29,322	4,044
Other Income				
Other Expenses	(100)	(14)	—	—
Interest Income	25	3	105	14
Interest Expense	(1,359)	(187)	(2,152)	(297)
Government Subsidy	237	33	50	7
Total other income(expense), net	(1,197)	(165)	(1,997)	(276)
Income before income taxes	31,349	4,323	27,325	3,768
Income tax expense	(3,798)	(524)	(3,255)	(449)
Net income and total comprehensive income	27,551	3,799	24,070	3,319
Net income and comprehensive income attributable to noncontrolling interests	(4,452)	(614)	(3,889)	(536)
Net income and comprehensive income attributable to the Zhengye Biotechnology Holding Limited's shareholders	<u>23,099</u>	<u>3,185</u>	<u>20,181</u>	<u>2,783</u>
Earning per share:				
Ordinary shares – basic and diluted	2.41	0.33	2.11	0.29
Weighted average shares outstanding used in calculating basic and diluted earnings per share:				
Ordinary shares – basic and diluted	11,416,594	11,416,594	11,416,594	11,416,594

Year ended December 31, 2022 compared to year ended December 31, 2021, and six months ended June 30, 2023 compared to six months ended June 30, 2022

Net Revenues

Our revenue increased by 21.6% from RMB214.1 million (US\$31.0million) for the year ended December 31, 2021 to RMB260.3 million (US\$37.7 million) for the year ended December 31, 2022, primarily due to the increase of revenue from increased sales of swine vaccines.

Our revenue decreased by 5.3% from RMB123.4million (US\$17.0 million) for the six months ended June 30, 2022 to RMB116.9 million (US\$16.1 million) for the six months ended June 30, 2023, primarily due to the decrease of revenue from decreased sales of swine vaccines.

[Table of Contents](#)

Revenue from sales of swine vaccines. Our revenue from sales of swine vaccines grew from RMB183.2 million (US\$26.6 million) for the year ended December 31, 2021 to RMB235.6 million (US\$34.2 million) for the year ended December 31, 2022. Revenue from sales of swine vaccines increased as a result of the increased subscription of swine vaccines from the operating entity's biggest client MYF and the operating entity's increased production capacity.

Our revenue from sales of swine vaccines decreased from RMB112.2million (US\$15.5 million) for the six months ended June 30, 2022 to RMB103.4 million (US\$14.3 million) for the six months ended June 30, 2023. Revenue from sales of swine vaccines decreased as a result of the control of sales to the operating entity's largest customers in order to reduce the dependence on those customers.

Revenue from sales of poultry vaccines. Our revenue from sales of poultry vaccines dropped from RMB19.0 million (US\$2.8 million) for the year ended December 31, 2021 to RMB16.4 million (US\$2.4 million) for the year ended December 31, 2022. Revenue from sales of poultry vaccines decreased as most of the operating entity's production capacity was focused on the production of swine vaccines and therefore the production of poultry vaccines was reduced accordingly.

Our revenue from sales of poultry vaccines grew from RMB7.3million (US\$1.0 million) for the six months ended June 30, 2022 to RMB8.6million (US\$1.2 million) for the six months ended June30, 2023. Revenue from sales of poultry vaccines increased because the operating entity has completed the construction of the new workshop, which has expanded the operating entity's production capacity to accommodate the growing volume of orders for poultry vaccines.

Revenue from sales of other vaccines. Our revenue from sales of other vaccines dropped from RMB11.8 million (US\$1.7 million) for the year ended December 31, 2021 to RMB8.3 million (US\$1.2 million) for the year ended December 31, 2022. Revenue from sales of other vaccines decreased as most of the operating entity's production capacity focused on the production of swine vaccines and therefore the production of other vaccines was reduced accordingly.

Our revenue from sales of other vaccines grew from RMB3.8million (US\$0.5 million) for the six months ended June 30, 2022 to RMB4.8million (US\$0.7 million) for the six months ended June30, 2023. Revenue from sales of other vaccines increased because the operating entity has completed the construction of the new workshop, which has expanded the operating entity's production capacity to accommodate the growing volume of orders for other vaccines.

Cost of Revenues

Our cost of revenues increased by 20.4% from RMB88.7 million (US\$12.9 million) for the year ended December 31, 2021 to RMB106.8 million (US\$15.5 million) for the year ended December 31, 2022, which was largely in line with the increase in net revenues due to increased subscription of the operating entity's products.

Our cost of revenues decreased by 4.5% from RMB46.5million (US\$6.4 million) for the six months ended June 30, 2022 to RMB44.4 million (US\$6.1 million) for the six months ended June30, 2023, which was largely in line with the decrease in net revenues due to decreased subscription of the operating entity's products.

Gross Profit

As a result of the foregoing, our gross profit increased from RMB125.4million (US\$18.2 million) for the year ended December 31, 2021 to RMB153.5 million (US\$22.3 million) for the year ended December 31, 2022. Our gross profit margin increased from 58.9% for the year ended December 31, 2021 to 59.2% for the year ended December 31, 2022, mainly due to the increased revenue from swine vaccines with higher gross profit.

Our gross profit dropped from RMB76.8 million (US\$10.6 million) for the six months ended June 30, 2022 to RMB72.5 million (US\$10.0 million) for the six months ended June 30, 2023. Our gross profit margin increased from 62.3% for the six months ended June 30, 2022 to 62.0% for the six months ended June 30, 2023, with no significant change.

Operating expenses

Our total operating expenses increased from RMB73.0 million (US\$10.6 million) for the year ended December 31, 2021 to RMB87.7 million (US\$12.7 million) for the year ended December 31, 2022, our total operating expenses increased from RMB44.3 million (US\$6.1 million) for the six months ended June 30, 2022 to RMB43.1 million (US\$5.9 million) for the six months ended June 30, 2023, reflecting the increases in our general and administrative expenses, research and development expenses and allowance for credit losses, which were primarily attributable to our business restructuring under the new regulatory environment, the implementation of organizational and staff optimization plans and our more stringent and efficient cost management.

Sales and marketing expenses. Our sales and marketing expenses decreased from RMB35.9 million (US\$5.2 million) for the year ended December 31, 2021 to RMB34.6 million (US\$5.0 million) for the year ended December 31, 2022. The decrease of sales and marketing expenses mainly resulted from decrease in travel expenses, conference expenses, and technology service expenses, partially offset by an increase in payroll for sales staffs. Our sales and marketing expenses increased from RMB15.9 million (US\$2.2 million) for the six months ended June 30, 2022 to RMB16.6 million (US\$2.3 million) for the six months ended June 30, 2023. The increase of sales and marketing expenses was mainly due to an increase in conference expenses and marketing expenses.

General and administrative expenses. Our general and administrative expenses increased from RMB22.3 million (US\$3.2 million) for the year ended December 31, 2021 to RMB29.0 million (US\$4.2 million) for the year ended December 31, 2022. The increase in general and administrative expenses mainly resulted from increase in professional fees for the Company's initial public offering activities. Our general and administrative expenses increased from RMB12.4 million (US\$1.7 million) for the six months ended June 30, 2022 to RMB17.1 million (US\$2.4 million) for the six months ended June 30, 2023. The increase in general and administrative expenses was mainly due to an increase in professional fees and payrolls for administrative staffs.

Research and development expenses. Our research and development expenses increased from RMB11.4 million (US\$1.6 million) for the year ended December 31, 2021 to RMB13.4 million (US\$1.9 million) for the year ended December 31, 2022. The increase in research and development expenses mainly resulted from an increase in research and development material expenses and depreciation and amortization of research infrastructures. Our research and development expenses decreased from RMB9.0 million (US\$1.2 million) for the six months ended June 30, 2022 to RMB6.2 million (US\$0.8 million) for the six months ended June 30, 2023. The decrease in research and development expenses mainly resulted from a decrease in collaborating research expenses.

[Table of Contents](#)

The following table sets forth a summary of our total spending for each research and development project subsidized by the Government of Jilin Province, the PRC, for the six months ended June 30, 2023 and 2022.

Project	For the 6 months ended			
	June 30, 2023		June 30, 2022	
	Expense		Expense	
	RMB	USD	RMB	USD
The Development and Efficacy Evaluation of the Porcine Hemagglutinating Encephalomyelitis Virus DNA Vaccine	—	—	—	—
The Key Technique Study for the Development of the Live Gene-deletion-attenuated Vaccine against Ovine and Caprine Ecthyma (Orf)	587,952	81,082	—	—
The Development and Efficacy Evaluation of Jilin-region-specific High Efficiency Inactivated PED Vaccine	—	—	—	—
Recombinant Newcastle Disease Virus and Avian Influenza Virus Combined Duplex Inactivated Vaccine	—	—	23,681	3,266
Subsidized Project after Trading the Technology for Duck Tambusu Virus Live Vaccine	—	—	—	—
Establishing the OFTu Immortalized Cell Line and its Application in Developing Ovine and Caprine Poxvirus Vaccine	—	—	—	—
The Development of ASFV-PRV Nucleic Acid rapid Co-test Kit and its Application in the Quarantine of Cold-chain Pork	—	—	—	—
The Development of Fish Enteritis Gene-deletion-attenuated Live Vaccine	—	—	—	—
The Virus Study, Laboratory Sample Preparation and Efficacy Evaluation of Inactivated Bovine Akabane Disease Vaccine	431,363	59,488	320,708	44,228
The Development of Ovine and Caprine Contagious Pustular Virus mRNA Vaccine Based on Lipid Nanoparticle Technology	—	—	—	—
The Development of Combined VSV-SVV Nucleic Acid Rapid Test Kit and its Application in the Quarantine of Cold-chain Pork	—	—	—	—
The Study of Rapid Visual Nucleic Acid Test of Various SARS-CoV-2 Mutants	—	—	—	—
The Development of Animal Microecological Vaccine for the Biological Control of African Swine Fever	441,296	60,857	413,804	57,066
The Development and Application of Rapid Visual Test Technology for Key Viral Diseases in Goslings	—	—	—	—
The Development and Application of Fluorescent ERA Rapid Thermostatic Diagnostic Technology for Key Viral Diarrhea Diseases in Pigs	240,455	33,160	—	—
Total	1,701,066	234,587	758,193	104,560

The increase of the research and development expenses for project subsidized by the Government of Jilin Province mainly resulted from two new projects started in 2023, and one project which ended in 2022.

[Table of Contents](#)

The following table sets forth a summary of our total spending for each research and development project subsidized by the Government of Jilin Province, the PRC, for the years ended December 31, 2022 and 2021.

Project	For the years ended			
	December 31, 2022		December 31, 2021	
	Expense		Expense	
	RMB	USD	RMB	USD
The Development and Efficacy Evaluation of the Porcine Hemagglutinating Encephalomyelitis Virus DNA Vaccine	—	—	—	—
The Key Technique Study for the Development of the Live Gene-deletion-attenuated Vaccine against Ovine and Caprine Ecthyma (Orf)	471,633	68,380	0	0
The Development and Efficacy Evaluation of Jilin-region-specific High Efficiency Inactivated PED Vaccine	—	—	—	—
Recombinant Newcastle Disease Virus and Avian Influenza Virus Combined Duplex Inactivated Vaccine	23,681	3,433	2,167,714	314,289
Subsidized Project after Trading the Technology for Duck Tambusu Virus Live Vaccine	—	—	—	—
Establishing the OFTu Immortalized Cell Line and its Application in Developing Ovine and Caprine Poxvirus Vaccine	—	—	—	—
The Development of ASFV-PRV Nucleic Acid rapid Co-test Kit and its Application in the Quarantine of Cold-chain Pork	—	—	—	—
The Development of Fish Enteritis Gene-deletion-attenuated Live Vaccine	—	—	—	—
The Virus Study, Laboratory Sample Preparation and Efficacy Evaluation of Inactivated Bovine Akabane Disease Vaccine	659,009	95,547	—	—
The Development of Ovine and Caprine Contagious Pustular Virus mRNA Vaccine Based on Lipid Nanoparticle Technology	—	—	—	—
The Development of Combined VSV-SVV Nucleic Acid Rapid Test Kit and its Application in the Quarantine of Cold-chain Pork	—	—	—	—
The Study of Rapid Visual Nucleic Acid Test of Various SARS-CoV-2 Mutants	—	—	—	—
The Development of Animal Microecological Vaccine for the Biological Control of African Swine Fever	720,457	104,456	—	—
The Development and Application of Rapid Visual Test Technology for Key Viral Diseases in Goslings	—	—	—	—
The Development and Application of Fluorescent ERA Rapid Thermostatic Diagnostic Technology for Key Viral Diarrhea Diseases in Pigs	—	—	—	—
Total	1,874,780	271,816	2,167,714	314,289

The decrease of research and development expenses for project subsidized by the Government of Jilin Province, the PRC, was mainly due to the fact that most of research and development expenses for the project Recombinant Newcastle Disease Virus and Avian Influenza Virus Combined Duplex Inactivated Vaccine were incurred in the initial months of 2021, which were partially offset by the expenses for new projects started in 2022.

Allowance for credit losses. Our Allowance for credit losses increased from RMB1.9million (US\$0.3 million) for the year ended December 31, 2021 to RMB9.7 million (US\$1.4 million) for the year ended December 31, 2022. Our allowance for credit losses for the six months ended June 30, 2022 was RMB6.1 million (US\$0.8 million), and we reverted RMB1.4 million (US\$0.2 million) for the six months ended June 30, 2023.

Operating income

Our operating income was RMB65.8 million (US\$9.5 million) for the year ended December 31, 2022, compared to an operating income of RMB52.4 million (US\$7.6 million) for the year ended December 31, 2021. Our operating income was RMB29.3 million (US\$4.0 million) for the six months ended June 30, 2023, compared to the operating income of RMB32.5 million (US\$4.5 million) for the six months ended June 30, 2022.

Net income

As a result of the foregoing, we incurred a net income of RMB55.7 million (US\$8.1 million) for the year ended December 31, 2022, compared to a net income of RMB46.5 million (US\$6.6 million) for the year ended December 31, 2021. We incurred a net income of RMB24.1 million (US\$3.3 million) for the six months ended June 30, 2023, compared to the net income of RMB27.6 million (US\$3.8 million) for the six months ended June 30, 2022.

LIQUIDITY AND CAPITAL RESOURCES

The following table sets forth a summary of our cash flows for the years presented:

	For the years ended December 31,			
	2021		2022	
	RMB	US\$	RMB	US\$
	(in thousands)			
Net cash provided by operating activities	31,807	4,612	17,335	2,513
Net cash used in investing activities	(26,270)	(3,809)	(27,328)	(3,962)
Net cash provided by (used in) financing activities	(3,048)	(442)	13,455	1,951
Net increase in cash	2,489	361	3,462	502
Cash at beginning of year	3,795	550	6,284	911
Cash at end of year	6,284	911	9,746	1,413

As of the date of this prospectus, we have financed our operating and investing activities primarily through cash generated from operating and financing activities. As of December 31, 2021 and 2022, our cash were RMB6.3 million (US\$0.9 million) and RMB9.7 million (US\$1.4 million), respectively. Our cash primarily consists of bank deposits.

	For the six months ended June 30,			
	2022		2023	
	RMB	US\$	RMB	US\$
	(in thousands)			
Net cash provided by operating activities	8,356	1,152	7,942	1,095
Net cash used in investing activities	(20,456)	(2,821)	(1,124)	(155)
Net cash provided by financing activities	31,605	4,358	6,970	961
Net increase in cash	19,505	2,689	13,788	1,901
Cash at beginning of year	6,284	867	9,746	1,344
Cash at end of year	25,789	3,556	23,534	3,245

As of June 30, 2022 and 2023, our cash were RMB25.8 million (US\$3.6 million) and RMB23.5 million (US\$3.2 million), respectively. Our cash primarily consists of bank deposits.

We believe that our current cash and expected cash provided by operating and financing activities will be sufficient to meet our current and anticipated working capital requirements and capital expenditures for the next twelve months. We may, however, need additional cash resources in the future if we experience changes in business conditions or other developments. We may also need additional cash resources in the future if we identify and wish to pursue opportunities for investment, acquisition, capital expenditure or similar actions.

All of our revenues have been, and we expect that they are likely to continue to be, in the form of Renminbi. Under existing PRC foreign exchange regulations, payments of current account items, including profit distributions, interest payments and trade and service-related foreign exchange transactions, can be made in foreign currencies without prior SAFE approval as long as certain routine procedural requirements are fulfilled. Therefore, our PRC subsidiaries are allowed to pay dividends in foreign currencies to us without prior SAFE approval by following certain routine

[Table of Contents](#)

procedural requirements. However, current PRC regulations permit our PRC subsidiaries to pay dividends to us only out of their accumulated profits, if any, determined in accordance with Chinese accounting standards and regulations. Our PRC subsidiaries are required to set aside at least 10% of their after-tax profits after making up previous years' accumulated losses each year, if any, to fund certain reserve funds until the total amount set aside reaches 50% of their registered capital. These reserves are not distributable as cash dividends.

As a Cayman Islands exempted company and offshore holding company, we are permitted under PRC laws and regulations to provide funding to our PRC subsidiaries only through loans or capital contributions, subject to the approval, filings or registration of government authorities and limits on the amount of capital contributions and loans. This may delay us from using the proceeds from this offering to make loans or capital contributions to our PRC subsidiaries. We expect to invest substantially all of the proceeds from this offering in our PRC operations for general corporate purposes within the business scopes of our PRC subsidiaries.

Operating Activities

Net cash generated from operating activities was RMB17.3 million (US\$2.5 million) in 2022. The difference between our net cash provided by operating activities and our net income of RMB55.7 million (US\$8.1 million) was due to the combined effects of adjustments for non-cash items and changes in working capital. Adjustments for non-cash items primarily included depreciation and amortization of RMB18.8 million (US\$2.7 million), as compared to RMB16.0 million (US\$2.3 million) in 2021, for we had more Property, plant and equipment in 2022 than 2021. Allowance for credit losses of RMB9.7 million (US\$1.4 million), as compared to RMB1.9 million (US\$0.3 million) in 2021, because one of our client's bank debts and commercial notes were overdue in 2022, and we have made 100% provision of allowance for notes from the client. Changes in working capital mainly resulted from an increase in note receivables of RMB22.6 million (US\$3.3 million), as compared to RMB12.2 million (US\$1.8 million) in 2021, for we collected more revenues from our clients in form of banker's acceptance bill in 2022. An increase in accounts receivable of RMB25.0 million (US\$3.6 million), as compared to RMB28.5 million (US\$4.1 million) in 2021, for the growth rate of revenue in 2022 was slower than the growth rate of revenue in 2021. An increase in inventories of RMB12.3 million (US\$1.8 million), as compared to RMB12.3 million (US\$1.8 million) in 2021, which was almost unchanged and a decrease in accounts payable of RMB9.7 million (US\$1.4 million), as compared an increase of RMB17.6 million (US\$2.6 million) in 2021, because our purchasing scale was smaller in 2022 than that of 2021.

Net cash generated from operating activities was RMB7.9 million (US\$1.1 million) in the six months ended June 30, 2023. The difference between our net cash provided by operating activities and our net income of RMB24.1 million (US\$3.3 million) was due to the combined effects of adjustments for non-cash items and changes in working capital. Adjustments for non-cash items primarily included depreciation and amortization of RMB11.9 million (US\$1.6 million), compared to RMB8.5 million (US\$1.2 million) in the same period in 2022, for we had more property, plant and equipment in 2023 than 2022. Impairment for inventory and intangible assets was RMB4.7 million (US\$0.7 million), compared to RMB0.9 million (US\$0.1 million) of impairment for inventory and intangible assets in the same period in 2022, because during the six months ended June 30, 2022 and 2023, the Company recorded inventory write-down of RMB767 and inventory write-down of RMB4,747 (US\$655) for the obsolete inventories in cost of revenue, respectively. Changes in working capital mainly resulted from increase in accounts receivable of RMB12.0 million (US\$1.7 million), compared to a decrease in accounts receivable of RMB42.0 million (US\$5.8 million) in the same period in 2022, which was impacted by the orders of the operating entity's clients and their payment policy. There was a decrease in accounts payable of RMB30.5 million (US\$4.2 million), compared to an increase of RMB11.7 million (US\$1.6 million) in the same period in 2022, because the operating entity has completed the construction of the new workshop in 2022, and cleared accounts payable related to the investment in 2023.

Investing Activities

Net cash used in investing activities was RMB27.3 million (US\$4.0 million) in 2022, which represented payments for purchases of property and equipment.

Net cash used in investing activities was RMB26.3 million (US\$3.8 million) in 2021, which represented payments for purchases of property and equipment of RMB19.1 million (US\$2.8 million) and prepayment for purchase of intangible assets of RMB7.3 million (US\$1.1 million).

Net cash used in investing activities was RMB1.1 million (US\$0.2 million) in the six months ended June 30, 2023, which represented payments for purchases of property and equipment.

[Table of Contents](#)

Net cash used in investing activities was RMB20.5 million (US\$2.8 million) in the six months ended June 30, 2022, which represented payments for purchases of property and equipment of RMB19.7 million (US\$2.7 million) and prepayment for purchase of intangible assets of RMB0.7 million (US\$0.1 million).

Financing Activities

Net cash provided by financing activities was RMB13.5 million (US\$2.0 million) in 2022, which represented proceeds from loans of RMB99.9 million (US\$14.5 million), partially offset by repayment of loans of RMB65.0 million (US\$9.4 million) and dividend payment to shareholders of RMB21.4 million (US\$3.1million).

Net cash used by financing activities was RMB3.0 million (US\$0.4 million) in 2021, which represented proceeds from loans of RMB30.0 million (US\$4.3 million), offset by repayment of loans of RMB22.0 million (US\$3.2 million) and dividend payment to shareholders of RMB11.0 million (US\$1.6million).

Net cash provided by financing activities was RMB7.0million (US\$1.0 million) in the six months ended June 30, 2023, which represented proceeds from loans of RMB46.9 million (US\$6.5 million), partially offset by repayment of loans of RMB21.9 million (US\$3.0 million) and dividend payment to shareholders of RMB18.0 million (US\$2.5 million).

Net cash provided by financing activities was RMB31.6million (US\$4.4 million) in the six months ended June 30, 2022, which represented proceeds from loans of RMB66.9 million (US\$9.2 million), offset by repayment of loans of RMB22.0 million (US\$3.0 million) and dividend payment to shareholders of RMB13.3 million (US\$1.8 million).

MATERIAL CASH REQUIREMENTS

Our material cash requirements as of December 31, 2022 and any subsequent interim period primarily include our capital expenditures, operating lease commitments and working capital requirements.

Our capital expenditures are primarily incurred for purchases of intangible assets, property, plant and equipment. We made capital expenditures of RMB26.3 million (US\$3.8 million) in 2021 and RMB27.3 million (US\$4.0 million) in 2022, respectively. The increase of capital expenditures was mainly because we have been making Animal Medicine Production Quality Management Standards (Revised in 2020) renovation project since July 2021, one third of this project was finished in 2022, and the rest was finished in January 2023. In the six months ended June 30, 2023, we made capital expenditures of RMB1.1 million (US\$0.2 million), which were primarily incurred for purchases of property, plant and equipment. Our capital expenditures have been primarily funded by cash generated from the operating entity's operations. We expect to continue to make capital expenditures to support the expected growth of our business. We also expect that cash generated from the operating entity's operation activities and financing activities will meet our capital expenditure needs in the foreseeable future.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Foreign Exchange Risk

From July 21, 2005, RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between RMB and the U.S. dollar in the future. To the extent that we need to convert the U.S. dollar into RMB for capital expenditures and working capital and other business purposes, appreciation of RMB against U.S. dollar would have an adverse effect on the RMB amount we would receive from the conversion. Conversely, if we decide to convert RMB into the U.S. dollar for the purpose of making payments for dividends on ordinary shares, strategic acquisitions or investments or other business purposes, appreciation of the U.S. dollar against RMB would have a negative effect on the U.S. dollar amount available to us. In addition, a significant depreciation of RMB against the U.S. dollar may significantly reduce the U.S. dollar equivalent of our earnings or losses.

Political, social and economic risks

The Company has substantial operations in China through its PRC subsidiary, Jilin Zhengye. Accordingly, the Company's business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company's results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has

[Table of Contents](#)

not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1 of our consolidated financial statements, this may not be indicative of future results.

The Company's business, financial condition and results of operations may also be negatively impacted by risks related to regional wars, geopolitical tensions, natural disasters, extreme weather conditions, health epidemics and other catastrophic incidents, which could potentially and significantly disrupt the Company's operations.

Impact of COVID-19

The Company's operations may be further affected by the resurgence of COVID-19 pandemic. A resurgence could potentially cause temporary closure of the Company's factory, limited support from its employees due to quarantine, reduce the Company's capability to execute customer contract and collect customer payments, or disrupt the Company's supply chain, and the continued uncertainties associated with the COVID-19 pandemic may further negatively impact the Company's future revenue growth and cash flows.

Interest rate risk

The Company is exposed to interest rate risk on its interestbearing assets and liabilities. As part of its asset and liability risk management, the Company reviews and takes appropriate steps to manage its interest rate exposure on its interest-bearing assets and liabilities. The Company has not been exposed to material risks due to changes in market interest rates and has not used any derivative financial instruments to manage the interest risk exposure during the period/year presented.

Concentration of credit risk

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash in bank and accounts receivable. The Company places its cash with financial institutions with high credit ratings and quality.

The Company conducts credit evaluations of customers, and generally does not require collateral or other security from its customers. The Company establishes an allowance for expected credit losses primarily based upon the factors surrounding the credit risk of specific customers.

Concentration of customers and suppliers

As of December 31, 2022, one major client accounted for 75.0% of the Company's total accounts receivable. As of June 30, 2023, two major clients accounted for 57.8% and 18.1% of the Company's total accounts receivable, respectively.

For the six months ended June 30, 2022, one major client accounted for 75.9% of the Company's total revenues. For the six months ended June 30, 2023, two major clients accounted for 54.6% and 16.9% of the Company's total revenues.

As of December 31, 2022, one major vendor accounted for 10.9% of the Company's total account payable. As of June 30, 2023, no vendor accounted over 10% of the Company's total account payable.

For the six months ended June 30, 2022, two vendors accounted for 30.8% and 26.8% of the Company's total purchases, respectively. For the six months ended June 30, 2023, one vendor accounted for 10.1% of the Company's total purchases.

CRITICAL ACCOUNTING POLICIES, JUDGMENTS AND ESTIMATES

An accounting policy is considered critical if it requires an accounting estimate to be made based on assumptions about matters that are uncertain and requires significant judgment at the time such estimate is made, and if different accounting estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact the consolidated financial statements.

[Table of Contents](#)

We prepare our consolidated financial statements in accordance with U.S. GAAP. Significant accounting policies we follow in the preparation of the accompanying consolidated financial statements are summarized below.

Revenue recognition

The Company adopted Accounting Standards Codification (“ASC”) 606, *Revenue from Contracts with Customer*. To determine revenue recognition for contracts with customers, the Company performs the following five steps:

- Step 1: Identify the contract with the customer
- Step 2: Identify the performance obligations in the contract
- Step 3: Determine the transaction price
- Step 4: Allocate the transaction price to the performance obligations in the contract
- Step 5: Recognize revenue when the company satisfies a performance obligation

The Company manufactures and sells veterinary vaccines, with an emphasis on vaccines for livestock, to customers.

The Company enters into contract with their customers to provide veterinary vaccines, mainly vaccines for livestock. All of the Company’s contracts have single performance obligation as the promise is to transfer the goods to customers, and there are no other separately identifiable promises in the contracts. The Company recognizes revenue when it transfers its goods to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its products to its customers on a gross basis, because the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude in establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods. The Company’s revenue is recognized at a point in time when the control has been transferred, usually when the customer accepts the goods.

The Company offers their distributors with sales rebate. According to the items in the contract, the Company pays certain sales rebate, in the form of products with equivalent value, to distributor once the distributor purchases stipulated amount products from the Company. Sales rebate is considered as variable consideration. The Company estimates annual expected revenue of each individual distributor with reference to their historical results. The sales rebate reduces revenues recognized. At the end of each reporting period, the Company updates the estimated revenue to represent faithfully the circumstances present at the end of the reporting period.

Apart from the sales rebate, the Company’s products are sold with no right of return and the Company does not provide other credits or sales incentives to customers. Revenue is reported net of value added tax (“VAT”), business tax and surcharges collected on behalf of tax authorities in respect of product sales.

Use of estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, related disclosures of contingent assets and liabilities at the balance sheet date, and the reported revenue and expenses during the reported period in the consolidated financial statements and accompanying notes. Significant accounting estimates reflected in the Company’s consolidated financial statements mainly include, but are not limited to, allowance for credit losses, standalone selling price of each distinct performance obligation in revenue recognition, depreciable lives of property, equipment and software, assessment for impairment of long-lived assets, inventory valuation for excess and obsolete inventories, lower of cost and net realizable value of inventories and valuation of deferred tax assets.

Management bases the estimates on historical experience and on various other assumptions as discussed elsewhere to the consolidated financial statements that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. On an ongoing basis, management evaluates its estimates based on information that is currently available. Changes in circumstances, facts and experience may cause the Company to revise its estimates. Changes in estimates are recorded in the period in which they become known. Actual results could materially differ from these estimates.

Notes receivable, net

Notes receivable, generally due within twelve months and with specific payment terms and definitive due dates, are comprised of the bank acceptance notes issued by some customers to pay certain outstanding receivable balances to the Company. Bank acceptance notes do not bear interest.

Accounts receivable and allowance for credit losses

Accounts receivable are stated at the historical carrying amount net of allowance for expected credit losses.

The Company adopted ASU No. 2016-13, “Financial Instruments — Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments” on January 1, 2021 using a modified retrospective approach. The Company also adopted this guidance to notes receivable, advance to suppliers, other receivables and long-term prepayments. To estimate expected credit losses, the Company has identified the relevant risk characteristics of its customers and the related receivables. The Company considers the past collection experience, current economic conditions, future economic conditions (external data and macroeconomic factors) and changes in the Company’s customer collection trends. The allowance for credit losses and corresponding receivables were written off when they are determined to be uncollectible.

Inventories, net

Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the normal course of business less any costs to complete and sell products. Cost of inventory are determined using the weighted average method. The Company records inventory reserves for obsolete and slow-moving inventory.

Inventory reserves are based on inventory obsolescence trends, historical experience and application of the specific identification method.

Advance to suppliers

Advance to suppliers are mainly funds deposited for future raw material or finished goods purchases. The Company’s certain vendors require deposits as a guarantee that the Company will complete its purchases on a timely basis as well as securing the current agreed upon purchase price. Advance to suppliers is short-term in nature. Advance to suppliers is reviewed periodically to determine whether its carrying value has become impaired. The Company uses credit loss method to estimate the allowance for the questionable balances.

Property, plant and equipment, net

Property, plant and equipment are stated at cost less accumulated depreciation and impairment loss, if any. Property and equipment are depreciated at rates sufficient to write off their costs less impairment and residual value, if any, over their estimated useful lives on a straight-line basis.

Category	Estimated useful life
Buildings	13 – 30 years
Mechanical equipment	1 – 10 years
Motor vehicles	10 years

Intangible assets

Intangible assets are carried at cost less accumulated amortization and impairment, if any. Intangible assets are amortized using the straight-line method over the estimated useful lives from 3 to 10 years. The estimated useful lives of amortized intangible assets are reassessed if circumstances occur that indicate the original estimated useful lives have changed. During the years ended December 31, 2021 and 2022, the Company recorded impairment of intangible assets in the amount of RMB83 (US\$12) and RMB445 (US\$65), respectively. During the six months ended June 30, 2022 and 2023, the Company recorded impairment of intangible assets in the amount of RMB83 (US\$12) and nil, respectively.

Category	Estimated useful life
Purchased software	3 – 5 years
Patent	5 – 10 years

Impairment of long-lived assets other than goodwill

Long-lived assets are evaluated for impairment whenever events or changes in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying amount may not be fully recoverable or that the useful life is shorter than the Company had originally estimated. When these events occur, the Company evaluates the impairment by comparing carrying value of the assets to an estimate of future undiscounted cash flows expected to be generated from the use of the assets and their eventual disposition. If the sum of the expected future undiscounted cash flows is less than the carrying value of the assets, the Company recognizes an impairment loss based on the excess of the carrying value of the assets over the fair value of the assets. Impairment charges recognized for the years ended December 31, 2021 and 2022 were nil and nil, respectively. Impairment charge recognized for the six months ended June 30, 2022 and 2023 was nil.

RECENT ACCOUNTING PRONOUNCEMENTS

For detailed discussion on recent accounting pronouncements, see Note 2 to our Consolidated Financial Statements.

INDUSTRY

All the information and data presented in this section have been derived from the industry report of Frost & Sullivan (Beijing) Inc., Shanghai Branch Co. (“Frost & Sullivan”) commissioned by us in March 2023 entitled China’s Veterinary Vaccine Market Independent Market Research (the “Frost & Sullivan Report”), unless otherwise noted. Frost & Sullivan has advised us that the statistical and graphical information contained herein is drawn from its database and other sources. The following discussion contains projections for future growth, which may not occur at the rates that are projected or at all.

OVERVIEW OF CHINA’S VETERINARY VACCINE MARKET


Classification of Veterinary Vaccine

According to the product type, veterinary vaccine can be divided into live vaccine and inactivated vaccine.

Live Vaccine: Live vaccine is a live microbial preparation made from bacteria or virus pathogenic microorganisms, which can reduce toxicity under artificial cultivation, but still retain the immunogenicity and reproduction ability of pathogenic microorganisms or screen some non-toxic and micro-virus pathogens from the outside. Common live vaccines include classical swine fever rabbit attenuated vaccine, chicken pox live vaccine, sheep small ruminant disease live vaccine. Most live vaccines are freeze-dried by vacuum drying, which can prolong their storage time and maintain their potency.

Inactivated Vaccine: Inactivated vaccine is made of bacteria/virus culture, toxic tissue or cell culture, inactivated by chemical inactivator or heated to inactivate microorganisms and maintain immunogenicity, and then added with appropriate preservatives or immune adjuvants. Inactivated vaccines generally need adjuvants. Based on different adjuvants, inactivated vaccines can be divided into oily adjuvants vaccine (including oil in water, water in oil, and multiple water in oil in water), aluminum adjuvant vaccine (with longer action time), and propolis adjuvant vaccine (propolis increases immune effect).

Research Process of Veterinary Vaccine




Source: WHO, Frost & Sullivan Analysis

Market Size of Veterinary Vaccine in China

The market size of the China veterinary vaccine market increased from USD1.9 billion in 2018 to USD2.5 billion in 2022 at a compound annual growth rate (“CAGR”) of 6.6% and is expected to further increase to USD3.2 billion in 2026 with a CAGR of 6.5%.

Historical and Forecasted Market Size of Veterinary Vaccine in China, 2018-2026E



Source: China Veterinary Drug Association, Literature Review, and Frost & Sullivan Analysis

Growth Drivers and Future Trends of China's Veterinary Vaccine Market

Increased number of large-scale farms

In recent years, the livestock and poultry breeding has been increasing in scale. For example, the percentage of large-scale pig farms with an annual output of more than 500 pigs reached 70% in 2020. The risk of loss from disease caused by the large breeding density of large breeding enterprises is greater, and their average epidemic prevention cost is higher than that of retail investors, so the large-scale farms are more sensitive to the quality and cost-effectiveness of vaccines.

Immunization awareness and E-commercialization

Local governments have been attracting breeders' attention and promoting compulsory immunization to raise breeders' full awareness of the risk of animal epidemics and the necessity of immunization. At the same time, veterinary drug trading has gradually achieved e-commercialization. Some farmers began to use e-commerce platforms to purchase veterinary vaccines and exchange veterinary vaccine information.

Animal epidemics prevalence in some regions

In recent years, there have been many outbreaks of foot-and-mouth disease of type O, foot-and-mouth disease of type A, poultry H5 subtype highly pathogenic avian influenza, poultry H7N9 influenza, small ruminant disease, and other diseases in China. In 2021, a total of seven outbreaks of H5 subtype highly pathogenic avian influenza, which were sporadic and wide-ranging, were reported in China. The prevalence of animal epidemics results in a great demand for veterinary vaccines.

National policies of animal epidemic detection and prevention

China has promulgated a series of favorable epidemic detection and prevention policies in recent years.

For example, in 2021 the Chinese government amended the Animal Epidemic Prevention Law of the PRC. Prevention is the basis for preventing and controlling animal diseases and is an important measure to effectively reduce production costs and improve the economic benefits of animal husbandry. In the amended law, three new measures have been added in the prevention of animal diseases: improving the compulsory immunization system, improving the epidemic monitoring and early warning system, and establishing a regionalized management system for animal diseases. The law stipulates that companies and individuals who raise animals should fulfill their obligations of compulsory immunization against animal diseases and must properly conduct compulsory immunization. Compulsory immunization is closely related to the use of veterinary vaccines.

Second, in 2022, the Ministry of Agriculture and Rural Affairs issued the National Plan for the Prevention and Control of Zoonoses among Animals (2022-2030), which pointed out that zoonotic diseases among animals need to be prevented and controlled from the source, with the participation of multiple parties under the leadership of the government. Key tasks include (i) strengthening scientific and technological support for disease prevention and control technology; (ii) accelerating the introduction, research and development, registration and application of new vaccines and rapid diagnosis and differential diagnostic technology products; and (iii) improving the establishment of a repository for zoonotic pathogens between animals and humans, and a standard substance library for vaccines and diagnostic products.

In addition, the key tasks in the 14th Five-Year Plan for National Animal Husbandry and Veterinary Industry Development Plan issued by the Ministry of Agriculture and Rural Affairs also includes strengthening the prevention and control of animal diseases and ensuring the efficient and safe supply of breeding inputs. It requires to strictly control the production and use of veterinary drugs, promote the transformation and upgrading of the veterinary drug industry, improve vaccine production technology, and support the development of raw pharmaceutical materials and formulations specifically for animals, safe and efficient polyvalent combined vaccines, new labeled vaccines, and veterinary diagnostic products.

Entry Barriers and Success Factors of China's Veterinary Vaccine Market

Market access barriers

Given the need for vaccine upgrading, first-mover advantage is one of market access barriers. The product iteration speed of first-mover enterprises is faster than that of latecomers, so the leading enterprises can keep maintaining competitive advantages and a high profit margin through continuous upgrading of new products. Vaccine production capacity is another market access barrier. Vaccine developers with large-scale production capacity can obtain vaccines suitable for different animals, as well as vaccines with different serotype coverage and antigen composition, by adjusting production steps and parameters, which is difficult for new entrants to achieve in a short period of time.

Sales channel barrier

The supply of vaccines required by China's compulsory immunization against animal diseases system has gradually shifted from governmental procurement to the market supply, with the goal of completely eliminating the channels of governmental procurement by 2025. Since domestic veterinary vaccines are mainly sold in agricultural and pastoral areas and the terminals are scattered, there is a demand for the distribution channel capacity. Enterprises with excellent sales ability have formed a multi-channel layout of direct sales and distribution, and a sales team with wide coverage is conducive to improving market rate and achieving rapid expansion.

R&D technology & talent barriers

Veterinary vaccine is a product with a long R&D and production cycle. There must be a large amount of R&D investment to improve market competitiveness, so it is difficult for enterprises with insufficient funds to enter the industry. Besides, long-established companies have relatively sufficient technical personnel for veterinary vaccine production and after-sales technical services. New entrants cannot obtain sufficient human resources in the market, and the acquisition of talents mainly relies on the company's internal training.

Analysis of Domestic Top Players’ Product Portfolio


In 2022, according to Frost & Sullivan’s analysis, among domestic veterinary vaccine companies, the operating entity, Jilin Zhengye Biological Products Co., Ltd. (“ZYBIO”) has the most comprehensive product portfolio.

	Porcine Vaccines	Poultry Vaccines	Bovine and Ovine Vaccines	Pet Vaccines
ZYBIO	■	■	■	■
JINYU BIO	■	■	■	■
YEBIO	■	■	■	■
CAHIC	■	■	■	■
RINGPU	■	■	■	■
KEQIAN BIO	■	■	■	■
TECON	■	■	■	■
PULIKE BIO	■	■	■	■
WINSON	■	■	■	■
JINHE BIO	■	■	■	■
HILE BIO	■	■	■	■

Source: Company Websites, Public Information, Prospectus, and Frost & Sullivan Analysis

Ranking of Revenue of China’s Veterinary Vaccine Companies


In 2022, ZYBIO generated revenue of RMB260.3 million.



Source: Company Websites, Company Annual Report, and Frost & Sullivan Analysis

Ranking of Annual Growth Rate of China's Veterinary Vaccine Revenue

In 2022, the annual growth rate of ZYBIO's veterinary vaccine revenue reached 21.4%.



Source: Company Websites, Company Annual Report, and Frost & Sullivan Analysis


Overview of China's Porcine Vaccine Market

Overview of the Porcine Market

Pork is the most important source of animal protein for Chinese people and has long been dominant in China's national meat consumption. Porcine can be divided into two main groups, breeding porcine and commercial porcine. In 2021, from the supply side of porcine consumption market, China's pork production was 53 million tons, accounting for 44.09% of global pork production, ranking first in the world. From the demand side of porcine consumption market, China's pork consumption accounts for about 46% of the world's pork consumption and per capita pork consumption is about twice as much as the world's per capita pork consumption.

Market Size of Porcine Vaccine in China

The market size of the China porcine vaccine market increased from USD0.84 billion in 2018 to USD1.20 billion in 2022 at a CAGR of 9.4%, and is expected to further increase to USD1.45 billion in 2026 with a CAGR of 4.9%. In the short term, the outbreak of African Swine Fever had a negative impact on the animal husbandry industry, causing a decline in the number of live pigs and demand for porcine vaccines. In the long run, African Swine Fever has accelerated the withdrawal of small and medium-sized breeders from the market, and the concentration of the pig farming industry has further enhanced. The great demand for epidemic prevention from large-scale farms will bring long-term benefits to the veterinary vaccine market.



Source: China Veterinary Drug Association, Literature Review, and Frost & Sullivan Analysis

Ranking of China's Porcine Vaccine Revenue

In 2022, ZYBIO generated revenue of RMB235.6 million from the sales of porcine vaccines.



Source: Company Websites, Company Annual Report, and Frost & Sullivan Analysis


Overview of China's Poultry Vaccine Market

Overview of the Poultry market

Poultry can be divided into meat poultry, breeding poultry, and laying poultry. In addition to providing humans with meat and eggs, poultry also has an important economic value in their feathers and droppings. Poultry breeding has become one of the most common livestock production businesses in China.

Market Size of Poultry Vaccine in China

The market size of the China's poultry vaccine market increased from USD0.66 billion in 2018 to USD0.93 billion in 2022 at a CAGR of 9.0%, and is expected to further increase to USD1.20 billion in 2026 with a CAGR of 6.6%.



Source: China Veterinary Drug Association, Literature Review, and Frost & Sullivan Analysis

Ranking of China’s Poultry Vaccine Revenue

In 2022, ZYBIO generated revenue of RMB16.4 million from the sales of poultry vaccines.



Source: Company Websites, Company Annual Report, and Frost & Sullivan Analysis

Overview of China’s Bovine and Ovine Vaccines Market


Overview of the Bovine and Ovine market

Bovine is a species with high environmental adaptation ability. Cowhide, sheepskin, wool, and other materials can be processed to make garments, leather purses, etc. In China, ovine is mostly kept as goats and sheep. Sheep meat is nutrient-dense and popular in China. Due to unique dietary habits, there is a considerable dependence on sheep meat, particularly in the northwestern minor ethnic group communities.

Market Size of Bovine and Ovine Vaccine in China

The market size of the China bovine and ovine vaccine market dropped from USD0.37 billion in 2018 to USD0.29 billion in 2022 at a CAGR of -5.7% and is expected to increase to USD0.39 billion in 2026 with a CAGR of 7.8%.


Historical and Forecasted Market Size of Bovine and Ovine Vaccine in China, 2018-2026E



Source: China Veterinary Drug Association, Literature Review, and Frost & Sullivan Analysis

Ranking of China's Bovine and Ovine Vaccine Revenue

In 2022, ZYBIO generated revenue of RMB7.9 million from the sales of bovine and ovine vaccines.




Source: Company Websites, Company Annual Report, and Frost & Sullivan Analysis

Overview of China's Pet Vaccines Market

Overview of the Pet market

The pet industry provides goods and services connected to pets and pet owners in all aspects of their lives from birth to death, including food, clothing, livelihood, transportation, entertainment, and education. The pet industry can be divided into five categories: pet food, pet supplies, pet services, pet medical care, and live trading. China's pet medical market is one of the fastest growing segments in China's pet industry. The pet vaccine market, a large segment of pet medical care, is also on the rise, accounting for 8.9% of the overall pet medical market in 2021.

According to relevant studies, the first place in the ranking of the purpose of domestic pet owners visiting pet hospitals is vaccination, accounting for 70.3%. More than 90% of pet owners know that they need to vaccinate their pets regularly, but only 67.2% of pet owners regularly vaccinate their pets against rabies and 74.1% of them vaccinate their pets against infectious diseases every year. At present, the penetration rate of pet vaccines in China is less than 3%, which is still far from the level of 40% in foreign developed countries.




Source: Literature Review, 2021 China Pet Medical White Paper (consumption report), and Frost & Sullivan Analysis

Market Size of Pet Vaccine in China

The market size of the China pet and other vaccine market increased from USD0.03 billion in 2018 to USD0.05 billion in 2022 at a CAGR of 10.2% and is expected to further increase to USD0.10 billion in 2026 with a CAGR of 23.6%.

Historical and Forecasted Market Size of Pet and Other Vaccine in China, 2018-2026E



Source: China Veterinary Drug Association, Literature Review, and Frost & Sullivan Analysis

Note: This vaccine market includes vaccines for cats, dogs, rabbits, and other animals, most of which are pet vaccines.

Analysis of Domestic Top Players' Pet Vaccine Portfolio

As of March 31, 2023, according to Frost & Sullivan's analysis, among domestic veterinary vaccine companies, ZYBIO is granted one approval for sale and three approvals for clinical trial for its pet vaccines.

	Canine Vaccine in Product Commercialization	Canine Vaccine in Clinical Trials	Feline Vaccine in Clinical Trials	Total Number of Pet Vaccines
ZYBIO	1	1	2	4
JINYU BIO	1	2	1	4
RINGPU	1	1	1	3
KEQIAN BIO	2	0	0	2
YEBIO	1	1	0	2
PULIKE BIO	0	1	1	2
CAHIC	1	0	0	1

Source: China Veterinary Drug Association, Company Annual Report, and Frost & Sullivan Analysis

[Table of Contents](#)

Set forth below are the details regarding the clinical trials that ZYBIO has received approvals to commence.

Batch number	2022005	2021017	2021024
Project Name	Feline Panleukopenia, FCV, Feline Viral Rhinotracheitis Triple Inactivated Vaccine	Feline Rhinotracheitis, Feline Rhino conjunctivitis and Feline Panleukopenia Triple Inactivated Vaccine (Strain HB+Strain BJ+Strain ZJ)	Canine Distemper and Parvovirus Vaccine
Clinical Trials Status	Clinical trials completed	Clinical trials completed	Clinical trials completed
Clinical Trial Venue	Xinuo Laboratory Animal Room, Changchun City, Jilin Province, China; Zhou Ping Pet Hospital of Green Park, Changchun City, Jilin Province, China; Boren Pet Hospital of Chaoyang District, Changchun City, Jilin Province, China; Beisite Animal Clinic of High-tech Industrial Development Zone, Changchun City, Jilin Province, China; Zhou Ping Animal Clinic of Jingyue Hi-tech Industrial Development Zone, Changchun City, Jilin Province, China; Changchun Guancheng Animal Clinic, Changchun City, Jilin Province, China; Dr. Sun Animal Hospital of Nanguan District, Changchun City, Jilin Province, China;	Zhou Ping Pet Hospital of Green Park, Changchun City, Jilin Province, China; Jilin Zhonghe Agricultural Technology Co., Ltd. Pet Clinic, Changchun City, Jilin Province, China; Bangyou Animal Hospital of Hanyang District, Wuhan City, Hubei Province, China; Yixin Pet Hospital of Kangzhouwan District, Ningbo City, Zhejiang Province, China	Changchun Longsheng Laboratory Animal Science and Technology Co., Ltd., Changchun City, Jilin Province, China; Qingdao Zhongren Aolan Bioengineering Co., Ltd., Qingdao City, Shandong Province, China; Nanjing Yate Laboratory Animal Research Co., Ltd., Nanjing City, Jiangsu Province, China Beijing Kangwens Biotechnology Development Co., Ltd., Beijing City, China; Zhou Ping Pet Hospital of Green Park, Changchun City, Jilin Province, China; Boren Pet Hospital of Chaoyang District, Changchun City, Jilin Province, China; Beisite Animal Clinic of Hi-tech Industrial Development Zone, Changchun City, Jilin Province, China; Zhou Ping Animal Clinic of Jingyue Hi-tech Industrial Development Zone, Changchun City, Jilin Province, China;

[Table of Contents](#)

Batch number	2022005	2021017	2021024
Clinical Trial Venue	<p>Heng Ai Animal Hospital of Economic and Technological Development Zone, Changchun City, Jilin Province, China;</p> <p>Sanjia Boren Animal Hospital of Gaoxin Park, Changchun City, Jilin Province, China;</p> <p>Aiwei Animal Hospital of Erdao District, Changchun City, Jilin Province, China;</p> <p>Nuokang Animal Hospital of Licang District, Qingdao City, Shandong Province, China;</p> <p>Famous Dog Pavilion Animal Hospital of Wuhou District of Chengdu City, Sichuan Province, China;</p> <p>Kongxu Pet Hospital, Zhengzhou City, Henan Province, China</p>		<p>Changchun Guancheng Animal Clinic, Changchun City, Jilin Province, China;</p> <p>Dr. Xie Animal Hospital of Gaoxin Si District, Changchun City, Jilin Province, China;</p> <p>Dr. Sun Animal Hospital of Nanguan District, Changchun City, Jilin Province, China;</p> <p>Heng Ai Animal Hospital of Economic and Technological Development Zone, Jilin Province, China;</p> <p>Sanjia Boren Animal Hospital of Gaoxin Park, Jilin Province, China;</p> <p>Aiwei Animal Hospital of Erdao District, Changchun City, Jilin Province, China;</p> <p>Nuokang Animal Hospital of Licang District, Shandong City, Qingdao Province, China;</p> <p>Famous Dog Pavilion Animal Hospital of Wuhou District of Chengdu City, Sichuan Province, China;</p> <p>Caring Animal Hospital of Gaoxin District, Chengdu City, Sichuan Province, China;</p> <p>Shihuang Minking Animal Hospital of Jianye District, Nanjing City, Jiangsu Province, China</p>
Partners	<p>Changchun Xinuo Biotechnology Co., Ltd., and Guangxi Aichong Biotechnology Co., Ltd. Changchun Xinuo Biotechnology Co., Ltd. takes the lead in the clinical trial</p>	<p>Jili Biotechnology Co., Ltd., Jilin Jili Biotechnology Research Co., Ltd., Jili (Zhejiang) Inspection Service Co., Ltd., and Hangzhou Animal Vaccine Factory.</p> <p>Jili Biotechnology Co., Ltd. takes the lead in the clinical trial</p>	<p>Changchun Xinuo Biotechnology Co., Ltd., and Guangxi Yiyao Biotechnology Co., Ltd.</p> <p>Jili Biotechnology Co., Ltd. takes the lead in the clinical trial</p>

Batch number	2022005	2021017	2021024
Structure and Results	<p>The clinical trials were carried out from February 2022 to April 2023. A total of 255 cats were enrolled for the trial.</p> <p>The procedure comprised screening of subjects, allocating them into two groups (the test and control veterinary drug groups), administering vaccinations, and conducting regular monitoring, sampling, testing, and data compilation, culminating in safety and efficacy evaluations.</p> <p>The clinical trials showed that no severe adverse reactions were detected in either the group receiving the test veterinary drug or the control group. The safety profile for the trial cats was positive and consistent across both groups.</p> <p>Both the test veterinary drug and its control counterpart elicited a strong immune response in the trial cats. The onset, peak, and duration of antibody responses were similar between both groups. Notably, the antibody titers were higher in the group that received the test veterinary drug. Consequently, the immunogenic response of the test veterinary drug at the recommended dosage of 1ml per cat proved to be more effective than the control veterinary drug.</p>	<p>The clinical trials regarding safety and efficacy of the vaccine were carried out between 2021 and 2023, involving 260 cats.</p> <p>The procedure comprised screening of subjects, allocating them into two groups (the test and control veterinary drug groups), administering vaccinations, and conducting regular monitoring, sampling, testing, and data compilation, culminating in safety and efficacy evaluations.</p> <p>The clinical trials showed that no severe adverse reactions were detected in either the group receiving the test veterinary drug or the control group. The safety profile for the trial cats was positive and consistent across both groups.</p> <p>Both the test veterinary drug and its control counterpart elicited a strong immune response in the trial cats. The onset, peak, and duration of antibody responses were similar between both groups.</p> <p>In the vaccine trial, cats that received a single dose, multiple single doses, or an overdose exhibited no irregularities in body temperature, behavior, appetite, or fecal output. There were no cases of allergic reactions, vomiting, or other severe adverse effects observed. Additionally, the sites of injection did not show any signs of swelling,</p>	<p>The clinical trials regarding safety and efficacy of the vaccine were carried out between August 2021 and May 2022, involving 1150 dogs.</p> <p>The clinical trials demonstrated that no severe adverse reactions were detected in either the group receiving the test veterinary drug or the control group. The safety profile for the trial dogs was positive and consistent across both groups.</p> <p>Both the test veterinary drug and its control counterpart elicited a strong immune response in the trial dogs. The onset, peak, and duration of antibody responses were similar between both groups. However, in the trials completed in the animal hospitals, the test group exhibited a significantly stronger antibody response compared to the control group. This indicates that, at the recommended dosage, the test veterinary drug's immunogenicity was superior to the control drug.</p>

[Table of Contents](#)

Batch number	2022005	2021017	2021024
		<p>hardening, or ulceration. Autopsies conducted on the immunized cats revealed no abnormalities at the injection sites or in their major organs. Histological examination of tissue samples demonstrated effective absorption of the vaccine.</p> <p>Following the administration of the test vaccine in repeated single doses, blood samples were periodically taken to evaluate the neutralizing potency in cat serum against Feline Panleukopenia Virus and Feline Calicivirus, including the assessment of neutralizing antibodies specific to Feline Panleukopenia Virus. The efficacy rates of neutralizing antibodies for these viruses consistently aligned with the anticipated standards.</p> <p>Following the administration of repeated single doses of the test vaccine, exposure trials with Feline Herpesvirus, Feline Calicivirus, and Feline Panleukopenia Virus at 9 and 12 months post-vaccination resulted in 100% protection.</p>	

BUSINESS

Our Mission

Our mission is to become a world-leading manufacturer of veterinary vaccines and to provide reliable veterinary vaccines to the world.

Overview

We, through the operating entity, focus on the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For nearly 20 years, the operating entity has been committed to enhancing the health of animals. The operating entity markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity's products are available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan and Egypt.

Competitive Strengths

- **Diversified products.** The operating entity currently owns 43 veterinary vaccines in its product portfolio, which cover major veterinary vaccines for livestock, including monovalent vaccine, polyvalent vaccine, combined vaccine and combined and polyvalent vaccine. In addition to its focus on livestock vaccines, the operating entity is also developing vaccines for household animals. For example, as of the date of this prospectus, the operating entity has secured governmental approval for the sale of Rabies Vaccine, Inactivated (Strain Flury LEP), which is designed to treat dogs.
- **High production quality.** The operating entity has built three veterinary vaccine production floors, including 13 vaccine production lines, one quality examination center, and one animal facility for vaccine development, all operating in accordance with Good Manufacturing Practices for Veterinary Drugs issued by the Ministry of Agriculture and Rural Affairs of the PRC. Moreover, the operating entity has established a comprehensive quality management system, which complies with both Good Manufacturing Practices for Veterinary Drugs and the standards of ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018. Through its quality management system, the operating entity oversees all production procedures, such as packaging, storage, shipping, equipment usage, raw materials examination, and environment detection.
- **Strong research and development capabilities.** The operating entity has 49 employees working in the R&D department, many of which have over a decade of experience working in the veterinary vaccine industry. Additionally, the operating entity owns one research center, which collectively has helped the operating entity develop dozens of vaccines and inventions and utility models. In addition to independent R&D, the operating entity has also maintained long-term cooperative relationships with a number of universities and institutions in the PRC, such as China Agricultural University, Nanjing Agricultural University, Jilin University, and Shanghai Veterinary Research Institute of Chinese Academy of Agricultural Sciences. Through these cooperations, the operating entity capitalizes on fundamental research from institutes to develop and manufacture new products. For example, the Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, live (Strain huadu+Strain CV777+Strain NX), developed by both the operating entity and the Harbin Veterinary Research Institute, and owned by the Harbin Veterinary Research Institute, for which the operating entity agreed to make a payment of RMB56 million and to pay 5% of its annual revenue from the sale of this vaccine every year, has already been launched and is available for purchase; the Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010 -180P), developed by both the operating entity and Shanghai Veterinary Research Institute, and owned by the Shanghai Veterinary Research Institute, for which the operating entity agreed to make a payment of RMB6 million and to pay 5% of its annual revenue from the sale of this vaccine every year, has been launched; and Reassortant Newcastle Disease Virus and Avian Influenza Virus (H9 Subtype) Vaccine, Inactivated (Strain aSG10+Strain G), developed by both the operating entity and China Agricultural University, jointly owned by the China Agricultural University and the China Institute of Veterinary Drug Control, for which the operating entity agreed to pay RMB6 million, has also been launched. See “— Research and Development” for key terms of cooperative research agreements. As of the date of this prospectus, the operating entity has paid RMB4,225,181, RMB6,597,616, RMB500,000, RMB816,200, and RMB3,200,000, to Shanghai Veterinary Research Institute, Harbin Veterinary Research Institute, Jilin University, China Agricultural University, and Nanjing Agricultural University, respectively.

- **Extensive distribution channels.** The operating entity maintains a wide distribution network which allows it to sell its products both domestically and internationally. For the six months ended June 30, 2023 and the fiscal years ended December 31, 2022 and 2021, it had approximately 209, 195, and 145 domestic distributors, and 2, 2, and 2 exporting distributors, respectively. With the help of the domestic distributors, the Company through its operating entities is able to sell its products in 29 provincial level administrative regions of China. Through the exporting distributors, the operating entity sells its products in foreign countries, including Vietnam, Pakistan, and Egypt. Please refer to “— Distribution Network.”
- **Experienced management team and employees.** The operating entity has an experienced management team. Multiple officers have animal disease control and prevention and managerial experience in the animal product industry. For example, the chief manager of the operating entity, Songlin Song, graduated from China Agricultural University, and vice managers Wei Lian and Yuyou He, both graduated from Jilin Agricultural University. Moreover, Songlin Song is an advisor of the master programs in Jilin University College of Veterinary Medicine, Chinese Academy of Agricultural Sciences, and a guest professor of at Jilin Medical University. Wei Lian is an advisor of the master programs in Jilin University College of Veterinary Medicine and Chinese Academy of Agricultural Sciences. In addition to their academic background, the management team also has a deep understanding of both the industry and the operating entity. Yuyou He started working in the operating entity in 1984, and currently serves as the deputy manager and director of technology. Wei Lian started his career in the operating entity as well in 2005. He used to serve as the manager of the department of quality control and assistant general manager, and he has been the deputy general manager of the operating entity since 2021. Songlin Song has worked in the industry since 1998 and he has been the director and general manager of the operating entity since 2018. There are 27 employees holding master or doctoral degrees in majors including veterinary medicine, veterinary pharmacy, veterinary public health, microbiology, animal husbandry, and pharmaceutical engineering.

Growth Strategies

Develop high-demand products and expand the operating entity's business by entering into household animals vaccines industry. According to the section of The Market Demand Expectation of Veterinary Vaccines in the Frost & Sullivan Report, which lists certain high-demand vaccines, the operating entity intends to develop these high-demand products listed in the report, for example, Subunit Vaccine of Porcine Circovirus Type 2 (Recombinant Baculovirus Strain OKM), which is used to prevent Post-weaning Multisystemic Wasting Syndrome, Porcine Dermatitis and Nephropathy Syndrome, granulomatous enteritis, Porcine Respiratory Disease Complex, reproductive disorders in sows, and congenital tremors in piglets, etc., caused by Porcine Circovirus Type 2 (PCV2) infection, Swine Pseudorabies Vaccine, Inactivated (Strain JS-2012- Δ gI/gE), which is used to prevent pseudorabies in pigs caused by the infection of pseudorabies virus, and Combined Heat-resistant Protective Agent Live Vaccine against Newcastle disease and Infectious bronchitis (Strain LaSota+Stain SZ160), which is used to prevent avian respiratory diseases caused by infections of Newcastle disease virus and infectious bronchitis virus, among which the operating entity has received a Registration Certificate of New Veterinary Drugs and an Approval Number for Veterinary Biological Products for Subunit Vaccine of Porcine Circovirus Type 2 (Recombinant Baculovirus Strain OKM) issued by the Ministry of Agriculture and Rural Affairs of the PRC on September 26, 2021 and November 23, 2022, respectively, a Registration Certificate of New Veterinary Drugs and an Approval Number for Veterinary Biological Products for Swine Pseudorabies Vaccine, Inactivated (Strain JS-2012- Δ gI/gE) issued by the Ministry of Agriculture and Rural Affairs of the PRC on November 7, 2022 and January 13, 2023, respectively, and a Registration Certificate of New Veterinary Drugs for Subunit Vaccine of Porcine Circovirus Type 2 (Strain Recombinant Baculovirus OKM) issued by the Ministry of Agriculture and Rural Affairs of the PRC on December 28, 2022, and it expects to receive the certificate for Combined Heat-resistant Protective Agent Live Vaccine against Newcastle Disease and Infectious Bronchitis (Strain LaSota+Stain SZ160) and Porcine Circovirus Type 2 Baculovirus Vector and Mycoplasma Pneumoniae Combined Inactivated Vaccine (ZSTU01 Strain +MH03 Strain), which is used to prevent diseases caused by Porcine Circovirus infection and Mycoplasmal pneumonia of swine, within two years. As of the date of this prospectus, with regard to the vaccines described above in this paragraph, Subunit Vaccine of Porcine Circovirus Type 2 (Recombinant Baculovirus Strain OKM) and Swine Pseudorabies Vaccine, Inactivated (Strain JS-2012- Δ gI/gE) are approved for sale. In addition to develop products in great demand, the operating entity also intends to expand its business by developing and manufacturing vaccines for companion animals. As of the date of this prospectus, the operating entity has completed clinical trials for Feline Panleukopenia, FCV, Feline Viral Rhinotracheitis Triple Inactivated Vaccine, which is used to prevent the three most common infectious diseases in cats caused by feline panleukopenia, FCV, and

[Table of Contents](#)

feline viral rhinotracheitis, and Canine Distemper-Parvovirus Vaccine, Inactivated, which is used to prevent canine distemper and parvovirus. In addition, the operating entity's application for Registration Certificate of New Veterinary Drugs for Feline Panleukopenia, FCV, Feline Viral Rhinotracheitis Triple Inactivated Vaccine has been received by the Ministry of Agriculture and Rural Affairs of the PRC on August 9, 2023. The Company also intends to develop Canine Four-combination Live Vaccine, which is used to prevent diseases caused by canine distemper virus, canine parvovirus, adenovirus type II, and canine influenza virus. As of the date of this prospectus, with regard to the vaccines described in this paragraph, clinical trials for all vaccines are completed except for the Canine Four-combination Live Vaccine which has not yet undergone a clinical trial. See "Use of Proceeds."

Expand the operating entity's sales and distribution network. The operating entity intends to expand its sales and distribution network to enter new geographic markets, including countries in south-east Asia, such as Thailand and Philippines, and cities with developed animal husbandry in China, such as Gongzhuling City, Gaomi City, and Xuanwei City, further gaining market share in existing markets and accessing a broader range of customers. It will continue leveraging its local resources to quickly enter new markets, while also minimizing requirements for capital outlay.

Enhance the operating entity's ability to attract, incentivize and retain talented professionals. The operating entity believes its success greatly depends on its ability to attract, incentivize and retain talented professionals. With a view to maintaining and improving its competitive advantage in the market, it plans to implement a series of initiatives to attract additional and retain mid- to high-level personnel, including formulating a market-oriented employee compensation structure and implementing a standardized multilevel performance review mechanism.

Increase the investment in production lines. In order to increase the manufacturing capacity to address the growing needs of the market, the operating entity intends to invest RMB151.5 million from the net proceeds of this offering to demolish two obsolete animal facilities and one garage, and construct a new factory, equipped with supporting facilities such as sewage treatment system and water purification system, within two years. The estimated annual production capacity of the new factory includes 88 million Pseudorabies Live Vaccines, 2.3 million Canine Four-combination Live Vaccine, 4 million (8 million milliliter) Rabies Inactivated Vaccines, 35 million milliliter Combined Inactivated Vaccine Against Porcine Circovirus and Mycoplasma Hyopneumoniae (Porcine circovirus), 2 million (4 million milliliter) Feline Triple Inactivated Vaccines, and 40 million milliliter Swine Pseudorabies Inactive Vaccine (Porcine circovirus).

Increase R&D investment. The operating entity intends to increase its R&D investment in developing more veterinary vaccines. The operating entity intends to invest approximately RMB90.1 million from the net proceeds of this offering in developing multiple veterinary vaccines, including Feline Rhinotracheitis, Feline Rhinocconjunctivitis and Feline Panleukopenia Triple Inactivated vaccine (Strain JK+Strain FM+Strain CY), Inactivated Bovine Akabane Disease Vaccine, Gene-deleted Live Vaccine of Contagious Ecthyma Virus, Novel Duck Reovirus Live Vaccine, and Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Genetically Engineered Live Vaccine (Strain rHN-NP49). Please see "Use of Proceeds" for more details about these vaccines' R&D projects.

Revenue Model

The operating entity generates revenue through manufacturing and sales of veterinary vaccines under its own brand. For the six months ended June 30, 2023 and the fiscal years ended December 31, 2022 and 2021, we recognized RMB116.9 million (US\$16.1 million), RMB260.3 million (US\$37.7 million), and RMB214.1 million (US\$31.0 million) in revenue, respectively. The operating entity sells veterinary vaccines, both domestically and internationally. For the six months ended June 30, 2023 and the fiscal years ended December 31, 2022 and 2021, the revenue of domestic sales was RMB116.4 million (US\$16.0 million), RMB 259.5 million (\$37.6 million), and RMB213.6 million (US\$31.0 million), accounting for 99.6%, 99.7%, and 99.8%, respectively, of our revenue, and the revenue of international sales was RMB0.5 million (US\$0.1 million), RMB0.8 million (\$0.1 million), and RMB0.5 million (US\$0.1 million), accounting for 0.4%, 0.3%, and 0.2%, respectively, of our revenue.

Products

As of the date of this prospectus, the operating entity has a total of 43 veterinary vaccines in its product portfolio, 43 of which are sold domestically and six of which are sold internationally. Newcastle disease virus (La Sota strain), and Avian influenza virus (H9 subtype HL strain) Vaccine, Inactivated is currently sold in Pakistan, Newcastle Disease Vaccine, Live (La Sota strain) is currently sold in Egypt and Vietnam, Newcastle Disease Vaccine, Live (Strain Clone 30) is currently sold in Egypt, Newcastle Disease Vaccine, Inactivated is currently sold in Egypt and Pakistan,

[Table of Contents](#)

Infectious Bursal Disease Vaccine, Live (Strain B87) is currently sold in Vietnam, and Newcastle Disease, Infectious Bronchitis and Avian Influenza (H9 Subtype) Vaccine, Inactivated (Strain La Sota+Strain M41+Strain SY) is currently sold in Vietnam.

The 43 products and their indications for the six months ended June30, 2023 were as follows:

Primary Species	Product Name	Indication	International Sale
Swine	Subunit Vaccine of Porcine Circovirus Type 2 (Recombinant Baculovirus Strain OKM)	Protect against diseases caused by porcine circovirus-2 infection	N/A
Swine	Swine Pseudorabies Vaccine, Inactivated (Strain JS-2012- Δ gI/gE)	Protect against porcine pseudorabies	N/A
Swine	Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine, Inactivated	Protect against porcine transmissible gastroenteritis and porcine epidemic diarrhea. Mainly used to vaccinate pregnant sows for the piglets getting passive immunity, and to protect pigs of different ages by active immunity	N/A
Swine	Clostridium Perfringens Bivalent Vaccine for Piglets, Inactivated (Type A and C)	Protect against enterotoxemia in piglets caused by Clostridium Perfringens type A and C	N/A
Swine	Swine Erysipelas Vaccine, Live	Protect against swine erysipelas	N/A
Swine	Swine Fever Thermo-Stable Vaccine, Live (Tissue Origin)	Protect against swine fever	N/A
Swine	Swine Pasteurella Multocida Vaccine, Live (679-230 strain)	Protect against porcine pasteurella multocida disease (i.e., swine plague)	N/A
Swine	Paratyphus Vaccine for Piglets, Live	Protect against paratyphoid in piglets	N/A
Swine	Swine Parvovirus Disease Vaccine, Inactivated (CP-99 Strain)	Protect against porcine parvovirus disease	N/A
Swine	Porcine Circovirus Type 2 Vaccine, Inactivated (Strain SH)	Protect against diseases caused by porcine circovirus-2 infection	N/A
Swine	Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, Live (Strain huadu+Strain CV777+Strain NX)	Protect against diarrhea in pigs caused by porcine transmissible gastroenteritis virus, porcine epidemic diarrhea virus and porcine rotavirus (G5) infection	N/A
Swine	Classical Swine Fever Vaccine, Live (Tissue Culture Origin)	Protect against swine fever	N/A
Swine	Swine Fever Vaccine, only for Government Procurement, Live (Tissue Culture Origin)	Protect against swine fever	N/A
Swine	Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live (Strain HuN4-F112)	Protect against highly pathogenic porcine reproductive and respiratory syndrome (i.e. highly pathogenic porcine blue ear disease)	N/A
Swine	Mycoplasma Hyopneumoniae Vaccine, Live (Strain RM48)	Protect against porcine mycoplasmal pneumonia (i.e., porcine panting disease)	N/A
Swine	Swine Mycoplasma Hyopneumoniae Vaccine, Live	Prevent pig wheezing caused by Mycoplasma hyopneumoniae	N/A
Swine	Swine Fever Vaccine, only for Government Procurement, Live (Spleen and Lymph Tissue Origin)	Prevent swine fever	N/A
Swine	Classical Swine Fever Vaccine, Live (Rabbit Origin)	Prevent swine fever	N/A

[Table of Contents](#)

Primary Species	Product Name	Indication	International Sale
Swine, Bovine, and Ovine	Pseudorabies Vaccine, Live	Protect against pseudorabies in pigs, cattle and sheep	N/A
Poultry	Newcastle disease virus (La Sota strain), and Avian influenza virus (H9 subtype HL strain) Vaccine, Inactivated	Protect against Newcastle disease and H9 subtype avian influenza in chickens	Pakistan
Poultry	Avian influenza virus (H9 subtype SY strain) vaccine, Inactivated	Protect against avian influenza caused by H9 subtype avian influenza virus	N/A
Poultry	Newcastle Disease Vaccine, Live (La Sota strain)	Protect against Newcastle disease in chickens	Egypt, Vietnam
Poultry	Newcastle Disease Vaccine, Live (CS2 strain)	Protect against Newcastle disease in chickens	N/A
Poultry	Newcastle Disease Vaccine, Live (Strain Clone 30)	Protect against Newcastle disease in chickens	Egypt
Poultry	Newcastle Disease Vaccine, Inactivated	Protect against Newcastle disease in chickens	Egypt, Pakistan
Poultry	Combined Newcastle Disease and Infectious Bronchitis Vaccine, Live (Strain La Sota + Strain H52)	Protect against Newcastle disease and infectious bronchitis in chickens	N/A
Poultry	Newcastle Disease, Infectious Bronchitis and Egg Drop Syndrome Vaccine, Inactivated (Strain Clone30+StrainM41+StrainAV127)	Protect against Newcastle disease, infectious bronchitis and egg drop syndrome in chickens	N/A
Poultry	Combined Newcastle Disease and Infectious Bronchitis Vaccine, Live (Strain La Sota + Strain H120)	Protect against Newcastle disease and infectious bronchitis in chickens	N/A
Poultry	Infectious Coryza (Serotype A) Vaccine, Inactivated	Protect against infectious coryza in chickens caused by type A Avibacterium paragallinarum	N/A
Poultry	Infectious Bursal Disease Vaccine, Live (Strain B87)	Protect against infectious bursal disease in chickens	Vietnam
Poultry	Reassortant Newcastle Disease Virus and Avian Influenza Virus (H9 Subtype) Vaccine, Inactivated (Strain aSG10+ Strain G)	Protect against Newcastle disease and avian influenza caused by the H9 subtype of avian influenza virus in chickens	N/A
Poultry	Avian Pox Vaccine, Live (Quail-Adapted Strain)	Protect against chicken pox	N/A
Poultry	Mycoplasma Gallisepticum Vaccine, Live	Protect against chronic respiratory tract disorder caused by Mycoplasma gallisepticum	N/A
Poultry	Avian Pasteurella Multocida Vaccine, Live (Strain G190E40)	Protect against Pasteurella multocida disease (i.e., fowl cholera) in chickens, ducks and geese over 3 months of age	N/A
Poultry	Duck Plague Vaccine, Live	Protect against duck plague	N/A
Poultry	Newcastle Disease, Infectious Bronchitis, Egg Drop Syndrome and Avian Influenza (H9 Subtype) Vaccine, Inactivated (Strain La Sota+Strain M41+Strain HE02+Strain HN106)	Protect against Newcastle disease, infectious bronchitis, egg drop syndrome and H9 subtype avian influenza in chickens	N/A

[Table of Contents](#)

Primary Species	Product Name	Indication	International Sale
Poultry	Newcastle Disease, Infectious Bronchitis and Avian Influenza (H9 Subtype) Vaccine, Inactivated (Strain La Sota+Strain M41+Strain SY)	Protect against Newcastle disease, infectious bronchitis and H9 subtype avian influenza in chickens	Vietnam
Poultry	Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P)	Protect against duck Tembusu virus disease	N/A
Bovine and Ovine	Ovine Braxy, Struck, Lamb Dysentery, Enterotoxaemia, Vaccine, Inactivated (Dried Powder)	Protect against braxy, struck, lamb dysentery and enterotoxemia in sheep	N/A
Bovine and Ovine	Caprine Infectious Pleuropneumonia Vaccine, Inactivated	Protect against contagious pleuropneumonia in goats	N/A
Bovine and Ovine	Goat Pox Vaccine, Live	Protect against goat and sheep pox	N/A
Bovine and Ovine	Bovine Pasteurella Multocida Vaccine, Inactivated	Protect against bovine Pasteurella multocida disease (i.e., bovine hemorrhagic septicemia)	N/A
Canine	Rabies Vaccine, Inactivated (Strain Flury LEP)	Protect against rabies in dogs	

In addition to focus on livestock vaccines, the operating entity is also preparing to enter into the market of household animal vaccines. The operating entity has received an Approval Number for Veterinary Biological Products for its Rabies Vaccine, Inactivated (Strain Flury LEP) on April 13, 2020 and the vaccine is expected to be launched and available to purchase in the end of 2024.

Besides, it has completed clinical trials for Feline Panleukopenia, FCV, Feline Viral Rhinotracheitis Triple Inactivated Vaccine and its application for a Registration Certificate of New Veterinary Drugs for this vaccine has been received by the Ministry of Agriculture and Rural Affairs of the PRC on August 9, 2023, and the application materials have been submitted to the Ministry of Agriculture and Rural Affairs Veterinary Drug Evaluation Center (“Evaluation Center”). The vaccine is currently undergoing a technical review at the Evaluation Center, which will be completed within 120 working days after the Evaluation Center’s receipt of the application materials.

The operating entity has completed clinical trials for Feline Infectious Rhinotracheitis, Infectious Rhinconjunctivitis and Panleukopenia Triple Vaccine, Inactivated in October 2023, and it expects to receive an Approval Number for Veterinary Biological Products for the vaccine in 2024.

Moreover, the operating entity is researching about Feline Infectious Peritonitis Subunit Vaccine and Feline Leukemia and Feline Immunodeficiency Disease Duplex mRNA Vaccine. As of the date of this prospectus, the operating entity is still evaluating these two vaccines R&D projects, and none of the vaccines has started a clinical trial. As of the date of this prospectus, regarding these two projects, the operating entity has conducted preliminary safety assessments by administering the antigens to a limited number of animals. This early-stage evaluation monitors potential abnormalities at the injection site as well as local and systemic reactions.

Along with conventional vaccines, the operating entity also started exploring mRNA vaccines. The mRNA vaccine is a type of nucleic acid vaccine, which introduces mRNA fragments that encode antigen proteins into the human body for direct translation and the formation of corresponding antigen proteins. This process induces a specific immune response in the body, achieving the effect of preventive immunity. The mRNA vaccine is the third generation of vaccines developed based on the first-generation attenuated or inactivated vaccines and the second-generation subunit vaccines. The mRNA vaccines have several significant advantages, including high efficacy, rapid development capabilities, low production cost and greater safety. The mRNA vaccines can simulate the natural infection process of viruses to activate the immune system, potentially eliciting a stronger immune response. In addition, multiple mRNAs can be packaged in the same vaccine, increasing the vaccine’s applicability. Furthermore, the discovery and production of mRNA vaccines are faster compared to protein vaccines, allowing for quicker responses to emerging epidemic infections. Different mRNA vaccines can use the same production processes and facilities, decreasing manufacturing cost. Compared with subunit vaccines, inactivated virus vaccines, attenuated live virus vaccines, and DNA-based vaccines, mRNA vaccines use partial genetic sequences of the virus, instead of the virus itself, thereby avoiding potential risks of infection or insertion mutations. By constructing mRNA onto carrier molecules, it can be quickly taken up and expressed in the cytoplasm, thus achieving effective intracellular delivery. The operating

[Table of Contents](#)

entity places its focus on feline infectious peritonitis, feline immunodeficiency disease, porcine epizootic diarrhea, porcine reproductive and respiratory disorder syndrome, and it is conducting animal experiments to assess the immunity effectiveness of newly developed mRNA vaccines.

The operating entity is currently conducting animal experiments for its mRNA vaccines targeting Feline Infectious Peritonitis, Feline Immunodeficiency Virus, Porcine Epidemic Diarrhea, and Porcine Reproductive and Respiratory Syndrome. Each experiment involves two animals. By administering the vaccines to animals through intramuscular injection, the researchers observe for any abnormalities, both locally at the injection site and systemically throughout the body. The operating entity adheres to the fundamental principles of animal welfare and ethics during the animal experimentation process. Throughout the experimentation, once the results are known, the earlier stages where animals exhibit signs of pain and distress are promptly chosen as the endpoints of the experiment. Euthanasia is employed as a humane method to end the life of the animals, minimizing or eliminating any fear or pain to the greatest extent possible, allowing animals to pass away peacefully and swiftly. Subsequently, the animals are processed and disposed of as solid waste, following established procedures and regulations.

Regulatory Approvals for the Company’s Products

The operating entity has received a broad range of regulatory approvals for its products. The following chart sets forth a summary of the licenses and permissions obtained by the operating entity as of the date of this prospectus:

License/Permission	Issuing Authority	Countries/Regions	Validity	Corresponding Product
Certificate of Good Manufacturing Practices for Animal Drugs ⁽¹⁾ (2022) No. 07022	Jilin Animal Husbandry Bureau	Jilin Province, China	May 31, 2022 – May 30, 2027	N/A
Veterinary Drug Production Permit ⁽²⁾ (2022) No. 07022	Jilin Animal Husbandry Bureau	Jilin Province, China	May 31, 2022 – May 30, 2027	
Veterinary Drug Operation Permit ⁽³⁾ (2020) No. 07000099	Jilin Animal Husbandry Bureau	Jilin Province, China	January 20, 2020 – January 19, 2025	N/A
Use License of Experimental Animals ⁽⁴⁾ SYXK 2021-0009	Department of Science and Technology of Jilin Province	Jilin Province, China	June 21, 2021 – June 20, 2026	N/A
Use License of Experimental Animals SYXK 2021-0010	Department of Science and Technology of Jilin Province	Jilin Province, China	June 21, 2021 – June 20, 2026	N/A
Registration Certificate of New Veterinary Drugs ⁽⁵⁾ (2010) No. 07	Ministry of Agriculture and Rural Affairs of the PRC	China	No Expiration Date	Rabies Vaccine, Inactivated (Strain Flury LEP)
Registration Certificate of New Veterinary Drugs (2011) No. 09	Ministry of Agriculture and Rural Affairs of the PRC	China	No Expiration Date	Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live (Strain HuN4-F112)
Registration Certificate of New Veterinary Drugs (2013) No. 01	Ministry of Agriculture and Rural Affairs of the PRC	China	No Expiration Date	Newcastle Disease, Infectious Bronchitis, Egg Drop Syndrome and Avian Influenza (H9 Subtype) Vaccine, Inactivated (Strain La Sota+Strain M41+Strain HE02+Strain HN106)
Registration Certificate of New Veterinary Drugs (2013) No. 09	Ministry of Agriculture and Rural Affairs of the PRC	China	No Expiration Date	Bivalent Inactivated Vaccine against Duck Infectious Serositis (Type 1 SG4 Strain + Type 2 ZZY7 Strain)

[Table of Contents](#)

License/Permission	Issuing Authority	Countries/Regions	Validity	Corresponding Product
Registration Certificate of New Veterinary Drugs (2014) No. 14	Ministry of Agriculture and Rural Affairs of the PRC	China	No Expiration Date	Mycoplasma Hyopneumoniae Vaccine, Live (Strain RM48)
Registration Certificate of New Veterinary Drugs (2014) No. 54	Ministry of Agriculture and Rural Affairs of the PRC	China	No Expiration Date	Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, Live (Strain huadu+Strain CV777+Strain NX)
Registration Certificate of New Veterinary Drugs (2015) No. 39	Ministry of Agriculture and Rural Affairs of the PRC	China	No Expiration Date	Newcastle Disease, Infectious Bronchitis and Egg Drop Syndrome Vaccine, Inactivated (Strain Clone30+ StrainM41+StrainAV127)
Registration Certificate of New Veterinary Drugs (2018) No. 41	Ministry of Agriculture and Rural Affairs of the PRC	China	No Expiration Date	Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P)
Registration Certificate of New Veterinary Drugs (2019) No. 26	Ministry of Agriculture and Rural Affairs of the PRC	China	No Expiration Date	Reassortant Newcastle Disease Virus and Avian Influenza Virus (H9 Subtype) Vaccine, Inactivated (Strain aSG10+ Strain G)
Registration Certificate of New Veterinary Drugs (2019) No. 35	Ministry of Agriculture and Rural Affairs of the PRC	China	No Expiration Date	Combined Live Vaccine of Newcastle Disease and Infectious Bronchitis (Strain LaSota+Stain LDT3-A)
Registration Certificate of New Veterinary Drugs (2021) No. 62	Ministry of Agriculture and Rural Affairs of the PRC	China	No Expiration Date	Subunit Vaccine of Porcine Circovirus Type 2 (Recombinant Baculovirus Strain OKM)
Registration Certificate of New Veterinary Drugs (2022) No. 70	Ministry of Agriculture and Rural Affairs of the PRC	China	No Expiration Date	Swine Pseudorabies Vaccine, Inactivated (Strain JS-2012- Δ gI/gE)
Business Certificate	Jilin Administration for Market Supervision	Jilin Province, China	No Expiration Date	N/A

Note:

- (1) A Certificate of Good Manufacturing Practices for Animal Drugs attests that the manufacturer complies with the Veterinary Drug Production Quality Management Norms, and it is a required certificate for manufacturer to produce and market its veterinary products.
- (2) A Veterinary Drug Production Permit assures the manufacturer's ability to produce veterinary drugs.
- (3) A Veterinary Drug Operation Permit allows the manufacturer to sell veterinary drugs.
- (4) A Use License of Experimental Animals permits the license holder to use experimental animals to conduct experiments.
- (5) A Registration Certificate of New Veterinary Drugs verifies that this veterinary drug product has undergone all the necessary tests and evaluations to ensure its safety, efficacy, and quality, and it can be used for animals under the stipulated uses and dosages. It is a required certificate for a company before receiving an Approval Number for Veterinary Biological Products for a vaccine and commencing manufacturing such vaccine. See "Regulations — Regulations Related to Veterinary Drugs Production and Operation"

As of the date of this prospectus, the operating entity is granted approval by Egypt to sell its Newcastle Disease Vaccine, Live (Strain Clone 30), Infectious Coryza Vaccine, Inactivated, Newcastle Disease Vaccine, Live (LaSota strain), Newcastle Disease Vaccine, Inactivated, and Newcastle Disease and Egg Drop Syndrome Vaccine, Inactivated.

[Table of Contents](#)

As of the date of this prospectus, the operating entity is granted approval by Pakistan to sell its Combined Newcastle Disease & Egg Drop Syndrome Vaccine, Inactivated, Combined Newcastle Disease & Infectious Bronchitis Vaccine, Live, Newcastle Disease Vaccine, Inactivated, and New Castle Disease Virus (La Sota Strain) and Avian influenza virus (H9 subtype, HL strain, H9N2) Vaccine, Inactivated.

As of the date of this prospectus, the operating entity is granted approval by Vietnam to sell its Avian Pox Vaccine, Live, Newcastle Disease Vaccine, Live (LaSota strain), Newcastle Disease Vaccine, Inactivated, Newcastle Disease, Infectious Bronchitis and Avian Influenza (H9 subtype) Vaccine, Inactivated (Strain La Sota + Strain M41 + Strain SY), and Infectious Bursal Disease Vaccine, Live (Strain B87).

Customers

The operating entity has two types of customers, (i) direct end user customers, including livestock farmers and local governments; and (ii) distributors that distribute the operating entity's products to end-user customers, including domestic distributors and exporting distributors (See "— Sales and Distribution-Distribution Network"). The operating entity sources its customers through multiple channels, including (i) attending industry exhibitions/expos, and (ii) directly contacting potential distributor customers and direct-end customers. For the six months ended June 30, 2023 and the fiscal years ended December 31, 2022 and 2021, the operating entity had a total of 290, 274, and 222 customers, of which 79, 77, and 75 were direct end-user customers, and 211, 197, and 147 were distributor customers, respectively. For the six months ended June 30, 2023 and the fiscal years ended December 31, 2022 and 2021, the revenue generated from direct-end user customers amounted to RMB90.0 million (\$12.4 million), RMB212.4 million (\$30.78 million), and RMB160.2 million (US\$23.2 million), respectively. For the six months ended June 30, 2023 and the fiscal years ended December 31, 2022 and 2021, the revenue generated from distributor customers amounted to RMB26.8 million (\$3.7million), RMB47.9 million (\$6.94 million), and RMB53.9 million (US\$7.8 million), respectively. For the six months ended June 30, 2023, two customers, MYF and Shuangbaotai (Group) Corporation Limited, account for more than 10% of the Company's total revenue, accounting for 54.55% and 16.91% of total revenue, respectively. For the fiscal year ended December 31, 2022, MYF is the only customer that accounts for more than 10% of the Company's total revenue, accounting for 74.51% of total revenue. See "Risk Factors — Risks Relating to Our Business and Industry — High customer concentration exposes the operating entity to all of the risks faced by its major customer and may subject it to significant fluctuations or declines in revenue, which may have a material adverse impact on the operating entity's business, and its and our financial condition and results of operations."

The operating entity has long-term written sales agreements, ranging from one to three years, with its direct end user customers who are livestock farmers (for the description of direct-end user customers who are local governments, see "— Sales and Distribution-Government Tender and Procurement"). The key terms of these sales agreements (including those agreements with top customers) include:

- the product's name, type, quantity, and price;
- quality standard — vaccines qualifications, including business license, veterinary vaccines production and operation licenses, and inspection report;
- delivery time, method and payment terms;
- breach of contract terms, including remedies, such as refunds and return of products (for example, customers are entitled to refunds and may return the product if the wrong product is delivered or the product does not meet agreed upon quality standards);
- shipping costs, which are typically borne by the seller; and
- dispute solutions, including bringing a lawsuit at the local court where the direct-end user customers are located, if negotiations are unsuccessful.

In the course of dealing with overseas customers, the operating entity has maintained stable business relationships; however, such business relationships are not memorialized in any long-term agreements, but are rather provided for in short-form order sheets. In respect of their international sales, the risk of loss is borne by the customers upon delivery of the products. See "— Sales and Distribution — Distribution Network."

[Table of Contents](#)

The operating entity faces an inherent risk of liability claims or complaints from customers. When the products are found to be defective, they are required to recall the products according to usage of trade. When customers file product liability claims against the operating entity, conflict of laws and product liability laws of the countries or regions where they are located are applicable. Jurisdiction is determined by the sales agreements, and laws of the countries or regions where the customers are located will determine the issue if the sales agreements are absent of jurisdiction selection clauses.

As of the date of this prospectus, the operating entity is not aware of any warnings, investigations, prosecutions, disputes, claims or other proceedings in respect of veterinary vaccines it manufactures or distributes overseas, nor has it been penalized or can foresee any penalties to be made by any overseas jurisdiction with respect to veterinary vaccines safety.

Suppliers

The operating entity sources its suppliers through multiple channels: (i) referral by companies in the same industry, (ii) marketing by suppliers' salespersons, and (iii) direct contact with suppliers through public channel, for example, suppliers' websites.

The operating entity's suppliers are those providing raw materials for the manufacturing of the products. The raw and auxiliary materials include serum, culture medium, adjuvant, hatching egg, and experimental animal (primarily consisting of rats and chicken, which are mainly used in early-stage R&D and efficacy examination of vaccines. See "— Products"). All of which are purchased from certified and qualified suppliers in China. The operating entity's supply was affected during the COVID-19 pandemic because of two reasons: (i) lockdown resulted from the pandemic stopped suppliers' production or postponed their deliveries of raw materials; and (ii) the raw materials of the operating entity's products are similar to those of COVID-19 vaccines, therefore, the price of raw materials surged due to the mass production of COVID-19 vaccines. As of the date of this prospectus, the operating entity's supply is not affected by the conflict between Russia and Ukraine.

For the six months ended June 30, 2023, one supplier, Zhejiang Yishengke Biotechnology Co., Ltd., accounts for more than 10% of the operating entity's total supplies purchased, accounting for 10.15%. For the fiscal year ended December 31, 2022, two suppliers, Xinxiang Jiexin Biotechnology Co., Ltd. and Henan Shuocheng Biotechnology Co., Ltd., account for more than 10% of the operating entity's total supplies purchased, accounting for 25.3% and 12.9%, respectively.

As of the date of this prospectus, the operating entity has a total of 62 suppliers. Although the operating entity can utilize any supplier it determines, we believe that it has established healthy and stable relationships with its significant suppliers through years of cooperation. There are no minimum purchase requirements with any of the suppliers, including with the above significant ones. Each supplier order is typically governed by a brief purchase-order based purchase agreement. The key terms of the supplier purchase agreements (including those agreements with the significant suppliers) include:

- the product's name, type, quantity, and price;
- quality terms which are typically expressed with reference to national or industry standards;
- delivery time, method and payment terms. Shipping costs are the responsibility of the supplier; and
- breach of contract terms, including refund and return of products, compensatory damages. If the supplier cannot deliver the product within the time agreed, or if the products do not meet the stated quality standard, the supplier must compensate the operating entity for losses caused, including treble damages if the products are defective or counterfeit. In the event the operating entity cannot timely pay, liquidated damages are due to the supplier.

R&D

The operating entity invests in R&D, aiming to develop new products and improve its existing products to accommodate the market needs. The R&D expenses totaled approximately RMB6.2 million (\$0.8 million), RMB13.4 million (\$1.9 million), and RMB11.4 million (\$1.6 million) for the six months ended June 30, 2023 and the fiscal years ended December 31, 2022 and 2021, respectively. R&D expenses mainly consist of applicable personnel, sample manufacturing and materials expenses. As of the date of this prospectus, the operating entity has a total of 49 employees in the R&D department. Below is a list of some employees in the R&D department.

Name	Credential	Years of Experience	Achievement
Yuyou He	Bachelor of veterinary medicine, with senior professional title	39 years	One of the inventors of 17 inventions and utility models
Wei Lian	Master of preventive veterinary medicine, senior veterinarian	18 years	One of the inventors of 31 inventions and utility models
Shaoguo Bian	Master of preventive veterinary medicine, senior veterinarian	19 years	One of the inventors of 7 inventions and utility models; Owner of three China national scientific and technical achievements; Winner of Liaoning Province Animal Husbandry Science and Technology Contribution Award; Winner of Liaoning Province Science and Technology Award
Shushuai Yi	Doctor of preventive veterinary medicine	9 years	Led and participated in 5 provincial and ministerial-level science and technology projects in China, published nearly 50 research papers, ten of which are indexed in Science Citation Index.
Jiangting Niu	Doctor of preventive veterinary medicine	7 years	Led and participated in 3 provincial and ministerial-level science and technology projects in China, and published nearly 30 research papers
Guohui Wang	Bachelor of veterinary medicine, senior veterinarian	20 years	One of the inventors of 29 inventions and utility models
Jing Wu	Bachelor of veterinary medicine, assistant veterinarian	15 years	One of the inventors of 12 inventions and utility models
Zhiyun Yu	Bachelor of veterinary medicine, senior veterinarian	16 years	One of the inventors of 8 inventions and utility models

The operating entity currently has one R&D center, which was established in 2006 and located at No. 1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin Province, China. As of the date of this prospectus, the R&D center has developed 39 patents, and helped the operating entity receive 14 Registration Certificates of New Veterinary Drugs.

In addition to independent R&D, the operating entity also cooperates with universities and research institutions on multiple projects.

Due to the long development cycle, large investment, and high risk associated with veterinary vaccines, the early stage research for new products is mainly conducted within universities and research institutes. Manufacturers acquire new veterinary drug production technologies through technology transfer or cooperative R&D with universities or research institutes, and then mass-produce and commercialize the veterinary vaccines. In the process of cooperative R&D, universities and research institutes are mainly responsible for early-stage basic research. The operating entity, in addition to participating in basic research, is primarily responsible for pilot study and industrialization research. The operating entity has established relationships with veterinary research institutes and universities such as Harbin Veterinary Research Institute, Shanghai Veterinary Research Institute, China Agricultural University, Jilin University, and Nanjing Agricultural University, working on research cooperation and technology introduction. The associated costs incurred in the cooperation are funded by the operating entity's revenue.

[Table of Contents](#)

The key terms of cooperative research agreements with universities and research institutions include:

- name of the research, project objective, research methodology, research location, and term of agreement;
- division of responsibilities and payment terms. Normally it is the operating entity's responsibility to provide research funds and research institutions' responsibility to conduct research;
- intellectual property ownership, right of first refusal, and exclusive right of production. The operating entity is normally entitled to the right of first refusal and the exclusive right of production regarding the vaccine or technology that is intended to be developed under the agreement; and
- dispute solutions, including bringing a lawsuit at the local court, if negotiations are unsuccessful.

For example, in 2008, the operating entity entered into a strategic cooperation framework agreement with Shanghai Veterinary Research Institute, pursuant to which the operating entity agreed to pay RMB3 million each year, from September 2008 to September 2018, to Shanghai Veterinary Research Institute for the R&D of veterinary vaccines (the "Strategic Cooperation Framework Agreement"). The Strategic Cooperation Framework Agreement was in effect from September 9, 2008, until September 8, 2018. Under the terms of this agreement, should the operating entity fail to make timely payments, the Shanghai Veterinary Research Institute reserves the right to terminate the agreement without refunding any payments already made by the operating entity. Apart from that, should the contract be terminated due to a breach by either party, neither party will be subject to significant liabilities resulting from the breach.

On April 3, 2018, as the Strategic Cooperation Framework Agreement was about to expire, both parties signed a memorandum (the "Memorandum") and made subsequent plans for vaccines that had been approved to commence clinical trials but had not obtained Registration Certificate of New Veterinary Drugs, including Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P). In September 2019, pursuant to the Strategic Cooperation Framework Agreement and the memorandum, Shanghai Veterinary Research Institute transferred Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P) to the operating entity for commercialization. In return, after the operating entity receives an Approval Number for Veterinary Biological Products and commences producing this vaccine, the operating entity would remit 5% of the vaccine's five-year sales revenue as consideration. Neither the Strategic Cooperation Framework Agreement nor the Memorandum addresses or includes provisions for the cross-licensing of intellectual property rights. The Memorandum does not extend the duration of the Strategic Cooperation Framework Agreement, nor does it contain any provisions regarding its own duration or termination. As of October 31, 2023, the total aggregate amount of the shared revenue paid by the operating entity reached RMB1,869,594 (US\$257,829). The Company recognized the 5% of the sales revenue as cost of revenue since the cost was directly related to the revenue.

Moreover, the operating entity is also licensed to use vaccine production technologies and related intellectual properties owned by others to manufacture vaccines through technology licensing agreements.

For example, the operating entity entered into a technology licensing agreement with Harbin Veterinary Research Institute on April 5, 2012, pursuant to which Harbin Veterinary Research Institute permitted the operating entity to use the seed virus and production technology of Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, Live (Strain huadu+Strain CV777+Strain NX) to manufacture the vaccine. As of October 31, 2023, the total aggregate amount that has been paid by the operating entity pursuant to this agreement reach RMB55,563,975 (US\$7,662,623). The vaccine has been launched in July 2016. The operating entity recognized it as intangible asset, and amortized it over the useful life of the licensed technology. Set forth below are the materials terms of the technology licensing contract:

- Description of the technology: the Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, live (Strain huadu+Strain CV777+Strain NX) is used to prevent infection of porcine infectious gastroenteritis virus, porcine epidemic diarrhea virus, and porcine rotavirus (G5 type). The weak virus Huadu strain, weak virus CV777 strain, and NX strain are all cultivated by Harbin Veterinary Research Institute. The total immune protection rate of the vaccine is over 85%. The immune duration is 6 months. It is stored below -20 degree Celsius and has a validity period of 24 months.
- Performance: (i) Both parties jointly apply for a Registration Certificate of New Veterinary Drugs for the Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, live (Strain huadu+Strain CV777+Strain NX). The operating entity is only entitled to use the certificate, and it has no right to transfer the certificate; and (2) Within 30 days of obtaining the Registration Certificate of New Veterinary Drugs, Harbin Veterinary Research Institute shall furnish the seed virus and production process of the vaccine to the operating entity.

[Table of Contents](#)

- **Scope of usage of the technology:** Harbin Veterinary Research Institute shall exclusively own the technical achievements and their derived intellectual property rights. The operating entity shall be only entitled to use the technology to produce and sell the vaccines, and it shall not transfer the virus seed and production technology to a third party, nor shall it use the technology for the R&D or technical improvement of other new products or collaborate with a third party in production of the vaccine.
- **Contract duration:** April 5, 2012 to April 5, 2032. If the operating entity wishes to continue using the technology to produce vaccines after the expiration of this agreement, it shall obtain the consent of Harbin Veterinary Research Institute and comply with the payment term of this agreement. Harbin Veterinary Research Institute shall agree to renew the agreement, unless prevented by an event of *force majeure*.
- **Infringement Indemnity:** Harbin Veterinary Research Institute shall guarantee that this technology does not infringe on the legitimate rights of any third party. If a third party accuses the operating entity of infringement and the operating entity is ordered to pay compensation, Harbin Veterinary Research Institute shall cover the loss. Harbin Veterinary Research Institute shall not be liable if a third party maliciously infringes on the technology outlined in this agreement.
- **Confidentiality:** the seed virus and production process of the vaccine, and all information and data exchanged between the parties during the contract term are subject to strict confidentiality obligations. Should a party violate these confidentiality obligations, it will be liable to pay liquidated damages amounting to RMB10 million to the non-breaching party. Additionally, if the operating entity breaches its confidentiality obligations, it will not only be required to pay the stipulated liquidated damages but will also forfeit any right to reclaim paid royalties and must compensate Harbin Veterinary Research Institute for any economic losses arising from the disclosure of confidential information.
- **Subsequent Improvement:** the operating entity is not entitled to use the technology of this agreement for subsequent improvement. Harbin Veterinary Research Institute shall be entitled to make subsequent improvements to the technology of this agreement. The new technological achievements with substantive or creative technological progress resulting from the technology of this agreement shall belong to Harbin Veterinary Research Institute.
- **Payment terms:** the operating entity is obligated to pay Harbin Veterinary Research Institute royalties totaling RMB56 million, plus 5% of the vaccine's annual sales revenue, commencing from the first day of production of the vaccine. The operating entity has already paid Harbin Veterinary Research Institute an initial amount of RMB2 million. The remaining RMB 54 million is to be paid in installments. For the first installment, due by December 10, 2014, the operating entity is to pay Harbin Veterinary Research Institute royalties amounting to RMB21.6 million. For the second installment, due by October 20, 2015, the operating entity is to pay Harbin Veterinary Research Institute royalties amounting to RMB16.2 million. For the third installment, due by October 20, 2016, the operating entity is to pay Harbin Veterinary Research Institute royalties amounting to RMB16.2 million. Starting from the date of production of the vaccine, the operating entity is obligated to pay Harbin Veterinary Research Institute a lump sum of 5% of the sales revenue by December 10 each year.
- **Liabilities of the operating entity:** (i) if the operating entity fails to comply with the provision of confidentiality and scope of usage of the technology, it is obligated to pay Harbin Veterinary Research Institute liquidated damages of RMB10 million, and must compensate Harbin Veterinary Research Institute for any economic losses arising from the disclosure of confidential information; and (ii) if the operating entity fails to pay its royalties in full and on time, it is obligated to pay Harbin Veterinary Research Institute liquidated damages of RMB10 million and compensate for any incurred losses.
- **Liabilities of the Harbin Veterinary Research Institute:** if Harbin Veterinary Research Institute fails to comply with the agreed-upon provisions regarding performance, it is obligated to pay the operating entity liquidated damages of RMB 10 million and to refund all royalties previously paid by the operating entity.
- **Termination:** this agreement may be terminated if (i) there is an occurrence of an event of *force majeure*; or (ii) both parties agree to terminate this agreement.
- **Dispute resolution:** Any disputes incurred in connection with the performance of the contract shall be resolved through negotiation and mediation. If negotiation and mediation fail, the disputes shall be submitted to Harbin Arbitration Commission for arbitration.

Table of Contents

Additionally, the operating entity entered into a technology licensing agreement with China Agricultural University and China Institute of Veterinary Drug Control on July 16, 2018, pursuant to which the operating entity is permitted to use the seed virus and production technology of Reassortant Newcastle Disease Virus and Avian Influenza Virus (H9 Subtype) Vaccine, Inactivated (Strain aSG10+ Strain G). The vaccine has been launched in January 2020. As of October 31, 2023, the total aggregate amount that has been paid by the operating entity pursuant to this agreement reach RMB6,000,000 (US\$827,438). The operating entity recognized it as intangible assets, and amortized it over the useful life of the licensed technology. Set forth below are the materials terms of the technology licensing contract:

- Description of the technology: the Reassortant Newcastle Disease Virus and Avian Influenza Virus (H9 Subtype) Vaccine, Inactivated (Strain aSG10+ Strain G) is used to prevent Newcastle disease and H9 subtype avian influenza. The main content of this technical secret is the production process, production and testing of recombinant Newcastle disease virus and avian influenza (H9 subtype) inactivated vaccine, as well as related formulas. According to this agreement, the operating entity has the access to production technology of the vaccine, seed virus for production and testing, and related formula.
- Performance: After obtaining the Registration Certificate of New Veterinary Drugs and within 15 days since the operating entity fully pays the royalties, China Agricultural University and China Institute of Veterinary Drug Control shall furnish to the operating entity (i) attenuated strains of virus; (ii) manufacturing and inspection procedures; (iii) quality standards and user guidebook; and (iv) quality standards and testing techniques for raw and auxiliary materials.
- Scope of usage of the technology: the operating entity shall be only entitled to use the technology to produce and sell the vaccines under the supervision of the other two parties.
- Infringement Indemnity: China Agricultural University and China Institute of Veterinary Drug Control shall ensure that this technology does not violate the legitimate rights of any third party. Should a third party accuse the operating entity of infringement, both entities are obligated to assist the operating entity in defending its rights.
- Contract duration: July 16, 2018 to July 15, 2038.
- Confidentiality: the seed virus and production process of the vaccine, and all information and data exchanged among the parties during the contract term are subject to strict confidentiality obligations. Should the operating entity violate these confidentiality obligations, it will be liable to pay liquidated damages amounting to RMB18 million to the non-breaching parties. Additionally, it will also forfeit any right to reclaim paid royalties and the non-breaching parties can terminate the agreement. Should the other two parties breach these confidentiality obligations, the operating entity is entitled to seek compensation for any direct economic losses incurred, up to the total amount of royalties actually paid.
- Technical service and supervision: China Agricultural University shall provide on-site technical guidance and training to the operating entity, and China Institute of Veterinary Drug Control shall provide technical consultation. The operating entity is obligated to furnish China Agricultural University and China Institute of Veterinary Drug Control with all necessary conditions for utilizing the licensed technology, including trial production and technical training. The operating entity shall also cover associated costs, encompassing living and transportation expenses for technical supervisors and consultants.
- Subsequent Improvement: should the operating entity intend to make subsequent improvements to the technology stipulated in this agreement, it must seek approval from the other two parties. The operating entity is prohibited from utilizing the technology for the R&D of any other new products.
- Payment terms: the operating entity is obligated to pay royalties in installments, totaling RMB6 million, with RMB3.3 million to be paid to China Agricultural University, and the remaining RMB2.7 million to China Institute of Veterinary Drug Control. Within twenty working days after the effective date of this contract, the operating entity shall pay RMB2 million in royalties; RMB1.1 million to China Agricultural University, and the remaining RMB0.9 million to China Institute of Veterinary Drug Control. Within twenty working days after obtaining the Registration Certificate of New Veterinary Drugs, the operating entity shall pay an additional RMB4 million in royalties; RMB2.2 million to China Agricultural University, and the remaining RMB1.8 million to China Institute of Veterinary Drug Control. If the technical outcomes of this project fail to secure a Registration Certificate of New Veterinary Drugs, China Agricultural University and China Institute of Veterinary Drug Control shall refund all payments received from the operating entity, without interest, and shall not bear any further liabilities.

[Table of Contents](#)

- Termination and modification: (i) if a party cannot perform its obligations due to an event of force majeure, it will be exempted from liability for breach of contract, provided that it promptly informs the other two parties and submits a certificate proving inability to perform within thirty days; (ii) should a party be unable to fulfill its contractual obligations due to alterations in veterinary drug laws, regulations, or policies, it will be exempted from breach of contract liability, provided that it promptly informs the other two parties and supplies proof of inability to fulfill the contract within thirty days; and (iii) if this contract cannot be executed owing to factors like the production conditions of the operating entity, the entity may propose modifications to the contract but must compensate the other two parties for any losses incurred.
- Liabilities of the operating entity: (i) if the operating entity fails to fully pay its royalties on time, it will incur a breach of contract. If the payment is overdue by no more than one month, the operating entity is obligated to pay the owed royalties and an additional late fee of 0.5% of the payable amount for each day of delay to the other parties. Should the payment be overdue by more than one month, the other two parties may, following negotiations, notify the operating entity of the contract's termination. Any royalties previously paid by the operating entity are non-refundable; (ii) if the operating entity breaches the confidentiality provisions, it must pay the other two parties liquidated damages of RMB 18 million; (iii) should the operating entity violate any other provisions of this contract, it will incur liability for breach of contract and must compensate the other two parties with liquidated damages of RMB 18 million, in addition to ceasing the infringing acts immediately.
- Liabilities of China Agricultural University and China Institute of Veterinary Drug Control: if either of the two parties violates the confidentiality provisions, it shall incur liability for breach of contract. The operating entity reserves the right to require the violating party to compensate for all resulting economic losses, up to the amount of the royalties paid by the operating entity at that time.
- Dispute resolution: Any disputes incurred in connection with the performance of the contract shall be resolved through negotiation and mediation. If negotiation and mediation fail, the disputes shall be submitted to Beijing Arbitration Commission for arbitration.

The operating entity conducts research projects solely or cooperatively with third-party local universities. The associated costs incurred in these projects are solely funded by the operating entity. For certain research projects eligible for government subsidies, the operating entity receives subsidies from the government of Jilin Province, PRC, which the operating entity records as other income, government subsidies, in the consolidated statements of income and comprehensive income. Set forth below is a list of these research projects.

Project	Collaborator	Year
The Development and Efficacy Evaluation of the Porcine Hemagglutinating Encephalomyelitis Virus DNA Vaccine	Jilin University	2021
The Key Technique Study for the Development of the Live Gene-deletion-attenuated Vaccine against Ovine and Caprine Ecthyma (Orf)	Jilin University	2021
The Development and Efficacy Evaluation of Jilin-region-specific High Efficiency Inactivated PED Vaccine	Jilin Academy of Agricultural Sciences	2021
Recombinant Newcastle Disease Virus and Avian Influenza Virus Combined Duplex Inactivated Vaccine	N/A	2021
Subsidized Project after Trading the Technology for Duck Tambusu Virus Live Vaccine	N/A	2022
Establishing the OFTu Immortalized Cell Line and its Application in Developing Ovine and Caprine Poxvirus Vaccine	Jilin University	2022
The Development of ASFV-PRV Nucleic Acid rapid Co-test Kit and its Application in the Quarantine of Cold-chain Pork	Jilin University	2022
The Development of Fish Enteritis Gene-deletion-attenuated Live Vaccine	Jilin Agricultural University	2022
The Virus Study, Laboratory Sample Preparation and Efficacy Evaluation of Inactivated Bovine Akabane Disease Vaccine	N/A	2022
The Development of Ovine and Caprine Contagious Pustular Virus mRNA Vaccine Based on Lipid Nanoparticle Technology	Jilin University	2023

[Table of Contents](#)

Project	Collaborator	Year
The Development of Combined VSV-SVV Nucleic Acid Rapid Test Kit and its Application in the Quarantine of Cold-chain Pork	Jilin University	2023
The Study of Rapid Visual Nucleic Acid Test of Various SARS-CoV-2 Mutants	Jilin University	2023
The Development of Animal Microecological Vaccine for the Biological Control of African Swine Fever	Jilin Agricultural University	2023
The Development and Application of Rapid Visual Test Technology for Key Viral Diseases in Goslings	Jilin Agricultural University	2023
The Development and Application of Fluorescent ERA Rapid Thermo-static Diagnostic Technology for Key Viral Diarrhea Diseases in Pigs	Jilin Academy of Agricultural Sciences	2023
The Preparation Process Study of Immunoglobulin Y against Rotavirus Disease in Herbivorous Animals and its Prophylactic Application	Jilin Institute of Animal Husbandry and Veterinary Medicine	2023

For the project of the Development and Efficacy Evaluation of the Porcine Hemagglutinating Encephalomyelitis Virus DNA Vaccine, the operating entity entered into a cooperative research agreement with Jilin University on September 17, 2020. According to the agreement, Jilin University is responsible for designing and manufacturing the DNA vaccines against the porcine hemagglutinating encephalomyelitis virus and will test the vaccine for safety, immunogenicity, and efficacy. The operating entity is obligated to provide locations for animal testing, undertake the daily standardized breeding and management of the experimental animals, assist Jilin University with vaccination and sample collection, and ensure the harmless treatment of experimental animals. The agreement does not address or include provisions for the cross-licensing of intellectual property rights. The operating entity solely offered supplementary assistance and therefore, did not incur any direct costs.

For the project of the Key Technique Study for the Development of the Live Gene-deletion-attenuated Vaccine against Ovine and Caprine Ecthyma (Orf), the operating entity entered into a cooperation agreement of joint research project with Jilin University on September 18, 2020. According to the agreement, Jilin University is tasked with rescuing, identifying, and purifying attenuated vaccine strains that lack the main virulence genes of ORFV. They will screen for candidate vaccine strains for Orf, assess the biological safety and immune protection effects of these strains, and undertake laboratory research, including immunity optimization studies. The operating entity will refine the cell culture and freezing processes for candidate vaccines, furnish sites for animal testing, and enforce standard procedures for the breeding and management of experimental animals. It is also responsible for aiding Jilin University in vaccination and sample collection and ensuring the harmless treatment of experimental animals. Upon approval of their application, Jilin University is entitled to receive 90% of the government funding, while the operating entity is allocated the remaining 10%. The agreement does not address or include provisions for the cross-licensing of intellectual property rights. As of November 30, 2023, RMB1,351,744 were incurred as costs in this project, which included raw materials purchase costs, employees' salaries, electricity and gas costs, and depreciation expenses.

For the project of the Development and Efficacy Evaluation of Jilin-region-specific High Efficiency Inactivated PED Vaccine, the operating entity entered into a cooperation agreement of joint research project with Jilin Agricultural Science and Technology University on September 19, 2020. According to the agreement, Jilin Agricultural Science and Technology University is responsible for designing and implementing the project, overseeing the control and isolation of PEDV in the Jilin region, and initiating laboratory research into the development of a PED cocktail inactivated vaccine. The operating entity is tasked with conducting evaluations of immune effects and pilot studies pertaining to the project, and supplying the necessary experimental resources for executing animal experiments. The parties collectively submit an application for government scientific research funding in the amount of RMB500,000, provided by the Jilin Provincial Department of Science and Technology, with Jilin Agricultural Science and Technology University consenting to contribute an additional RMB300,000 towards the project. Once the government funding from the Jilin Provincial Department of Science and Technology is received, 80% will be allocated to Jilin Agricultural Science and Technology University, and 20% will be allocated to the operating entity. The theoretical outcomes, including papers and monographs, developed independently by either party through their individual research, as well as the applied technical outcomes such as patents and the property rights of any resulting products, shall be respectively owned by the respective originating party. The ownership of scientific and technological outcomes from the project is collectively owned by both parties. Both parties may collectively apply for the registration of new veterinary drugs and evenly allocate intellectual property rights as well as the benefits derived from the conversion of scientific and technological achievements. The agreement does not address or include provisions for the cross-licensing of intellectual property

[Table of Contents](#)

rights. The operating entity shall have priority in the manufacturing of products developed from the research. The project was completed in July 2020. As of July 31, 2020, RMB1,888,709 were incurred as costs in this project, which included raw materials purchase costs, employees' salaries, electricity and gas costs, and depreciation expenses.

For the project of Establishing the OFTu Immortalized Cell Line and its Application in Developing Ovine and Caprine Poxvirus Vaccine, the operating entity entered into a cooperative research agreement with Jilin University on October 14, 2021. According to the agreement, Jilin University is assigned to construct an immortalized cell line of sheep nasal concha osseous tissue cells (OFTu) and is responsible for evaluating the proliferation capability of the OFTu cell line. Jilin University will also carry out chromosomal karyotype analysis and assess the potential tumorigenic capability of the OFTu cell line, along with evaluating the amplification capacity of sheep-derived poxvirus within the OFTu cell line. The operating entity is responsible for optimizing the large-scale cultivation and inheritance processes of the OFTu cell line and will provide assistance to Jilin University in conducting amplification tests on the smallpox virus vaccine strain within the OFTu cell line. The agreement does not address or include provisions for the cross-licensing of intellectual property rights. Following the planned task schedule, the operating entity has not initiated its activities, resulting in no incurred expenses as of the date of this prospectus.

For the project of the Development of ASFV-PRV Nucleic Acid rapid Co-test Kit and its Application in the Quarantine of Cold-chain Pork, the operating entity entered into a cooperative research agreement with Health Commission of Jilin Province and Jilin University on October 14, 2021. According to the agreement, Jilin University is tasked with establishing a multiplex fluorescence quantitative PCR test method to identify ASFV, PRV wild-type strains, and vaccine strains. It is also responsible to acquire an ASFV-PRV nucleic acid synchronous rapid detection kit and formulate a food safety quarantine report focusing on ASFV and PRV in cold-chain pork within Jilin Province. Health Commission of Jilin Province is responsible for supplying a P3 biosafety laboratory suitable for virus nucleic acid extraction and PCR amplification. It will assist Jilin University in sample collection and ensure the harmless treatment of all experimental materials. The operating entity will assemble the test kits and spearhead the marketing promotion. It will also assist Jilin University in collecting samples and conducting food safety quarantine against ASFV and PRV of cold-chain pork in Jilin Province. The agreement does not address or include provisions for the cross-licensing of intellectual property rights. Following the planned task schedule, the operating entity has not initiated its activities, resulting in no incurred expenses as of the date of this prospectus.

For the project of the Development of Fish Enteritis Gene-deletion-attenuated Live Vaccine, the operating entity entered into a cooperative research agreement with Jilin Agricultural University on October 9, 2021. According to the agreement, Jilin Agricultural University, as the host for the research project, is mandated to report, implement, and summarize the project, it is also responsible for a research project called "Construction and Immune Effect Evaluation of Live Attenuated Vaccine Strains Caused by Bacterial Enteritis Gene Deletion in Fish, and Screening of Frozen Protective Agents for Live Attenuated Vaccine Strains Caused by Bacterial Enteritis Gene Deletion in Fish". The operating entity, on the other hand, is entrusted with the responsibility to optimize the processes pertaining to the attenuated live vaccine developed due to gene deletion causing bacterial enteritis in fish, as part of the aforementioned project. Upon receipt of the project funding, Jilin Agricultural University is to allocate RMB50,000 to the operating entity. Additionally, the operating entity is committed to contributing RMB250,000 towards the research project. The agreement does not address or include provisions for the cross-licensing of intellectual property rights. Should any disputes arise from the execution of this contract between the parties, the parties should endeavor to resolve them through negotiation and mediation. In instances where a resolution cannot be attained through negotiation and mediation, the aggrieved party has the right to initiate legal proceedings in the competent People's Court in accordance with applicable laws. Following the planned task schedule, the operating entity has not initiated its activities, resulting in no incurred expenses as of the date of this prospectus.

For the project of the Development of Ovine and Caprine Contagious Pustular Virus mRNA Vaccine Based on Lipid Nanoparticle Technology, the operating entity entered into a cooperative research agreement with Jilin University on September 13, 2022. According to the agreement, Jilin University is tasked with orchestrating the comprehensive design of the project. Its responsibilities include screening for the principal immunogenic proteins of the sheep infectious pus virus and conducting the antigen sequence design. It will also be creating mRNA preparations and developing mRNA lipid nanoparticles. Additionally, it will assess the safety and efficacy of the vaccine particles, ensuring thorough evaluation and compliance with relevant guidelines. The operating entity will refine the preparation, purification, and other pertinent processes related to the sheep infectious pus virus mRNA vaccine stock solution. It will supply sites for animal testing and oversee the daily standardized breeding and management of the experimental animals. Furthermore, it will assist Jilin University with vaccination procedures and sample collection and ensure the harmless treatment and ethical management of all experimental animals involved. The agreement does not address or include provisions for the cross-licensing of intellectual property rights. Following the planned task schedule, the operating entity has not initiated its activities, resulting in no incurred expenses as of the date of this prospectus.

[Table of Contents](#)

For the project of the Development of Combined VSV-SVV Nucleic Acid Rapid Test Kit and its Application in the Quarantine of Cold-chain Pork, the operating entity entered into a cooperative research agreement with Jilin University and Health Commission of Jilin Province on September 9, 2022. According to the agreement, Jilin University is responsible for leading the comprehensive design of the experimental project. It will develop a dual fluorescence quantitative PCR nucleic acid test method for the detection of Vesicular Stomatitis Virus (VSV) and Seneca Valley Virus (SVV). It will also assemble a combined VSV-SVV nucleic acid rapid test kit, assess its practical applications, and author a food safety quarantine report detailing the presence of VSV and SVV in cold-chain pork within Jilin Province. Health Commission of Jilin Province is tasked with supplying a P3 biosafety laboratory suitable for virus nucleic acid extraction and PCR amplification. It will support Jilin University in collecting samples and ensure the safe and harmless treatment of experimental materials. The operating entity will assemble the test kits and lead the marketing promotions. Additionally, it will aid Jilin University in collecting samples and conducting food safety quarantines against VSV and SVV in cold-chain pork within Jilin Province. Additionally, the operating entity is committed to contributing RMB260,000 towards the research project. The agreement does not address or include provisions for the cross-licensing of intellectual property rights. Following the planned task schedule, the operating entity has not initiated its activities, resulting in no incurred expenses as of the date of this prospectus.

For the project of the Study of Rapid Visual Nucleic Acid Test of Various SARS-CoV-2 Mutants, the operating entity entered into a cooperative research agreement with Jilin University on September 16, 2022. According to the agreement, Jilin University is entrusted with designing the project and is responsible for preparing probes labeled with organic luminescent materials. Its duties also include optimizing the conditions for isothermal amplification and assessing both the sensitivity and the applicability of the SARS-CoV-2 rapid nucleic acid visualization detection method on clinical samples. The operating entity is assigned to conduct comparative analyses on the complete gene sequences of multiple SARS-CoV-2 variants. They will design the necessary primers and probes and are responsible for evaluating the specificity of the SARS-CoV-2 rapid nucleic acid visualization detection method. The operating entity will invest RMB260,000 as R&D expenses for the project. The agreement does not address or include provisions for the cross-licensing of intellectual property rights. Following the planned task schedule, the operating entity has not initiated its activities, resulting in no incurred expenses as of the date of this prospectus.

For the project of the Development of Animal Microecological Vaccine for the Biological Control of African Swine Fever, the operating entity entered into a cooperative research agreement with Jilin Agricultural University on September 13, 2022. According to the agreement, Jilin Agricultural University is assigned to handle the tasks related to the application, execution, and summarization of the project. Its responsibilities encompass the identification of strains and the development of a composite lactobacillus vaccine. It is also responsible for conducting a biosafety intermediate test and generating the corresponding biosafety intermediate test report to ensure the safety and compliance of the developed products. Meanwhile, the operating entity is responsible for undertaking the product inspection to ensure that the final output meets the required standards and specifications. Upon approval of the project funding, Jilin Agricultural University is allocated 90% of the government-provided funds, with the remaining 10% being designated to the operating entity. Throughout the duration of the research project, ownership of research outcomes and associated intellectual property rights originating from the research conducted by either party shall be vested in the party that conducts the research. Nonetheless, Jilin Agricultural University is granted the right to utilize the operating entity's project information for non-commercial endeavors, such as the creation of government meeting presentations, reports, documents, and references to statistical data, etc. During the period of project execution, intellectual property rights will be mutually shared by both parties. The agreement does not address or include provisions for the cross-licensing of intellectual property rights. As of November 30, 2023, RMB1,493,245 were incurred as costs in this project, which included raw materials purchase costs, employees' salaries, electricity and gas costs, and depreciation expenses.

For the project of the Development and Application of Rapid Visual Test Technology for Key Viral Diseases in Goslings, the operating entity entered into a cooperative research agreement with Jilin Agricultural University and Jilin Provincial Center for Animal Disease Prevention and Control on September 13, 2022. According to the agreement, Jilin Agricultural University has been designated as the project host and is thereby responsible for the tasks of project application, implementation, and summarization. Within the scope of the project, Jilin Agricultural University will undertake the research focused on "the development of fluorescence quantitative PCR and visualization detection methods for prevalent viral diseases in goslings". The operating entity is assigned the responsibility of marketing promotion for the developed detection methods. Jilin Provincial Center for Animal Disease Prevention and Control is entrusted with the tasks related to quality and standard inspection of the detection methods. Once the project funding is secured, Jilin Agricultural University is obligated to allocate an amount of RMB50,000 to the operating entity. Given that the project funding is dispersed in installments, Jilin Agricultural University shall ensure the transfer of the allocated amount to the operating entity within 30 days following the receipt of each installment. The operating entity is committed to

[Table of Contents](#)

contributing RMB250,000 towards the research project, representing 30.1% of the overall project budget. None of the parties shall, without the prior consent of the others, disclose to any third party the contents of this agreement or any related technical information or materials. The obligation to maintain confidentiality will be enforced for a period of three years from the date of the agreement. Should any disputes arise from the execution of this contract between the parties, the parties should endeavor to resolve them through negotiation and mediation. In instances where a resolution cannot be attained through negotiation and mediation, the aggrieved party has the right to initiate legal proceedings in the competent People's Court in accordance with applicable laws. The agreement does not address or include provisions for the cross-licensing of intellectual property rights. Following the planned task schedule, the operating entity has not initiated its activities, resulting in no incurred expenses as of the date of this prospectus.

For the project of the Development and Application of Fluorescent ERA Rapid Thermostatic Diagnostic Technology for Key Viral Diarrhea Diseases in Pigs, the operating entity entered into a cooperative research agreement with Jilin Academy of Agricultural Sciences on September 19, 2022. According to the agreement, Jilin Academy of Agricultural Sciences is mandated to investigate conventional diagnostic markers for identical pathogens and specific markers for distinct pathogens, and to fabricate uniform and stable nucleic acid reference materials. This includes the design of primers and exo probes for pathogen diagnostic markers, optimization of primers, reaction systems, and conditions, and the assessment of specificity, sensitivity, stability, and accuracy. It is tasked with establishing a fluorescence ERA constant temperature detection method, enabling on-site rapid detection within 15-20 minutes. Furthermore, it will conduct background investigations on four types of porcine viral diarrhea pathogens prevalent in Jilin Province, finalize the prototype production of rapid diagnostic reagents, and facilitate the dissemination of grassroots technology. The operating entity, on the other hand, is obligated to grant access to the Jilin Province Animal Vaccine Engineering Research Center and is responsible for assembling a research and development team to standardize a constant temperature testing methodology. Additionally, it will provide existing vaccine strains and samples procured from pig farms situated in Jilin Province. The parties mutually acknowledge and agree that the ownership of the Fluorescent ERA Rapid Thermostatic Diagnostic Technology for Key Viral Diarrhea Diseases in Pigs, developed within the scope of this project, shall be vested solely in Jilin Academy of Agricultural Sciences. Consequently, any economic benefits derived from this technology will accrue to Jilin Academy of Agricultural Sciences. Additionally, all innovations, products, patents, and other intellectual property generated during the research phase of this project are to be the exclusive property of Jilin Academy of Agricultural Sciences. However, it is agreed that Jilin Academy of Agricultural Sciences shall, with priority, transfer any such advancements to the operating entity. The agreement does not address or include provisions for the cross-licensing of intellectual property rights. The parties concur to jointly apply for governmental scientific and technological research funding amounting to RMB500,000 for the project. In addition, the operating entity commits to contributing RMB250,000 to the project. Upon successful acquisition of the government funding, it is planned that 80% of such funds will be allocated to Jilin Academy of Agricultural Sciences, and the remaining 20% will be assigned to the operating entity. As of November 30, 2023, RMB1,007,846 were incurred as costs in this project, which included raw materials purchase costs, employees' salaries, electricity and gas costs, and depreciation expenses.

For the project of the Preparation Process Study of Immunoglobulin Y against Rotavirus Disease in Herbivorous Animals and its Prophylactic Application, the operating entity entered into a cooperative research agreement with Jilin Institute of Animal Husbandry and Veterinary Medicine on September 20, 2022. According to the agreement, Jilin Institute of Animal Husbandry and Veterinary Medicine, serving as the project leader, will organize and execute the research by undertaking the following tasks: (i) conduct comprehensive molecular genetic analyses on rotavirus isolates obtained from varied hosts to identify the optimal antigenic epitopes; (ii) develop a multi-antigen epitope tandem expression vector, utilizing a rod-shaped virus multi-gene expression system, to facilitate the preparation of specific antigens; and (iii) refine the immunization regimen, augment the production efficiency of IgY antibodies, and perform comparative studies on the biological activity of antibodies yielded by various purification methodologies. The operating entity will act as a supporting member for the project, focusing on refining the production processes such as IgY drying and coating. It will also assess the clinical effectiveness of the products in preventing and controlling disease and will lead demonstrations and promotional activities on breeding farms. The project has a budget of RMB800,000, with 70% being sourced from the Jilin Provincial Science and Technology Innovation Research Funding and the remaining 30% contributed by the operating entity. The approved funds will be split at a 4:1 ratio, with Jilin Institute of Animal Husbandry and Veterinary Medicine receiving four times the amount allocated to the operating entity. Jilin Institute of Animal Husbandry and Veterinary Medicine holds ownership of the "Preparation Process Study of Immunoglobulin Y against Rotavirus Disease in Herbivorous Animals and its Prophylactic Application," including all economic benefits, new technologies, products, patents, and other achievements derived from it. However, the operating entity retains the right of authorship for any patented achievements from the project. The agreement does not address or include provisions for the cross-licensing of intellectual property rights. The parties concur that should *force majeure* or technical risks

[Table of Contents](#)

arise during the execution of this agreement, hindering its continuation, prompt notification is required to mitigate losses and discuss alterations or termination of the agreement mutually. Any party can modify or terminate this agreement by providing a written notice to the other, 60 working days in advance. Following the planned task schedule, the operating entity has not initiated its activities, resulting in no incurred expenses as of the date of this prospectus.

For the above projects, since the further costs involved cannot be measured reliably, the outcome or result under the research is not for sure, and the future economic benefits are uncertain, therefore, the operating entity recognized the costs incurred during the research as research and development expenses.

The operating entity expects that the R&D expenses will increase significantly in the future, as it continues to develop new products, enhance its existing products and technologies, and perform activities related to obtaining additional regulatory approval.

As of the date of this prospectus, the operating entity has 39 registered patents in mainland China. See “— Intellectual Property.” Faced with the ever-changing market demands, it continues to invest in acquiring new patents and technologies that are tailored to the market’s fast changing requirements.

Sales and Distribution

As of the date of this prospectus, the operating entity has a sales team of 68 employees. The operating entity provides its sales team with regular training and internally developed systems to assist them in quickly becoming proficient and productive sales personnel. The employment agreements with the sales team members include, contract period (fixed time or indefinite duration), job description, occupational hazard protection, termination provisions, and compliance with the Labor Law of the People’s Republic of China and the Labor Contract Law of the People’s Republic of China in all material aspects. The compensation package for the sales team includes vacation, social insurance, fixed base salaries and commissions based on the revenue or collection they achieve.

With the efforts of the sales team, the operating entity markets and sells its products through three main channels: (i) through its direct sales channel, (ii) through its distribution network, and (iii) through government tender and procurement, which account for 76%, 23%, and 1%, respectively, for the six months ended June 30, 2023, and 80%, 18%, and 2%, respectively, for the fiscal year ended December 31, 2022.

Direct Sales Channel

The operating entity sells its products through its direct sales channel mainly by participating tender and procurement of major breeding companies and directly contracting with breeders.

Distribution Network

The operating entity’s domestic distributors cover 29 provincial-level administrative regions of the PRC for the resale of the operating company’s products in the Chinese market. Domestic distributors market and distribute the products in the regions where they are located.

The operating entity’s exporting distributors are local distributors in their respective countries. Through the efforts of these exporting distributors, the operating entity is able to sell its products overseas. The operating entity secures its exporting distributors mainly through Alibaba.com. The operating entity pays an annual fee to Alibaba.com. In return, Alibaba.com provides the operating entity with an online store on Alibaba.com where it can promote its products. Exporting distributors can find the operating entity and send inquiry emails by searching for product information at Alibaba.com.

The operating entity has either long-term written agreements, the term of which is normally one year, or brief purchase order-based sales agreements with its distributors, based on the demand of its distributor customers. The key terms of the distributor purchase agreements include:

- the product’s name, type, quantity, and price;
- qualifications, including business license, veterinary vaccines production and operation licenses, and inspection report. (The absence of any of these qualifications will result in termination of the agreements);
- delivery method and payment terms: shipping costs are typically borne by the operating entity and payment shall be made before delivery;

Table of Contents

- risk of loss, which is typically borne by the operating entity until delivery;
- breach of contract terms, including refunds and return of products (e.g., distributors are entitled to refunds and may return a product if the wrong product is delivered, or the product does not meet agreed upon quality standards); and
- dispute solutions, including bringing a lawsuit at the local court where the distributors are located.


Government Tender and Procurement

Local governments are also direct-end user customers. The veterinary authority of provincial-level administrative regions government drafts an annual plan of veterinary vaccines procurement based on the animal epidemic within its territory, and purchases vaccines through a tender process. The authority arranges one or two tenders each year, which are delegated to a third-party tender agency company. There are two kinds of tenders, namely Qualification Tender and Quantity Tender. For Qualification Tender, the bidder only bids for the inclusion of the sales qualifications list and unit price of the product. For Quantity Tender, on the other hand, the bidder bids for the exact sales qualification which allow the bidder to enter into the particular procurement contract with the authority, and the unit price and quantity of the product. After the tender and bid, the company will enter into a contract with the authority or its subordinate center for animal disease control and prevention. After entering into the contract, the authority will place orders based on demand, and after delivery of the products, the company will be paid annually or semiannually. As of the date of this prospectus, the operating entity is participating in three procurement contracts with three provincial and local veterinary authorities, providing Classical Swine Fever Vaccine, Live (Tissue Culture Origin), Swine Fever Vaccine, only for Government Procurement, Live (Tissue Culture Origin), and Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live (Strain HuN4-F112). The key terms of procurement contracts include:

- name of the vaccine, quantity, unit price and total price;
- delivery terms, including time, location and receiver;
- shipping fee, insurance, and payment terms; Shipping costs are the responsibility of the operating entity;
- breach of contract terms, including return of products and compensatory damages; and
- dispute solutions, including bringing a lawsuit at the local court, if negotiations are unsuccessful.

Production and Manufacturing

The operating entity production lines are all located at their facilities in the Jilin Economic & Technical Development Zone, Jilin Province, in the PRC. The operating entity produces products and stock inventory of raw materials at the facilities pursuant to the market demand, orders it receives or plans to receive, its production plan and capacity, and procurement information from its distributors. The production process is as follows:



[Table of Contents](#)

The production process is subject to continuous review and monitoring by the quality control team to ensure that finished products are of the highest quality and meet both regulatory and customer requirements.

The operating entity production lines run eight hours per day and 280 to 320 days per year. The annual production capacity of the operating entity's manufacturing facilities in the fiscal year ended December 31, 2022 is demonstrated in the following table:

Veterinary Vaccines	Number
Swine Vaccine	293,768,387
Poultry Vaccine	1,233,378,150
Bovine and Ovine Vaccine	68,731,970

Quality Control

Quality and safety are always the operating entity's core value. Reliable, safe and stable product quality is an important driving factor for maintaining market competitiveness. We believe that the operating entity has developed a sophisticated quality control management system in accordance with the requirements of Chinese laws and regulations.

The quality control management system fully covers the whole process of manufacturing, which consists of three parts: raw materials and viral seeds inspection, work in process check, and product examination.

Raw materials are inspected when they arrive the operating entity's manufacturing facilities. The operating entity's inspectors check their names, sizes, models, quantities, packaging, and supplier qualifications, to make sure they are in accordance with the purchasing order or receipt. After a work in process is made, it is subject to quality check. If it passes the quality check, the operating entity starts manufacturing vaccines based on the work in process. If it fails to pass the check, on the other hand, it is harmlessly disposed. The operating entity also inspects all its products before shipping them to customers.

Although different vaccine products require different inspections, the examinations of the operating entity's viral seeds, works in process and products can be summarized as follows:

- i. Physical property inspection. Quality inspector observes whether the appearance, properties, dosage form, color, and other aspects of the product comply with the quality standard requirements.
- ii. Sterility testing. The tested samples should be free from bacterial contamination.
- iii. Safety testing. When the tested samples are injected into experimental animals, there should be no significant changes in the animals' body temperature, appetite, and activity level.
- iv. Efficacy testing. Different vaccine samples undergo different efficacy tests, such as antibody assays, animal challenge studies, etc.

The operating entity prioritizes product quality management. It is committed to strengthening the professional ethics and cultivating quality consciousness of its employees and forming a strict quality management system, which we believe is in line with international standards. However, despite the quality control management system, the operating entity cannot eliminate the risks of errors, defects, or failures. See "Risk Factors-Risks Relating to Our Business and Industry-The operating entity may fail to detect or cure defects of its products."

As of the date of this prospectus, we or the operating entity is not aware of any other investigations, prosecutions, disputes, claims or other proceedings in respect of quality issues, nor have we or the operating entity been penalized additionally or can foresee any penalty to be made by any related PRC government authorities.

Competition

The veterinary vaccine industry is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities of industry participants. The operating entity competes or plans to compete with manufacturers of veterinary vaccines. Some of these competitors are large, well-capitalized companies with greater market share, resources and experience than the operating entity has. As a consequence, they are able to spend more on product development, marketing, sales and other product initiatives than the operating entity can. The operating entity competes based on factors such as price, value, customer support, brand recognition, reputation, and product functionality, reliability, and compatibility.

[Table of Contents](#)

Below is a list of the operating entity's major competitors.

Name	Aspects of Competition
Jinyu Bio-Technology Co., Ltd.	Vaccines for Swine, Poultry, Cattle, Sheep and Goat
Wuhan Keqian Biology Co., Ltd.	Vaccines for Swine and Poultry
Shanghai Shenlian Biomedical Co., Ltd.	Vaccines for Swine
Guangdong Yongshun Biopharmaceutical Co., Ltd.	Vaccines for Swine and Poultry
Shanghai Haili Biotechnology Co., Ltd.	Vaccines for Swine and Poultry

Although there can be no assurance that the operating entity will be able to continue to compete successfully in the future, we believe that the operating entity can compete successfully with these companies by offering products of better quality at comparable prices.

Intellectual Property

The operating entity's business is dependent on a combination of trademarks, patents, domain names, and other proprietary rights in order to protect the operating entity's intellectual property rights. As of the date of this prospectus, the operating entity has eight registered trademarks, 39 registered patents, one domain name and six registered copyrights in China. Set forth below is a detailed description of the operating entity's registered intellectual properties.

Patent

Patent No.	Title	Patent Publication Date	Type of Patent Application	Expiration Date
ZL201410109323.4	Preparation Methods and Products of Live Pseudorabies Vaccine	February 24, 2016	Invention	February 23, 2036
ZL201410150556.9	H9N2 Avian Influenza Virus Strain, the Inactivated Vaccine and its Application	May 11, 2016	Invention	May 10, 2036
ZI201510063873.1	Vaccine Adjuvant and its Application on the Preparation of Newcastle Disease Inactivated Vaccine	November 10, 2017	Invention	November 9, 2037
ZL201821162503.9	A Fixing Strap of Temperature Transmitter for Livestock Temperature Measurement	January 18, 2019	Utility Model	January 17, 2029
ZL201821162650.6	An Aseptic Sampling Device for Bioreactors	June 4, 2019	Utility Model	June 3, 2029
ZL201821162656.3	A Fixing Device for Experimental Animals	September 3, 2019	Utility Model	September 2, 2029
ZL201821162502.4	A Temperature Adjustable Mouse Restrainer for Intravenous Injections	August 30, 2019	Utility Model	August 29, 2029
ZL201510320280.9	Porcine Circovirus Type 2 (Pcv2) Strain, the Inactivated Vaccine and its Application	September 7, 2018	Invention	September 6, 2038
ZL201521092537.1	A Chicken Embryo Allantoic Fluid Collector	June 15, 2016	Utility Model	June 14, 2026
ZL201521092546.0	A Liquid Tank Filter	May 25, 2016	Utility Model	May 24, 2026
ZL201520929535.7	Aseptic Protection Device for Reagent Bottles Capable of Controlling Liquid Level	April 27, 2016	Utility Model	April 26, 2026
ZL201520929411.9	A Thawing Device for Vaccines	April 27, 2016	Utility Model	April 26, 2026
ZL201520929389.8	A Container for Cell Culture Flasks	April 27, 2016	Utility Model	April 26, 2026
ZL201520929412.3	Vaccine Stir Bar with Movable Paddles	April 27, 2016	Utility Model	April 26, 2026
ZL201520929555.4	Folding Hand Cart	April 27, 2016	Utility Model	April 26, 2026

[Table of Contents](#)

Patent No.	Title	Patent Publication Date	Type of Patent Application	Expiration Date
ZL201711107884.0	Porcine Rotavirus Strain, the Inactivated Vaccine and its Application	June 15, 2021	Invention	June 14, 2041
ZL202021428573.1	A Sealed Vaccine Refrigerator	April 30, 2021	Utility Model	April 29, 2031
ZL202021300518.4	An Easy-to-Transport Receiving Cart for Vaccine Production	March 16, 2021	Utility Model	March 15, 2031
ZL202021302199.0	A Make-Up Tank for Vaccine Production	May 18, 2021	Utility Model	May 17, 2031
ZL202021297863.7	A Water Bath for Vaccine Production	May 18, 2021	Utility Model	May 17, 2031
ZL202021598646.1	An Angle Adjustable Low-Temperature Storage Device for Vaccine	May 18, 2021	Utility Model	May 17, 2031
ZL202021599219.5	An Anti-Collision Transport and Storage Device for Veterinary Vaccine	May 18, 2021	Utility Model	May 17, 2031
ZL202120600080.X	A Sealer for Discharge Pipe	October 15, 2021	Utility Model	October 14, 2031
ZL202120616940.9	A Steam Sterilizer	December 14, 2021	Utility Model	December 13, 2031
ZL202120630917.5	A Foot-Operated Pressurization Device For 10,000 MI Bottle	November 9, 2021	Utility Model	November 8, 2031
ZL202120655608.3	A Multi-Slot Egg Candler	November 23, 2021	Utility Model	November 22, 2031
ZL202120641694.2	An Easy-To-Use Fertile Egg Candler	October 15, 2021	Utility Model	October 14, 2031
ZL202021428550.0	A High-Volume Mixer for Veterinary Disinfectant	July 23, 2021	Utility Model	July 22, 2031
ZL202120651166.5	Flame Sterilizer for Low Volume Glasswares	March 31, 2021	Utility Model	March 30, 2031
ZL202222003543.1	A Low-temperature Storage Device for Feline Herpesvirus Vaccine	August 1, 2022	Utility Model	July 31, 2032
ZL202222022892.8	A Vessel for Culturing Cat Parvovirus	August 3, 2022	Utility Model	August 2, 2032
ZL202123045827.9	Puncher for the Agarose Diffusion Method	December 6, 2021	Utility Model	December 5, 2031
ZL202123039252.X	A Device for Cleaning the Internal Mechanism of Small Fermentation Tanks	December 6, 2021	Utility Model	December 5, 2031
ZL202122501249.9	A Liquid Dispenser with Damping Structure	October 18, 2021	Utility Model	October 17, 2031
ZL202122490625.9	A Cell Culture Bottle that Can be Sampled Multiple Times	October 14, 2021	Utility Model	October 13, 2031
ZL202021430170.0	A Dilution Device for Veterinary Vaccine	July 23, 2021	Utility Model	July 22, 2031
ZL202110408829.5	An Easy-to-operate Double-container Device and Method for the Proportional Dilution of Solutions	April 16, 2021	Invention	April 15, 2041
ZL202110409020.4	A Hand-held Shell Puncher for Embryonated Chicken Eggs	April 16, 2021	Invention	April 15, 2041
ZL202210137800.2	A Portable Device and Method for Detecting Mycoplasma in Chicken Serum	February 15, 2022	Invention	February 14, 2042

Trademarks

Trademark	Registration No.	Name	Registration Date	Classes	Term
	33129332	正无泄	June 7, 2019	5	June 6, 2029
	50312241	正圆臻	July 7, 2021	5	July 6, 2031
	538324	吉生	December 30, 1990	5	December 29, 2030
	50346346	正无梭	August 7, 2021	5	August 6, 2031
	50331020	正无蓝	August 7, 2021	5	August 6, 2031
	40734059	7G	April 14, 2020	5	April 13, 2030
	33129152	正伪净	September 14, 2019	5	September 13, 2029
	33148263	正圆安	June 21, 2019	5	June 20, 2029

Domain Name

The operating entity owns the domain name of “jlzybio.com” with a registration date of May 14, 2018 and an expiration date of May 14, 2026.

Copyrights

The operating entity owns six copyrights, the protection period of which lasts for 50 years from the first publication date of the work.

Copyright No.	Copyright Name	Copyright Publication Date	Type of Copyright	Copyright Application Date
00816517	抗非护猪保生产	April 12, 2019	works of fine arts	June 28, 2019
00802343	正业生物	June 8, 2018	works of fine arts	June 5, 2019
00793306	正喘停	June 8, 2018	works of fine arts	May 31, 2019
01338417	禽正好	N/A	works of fine arts	May 14, 2021
00793307	正业生物科技让动物更美好	June 8, 2018	works of fine arts	May 31, 2019
01338418	鸭正步	N/A	works of fine arts	May 14, 2021

Seasonality

The operating entity’s business is subject to seasonality. The seasonality is mainly due to the impact of the prevalence of animal diseases and the effect of temperature changes during different seasons on animal’s ability to resist various pathogens. Generally, with the change of seasons, especially the cooling of fall and winter, the immune ability of animal is weakened, and the prevalence of animal epidemic diseases is more likely to occur.

With the occurrence of animal diseases, the demand for veterinary products also increases, therefore, the veterinary product industry is subject to seasonality to some extent. However, with the mass production and conglomeration of downstream companies, raising awareness of epidemic prevention of livestock farmers, and enhanced planning and routinization of epidemic prevention, the seasonality of veterinary product industry is gradually attenuating.

Employees

As of September 30, 2023, December 31, 2022, 2021 and 2020, the operating entity had 299, 294, 276 and 271 full-time employees, respectively.

The following table provides a breakdown of the operating entity's employees by function as of September 30, 2023:

Function	Number of Employees
Manufacturing	115
Sales	68
Research and Development	49
Management	9
General	58
Total	299

The operating entity's success depends on its ability to attract, motivate, train and retain qualified personnel. We believe the operating entity offers its employees competitive compensation packages and an environment that encourages self-development and, as a result, has generally been able to attract and retain qualified personnel and maintain a stable core management team.

As required by PRC laws and regulations, the operating entity participates in various employee benefit plans that are organized by municipal and provincial governments, including pension, medical insurance, unemployment insurance, maternity insurance, on-the-job injury insurance, and housing fund plans through a PRC government-mandated benefit contribution plan. The operating entity is required under PRC laws to make contributions to employee benefit plans at specified percentages of the salaries, bonuses and certain allowances of their employees.

We believe the operating entity maintains a good working relationship with its employees, and the operating entity has not experienced any material labor disputes. None of its employees are represented by a labor union.

Properties

The operating entity's office, storage and manufacturing facilities are located in Jilin Economic & Technical Development Zone, Jilin City, Jilin Province, the PRC.

Property the Operating Entity Owns

The operating entity owns the premises of its offices, storage and manufacturing facilities, which are all located at No. 1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin Province, the PRC, and cover an aggregate building area of approximately 510,513 square feet, with the breakdown set for in the below table:

Description/Use	Area (Square Feet)
Hog House	4,338
Quality Inspection Room No. 5	10,043
Power Center No. 3	23,322
Quality Inspection Room No. 4	6,724
Sewage Treatment Facility	1,049
Spleen and Lymph Vaccine Production Floor	28,395
Viral Strain Production Floor No. 2	24,434
Animal Health Room No. 6	14,671
Office Building	25,500
Electrical Substation Facility	1,632
SPF Chicken Facility	18,880
New Refrigerated Storage Facility	3,972
Vaccine Production Floor No. 1 Sector B	61,225

[Table of Contents](#)

Description/Use	Area (Square Feet)
Garage	3,757
Water Pumping Facility	1,012
Animal Feed Storage Room	3,767
Dry Coal Shed	8,138
Boiler Room	10,484
Air Defense Basement	538
Cell Culture Facility	83,065
Cell Culture Facility	82,906
Power Center	31,058
Animal Experiment Center	30,592
Animal Experiment Center	30,473
Cement Storage Room	538

Property the Operating Entity Leases

In addition to the above-mentioned properties that the operating entity owns, it currently leases several properties in Jilin, Jilin province, the PRC and Jinan, Shandong province, the PRC for an aggregate area of approximately 9,536 square feet for warehouses and residences. The breakdown of the leased properties is as follows:

Lessor	Lessee	Location	Area (Square Feet)	Total Rent	Term	Use
Qimin Han	Jilin Zhengye	Middle Chamber, Floor 6, Unit 4, No. 10 Sanhexinyuan, Economic Development District, Jilin, Jilin Province	710	RMB4,800	November 21, 2023 – May 20, 2024	Residence
Jinbao Zhang	Jilin Zhengye	Middle Chamber, Floor 3, Unit 2, No. 5 Sanhexinyuan, Economic Development District, Jilin, Jilin Province	667	RMB10,000	August 17, 2023 – August 16, 2024	Residence
Kai Liu	Jilin Zhengye	Right Chamber, Floor 4, Unit 2, No. 7 Sanhexinyuan, Economic Development District, Jilin, Jilin Province	710	RMB9,600	May 11, 2023 – May 10, 2024	Residence
Jian Sun	Jilin Zhengye	Rm. 301, Baofangyuan, Wangsheren Street, Licheng District, Shandong Province	700	RMB7,200 (January 1, 2023 – June 30, 2023) RMB14,400 (July 1, 2023 – June 30, 2024)	January 1, 2023 – June 30, 2023 July 1, 2023 – June 30, 2024	Residence
Shangdong Taishengyuan Logistics Development Co., Ltd.	Jilin Zhengye	Warehouse 8-1, No.1 Kaiyuan Road, Licheng District, Jinan, Shandong Province	3,229	RMB76,650	April 1, 2023 – March 31, 2024	Warehouse
Changcheng Li	Jilin Zhengye	No. 80, Floor 3, Unit 5, No. 20 Sanhexinyuan, Economic Development District, Jilin, Jilin Province	592	RMB9,000 (June 13, 2022 – June 12, 2023) RMB10,000 (June 13, 2023 – June 12, 2024)	June 13, 2022 – June 12, 2023 June 13, 2023 – June 12, 2024	Residence
Xinchen Wu	Jilin Zhengye	Room 1301, Unit 3, Building No. 4, Huaye International, Changyi District, Jilin, Jilin Province	872	RMB13,800	March 21, 2023 – March 20, 2024	Residence

[Table of Contents](#)

Lessors	Lessee	Location	Area (Square Feet)	Total Rent	Term	Use
Haitao Su	Jilin Zhengye	Right Chamber, Floor 2, Unit 1, No. 3 Sanhexinyuan, Economic Development District, Jilin, Jilin Province	969	RMB18,000	April 13, 2023 – April 12, 2024	Residence
Yanping Qi	Jilin Zhengye	Room 2601, Unit 2, Building No. 12, Wanda Jiangpan Huacheng, Changyi District, Jilin, Jilin Province	958	RMB7,000 (March 19, 2023 – December 31, 2023) RMB7,000 (January 1, 2024 – March 19, 2024)	March 19, 2023 – December 31, 2023 January 1, 2024 – March 19, 2024	Residence
Guoliang Shi	Jilin Zhengye	No. 1547 Parking Space, 1 st Floor, Wanda Plaza, Changyi District, Jilin, Jilin Province	129	RMB4,000	September 2, 2023 – September 1, 2024	Garage

Land Use Right

The operating entity is entitled to use a piece of national land of 979,765 square feet, for industrial purpose, located at No. 1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin Province, the PRC, with an expiration date of November 8, 2055.

Mortgage

Set forth below are the properties subject to mortgage, which are all located at No. 1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin Province, the PRC. The expiration date of the below mortgages will be September 7, 2025.

Properties	Area (Square Feet)	Real Estate Mortgage Document Number
Power Center No. 3	23,322	0029509
Spleen and Lymph Vaccine Production Floor	28,395	0029496
Viral Strain Production Floor No. 2	24,434	0029515
Animal Health Room No. 6	14,671	0029535
Vaccine Production Floor No. 1 Sector B	61,225	0029511
Quality Inspection Room No. 5	10,043	0029539
Quality Inspection Room No. 4	6,724	0029524
Office Building	25,500	0029520
SPF Chicken Facility	18,880	0029540
Hog House	4,338	0029521
New Refrigerated Storage Facility	3,972	0029512
Garage	3,757	0029519
Electrical Substation Facility	2,314	0029537
Water Pumping Facility	1,012	0029514
Animal Feed Storage Room	3,767	0029536
Dry Coal Shed	8,138	0029541
Boiler Room	10,484	0029518
Cement Storage Room	538	0029513
Animal Experiment Center	30,592	0029538
Power Center	31,058	0029533
Cell Culture Facility	82,906	0029497
Sewage Treatment Facility	1,049	0029534

Insurance

The operating entity provides social security insurance including pension, medical insurance, unemployment insurance, maternity insurance, on-the-job injury insurance and housing fund plans through a PRC government-mandated benefit contribution plan for its employees. It does not carry any key-man life insurance, product liability and professional liability insurance and has not purchased any property insurance or business interruption insurance. It has determined that the costs of insuring for related risks and the difficulties associated with acquiring such insurance on commercially reasonable terms make it impractical. We consider the insurance coverage to be sufficient for the operating entity's business operations in China.

Environmental Matters

As a manufacturer of veterinary vaccines, the operating entity production activities are governed by PRC laws and regulations, including the Environmental Protection Law of the PRC, Law of the PRC on the Prevention and Control of Environment Pollution Caused by Solid Wastes, the Regulations on Discharge of Pollutants (Provisional), the Regulation on Urban Drainage and Sewage Treatment and the Measures for the Administration of Permits for Discharging Urban Sewage into the Drainage Pipeline. In order to better comply to these laws and regulations, the operating entity has invested RMB193,000 in pollutant detection and treatment for the past three years.

The wastewater the operating entity generates can be divided into domestic wastewater and active toxic sewage. Domestic wastewater can be disposed directly into municipal pipelines, while active toxic sewage can be disposed into sewage treatment station after being subject to high-temperature sterilization and inspection. The corner wastes generated are cleaned and collected by the cleaning personnel on time, and transported to the municipal garbage disposal site for treatment by the local sanitation department. Solid wastes generated during operation are collected and sent to relevant manufacturers for recycling. If new products are developed in the future, the operating entity will take corresponding environmental protection measures according to relevant laws and regulations.

As of the date of this prospectus, except as disclosed in this prospectus, we are not aware of any warning, investigations, prosecutions, disputes, claims or other proceedings in respect of environmental protection, nor has it been punished or can foresee any punishment to be made by any government authorities of the PRC.

Legal Proceedings

As of the date of this prospectus, neither we nor the operating entity is a party to any material legal or administrative proceedings. From time to time, the operating entity may be subject to various claims and legal actions arising in the ordinary course of business. Litigation or any other legal or administrative proceeding, regardless of the outcome, is likely to result in substantial cost and diversion of the operating entity's resources, including management's time and attention. Furthermore, as of the date of this prospectus, the operating entity is not a party to any international claims or litigation with respect to defective products or other matters.

REGULATIONS

This section sets forth a summary of applicable laws, rules, regulations, government and industry policies and requirements that have a significant impact on our PRC subsidiary and the operating entity's operations and business. This summary does not purport to be a complete description of all laws and regulations that apply to our PRC subsidiaries and the operating entity's business and operations. Investors should note that the following summary is based on relevant laws and regulations in force as of the date of this prospectus, which may be subject to change.

Regulations Related to Foreign Investment

The establishment, operation and management of companies in the PRC are mainly governed by the Company Law, which was issued by the Standing Committee of the National People's Congress and was last amended in October 2018. The Company Law applies to both PRC domestic companies and foreign-invested companies. The investment activities in China of foreign investors are also governed by the Foreign Investment Law, which was approved by the National People's Congress of China in March 2019 and took effect on January 1, 2020. Along with the Foreign Investment Law, the Implementing Rules of Foreign Investment Law promulgated by the State Council and the Interpretation of the Supreme People's Court on Several Issues Concerning the Application of the Foreign Investment Law promulgated by the Supreme People's Court became effective on January 1, 2020. Pursuant to the Foreign Investment Law, the term "foreign investments" refers to any direct or indirect investment activities conducted by any foreign investors in the PRC, including foreign individuals, enterprises or organizations; such investment includes any of the following circumstances: (i) foreign investors establishing foreign-invested enterprises in the PRC solely or jointly with other investors, (ii) foreign investors acquiring shares, equity interests, property portions or other similar rights and interests thereof within the PRC, (iii) foreign investors investing in new projects in the PRC solely or jointly with other investors, and (iv) other forms of investments as defined by laws, regulations, or as otherwise stipulated by the State Council.

Pursuant to the Foreign Investment Law, the State Council shall promulgate or approve a list of special administrative measures for access of foreign investments, which is referred to as "the Negative List." The Foreign Investment Law grants treatment to foreign investors and their investments at the market access stage which is no less favorable than that given to domestic investors and their investments, except for the investments of foreign investors in industries deemed to be either "restricted" or "prohibited" on the Negative List. The Foreign Investment Law provides that foreign investors shall not invest in the "prohibited" industries on the Negative List, and shall meet such requirements as stipulated by the Negative List for making investment in "restricted" industries on the Negative List. Accordingly, the National Development and Reform Commission, or the NDRC, and the Ministry of Commerce promulgated the Negative List (2021), which took effect on January 1, 2022, and the NDRC and the Ministry of Commerce promulgated the Encouraged Industry Catalogue for Foreign Investment (2022 version), or the 2022 Encouraged Industry Catalogue, which took effect on January 1, 2023. Industries not listed on the Negative List (2021) are generally open for foreign investments unless specifically restricted by other PRC laws.

The Foreign Investment Law and its implementing rules also provide several protective rules and principles for foreign investors and their investments in the PRC, including, among others, that local governments shall abide by their commitments to the foreign investors; foreign-invested enterprises are allowed to issue stocks and corporate bonds, except for special circumstances, in which case statutory procedures shall be followed and fair and reasonable compensation shall be made in a timely manner; expropriation or requisition of the investment of foreign investors is prohibited; mandatory technology transfer is prohibited; and the capital contributions, profits, capital gains, proceeds out of asset disposal, licensing fees of intellectual property rights, indemnity or compensation legally obtained, or proceeds received upon settlement by foreign investors within China, may be freely remitted inward and outward in RMB or a foreign currency. Also, foreign investors or the foreign investment enterprises are legally liable for failing to report investment information in accordance with the requirements. Furthermore, the Foreign Investment Law provides that foreign-invested enterprises established prior to the effectiveness of the Foreign Investment Law may maintain their legal form and structure of corporate governance within five years after January 1, 2020.

Regulations Related to Veterinary Drugs Production and Operation

On April 9, 2004, State Council promulgated the Regulation on Veterinary Drug Administration, which was most recently amended on March 27, 2020. These regulations apply to the research and development, production, marketing, import and export, use, as well as supervision and administration of veterinary drugs within the PRC. Pursuant to the Regulation on Veterinary Drug Administration, any enterprise which produces veterinary drugs requires a Veterinary Drug Production License; and any enterprise which deals in veterinary drugs requires a Veterinary Drug Operation

[Table of Contents](#)

License. The validity periods of the Veterinary Drug Production License and the Veterinary Drug Operation License are both five years. Enterprises that produce or manage veterinary drugs without the Veterinary Drug Production License or the Veterinary Drug Distribution License will be ordered to stop their production or business and their illegal income will be confiscated. In serious cases, they will be investigated for the crime of illegal operation.

On April 21, 2020, the Ministry of Agriculture and Rural Affairs of the PRC promulgated a new version of the Measures for the Production and Quality Control of Veterinary Biological Products with an effective date of June 1, 2020, governing the production, storage, supervision and administration of veterinary biological products within the PRC. According to these measures, any enterprise producing veterinary drugs shall establish a quality assurance system that conforms to the requirements of quality control for veterinary drugs, and ensure that the production, control, storage and sales of veterinary drugs meet the registration requirements of veterinary drugs.

The veterinary drug operators in the PRC shall also comply with the Norms for the Business Operation and Quality Management of Veterinary Drugs, which was promulgated by the Ministry of Agriculture and Rural Affairs on January 15, 2010 and amended on November 30, 2017. It is a set of standards regulating the quality management of veterinary drugs operators in the PRC, including but not limited to operation sites, equipment, personnel, bylaws, purchases, warehousing, distribution and freight.

On March 17, 2021, the Ministry of Agriculture and Rural Affairs of the PRC promulgated a new version of the Measures for the Administration of the Business Operation of Veterinary Biological Products with an effective date of May 15, 2021, governing the distribution, operation, supervision and administration of veterinary biological products within the PRC. According to these measures, any enterprise that engages in the business operation of biological products for veterinary use shall obtain a Veterinary Drug Operation License. The business scope in the Veterinary Drug Operation License shall specifically state the categories of biological products, for example, whether they are national compulsory immunity biological products, and the name of the entrusted production enterprise of biological products for veterinary use.

According to the Measures for the Administration of Veterinary Drug Registration, after completing clinical trials, new veterinary drug registration applicants should submit an application to the Ministry of Agriculture and Rural Affairs and provide relevant documents as required by Announcement No. 442 of the People's Republic of China's Ministry of Agriculture and Rural Affairs on veterinary drug registration materials. After receiving the application materials, the Ministry of Agriculture and Rural Affairs forwards them to the review center, which completes a formal review within 10 working days. If the requirements are met, a Notice of Acceptance for Veterinary Drug Registration Application will be issued. If the requirements are not met, a Notice of Non-Acceptance for Veterinary Drug Registration Application will be issued, along with reasons for the decision.

After the acceptance of the veterinary drug registration, the applicant should submit the application materials to the review center within 20 working days. Upon receiving the application materials, the review center completes all technical evaluations within a cumulative total of 120 working days and presents its review opinions and conclusions to the Ministry of Agriculture and Rural Affairs.

If the initial review identifies significant defects, the review center will suggest non-approval based on the existing application materials. If additional materials are needed, the review center should request all supplementary materials at once, and the applicant should provide all required supplementary materials within 132 working days. After the applicant provides the supplementary materials, if substantive defects still exist, the review center will suggest non-approval. If the applicant doesn't need to supply new technical materials and only needs to provide explanatory notes for the application materials, the review center will notify the applicant to submit the relevant explanations within 20 working days. If the review center needs to review the applicant's supplementary materials or explanatory notes again, the review period for that application will be extended by 40 working days.

If, after the initial review, the application generally meets the requirements and needs to undergo registration inspection, the review center will notify the applicant and inform the provincial veterinary department where the pilot production enterprise is located to carry out on-site verification and sampling. The China Veterinary Drug Monitoring Institute should, based on the product quality standards approved by the review center and confirmed by the applicant, determine quality inspection items based on risk and organize quality inspections and standard reviews for the new veterinary drugs being registered. The China Veterinary Drug Monitoring Institute should deliver the quality inspection report and standard review opinions of the registered sample to the review center within 120 working days, and at the same time, send a copy to the applicant. Registration inspection for special veterinary drugs and vaccine products can be completed within 150 working days.

[Table of Contents](#)

After receiving the applicant's supplementary materials or explanations, as well as various other reports from verification, inspection, validation, and review, the review center initiates the re-review process. It then formulates review opinions and conclusions and, along with relevant materials, submits them to the Ministry of Agriculture and Rural Affairs. The Ministry of Agriculture and Rural Affairs should complete its review within 60 working days from the date of receiving the review opinions and conclusions from the review center. For veterinary drugs that meet the requirements, they will be announced. The applicant will be issued a New Veterinary Drug Registration Certificate, accompanied by approved production processes, registration standards, and sample drafts of labels and instructions. Registration Certificate of New Veterinary Drugs verifies that the veterinary drug product has undergone all the necessary tests and evaluations to ensure its safety, efficacy, and quality, and it can be used for animals under the stipulated uses and dosages. It is a required certificate for a manufacturer before receiving an Approval Number for Veterinary Biological Products for a vaccine and commencing manufacturing such vaccine.

After obtaining the New Veterinary Drug Registration Certificate, the applicant is able to submit an application for an Approval Number for Veterinary Biological Products to the Ministry of Agriculture and Rural Affairs. The Ministry of Agriculture and Rural Affairs organizes the China Institute of Veterinary Drug Control to conduct a technical review of the application materials in accordance with regulations. If sample testing is required, it is conducted by the China Institute of Veterinary Drug Control. The Veterinary Bureau of the Ministry of Agriculture and Rural Affairs proposes an approval plan based on the review opinions, and after approval by the minister, the Approval Number for Veterinary Biological Products will be issued to the applicant. With the Approval Number for Veterinary Biological Products, the manufacturer is able to produce the vaccine.

After receiving the New Veterinary Drug Registration Certificate and Approval Number for Veterinary Biological Products, the manufacturer should complete the Veterinary Biological Product Lot Release Record Form and submit it to the China Institute of Veterinary Drug Control along with documents such as the Certificate of Good Manufacturing Practices for Animal Drugs, Veterinary Drug Production Permit, and Approval Number for Veterinary Biological Products. If the record information meets the requirements, the China Institute of Veterinary Drug Control issues a Veterinary Biological Product Lot Release Record Documentation to the manufacturer. The manufacturer, with the Veterinary Biological Product Lot Release Record Documentation, apply for sampling to provincial veterinary drug supervision and inspection institutions and provide the China Institute of Veterinary Drug Control with the Lot Release Product Catalog, Veterinary Biological Product Production and Inspection Report, and Veterinary Biological Product Lot Release Sampling Form. Upon receiving the sampling application submitted by the manufacturer, the provincial veterinary drug supervision and inspection institution should complete the sampling work within 7 working days. The China Institute of Veterinary Drug Control should complete the review within 7 working days after receiving the materials and, when necessary, conduct spot checks and inspections. If compliant with regulations, a Veterinary Biological Product Lot Release Qualification Notice will be issued to the manufacturer. With the Veterinary Biological Product Lot Release Qualification Notice, the manufacturer is able to sell its vaccines domestically.

Regulations Related to Breeding and Use of Animals in Experiment

According to the Regulation on the Administration of Laboratory Animals issued by the National Science and Technology Committee (now known as "the Ministry of Science and Technology") in November 1988 and amended by the State Council in March 2017, the government has adopted a quality certification system for the supervision of animal experiment in respect of the breeding, quarantine and epidemic prevention, use of animals in experiments, import and export of laboratory animals, as well as the qualification of personnel involving in animal experiment.

The State Science and Technology Commission and the State Bureau of Quality and Technical Supervision jointly promulgated the Administration Measures on Good Practice of Experimental Animals in December 1997. The Ministry of Science and Technology and other regulatory authorities promulgated the Administrative Measures on the Certificate for Experimental Animals (Trial) in December 2001. All of these laws and regulations require a Certificate for Use of Laboratory Animals for performing experiments on animals. A laboratory animal operation license is required for personnel involved in the breeding, reproduction, supply, transportation and commercial operation of laboratory animals. Any entity or individual who uses laboratory animals for scientific research and experiment is required to obtain a permit for the use of laboratory animals. Applicants of laboratory animal operation license and use permit shall satisfy certain conditions. No entity or individual shall perform animal experiment and operation without such license or permit. The results of animal experiment will not be recognized if the experiment is conducted by an entity or individual without such license or permit or that the animal and relevant materials are supplied by a provider without the operation license.

Regulations Related to Product Quality

According to the Product Quality Law of the PRC, which was effective as from September 1, 1993 and last amended by the SCNPC on December 29, 2018, products for sale must satisfy relevant safety standards and sellers shall adopt measures to maintain the quality of products for sale. Sellers may not mix impurities or imitations into products, or pass counterfeit goods off as genuine ones, or defective products as good ones or substandard products as standard ones. For sellers, any violation of state or industrial standards of health and safety or other requirements may result in civil liabilities and be imposed on administrative penalties, such as compensation for damages, fines, confiscation of products illegally manufactured or sold and the proceeds from the sales of such products, and even revoking business license. In addition, severe violations may subject the responsible individual or enterprise to criminal investigation.

Pursuant to the Civil Code of the PRC, which became effective on January 1, 2021, the infringed party may claim for compensation from the manufacturer or the seller of the relevant product in which the defects have caused damage. Where the product defects are caused by the producers, the sellers shall have the right to recover the same from the producers after paying compensation. If the products are defective due to the fault of the seller, the producer may, after paying compensation, claim the same from the seller.

Regulations Related to Export and Import

Pursuant to the Regulations of the PRC on the Administration of Import and Export of Goods promulgated by the State Council on December 10, 2001 which came into effect on January 1, 2002, the Foreign Trade Law of the PRC promulgated by the Standing Committee of National People's Congress, or the SCNPC, on May 12, 1994 which came into effect on July 1, 1994 and last amended on December 30, 2022, the Customs Law of the PRC promulgated by the SCNPC, on January 22, 1987 which came into effect on July 1, 1987 and last amended on April 29, 2021, the Measures for Record Filing and Registration by Foreign Trade Dealer promulgated by the Ministry of Commerce (the "MOFCOM") on June 25, 2004, which came into effect on July 1, 2004 and last amended on May 10, 2021 and the Administrative Provisions of the Customs of the PRC on Record-filing of Customs Declaration Entities promulgated by the General Administration of Customs of the PRC on November 19, 2021 which came into effect on January 1, 2022, foreign trade business operators engaging in the import or export of goods or technology must go through the record filing and registration formalities with the MOFCOM or the agency entrusted by the MOFCOM. Unless otherwise provided for, the declaration of import or export goods and the payment of duties may be made by the consignees or consignors themselves, or by entrusted customs brokers. Customs declaration entities refer to consignees or consignors of imported or exported goods or customs brokers that have filed for record with Customs. Customs declaration entities may conduct customs declaration business within the customs territory of the PRC.

Regulations Related to Intellectual Property

Patent

Patents in the PRC are principally protected under the PRC Patent Law, which was initially promulgated by the SCNPC in 1984 and was most recently amended in 2020. A patent is valid for twenty years in the case of an invention and ten years in the case of utility models and designs.

Copyright

Copyrights in the PRC, including software copyrights, is principally protected under the PRC Copyright Law, which took effect in 1991 and was most recently amended in 2020, and other related rules and regulations. Under the PRC Copyright Law, the term of protection for software copyrights is 50 years. The Regulation on the Protection of the Right to Communicate Works to the Public over Information Networks, as most recently amended on January 30, 2013, provides specific rules on fair use, statutory license, and a safe harbor for use of copyrights and copyright management technology and specifies various entities which may be held liable for violations, including copyright holders, libraries and Internet service providers.

Trademark

Registered trademarks are protected under the PRC Trademark Law, which was adopted by the SCNPC in 1982 and most recently amended in 2019, as well as the Implementation Regulations of the PRC Trademark Law adopted by the State Council in 2002 and most recently amended in 2014, and other related rules and regulations. The State

[Table of Contents](#)

Intellectual Property Office, formerly known as the Trademark Office of the State Administration for Industry and Commerce, handles trademark registrations and grants a protection term of ten years to registered trademarks and the term may be renewed for another ten-year period upon request by the trademark owner.

Domain Name

Domain names are protected under the Administrative Measures on Internet Domain Names promulgated by the Ministry of Industry and Information Technology (the “MIIT”) on August 24, 2017 and became effective since November 1, 2017. Domain name registrations are handled through domain name service agencies established under the relevant regulations, and applicants become domain name holders upon successful registration.

Regulations Relating to Environmental Protection

Environmental Protection Law

The Environmental Protection Law of the PRC, or the Environmental Protection Law, was promulgated and effective on December 26, 1989, and most recently amended on April 24, 2014. This Environmental Protection Law has been formulated for the purpose of protecting and improving both the living environment and the ecological environment, preventing and controlling pollution, other public hazards and safeguarding people’s health.

According to the provisions of the Environmental Protection Law, in addition to other relevant laws and regulations of the PRC, the Ministry of Environmental Protection and its local counterparts take charge of administering and supervising said environmental protection matters. Pursuant to the Environmental Protection Law, the environmental impact statement on any construction project must assess the pollution that the project is likely to produce and its impact on the environment, and stipulate preventive and curative measures. The statement shall be submitted to the competent administrative department of environmental protection for approval. Installations for the prevention and control of pollution in construction projects must be designed, built and commissioned together with the principal part of the project.

Permission to commence production or utilize any construction project shall not be granted until its installations for the prevention and control of pollution have been examined and confirmed to meet applicable standards by the appropriate administrative department of environmental protection that examined and approved the environmental impact statement. Installations for the prevention and control of pollution shall not be dismantled or left idle without authorization. Where it is absolutely necessary to dismantle any such installation or leave it idle, prior approval shall be obtained from the competent local administrative department of environmental protection.

The Environmental Protection Law makes it clear that the legal liabilities of any violation of said law include warning, fine, rectification within a time limit, compulsory cease operation, compulsory reinstallation of dismantled installations of the prevention and control of pollution or compulsory reinstallation of those left idle, compulsory shutout or closedown, and even criminal punishment.

As of the date of this prospectus, we or the operating entity is not aware of any warning, investigations, prosecutions, disputes, claims or other proceedings in respect of environmental protection, nor have we or the operating entity been punished or can foresee any punishment to be made by any government authorities of the PRC.

Regulations on Disposal of Hazardous Waste

Pursuant to the Law on the Prevention and Control of Environmental Pollution Caused by Solid Waste, which was promulgated by the SCNPC in 1995 and was latest amended on April 29, 2020, entities generating hazardous waste shall store, utilize and dispose hazardous waste according to the relevant requirements of the state and environmental protection standards, and shall not dump or pile up hazardous waste without authorization. Furthermore, it is forbidden to entrust entities without a permit for disposal to dispose of hazardous waste, otherwise the competent ecological and environmental authorities shall impose fines, confiscate illegal gains, order the entities to make rectification, and in serious circumstance, order the entities to suspend business or close down upon the approval of the government authorities.

Regulations on Urban Drainage and Sewage Treatment

According to the Regulations on Discharge of Pollutants (Provisional) promulgated by the Ministry of Ecology and Environment of the PRC (formerly known as Ministry of Environmental Protection of the PRC) on January 10, 2018 and amended on August 22, 2019 and the Regulations on the Administration of Pollutant Discharge Permits promulgated by the State Council on January 24, 2021, business units and entities that discharge pollutant registered in the list of regular pollutant sources shall apply for permit for discharge of pollutants. No discharge of pollutants shall be allowed if such permit is required.

According to the Regulation on Urban Drainage and Sewage Treatment, which was promulgated by the State Council in 2013, and the Measures for the Administration of Permits for Discharging Urban Sewage into the Drainage Pipeline, which was promulgated by the Ministry of Housing and Urban-Rural Development in 2015 and last amended in 2022, enterprises, institutions and individually-owned businesses engaging in industry, construction, food and beverage, medical service and other activities which discharge sewage into urban drainage facilities shall apply to the competent urban drainage authorities for a permit for sewage discharge into the drainage pipe network, or the Drainage Permit. Entities discharging sewage into urban drainage facilities without obtaining a Drainage Permit shall be ordered by the relevant urban drainage authority to suspend their illegal activities, take remedial measures within a time limit, re-apply the Drainage Permit, and may be imposed a fine of less than RMB500,000.

Regulations on Consumer Rights Protection

The Consumer Rights and Interests Protection Law, as promulgated on October 31, 1993 and most recently amended in 2013 by the SCNPC, imposes stringent requirements and obligations on business operators. Failure to comply with the consumer protection requirements could subject the business operators to administrative penalties including warning, confiscation of illegal income, imposition of fines, an order to cease business operations, revocation of business licenses, as well as potential civil or criminal liabilities.

Regulations Related to Foreign Exchange and Dividend Distribution

Regulations on Foreign Currency Exchange

The principal regulations governing foreign currency exchange in China are the Foreign Exchange Administration Regulations, as most recently amended in 2008. Under these regulations, payments of current account items, such as profit distributions, interest payments and trade and service-related foreign exchange transactions, can be made in foreign currencies without prior approval from the State Administration of Foreign Exchange, or SAFE, by complying with certain procedural requirements. By contrast, approval from or registration with appropriate government authorities is required where RMB is to be converted into foreign currency and remitted out of China to pay capital account items, such as direct investments, repayment of foreign currency-denominated loans, repatriation of investments and investments in securities outside of China.

In 2012, SAFE promulgated the Circular of Further Improving and Adjusting Foreign Exchange Administration Policies on Foreign Direct Investment, or Circular 59, which substantially amends and simplifies the previous foreign exchange procedure. Pursuant to Circular 59, the opening and deposit of various special purpose foreign exchange accounts, such as pre-establishment expenses accounts, foreign exchange capital accounts and guarantee accounts, the reinvestment of RMB proceeds derived by foreign investors in the PRC, and remittance of foreign exchange profits and dividends by a foreign-invested enterprise to its foreign shareholders no longer requires the approval or verification of SAFE, and multiple capital accounts for the same entity may be opened in different provinces, which was not possible previously. In 2013, SAFE promulgated the Notice on Promulgation of the Provisions on Foreign Exchange Control on Direct Investments in China by Foreign Investors and Supporting Documents, which specified that the administration by SAFE or its local branches over direct investment by foreign investors in the PRC must be conducted by way of registration, and banks must process foreign exchange business relating to the direct investment in the PRC based on the registration information provided by SAFE and its branches. In February 2015, SAFE promulgated the Notice on Further Simplifying and Improving the Administration of the Foreign Exchange Concerning Direct Investment, or SAFE Notice 13. Instead of applying for approvals regarding foreign exchange registrations of foreign direct investment and overseas direct investment from SAFE, entities and individuals may apply for such foreign exchange registrations from qualified banks. The qualified banks, under the supervision of SAFE, may directly review the applications, conduct the registration, and perform statistical monitoring and reporting responsibilities.

In March 2015, SAFE promulgated the Circular of the SAFE on Reforming the Management Approach Regarding the Settlement of Foreign Capital of Foreign-invested Enterprise, or Circular 19, which expands a pilot reform of the administration of the settlement of the foreign exchange capitals of foreign-invested enterprises nationwide. Circular 19 allows all foreign-invested enterprises established in the PRC to settle their foreign exchange capital on a discretionary basis according to the actual needs of their business operation, provides the procedures for foreign invested companies to use RMB converted from foreign currency-denominated capital for equity investments and removes certain other restrictions under previous rules and regulations. However, Circular 19 continues to prohibit foreign-invested enterprises from, among other things, using RMB funds converted from their foreign exchange capital for expenditure beyond their business scope and providing entrusted loans or repaying loans between non-financial enterprises. SAFE promulgated the Notice of the State Administration of Foreign Exchange on Reforming and Standardizing the Foreign Exchange Settlement Management Policy of Capital Account, or Circular 16, effective in June 2016, which reiterates some of the rules set forth in Circular 19. Circular 16 provides that discretionary foreign exchange settlement applies to foreign exchange capital, foreign debt offering proceeds and remitted foreign listing proceeds, and the corresponding RMB capital converted from foreign exchange may be used to extend loans to related parties or repay inter-company loans (including advances by third parties). However, there are substantial uncertainties with respect to Circular 16's interpretation and implementation in practice.

In January 2017, SAFE promulgated the Circular on Further Improving Reform of Foreign Exchange Administration and Optimizing Genuineness and Compliance Verification, or Circular 3, which stipulates several capital control measures with respect to the outbound remittance of profits from domestic entities to offshore entities, including that (i) banks must check whether the transaction is genuine by reviewing board resolutions regarding profit distribution, original copies of tax filing records and audited financial statements and stamp with the outward remittance sum and date on the original copies of tax filing records, and (ii) domestic entities must retain income to account for previous years' losses before remitting any profits. Moreover, pursuant to Circular 3, domestic entities must explain in detail the sources of capital and how the capital will be used, and provide board resolutions, contracts and other proof as a part of the registration procedure for outbound investment.

On October 23, 2019, SAFE issued Circular of the State Administration of Foreign Exchange on Further Promoting the Facilitation of Cross-border Trade and Investment, or the Circular 28, which took effect on the same day. Circular 28 allows non-investment foreign-invested enterprises to use their capital funds to make equity investments in China, with genuine investment projects and in compliance with effective foreign investment restrictions and other applicable laws. However, as the Circular 28 was newly issued, there are still substantial uncertainties as to its interpretation and implementations in practice.

Regulations on Dividend Distribution

The principal regulations governing dividends distributions by companies is the PRC Company Law. Under these laws and regulations, both domestic companies and foreign-invested companies in the PRC are required to set aside as general reserves at least 10% of their after-tax profit, until the cumulative amount of their reserves reaches 50% of their registered capital unless the laws and regulations regarding foreign investment provide otherwise. PRC companies are not permitted to distribute any profits until any losses from prior fiscal years have been offset. Profits retained from prior fiscal years may be distributed together with distributable profits from the current fiscal year.

Regulations Related to Tax

Enterprise Income Tax

On March 16, 2007, the SCNPC promulgated the Enterprise Income Tax Law of the PRC which was last amended on December 29, 2018, and on December 6, 2007. The State Council enacted the Regulations for the Implementation of the Enterprise Income Tax Law, which came into effect on January 1, 2008 and was amended on April 23, 2019. Both laws are collectively referred to as the EIT Law. Under the EIT Law, both resident enterprises and non-resident enterprises are subject to tax in the PRC. Resident enterprises are defined as enterprises that are established in China in accordance with PRC laws, or that are established in accordance with the laws of foreign countries but are actually or in effect controlled from within the PRC. Non-resident enterprises are defined as enterprises that are organized under the laws of foreign countries and whose actual management is conducted outside the PRC, but have established institutions or premises in the PRC, or have no such established institutions or premises but have income generated from inside the PRC. Under the EIT Law and relevant implementing regulations, a uniform corporate income tax rate

of 25% is applied. However, if non-resident enterprises have not formed permanent establishments or premises in the PRC, or if they have formed permanent establishment or premises in the PRC but there is no actual relationship between the relevant income derived in the PRC and the established institutions or premises set up by them, enterprise income tax is set at the rate of 10% with respect to their income sourced from inside the PRC.

Value-added Tax

The Provisional Regulations of the PRC on Value-added Tax were promulgated by the State Council on December 13, 1993 and came into effect on January 1, 1994 which were subsequently amended from time to time. The Detailed Rules for the Implementation of the Provisional Regulations of the PRC on Value-added Tax (Revised in 2011) was promulgated by the Ministry of Finance of the PRC (the “MOF”) on December 25, 1993 and subsequently amended on December 15, 2008 and October 28, 2011. Both regulations are collectively referred to as the VAT Law. On November 19, 2017, the State Council promulgated the Decisions on Abolishing the Provisional Regulations of the PRC on Business Tax and Amending the Provisional Regulations of the PRC on Value-added Tax, or the Order 691. According to the VAT Law and the Order 691, all enterprises and individuals engaged in the sale of goods, the provision of processing, repair and replacement services, sales of services, intangible assets, real property and the importation of goods within the territory of the PRC are the taxpayers of Value-added Tax (the “VAT”). The VAT tax rates generally applicable are simplified as 13%, 9%, 6% and 0%, and the VAT tax rate applicable to the small -scale taxpayers is 3%. According to the Notice of the Ministry of Finance and the State Administration of Taxation on Value -Added Tax Policies Concerning the Application of Low Tax Rates and Simplified Taxation Method for Certain Goods promulgated on January 19, 2009 and the Notice of the Ministry of Finance and the State Administration of Taxation on Simplifying Value -added Tax Rate Policies promulgated on June 13, 2014, if general taxpayers sell biological products which are made of microbes, metabolin of microbes, animal toxin, blood or organism of human beings or animals, VAT shall be paid and calculated at the rate of 3% under the simplified method.

Dividends Withholding Tax

According to the EIT Law, dividends paid to their foreign investors by foreign-invested companies that are non-resident enterprises as defined under the law are subject to withholding tax at a rate of 10%, unless otherwise provided in the relevant tax agreements entered into with the central government of the PRC. Pursuant to the Arrangement Between the Mainland China and the Hong Kong Special Administrative Region for the Double Tax Avoidance Arrangement and Tax Evasion on Income promulgated on August 21, 2006, if a Hong Kong resident enterprise is determined by the competent PRC tax authority to have satisfied the relevant conditions and requirements under such tax arrangement, the withholding tax rate on the dividends the Hong Kong resident enterprise receives from a PRC resident enterprise may be reduced to 5% from 10% applicable under the EIT Law and the EITIR. However, based on the Notice of the State Administration of Taxation on Certain Issues with Respect to the Enforcement of Dividend Provisions in Tax Treaties promulgated by the State Administration of Taxation (the “SAT”) and effective on February 20, 2009, if the relevant PRC tax authorities determine, in their discretion, that a company benefits from such reduced income tax rate due to a structure or arrangement that is primarily tax-driven, such PRC tax authorities may adjust the preferential tax treatment. Furthermore, in October 2019, the SAT promulgated the Administrative Measures for Non -Resident Taxpayers to Enjoy Treaty Treatments (the “Circular 35”), which became effective on January 1, 2020 and superseded the Administrative Measures for Non-Resident Enterprises to Enjoy Treatments under Tax Treaties promulgated in 2015. The Circular 35 abolishes the record-filing procedure for justifying the tax treaty eligibility of taxpayers, and stipulates that non-resident taxpayers can enjoy tax treaty benefits via the “self-assessment of eligibility, claiming treaty benefits, retaining documents for inspection” mechanism.

Non-resident taxpayers can claim tax treaty benefits after self-assessment provided that relevant supporting documents shall be collected and retained for post-filing inspection by the tax authorities. Based on the Notice of the State Administration of Taxation on the Recognition of Beneficial Owners in Tax Treaties, which was promulgated by SAT on February 3, 2018 and came into effect on April 1, 2018, a comprehensive analysis is used to determine beneficial ownership based on the actual situation of a specific case combined with certain principles, and if an applicant is obliged to pay more than 50% of its income to a third country (region) resident within 12 months of the receipt of the income, or the business activities undertaken by an applicant do not constitute substantive business activities including substantive manufacturing, distribution, management and other activities, the applicant is unlikely to be recognized as an beneficial owner to enjoy tax treaty benefits.

Enterprise Income Tax on Indirect Transfer of Non-Resident Enterprises

On December 10, 2009, the SAT issued the Notice on Strengthening the Administration of Enterprise Income Tax on Equity Transfers of Non-resident Enterprises (the “Circular 698”). By promulgating and implementing the Circular 698, the PRC tax authorities have enhanced their scrutiny over the indirect transfer of equity interests in a PRC resident enterprise by a non-resident enterprise. The SAT further issued the Public Announcement on Several Issues Concerning Enterprise Income Tax for Indirect Transfer of Assets by Non-Resident Enterprises (the “Circular 7”) on February 3, 2015, which replaces certain provisions in the Circular 698. The Circular 7 introduces a new tax regime that is significantly different from that under the Circular 698. The Circular 7 extends its tax jurisdiction to capture not only indirect transfer as set forth under the Circular 698, but also transactions involving transfer of immovable property in China and assets held under the establishment and place in China of a foreign company through the offshore transfer of a foreign intermediate holding company. The Circular 7 also provides clearer criteria than the Circular 698 on how to assess reasonable commercial purposes and introduces safe harbor scenarios applicable to internal group restructurings. Where a non-resident enterprise indirectly transfers equity interests or other assets of a PRC resident enterprise by implementing arrangements that are not for reasonable commercial purposes to avoid its obligation to pay enterprise income tax, such indirect transfer shall, in accordance with the EIT Law, be recognized by the competent PRC tax authorities as a direct transfer of equity interests or other assets of the PRC resident enterprise.

On October 17, 2017, the SAT promulgated the Announcement on Matters Concerning Withholding and Payment of Income Tax of Non-resident Enterprises from Source (the “SAT Circular 37”), which came into force and replace the Circular 698 and certain provisions in the Circular 7 on December 1, 2017 and was partly amended on June 15, 2018. The SAT Circular 37, among other things, simplifies the procedures of withholding and payment of income tax levied on non-resident enterprises. Pursuant to SAT Circular 37, where the party responsible for withholding such income tax does not, or is unable to, withhold the taxes that should have been withheld to the relevant tax authority, the party may be subject to penalties. Where the non-resident enterprise receiving such income fails to declare and pay taxes that should have been withheld to the relevant tax authority, the party may be ordered to rectify within a specific time limit.

Regulations Related to Employment, Social Insurance and Housing Fund

Pursuant to the PRC Labor Law, which was promulgated in 1994 and most recently amended in 2008, and the PRC Labor Contract Law, which was promulgated on June 29, 2007 and amended on December 28, 2008, employers must execute written labor contracts with full-time employees. All employers must comply with local minimum wage standards. Violations of the PRC Labor Contract Law and the PRC Labor Law may result in the imposition of fines and other administrative and criminal penalties in the case of serious violations. In addition, according to the PRC Social Insurance Law implemented on July 1, 2010 and most recently amended on December 29, 2018 and the Regulations on the Administration of Housing Funds, which was promulgated by the State Council in 1999 and most recently amended in 2019, employers in China must provide employees with welfare schemes covering pension insurance, unemployment insurance, maternity insurance, work-related injury insurance, and medical insurance and housing funds.

Regulations Related to M&A Rules and Overseas Listing

On August 8, 2006, six PRC regulatory agencies, including the MOFCOM, the State-owned Assets Supervision and Administration Commission of the State Council, the SAT, the SAIC, the CSRC, and the SAFE, issued the M&A Rules, which took into effect on September 8, 2006 and was amended by the MOFCOM on June 22, 2009. The M&A Rules, among other things, require that if an overseas company established or controlled by PRC companies or individuals intends to acquire equity interests or assets of any other PRC domestic company affiliated with such PRC companies or individuals, such acquisition must be submitted to MOFCOM for approval. The M&A Rules also require offshore special purpose vehicles formed for overseas listing purposes through acquisitions of PRC domestic companies and controlled by PRC companies or individuals, to obtain the approval of CSRC prior to publicly listing their securities on an overseas stock exchange.

Since the Foreign Investment Law (the “FIL”) and its implementation regulations became effective on January 1, 2020, the provisions of the M&A Rules remain effective to the extent they are not inconsistent with the FIL and its implementation regulations. According to the Anti-Monopoly Law which took effect on August 1, 2008, where the concentration of business operators reaches the filing threshold stipulated by the State Council, business operators shall file a declaration with the SAMR, and no concentration shall be implemented until the SAMR clears the

[Table of Contents](#)

anti-monopoly filing. We currently are not subject to the Anti-Monopoly Law because we do not reach the filing threshold stipulated by the State Council. If we will be found to be subject to the Anti-Monopoly Law, we will be required to file a declaration with the SAMR, and no concentration shall be implemented until the SAMR clears the anti-monopoly filing. During such reviews, we may be required to suspend the operations or experience other disruptions to the operation, which will also result in negative publicity with respect to our Company and diversion of our managerial and financial resources, which could materially and adversely affect our business, financial conditions, and results of operations.

Pursuant to the Notice of the General Office of the State Council on the Establishment of the Security Review System for Mergers and Acquisitions of Domestic Enterprises by Foreign Investors and the Security Review Rules issued by the General Office of the State Council on February 3, 2011 and became effective on March 3, 2011, mergers and acquisitions by foreign investors that raise “national defense and security” concerns, and mergers and acquisitions through which foreign investors may acquire de facto control over domestic enterprises that raise “national security” concerns, are subject to strict review by the PRC government authorities. On August 25, 2011, the MOFCOM issued the Provisions of the Ministry of Commerce for the Implementation of the Security Review System for Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, which provides that if a foreign investor’s merger or acquisition of a domestic enterprise falls within the scope of security review specified in the Notice of the General Office of the State Council on the Establishment of the Security Review System for Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, the foreign investor shall file an application with MOFCOM for security review. Whether a foreign investor’s merger or acquisition of a domestic enterprise falls within the scope of security review or not shall be determined based on the substance and actual influence of the merger or acquisition transaction. No foreign investor is allowed to substantially avoid the security review in any way, including but not limited to, holding shares on behalf of others, trust arrangements, multi-level reinvestment, leasing, loans, contractual control, or overseas transactions.

On February 17, 2023, the CSRC promulgated the Overseas Listing Trial Measures and relevant five guidelines, which became effective on March 31, 2023. The Overseas Listing Trial Measures comprehensively improve and reform the existing regulatory regime for overseas offering and listing of PRC domestic companies’ securities and regulate both direct and indirect overseas offering and listing of PRC domestic companies’ securities by adopting a filing-based regulatory regime.

According to the Overseas Listing Trial Measures, PRC domestic companies that seek to offer and list securities in overseas markets, either in direct or indirect means, are required to fulfill the filing procedure with the CSRC and report relevant information. The Overseas Listing Trial Measures provides that an overseas listing or offering is explicitly prohibited, if any of the following: (i) such securities offering and listing is explicitly prohibited by provisions in laws, administrative regulations and relevant state rules; (ii) the intended securities offering and listing may endanger national security as reviewed and determined by competent authorities under the State Council in accordance with law; (iii) the domestic company intending to make the securities offering and listing, or its controlling shareholder(s) and the actual controller, have committed relevant crimes such as corruption, bribery, embezzlement, misappropriation of property or undermining the order of the socialist market economy during the latest three years; (iv) the domestic company intending to make the securities offering and listing is currently under investigations for suspicion of criminal offenses or major violations of laws and regulations, and no conclusion has yet been made thereof; or (v) there are material ownership disputes over equity held by the domestic company’s controlling shareholder(s) or by other shareholder(s) that are controlled by the controlling shareholder(s) and/or actual controller.

The Overseas Listing Trial Measures also provides that if the issuer both meets the following criteria, the overseas securities offering and listing conducted by such issuer will be deemed as indirect overseas offering by PRC domestic companies: (i) 50% or more of any of the issuer’s operating revenue, total profit, total assets or net assets as documented in its audited consolidated financial statements for the most recent fiscal year is accounted for by domestic companies; and (ii) the main parts of the issuer’s business activities are conducted in mainland China, or its main place(s) of business are located in mainland China, or the majority of senior management staff in charge of its business operations and management are PRC citizens or have their usual place(s) of residence located in mainland China. Where an issuer submits an application for initial public offering to competent overseas regulators, such issuer must file with the CSRC within three business days after such application is submitted. The Overseas Listing Trial Measures also requires subsequent reports to be filed with the CSRC on material events, such as change of control or voluntary or forced delisting of the issuer(s) who have completed overseas offerings and listings.

[Table of Contents](#)

On February 24, 2023, the CSRC promulgated the Confidentiality and Archives Administration Provisions, which also became effective on March 31, 2023. According to the Confidentiality and Archives Administration Provisions, domestic companies that seek overseas offering and listing (either in direct or indirect means) and the securities companies and securities service (either incorporated domestically or overseas) providers that undertake relevant businesses shall institute a sound confidentiality and archives administration system, and take necessary measures to fulfill confidentiality and archives administration obligations. They shall not leak any state secret and working secret of government agencies, or harm national security and public interest. Therefore, a domestic company that plans to, either directly or through its overseas listed entity, publicly disclose or provide to relevant individuals or entities including securities companies, securities service providers and overseas regulators, any documents and materials that contain state secrets or working secrets of government agencies, shall first obtain approval from competent authorities according to law, and file with the secrecy administrative department at the same level. The above-mentioned documents and materials that, if leaked, will be detrimental to national security or public interest, the domestic company shall strictly fulfill relevant procedures stipulated by applicable regulations. Furthermore, the Confidentiality and Archives Administration Provisions stipulates that a domestic company that provides accounting archives or copies of accounting archives to any entities including securities companies, securities service providers and overseas regulators and individuals shall fulfill due procedures in compliance with applicable regulations. Working papers produced in the Chinese mainland by securities companies and securities service providers in the process of undertaking businesses related to overseas offering and listing by domestic companies shall be retained in the Chinese mainland. Where such documents need to be transferred or transmitted to outside the Chinese mainland, relevant approval procedures stipulated by regulations shall be followed.

MANAGEMENT

Set forth below is information concerning our directors, director nominees, and executive officers.

The following individuals are our executive management and members of the board of directors.

Name	Age	Position(s)
Zhenfa Han	70	Director and Chairman of the Board
Songlin Song	48	Chief Executive Officer
Wenhua Sun	56	Director
Ping Wang	43	Chief Financial Officer
Zhongyao Liu	38	Vice General Manager
Wei Lian	42	Vice General Manager
Yawen Dong	60	Vice General Manager
Yuyou He	61	Vice General Manager
Wanlin Zhang	62	Vice General Manager
Yuhong Cheng	47	Vice General Manager
[•]		Independent Director Nominee*
[•]		Independent Director Nominee*
[•]		Independent Director Nominee*

* These individuals will become directors of the Company upon the effectiveness of the registration statement of which this prospectus forms a part.

The following is a brief biography of each of our executive officers and directors:

Zhenfa Han has been our Director since March 2023 and Chairman of the Board since May 2023. He has served as the Director of the operating entity since April 2004, and he served as the Chairman of the Board of the operating entity from September 2015 to September 2018. He reassumed the role of Chairman of the Board of the operating entity since January 2022. Mr. Han also held the following prominent positions outside of our Company: a member of the 10th, 11th, and 12th National Committee of the Chinese People's Political Consultative Conference ("CPPCC"), a member of the Social and Legal Affairs Committee of the CPPCC, a standing committee member of the Jilin Provincial CPPCC, the Deputy Director of the Legal Affairs Committee of the Jilin Provincial CPPCC, a standing committee member of the All-China Federation of Industry and Commerce, the Vice President of the Agricultural Industry Chamber of Commerce under the All-China Federation of Industry and Commerce, the Vice President of the Jilin Provincial Federation of Industry and Commerce, the Executive Director of China Society for Promotion of the Guangcai Program, the Executive Director of the China Animal Agriculture Association, and the President of the Jilin Provincial Animal Husbandry Association. The National Equities Exchange and Quotations of the PRC (the "NEEQ") circulated a notice of criticism towards Mr. Han, which was recorded in the Securities and Futures Market Integrity File on May 18, 2022. The Securities and Futures Market Integrity File, established and maintained by the CSRC, is a system that records various information of the regulatory authorities and individuals and entities engaged in the securities and futures market activities, including notices of criticism circulated by the CSRC towards securities issuers and their management, for their non-compliance with securities laws and regulations, which can be accessed by the public and affect the reputations of those recorded in it. Information of more serious violations, such as administrative penalties, market bans, and criminal penalties, is also included in the Securities and Futures Market Integrity File. Notices of criticism will remain in the Securities and Futures Market Integrity File for three years, while information of more serious violations will remain for five years. The criticism was due to his failure to diligently and faithfully perform his duties, and he was responsible for Jilin Zhengye's delay in reviewing and disclosing two agreements. Further, Jilin Zhengye was deemed the primary party responsible for the obligations of special clauses, i.e. valuation adjustment mechanism. The issuance of a notice of criticism may impact the reputations of the individual or entity documented within it. It may influence investors' investment decisions, by providing insights into the integrity and reliability of the listed individual or entity. As confirmed by our PRC counsel, Guantao, there is no negative impact on the value of the Ordinary Shares or the operating entity's business, given that: (i) Jilin Zhengye voluntarily disclosed to the CSRC in the form of a public announcement about its delay in reviewing and disclosing two agreements; (ii) the notice of criticism is the lightest punishment and Mr. Hans's non-compliance does not involve

any administrative penalties, market bans, or criminal penalties; and (iii) the notice of criticism is the punishment for the operating entity's past behavior and will neither affect the operating entity's business nor the Company's listing. He obtained his Bachelor degree in Philosophy from Jilin Provincial Party School in the PRC in 1989.

Songlin Song has been our Chief Executive Officer since May 2023. He has served as the Director and General Manager of the operating entity since September 2018. Prior to joining the operating entity, Mr. Song was a General Manager of China Animal Husbandry Industry Co., Ltd., from April 2018 to August 2018. Mr. Song is an advisor of the master programs in Jilin University College of Veterinary Medicine. Mr. Song holds Senior Veterinarian Professional Title and Principal Senior Economist Professional Title in China. He obtained his Bachelor degree in Veterinary Medicine from China Agriculture University in 1998.

Wenhua Sun has been our Director since May 2023. Ms. Sun has been the General Manager of Beijing Huazheng Property Management Co., Ltd. since January 2020. She also has been the Director of Zhengye Investment Co., Ltd. and the Director and General Manager of Beijing Hanzhenyuan International Hotel Co., Ltd. since April 2018. Ms. Sun obtained her Bachelor degree in Party and Government Management from Changchun Radio and Television University in the PRC in 1987.

Ping Wang has been our Chief Financial Officer ("CFO") since May 2023. He has served as the CFO of the operating entity since December 2021. Mr. Wang has over nineteen years of experience in finance performance control. Prior to joining the operating entity, Mr. Wang was a Financial Director of Beijing San Environmental Protection New Materials Co., Ltd., from March 2018 to November 2021. Mr. Wang holds Intermediate Accountant Qualification and Auditor Qualification in China. He obtained his Bachelor degree in Financial Accounting Education from Jilin Agricultural University in the PRC in 2003. Mr. Wang became a Certified Internal Auditor of the Institute of Internal Auditors in November 2014.

Zhongyao Liu has been our Vice General Manager since May 2023. He has served as the Director, Vice General Manager, and Board Secretary of the operating entity since April 2021. Prior to joining the operating entity, Mr. Liu was an M&A Manager of Beijing Oriental Yuhong Waterproof Technology Co., Ltd. From March 2019 to September 2020, Mr. Liu served as a Senior Investment Manager at Beijing New Building Materials Public Limited. From April 2018 to March 2019, he served as an Oversea Investment Manager at Jilin Yatai (Group) Co., Ltd. He obtained Bachelor's degree in Marketing from Jilin University in the PRC in 2008. He also obtained a Master degree of Financial Engineering from Nagasaki University in Japan in 2012. Mr. Liu became a Certified Management Accountant of the Institute of Certified Management Accountants of the U.S. in September 2018.

Wei Lian has been our Vice General Manager since May 2023. He has served as the Deputy General Manager of the operating entity since April 2018. Mr. Lian is an advisor of the master programs in Jilin Agricultural University School of Veterinary Medicine. He holds Senior Veterinarian Professional Title in China. Mr. Lian obtained his Bachelor's degree in Animal Medicine from Jilin Agricultural University in the PRC in 2005. He also obtained a Master degree of Veterinary from Jilin Agricultural University in the PRC in 2012.

Yawen Dong has been our Vice General Manager since May 2023. He has served as the Deputy General Manager of the operating entity since April 2018. He holds Senior Veterinarian Professional Title in China. Mr. Dong obtained his Junior College's degree in Animal Husbandry and Veterinary Medicine in Heilongjiang Provincial Ethnic Cadre College in the PRC in 1990. He obtained his Master's degree in Preventive Veterinary Medicine in Northeast Agricultural University in the PRC in 2000.

Yuyou He has been our Vice General Manager since May 2023. He has served as the Deputy General Manager of the operating entity since April 2018. Mr. He is an advisor of the master programs in Shanghai Veterinary Research Institute of Chinese Academy of Agricultural Sciences. He holds Senior Veterinarian Professional Title in China. He obtained his Bachelor's degree in Veterinary from Jilin Agricultural University in the PRC in 1984.

Wanlin Zhang has been our Vice General Manager since May 2023. He has served as the Deputy General Manager of the operating entity since April 2021. Prior to joining the operating entity, he was an Executive Deputy General Manager of Zhongchong Xinnuo Biopharmaceutical Taizhou Co., Ltd., from March 2019 to March 2021. Mr. Zhang served as General Manager at Beijing Xindewite Technology Co., Ltd., from March 2018 to December 2018. He holds Senior Veterinarian Professional Title in China. He obtained his Bachelor's degree in Veterinary in Chinese People's Liberation Army Quartermaster University in 1998 and his Master degree of Veterinary from Jilin University in the PRC in 2004.

[Table of Contents](#)

Yuhong Cheng has been our Vice General Manager since May 2023. She has served as the Deputy General Manager of the operating entity since August 2020. She was the Director of Human Resources and Administration of the operating entity from October 2018 to August 2020. Ms. Cheng obtained her Bachelor's degree in Industrial Foreign Trade from Jilin Institute of Chemical Technology in the PRC in 1998, and Master's degree in English Education from Northeast Normal University in the PRC in 2002.

Family Relationships

Mrs. Wenhua Sun, our Director, is the spouse of Mr. Zhenfa Han, our Chief Executive Officer, Director, and Chairman of the Board. Except as disclosed, no other directors or executive officers has a family relationship as defined in Item 401 of Regulation S-K.

Board of Directors

Our board of directors will consist of [•] directors upon closing of this offering, [•] of whom will be "independent" within the meaning of the corporate governance standards of the Nasdaq listing rules and will meet the criteria for independence set forth in Rule 10A-3 of the Exchange Act.

Duties of Directors

Under Cayman Islands law, our directors owe fiduciary duties to our Company, including a duty of loyalty, a duty to act honestly, and a duty to act in what they consider in good faith to be in the best interests of our Company. Our directors must also exercise their powers only for a proper purpose. Our directors also owe to our Company a duty to act with skill and care. It was previously considered that a director need not exhibit in the performance of his duties a greater degree of skill than may reasonably be expected from a person of his knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care and these authorities are likely to be followed in the Cayman Islands. In fulfilling their duty of care to our Company, our directors must ensure compliance with the memorandum and articles of association of our Company, as amended and restated from time to time. Our Company has the right to seek damages if a duty owed by our directors is breached. In limited exceptional circumstances, a shareholder may have the right to seek damages in the name of our Company if a duty owed by our directors is breached. You should refer to "Description of Share Capital — Differences in Corporate Law" for additional information on our standard of corporate governance under Cayman Islands law.

The functions and powers of our board of directors include, among others:

- convening shareholders' annual general meetings and reporting its work to shareholders at such meetings;
- appointing officers and determining the term of office of the officers;
- declaring dividends and distributions;
- exercising the borrowing powers of the company and mortgaging the property of the company;
- maintaining or registering a register of mortgages, charges, or other encumbrances of the company.

Terms of Directors and Executive Officers

Our directors may be appointed by an ordinary resolution of its shareholders. In addition, our board may, by the affirmative vote of a simple majority of our directors present and voting at a board meeting appoint any person as a director either to fill a casual vacancy on its board or as an addition to the existing board. Our directors are not subject to a term of office and will hold office until such time as they resign or otherwise removed from office by ordinary resolution of the shareholders. Our director will be cease to be a director automatically if, among other thing, the director (i) becomes bankrupt or has a receiving order made against him or suspends payment or compounds with his creditors; (ii) is found to be or becomes of unsound mind or dies; (iii) resigns his office by notice in writing to our Company; (iv) without special leave of absence from our board of directors, is absent from three consecutive meetings of our board and our board resolves that his office be vacated; (v) is prohibited by law from being a director; or (vi) is removed from office pursuant to the laws of the Cayman Islands or any other provisions of our post-offering articles of association. All of our executive officers are appointed by and serve at the discretion of our board of directors.

Qualification

There is currently no shareholding qualification for directors, although a shareholding qualification for directors may be fixed by our shareholders by amending our articles of association.

Employment Agreements and Indemnification Agreements

We have entered into employment agreements with each of our executive officers. Pursuant to employment agreements, the form of which is filed as Exhibit 10.1 to this registration statement, we agree to employ each of our executive officers for a specified time period, which may be renewed upon both parties' agreement 30 days before the end of the current employment term. We may terminate the employment for cause, at any time, without notice or remuneration, for certain acts of the executive officer, including but not limited to the commitments of any serious or persistent breach or non-observance of the terms and conditions of the employment, conviction of a criminal offense, willful disobedience of a lawful and reasonable order, fraud or dishonesty, receipt of bribery, or severe neglect of his or her duties. An executive officer may terminate his or her employment at any time with a one-month prior written notice. Each executive officer has agreed to hold, both during and after the employment agreement expires, in strict confidence and not to use or disclose to any person, corporation or other entity without written consent, any confidential information.

We will also enter into indemnification agreements with each of our directors and executive officers. Under these agreements, we agree to indemnify our directors and executive officers against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being a director or officer of our company.

Compensation of Directors and Executive Officers

For the fiscal year ended December 31, 2022, we paid an aggregate of \$626,944 as compensation to our executive officers and directors. Within this amount, we paid \$144,551 to our Chief Executive Officer Songlin Song, \$39,001 to our Chief Financial Officer Ping Wang, \$84,986 to our Vice General Manager Wei Lian, \$98,155 to our Vice General Manager Yawen Dong, \$79,453 to our Vice General Manager Yuyou He, \$71,333 to our Vice General Manager Wanlin Zhang, \$53,065 to our Vice General Manager Yuhong Cheng, and \$56,400 to our Vice General Manager and board secretary Zhongyao Liu.

We have not set aside or accrued any amount to provide pension, retirement, or other similar benefits to our directors and executive officers. The operating entity is required by law to make contributions equal to certain percentages of each employee's salary for his or her pension insurance, medical insurance, unemployment insurance, and other statutory benefits and a housing provident fund.

Insider Participation Concerning Executive Compensation

Chairman of the Board of Directors and director, Mr. Zhenfa Han has been making all determinations regarding executive officer compensation from the inception of our Company. When our Compensation Committee is set up, it will be making all determination regarding executive officer compensation (please see below).

Committees of the Board of Directors

We will establish three committees under the board of directors prior to the closing of this offering: an audit committee, a compensation committee, and a nominating and corporate governance committee. The appointment to the committees will be effective immediately upon the effective date of the registration statement of which this prospectus forms a part. We will adopt a charter for each of the three committees. Each committee's members and functions are described below.

Audit Committee. Our audit committee will consist of [•], [•], and [•]. [•] will be the chairperson of our audit committee. We have determined that [•], [•], and [•] will satisfy the "independence" requirements of the Nasdaq listing rules under and Rule 10A-3 under the Securities Exchange Act. Our board also has determined that [•] qualifies as an audit committee financial expert within the meaning of the SEC rules or possesses financial sophistication within the meaning of the Nasdaq listing rules. The audit committee will oversee our accounting and financial reporting processes and the audits of the financial statements of our Company. The audit committee will be responsible for, among other things:

- appointing the independent auditors and pre-approving all auditing and non-auditing services permitted to be performed by the independent auditors;
- reviewing with the independent auditors any audit problems or difficulties and management's response;

[Table of Contents](#)

- discussing the annual audited financial statements with management and the independent auditors;
- reviewing the adequacy and effectiveness of our accounting and internal control policies and procedures and any steps taken to monitor and control major financial risk exposures;
- reviewing and approving all proposed related party transactions;
- meeting separately and periodically with management and the independent auditors; and
- monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance.

Compensation Committee. Our compensation committee will consist of [•], [•], and [•]. [•] will be the chairperson of our compensation committee. We have determined that [•], [•], and [•] will satisfy the “independence” requirements of the Nasdaq listing rules and Rule 10C-1 under the Securities Exchange Act. The compensation committee will assist the board in reviewing and approving the compensation structure, including all forms of compensation, relating to our directors and executive officers. Our chief executive officer may not be present at any committee meeting during which his compensation is deliberated. The compensation committee will be responsible for, among other things:

- reviewing and approving the total compensation package for our most senior executive officers;
- approving and overseeing the total compensation package for our executives other than the most senior executive officers;
- reviewing and recommending to the board with respect to the compensation of our directors;
- reviewing periodically and approving any long-term incentive compensation or equity plans;
- selecting compensation consultants, legal counsel or other advisors after taking into consideration all factors relevant to that person’s independence from management; and
- reviewing programs or similar arrangements, annual bonuses, employee pension and welfare benefit plans.

Nominating and Corporate Governance Committee. Our nominating and corporate governance committee will consist of [•], [•], and [•]. [•] will be the chairperson of our nominating and corporate governance committee. We have determined that [•], [•], and [•] will satisfy the “independence” requirements of the Nasdaq listing rules. The nominating and corporate governance committee will assist the board of directors in selecting individuals qualified to become our directors and in determining the composition of the board and its committees. The nominating and corporate governance committee will be responsible for, among other things:

- identifying and recommending nominees for election or re-election to our board of directors or for appointment to fill any vacancy;
- reviewing annually with our board of directors its current composition in light of the characteristics of independence, age, skills, experience and availability of service to us;
- identifying and recommending to our board the directors to serve as members of committees;
- advising the board periodically with respect to significant developments in the law and practice of corporate governance as well as our compliance with applicable laws and regulations, and making recommendations to our board of directors on all matters of corporate governance and on any corrective action to be taken; and
- monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance.

Code of Business Conduct and Ethics

Our board of directors will adopt a code of business conduct and ethics, which is to be filed as Exhibit 99.1 of this registration statement and applicable to all of our directors, officers and employees. We will make our code of business conduct and ethics publicly available on our website prior to the initial closing of this offering.

PRINCIPAL SHAREHOLDERS

The following table sets forth information with respect to the beneficial ownership, within the meaning of Rule 13d-3 under the Exchange Act, of our Ordinary Shares as of the date of this prospectus, and as adjusted to reflect the sale of the Ordinary Shares offered in this offering for:

- each of our directors and executive officers who beneficially own our Ordinary Shares;
- our directors and executive officers as a group; and
- each person known to us to own beneficially more than 5% of our Ordinary Shares.

Beneficial ownership includes voting or investment power with respect to the securities. Except as indicated below, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all Ordinary Shares shown as beneficially owned by them. Percentage of beneficial ownership of each listed person prior to this offering is based on [•] Ordinary Shares outstanding as of the date of this prospectus immediately prior to the effectiveness of the registration statement of which this prospectus is a part. Percentage of beneficial ownership of each listed person after this offering includes Ordinary Shares outstanding immediately after the completion of this offering.

Information with respect to beneficial ownership has been furnished by each director, officer, or beneficial owner of 5% or more of our Ordinary Shares. Beneficial ownership is determined in accordance with the rules of the SEC and generally requires that such person have voting or investment power with respect to securities. In computing the number of Ordinary Shares beneficially owned by a person listed below and the percentage ownership of such person, Ordinary Shares underlying options, warrants, or convertible securities held by each such person that are exercisable or convertible within 60 days of the date of this prospectus are deemed outstanding, but are not deemed outstanding for computing the percentage ownership of any other person. Except as otherwise indicated in the footnotes to this table, or as required by applicable community property laws, all persons listed have sole voting and investment power for all Ordinary Shares shown as beneficially owned by them. As of the date of this prospectus, we have five shareholders of record, none of whom are located in the United States. We will be required to have at least 300 unrestricted round lot shareholders at closing in order to satisfy the Nasdaq listing rules.

	Ordinary Shares Beneficially Owned Prior to this Offering		Ordinary Shares Beneficially Owned After this Offering	
	Number	Percent	Number	Percent
Directors and Executive Officers⁽¹⁾:				
Zhenfa Han ⁽²⁾⁽⁵⁾	11,140,518	97.5818%		%
Wenhua Sun	—	—%		%
Ping Wang	—	—%		%
Songlin Song	—	—%		%
Zhongyao Liu	—	—%		%
Wei Lian ⁽³⁾⁽ⁱ⁾	20,765	0.1819%		%
Yawen Dong ⁽³⁾⁽ⁱⁱ⁾	31,148	0.2728%		%
Yuyou He ⁽³⁾⁽ⁱⁱⁱ⁾	12,516	0.1096%		%
Wanlin Zhang	—	—%		%
Yuhong Cheng	—	—%		%
[]				
[]				
[]				
All directors and executive officers as a group (13 individuals):				
	11,140,518	97.5818%		%
5% Shareholders:				
				%
Zhenfa Han ⁽⁵⁾	11,140,518	97.5818%		%
Securingium Holding Limited ⁽²⁾⁽⁵⁾	10,000,000	87.5918%		%
VVAX Holdings Limited ⁽⁴⁾⁽⁵⁾	570,830	5%		%

Notes:

- (1) Unless otherwise indicated, the business address of each of the individuals is No.1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin City, Jilin Province, China.

[Table of Contents](#)

- (2) Represents 10,000,000 Ordinary Shares held by Securingium Holding Limited, a BVI company, which is (i) 0.01% owned by Jiahe Developments Limited, which itself is 100% owned by Zhenfa Han, and (ii) 99.99% owned by TSset Holding Limited, which itself is 100% owned by Trident Trust Company (HK) Limited, which acts as the trustee of Generations United Trust. The settlor, beneficiary, and protector of Generations United Trust is Zhenfa Han. The registered address of Securingium Holding Limited is Sea Meadow House, P.O. Box 116, Road Town, Tortola, British Virgin Islands.
- (3) Represents 569,688 Ordinary Shares held by Vanguard Skyline Holdings Limited, a BVI company, which is 100% owned by Changchun Feier Investment Center (Limited Partnership).
 - (i) Wei Lian owns 3.645% interest in Changchun Feier Investment Center (Limited Partnership), which in turn holds 0.1819% interest in the Company;
 - (ii) Yawen Dong owns 5.4675% interest in Changchun Feier Investment Center (Limited Partnership), which in turn holds 0.2728% interest in the Company; and
 - (iii) Yuyou He owns 2.197% interest in Changchun Feier Investment Center (Limited Partnership), which in turn holds 0.1096% interest in the Company.
- (4) Represents 570,830 Ordinary Shares held by VVAX Holdings Limited, a BVI company, which is 100% owned by Jilin Zhengye Group Co., Ltd., which is 99% owned by Zhenfa Han and 1% owned by Lihua Sun. The registered address of VVAX Holdings Limited is Sea Meadow House, P.O. Box 116, Road Town, Tortola, British Virgin Islands.
- (5) Zhenfa Han, our Director and Chairman of the Board, beneficially owns (i) 10,000,000 Ordinary Shares through Securingium Holding Limited, (ii) 570,830 Ordinary Shares through VVAX Holdings Limited, and (iii) 569,688 Ordinary Shares through Vanguard Skyline Holdings Limited.

As of the date of this prospectus, none of our outstanding Ordinary Shares are held by record holders in the United States.

We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our Company.

RELATED PARTY TRANSACTIONS

Material Transactions with Related Parties

For the years ended December 31, 2021 and 2022, the operating entity purchased inventory from Jilin Huazheng Agriculture and Animal Husbandry Development Co., Ltd. (“Jilin Huazheng”), which is controlled by Mr. Zhenfa Han, the principal shareholder, director, and chairman of the board of the Company, in the amount of RMB65,423 (US\$9,485) and RMB90,556 (US\$13,129), respectively.

For the years ended December 31, 2021 and 2022, the operating entity had no revenue generated from Jilin Huazheng. As of December 31, 2021 and 2022, the Company had account receivable from this related party in the amount of RMB232,650 (US\$33,731) and RMB nil (US\$ nil), respectively.

For the six months ended June 30, 2022 and 2023, the operating entity purchased inventory from Jilin Huazheng, in the amount of RMB87,000 and RMB127,000 (US\$18,000), respectively.

For the six months ended June 30, 2022 and 2023, the operating entity had no revenue generated from Jilin Huazheng. As of December 31, 2022 and June 30, 2023, the Company had account receivable from this related party in the amount of RMB nil and RMB nil (“US\$ nil”), respectively.

Employment Agreements and Indemnification Agreements

See “Management — Employment Agreements and Indemnification Agreements.”

DESCRIPTION OF SHARE CAPITAL

We are a Cayman Islands exempted company with limited liability and our affairs are governed by our memorandum and articles of association, as amended and restated from time to time, the Companies Act (As Revised) of the Cayman Islands, which we refer to as the Companies Act below, and the common laws of Cayman Islands.

As of the date of this prospectus, our authorized share capital is \$50,000 divided into 500,000,000 Ordinary Shares, par value \$0.0001 per share. As of the date of this prospectus, there are 11,416,594 Ordinary Shares issued and outstanding. All of our issued and outstanding Ordinary Shares prior to the completion of the offering are fully paid, and all of our Ordinary Shares to be issued in the offering will be issued as fully paid.

Our Post-Offering Articles of Association

We will adopt amended and restated articles of association, which will become effective and replace our current articles of association in its entirety immediately prior to the completion of this offering. The following are summaries of certain material provisions of the post-offering articles of association and of the Companies Act, insofar as they relate to the material terms of our Ordinary Shares.

Objects of Our Company. Under our memorandum of association, the objects of our Company are unrestricted, and we have the full power and authority to carry out any object not prohibited by the Companies Act or any other law of the Cayman Islands and are capable of exercising all the powers exercisable by a natural person or body corporate in any part of the world.

Ordinary Shares. Our Ordinary Shares are issued in registered form and are issued when registered in our register of members. We may not issue shares to bearer. Our shareholders who are non-residents of the Cayman Islands may freely hold and vote their shares.

Dividends. The holders of our Ordinary Shares are entitled to such dividends as may be declared by our board of directors. Our post-offering articles of association provide that dividends may be declared and paid out of the funds of our company lawfully available therefor. Under the laws of the Cayman Islands, our Company may pay a dividend out of profit and/or share premium account; provided that in no circumstances may a dividend be paid out of our share premium if this would result in our company being unable to pay its debts as they fall due in the ordinary course of business.

Voting Rights. Voting at any meeting of shareholders is by show of hands unless a poll is demanded. A poll may be demanded by:

- the chairperson of such meeting;
- by at least three shareholders present in person or by proxy for the time being entitled to vote at the meeting;
- by shareholder(s) present in person or by proxy representing not less than one-tenth of the total voting rights of all shareholders having the right to vote at the meeting; and
- by shareholder(s) present in person or by proxy and holding shares in us conferring a right to vote at the meeting being shares on which an aggregate sum has been paid up equal to not less than one-tenth of the total sum paid up on all shares conferring that right.

An ordinary resolution to be passed at a meeting by the shareholders requires the affirmative vote of a simple majority of the votes attaching to the Ordinary Shares cast at a meeting, while a special resolution requires the affirmative vote of no less than two-thirds of the votes cast attaching to the issued and outstanding Ordinary Shares at a meeting. A special resolution will be required for important matters such as a change of name, making changes to our post-offering articles of association, a reduction of our share capital and the winding up of our Company. Our shareholders may, among other things, divide or combine their shares by ordinary resolution.

General Meetings of Shareholders. As a Cayman Islands exempted company, we are not obliged by the Companies Act to call shareholders' annual general meetings. Our post-offering articles of association provide that we shall, if required by the Companies Act, in each year hold a general meeting as our annual general meeting, and shall specify

[Table of Contents](#)

the meeting as such in the notices calling it, and the annual general meeting shall be held at such time and place as may be determined by our directors. General meetings, including annual general meetings, may be held at such times and in any location in the world as may be determined by the Board. A general meeting or any class meeting may also be held by means of such telephone, electronic or other communication facilities as to permit all persons participating in the meeting to communicate with each other, and participation in such a meeting constitutes presence at such meeting.

Shareholders' general meetings may be convened by the chairperson of our board of directors or by a majority of our board of directors. Advance notice of at least ten clear days is required for the convening of our annual general shareholders' meeting (if any) and any other general meeting of our shareholders. A quorum required for any general meeting of shareholders consists of, at the time when the meeting proceeds to business, two shareholders holding shares which carry in aggregate (or representing by proxy) not less than one-third of all votes attaching to issued and outstanding shares in our company entitled to vote at such general meeting.

The Companies Act does not provide shareholders with any right to requisition a general meeting or to put any proposal before a general meeting. However, these rights may be provided in a company's articles of association. Our post-offering articles of association provide that upon the requisition of any one or more of our shareholders holding shares which carry in aggregate not less than one-third of all votes attaching to the issued and outstanding shares of our Company entitled to vote at general meetings, our board will convene an extraordinary general meeting and put the resolutions so requisitioned to a vote at such meeting. However, our post-offering articles of association do not provide our shareholders with any right to put any proposals before annual general meetings or extraordinary general meetings not called by such shareholders.

Transfer of Ordinary Shares. Subject to the restrictions set out below, any of our shareholders may transfer all or any of his or her Ordinary Shares by an instrument of transfer in the usual or common form or in a form prescribed by Nasdaq or any other form approved by our board of directors. Notwithstanding the foregoing, Ordinary Shares may also be transferred in accordance with the applicable rules and regulations of Nasdaq.

Our board of directors may, in its absolute discretion, decline to register any transfer of any Ordinary Share which is not fully paid up or on which we have a lien. Our board of directors may also decline to register any transfer of any Ordinary Share unless:

- the instrument of transfer is lodged with us, accompanied by the certificate for the Ordinary Shares to which it relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer;
- the instrument of transfer is in respect of only one class of Ordinary Shares;
- the instrument of transfer is properly stamped, if required;
- in the case of a transfer to joint holders, the number of joint holders to whom the Ordinary Share is to be transferred does not exceed four; and
- a fee of such maximum sum as the Nasdaq may determine to be payable or such lesser sum as our directors may from time to time require is paid to us in respect thereof.

If our directors refuse to register a transfer they shall, within two months after the date on which the instrument of transfer was lodged, send to each of the transferor and the transferee notice of such refusal.

The registration of transfers may, after compliance with any notice required in accordance with the rules of the Nasdaq, be suspended and the register closed at such times and for such periods as our board of directors may from time to time determine; provided, however, that the registration of transfers shall not be suspended nor the register closed for more than 30 days in any year as our board may determine. The period of 30 days may be extended for a further period or periods not exceeding 30 days in respect of any year if approved by our shareholders by ordinary resolution.

Liquidation. On the winding up of our company, if the assets available for distribution amongst our shareholders shall be more than sufficient to repay the whole of the share capital at the commencement of the winding up, the surplus shall be distributed amongst our shareholders in proportion to the par value of the shares held by them at the commencement of the winding up, subject to a deduction from those shares in respect of which there are monies due, of all monies payable to our company for unpaid calls or otherwise. If our assets available for distribution are insufficient to repay all of the paid-up capital, such assets will be distributed so that, as nearly as may be, the losses are borne by our shareholders in proportion to the par value of the shares held by them.

Calls on Shares and Forfeiture of Shares. Our board of directors may from time to time make calls upon shareholders for any amounts unpaid on their shares in a notice served to such shareholders at least 14 days prior to the specified time and place of payment. The shares that have been called upon and remain unpaid are subject to forfeiture.

Redemption, Repurchase and Surrender of Shares. We may issue shares on terms that such shares are subject to redemption, at our option or at the option of the holders of these shares, on such terms and in such manner as may be determined by our board of directors. Our company may also repurchase any of our shares on such terms and in such manner as have been approved by our board of directors. Under the Companies Act, the redemption or repurchase of any share may be paid out of our company's profits, share premium or out of the proceeds of a new issue of shares made for the purpose of such redemption or repurchase, or out of capital if our company can, immediately following such payment, pay its debts as they fall due in the ordinary course of business. In addition, under the Companies Act no such share may be redeemed or repurchased (a) unless it is fully paid up, (b) if such redemption or repurchase would result in there being no shares outstanding or (c) if the company has commenced liquidation. In addition, our company may accept the surrender of any fully paid share for no consideration.

Variations of Rights of Shares. Whenever the capital of our company is divided into different classes the rights attached to any such class may, subject to any rights or restrictions for the time being attached to any class, only be varied with the sanction of a resolution passed by a majority of two-thirds of the votes cast at a separate meeting of the holders of the shares of that class. The rights conferred upon the holders of the shares of any class issued with preferred or other rights shall not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation, allotment or issue of further shares ranking *pari passu* with such existing class of shares.

Issuance of Additional Shares. Our post-offering articles of association authorize our board of directors to issue additional Ordinary Shares from time to time as our board of directors shall determine, to the extent of available authorized but unissued shares.

Our post-offering articles of association also authorize our board of directors to establish from time to time one or more series of preference shares and to determine, with respect to any series of preference shares, the terms and rights of that series, including, among other things:

- the designation of the series;
- the number of shares of the series;
- the dividend rights, dividend rates, conversion rights and voting rights; and
- the rights and terms of redemption and liquidation preferences.

Our board of directors may issue preference shares without action by our shareholders to the extent of available authorized but unissued shares. Issuance of these shares may dilute the voting power of holders of Ordinary Shares.

[Table of Contents](#)

Inspection of Books and Records. Holders of our Ordinary Shares will have no general right under Cayman Islands law to inspect or obtain copies of our list of shareholders or our corporate records. However, our post-offering articles of association have provisions that provide our shareholders the right to inspect our register of shareholders without charge, and to receive our annual audited financial statements. See “Where You Can Find Additional Information.”

Anti-Takeover Provisions. Some provisions of our post-offering articles of association may discourage, delay or prevent a change of control of our company or management that shareholders may consider favorable, including provisions that:

- authorize our board of directors to issue preference shares in one or more series and to designate the price, rights, preferences, privileges and restrictions of such preference shares without any further vote or action by our shareholders; and
- limit the ability of shareholders to requisition and convene general meetings of shareholders.

However, under Cayman Islands law, our directors may only exercise the rights and powers granted to them under our post-offering articles of association for a proper purpose and for what they believe in good faith to be in the best interests of our company.

Exempted Company. We are an exempted company with limited liability under the Companies Act. The Companies Act distinguishes between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an exempted company are essentially the same as for an ordinary company except that an exempted company:

- does not have to file an annual return of its shareholders with the Registrar of Companies;
- is not required to open its register of members for inspection;
- does not have to hold an annual general meeting;
- may issue shares with no par value;
- may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 20 years in the first instance);
- may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;
- may register as an exempted limited duration company; and
- may register as a segregated portfolio company.

“Limited liability” means that the liability of each shareholder is limited to the amount unpaid by the shareholder on that shareholder’s shares of the company (except in exceptional circumstances, such as involving fraud, the establishment of an agency relationship or an illegal or improper purpose or other circumstances in which a court may be prepared to pierce or lift the corporate veil).

Differences in Corporate Law

The Companies Act is derived, to a large extent, from the older Companies Acts of England and Wales but does not follow recent United Kingdom statutory enactments, and accordingly there are significant differences between the Companies Act and the current Companies Act of the UK. In addition, the Companies Act differs from laws applicable to United States corporations and their shareholders. Set forth below is a summary of certain significant differences between the provisions of the Companies Act applicable to us and the comparable laws applicable to companies incorporated in the State of Delaware in the United States.

	Delaware	Cayman Islands
<i>Title of Organizational Documents</i>	Certificate of Incorporation and Bylaws	Certificate of Incorporation and Memorandum and Articles of Association
<i>Duties of Directors</i>	Under Delaware law, the business and affairs of a corporation are managed by or under the direction of its board of directors. In exercising their powers, directors are charged with a fiduciary duty of care to protect the interests of the corporation and a fiduciary duty of loyalty to act in the best interests of its shareholders. The duty of care requires that directors act in an informed and deliberative manner and inform themselves, prior to making a business decision, of all material information reasonably available to them. The duty of care also requires that directors exercise care in overseeing and investigating the conduct of the corporation's employees. The duty of loyalty may be summarized as the duty to act in good faith, not out of self-interest, and in a manner which the director reasonably believes to be in the best interests of the shareholders.	As a matter of Cayman Islands law, a director of a Cayman Islands company is in the position of a fiduciary with respect to the company and therefore it is considered that he owes the following duties to the company — a duty to act in good faith in the best interests of the company, a duty not to make a personal profit based on his position as director (unless the company permits him to do so), a duty not to put himself in a position where the interests of the company conflict with his personal interest or his duty to a third party and a duty to exercise powers for the purpose for which such powers were intended. A director of a Cayman Islands company owes to the company a duty to act with skill and care. It was previously considered that a director need not exhibit in the performance of his duties a greater degree of skill than may reasonably be expected from a person of his knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care and these authorities are likely to be followed in the Cayman Islands.

	Delaware	Cayman Islands
<i>Limitations on Personal Liability of Directors</i>	<p>Subject to the limitations described below, a certificate of incorporation may provide for the elimination or limitation of the personal liability of a director to the corporation or its shareholders for monetary damages for a breach of fiduciary duty as a director. Such provision cannot limit liability for breach of loyalty, bad faith, intentional misconduct, unlawful payment of dividends or unlawful share purchase or redemption. In addition, the certificate of incorporation cannot limit liability for any act or omission occurring prior to the date when such provision becomes effective.</p>	<p>Under Cayman Islands law, directors owe various duties to the company they serve, including the duty to act in good faith in the best interests of the company, the duty to exercise reasonable care, skill, and diligence, and the duty to avoid conflicts of interest. If a director breaches any of these duties, they may be held personally liable for any losses suffered by the company as a result of their breach.</p> <p>However, Cayman Islands law also provides certain limitations on the personal liability of directors. For example, directors may be protected by the company's articles of association, which may contain provisions limiting or excluding their liability to the company or its shareholders. In addition, directors may be protected by indemnity provisions in the company's articles or by separate indemnity agreements, which may require the company to indemnify the director for any losses or liabilities they incur in the course of their duties.</p>
<i>Indemnification of Directors, Officers, Agents, and Others</i>	<p>A corporation has the power to indemnify any director, officer, employee, or agent of corporation who was, is, or is threatened to be made a party who acted in good faith and in a manner he believed to be in the best interests of the corporation, and if with respect to a criminal proceeding, had no reasonable cause to believe his conduct would be unlawful, against amounts actually and reasonably incurred.</p>	<p>Cayman Islands law does not limit the extent to which a company's memorandum and articles of association may provide for indemnification of directors and officers, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against the consequences of committing a crime, or against the indemnified person's own fraud or dishonesty.</p> <p>Our post-offering articles of association provide to the extent permitted by law, we shall indemnify our directors and officers, and their personal representatives, against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such persons, other than by reason of such person's dishonesty, willful default or fraud, in or about the conduct of our company's business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such director or officer in defending (whether successfully or otherwise) any civil proceedings concerning our company or its affairs in any court whether in the Cayman Islands or elsewhere.</p>

	Delaware	Cayman Islands
<i>Interested Directors</i>	<p>Under Delaware law, a transaction in which a director who has an interest in such transaction would not be voidable if (i) the material facts as to such interested director’s relationship or interests are disclosed or are known to the board of directors and the board in good faith authorizes the transaction by the affirmative vote of a majority of the disinterested directors, even though the disinterested directors are less than a quorum, (ii) such material facts are disclosed or are known to the shareholders entitled to vote on such transaction and the transaction is specifically approved in good faith by vote of the shareholders, or (iii) the transaction is fair as to the corporation as of the time it is authorized, approved or ratified. Under Delaware law, a director could be held liable for any transaction in which such director derived an improper personal benefit.</p>	<p>Interested director transactions are governed by the terms of a company’s memorandum and articles of association.</p>
<i>Voting Requirements</i>	<p>The certificate of incorporation may include a provision requiring supermajority approval by the directors or shareholders for any corporate action.</p> <p>In addition, under Delaware law, certain business combinations involving interested shareholders require approval by a supermajority of the non-interested shareholders.</p>	<p>For the protection of shareholders, certain matters must be approved by special resolution of the shareholders as a matter of Cayman Islands law, including alteration of the memorandum or articles of association, appointment of inspectors to examine company affairs, reduction of share capital (subject, in relevant circumstances, to court approval), change of name, authorization of a plan of merger or transfer by way of continuation to another jurisdiction or consolidation or voluntary winding up of the company.</p> <p>The Companies Act requires that a special resolution be passed by a majority of at least two-thirds or such higher percentage as set forth in the memorandum and articles of association, of shareholders being entitled to vote and do vote in person or by proxy at a general meeting, or by unanimous written consent of shareholders entitled to vote at a general meeting.</p>
<i>Voting for Directors</i>	<p>Under Delaware law, unless otherwise specified in the certificate of incorporation or bylaws of the corporation, directors shall be elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors.</p>	<p>The Companies Act defines a “special resolution” only. A company’s memorandum and articles of association can therefore tailor the definition of an “ordinary resolution” as a whole, or with respect to specific provisions.</p>

	Delaware	Cayman Islands
<i>Cumulative Voting</i>	No cumulative voting for the election of directors unless so provided in the certificate of incorporation.	There are no prohibitions in relation to cumulative voting under the Companies Act but our post-offering amended and restated articles of association do not provide for cumulative voting
<i>Directors' Powers Regarding Bylaws</i>	The certificate of incorporation may grant the directors the power to adopt, amend or repeal bylaws.	The memorandum and articles of association may only be amended by a special resolution of the shareholders.
<i>Nomination and Removal of Directors and Filling Vacancies on Board</i>	Shareholders may generally nominate directors if they comply with advance notice provisions and other procedural requirements in company bylaws. Holders of a majority of the shares may remove a director with or without cause, except in certain cases involving a classified board or if the company uses cumulative voting. Unless otherwise provided for in the certificate of incorporation, directorship vacancies are filled by a majority of the directors elected or then in office.	Nomination and removal of directors and filling of board vacancies are governed by the terms of the memorandum and articles of association.

Anti-money Laundering — Cayman Islands

In order to comply with legislation or regulations aimed at the prevention of money laundering, we are required to adopt and maintain anti-money laundering procedures and may require subscribers to provide evidence to verify their identity and source of funds. Where permitted, and subject to certain conditions, we may also delegate the maintenance of our anti-money laundering procedures (including the acquisition of due diligence information) to a suitable person.

We reserve the right to request such information as is necessary to verify the identity of a subscriber.

In the event of delay or failure on the part of the subscriber in producing any information required for verification purposes, we may refuse to accept the application, in which case any funds received will be returned without interest to the account from which they were originally debited.

If any person resident in the Cayman Islands knows or suspects or has reason for knowing or suspecting that another person is engaged in criminal conduct or is involved with terrorism or terrorist property and the information for that knowledge or suspicion came to their attention in the course of their business in the regulated sector, or other trade, profession, business or employment, the person will be required to report such knowledge or suspicion to (i) a nominated officer (appointed in accordance with the Proceeds of Crime Act (Revised) of the Cayman Islands) or the Financial Reporting Authority of the Cayman Islands, pursuant to the Proceeds of Crime Act (Revised), if the disclosure relates to criminal conduct or money laundering or (ii) to a police constable or a nominated officer (pursuant to the Terrorism Act (Revised) of the Cayman Islands) or the Financial Reporting Authority, pursuant to the Terrorism Act (Revised), if the disclosure relates to involvement with terrorism or terrorist financing and terrorist property. Such a report shall not be treated as a breach of confidence or of any restriction upon the disclosure of information imposed by any enactment or otherwise.

Data Protection in the Cayman Islands — Privacy Notice

We have certain duties under the Data Protection Act (as revised) of the Cayman Islands (the “DPA”), based on internationally accepted principles of data privacy.

Privacy Notice

This privacy notice puts shareholders of our Company on notice that through your investment into us you will provide us with certain personal information which constitutes personal data within the meaning of the DPA, or personal data.

Investor Data

We will collect, use, disclose, retain and secure personal data to the extent reasonably required only and within the parameters that could be reasonably expected during the normal course of business. We will only process, disclose, transfer or retain personal data to the extent legitimately required to conduct our activities on an ongoing basis or to comply with legal and regulatory obligations to which we are subject. We will only transfer personal data in accordance with the requirements of the DPA, and will apply appropriate technical and organizational information security measures designed to protect against unauthorized or unlawful processing of the personal data and against the accidental loss, destruction or damage to the personal data.

In our use of this personal data, we will be characterized as a “data controller” for the purposes of the DPA, while our affiliates and service providers who may receive this personal data from us in the conduct of our activities may either act as our “data processors” for the purposes of the DPA or may process personal information for their own lawful purposes in connection with services provided to us.

We may also obtain personal data from other public sources. Personal data includes, without limitation, the following information relating to a shareholder and/or any individuals connected with a shareholder as an investor: name, residential address, email address, contact details, corporate contact information, signature, nationality, place of birth, date of birth, tax identification, credit history, correspondence records, passport number, bank account details, source of funds details and details relating to the shareholder’s investment activity.

Who this Affects

If you are a natural person, this will affect you directly. If you are a corporate investor (including, for these purposes, legal arrangements such as trusts or exempted limited partnerships) that provides us with personal data on individuals connected to you for any reason in relation to your investment in us, this will be relevant for those individuals and you should transmit the content of this Privacy Notice to such individuals or otherwise advise them of its content.

How We May Use a Shareholder’s Personal Data

We may, as the data controller, collect, store and use personal data for lawful purposes, including, in particular: (i) where this is necessary for the performance of our rights and obligations under any agreements; (ii) where this is necessary for compliance with a legal and regulatory obligation to which we are or may be subject (such as compliance with anti-money laundering and FATCA/CRS requirements); and/or (iii) where this is necessary for the purposes of our legitimate interests and such interests are not overridden by your interests, fundamental rights or freedoms.

Should we wish to use personal data for other specific purposes (including, if applicable, any purpose that requires your consent), we will contact you.

Why We May Transfer Your Personal Data

In certain circumstances we may be legally obliged to share personal data and other information with respect to your shareholding with the relevant regulatory authorities such as the Cayman Islands Monetary Authority or the Tax Information Authority. They, in turn, may exchange this information with foreign authorities, including tax authorities.

We anticipate disclosing personal data to persons who provide services to us and their respective affiliates (which may include certain entities located outside the US, the Cayman Islands or the European Economic Area), who will process your personal data on our behalf.

The Data Protection Measures We Take

Any transfer of personal data by us or our duly authorized affiliates and/or delegates outside of the Cayman Islands shall be in accordance with the requirements of the DPA.

We and our duly authorized affiliates and/or delegates shall apply appropriate technical and organizational information security measures designed to protect against unauthorized or unlawful processing of personal data, and against accidental loss or destruction of, or damage to, personal data.

[Table of Contents](#)

We shall notify you of any personal data breach that is reasonably likely to result in a risk to your interests, fundamental rights or freedoms or those data subjects to whom the relevant personal data relates.

You have certain rights under the DPA, including (a) the right to be informed as to how we collect and use your personal data (and this privacy notice fulfils our obligation in this respect), (b) the right to obtain a copy of your personal data, (c) the right to require us to stop direct marketing, (d) the right to have inaccurate or incomplete personal data corrected, (e) the right to withdraw your consent and require us to stop processing or restrict the processing, or not begin the processing of your personal data, (f) the right to be notified of a data breach (unless the breach is unlikely to be prejudicial), (g) the right to obtain information as to any countries or territories outside the Cayman Islands to which we, whether directly or indirectly, transfer, intend to transfer, or wish to transfer your personal data, general measures we take to ensure the security of personal data, and any information available to us as to the source of your personal data, (h) the right to complain to the Office of the Ombudsman of the Cayman Islands, and (i) the right to require us to delete your personal data in some limited circumstances.

If you consider that your personal data has not been handled correctly, or you are not satisfied with our responses to any requests you have made regarding the use of your personal data, you have the right to complain to the Cayman Islands' Ombudsman. The Ombudsman can be contacted by calling +1 (345) 946-6283 or by email at info@ombudsman.ky.

Legislation of the Cayman Islands

The Cayman Islands, together with several other non-European Union jurisdictions, have introduced legislation aimed at addressing concerns raised by the Council of the European Union as to offshore structures engaged in certain activities which attract profits without real economic activity. The International Tax Co-operation (Economic Substance) Act (Revised) (the "Substance Act") came into force in the Cayman Islands in January 2019 introducing certain economic substance requirements for in-scope Cayman Islands entities which are engaged in certain "relevant activities." As our Company is a Cayman Islands company, compliance obligations include filing annual notifications, which need to state whether our Company is carrying out any relevant activities and if so, whether our Company has satisfied economic substance tests to the extent required under the Substance Act. Failure to satisfy these requirements may subject us to penalties under the Substance Act. Our Company being a holding company with no material operations will likely be subject to more limited substance requirements.

History of Share Issuances

The following is a summary of our share capital since incorporation.

Share Transfer and Allotment in March 2023

Zhengye Cayman was incorporated on March 24, 2023, and one Ordinary Share was issued to ICS Corporate Services (Cayman) Limited as the subscriber and incorporation founder, which was transferred to VVAX Holdings Limited on the same day.

On March 24, 2023, we issued 9,999,999 Ordinary Shares to our founding shareholders as below:

Allottee	Number of Ordinary Shares	Consideration
VVAX Holdings Limited	6,553,004	\$ 655,3004
Windsor Holdings Co., Ltd.	3,074,347	\$ 307,4347
Vanguards Skyline Holdings Limited	372,648	\$ 37,2648
Total	9,999,999	\$ 999,9999

Share Repurchase and Allotment in May 2023

On May 18, 2023, we repurchased 10,000,000 Ordinary Shares from our founding shareholders as below:

Transferor	Transferee	Number of Ordinary Shares	Consideration
VVAX Holdings Limited	Zhengye Cayman	6,553,005	\$ 655.3005
Windsor Holdings Co., Ltd.		3,074,347	\$ 307.4347
Vanguards Skyline Holdings Limited		372,648	\$ 37.2648
Total		10,000,000	\$ 1,000

On the same day, we issued 10,000,000 Ordinary Shares to Securingium Holding Limited, for a consideration of \$1,000.

Allotment in June 2023

On June 21, 2023, we issued 1,416,594 Ordinary Shares to TLjinmao Limited, XZjinyuan Limited, Vanguards Skyline Holdings Limited, and VVAX Holdings Limited as below:

Allottee	Number of Ordinary Shares	Consideration
TLjinmao Limited	259,465	\$ 25.9465
XZjinyuan Limited	16,611	\$ 1.6611
Vanguards Skyline Holdings Limited	569,688	\$ 56.9688
VVAX Holdings Limited	570,830	\$ 57.083
Total	1,416,594	\$ 141.6594

SHARES ELIGIBLE FOR FUTURE SALE

Before our initial public offering, there has not been a public market for our Ordinary Shares, and although we have applied to list our Ordinary Shares on the Nasdaq Global Market, a regular trading market for our Ordinary Shares may not develop. Future sales of substantial amounts of shares of our Ordinary Shares in the public market after our initial public offering, or the possibility of these sales occurring, could cause the prevailing market price for our Ordinary Shares to fall or impair our ability to raise equity capital in the future. Upon completion of this offering, we will have outstanding Ordinary Shares held by public shareholders representing approximately [•]% of our Ordinary Shares in issue. All of the Ordinary Shares sold in this offering will be freely transferable by persons other than our “affiliates” without restriction or further registration under the Securities Act.

Lock-Up Agreements

See “Underwriting — Lock-Up Agreements” for more information.

Rule 144

All of our Ordinary Shares outstanding prior to the closing of this offering are “restricted securities” as that term is defined in Rule 144 under the Securities Act and may be sold publicly in the United States only if they are subject to an effective registration statement under the Securities Act or pursuant to an exemption from the registration requirement such as those provided by Rule 144 and Rule 701 promulgated under the Securities Act.

In general, under Rule 144 as currently in effect, beginning 90 days after the date of this prospectus, a person who is not deemed to have been our affiliate at any time during the three months preceding a sale and who has beneficially owned restricted securities within the meaning of Rule 144 for more than six months would be entitled to sell an unlimited number of those shares, subject only to the availability of current public information about us. A non-affiliate who has beneficially owned restricted securities for at least one year from the later of the date these shares were acquired from us or from our affiliate would be entitled to freely sell those shares.

A person who is deemed to be an affiliate of ours and who has beneficially owned “restricted securities” for at least six months would be entitled to sell, within any three-month period, a number of shares that is not more than the greater of:

- 1% of the number of Ordinary Shares then outstanding, in the form of Ordinary Shares or otherwise, which will equal approximately [•] shares immediately after this offering; or
- the average weekly trading volume of the Ordinary Shares on the Nasdaq Global Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale.

Sales under Rule 144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us.

Rule 701

In general, under Rule 701 of the Securities Act as currently in effect, each of our employees, consultants, or advisors who purchases our Ordinary Shares from us in connection with a compensatory stock plan or other written agreement executed prior to the completion of this offering is eligible to resell those Ordinary Shares in reliance on Rule 144, but without compliance with some of the restrictions, including the holding period, contained in Rule 144. However, the Rule 701 shares would remain subject to lock-up arrangements and would only become eligible for sale when the lock-up period expires.

Regulation S

Regulation S provides generally that sales made in offshore transactions are not subject to the registration or prospectus-delivery requirements of the Securities Act.

MATERIAL INCOME TAX CONSIDERATION

PRC Taxation

Enterprise Taxation and Withholding Tax

The following brief description of Chinese enterprise income taxation is designed to highlight the enterprise-level taxation on our earnings, which will affect the amount of dividends, if any, we are ultimately able to pay to our shareholders. See “Dividend Policy.”

According to the EIT Law, which was promulgated by the SCNPC on March 16, 2007, became effective on January 1, 2008, and was then last amended on December 29, 2018, and the *Implementation Rules of the EIT Law*, which were promulgated by the State Council on December 6, 2007, and became effective on January 1, 2008, and last amended on April 23, 2018, enterprises are divided into resident enterprises and non-resident enterprises. Resident enterprises pay enterprise income tax on their incomes obtained in and outside the PRC at the rate of 25%. Non-resident enterprises setting up institutions in the PRC pay enterprise income tax on the incomes obtained by such institutions in and outside the PRC at the rate of 25%. Non-resident enterprises with no institutions in the PRC, and non-resident enterprises with income having no substantial connection with their institutions in the PRC, pay enterprise income tax on their income obtained in the PRC at a reduced rate of 10%.

We are a holding company incorporated in the Cayman Islands and we gain substantial income by way of dividends paid to us from the PRC subsidiaries. The EIT Law and its implementation rules provide that China-sourced income of foreign enterprises, such as dividends paid by a PRC subsidiary to its equity holders that are non-resident enterprises, will normally be subject to PRC withholding tax at a rate of 10%, unless any such foreign investor’s jurisdiction of incorporation has a tax treaty with China that provides for a preferential tax rate or a tax exemption.

Under the EIT Law, an enterprise established outside of China with a “de facto management body” within China is considered a “resident enterprise,” which means that it is treated in a manner similar to a Chinese enterprise for enterprise income tax purposes. Although the implementation rules of the EIT Law define “de facto management body” as a managing body that actually, comprehensively manage and control the production and operation, staff, accounting, property, and other aspects of an enterprise, the only official guidance for this definition currently available is set forth in SAT Notice 82, which provides guidance on the determination of the tax residence status of a Chinese-controlled offshore incorporated enterprise, defined as an enterprise that is incorporated under the laws of a foreign country or territory and that has a PRC enterprise or enterprise group as its primary controlling shareholder. Although Zhengye Cayman does not have a PRC enterprise or enterprise group as our primary controlling shareholder and is therefore not a Chinese-controlled offshore incorporated enterprise within the meaning of SAT Notice 82, in the absence of guidance specifically applicable to us, we have applied the guidance set forth in SAT Notice 82 to evaluate the tax residence status of Zhengye Cayman and its subsidiaries organized outside the PRC.

According to SAT Notice 82, a Chinese-controlled offshore incorporated enterprise will be regarded as a PRC tax resident by virtue of having a “de facto management body” in China and will be subject to PRC enterprise income tax on its worldwide income only if all of the following criteria are met: (i) the places where senior management and senior management departments that are responsible for daily production, operation and management of the enterprise perform their duties are mainly located within the territory of China; (ii) financial decisions (such as money borrowing, lending, financing and financial risk management) and personnel decisions (such as appointment, dismissal and salary and wages) are decided or need to be decided by organizations or persons located within the territory of China; (iii) main property, accounting books, corporate seal, the board of directors and files of the minutes of shareholders’ meetings of the enterprise are located or preserved within the territory of China; and (iv) one half (or more) of the directors or senior management staff having the right to vote habitually reside within the territory of China.

We believe that we do not meet some of the conditions outlined in the immediately preceding paragraph. For example, as a holding company, the key assets and records of Zhengye Cayman, including the resolutions and meeting minutes of our board of directors and the resolutions and meeting minutes of our shareholders, are located and maintained outside the PRC. In addition, we are not aware of any offshore holding companies with a corporate structure similar to ours that has been deemed a PRC “resident enterprise” by the PRC tax authorities. Accordingly, we believe that Zhengye Cayman and its offshore subsidiaries should not be treated as a “resident enterprise” for PRC tax purposes if the criteria for “de facto management body” as set forth in SAT Notice 82 were deemed applicable to us. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain

[Table of Contents](#)

with respect to the interpretation of the term “de facto management body.” There can be no assurance that the PRC government will ultimately take a view that is consistent with our position and there is a risk that the PRC tax authorities may deem our company as a PRC resident enterprise since a substantial majority of the members of our management team are located in China, in which case we would be subject to the EIT at the rate of 25% on worldwide income.

See “Risk Factors — Risks Relating to Doing Business in the PRC — Under the PRC Enterprise Income Tax Law, we may be classified as a PRC ‘resident enterprise’ for PRC enterprise income tax purposes. Such classification would likely result in unfavorable tax consequences to us and our non-PRC shareholders and have a material adverse effect on our results of operations and the value of your investment.”

If the PRC tax authorities determine that Zhengye Cayman is a PRC resident enterprise for enterprise income tax purposes, a number of unfavorable PRC tax consequences could follow. First, we will be subject to the uniform 25% enterprise income tax on our world-wide income, which could materially reduce our net income. In addition, we will also be subject to PRC enterprise income tax reporting obligations. Finally, dividends payable by us to our investors and gains on the sale of our Ordinary Shares may become subject to PRC withholding tax, at a rate of 10% in the case of non-PRC enterprises or 20% in the case of non-PRC individuals (in each case, subject to the provisions of any applicable tax treaty), if such gains are deemed to be from PRC sources. It is unclear whether non-PRC shareholders of our company would be able to claim the benefits of any tax treaties between their country of tax residence and the PRC in the event that we are treated as a PRC resident enterprise. Any such tax may reduce the returns on your investment in our shares. Although up to the date of this prospectus, Zhengye Cayman has not been notified or informed by the PRC tax authorities that it has been deemed to be a resident enterprise for the purpose of the EIT Law, we cannot assure you that it will not be deemed to be a resident enterprise in the future.

Value-added Tax

Under the Circular on Comprehensively Promoting the Pilot Program of the Collection of Value-added Tax to Replace Business Tax, or Circular 36, which was promulgated by the Ministry of Finance and the SAT on March 23, 2016 and became effective on May 1, 2016, entities and individuals engaging in the sale of services, intangible assets or fixed assets within the territory of the PRC are required to pay value added tax, or VAT, instead of business tax.

According to the Circular of the Ministry of Finance and the SAT on Adjusting Value-added Tax Rates, where a taxpayer engages in a taxable sales activity for the value-added tax purpose or imports goods, the previous applicable 17% tax rates are lowered to 16%.

According to the Circular on Policies to Deepen Value-added Tax Reform, where a taxpayer engages in a taxable sales activity for the value-added tax purpose or imports goods, the previous applicable 16% and 10% tax rates are lowered to 13% and 9%, respectively.

According to the Notice of the Ministry of Finance and the State Administration of Taxation on Value-Added Tax Policies Concerning the Application of Low Tax Rates and Simplified Taxation Method for Certain Goods promulgated on January 19, 2009 and the Notice of the Ministry of Finance and the State Administration of Taxation on Simplifying Value-added Tax Rate Policies promulgated on June 13, 2014 and the Circular 36, the operating entity is subject to VAT, at a rate of 3% on proceeds from sales of biological products which are made of microbes, metabolin of microbes, animal toxin, blood or organism of human beings or animals.

Hong Kong Taxation

Peg Biotechnology is incorporated in Hong Kong, which is a two-tiered profits tax rates regime, in which the first HK\$2 million of assessable profits will be taxed at the rate of 8.25%, and assessable profits above HK\$2 million will be taxed at the rate of 16.5%.

Cayman Islands Taxation

The Cayman Islands currently levies no taxes on individuals or corporations based upon profits, income, gains, or appreciation and there is no taxation in the nature of inheritance tax or estate duty. There are no other taxes likely to be material to us levied by the Government of the Cayman Islands except for stamp duties which may be applicable on instruments executed in, or, after execution, brought within the jurisdiction of the Cayman Islands. The Cayman Islands are a party to a double tax treaty entered into with the United Kingdom in 2010 but otherwise is not party to any double tax treaties. There are no exchange control regulations or currency restrictions in the Cayman Islands.

Payments of dividends and capital in respect of our Ordinary Shares will not be subject to taxation in the Cayman Islands and no withholding will be required on the payment of a dividend or capital to any holder of our Ordinary Shares, as the case may be, nor will gains derived from the disposal of our Ordinary Shares be subject to Cayman Islands income or corporation tax.

Under the laws of the Cayman Islands, no stamp duty is payable in the Cayman Islands on the issue of shares by, or any transfers of shares of, Cayman Islands companies (except those which hold interests in land in the Cayman Islands).

Material United States Federal Income Tax Consequences

The following discussion is a summary of U.S. federal income tax considerations generally applicable to the ownership and disposition of our Ordinary Shares by a U.S. Holder (as defined below) that acquires our Ordinary Shares in this offering and holds our Ordinary Shares as “capital assets” (generally, property held for investment) under the U.S. Internal Revenue Code of 1986, as amended, or the Code. This discussion is based upon existing U.S. federal tax law, which is subject to differing interpretations or change, possibly with retroactive effect. No ruling has been sought from the Internal Revenue Service, or the IRS, with respect to any U.S. federal income tax consequences described below, and there can be no assurance that the IRS or a court will not take a contrary position. This discussion, moreover, does not address the U.S. federal estate, gift, Medicare, and alternative minimum tax considerations, any withholding or information reporting requirements, or any state, local and non-U.S. tax considerations relating to the ownership or disposition of our Ordinary Shares. The following does not address all aspects of U.S. federal income taxation that may be important to particular investor or to persons in special tax situations such as:

- banks and other financial institutions;
- insurance companies;
- pension plans;
- cooperatives;
- regulated investment companies;
- real estate investment trusts;
- broker-dealers;
- traders that elect to use a market-to-market method of accounting;
- certain former U.S. citizens or long-term residents;
- governments or agencies or instrumentalities thereof;
- tax-exempt entities (including private foundations);
- holders who acquired our ordinary shares pursuant to the exercise of any employee share option or otherwise as compensation;
- investors that will hold our ordinary shares as part of a straddle, hedging, conversion or other integrated transaction for U.S. federal income tax purposes;
- persons holding their ordinary shares in connection with a trade or business outside the United States;
- persons that actually or constructively own 10% or more of our voting power or value (including by reason of owning our ordinary shares);
- investors required to accelerate the recognition of any item of gross income with respect to their ordinary shares as a result of such income being recognized on an applicable financial statement;
- investors that have a functional currency other than the U.S. dollar;
- partnerships or other entities taxable as partnerships for U.S. federal income tax purposes, or persons holding ordinary shares through such entities, all of whom may be subject to tax rules that differ significantly from those discussed below.

[Table of Contents](#)

The discussion set forth below is addressed only to U.S. Holders that purchase Ordinary Shares in this offering. Prospective purchasers are urged to consult with their own tax advisors about the application of the U.S. federal income tax rules to their particular circumstances as well as the state, local, foreign and other tax consequences to them of the purchase, ownership and disposition of our Ordinary Shares.

General

For purposes of this discussion, a “U.S. Holder” is a beneficial owner of our Ordinary Shares that is, for U.S. federal income tax purposes, (i) an individual who is a citizen or resident of the United States, (ii) a corporation (or other entity treated as a corporation for United States federal income tax purposes) created in, or organized under the laws of, the United States or any state thereof or the District of Columbia, (iii) an estate whose income is subject to U.S. federal income taxation regardless of its source; or (iv) a trust that (A) is subject to the primary supervision of a court within the United States and the control of one or more U.S. persons for all substantial decisions or (B) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person.

If a partnership (or other entity treated as a partnership for U.S. federal income tax purposes) is a beneficial owner of our Ordinary Shares, the tax treatment of a partner in the partnership will generally depend upon the status of the partner and the activities of the partnership. Partnerships holding our Ordinary Shares and their partners are urged to consult their tax advisors regarding an investment in our Ordinary Shares.

PFIC Consequences

A non-U.S. corporation is considered a PFIC, as defined in Section 1297(a) of the US Internal Revenue Code, for any taxable year if either:

- at least 75% of its gross income for such taxable year is passive income; or
- at least 50% of the value of its assets (based on an average of the quarterly values of the assets during a taxable year) is attributable to assets that produce or are held for the production of passive income (the “asset test”).

Passive income generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business) and gains from the disposition of passive assets. We will be treated as owning our proportionate share of the assets and earning our proportionate share of the income of any other corporation in which we own, directly or indirectly, at least 25% (by value) of the stock. In determining the value and composition of our assets for purposes of the PFIC asset test, (1) the cash we raise in this offering will generally be considered to be held for the production of passive income and (2) the value of our assets must be determined based on the market value of our Ordinary Shares from time to time, which could cause the value of our non-passive assets to be less than 50% of the value of all of our assets (including the cash raised in this offering) on any particular quarterly testing date for purposes of the asset test.

Based on our operations, current and projected income and assets, and the composition of our income and assets (taking into account the current and expected income generated from our investment products purchased from banks), we do not expect to be treated as a PFIC for the current taxable year or the foreseeable future under the current PFIC rules. We must make a separate determination each year as to whether we are a PFIC, however, and there can be no assurance with respect to our status as a PFIC for our current taxable year or any future taxable year. Depending on the amount of cash we raise in this offering, together with any other assets held for the production of passive income, it is possible that, for our current taxable year or for any subsequent taxable year, more than 50% of our assets may be assets held for the production of passive income. We will make this determination following the end of any particular tax year. Because the value of our assets for purposes of the asset test will generally be determined based on the market price of our Ordinary shares and because cash is generally considered to be an asset held for the production of passive income, our PFIC status will depend in large part on the market price of our Ordinary Shares and the amount of cash we raise in this offering. Accordingly, fluctuations in the market price of the Ordinary Shares may cause us to become a PFIC. In addition, the application of the PFIC rules is subject to uncertainty in several respects and the composition of our income and assets will be affected by how, and how quickly, we spend the cash we raise in this offering. We are under no obligation to take steps to reduce the risk of our being classified as a PFIC, and as stated above, the determination of the value of our assets will depend upon material facts (including the market price of our Ordinary Shares from time to time and the amount of cash we raise in this offering) that may not be within our control.

[Table of Contents](#)

If we are a PFIC for any year during which you hold ordinary shares, we will continue to be treated as a PFIC for all succeeding years during which you hold Ordinary Shares. If we cease to be a PFIC and you did not previously make a timely “mark-to-market” election as described below, you may avoid some of the adverse effects of the PFIC regime by making a “purging election” (as described below) with respect to the Ordinary Shares.

If we are a PFIC for your taxable year(s) during which you hold Ordinary Shares, you will be subject to special tax rules with respect to any “excess distribution” that you receive and any gain you realize from a sale or other disposition (including a pledge) of the Ordinary Shares, unless you make a “mark-to-market” election as discussed below. Distributions you receive in a taxable year that are greater than 125% of the average annual distributions you received during the shorter of the three preceding taxable years or your holding period for the Ordinary Shares will be treated as an excess distribution. Under these special tax rules:

- the excess distribution or gain will be allocated ratably over your holding period for the Ordinary Shares;
- the amount allocated to your current taxable year, and any amount allocated to any of your taxable year(s) prior to the first taxable year in which we were a PFIC, will be treated as ordinary income, and
- the amount allocated to each of your other taxable year(s) will be subject to the highest tax rate in effect for that year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year.

The tax liability for amounts allocated to years prior to the year of disposition or “excess distribution” cannot be offset by any net operating losses for such years, and gains (but not losses) realized on the sale of the Ordinary shares cannot be treated as capital, even if you hold the Ordinary Shares as capital assets.

A U.S. Holder of “marketable stock” (as defined below) in a PFIC may make a mark-to-market election under Section 1296 of the US Internal Revenue Code for such stock to elect out of the tax treatment discussed above. If you make a mark-to-market election for first taxable year which you hold (or are deemed to hold) Ordinary Shares and for which we are determined to be a PFIC, you will include in your income each year an amount equal to the excess, if any, of the fair market value of the Ordinary Shares as of the close of such taxable year over your adjusted basis in such Ordinary Shares, which excess will be treated as ordinary income and not capital gain. You are allowed an ordinary loss for the excess, if any, of the adjusted basis of the Ordinary Shares over their fair market value as of the close of the taxable year. Such ordinary loss, however, is allowable only to the extent of any net mark-to-market gains on the Ordinary Shares included in your income for prior taxable years. Amounts included in your income under a mark-to-market election, as well as gain on the actual sale or other disposition of the Ordinary Shares, are treated as ordinary income. Ordinary loss treatment also applies to any loss realized on the actual sale or disposition of the Ordinary Shares, to the extent that the amount of such loss does not exceed the net mark-to-market gains previously included for such Ordinary Shares. Your basis in the Ordinary Shares will be adjusted to reflect any such income or loss amounts. If you make a valid mark-to-market election, the tax rules that apply to distributions by corporations which are not PFICs would apply to distributions by us, except that the lower applicable capital gains rate for qualified dividend income discussed below under “— Taxation of Dividends and Other Distributions on our Ordinary Shares” generally would not apply.

The mark-to-market election is available only for “marketable stock,” which is stock that is traded in other than de minimis quantities on at least 15 days during each calendar quarter (“regularly traded”) on a qualified exchange or other market (as defined in applicable U.S. Treasury regulations), including Nasdaq. If the Ordinary Shares are regularly traded on Nasdaq and if you are a holder of Ordinary shares, the mark-to-market election would be available to you were we to be or become a PFIC.

Alternatively, a U.S. Holder of stock in a PFIC may make a “qualified electing fund” election under Section 1295(b) of the US Internal Revenue Code with respect to such PFIC to elect out of the tax treatment discussed above. A U.S. Holder who makes a valid qualified electing fund election with respect to a PFIC will generally include in gross income for a taxable year such holder’s pro rata share of the corporation’s earnings and profits for the taxable year. The qualified electing fund election, however, is available only if such PFIC provides such U.S. Holder with certain information regarding its earnings and profits as required under applicable U.S. Treasury regulations. We do not currently intend to prepare or provide the information that would enable you to make a qualified electing fund election. If you hold Ordinary Shares in any taxable year in which we are a PFIC, you will be required to file U.S. Internal Revenue Service Form 8621 in each such year and provide certain annual information regarding such Ordinary Shares, including regarding distributions received on the Ordinary Shares and any gain realized on the disposition of the Ordinary Shares.

[Table of Contents](#)

If you do not make a timely “mark-to-market” election (as described above), and if we were a PFIC at any time during the period you hold our Ordinary Shares, then such Ordinary Shares will continue to be treated as stock of a PFIC with respect to you even if we cease to be a PFIC in a future year, unless you make a “purging election” for the year we cease to be a PFIC. A “purging election” creates a deemed sale of such Ordinary Shares at their fair market value on the last day of the last year in which we are treated as a PFIC. The gain recognized by the purging election will be subject to the special tax and interest charge rules treating the gain as an excess distribution, as described above. As a result of the purging election, you will have a new basis (equal to the fair market value of the Ordinary Shares on the last day of the last year in which we are treated as a PFIC) and holding period (which new holding period will begin the day after such last day) in your Ordinary Shares for tax purposes.

IRC Section 1014(a) provides for a step-up in basis to the fair market value for our Ordinary Shares when inherited from a decedent that was previously a holder of our Ordinary Shares. However, if we are determined to be a PFIC and a decedent that was a U.S. Holder did not make either a timely qualified electing fund election for our first taxable year as a PFIC in which the U.S. Holder held (or was deemed to hold) our ordinary shares, or a mark-to-market election and ownership of those Ordinary Shares are inherited, a special provision in IRC Section 1291(e) provides that the new U.S. Holder’s basis should be reduced by an amount equal to the Section 1014 basis minus the decedent’s adjusted basis just before death. As such if we are determined to be a PFIC at any time prior to a decedent’s passing, the PFIC rules will cause any new U.S. Holder that inherits our Ordinary Shares from a U.S. Holder to not get a step-up in basis under Section 1014 and instead will receive a carryover basis in those Ordinary Shares.

You are urged to consult your tax advisors regarding the application of the PFIC rules to your investment in our Ordinary Shares and the elections discussed above.

Taxation of Dividends and Other Distributions on Our Ordinary Shares

Subject to the PFIC rules discussed above, the gross amount of distributions made by us to you with respect to the Ordinary Shares (including the amount of any taxes withheld therefrom) will generally be includable in your gross income as dividend income on the date of receipt by you, but only to the extent that the distribution is paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). With respect to corporate U.S. Holders, the dividends will not be eligible for the dividends-received deduction allowed to corporations in respect of dividends received from other U.S. corporations.

With respect to non-corporate U.S. Holders, including individual U.S. Holders, dividends will be taxed at the lower capital gains rate applicable to qualified dividend income, provided that (1) the Ordinary Shares are readily tradable on an established securities market in the United States, or we are eligible for the benefits of an approved qualifying income tax treaty with the United States that includes an exchange of information program, (2) we are not a PFIC for either our taxable year in which the dividend is paid or the preceding taxable year, and (3) certain holding period requirements are met. Because there is not an income tax treaty between the United States and the Cayman Islands, clause (1) above can be satisfied only if the Ordinary Shares are readily tradable on an established securities market in the United States. Under U.S. Internal Revenue Service authority, Ordinary shares are considered for purpose of clause (1) above to be readily tradable on an established securities market in the United States if they are listed on certain exchanges, which presently include the NYSE and the Nasdaq Stock Market. You are urged to consult your tax advisors regarding the availability of the lower rate for dividends paid with respect to our Ordinary Shares, including the effects of any change in law after the date of this prospectus.

Dividends will constitute foreign source income for foreign tax credit limitation purposes. If the dividends are taxed as qualified dividend income (as discussed above), the amount of the dividend taken into account for purposes of calculating the foreign tax credit limitation will be limited to the gross amount of the dividend, multiplied by the reduced rate divided by the highest rate of tax normally applicable to dividends. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income. For this purpose, dividends distributed by us with respect to our Ordinary Shares will constitute “passive category income” but could, in the case of certain U.S. Holders, constitute “general category income.”

To the extent that the amount of the distribution exceeds our current and accumulated earnings and profits (as determined under U.S. federal income tax principles), it will be treated first as a tax-free return of your tax basis in your Ordinary Shares, and to the extent the amount of the distribution exceeds your tax basis, the excess will be

[Table of Contents](#)

taxed as capital gain. We do not intend to calculate our earnings and profits under U.S. federal income tax principles. Therefore, a U.S. Holder should expect that a distribution will be treated as a dividend even if that distribution would otherwise be treated as a non-taxable return of capital or as capital gain under the rules described above.

Taxation of Dispositions of Ordinary Shares

Subject to the passive foreign investment company rules discussed above, you will recognize taxable gain or loss on any sale, exchange or other taxable disposition of a share equal to the difference between the amount realized (in U.S. dollars) for the share and your tax basis (in U.S. dollars) in the Ordinary Shares. The gain or loss will be capital gain or loss. If you are a non-corporate U.S. Holder, including an individual U.S. Holder, who has held the Ordinary Shares for more than one year, you will generally be eligible for reduced tax rates. The deductibility of capital losses is subject to limitations. Any such gain or loss that you recognize will generally be treated as United States source income or loss for foreign tax credit limitation purposes which will generally limit the availability of foreign tax credits.

Information Reporting and Backup Withholding

Dividend payments with respect to our Ordinary Shares and proceeds from the sale, exchange or redemption of our Ordinary Shares may be subject to information reporting to the U.S. Internal Revenue Service and possible U.S. backup withholding under Section 3406 of the US Internal Revenue Code with at a current flat rate of 24%. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct taxpayer identification number and makes any other required certification on U.S. Internal Revenue Service Form W-9 or who is otherwise exempt from backup withholding. U.S. Holders who are required to establish their exempt status generally must provide such certification on U.S. Internal Revenue Service Form W-9. U.S. Holders are urged to consult their tax advisors regarding the application of the U.S. information reporting and backup withholding rules.

Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against your U.S. federal income tax liability, and you may obtain a refund of any excess amounts withheld under the backup withholding rules by filing the appropriate claim for refund with the U.S. Internal Revenue Service and furnishing any required information. We do not intend to withhold taxes for individual shareholders. Transactions effected through certain brokers or other intermediaries, however, may be subject to withholding taxes (including backup withholding), and such brokers or intermediaries may be required by law to withhold such taxes.

Under the Hiring Incentives to Restore Employment Act of 2010, certain U.S. Holders are required to report information relating to our Ordinary Shares, subject to certain exceptions (including an exception for Ordinary Shares held in accounts maintained by certain financial institutions), by attaching a complete Internal Revenue Service Form 8938, Statement of Specified Foreign Financial Assets, with their tax return for each year in which they hold Ordinary Shares.

UNDERWRITING

We expect to enter into an underwriting agreement with US Tiger Securities, Inc., the representative of the underwriters named below (the "Representative"), with respect to the Ordinary Shares in this offering. The Representative may retain other brokers or dealers to act as sub-agents on its behalf in connection with this offering and may pay any sub-agent a solicitation fee with respect to any securities placed by it. Under the terms and subject to the conditions contained in the underwriting agreement, we have agreed to issue and sell to the underwriters the number of Ordinary Shares as indicated below.

Underwriters	Number of Ordinary Shares
US Tiger Securities, Inc.	[•]
Total	[•]

The underwriters are offering the Ordinary Shares subject to their acceptance of the Ordinary Shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the underwriters to pay for and accept delivery of the Ordinary Shares offered by this prospectus are subject to the approval of certain legal matters by their counsel and to other conditions. The underwriters are obligated to take and pay for all of the Ordinary Shares offered by this prospectus if any such Ordinary Shares are taken. However, the underwriters are not required to take or pay for the Ordinary Shares covered by the underwriters' option to purchase additional Ordinary Shares described below.

Underwriting Discounts and Expenses

The underwriters have advised us that they propose to offer the Ordinary Shares to the public at the public offering price set forth on the cover page of this prospectus and to certain dealers at that price less a concession. After this offering, the initial public offering price, concession, and reallowance to dealers may be reduced by the underwriters. No change in those terms will change the amount of proceeds to be received by us as set forth on the cover of this prospectus. The securities are offered by the underwriter as stated herein, subject to their receipt and acceptance and subject to their right to reject any order in whole or in part.

The following table shows the public offering price, underwriting discount, and proceeds, before expenses, to us.

	Per Share	Total
Initial public offering price	\$	\$
Underwriters' discounts⁽¹⁾	\$	\$
Proceeds to our company before expenses	\$	\$

(1) Represents an underwriting discount equal to 7% per share. The fees do not include the expense reimbursement provisions described below.

We have agreed to reimburse the Representative up to a maximum of \$250,000 for our-of-pocket accountable expenses. We have also agreed to pay to the Representative a non-accountable fee of 1% of the gross proceeds received by the Company upon closing of this offering.

We estimate that expenses payable by us in connection with this offering, other than the underwriting discounts referred to above and underwriter expense reimbursement, will be approximately \$[•].

Listing

We submitted our application to list our Ordinary Shares on the Nasdaq Global Market under the symbol "ZYBT." At this time, Nasdaq has not yet approved our application to list our Ordinary Shares. The closing of this offering is conditioned upon Nasdaq's final approval of our listing application, and there is no guarantee or assurance that our Ordinary Shares will be approved for listing on Nasdaq.

Indemnification

We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act and liabilities arising from breaches of representations and warranties contained in the underwriting agreement, or to contribute to payments that the underwriters may be required to make in respect of those liabilities.

Lock-Up Agreements

We, and any successors of us, will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of (including entering into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequence of ownership of our capital shares), directly or indirectly, any of our Ordinary Shares or any securities that are convertible into or exercisable or exchangeable for our Ordinary Shares, (ii) file or cause to be filed any registration statement with the SEC relating to the offering of any Ordinary Shares or any securities convertible into or exercisable or exchangeable for Ordinary Shares, or (iii) complete any offering of our debt securities, other than entering into a line of credit with a traditional bank, without the prior written consent of the Representative for one hundred eighty (180) days from the date of commencement of sales of this offering, except issuances pursuant to the exercise of employee share options outstanding on the date hereof and certain other exceptions.

Each of our directors, officers, and shareholders owning 5% or more of our Ordinary Shares has agreed, for one hundred eighty (180) days from the date of commencement of sales of this offering, subject to certain exceptions, not to offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer, or dispose of, directly or indirectly, any of our Ordinary Shares and securities that are substantially similar to our Ordinary Shares, without the prior written consent of the Representative.

Pricing of the Offering

Prior to this offering, there has been no public market for our Ordinary Shares. The initial public offering price of the Ordinary Shares has been negotiated between us and the underwriters. Among the factors considered in determining the initial public offering price of the Ordinary Shares, in addition to the prevailing market conditions, are our historical performance, estimates of our business potential and earnings prospects, an assessment of our management, and the consideration of the above factors in relation to market valuation of companies in related businesses.

Electronic Offer, Sale, and Distribution of Ordinary Shares

A prospectus in electronic format may be made available on the websites maintained by the underwriters or selling group members, if any, participating in this offering and the underwriters may distribute prospectuses electronically. The underwriters may agree to allocate a number of Ordinary Shares to selling group members for sale to their online brokerage account holders. The Ordinary Shares to be sold pursuant to internet distributions will be allocated on the same basis as other allocations. Other than the prospectus in electronic format, the information on these websites is not part of, nor incorporated by reference into, this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or the underwriters, and should not be relied upon by investors.

Price Stabilization, Short Positions, and Penalty Bids

In connection with this offering, the underwriters may engage in transactions that stabilize, maintain, or otherwise affect the price of our Ordinary Shares. Specifically, the underwriters may sell more Ordinary Shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no greater than the number of Ordinary Shares available for purchase by the underwriters under option to purchase additional Ordinary Shares. The underwriters can close out a covered short sale by exercising the option to purchase additional Ordinary Shares or purchasing Ordinary Shares in the open market. In determining the source of Ordinary Shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of Ordinary Shares compared to the price available under the option to purchase additional Ordinary Shares. The

[Table of Contents](#)

underwriters may also sell Ordinary Shares in excess of the option to purchase additional Ordinary Shares, creating a naked short position. The underwriters must close out any naked short position by purchasing Ordinary Shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the Ordinary Shares in the open market after pricing that could adversely affect investors who purchase in the offering.

The underwriters may also impose a penalty bid. This occurs when a particular underwriter or dealer repays selling concessions allowed to it for distributing our Ordinary Shares in this offering because such underwriter repurchases those Ordinary Shares in stabilizing or short covering transactions.

Finally, the underwriters may bid for, and purchase, our Ordinary Shares in market making transactions, including “passive” market making transactions as described below.

These activities may stabilize or maintain the market price of our Ordinary Shares at a price that is higher than the price that might otherwise exist in the absence of these activities. The underwriters are not required to engage in these activities, and may discontinue any of these activities at any time without notice. These transactions may be effected on the Nasdaq Global Market, in the over-the-counter market, or otherwise.

Passive Market Making

In connection with this offering, the underwriters may engage in passive market making transactions in our Ordinary Shares on the Nasdaq Global Market in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement of offers or sales of the Ordinary Shares and extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker’s bid, then that bid must then be lowered when specified purchase limits are exceeded.

Potential Conflicts of Interest

The underwriters and their affiliates may, from time to time, engage in transactions with and perform services for us in the ordinary course of their business for which they may receive customary fees and reimbursement of expenses. In the ordinary course of their various business activities, the underwriters and their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own accounts and for the accounts of their customers and such investment and securities activities may involve securities and/or instruments of our Company. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.

Other Relationships

The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing, and brokerage activities. Some of the underwriters and certain of their affiliates may in the future engage in investment banking and other commercial dealings in the ordinary course of business with us and our affiliates, for which they may in the future receive customary fees, commissions, and expenses.

In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long, and/or short positions in such securities and instruments.

Stamp Taxes

If you purchase Ordinary Shares offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus.

Selling Restrictions

No action has been taken in any jurisdiction (except in the United States) that would permit a public offering of the Ordinary Shares, or the possession, circulation or distribution of this prospectus or any other material relating to us or the Ordinary Shares, where action for that purpose is required. Accordingly, the Ordinary Shares may not be offered or sold, directly or indirectly, and neither this prospectus nor any other offering material or advertisements in connection with the Ordinary Shares may be distributed or published, in or from any country or jurisdiction except in compliance with any applicable rules and regulations of any such country or jurisdiction.

EXPENSES RELATING TO THIS OFFERING

Set forth below is an itemization of the total expenses, excluding underwriting discounts. With the exception of the SEC registration fee, the FINRA filing fee, and the Nasdaq Global Market listing fee, all amounts are estimates.

Securities and Exchange Commission Registration Fee	\$	2,952
Nasdaq Global Market Listing Fee	\$	295,000
FINRA Filing Fee	\$	3,500
Legal Fees and Other Expenses	\$	742,500
Accounting Fees and Expenses	\$	410,000
Printing Expenses	\$	85,000
Transfer Agent Expenses	\$	19,800
Miscellaneous Expenses	\$	384,000
Total Expenses	\$	1,942,752

These expenses will be borne by us. Underwriting discounts will be borne by us in proportion to the numbers of Ordinary Shares sold in the offering.

LEGAL MATTERS

We are being represented by Hunter Taubman Fischer & Li LLC with respect to certain legal matters as to United States federal securities and New York State law. The Representative is being represented by VCL Law LLP with respect to certain legal matters as to United States federal securities and New York State law. The validity of the Ordinary Shares offered in this offering and certain other legal matters as to Cayman Islands law will be passed upon for us by Conyers Dill & Pearman, our counsel as to Cayman Islands law. Legal matters as to PRC law will be passed upon for us by Guantao Law Firm Hangzhou Office and for the Representative by Jincheng Tongda & Neal Law Firm.

EXPERTS

The consolidated financial statements for the six months ended June 30, 2023 and the years ended December 31, 2022 and 2021, included in this prospectus have been so included in reliance on the report of WWC, P.C., an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. The office of WWC, P.C. is located at 2010 Pioneer Court, San Mateo, CA 94403.

WHERE YOU CAN FIND ADDITIONAL INFORMATION

We have filed with the SEC a registration statement on Form F-1, including relevant exhibits and schedules under the Securities Act, covering the Ordinary Shares offered by this prospectus. You should refer to our registration statements and their exhibits and schedules if you would like to find out more about us and about the Ordinary Shares. This prospectus summarizes material provisions of contracts and other documents that we refer you to. Since the prospectus may not contain all the information that you may find important, you should review the full text of these documents.

Immediately upon the completion of this offering, we will be subject to periodic reporting and other informational requirements of the Exchange Act, as applicable to foreign private issuers. Accordingly, we will be required to file reports, including annual reports on Form 20-F, and other information with the SEC. As a foreign private issuer, we are exempt from the rules of the Exchange Act prescribing the furnishing and content of proxy statements to shareholders under the federal proxy rules contained in Sections 14(a), (b) and (c) of the Exchange Act, and our executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act.

The SEC maintains a website that contains reports, proxy statements, and other information about issuers, such as us, who file electronically with the SEC. The address of that website is <http://www.sec.gov>. The information on that website is not a part of this prospectus.

No dealers, salesperson, or other person is authorized to give any information or to represent anything not contained in this prospectus. You must not rely on any unauthorized information or representations. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED

INDEX TO FINANCIAL STATEMENTS

	Page(s)
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM	F-2
CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2021 AND 2022	F-3
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2022	F-4
CONSOLIDATED STATEMENTS OF CHANGE IN SHAREHOLDERS' EQUITY FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2022	F-5
CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2022	F-6
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2022	F-7
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2022 AND JUNE 30, 2023	F-27
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME FOR THE SIX MONTHS ENDED JUNE 30, 2022 AND 2023	F-28
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN SHAREHOLDERS' EQUITY FOR THE SIX MONTHS ENDED JUNE 30, 2022 AND 2023	F-29
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED JUNE 30, 2022 AND 2023	F-30
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	F-31



REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of
Zhengye Biotechnology Holding Limited

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Zhengye Biotechnology Holding Limited and its subsidiaries (collectively the “Company”) as of December 31, 2021 and 2022 and the related consolidated statements of income and comprehensive income, change in shareholders’ equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021, and 2022, and the results of its operations and its cash flows for each of the years then ended in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of our management. Our responsibility is to express an opinion on our financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of our internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

WWC, P.C.

WWC, P.C.
Certified Public Accountants
PCAOB ID: 1171

We have served as our auditor since 2023.
San Mateo, California

August 4, 2023, except for the reclassification discussed in Note 2 as to which the date is November 17, 2023.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
CONSOLIDATED BALANCE SHEETS
(Amounts in thousands of RMB and US\$, except for number of shares)

	As of December 31,		
	2021	2022	
	RMB	RMB	US\$
ASSETS			
Current assets:			
Cash	6,284	9,746	1,413
Notes receivable, net	18,278	30,679	4,448
Accounts receivable, net	83,187	102,899	14,919
Account receivable-related party	233	—	—
Advance to suppliers	1,707	2,433	353
Inventories, net	43,622	55,424	8,036
Other receivable, net	489	672	97
Deferred tax assets	11,144	12,455	1,806
Total current assets	164,944	214,308	31,072
Non-current assets:			
Property, plant and equipment, net	246,343	275,171	39,896
Land use rights, net	8,702	8,445	1,224
Intangible assets, net	12,049	19,458	2,821
Operating lease right-of-use assets, net	71	58	8
Long-term prepayments	13,170	2,234	324
Total non-current assets	280,335	305,366	44,273
Total assets	445,279	519,674	75,345
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current liabilities:			
Short-term loans	30,000	54,890	7,958
Accounts payable	77,566	79,276	11,494
Contract liabilities	4,284	4,601	667
Tax payables	6,806	9,996	1,449
Dividend payables	3,713	—	—
Accrued expenses and other liabilities	3,257	3,464	502
Total current liabilities	125,626	152,227	22,070
Non-current liabilities:			
Long-term loans	—	9,990	1,448
Other payables – non-current	816	590	86
Total non-current liabilities	816	10,580	1,534
Total liabilities	126,442	162,807	23,604
Shareholders' equity:			
Ordinary shares (US\$0.0001 par value; 500,000,000 shares authorized; 11,416,594 shares issued and outstanding as of December 31, 2021 and 2022)	8	8	1
Additional paid-in capital	203,150	203,150	29,454
Statutory reserves	21,991	27,565	3,997
Retained earnings	42,325	65,774	9,536
Total Zhengye Biotechnology Holding Limited's shareholders' equity	267,474	296,497	42,988
Noncontrolling interests	51,363	60,370	8,753
Total shareholders' equity	318,837	356,867	51,741
Total liabilities and shareholders' equity	445,279	519,674	75,345

The accompanying notes are an integral part of these consolidated financial statements.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

	For the years ended December 31,		
	2021	2022	
	RMB	RMB	US\$
Net revenues	214,067	260,269	37,735
Cost of revenues	(88,674)	(106,750)	(15,477)
Gross profit	125,393	153,519	22,258
Sales and marketing expenses	(35,904)	(34,565)	(5,012)
General and administrative expenses	(22,290)	(28,993)	(4,204)
Research and development expenses	(11,370)	(13,424)	(1,946)
Allowance for credit losses	(1,925)	(9,735)	(1,411)
Impairment for inventory and intangible asset	(1,521)	(968)	(140)
Total operating expenses	(73,010)	(87,685)	(12,713)
Operating income	52,383	65,834	9,545
Other income (expenses):			
Other income	53	650	94
Other expenses	(137)	(100)	(14)
Interest income	112	114	17
Interest expense	(1,046)	(2,839)	(412)
Government subsidy	1,701	255	37
Total other income (expense), net	683	(1,920)	(278)
Income before income taxes	53,066	63,914	9,267
Income tax expense	(6,599)	(8,172)	(1,185)
Net income and total comprehensive income	46,467	55,742	8,082
Net income and comprehensive income attributable to noncontrolling interests	(7,508)	(9,007)	(1,306)
Net income and comprehensive income attributable to the Zhengye Biotechnology Holding Limited's shareholders	<u>38,959</u>	<u>46,735</u>	<u>6,776</u>
Earnings per share:			
Ordinary shares – basic and diluted	4.07	4.88	0.71
Weighted average shares outstanding used in calculating basic and diluted earnings per share:			
Ordinary shares – basic and diluted	11,416,594	11,416,594	11,416,594

The accompanying notes are an integral part of these consolidated financial statements.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
CONSOLIDATED STATEMENTS OF CHANGE IN SHAREHOLDERS' EQUITY
(Amounts in thousands of RMB and US\$, except for number of shares)

	Ordinary shares		Additional paid-in capital	Statutory reserve	Retained earnings	Total Zhengye Biotechnology Holding Limited's shareholders' equity	Non- controlling interests	Total shareholder's Equity
	Shares	Amount						
Balance, December 31, 2020 (RMB)	11,416,594	8	203,150	17,344	22,773	243,275	43,855	287,130
Net income	—	—	—	—	38,959	38,959	7,508	46,467
Transfer to statutory reserve	—	—	—	4,647	(4,647)	—	—	—
Dividend	—	—	—	—	(14,760)	(14,760)	—	(14,760)
Balance, December 31, 2021 (RMB)	11,416,594	8	203,150	21,991	42,325	267,474	51,363	318,837
Net income	—	—	—	—	46,735	46,735	9,007	55,742
Transfer to statutory reserve	—	—	—	5,574	(5,574)	—	—	—
Dividend	—	—	—	—	(17,712)	(17,712)	—	(17,712)
Balance, December 31, 2022 (RMB)	11,416,594	8	203,150	27,565	65,774	296,497	60,370	356,867
Balance, December 31, 2022 (US\$)	—	1	29,454	3,997	9,536	42,988	8,753	51,741

The accompanying notes are an integral part of these consolidated financial statements.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands of RMB and US\$, except for number of shares)

	For the years ended December 31,		
	2021	2022	
	RMB	RMB	US\$
CASH FLOWS FROM OPERATING ACTIVITIES			
Net income	46,467	55,742	8,082
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	16,012	18,800	2,726
Allowance for credit losses	1,925	9,735	1,411
Impairment for inventory and intangible assets	1,521	968	140
Gain on disposal of property and equipment	(53)	—	—
Deferred tax benefits	(517)	(1,311)	(190)
Noncash lease expense	159	217	32
Changes in operating assets and liabilities:			
Note receivables, net	(12,180)	(22,650)	(3,284)
Accounts receivable, net	(28,529)	(24,957)	(3,618)
Account receivable-related party	27	233	34
Inventories, net	(12,343)	(12,325)	(1,787)
Other receivables, net	(223)	(4)	(1)
Advances to suppliers	(259)	(726)	(105)
Lease liabilities	(230)	(204)	(30)
Accounts payable	17,633	(9,673)	(1,403)
Tax payables	801	3,191	463
Accrued expense and other liabilities	521	207	30
Contract liabilities	1,396	317	46
Other payables – non-current	(323)	(225)	(33)
Net cash provided by operating activities	<u>31,807</u>	<u>17,335</u>	<u>2,513</u>
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment	(19,060)	(27,328)	(3,962)
Prepayment for purchase of intangible assets	(7,338)	—	—
Proceeds from disposal of property, plant and equipment	128	—	—
Net cash used in investing activities	<u>(26,270)</u>	<u>(27,328)</u>	<u>(3,962)</u>
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from loans	30,000	99,852	14,477
Repayment of loans	(22,000)	(64,972)	(9,420)
Dividend payment to shareholders	(11,048)	(21,425)	(3,106)
Net cash provided by (used in) financing activities	<u>(3,048)</u>	<u>13,455</u>	<u>1,951</u>
Net increase in cash	2,489	3,462	502
Cash at beginning of year	3,795	6,284	911
Cash at end of year	<u>6,284</u>	<u>9,746</u>	<u>1,413</u>
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:			
Cash paid for:			
Interest	1,046	2,839	412
Income taxes	6,985	8,481	1,230
NON-CASH INVESTING AND FINANCING ACTIVITIES:			
Right of use assets obtained in exchange for operating lease obligation	230	204	30
Liabilities assumed in connection with purchase of property, plant and equipment	22,735	11,379	1,650

The accompanying notes are an integral part of these consolidated financial statements.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

1. ORGANIZATION**Nature of operations**

Zhengye Biotechnology Holding Limited (the “Company”) was incorporated in the Cayman Islands in March 2023 under the Cayman Islands Companies Act as an exempted company with limited liability. The Company through its consolidated subsidiaries principally focused on the research, development, manufacture and sales of veterinary vaccines, with an emphasis on vaccines for livestock in the People’s Republic of China (the “PRC” or “China”).

Reorganization

In preparation of its initial public offering (“IPO”) in the United States, the following transactions were undertaken to reorganize the legal structure of Operating Entities. The Company was incorporated in connection with a reorganization of Jilin Zhengye Biological Products Co., Ltd. (“Jilin Zhengye”). On April 3, 2023, the Company incorporated a wholly-owned subsidiary, VVAX Skyline Holdings Limited (“VVAX Skyline”), in British Virgin Island. On April 18, 2023, Zhengye BVI incorporated a wholly-owned subsidiary, Peg Biotechnology (HK) Holding Limited (“Peg Biotechnology”) in Hong Kong. On May 22, 2023, Zhengye HK incorporated a wholly-owned subsidiary, Hainan Senhan Biotechnology Co., Ltd. (“Hainan Senhan”) in the PRC. On May 30, 2023, VVAX Skyline acquired 100% of the equity interests in Windsor Holdings Co., Ltd. (“Windsor Holdings”) from its original shareholders. Windsor Holdings was incorporated in British Virgin Island.

Prior to the Reorganization described below, Jilin Zhengye was controlled by several individual, corporation and institution shareholders. A reorganization of the Company’s legal structure (“Reorganization”) was completed on June 21, 2023. The reorganization involved the transfer of 58.689% and 25.1524% interest of Jilin Zhengye from its former shareholders to Hainan Senhan and Windsor Holdings, respectively. As the result of this Reorganization, Jilin Zhengye became a subsidiary of the Company.

Upon the completion of the above Reorganization, the Company became the ultimate holding company of all other entities mentioned above. The Company is effectively controlled by the same group of controlling shareholders before and after the Reorganization; therefore, the Reorganization is considered as a recapitalization of these entities under common control. The consolidation of the Company and its subsidiaries was accounted for at historical cost and prepared on the basis as if the aforementioned transactions had become effective as of the beginning of the first period presented in the accompanying consolidated financial statements. Results of operations for the period presented comprise those of the previous separate entries combined from the beginning of the period to the end of the period, eliminating the effects of intra-entity transactions.

As of the date of this report, the details of the Company’s principal subsidiaries are as follows:

Entity	Date of incorporation/ acquisition	Place of incorporation	Percentage of direct or indirect ownership by the Company	Principal activities
Subsidiaries:				
VVAX Skyline Holdings Limited (“VVAX Skyline”)	April 3, 2023	British Virgin Island	100% owned by the Company	Investment holding
Windsor Holdings Co., Ltd. (“Windsor Holdings”)	May 30, 2023	British Virgin Island	100% owned by VVAX Skyline	Investment holding
Peg Biotechnology (HK) Holding Limited (“Peg Biotechnology”)	April 18, 2023	Hong Kong	100% owned by VVAX Skyline	Investment holding
Hainan Senhan Biotechnology Co., Ltd. (“Hainan Senhan”)	May 22, 2023	PRC	100% owned by Peg Biotechnology	Investment holding
Jilin Zhengye Biological Products Co., Ltd. (“Jilin Zhengye”)	May 18, 2004	PRC	58.689% owned by Hainan Senhan and 25.1524% owned by Windsor Holdings	Research, development, manufacture and sales of veterinary vaccines

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for information pursuant to the rules and regulations of the U.S. Securities and Exchange Commission.

Principles of consolidation

The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.

Reclassification

RMB666 and RMB533 of selling expenses for the years ended December 31, 2021 and 2022, respectively, had been reclassified into cost of revenue due to the expenses directly related to the revenue. These reclassifications had no impact on the Company’s income tax expense, net income, or financial position.

Use of estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, related disclosures of contingent assets and liabilities at the balance sheet date, and the reported revenue and expenses during the reported period in the consolidated financial statements and accompanying notes. Significant accounting estimates reflected in the Company’s consolidated financial statements mainly include, but are not limited to, allowance for credit losses, standalone selling price of each distinct performance obligation in revenue recognition, depreciable lives of property, equipment and software, assessment for impairment of long-lived assets, inventory valuation for excess and obsolete inventories, lower of cost and net realizable value of inventories and valuation of deferred tax assets.

Management bases the estimates on historical experience and on various other assumptions as discussed elsewhere to the consolidated financial statements that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. On an ongoing basis, management evaluates its estimates based on information that is currently available. Changes in circumstances, facts and experience may cause the Company to revise its estimates. Changes in estimates are recorded in the period in which they become known. Actual results could materially differ from these estimates.

Foreign currency

The Company’s reporting currency is the Renminbi (“RMB”). The functional currency of the Company and its subsidiaries which are incorporated in British Virgin Island (“BVI”) and Hong Kong (“HK”) are United States dollars (“US\$”). The functional currencies of the other subsidiaries are their respective local currencies. The determination of the respective functional currency is based on the criteria set out by ASC 830, *Foreign Currency Matters*, (“ASC 830”).

Transactions denominated in currencies other than in the functional currency are translated into the functional currency using the exchange rates prevailing at the transaction dates. Monetary assets and liabilities denominated in foreign currencies are translated into functional currency using the applicable exchange rates at the balance sheet date. Non-monetary items that are measured in terms of historical cost in foreign currency are remeasured using the exchange rates at the dates of the initial transactions. Exchange gains or losses arising from foreign currency transactions are included in the consolidated statements of comprehensive income.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

The financial statements of the Company's entities of which the functional currency is not RMB are translated from their respective functional currency into RMB. Assets and liabilities denominated in foreign currencies are translated into RMB at the exchange rates at the balance sheet date. Equity accounts other than earnings generated in current period are translated into RMB at the appropriate historical rates. Income and expense items are translated into RMB using the periodic average exchange rates. The resulting foreign currency translation adjustments are recorded in other comprehensive income in the consolidated statements of comprehensive income, and the accumulated foreign currency translation adjustments are presented as a component of accumulated other comprehensive income in the consolidated statements of shareholders' equity if any.

Convenience translation

Translations of balances in the consolidated balance sheets, consolidated statements of income and comprehensive income and consolidated statements of cash flows from RMB into US\$ as of and for the year ended December 31, 2022 are solely for the convenience of the reader and were calculated at the rate of US\$1.00 to RMB6.8972, representing the noon buying rate in The City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New York on December 31, 2022. No representation is made that the RMB amounts represent or could have been, or could be, converted, realized or settled into US\$ at that rate on December 31, 2022, or at any other rate.

Cash

Cash consists of cash on hand and cash in bank, which are highly liquid and have original maturities of three months or less and are unrestricted as to withdrawal or use. The Company maintains cash with various financial institutions primarily in mainland China. The Company has not experienced any losses in bank accounts.

Notes receivable, net

Notes receivable, generally due within twelve months and with specific payment terms and definitive due dates, are comprised of the bank acceptance notes issued by some customers to pay certain outstanding receivable balances to the Company. Bank acceptance notes do not bear interest.

Accounts receivable and allowance for credit losses

Accounts receivable are stated at the historical carrying amount net of allowance for expected credit losses.

The Company adopted ASU No. 2016-13, "Financial Instruments — Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments" on January 1, 2021 using a modified retrospective approach. The Company also adopted this guidance to notes receivable, advance to suppliers, other receivables and long-term prepayments. To estimate expected credit losses, the Company has identified the relevant risk characteristics of its customers and the related receivables. The Company considers the past collection experience, current economic conditions, future economic conditions (external data and macroeconomic factors) and changes in the Company's customer collection trends. The allowance for credit losses and corresponding receivables were written off when they are determined to be uncollectible.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)**Inventories, net**

Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the normal course of business less any costs to complete and sell products. Cost of inventory are determined using the weighted average method. The Company records inventory reserves for obsolete and slow-moving inventory. Inventory reserves are based on inventory obsolescence trends, historical experience and application of the specific identification method.

Advance to suppliers

Advance to suppliers are mainly funds deposited for future raw material or finished goods purchases. The Company's certain vendors require deposits as a guarantee that the Company will complete its purchases on a timely basis as well as securing the current agreed upon purchase price. Advance to suppliers is short-term in nature. Advance to suppliers is reviewed periodically to determine whether its carrying value has become impaired. The Company uses credit loss method to estimate the allowance for the questionable balances.

Property, plant and equipment, net

Property, plant and equipment are stated at cost less accumulated depreciation and impairment loss, if any. Property and equipment are depreciated at rates sufficient to write off their costs less impairment and residual value, if any, over their estimated useful lives on a straight-line basis.

Category	Estimated useful life
Buildings	13 – 30 years
Mechanical equipment	1 – 10 years
Motor vehicles	10 years

Intangible assets

Intangible assets are carried at cost less accumulated amortization and impairment, if any. Intangible assets are amortized using the straight-line method over the estimated useful lives from 3 to 10 years. The estimated useful lives of amortized intangible assets are reassessed if circumstances occur that indicate the original estimated useful lives have changed.

Category	Estimated useful life
Purchased software	3 – 5 years
Patent	5 – 10 years

Land use right

The land use rights represent the amounts paid and relevant costs incurred for the rights to use land in the PRC, which are carried at cost less accumulated amortization. Amortization of the prepayments is provided on a straight-line basis over the terms of the respective land use rights certificates.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Long-term prepayments

Long-term prepayments represent the payments prepaid for purchase of intangible assets.

Long-term prepayments are reviewed periodically to determine whether its carrying value has become impaired. The Company uses credit loss method to estimate the allowance for the questionable balances.

Impairment of long-lived assets other than goodwill

Long-lived assets are evaluated for impairment whenever events or changes in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying amount may not be fully recoverable or that the useful life is shorter than the Company had originally estimated. When these events occur, the Company evaluates the impairment by comparing carrying value of the assets to an estimate of future undiscounted cash flows expected to be generated from the use of the assets and their eventual disposition. If the sum of the expected future undiscounted cash flows is less than the carrying value of the assets, the Company recognizes an impairment loss based on the excess of the carrying value of the assets over the fair value of the assets. Impairment charge recognized for the years ended December 31, 2021 and 2022 was nil.

Fair value of financial instruments

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be either recorded or disclosed at fair value, the Company considers the principal or most advantageous market in which it would transact, and it also considers assumptions that market participants would use when pricing the asset or liability.

Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

- | |
|--|
| Level 1 — Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. |
| Level 2 — Other inputs that are directly or indirectly observable in the marketplace. |
| Level 3 — Unobservable inputs which are supported by little or no market activity. |

Financial assets and liabilities of the Company primarily consist of cash, notes receivables, accounts receivable, accounts receivable-related party, advance to suppliers, other receivables, accounts payables, accrued expenses and other liabilities and contract liabilities. As of December 31, 2021 and 2022, the carrying values of these financial assets and liabilities approximate their fair values due to the short-term nature.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Revenue recognition

The Company adopted Accounting Standards Codification (“ASC”) 606, *Revenue from Contracts with Customer*. To determine revenue recognition for contracts with customers, the Company performs the following five steps:

- Step 1: Identify the contract with the customer
- Step 2: Identify the performance obligations in the contract
- Step 3: Determine the transaction price
- Step 4: Allocate the transaction price to the performance obligations in the contract
- Step 5: Recognize revenue when the company satisfies a performance obligation

The Company manufactures and sells veterinary vaccines, with an emphasis on vaccines for livestock, to customers.

The Company enters into contract with their customers to provide veterinary vaccines, mainly vaccines for livestock. All of the Company’s contracts have single performance obligation as the promise is to transfer the goods to customers, and there are no other separately identifiable promises in the contracts. The Company recognizes revenue when it transfers its goods to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its products to its customers on a gross basis, because the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude in establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods. The Company’s revenue is recognized at a point in time when the control has been transferred, usually when the customer accepts the goods.

The Company offers their distributors with sales rebate. According to the items in the contract, the Company pays certain sales rebate, in the form of products with equivalent value, to distributor once the distributor purchases stipulated amount products from the Company. Sales rebate is considered as variable consideration. The Company estimates annual expected revenue of each individual distributor with reference to their historical results. The sales rebate reduces revenues recognized. At the end of each reporting period, the Company updates the estimated revenue to represent faithfully the circumstances present at the end of the reporting period.

Apart from the sales rebate, the Company’s products are sold with no right of return and the Company does not provide other credits or sales incentives to customers. Revenue is reported net of value added tax (“VAT”), business tax and surcharges collected on behalf of tax authorities in respect of product sales.

Disaggregation of Revenue

The Company disaggregates its revenue from contracts by product category and distribution channel. See Note 15 for information regarding revenue disaggregation.

Contract assets and liabilities

The Company did not have contract assets as of December 31, 2021 and 2022, respectively.

The Company’s contract liabilities primarily relate to unsatisfied performance obligations, such as sales rebate and payment which has been received from customers before the Company’s products are delivered. Costs of fulfilling customers’ purchase orders, such as shipping, handling and delivery, which occur prior to the transfer of control, are recognized in cost of revenue when incurred. Contract liabilities amounted to RMB4,284 and RMB4,601 (US\$667) as of December 31, 2021 and 2022, respectively. Revenue included in the beginning balance of contract liabilities and recognized in the years ended December 31, 2021 and 2022 amounted to RMB2,739 and RMB4,284 (US\$621), respectively.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Cost of revenues

Costs of revenues consist primarily of materials costs, labor costs, shipping and handling expense, inspection costs, depreciation and amortization expenses and related costs, which are directly attributable to production. Write-down of inventories is also recorded in cost of sales, if any.

Shipping and handling costs incurred to transport goods to customers are expensed in the periods incurred and are included in cost of revenues. The Company accounts for shipping and handling expenses as fulfillment costs because shipping and handling activities occur before the customers obtains control of the goods. Shipping and handling expenses amounted to RMB3,185 and RMB3,389 (US\$491) for the years ended December 31, 2021 and 2022, respectively.

Sales and marketing expenses

Sales and marketing expenses consist primarily of travelling expenses, marketing conference expenses, advertising expenses and salaries and other compensation-related expenses to sales and marketing personnel. The Company expenses all advertising costs as incurred. Advertising costs amounted to RMB2,226 and RMB2,578 (US\$374) for the years ended December 31, 2021 and 2022, respectively.

Research and development expenses

Research and development costs are expensed as incurred. These costs primarily consist of production and procurement expense related to research and development activities, technical expenses, payroll and related expenses for personnel engaged in research and development activities, depreciation and amortization of fixed assets which are used in research and development activities.

General and administrative expenses

General and administrative expenses consist primarily of salaries, bonuses and benefits for employees involved in general corporate functions and those not specifically dedicated to research and development activities, depreciation and amortization of fixed assets which are not used in research and development activities, legal and other professional services fees, rental and other general corporate related expenses.

Government subsidy

Government subsidy represent cash subsidies received from the PRC government. Cash subsidies that have no defined rules and regulations to govern the criteria necessary for companies to enjoy the benefits are recognized when received. Such subsidies are generally provided as incentives from the local government to encourage the expansion of local business.

Value-added taxes

Revenue is recognized net of VAT. VAT is based on gross sales price and the VAT rate applicable to the Company is 3% for the years ended December 31, 2021 and 2022. Entities that are VAT general taxpayers are allowed to offset qualified input VAT paid to suppliers against their output VAT liabilities. Net VAT balance between input VAT and output VAT is recorded as VAT payable if output VAT is larger than input VAT and is recorded as VAT recoverable if input VAT is larger than output VAT. All of the VAT returns filed by the Company's subsidiaries in China, have been and remain subject to examination by the tax authorities.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Income taxes

Current income taxes are recorded in accordance with the regulations of the relevant tax jurisdiction. The Company accounts for income taxes under the asset and liability method in accordance with ASC 740, *Income Tax*, (“ASC 740”). Under this method, deferred tax assets and liabilities are recognized for the tax consequences attributable to differences between carrying amounts of existing assets and liabilities in the financial statements and their respective tax basis, and operating loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred taxes of a change in tax rates is recognized in the consolidated statements of comprehensive income in the period of change. Valuation allowances are established when necessary to reduce the amount of deferred tax assets if it is considered more likely than not that amount of the deferred tax assets will not be realized.

An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. No penalties and interest incurred related to underpayment of income tax are classified as income tax expenses in the period incurred.

Related party transactions

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operational decisions. Parties are also considered to be related if they are subject to common control or common significant influence. Related parties may be individuals or corporate entities. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’s-length transactions unless such representations can be substantiated. It is not, however, practical to determine the fair value of amounts due from/to related parties due to their related party nature.

Noncontrolling interests

A noncontrolling interest is recognized to reflect the portion of a subsidiary’s equity which is not attributable, directly or indirectly, to the Company. Among them, 15.2439% of the noncontrolling interests of Jilin Zhengye is held by Jilin Economic and Technological Development Zone Economic and Technological Development General Corporation, 0.9146% of the noncontrolling interests of Jilin Zhengye is held by Jilin Jinqiao Investment Co. Ltd., and 0.0001% of the noncontrolling interests of Jilin Zhengye is held by Yufeng Liu. Consolidated net income on the consolidated statements of comprehensive income includes the net income attributable to noncontrolling interests when applicable. The cumulative results of operations attributable to noncontrolling interests are also recorded as noncontrolling interests in the Company’s consolidated balance sheets.

Earnings per share

The Company computes earnings per share (“EPS”) in accordance with ASC 260, “Earnings per Share”. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is measured as net income (loss) attributable to Zhengye Biotechnology Holding Limited, divided by the weighted average ordinary share outstanding for the period. Diluted EPS presents the dilutive effect on a per-share basis of the potential ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Comprehensive income

The Company applies ASC 220, *Comprehensive Income* (“ASC 220”), with respect to reporting and presentation of comprehensive income and its components in a full set of financial statements. Comprehensive income is defined to include all changes in equity of the Company during a period arising from transactions and other event and circumstances except those resulting from investments by shareholders and distributions to shareholders. For the years ended December 31, 2021 and 2022, the Company’s comprehensive income includes net income only.

Statutory reserves

Pursuant to the laws applicable to the PRC, PRC entities must make appropriations from after-tax profit to the non-distributable “statutory surplus reserve fund”. Subject to certain cumulative limits, the “statutory surplus reserve fund” requires annual appropriations of 10% of after-tax profit until the aggregated appropriations reach 50% of the registered capital (as determined under accounting principles generally accepted in the PRC (“PRC GAAP”) at each year-end). For foreign-invested enterprises and joint ventures in the PRC, annual appropriations should be made to the “reserve fund”. For foreign-invested enterprises, the annual appropriation for the “reserve fund” cannot be less than 10% of after-tax profits until the aggregated appropriations reach 50% of the registered capital (as determined under PRC GAAP at each year-end). If the Company has accumulated loss from prior periods, the Company is able to use the current period net income after tax to offset the accumulated loss.

Commitments and Contingencies

In the normal course of business, the Company is subject to contingencies, including legal proceedings and claims arising out of the business that relate to a wide range of matters, such as government investigations and tax matters. The Company recognizes a liability for such contingency if it determines it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may consider many factors in making these assessments including historical performance and the specific facts and circumstances of each matter.

Leases

The Company adopts Accounting Standards Update (“ASU”) 2016-02, Lease (FASB ASC Topic 842) to account its lease. ASC 842 requires that lessees recognize right-of-use (“ROU”) assets and lease liabilities calculated based on the present value of lease payments for all lease agreements with terms that are greater than twelve months. ASC 842 distinguishes leases as either a finance lease or an operating lease on the consolidated balance sheets that affects how the leases are measured and presented in the statement of operations and statement of cash flows.

Right-of-use (“ROU”) assets represent the Company’s right to use underlying assets for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. At inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period of time in exchange of a consideration. To assess whether a contract is or contains a lease, the Company assess whether the contract involves the use of an identified asset, whether it has the right to obtain substantially all the economic benefits from the use of the asset and whether it has the right to control the use of the asset.

The right-of-use of asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and less any lease incentive received. The right-of-use assets and related lease liabilities are recognized at the lease commencement date. The Company recognizes operating lease expenses on a straight-line basis over the lease term.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Lease liability is initially measured at the present value of the outstanding lease payments at the commencement date, discounted using the Company's incremental borrowing rate. Lease payments included in the measurement of the lease liability comprise fixed lease payments, variable lease payments that depend on an index or a rate, amounts expected to be payable under a residual value guarantee and any exercise price under a purchase option that the Company is reasonably certain to exercise.

Lease liability is measured at amortized cost using the effective interest rate method. It is remeasured when there is a change in future lease payments, if there is a change in the estimate of the amount expected to be payable under a residual value guarantee, or if there is any change in the Company assessment of option purchases, contract extensions or termination options.

Segment reporting

ASC 280, *Segment Reporting*, ("ASC 280"), establishes standards for companies to report in their financial statements information about operating segments, products, services, geographic areas, and major customers.

Based on the criteria established by ASC 280, our chief operating decision maker ("CODM") has been identified as our Chief Executive Officer, who reviews consolidated results when making decisions about allocating resources and assessing performance of the company. As a whole and hence, we have only one reportable segment. We do not distinguish between markets or segments for the purpose of internal reporting. As our long-lived assets are substantially located in the PRC, no geographical segments are presented.

Uncertainty and risks

Political, social and economic risks

The Company has substantial operations in China through its PRC subsidiaries. Accordingly, the Company's business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company's results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results.

The Company's business, financial condition and results of operations may also be negatively impacted by risks related to regional wars, geopolitical tensions, natural disasters, extreme weather conditions, health epidemics and other catastrophic incidents, which could potentially and significantly disrupt the Company's operations.

Impact of COVID-19

The Company's operations may be further affected by the resurgence of COVID-19 pandemic. A resurgence could potentially cause temporary closure of the Company's factory, limited support from its employees due to quarantine, reduce the Company's capability to execute customer contract and collect customer payments, or disrupt the Company's supply chain, and the continued uncertainties associated with the COVID-19 pandemic may further negatively impact the Company's future revenue growth and cash flows.

Interest rate risk

The Company is exposed to interest rate risk on its interest-bearing assets and liabilities. As part of its asset and liability risk management, the Company reviews and takes appropriate steps to manage its interest rate exposure on its interest-bearing assets and liabilities. The Company has not been exposed to material risks due to changes in market interest rates and has not used any derivative financial instruments to manage the interest risk exposure during the period/year presented.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Concentration risks

Concentration of credit risk

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash in bank and accounts receivable. The Company places its cash with financial institutions with high credit ratings and quality.

The Company conducts credit evaluations of customers, and generally does not require collateral or other security from its customers. The Company establishes an allowance for expected credit losses primarily based upon the factors surrounding the credit risk of specific customers.

Concentration of customers and suppliers

As of December 31, 2021, one major client accounted for 66.6% of the Company's total accounts receivable. As of December 31, 2022, one major client accounted for 75.0% of the Company's total accounts receivable. The client is a listed company and a leading pig farming company in China. The Company's outstanding account receivable from this client as of December 31, 2021 has been collected in full. No credit loss expense incurred historically for this client.

For the year ended December 31, 2021, one major client accounted for 55.6% of the Company's total revenues. For the year ended December 31, 2022, one major client accounted for 74.5% of the Company's total revenues.

As of December 31, 2021, one major vendor accounted for 12.0% of the Company's total account payable. As of December 31, 2022, one major vendor accounted for 10.9% of the Company's total account payable.

For the year ended December 31, 2021, three vendors accounted for 20.5%, 13.0% and 10.1% of the Company's total purchases, respectively. For the year ended December 31, 2022, two vendors accounted for 25.3% and 12.9% of the Company's total purchases, respectively.

Recent accounting pronouncements

The Company is an emerging growth company ("EGC") as defined by the Jumpstart Our Business Startups Act ("JOBS Act"). The JOBS Act provides that an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those standards would otherwise apply to private companies.

In June 2016, the FASB issued ASU 2016-13, Credit Losses, Measurement of Credit Losses on Financial Instruments. This ASU provides more useful information about expected credit losses to financial statement users and changes how entities will measure credit losses on financial instruments and timing of when such losses should be recognized. This ASU is effective for annual and interim periods beginning after December 15, 2019 for issuers and December 15, 2020 for non-issuers. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. In May 2019, the FASB issued ASU 2019-05, Financial Instruments — Credit Losses (Topic 326): Targeted Transition Relief. This update adds optional transition relief for entities to elect the fair value option for certain financial assets previously measured at amortized cost basis to increase comparability of similar financial assets. The updates should be applied through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified retrospective approach). On November 19, 2019, the FASB issued ASU 2019-10 to amend the effective date for ASU 2016-13 to be fiscal years beginning after December 15, 2022 and interim periods therein. The Company early adopted this guidance on January 1, 2021, and the adoption did not have a material impact on its consolidated financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes ("ASU 2019-12"), which simplifies the accounting for income taxes by removing exceptions and simplifies the accounting for income taxes regarding franchise tax, goodwill, separate financial statements, enacted change in tax laws or rates and employee stock

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

ownership plans. For public business entities, ASU 2019-12 will be effective for annual and interim periods beginning after December 15, 2020. For all other entities, ASU 2019-12 will be effective for annual reporting periods beginning after December 15, 2021 and interim periods beginning after December 15, 2022. Early adoption of the amendments is permitted.

Other accounting standards that have been issued by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on, or are unrelated to, its consolidated financial condition, results of operations, cash flows or disclosures.

3. ACCOUNTS RECEIVABLE, NET

Accounts receivable and the allowance for credit losses consisted of the following:

	As of December 31,		
	2021	2022	
	RMB	RMB	US\$
Accounts receivable	103,355	124,276	18,018
Less: allowance for credit losses	(20,168)	(21,377)	(3,099)
Accounts receivable, net	<u>83,187</u>	<u>102,899</u>	<u>14,919</u>

An analysis of the allowance for credit losses was as follows:

	As of December 31,		
	2021	2022	
	RMB	RMB	US\$
Balance at beginning of the year	(18,227)	(20,168)	(2,924)
Additional provision charged to expense	(1,941)	(1,209)	(175)
Balance at the end of the year	<u>(20,168)</u>	<u>(21,377)</u>	<u>(3,099)</u>

4. NOTES RECEIVABLE, NET

Notes receivable and the allowance for credit losses consisted of the following:

	As of December 31,		
	2021	2022	
	RMB	RMB	US\$
Notes receivable	18,843	35,718	5,179
Less: allowance for credit losses	(565)	(5,039)	(731)
Notes receivable, net	<u>18,278</u>	<u>30,679</u>	<u>4,448</u>

	As of December 31,		
	2021	2022	
	RMB	RMB	US\$
Balance at beginning of the year	(649)	(565)	(82)
Additional reverse (provision) charged to expense	84	(4,474)	(649)
Balance at the end of the year	<u>(565)</u>	<u>(5,039)</u>	<u>(731)</u>

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

5. INVENTORIES, NET

Inventories consisted of the following:

	As of December 31,		
	2021	2022	
	RMB	RMB	US\$
Finished goods	10,405	13,984	2,027
Work in process	27,019	33,894	4,914
Raw materials	9,035	10,906	1,582
	46,459	58,784	8,523
Less: inventory write-down	(2,837)	(3,360)	(487)
	43,622	55,424	8,036

During the years ended December 31, 2021 and 2022, the Company recorded inventory write-down of RMB1,438 and RMB523 (US\$76) for the obsolete inventories in cost of revenue, respectively.

6. PROPERTY, PLANT AND EQUIPMENT, NET

Property, plant and equipment consisted of the following:

	As of December 31,		
	2021	2022	
	RMB	RMB	US\$
At cost:			
Buildings	166,898	119,789	17,368
Mechanical equipment	114,683	143,420	20,794
Motor vehicles	3,320	3,320	481
	284,901	266,529	38,643
Less: Accumulated depreciation	(91,313)	(73,422)	(10,645)
	193,588	193,107	27,998
Construction-in-progress	52,755	82,064	11,898
	246,343	275,171	39,896

For the year ended December 31, 2021, the Company sold fixed assets with a net carrying value of RMB75, and recorded gain on sale of fixed assets of RMB53. For the year ended December 31, 2022, the Company had no fixed assets disposed.

Depreciation expense was RMB12,220 and RMB15,655 (US\$2,270) for the years ended December 31, 2021 and 2022, respectively.

The carrying amounts of property and equipment pledged by the Company to secure loans (Note 9) granted to the Company at the respective balance sheet dates were as follows:

	As of December 31,		
	2021	2022	
	RMB	RMB	US\$
Buildings	41,542	72,531	10,516
Mechanical equipment	—	66,396	9,626
Construction-in-progress	4,926	2,774	402

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

7. LAND USE RIGHTS, NET

The following table presents the Company's land use rights as of the respective balance sheet dates:

	As of December 31,		
	2021	2022	
	RMB	RMB	US\$
Cost	12,860	12,860	1,865
Accumulated amortization	(4,158)	(4,415)	(641)
Land use rights, net	8,702	8,445	1,224

As of December 31, 2021 and 2022, the carrying amount of land use right were fully pledged to secure loans (Note 9).

Amortization expense was RMB257 and RMB257 (US\$37) for the year ended December 31, 2021 and 2022, respectively.

8. INTANGIBLE ASSETS, NET

The following table presents the Company's intangible assets as of the respective balance sheet dates:

	As of December 31,		
	2021	2022	
	RMB	RMB	US\$
Purchased software	231	473	69
Patents	53,395	63,450	9,199
	53,626	63,923	9,268
Less: Accumulated amortization	(41,577)	(44,465)	(6,447)
	12,049	19,458	2,821

Amortization expense was RMB3,535 and RMB2,888 (US\$419) for the year ended December 31, 2021 and 2022, respectively.

During the years ended December 31, 2021 and 2022, the Company recorded impairment of intangible assets in the amount of RMB83 and RMB445 (US\$65), respectively.

The annual estimated amortization expenses for the intangible assets for each of the next five years are as follows:

	RMB	US\$
2023	3,396	492
2024	3,219	467
2025	2,628	381
2026	2,221	322
2027	1,824	264
Thereafter	6,170	895
	19,458	2,821

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

9. LOANS

Outstanding balances of loans consist of the following:

As of December 31, 2022	Balance		Maturity Date	Effective Interest Rate	Collateral/Guarantee
	RMB	US\$			
Short-term loan					
Industrial Bank Jilin Branch	21,900	3,175	April 1, 2023	4.50%	Collateral: mechanical equipment
Industrial Bank Jilin Branch	5,000	725	October 9, 2023	4.50%	Collateral: land use right and construction-in-progress
Industrial Bank Jilin Branch	23,000	3,335	December 13, 2023	4.50%	Collateral: land use right and construction-in-progress
China Minsheng Bank Jilin Branch	4,990	723	December 23, 2023	3.85%	Guarantee: Jilin Zhengye Group Co., Ltd.
Total	54,890	7,958			
Long-term loan					
Industrial Bank Jilin Branch	9,990	1,448	April 10, 2025	4.90%	Collateral: buildings, land use right and construction-in-progress
Total	9,990	1,448			

As of December 31, 2021	Balance	Maturity Date	Effective Interest Rate	Collateral/Guarantee
Industrial Bank Jilin Branch	22,000	April 6, 2022	4.50%	Collateral: buildings, land use right and construction-in-progress
Industrial Bank Jilin Branch	8,000	December 16, 2022	4.50%	Collateral: buildings, land use right and construction-in-progress
Total loans	30,000			

Interest expense for the year ended December 31, 2021 and 2022 amounted to RMB1,046 and RMB2,839 (US\$412), respectively.

As of December 31, 2022, the Company's future long-term loan obligations according to the terms of the loan agreement are as follows:

	RMB	US\$
2023	—	—
2024	—	—
2025	9,990	1,448
2026	—	—
2027	—	—
Thereafter	—	—
	9,990	1,448

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

10. ACCRUED EXPENSES AND OTHER LIABILITIES

Accrued expenses and other liabilities consisted of the following:

	As of December 31,		
	2021	2022	
	RMB	RMB	US\$
Reimbursement payables	1,474	1,895	275
Deferred income	—	100	14
Social welfare payables	320	306	44
Deposit	310	10	1
Maintenance fee payables	284	267	39
Others	869	886	129
	<u>3,257</u>	<u>3,464</u>	<u>502</u>

11. TAXATION

Enterprise income tax (“EIT”)

Cayman Islands

The Company is incorporated in the Cayman Islands and conducts its primary business operations through the subsidiaries in the PRC. Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gain arising in Cayman Islands.

British Virgin Islands (“BVI”)

The Company’s subsidiaries incorporated in the BVI are not subject to tax on income or capital gain, in addition, payments of dividend by these subsidiaries to their shareholders are not subject to withholding tax in the BVI.

Hong Kong

The Company’s subsidiary in Hong Kong is subject to Hong Kong profits tax rate of 16.5%. Additionally, upon payments of dividends by the Company to its shareholders, no HK withholding tax will be imposed.

PRC

The Company’s PRC subsidiaries are governed by the income tax laws of the PRC and the income tax provision in respect to operations in the PRC is calculated at the applicable tax rates on the taxable income for the periods based on existing legislation, interpretations and practices in respect thereof. Under the Enterprise Income Tax Laws of the PRC (the “EIT Laws”), domestic enterprises and Foreign Investment Enterprises (the “FIE”) are usually subject to a unified 25% enterprise income tax rate while preferential tax rates, tax holidays and even tax exemption may be granted on case-by-case basis. EIT grants preferential tax treatment to certain High and New Technology Enterprises (“HNTEs”). Under this preferential tax treatment, HNTEs are entitled to an income tax rate of 15%, subject to a requirement that they re-apply for the HNTE status every three years. Jilin Zhengye obtained the HNTE tax status in 2019 and renewed it in 2022, which reduced its statutory income tax rate to 15% for the years ended December 31, 2021 and 2022.

Income tax expenses comprised of:

	For the years ended December 31,		
	2021	2022	
	RMB	RMB	US\$
Current	7,116	9,483	1,375
Deferred	(517)	(1,311)	(190)
	<u>6,599</u>	<u>8,172</u>	<u>1,185</u>

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

11. TAXATION (cont.)

The reconciliation of tax computed by applying the statutory income tax rate of 25% for the years ended December 31, 2021 and 2022 applicable to the PRC operations to income tax expense were as follows:

	For the years ended December 31,	
	2021	2022
Statutory income tax rate	25.0%	25.0%
Effect of income tax exemptions and reliefs	(11.4)%	(9.9)%
Effect of non-deductible expense	4.0%	2.2%
Additional deduction for development and research expense	(5.2)%	(4.5)%
Income tax expense	12.4%	12.8%

The component of deferred tax assets are as follows:

	As of December 31,		
	2021	2022	
	RMB	RMB	US\$
Deferred tax assets			
Impairment of long-lived assets	7,073	7,218	1,046
Allowance for credit losses	3,131	3,986	578
Others	940	1,251	182
Valuation allowance	—	—	—
Total deferred tax assets	11,144	12,455	1,806

Realization of the net deferred tax assets is dependent on factors including future reversals of existing taxable temporary differences and adequate future taxable income. The Company and its subsidiaries evaluate the potential realization of deferred tax assets on an entity-by-entity basis.

12. SHAREHOLDER'S EQUITY

The Company was incorporated in the Cayman Islands in March 2023 under the Cayman Islands Companies Act as an exempted company with limited liability. The Company authorized 500,000,000 shares with US\$0.0001 par value. In 2023, the Company issued 11,416,594 shares with US\$0.0001 par value to five institute shareholders. The issuance of ordinary shares is considered as a part of the Reorganization of the Company, which was retroactively applied as if the transaction occurred at the beginning of the period presented.

Dividends

For the years ended December 31, 2021 and 2022, the Company declared cash dividends of RMB14,760 and RMB17,712 (US\$2,568), respectively. For the years ended December 31, 2021 and 2022, the Company actually paid dividends in cash of RMB11,048 and RMB 21,425 (US\$3,106), respectively.

13. RESTRICTED NET ASSETS

As a result of the PRC laws and regulations and the requirement that distributions by PRC entities can only be paid out of distributable profits computed in accordance with PRC GAAP, the PRC entities are restricted from transferring a portion of their net assets to the Company. Amounts restricted include paid-in capital, additional paid-in capital, and the statutory reserves of the Company's PRC subsidiaries.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

13. RESTRICTED NET ASSETS (cont.)

	As of December 31,		
	2021	2022	
	RMB	RMB	US\$
Paid-in capital	8	8	1
Additional paid-in-capital	203,150	203,150	29,454
Statutory reserve	21,991	27,565	3,997
	225,149	230,723	33,452

14. LEASES

The Company entered into operating lease agreements for employee dormitories. None of the amounts disclosed below for these leases contains variable payments, residual value guarantees or options that were recognized as part of the right-of-use assets and lease liabilities. As the Company's leases did not provide an implicit discount rate, the Company used an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.

As of December 31, 2022, the Company recognized operating lease liabilities, including current and noncurrent, in the amount of nil and the corresponding operating lease right-of-use assets of RMB58 (US\$8).

Rent expense for the year ended December 31, 2021 and 2022 was RMB159 and RMB217 (US\$32) respectively.

As of December 31, 2022, the Company's operating lease liabilities is nil and the Company didn't have any lease commitment.

Supplemental disclosure related to operating leases were as follows:

	For the year ended December 31, 2021	For the year ended December 31, 2022
Cash paid for amounts included in the measurement of lease liabilities		
Operating cash flows for operating leases	230	204
Weighted average remaining lease term of operating leases	0.48 years	0.39 years
Weighted average discount rate of operating leases	4.50%	4.50%

15. SEGMENT INFORMATION

The following table summarizes the revenues generated from different product category for the years ended December 31, 2021 and 2022:

	For the years ended December 31,		
	2021	2022	
	RMB	RMB	US\$
Swine vaccines	183,203	235,610	34,160
Poultry vaccines	19,027	16,370	2,373
Other vaccines	11,837	8,289	1,202
	214,067	260,269	37,735

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

15. SEGMENT INFORMATION (cont.)

The following table summarizes the revenues generated from different distribution channels for the years ended December 31, 2021 and 2022:

	For the years ended December 31,		
	2021	2022	
	RMB	RMB	US\$
Direct sales channel	151,256	207,324	30,059
Distribution network	53,886	47,845	6,937
Government tender and procurement	8,925	5,100	739
	<u>214,067</u>	<u>260,269</u>	<u>37,735</u>

16. RELATED PARTY TRANSCATIONS

For the years ended December 31, 2021 and 2022, the operating entity purchased inventory from Jilin Huazheng Agriculture and Animal Husbandry Development Co., Ltd. (“Jilin Huazheng”), which is controlled by Mr. Zhenfa Han, the principal shareholder, director, and chairman of the board of the Company, in the amount of RMB65 and RMB91 (US\$13), respectively.

For the years ended December 31, 2021 and 2022, the operating entity had no revenue generated from Jilin Huazheng. As of December 31, 2021 and 2022, the Company had account receivable from this related party in the amount of RMB 233 and RMB nil (US\$ nil), respectively.

17. SUBSEQUENT EVENTS

The Company has assessed all events from December 31, 2022 up through August 4, 2023, which is the date that these consolidated financial statements are available to be issued, unless as disclosed below, there are not any material subsequent events that require disclosure in these consolidated financial statements.

On January 4, 2023, the Company entered into a loan agreement with China Minsheng Bank Jilin Branch, pursuant to which the Company obtained a loan in the amount of RMB4,990 (US\$723) for one year at the interest rate of 3.85%.

On January 31, 2023, the Company entered into a loan agreement with Industrial Bank Jilin Branch, pursuant to which the Company obtained a loan in the amount of RMB9,990 (US\$1,448) for one year at the interest rate of 4.35%.

On March 28, 2023, the Company entered into a loan agreement with Industrial Bank Jilin Branch, pursuant to which the Company obtained a loan in the amount of RMB9,990 (US\$1,448) for one year at the interest rate of 4.35%.

On March 31, 2023, the Company renewed its loan agreement with Industrial Bank Jilin Branch, pursuant to which the Company obtained a loan in the amount of RMB21,900 (US\$3,175) for one year at the interest rate of 4.35% to repay the original loan in the same amount which matured on April 1, 2023.

On April 28, 2023, the shareholders of the operating entity passed the resolution of the dividend plan for 2022, with the dividend amount of RMB55,104 (US\$7,989).

On July 5, 2023, the Company entered into a notes cooperation agreement and notes pledge agreement with Industrial Bank Jilin Branch, pursuant to which the Company pledged notes receivable in the amount of RMB 25,600 (US\$3,712) as collaterals for line of credit in the amount of RMB 30,900 (US\$4,480) for the period from July 6, 2023 to July 5, 2024. In addition, based on the agreement, the pledged notes receivable were also the collaterals for the loans in the amount of RMB23,000 (US\$3,335) and RMB21,900 (US\$3,175) obtained on December 14, 2022 and March 31, 2023, respectively, which means no available line of credit can be used to obtain new loan.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

18. CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY

Regulation S-X requires the condensed financial information of registrant shall be filed when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year. For purposes of the above test, restricted net assets of consolidated subsidiaries shall mean that amount of the registrant's proportionate share of net assets of consolidated subsidiaries (after intercompany eliminations) of which as of the end of the most recent fiscal year may not be transferred to the parent company by subsidiaries in the form of loans, advances or cash dividends without the consent of a third party. The condensed parent company financial statements have been prepared in accordance with Rule 12-04, Schedule I of Regulation S-X as the restricted net assets of the Company's PRC subsidiaries exceed 25% of the consolidated net assets of the Company.

Certain information and footnote disclosures normally included in financial statements prepared in conformity with U.S. GAAP have been condensed or omitted. The Company's investment in subsidiary is stated at cost plus equity in undistributed earnings of subsidiaries.

Share of income of subsidiaries on the Condensed Balance Sheets is comprised of the Parent Company's net investment in its subsidiaries under the equity method of accounting.

Condensed Balance Sheets

	As of December 31,		
	2021	2022	
	RMB	RMB	US\$
ASSETS			
Non-current assets:			
Investment in subsidiaries	267,474	296,497	42,988
Total non-current assets	267,474	296,497	42,988
Total assets	<u>267,474</u>	<u>296,497</u>	<u>42,988</u>
LIABILITIES AND SHAREHOLDERS' EQUITY			
Total liabilities	<u>—</u>	<u>—</u>	<u>—</u>
Commitments and contingencies			
Shareholders' equity:			
Ordinary shares (US\$0.0001 par value; 500,000,000 shares authorized; 11,416,594 shares issued and outstanding as of December 31, 2021 and 2022)	8	8	1
Additional paid-in capital	203,150	203,150	29,454
Statutory reserve	21,991	27,565	3,997
Retained earnings	42,325	65,774	9,536
Total shareholders' equity	<u>267,474</u>	<u>296,497</u>	<u>42,988</u>
Total liabilities and shareholders' earnings	<u>267,474</u>	<u>296,497</u>	<u>42,988</u>

Condensed Statements of Comprehensive Income

	Year ended December 31,		
	2021	2022	
	RMB	RMB	US\$
Operating costs and expenses:			
Selling, general and administrative	—	—	—
Operating income			
Share of income of subsidiaries	38,959	46,735	6,776
Net income	<u>38,959</u>	<u>46,735</u>	<u>6,776</u>

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands of RMB and US\$, except for number of shares)

	As of		
	December 31, 2022	June 30, 2023 (unaudited)	
	RMB	RMB	US\$
ASSETS			
Current assets:			
Cash	9,746	23,534	3,245
Notes receivable, net	30,679	30,900	4,261
Accounts receivable, net	102,899	91,994	12,687
Advance to suppliers	2,433	2,599	358
Inventories, net	55,424	53,977	7,444
Other receivable, net	672	1,107	153
Deferred tax assets	12,455	12,806	1,766
Total current assets	214,308	216,917	29,914
Non-current assets:			
Property, plant and equipment, net	275,171	266,445	36,744
Land use rights, net	8,445	8,316	1,147
Intangible assets, net	19,458	17,806	2,456
Operating lease right-of-use assets, net	58	137	19
Long-term prepayments	2,234	4,209	580
Total non-current assets	305,366	296,913	40,946
Total assets	519,674	513,830	70,860
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current liabilities:			
Short-term loans	54,890	79,860	11,013
Accounts payable	79,276	48,954	6,750
Contract liabilities	4,601	4,311	595
Tax payables	9,996	3,154	435
Dividend payables	—	37,104	5,117
Accrued expenses and other liabilities	3,464	4,034	556
Total current liabilities	152,227	177,417	24,466
Non-current liabilities:			
Long-term loans	9,990	9,990	1,378
Other payables- non-current	590	590	81
Total non-current liabilities	10,580	10,580	1,459
Total liabilities	162,807	187,997	25,925
Shareholders' equity:			
Ordinary shares (US\$0.0001 par value; 500,000,000 shares authorized; 11,416,594 shares issued and outstanding as of December 31, 2022 and June 30, 2023)	8	8	1
Additional paid-in capital	203,150	203,150	28,016
Statutory reserves	27,565	27,565	3,801
Retained earnings	65,774	30,851	4,255
Total Zhengye Biotechnology Holding Limited's shareholders' equity	296,497	261,574	36,073
Noncontrolling interests	60,370	64,259	8,862
Total shareholders' equity	356,867	325,833	44,935
Total liabilities and shareholders' equity	519,674	513,830	70,860

The accompanying notes are an integral part of these unaudited consolidated financial statements.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND
COMPREHENSIVE INCOME
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

	For the six months ended June 30,		
	2022	2023	
	RMB	RMB	US\$
Net revenues	123,351	116,852	16,115
Cost of revenues	(46,507)	(44,401)	(6,123)
Gross profit	76,844	72,451	9,992
Sales and marketing expenses	(15,941)	(16,581)	(2,287)
General and administrative expenses	(12,428)	(17,055)	(2,351)
Research and development expenses	(8,967)	(6,154)	(849)
Allowance for credit losses	(6,112)	1,408	194
Impairment for inventory and intangible asset	(850)	(4,747)	(655)
Total operating expenses	(44,298)	(43,129)	(5,948)
Operating income	32,546	29,322	4,044
Other income (expenses):			
Other income	—	—	—
Other expenses	(100)	—	—
Interest income	25	105	14
Interest expense	(1,359)	(2,152)	(297)
Government subsidy	237	50	7
Total other income (expense), net	(1,197)	(1,997)	(276)
Income before income taxes	31,349	27,325	3,768
Income tax expense	(3,798)	(3,255)	(449)
Net income and total comprehensive income	27,551	24,070	3,319
Net income and comprehensive income attributable to noncontrolling interests	(4,452)	(3,889)	(536)
Net income and comprehensive income attributable to the Zhengye Biotechnology Holding Limited's shareholders	<u>23,099</u>	<u>20,181</u>	<u>2,783</u>
Earnings per share:			
Ordinary shares – basic and diluted	2.41	2.11	0.29
Weighted average shares outstanding used in calculating basic and diluted earnings per share:			
Ordinary shares – basic and diluted	11,416,594	11,416,594	11,416,594

The accompanying notes are an integral part of these unaudited consolidated financial statements.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN
SHAREHOLDERS' EQUITY
(Amounts in thousands of RMB and US\$, except for number of shares)

	Ordinary shares		Additional paid-in capital	Statutory reserve	Retained earnings	Total Zhengye Biotechnology Holding Limited's shareholders' equity	Non-controlling interests	Total shareholder's Equity
	Shares	Amount						
	Balance, December 31, 2021 (RMB)	11,416,594						
Net income	—	—	—	—	23,099	23,099	4,452	27,551
Transfer to statutory reserve	—	—	—	15	(15)	—	—	—
Dividend	—	—	—	—	(17,712)	(17,712)	—	(17,712)
Balance, June 30, 2022 (RMB)	11,416,594	8	203,150	22,006	47,697	272,861	55,815	328,676
Balance, December 31, 2022 (RMB)	11,416,594	8	203,150	27,565	65,774	296,497	60,370	356,867
Net income	—	—	—	—	20,181	20,181	3,889	24,070
Dividend	—	—	—	—	(55,104)	(55,104)	—	(55,104)
Balance, June 30, 2023 (RMB)	11,416,594	8	203,150	27,565	30,851	261,574	64,259	325,833
Balance, June 30, 2023 (US\$)	11,416,594	1	28,016	3,801	4,255	36,073	8,862	44,935

The accompanying notes are an integral part of these unaudited consolidated financial statements.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands of RMB and US\$, except for number of shares)

	For the six months ended June 30,		
	2022		2023
	RMB	RMB	US\$
CASH FLOWS FROM OPERATING ACTIVITIES			
Net income	27,551	24,070	3,319
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	8,506	11,864	1,636
Allowance for credit losses	6,112	(1,408)	(194)
Impairment for inventory and intangible assets	850	4,747	655
Deferred tax benefits	(147)	(352)	(48)
Noncash lease expense	113	107	15
Changes in operating assets and liabilities:			
Note receivables, net	668	179	25
Accounts receivable, net	(42,023)	11,964	1,650
Account receivable-related party	233	—	—
Inventories, net	(12,498)	(3,299)	(455)
Other receivables, net	3,866	(2,551)	(352)
Advances to suppliers	166	(166)	(23)
Lease liabilities	(162)	(185)	(26)
Accounts payable	11,720	(30,465)	(4,202)
Tax payables	2,247	(6,842)	(944)
Accrued expense and other liabilities	1,092	570	79
Contract liabilities	82	(290)	(40)
Other payables- non-current	(20)	(1)	—
Net cash provided by operating activities	<u>8,356</u>	<u>7,942</u>	<u>1,095</u>
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment	(19,714)	(1,124)	(155)
Prepayment for purchase of intangible assets	(742)	—	—
Net cash used in investing activities	<u>(20,456)</u>	<u>(1,124)</u>	<u>(155)</u>
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from loans	66,862	46,870	6,463
Repayment of loans	(22,000)	(21,900)	(3,020)
Dividend payment to shareholders	(13,257)	(18,000)	(2,482)
Net cash provided by financing activities	<u>31,605</u>	<u>6,970</u>	<u>961</u>
Net increase in cash	19,505	13,788	1,901
Cash at beginning of year	6,284	9,746	1,344
Cash at end of year	<u>25,789</u>	<u>23,534</u>	<u>3,245</u>
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:			
Cash paid for:			
Interest	1,231	2,152	297
Income taxes	2,819	7,339	1,012
NON-CASH INVESTING AND FINANCING ACTIVITIES:			
Right of use assets obtained in exchange for operating lease obligation	162	185	26
Liabilities assumed in connection with purchase of property, plant and equipment	6,636	145	20

The accompanying notes are an integral part of these unaudited consolidated financial statements.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

1. ORGANIZATION**Nature of operations**

The Company was incorporated in the Cayman Islands in March 2023 under the Cayman Islands Companies Act as an exempted company with limited liability. The Company through its consolidated subsidiaries principally focused on the research, development, manufacture and sales of veterinary vaccines, with an emphasis on vaccines for livestock in the PRC.

Reorganization

In preparation of its IPO in the United States, the following transactions were undertaken to reorganize the legal structure of Operating Entities. The Company was incorporated in connection with a reorganization of Jilin Zhengye. On April 3, 2023, the Company incorporated a wholly-owned subsidiary, VVAX Skyline, in British Virgin Island. On April 18, 2023, Zhengye BVI incorporated a wholly-owned subsidiary, Peg Biotechnology in Hong Kong. On May 22, 2023, Zhengye HK incorporated a wholly-owned subsidiary, Hainan Senhan in the PRC. On May 30, 2023, VVAX Skyline acquired 100% of the equity interests in Windsor Holdings from its original shareholders. Windsor Holdings was incorporated in British Virgin Island.

Prior to the Reorganization described below, Jilin Zhengye was controlled by several individual, corporation and institution shareholders. The Reorganization of the Company's legal structure was completed on June 21, 2023. The reorganization involved the transfer of 58.689% and 25.1524% interest of Jilin Zhengye from its former shareholders to Hainan Senhan and Windsor Holdings, respectively. As the result of this Reorganization, Jilin Zhengye became a subsidiary of the Company.

Upon the completion of the above Reorganization, the Company became the ultimate holding company of all other entities mentioned above. The Company is effectively controlled by the same group of controlling shareholders before and after the Reorganization; therefore, the Reorganization is considered as a recapitalization of these entities under common control. The consolidation of the Company and its subsidiaries was accounted for at historical cost and prepared on the basis as if the aforementioned transactions had become effective as of the beginning of the first period presented in the accompanying consolidated financial statements. Results of operations for the period presented comprise those of the previous separate entries combined from the beginning of the period to the end of the period, eliminating the effects of intra-entity transactions.

As of the date of this report, the details of the Company's principal subsidiaries are as follows:

Entity	Date of incorporation/ acquisition	Place of incorporation	Percentage of direct or indirect ownership by the Company	Principal activities
<u>Subsidiaries:</u>				
VVAX Skyline	April 3, 2023	British Virgin Island	100% owned by the Company	Investment holding
Windsor Holdings	May 30, 2023	British Virgin Island	100% owned by VVAX Skyline	Investment holding
Peg Biotechnology	April 18, 2023	Hong Kong	100% owned by VVAX Skyline	Investment holding
Hainan Senhan	May 22, 2023	PRC	100% owned by Peg Biotechnology	Investment holding
Jilin Zhengye	May 18, 2004	PRC	58.689% owned by Hainan Senhan and 25.1524% owned by Windsor Holdings	Research, development, manufacture and sales of veterinary vaccines

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. GAAP for information pursuant to the rules and regulations of the U.S. Securities and Exchange Commission.

Principles of consolidation

The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.

Use of estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, related disclosures of contingent assets and liabilities at the balance sheet date, and the reported revenue and expenses during the reported period in the consolidated financial statements and accompanying notes. Significant accounting estimates reflected in the Company's consolidated financial statements mainly include, but are not limited to, allowance for credit losses, standalone selling price of each distinct performance obligation in revenue recognition, depreciable lives of property, equipment and software, assessment for impairment of long-lived assets, inventory valuation for excess and obsolete inventories, lower of cost and net realizable value of inventories and valuation of deferred tax assets.

Management bases the estimates on historical experience and on various other assumptions as discussed elsewhere to the consolidated financial statements that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. On an ongoing basis, management evaluates its estimates based on information that is currently available. Changes in circumstances, facts and experience may cause the Company to revise its estimates. Changes in estimates are recorded in the period in which they become known. Actual results could materially differ from these estimates.

Unaudited interim condensed consolidated financial statements

The accompanying condensed consolidated balance sheet as of June 30, 2023 and the condensed consolidated statements of income and comprehensive income, the condensed consolidated statements of cash flows and the condensed consolidated statements of change in shareholders' equity for the six months ended June 30, 2023 and 2022 are unaudited. The financial data and other information disclosed in these notes related to the six months ended June 30, 2022 and 2023 are also unaudited. The condensed consolidated balance sheet data as of December 31, 2022 was derived from audited financial statements as of that date, but does not include all disclosures required by GAAP.

The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company's financial position as of June 30, 2023, and the results of its operations and its cash flows for the six months ended June 30, 2022 and 2023. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2022, and the notes thereto, which are included elsewhere in this registration statement. The results for the six months ended June 30, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023, any other interim periods, or any future year or periods.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Foreign currency

The Company's reporting currency is the RMB. The functional currency of the Company and its subsidiaries which are incorporated in BVI and HK are US\$. The functional currencies of the other subsidiaries are their respective local currencies. The determination of the respective functional currency is based on the criteria set out by ASC 830, *Foreign Currency Matters*, ("ASC 830").

Transactions denominated in currencies other than in the functional currency are translated into the functional currency using the exchange rates prevailing at the transaction dates. Monetary assets and liabilities denominated in foreign currencies are translated into functional currency using the applicable exchange rates at the balance sheet date. Non-monetary items that are measured in terms of historical cost in foreign currency are remeasured using the exchange rates at the dates of the initial transactions. Exchange gains or losses arising from foreign currency transactions are included in the consolidated statements of comprehensive income.

The financial statements of the Company's entities of which the functional currency is not RMB are translated from their respective functional currency into RMB. Assets and liabilities denominated in foreign currencies are translated into RMB at the exchange rates at the balance sheet date. Equity accounts other than earnings generated in current period are translated into RMB at the appropriate historical rates. Income and expense items are translated into RMB using the periodic average exchange rates. The resulting foreign currency translation adjustments are recorded in other comprehensive income in the consolidated statements of comprehensive income, and the accumulated foreign currency translation adjustments are presented as a component of accumulated other comprehensive income in the consolidated statements of shareholders' equity if any.

Convenience translation

Translations of balances in the consolidated balance sheets, consolidated statements of comprehensive income and consolidated statements of cash flows from RMB into US\$ as of and for the year ended June 30, 2023 are solely for the convenience of the reader and were calculated at the rate of US\$1.00 to RMB7.2513, representing the noon buying rate in The City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New York on June 30, 2023. No representation is made that the RMB amounts represent or could have been, or could be, converted, realized or settled into US\$ at that rate on June 30, 2023, or at any other rate.

Cash

Cash consists of cash on hand and cash in bank, which are highly liquid and have original maturities of three months or less and are unrestricted as to withdrawal or use. The Company maintains cash with various financial institutions primarily in mainland China. The Company has not experienced any losses in bank accounts.

Notes receivable, net

Notes receivable, generally due within twelve months and with specific payment terms and definitive due dates, are comprised of the bank acceptance notes issued by some customers to pay certain outstanding receivable balances to the Company. Bank acceptance notes do not bear interest.

Accounts receivable and allowance for credit losses

Accounts receivable are stated at the historical carrying amount net of allowance for expected credit losses.

The Company adopted ASU No. 2016-13, "Financial Instruments — Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments" on January 1, 2021 using a modified retrospective approach. The Company also adopted this guidance to notes receivable, advance to suppliers, other receivables and long-term prepayments. To estimate expected credit losses, the Company has identified the relevant risk characteristics of its customers and the related receivables. The Company considers the past collection experience, current economic conditions, future

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

economic conditions (external data and macroeconomic factors) and changes in the Company's customer collection trends. The allowance for credit losses and corresponding receivables were written off when they are determined to be uncollectible.

Inventories, net

Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the normal course of business less any costs to complete and sell products. Cost of inventory are determined using the weighted average method. The Company records inventory reserves for obsolete and slow-moving inventory. Inventory reserves are based on inventory obsolescence trends, historical experience and application of the specific identification method.

Advance to suppliers

Advance to suppliers are mainly funds deposited for future raw material or finished goods purchases. The Company's certain vendors require deposits as a guarantee that the Company will complete its purchases on a timely basis as well as securing the current agreed upon purchase price. Advance to suppliers is short-term in nature. Advance to suppliers is reviewed periodically to determine whether its carrying value has become impaired. The Company uses credit loss method to estimate the allowance for the questionable balances.

Property, plant and equipment, net

Property, plant and equipment are stated at cost less accumulated depreciation and impairment loss, if any. Property and equipment are depreciated at rates sufficient to write off their costs less impairment and residual value, if any, over their estimated useful lives on a straight-line basis.

Category	Estimated useful life
Buildings	13 – 30 years
Mechanical equipment	1 – 10 years
Motor vehicles	10 years

Intangible assets

Intangible assets are carried at cost less accumulated amortization and impairment, if any. Intangible assets are amortized using the straight-line method over the estimated useful lives from 3 to 10 years. The estimated useful lives of amortized intangible assets are reassessed if circumstances occur that indicate the original estimated useful lives have changed.

Category	Estimated useful life
Purchased software	3 – 5 years
Patent	5 – 10 years

Land use right

The land use rights represent the amounts paid and relevant costs incurred for the rights to use land in the PRC, which are carried at cost less accumulated amortization. Amortization of the prepayments is provided on a straight-line basis over the terms of the respective land use rights certificates.

Long-term prepayments

Long-term prepayments represent the payments prepaid for purchase of intangible assets.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Long-term prepayments are reviewed periodically to determine whether its carrying value has become impaired. The Company uses credit loss method to estimate the allowance for the questionable balances.

Impairment of long-lived assets other than goodwill

Long-lived assets are evaluated for impairment whenever events or changes in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying amount may not be fully recoverable or that the useful life is shorter than the Company had originally estimated. When these events occur, the Company evaluates the impairment by comparing carrying value of the assets to an estimate of future undiscounted cash flows expected to be generated from the use of the assets and their eventual disposition. If the sum of the expected future undiscounted cash flows is less than the carrying value of the assets, the Company recognizes an impairment loss based on the excess of the carrying value of the assets over the fair value of the assets. Impairment charge recognized for the six months ended June 30, 2022 and 2023 was nil.

Fair value of financial instruments

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be either recorded or disclosed at fair value, the Company considers the principal or most advantageous market in which it would transact, and it also considers assumptions that market participants would use when pricing the asset or liability.

Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

- | |
|--|
| Level 1 — Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. |
| Level 2 — Other inputs that are directly or indirectly observable in the marketplace. |
| Level 3 — Unobservable inputs which are supported by little or no market activity. |

Financial assets and liabilities of the Company primarily consist of cash, notes receivables, accounts receivable, accounts receivable-related party, advance to suppliers, other receivables, accounts payables, accrued expenses and other liabilities and contract liabilities. As of December 31, 2022 and June 30, 2023, the carrying values of these financial assets and liabilities approximate their fair values due to the short-term nature.

Revenue recognition

The Company adopted Accounting Standards Codification ("ASC") 606, *Revenue from Contracts with Customer*. To determine revenue recognition for contracts with customers, the Company performs the following five steps:

- Step 1: Identify the contract with the customer
- Step 2: Identify the performance obligations in the contract
- Step 3: Determine the transaction price
- Step 4: Allocate the transaction price to the performance obligations in the contract
- Step 5: Recognize revenue when the company satisfies a performance obligation

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

The Company manufactures and sells veterinary vaccines, with an emphasis on vaccines for livestock, to customers.

The Company enters into contract with their customers to provide veterinary vaccines, mainly vaccines for livestock. All of the Company's contracts have single performance obligation as the promise is to transfer the goods to customers, and there are no other separately identifiable promises in the contracts. The Company recognizes revenue when it transfers its goods to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its products to its customers on a gross basis, because the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude in establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods. The Company's revenue is recognized at a point in time when the control has been transferred, usually when the customer accepts the goods.

The Company offers their distributors with sales rebate. According to the items in the contract, the Company pays certain sales rebate, in the form of products with equivalent value, to distributor once the distributor purchases stipulated amount products from the Company. Sales rebate is considered as variable consideration. The Company estimates annual expected revenue of each individual distributor with reference to their historical results. The sales rebate reduces revenues recognized. At the end of each reporting period, the Company updates the estimated revenue to represent faithfully the circumstances present at the end of the reporting period.

Apart from the sales rebate, the Company's products are sold with no right of return and the Company does not provide other credits or sales incentives to customers. Revenue is reported net of VAT, business tax and surcharges collected on behalf of tax authorities in respect of product sales.

Disaggregation of Revenue

The Company disaggregates its revenue from contracts by product category and distribution channel. See Note 15 for information regarding revenue disaggregation.

Contract assets and liabilities

The Company did not have contract assets as of December 31, 2022 and June 30, 2023, respectively.

The Company's contract liabilities primarily relate to unsatisfied performance obligations, such as sales rebate and payment which has been received from customers before the Company's products are delivered. Costs of fulfilling customers' purchase orders, such as shipping, handling and delivery, which occur prior to the transfer of control, are recognized in cost of revenue when incurred. Contract liabilities amounted to RMB4,601 and RMB4,311 (US\$595) as of December 31, 2022 and June 30, 2023, respectively. Revenue included in the beginning balance of contract liabilities and recognized in the six months ended, 2022 and 2023 amounted to RMB1,564 and RMB2,084 (US\$287), respectively.

Cost of revenues

Costs of revenues consist primarily of materials costs, labor costs, shipping and handling expense, inspection costs, depreciation and amortization expenses and related costs, which are directly attributable to production. Write-down of inventories is also recorded in cost of sales, if any.

Shipping and handling costs incurred to transport goods to customers are expensed in the periods incurred and are included in cost of revenues. The Company accounts for shipping and handling expenses as fulfillment costs because shipping and handling activities occur before the customers obtains control of the goods. Shipping and handling expenses amounted to RMB1,416 and RMB2,469 (US\$340) for the six months ended June 30, 2022 and 2023, respectively.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Sales and marketing expenses

Sales and marketing expenses consist primarily of travelling expenses, marketing conference expenses, advertising expenses and salaries and other compensation-related expenses to sales and marketing personnel. The Company expenses all advertising costs as incurred. Advertising costs amounted to RMB545 and RMB1,105 (US\$152) for the six months ended June 30, 2022 and 2023, respectively.

Research and development expenses

Research and development costs are expensed as incurred due to the uncertainty of the outcome or result. These costs primarily consist of production and procurement expense related to research and development activities, technical expenses, payroll and related expenses for personnel engaged in research and development activities, depreciation and amortization of fixed assets which are used in research and development activities and expenses incurred to third parties, such as universities or research and development institutions, for cooperative research and development projects. The third-party research and development costs are expensed when the contracted service has been rendered or as milestone results have been achieved. The cooperative agreements with third parties do not contain any funding commitments items. Each party has the right to give notice in advance to terminate the cooperative agreement without returning received payments or disbursing liquidated damages. Both parties may collectively apply for and jointly own the intellectual property rights derived from the research and development projects, if any.

The Company's research and development projects are conducted solely by the Company or cooperatively with third parties. The associated costs incurred in these projects are solely funded by the Company. For certain research and development projects that meet the criteria for government incentives, the Company is eligible for government grants. The government grants are provided to the Company for the research and development expenses that have incurred. The Company has no obligation to repay any of the grants received regardless of the outcome of the research and development. Therefore, the Company recognized the grants as other income-government subsidy rather than accounting for them in accordance with ASC 730-20.

General and administrative expenses

General and administrative expenses consist primarily of salaries, bonuses and benefits for employees involved in general corporate functions and those not specifically dedicated to research and development activities, depreciation and amortization of fixed assets which are not used in research and development activities, legal and other professional services fees, rental and other general corporate related expenses.

Government subsidy

Government subsidy represent cash subsidies received from the PRC government. Cash subsidies that have no defined rules and regulations to govern the criteria necessary for companies to enjoy the benefits are recognized when received. Such subsidies are generally provided as incentives from the local government to encourage the expansion of local business.

Value-added taxes

Revenue is recognized net of VAT. VAT is based on gross sales price and the VAT rate applicable to the Company is 3% for the years ended December 31, 2022 and June 30, 2023. Entities that are VAT general taxpayers are allowed to offset qualified input VAT paid to suppliers against their output VAT liabilities. Net VAT balance between input VAT and output VAT is recorded as VAT payable if output VAT is larger than input VAT and is recorded as VAT recoverable if input VAT is larger than output VAT. All of the VAT returns filed by the Company's subsidiaries in China, have been and remain subject to examination by the tax authorities.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Income taxes

Current income taxes are recorded in accordance with the regulations of the relevant tax jurisdiction. The Company accounts for income taxes under the asset and liability method in accordance with ASC 740. Under this method, deferred tax assets and liabilities are recognized for the tax consequences attributable to differences between carrying amounts of existing assets and liabilities in the financial statements and their respective tax basis, and operating loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred taxes of a change in tax rates is recognized in the consolidated statements of comprehensive income in the period of change. Valuation allowances are established when necessary to reduce the amount of deferred tax assets if it is considered more likely than not that amount of the deferred tax assets will not be realized.

An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. No penalties and interest incurred related to underpayment of income tax are classified as income tax expenses in the period incurred.

Related party transactions

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operational decisions. Parties are also considered to be related if they are subject to common control or common significant influence. Related parties may be individuals or corporate entities. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’s-length transactions unless such representations can be substantiated. It is not, however, practical to determine the fair value of amounts due from/to related parties due to their related party nature.

Noncontrolling interests

A noncontrolling interest is recognized to reflect the portion of a subsidiary’s equity which is not attributable, directly or indirectly, to the Company. Among them, 15.2439% of the noncontrolling interests of Jilin Zhengye is held by Jilin Economic and Technological Development Zone Economic and Technological Development General Corporation, 0.9146% of the noncontrolling interests of Jilin Zhengye is held by Jilin Jinqiao Investment Co. Ltd., and 0.0001% of the noncontrolling interests of Jilin Zhengye is held by Yufeng Liu. Consolidated net income on the consolidated statements of comprehensive income includes the net income attributable to noncontrolling interests when applicable. The cumulative results of operations attributable to noncontrolling interests are also recorded as noncontrolling interests in the Company’s consolidated balance sheets.

Earnings per share

The Company computes EPS in accordance with ASC 260, “Earnings per Share”. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is measured as net income (loss) attributable to Zhengye Biotechnology Holding Limited, divided by the weighted average ordinary share outstanding for the period. Diluted EPS presents the dilutive effect on a per-share basis of the potential ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Comprehensive income

The Company applies ASC 220, with respect to reporting and presentation of comprehensive income and its components in a full set of financial statements. Comprehensive income is defined to include all changes in equity of the Company during a period arising from transactions and other event and circumstances except those resulting from investments by shareholders and distributions to shareholders. For the six months ended June 30, 2022 and 2023, the Company's comprehensive income includes net income only.

Statutory reserves

Pursuant to the laws applicable to the PRC, PRC entities must make appropriations from after-tax profit to the non-distributable "statutory surplus reserve fund". Subject to certain cumulative limits, the "statutory surplus reserve fund" requires annual appropriations of 10% of after-tax profit until the aggregated appropriations reach 50% of the registered capital (as determined under PRC GAAP at each year-end). For foreign-invested enterprises and joint ventures in the PRC, annual appropriations should be made to the "reserve fund". For foreign-invested enterprises, the annual appropriation for the "reserve fund" cannot be less than 10% of after-tax profits until the aggregated appropriations reach 50% of the registered capital (as determined under PRC GAAP at each year-end). If the Company has accumulated loss from prior periods, the Company is able to use the current period net income after tax to offset the accumulated loss.

Commitments and Contingencies

In the normal course of business, the Company is subject to contingencies, including legal proceedings and claims arising out of the business that relate to a wide range of matters, such as government investigations and tax matters. The Company recognizes a liability for such contingency if it determines it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may consider many factors in making these assessments including historical performance and the specific facts and circumstances of each matter.

Leases

The Company adopts ASU 2016-02, Lease (FASB ASC Topic 842) to account its lease. ASC 842 requires that lessees recognize ROU assets and lease liabilities calculated based on the present value of lease payments for all lease agreements with terms that are greater than twelve months. ASC 842 distinguishes leases as either a finance lease or an operating lease on the consolidated balance sheets that affects how the leases are measured and presented in the statement of operations and statement of cash flows.

ROU assets represent the Company's right to use underlying assets for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. At inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period of time in exchange of a consideration. To assess whether a contract is or contains a lease, the Company assess whether the contract involves the use of an identified asset, whether it has the right to obtain substantially all the economic benefits from the use of the asset and whether it has the right to control the use of the asset.

The ROU of asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and less any lease incentive received. The ROU assets and related lease liabilities are recognized at the lease commencement date. The Company recognizes operating lease expenses on a straight-line basis over the lease term.

Lease liability is initially measured at the present value of the outstanding lease payments at the commencement date, discounted using the Company's incremental borrowing rate. Lease payments included in the measurement of the lease liability comprise fixed lease payments, variable lease payments that depend on an index or a rate, amounts expected to be payable under a residual value guarantee and any exercise price under a purchase option that the Company is reasonably certain to exercise.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Lease liability is measured at amortized cost using the effective interest rate method. It is remeasured when there is a change in future lease payments, if there is a change in the estimate of the amount expected to be payable under a residual value guarantee, or if there is any change in the Company assessment of option purchases, contract extensions or termination options.

Segment reporting

ASC 280 establishes standards for companies to report in their financial statements information about operating segments, products, services, geographic areas, and major customers.

Based on the criteria established by ASC 280, our CODM has been identified as our Chief Executive Officer, who reviews consolidated results when making decisions about allocating resources and assessing performance of the company. As a whole and hence, we have only one reportable segment. We do not distinguish between markets or segments for the purpose of internal reporting. As our long-lived assets are substantially located in the PRC, no geographical segments are presented.

Uncertainty and risks

Political, social and economic risks

The Company has substantial operations in China through its PRC subsidiaries. Accordingly, the Company's business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company's results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results.

The Company's business, financial condition and results of operations may also be negatively impacted by risks related to regional wars, geopolitical tensions, natural disasters, extreme weather conditions, health epidemics and other catastrophic incidents, which could potentially and significantly disrupt the Company's operations.

Impact of COVID-19

The Company's operations may be further affected by the resurgence of COVID-19 pandemic. A resurgence could potentially cause temporary closure of the Company's factory, limited support from its employees due to quarantine, reduce the Company's capability to execute customer contract and collect customer payments, or disrupt the Company's supply chain, and the continued uncertainties associated with the COVID-19 pandemic may further negatively impact the Company's future revenue growth and cash flows.

Interest rate risk

The Company is exposed to interest rate risk on its interestbearing assets and liabilities. As part of its asset and liability risk management, the Company reviews and takes appropriate steps to manage its interest rate exposure on its interest-bearing assets and liabilities. The Company has not been exposed to material risks due to changes in market interest rates and has not used any derivative financial instruments to manage the interest risk exposure during the period/year presented.

Concentration risks

Concentration of credit risk

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash in bank and accounts receivable. The Company places its cash with financial institutions with high credit ratings and quality.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

The Company conducts credit evaluations of customers, and generally does not require collateral or other security from its customers. The Company establishes an allowance for expected credit losses primarily based upon the factors surrounding the credit risk of specific customers.

Concentration of customers and suppliers

As of December 31, 2022, one major client accounted for 75.0% of the Company's total accounts receivable. As of June 30, 2023, two major clients accounted for 57.8% and 18.1% of the Company's total accounts receivable, respectively.

For the six months ended June 30, 2022, one major client accounted for 75.9% of the Company's total revenues. For the six months ended June 30, 2023, two major clients accounted for 54.6% and 16.9% of the Company's total revenues.

As of December 31, 2022, one major vendor accounted for 10.9% of the Company's total account payable. As of June 30, 2023, no vendor accounted over 10% of the Company's total account payable.

For the six months ended June 30, 2022, two vendors accounted for 30.8% and 26.9% of the Company's total purchases, respectively. For the six months ended June 30, 2023, one vendor accounted for 10.2% of the Company's total purchases.

Recent accounting pronouncements

The Company is an EGC as defined by the JOBS Act. The JOBS Act provides that an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those standards would otherwise apply to private companies.

In June 2016, the FASB issued ASU 2016-13, Credit Losses, Measurement of Credit Losses on Financial Instruments. This ASU provides more useful information about expected credit losses to financial statement users and changes how entities will measure credit losses on financial instruments and timing of when such losses should be recognized. This ASU is effective for annual and interim periods beginning after December 15, 2019 for issuers and December 15, 2020 for non-issuers. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. In May 2019, the FASB issued ASU 2019-05, Financial Instruments — Credit Losses (Topic 326): Targeted Transition Relief. This update adds optional transition relief for entities to elect the fair value option for certain financial assets previously measured at amortized cost basis to increase comparability of similar financial assets. The updates should be applied through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified retrospective approach). On November 19, 2019, the FASB issued ASU 2019-10 to amend the effective date for ASU 2016-13 to be fiscal years beginning after December 15, 2022 and interim periods therein. The Company early adopted this guidance on January 1, 2021, and the adoption did not have a material impact on its consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, which simplifies the accounting for income taxes by removing exceptions and simplifies the accounting for income taxes regarding franchise tax, goodwill, separate financial statements, enacted change in tax laws or rates and employee stock ownership plans. For public business entities, ASU 2019-12 will be effective for annual and interim periods beginning after December 15, 2020. For all other entities, ASU 2019-12 will be effective for annual reporting periods beginning after December 15, 2021 and interim periods beginning after December 15, 2022. Early adoption of the amendments is permitted.

Other accounting standards that have been issued by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on, or are unrelated to, its consolidated financial condition, results of operations, cash flows or disclosures.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

3. ACCOUNTS RECEIVABLE, NET

Accounts receivable and the allowance for credit losses consisted of the following:

	As of		
	December 31, 2022	June 30, 2023	
	RMB	RMB	US\$
Accounts receivable	124,276	112,311	15,489
Less: allowance for credit losses	(21,377)	(20,317)	(2,802)
Accounts receivable, net	<u>102,899</u>	<u>91,994</u>	<u>12,687</u>

An analysis of the allowance for credit losses was as follows:

	As of		
	December 31, 2022	June 30, 2023	
	RMB	RMB	US\$
Balance at beginning of the period	(20,168)	(21,377)	(2,948)
Additional reverse (provision) charged to expense	(1,209)	1,060	146
Balance at the end of the period	<u>(21,377)</u>	<u>(20,317)</u>	<u>(2,802)</u>

4. NOTES RECEIVABLE, NET

Notes receivable and the allowance for credit losses consisted of the following:

	As of		
	December 31, 2022	June 30, 2023	
	RMB	RMB	US\$
Notes receivable	35,718	35,539	4,901
Less: allowance for credit losses	(5,039)	(4,639)	(640)
Notes receivable, net	<u>30,679</u>	<u>30,900</u>	<u>4,261</u>

	As of		
	December 31, 2022	June 30, 2023	
	RMB	RMB	US\$
Balance at beginning of the period	(565)	(5,039)	(695)
Additional reverse (provision) charged to expense	(4,474)	400	55
Balance at the end of the period	<u>(5,039)</u>	<u>(4,639)</u>	<u>(640)</u>

5. INVENTORIES, NET

Inventories consisted of the following:

	As of		
	December 31, 2022	June 30, 2023	
	RMB	RMB	US\$
Finished goods	13,984	14,610	2,015
Work in process	33,894	37,216	5,132
Raw materials	10,906	10,258	1,415
	58,784	62,084	8,562
Less: inventory write-down	(3,360)	(8,107)	(1,118)
	<u>55,424</u>	<u>53,977</u>	<u>7,444</u>

During the six months ended June 30, 2022 and 2023, the Company recorded inventory write-down of RMB767 and inventory write-down of RMB4,747(US\$655) for the obsolete inventories in cost of revenue, respectively.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

6. PROPERTY, PLANT AND EQUIPMENT, NET

Property, plant and equipment consisted of the following:

	As of		
	December 31, 2022	June 30, 2023	
	RMB	RMB	US\$
At cost:			
Buildings	119,789	197,896	27,291
Mechanical equipment	143,420	147,246	20,306
Motor vehicles	3,320	4,082	563
	<u>266,529</u>	<u>349,224</u>	<u>48,160</u>
Less: Accumulated depreciation	(73,422)	(83,417)	(11,504)
	<u>193,107</u>	<u>265,807</u>	<u>36,656</u>
Construction-in-progress	82,064	638	88
	<u>275,171</u>	<u>266,445</u>	<u>36,744</u>

For the six months ended June 30, 2022 and 2023, the Company had no fixed assets disposed.

Depreciation expense was RMB6,932 and RMB9,994 (US\$1,378) for the six months ended June 30, 2022 and 2023, respectively.

The carrying amounts of property and equipment pledged by the Company to secure loans (Note 9) granted to the Company at the respective balance sheet dates were as follows:

	As of		
	December 31, 2022	June 30, 2023	
	RMB	RMB	US\$
Buildings	72,531	79,310	10,937
Mechanical equipment	66,396	63,165	8,711
Construction-in-progress	2,774	638	88

7. LAND USE RIGHTS, NET

The following table presents the Company's land use rights as of the respective balance sheet dates:

	As of		
	December 31, 2022	June 30, 2023	
	RMB	RMB	US\$
Cost	12,860	12,860	1,774
Accumulated amortization	(4,415)	(4,544)	(627)
Land use rights, net	<u>8,445</u>	<u>8,316</u>	<u>1,147</u>

As of December 31, 2022 and June 30, 2023, the carrying amount of land use right were fully pledged to secure loans (Note 9).

Amortization expense was RMB129 and RMB129 (US\$18) for the six months ended June 30, 2022 and 2023, respectively.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

8. INTANGIBLE ASSETS, NET

The following table presents the Company's intangible assets as of the respective balance sheet dates:

	As of		
	December 31, 2022	June 30, 2023	
	RMB	RMB	US\$
Purchased software	473	562	78
Patents obtained from Harbin Veterinary Research Institute	26,439	26,439	3,646
Patents obtained from China Agricultural University	3,300	3,300	455
Patents obtained from China Institute of Veterinary Drug Control	5,800	5,800	800
Patents obtained from Jiangsu Nannong High-Tech Co., Ltd.	7,200	7,200	993
Patents obtained from Nanjing Agricultural University	7,600	7,600	1,048
Patents obtained from others	13,111	13,111	1,808
Total cost	63,923	64,012	8,828
Less: Accumulated amortization of purchased software	(288)	(326)	(45)
Accumulated amortization of patents obtained from Harbin Veterinary Research Institute	(24,788)	(25,024)	(3,451)
Accumulated amortization of patents obtained from China Agricultural University	(1,018)	(1,183)	(163)
Accumulated amortization of patents obtained from China Institute of Veterinary Drug Control	(2,575)	(2,835)	(391)
Accumulated amortization of patents obtained from Jiangsu Nannong High-Tech Co., Ltd.	(1,020)	(1,390)	(192)
Accumulated amortization of patents obtained from Nanjing Agricultural University	(2,827)	(3,237)	(446)
Accumulated amortization of patents obtained from others	(11,949)	(12,211)	(1,684)
Total accumulated amortization	(44,465)	(46,206)	(6,372)
Intangible assets, net	19,458	17,806	2,456

Amortization expense was RMB1,446 and RMB1,741 (US\$240) for the six months ended June 30, 2022 and 2023, respectively.

During the six months ended June 30, 2022 and 2023, the Company recorded impairment of intangible assets in the amount of RMB83 and nil, respectively.

The annual estimated amortization expenses for the intangible assets for each of the next five years are as follows:

	RMB	US\$
Remainder of 2023	1,670	230
2024	3,237	446
2025	2,645	365
2026	2,238	309
2027	1,842	254
For the six months ended June 30, 2028	878	121
Thereafter	5,296	731
	17,806	2,456

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

9. LOANS

Outstanding balances of loans consist of the following:

As of June 30, 2023	Balance		Maturity Date	Effective Interest Rate	Collateral/Guarantee
	RMB	US\$			
Short-term loan					
Industrial Bank Jilin Branch	5,000	690	October 9, 2023	4.50%	Collateral: land use right and construction-in-progress
Industrial Bank Jilin Branch	23,000	3,171	December 13, 2023	4.50%	Collateral: land use right and construction-in-progress
Industrial Bank Jilin Branch	9,990	1,378	January 30, 2024	4.35%	N/A
Industrial Bank Jilin Branch	9,990	1,378	March 26, 2024	4.35%	Collateral: land use right and construction-in-progress
Industrial Bank Jilin Branch	21,900	3,020	March 30, 2024	4.35%	Collateral: Mechanical equipment
China Minsheng Bank Jilin Branch	4,990	688	December 23, 2023	3.85%	Guarantee: Jilin Zhengye Group Co., Ltd.
China Minsheng Bank Jilin Branch	4,990	688	January 4, 2024	3.85%	Guarantee: Jilin Zhengye Group Co., Ltd.
Total	79,860	11,013			
Long-term loan					
Industrial Bank Jilin Branch	9,990	1,378	April 10, 2025	4.90%	Collateral: buildings, land use right and construction-in-progress
Total	9,990	1,378			

As of December 31, 2022	Balance		Maturity Date	Effective Interest Rate	Collateral/Guarantee
	RMB	US\$			
Short-term loan					
Industrial Bank Jilin Branch	21,900	3,175	April 1, 2023	4.50%	Collateral: mechanical equipment
Industrial Bank Jilin Branch	5,000	725	October 9, 2023	4.50%	Collateral: land use right and construction-in-progress
Industrial Bank Jilin Branch	23,000	3,335	December 13, 2023	4.50%	Collateral: land use right and construction-in-progress
China Minsheng Bank Jilin Branch	4,990	723	December 23, 2023	3.85%	Guarantee: Jilin Zhengye Group Co., Ltd.
Total	54,890	7,958			
Long-term loan					
Industrial Bank Jilin Branch	9,990	1,448	April 10, 2025	4.90%	Collateral: buildings, land use right and construction-in-progress
Total	9,990	1,448			

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

9. LOANS (cont.)

Interest expense for the six months ended June 30, 2022 and 2023 amounted to RMB1,369 and RMB2,152 (US\$297), respectively.

As of June 30, 2023, the Company's future long-term loan obligations according to the terms of the loan agreement are as follows:

	RMB	US\$
Remainder of 2023	—	—
2024	—	—
2025	9,990	1,378
2026	—	—
2027	—	—
2028	—	—
Thereafter	—	—
	<u>9,990</u>	<u>1,378</u>

10. ACCRUED EXPENSES AND OTHER LIABILITIES

Accrued expenses and other liabilities consisted of the following:

	As of		
	December 31, 2022	June 30, 2023	
	RMB	RMB	US\$
Reimbursement payables	1,895	1,193	165
Deferred income	100	325	45
Social welfare payables	306	308	42
Deposit	10	10	1
Maintenance fee payables	267	267	37
Others	886	1,931	266
	<u>3,464</u>	<u>4,034</u>	<u>556</u>

11. TAXATION***EIT******Cayman Islands***

The Company is incorporated in the Cayman Islands and conducts its primary business operations through the subsidiaries in the PRC. Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gain arising in Cayman Islands.

BVI

The Company's subsidiaries incorporated in the BVI are not subject to tax on income or capital gain, in addition, payments of dividend by these subsidiaries to their shareholders are not subject to withholding tax in the BVI.

Hong Kong

The Company's subsidiary in Hong Kong is subject to Hong Kong profits tax rate of 16.5%. Additionally, upon payments of dividends by the Company to its shareholders, no HK withholding tax will be imposed.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

11. TAXATION (cont.)

PRC

The Company's PRC subsidiaries are governed by the income tax laws of the PRC and the income tax provision in respect to operations in the PRC is calculated at the applicable tax rates on the taxable income for the periods based on existing legislation, interpretations and practices in respect thereof. Under the EIT Laws, domestic enterprises and the FIE are usually subject to a unified 25% enterprise income tax rate while preferential tax rates, tax holidays and even tax exemption may be granted on case-by-case basis. EIT grants preferential tax treatment to certain HNTEs. Under this preferential tax treatment, HNTEs are entitled to an income tax rate of 15%, subject to a requirement that they re-apply for the HNTE status every three years. Jilin Zhengye obtained the HNTE tax status in 2019 and renewed it in 2022, which reduced its statutory income tax rate to 15% for the six months ended June 30, 2022 and 2023.

Income tax expenses comprised of:

	For the six months ended June 30,		
	2022		2023
	RMB	RMB	US\$
Current	3,945	3,607	498
Deferred	(147)	(352)	(49)
	<u>3,798</u>	<u>3,255</u>	<u>449</u>

The reconciliation of tax computed by applying the statutory income tax rate of 25% for the years ended June 30, 2022 and 2023 applicable to the PRC operations to income tax expense were as follows:

	For the six months ended June 30,	
	2022	2023
Statutory income tax rate	25.0%	25.0%
Effect of income tax exemptions and reliefs	(8.4)%	(8.8)%
Effect of non-deductible expense	1.8%	1.1%
Additional deduction for development and research expense	(6.3)%	(5.4)%
Income tax expense	<u>12.1%</u>	<u>11.9%</u>

The component of deferred tax assets are as follows:

	As of		
	December 31, 2022	June 30, 2023	
	RMB	RMB	US\$
Deferred tax assets			
Impairment of long-lived assets	7,218	7,930	1,094
Allowance for credit losses	3,986	3,775	521
Others	1,251	1,101	151
Valuation allowance	—	—	—
Total deferred tax assets	<u>12,455</u>	<u>12,806</u>	<u>1,766</u>

Realization of the net deferred tax assets is dependent on factors including future reversals of existing taxable temporary differences and adequate future taxable income. The Company and its subsidiaries evaluate the potential realization of deferred tax assets on an entity-by-entity basis.

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

12. SHAREHOLDER'S EQUITY

The Company was incorporated in the Cayman Islands in March 2023 under the Cayman Islands Companies Act as an exempted company with limited liability. The Company authorized 500,000,000 shares with US\$0.0001 par value. In 2023, the Company issued 11,416,594 shares with US\$0.0001 par value to five institute shareholders. The issuance of ordinary shares is considered as a part of the Reorganization of the Company, which was retroactively applied as if the transaction occurred at the beginning of the period presented.

Dividends

For the six months ended June 30, 2022 and 2023, the Company declared cash dividends of RMB17,712 and RMB55,104 (US\$7,599), respectively. For the six months ended June 30, 2022 and 2023, the Company actually paid dividends in cash of RMB13,257 and RMB18,000 (US\$2,482), respectively.

13. RESTRICTED NET ASSETS

As a result of the PRC laws and regulations and the requirement that distributions by PRC entities can only be paid out of distributable profits computed in accordance with PRC GAAP, the PRC entities are restricted from transferring a portion of their net assets to the Company. Amounts restricted include paid-in capital, additional paid-in capital, and the statutory reserves of the Company's PRC subsidiaries.

	As of		
	December 31, 2022	June 30, 2023	
	RMB	RMB	US\$
Paid-in capital	8	8	1
Additional paid-in-capital	203,150	203,150	28,016
Statutory reserve	27,565	27,565	3,801
	<u>230,723</u>	<u>230,723</u>	<u>31,818</u>

14. LEASES

The Company entered into operating lease agreements for employee dormitories. None of the amounts disclosed below for these leases contains variable payments, residual value guarantees or options that were recognized as part of the ROU assets and lease liabilities. As the Company's leases did not provide an implicit discount rate, the Company used an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.

As of June 30, 2023, the Company recognized operating lease liabilities, including current and noncurrent, in the amount of nil and the corresponding operating lease right-of-use assets of RMB137 (US\$19).

Rent expense for the six months ended June 30, 2022 and 2023 was RMB113 and RMB107 (US\$15) respectively.

As of June 30, 2023, the Company's operating lease liabilities is nil and the Company didn't have any lease commitment.

Supplemental disclosure related to operating leases were as follows:

	For the six months ended June 30, 2022	For the six months ended June 30, 2023
Cash paid for amounts included in the measurement of lease liabilities		
Operating cash flows for operating leases	162	185
Weighted average remaining lease term of operating leases	0.73 years	0.75 years
Weighted average discount rate of operating leases	4.50%	4.50%

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

15. SEGMENT INFORMATION

The following table summarizes the revenues generated from different product category for the six months ended June 30, 2022 and 2023:

	For the six months ended June 30,		
	2022		2023
	RMB	RMB	US\$
Swine vaccines	112,172	103,436	14,264
Poultry vaccines	7,341	8,607	1,188
Other vaccines	3,838	4,809	663
	<u>123,351</u>	<u>116,852</u>	<u>16,115</u>

The following table summarizes the revenues generated from different distribution channels for the six months ended June 30, 2022 and 2023:

	For the six months ended June 30,		
	2022		2023
	RMB	RMB	US\$
Direct sales channel	101,404	88,966	12,269
Distribution network	19,037	26,842	3,702
Government tender and procurement	2,910	1,044	144
	<u>123,351</u>	<u>116,852</u>	<u>16,115</u>

16. RELATED PARTY TRANSCATIONS

For the six months ended June 30, 2022 and 2023, the operating entity purchased inventory from Jilin Huazheng, which is controlled by Mr. Zhenfa Han, the principal shareholder, director, and chairman of the board of the Company, in the amount of RMB87 and RMB127 (US\$18), respectively.

For the six months ended June 30, 2022 and 2023, the operating entity had no revenue generated from Jilin Huazheng. As of December 31, 2022 and June 30, 2023, the Company had account receivable from this related party in the amount of RMB nil and RMB nil (US\$ nil), respectively.

17. SUBSEQUENT EVENTS

The Company has assessed all events from June 30, 2023 up through November 17, 2023, which is the date that these consolidated financial statements are available to be issued, unless as disclosed below, there are not any material subsequent events that require disclosure in these consolidated financial statements.

On July 5, 2023, the operating entity entered into a notes cooperation agreement and notes pledge agreement with Industrial Bank Jilin Branch, pursuant to which the operating entity pledged notes receivable in the amount of RMB25,600 (US\$3,530) as collaterals for line of credit in the amount of RMB30,900 (US\$4,261) for the period from July 6, 2023 to July 5, 2024. In addition, based on the agreement, the pledged notes receivable were also the collaterals for the loans in the amount of RMB23,000 (US\$3,172) and RMB21,900 (US\$3,020) obtained on December 14, 2022 and March 31, 2023, respectively, which means no available line of credit can be used to obtain new loan.

On August 30, 2023, the operating entity entered into a loan agreement with Industrial Bank Jilin Branch, pursuant to which the operating entity obtained a loan in the amount of RMB5,000 (US\$690) for one year at the interest rate of 4.35%.

18. CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY

Regulation S-X requires the condensed financial information of registrant shall be filed when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year. For purposes of the above test, restricted net assets of consolidated subsidiaries shall mean that amount

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands of RMB and US\$, except for number of shares and per share data)

18. CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY (cont.)

of the registrant's proportionate share of net assets of consolidated subsidiaries (after intercompany eliminations) of which as of the end of the most recent fiscal year may not be transferred to the parent company by subsidiaries in the form of loans, advances or cash dividends without the consent of a third party. The condensed parent company financial statements have been prepared in accordance with Rule 12-04, Schedule I of Regulation S-X as the restricted net assets of the Company's PRC subsidiaries exceed 25% of the consolidated net assets of the Company.

Certain information and footnote disclosures normally included in financial statements prepared in conformity with U.S. GAAP have been condensed or omitted. The Company's investment in subsidiary is stated at cost plus equity in undistributed earnings of subsidiaries.

Share of income of subsidiaries on the Condensed Balance Sheets is comprised of the Parent Company's net investment in its subsidiaries under the equity method of accounting.

Condensed Balance Sheets

	As of		
	December 31, 2022	June 30, 2023	
	RMB	RMB	US\$
ASSETS			
Non-current assets:			
Investment in subsidiaries	296,497	261,574	36,073
Total non-current assets	296,497	261,574	36,073
Total assets	<u>296,497</u>	<u>261,574</u>	<u>36,073</u>
LIABILITIES AND SHAREHOLDERS' EQUITY			
Total liabilities	<u>—</u>	<u>—</u>	<u>—</u>
Commitments and contingencies			
Shareholders' equity:			
Ordinary shares (US\$0.0001 par value; 500,000,000 shares authorized; 11,416,594 shares issued and outstanding as of December 31, 2022 and June 30, 2023)	8	8	1
Additional paid-in capital	203,150	203,150	28,016
Statutory reserve	27,565	27,565	3,801
Retained earnings	65,774	30,851	4,255
Total shareholders' equity	<u>296,497</u>	<u>261,574</u>	<u>36,073</u>
Total liabilities and shareholders' earnings	<u>296,497</u>	<u>261,574</u>	<u>36,073</u>

Condensed Statements of Comprehensive Income

	For the six months ended June 30,		
	2022	2023	
	RMB	RMB	US\$
Operating costs and expenses:			
Selling, general and administrative	—	—	—
Operating income			
Share of income of subsidiaries	23,099	20,181	2,783
Net income	<u>23,099</u>	<u>20,181</u>	<u>2,783</u>

Until [•], 2024 (the 25th day after the date of this prospectus), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

[•] Ordinary Shares



Zhengye Biotechnology Holding Limited

Prospectus dated [•], 2024

PART II**INFORMATION NOT REQUIRED IN PROSPECTUS****ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.**

The Cayman Islands law does not limit the extent to which a company's articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. Our post-offering articles of association, which will become effective upon completion of this offering, provide that, to the extent permitted by law, we shall indemnify our directors and officers, and their personal representatives against and their personal representatives, against all actions, proceedings, costs, charges, expenses, losses, damages, or liabilities incurred or sustained by such persons, other than by reason of such person's dishonesty, willful default, or fraud, in or about the conduct of our Company's business or affairs (including as a result of any mistake of judgment), or in the execution or discharge of his duties, powers, authorities, or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses, or liabilities incurred by such director or officer in defending (whether successfully or otherwise) any civil proceedings concerning our Company or its affairs in any court whether in the Cayman Islands or elsewhere.

Pursuant to indemnification agreements, the form of which will be filed as Exhibit 10.2 to this registration statement, we will agree to indemnify our directors and officers against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being such a director or officer.

The Underwriting Agreement, the form of which will be filed as Exhibit 1.1 to this registration statement, will also provide for indemnification of us and our officers and directors.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

ITEM 7. RECENT SALES OF UNREGISTERED SECURITIES.

During the past three years, we have issued the following securities which were not registered under the Securities Act. We believe that each of the following issuance was exempt from registration under the Securities Act in reliance on Regulation D under the Securities Act or pursuant to Section 4(a)(2) of the Securities Act regarding transactions not involving a public offering or in reliance on Regulation S under the Securities Act regarding sales by an issuer in offshore transactions. No underwriters were involved in these issuances of securities.

Securities/Purchaser	Date of Issuance	Number of Securities	Consideration
Ordinary Shares			
VVAX Holdings Limited ⁽²⁾	March 24, 2023	6,553,005 ⁽¹⁾	\$ 655.3005
Windsor Holdings Co., Ltd. ⁽²⁾	March 24, 2023	3,074,347	\$ 307.4347
Vanguards Skyline Holdings Limited ⁽²⁾	March 24, 2023	372,648	\$ 37.2648
Securingium Holding Limited ⁽²⁾	May 18, 2023	10,000,000	\$ 1,000
VVAX Holdings Limited	June 21, 2023	570,830	\$ 57.083
Vanguards Skyline Holdings Limited	June 21, 2023	569,688	\$ 56.9688
XZjinyuan Limited	June 21, 2023	16,611	\$ 1.6611
TLjinmao Limited	June 21, 2023	259,465	\$ 25.9465

(1) On March 24, 2023, Zhengye Cayman was incorporated, and the subscriber received 1 Ordinary Share as incorporation founder. On the same day, the subscriber's share was transferred to VVAX Holdings Limited, and the Company issued 6,553,004 Ordinary Shares to VVAX Holdings Limited.

(2) On May 18, 2023, Zhengye Cayman repurchased an aggregate of 10,000,000 Ordinary Shares from VVAX Holdings Limited, Windsor Holdings Co., Ltd., and Vanguards Skyline Holdings Limited. On the same day, Zhengye Cayman issued 10,000,000 Ordinary Shares to Securingium Holding Limited.

ITEM 8. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

(a) Exhibits

See Exhibit Index beginning on page II-4 of this registration statement.

(b) Financial Statement Schedules

Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the Consolidated Financial Statements or the Notes thereto.

ITEM 9. UNDERTAKINGS.

The undersigned registrant hereby undertakes to provide to the Underwriters at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the Underwriters to permit prompt delivery to each purchaser.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the provisions described in Item 6, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

The undersigned registrant hereby undertakes that:

- (1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant under Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.
- (2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
- (3) For the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

[Table of Contents](#)

- (4) For the purpose of determining any liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
- (i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;
 - (ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;
 - (iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
 - (iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

EXHIBIT INDEX

Description	
1.1*	Form of Underwriting Agreement
3.1**	Memorandum of Association, as currently in effect
3.2**	Form of the Amended and Restated Articles of Association, to be effective immediately prior to the completion of this offering
4.1**	Specimen Certificate for Ordinary Shares
5.1*	Opinion of Conyers Dill & Pearman regarding the validity of the Ordinary Shares being registered
10.1**	Form of Employment Agreement by and between executive officers and the Registrant
10.2**	Form of Indemnification Agreement with the Registrant’s directors and officers
10.3**	Form of Director Offer Letter between the Registrant and its directors
10.4**	English Translation of the Form of Sales Agreement
10.5**	English Translation of the Form of Supplying Agreement
10.6**	English Translation of the Form of Distribution Agreement
10.7**	English Translation of the Form of Technology Transfer Agreement
10.8**	English Translation of the Form of Cooperative Research and Development Agreement
10.9**	Technology Development Contract by and between Jilin Zhengye and Shanghai Veterinary Research Institute on April 22, 2015
10.10**	Memorandum by and between Jilin Zhengye and Shanghai Veterinary Research Institute on April 3, 2018
10.11**	Technology Licensing Agreement by and between Jilin Zhengye and Harbin Veterinary Research Institute on April 5, 2012
10.12**	Technology Licensing Agreement by and between Jilin Zhengye and China Agricultural University on July 16, 2018
10.13**	Cooperation Agreement by and between Jilin Zhengye and Jilin University on September 17, 2020
10.14**	Cooperation Agreement by and between Jilin Zhengye and Jilin University on September 18, 2020
10.15**	Cooperation Agreement by and between Jilin Zhengye and Jilin Agricultural Science and Technology University on September 19, 2020
10.16**	Cooperation Agreement by and between Jilin Zhengye and Jilin University on October 14, 2021
10.17**	Cooperation Agreement by and between Jilin Zhengye and Jilin University and Health Commission of Jilin Province on October 14, 2021
10.18**	Cooperation Agreement by and between Jilin Zhengye and Jilin Agricultural University on October 9, 2021
10.19**	Cooperation Agreement by and between Jilin Zhengye and Jilin University on September 13, 2022
10.20**	Cooperation Agreement by and between Jilin Zhengye and Jilin University and Health Commission of Jilin Province on September 9, 2022
10.21**	Cooperation Agreement by and between Jilin Zhengye and Jilin University on September 16, 2022
10.22**	Cooperation Agreement by and between Jilin Zhengye and Jilin Agricultural University on September 13, 2022
10.23**	Cooperation Agreement by and between Jilin Zhengye and Jilin Agricultural University on September 13, 2022
10.24**	Cooperation Agreement by and between Jilin Zhengye and Jilin Academy of Agricultural Sciences on September 19, 2022
10.25**	Cooperation Agreement by and between Jilin Zhengye and Jilin Institute of Animal Husbandry and Veterinary Medicine on September 20, 2022
21.1**	List of Subsidiaries
23.1**	Consent of WWC, P.C.
23.2*	Consent of Conyers Dill & Pearman (included in Exhibit 5.1)
23.3*	Consent of Guantao Law Firm (included in Exhibit 99.3)
24.1**	Powers of Attorney (included on signature page)
99.1**	Code of Business Conduct and Ethics of the Registrant
99.2*	Consent of Frost & Sullivan
99.3*	Opinion of Guantao Law Firm regarding certain PRC law matters

[Table of Contents](#)

Description	
99.4**	Audit Committee Charter
99.5**	Compensation Committee Charter
99.6**	Nominating and Corporate Governance Charter
99.7*	Consent of [Independent Director Nominee]
99.8*	Consent of [Independent Director Nominee]
99.9*	Consent of [Independent Director Nominee]
107**	Filing Fee Table

* To be filed by amendment
** Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Jilin, China, on January 9, 2024.

Zhengye Biotechnology Holding Limited
By: <u>/s/ Songlin Song</u> Songlin Song Chief Executive Officer (Principal Executive Officer)

Power of Attorney

Each person whose signature appears below constitutes and appoints each of Songlin Song and Ping Wang as attorneys-in-fact with full power of substitution, for him or her in any and all capacities, to do any and all acts and all things and to execute any and all instruments which said attorney and agent may deem necessary or desirable to enable the registrant to comply with the Securities Act, and any rules, regulations, and requirements of the Securities and Exchange Commission thereunder, in connection with the registration under the Securities Act of ordinary shares of the registrant, including, without limitation, the power and authority to sign the name of each of the undersigned in the capacities indicated below to the Registration Statement on Form F-1 (the "Registration Statement") to be filed with the Securities and Exchange Commission with respect to such Shares, to any and all amendments or supplements to such Registration Statement, whether such amendments or supplements are filed before or after the effective date of such Registration Statement, to any related Registration Statement filed pursuant to Rule 462(b) under the Securities Act, and to any and all instruments or documents filed as part of or in connection with such Registration Statement or any and all amendments thereto, whether such amendments are filed before or after the effective date of such Registration Statement; and each of the undersigned hereby ratifies and confirms all that such attorney and agent shall do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
<u>/s/ Songlin Song</u> Name: Songlin Song	Chief Executive Officer (Principal Executive Officer)	January 9, 2024
<u>/s/ Ping Wang</u> Name: Ping Wang	Chief Financial Officer (Principal Accounting and Financial Officer)	January 9, 2024
<u>/s/ Wenhua Sun</u> Name: Wenhua Sun	Director	January 9, 2024
<u>/s/ Zhenfa Han</u> Name: Zhenfa Han	Director and Chairman of the Board of Directors	January 9, 2024

SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

Pursuant to the Securities Act of 1933 as amended, the undersigned, the duly authorized representative in the United States of America of Zhengye Biotechnology Holding Limited, has signed this registration statement or amendment thereto in New York, NY on January 9, 2024.

Cogency Global Inc. Authorized U.S. Representative By: /s/ Colleen A. De Vries Name: Colleen A. De Vries Title: Sr. Vice President on behalf of Cogency Global Inc.
--



EXEMPTED Company Registered and
filed as No. 398683 On 24-Mar-2023

Acting Assistant Registrar

THE CAYMAN ISLANDS

**THE COMPANIES ACT
(AS AMENDED)**

**Memorandum of Association
of
Zhengye Biotechnology Holding Limited**

ICS Corporate Services (Cayman) Limited
3-212 Governors Square
23 Lime Tree Bay Avenue
P.O. Box 30746, Seven Mile Beach
Grand Cayman KY1-1203
Cayman Islands

Auth Code: J14486650066
www.verify.gov.ky



EXEMPTED Company Registered and
filed as No. 398683 On 24-Mar-2023

Acting Assistant Registrar

**THE COMPANIES ACT
(AS AMENDED)**

COMPANY LIMITED BY SHARES

**MEMORANDUM OF ASSOCIATION
OF
Zhengye Biotechnology Holding Limited**

1. The name of the Company is Zhengye Biotechnology Holding Limited.
2. The registered office will be situated at the offices of ICS Corporate Services (Cayman) Limited, 3-212 Governors Square, 23 Lime Tree Bay Avenue, P.O. Box 30746, Seven Mile Beach, Grand Cayman KY1-1203, Cayman Islands or at such other place in the Cayman Islands as the Directors may from time to time decide.
3. The objects for which the Company is established are unrestricted and the Company shall have full power and authority to carry out any object not prohibited by the Companies Act (As Amended) or any other law of the Cayman Islands and shall have and be capable of from time to time and at all times exercising any and all of the powers at any time or from time to time exercisable by a natural person or body corporate in any part of the world whether as principal, agent, contractor or otherwise.
4. The Company shall not be permitted to carry on any business where a licence is required under the laws of the Cayman Islands to carry on such a business until such time as the relevant licence has been obtained.
5. As an exempted company, the Company's operations will be carried on subject to the provisions of Section 174 of the Companies Act (As Amended).
6. The liability of each Shareholder is limited to the amount from time to time unpaid on such Shareholder's share.
7. The authorised share capital of the Company is USD50,000.00 divided into 500,000,000.00 Ordinary Shares of USD0.0001 each, with the power for the Company to increase or reduce the said capital and to issue any part of its capital, original or increased, with or without any preference, priority or special privilege or subject to any postponement of rights or to any conditions or restrictions; and so that, unless the condition of issue shall otherwise expressly declare, every issue of shares, whether declared to be preference or otherwise, shall be subject to the power hereinbefore contained.



EXEMPTED Company Registered and
filed as No. 398683 On 24-Mar-2023

A handwritten signature in blue ink, likely belonging to the Acting Assistant Registrar.

Acting Assistant Registrar

8. The Company has power to register by way of continuation as a body corporate limited by shares under the laws of any jurisdiction outside the Cayman Islands and to be deregistered in the Cayman Islands.
9. Capitalised terms that are not defined in this Memorandum of Association bear the same meaning as those given in the Articles of Association of the Company.

The Subscriber whose name and address is subscribed herein is desirous of being formed into a Company limited by shares and in pursuance of this Memorandum of Association, the Subscriber agrees to take the shares in the capital of the Company set opposite their name.

<u>Name and Address of Subscriber</u>	<u>Occupation</u>	<u>Number of shares Taken by Subscriber</u>
ICS Corporate Services (Cayman) Limited 3-212 Governors Square 23 Lime Tree Bay Avenue P.O. Box 30746, Seven Mile Beach Grand Cayman KY1-1203 Cayman Islands	Company	One Ordinary Share

A handwritten signature in black ink, likely belonging to Dandan Li.

Signed by Dandan Li as an authorised
signatory for and on behalf of
ICS Corporate Services (Cayman) Limited

A handwritten signature in black ink, likely belonging to Sixin Hao.

Sixin Hao
Witness

DATED the 24th March 2023

The Companies Act (As Revised)
Exempted Company Limited by Shares

THE AMENDED AND RESTATED

ARTICLES OF ASSOCIATION

OF

Zhengye Biotechnology Holding Limited

(Conditionally adopted by way of a special resolution passed on July 21st 2023 and to become effective immediately prior to the completion of the initial public offering of the Company's ordinary shares with effect from [●])

I N D E X

SUBJECT	Article No.
Table A	1
Interpretation	2
Share Capital	3
Alteration Of Capital	4-7
Share Rights	8-10
Variation Of Rights	11-12
Shares	13-16
Share Certificates	17-22
Lien	23-25
Calls On Shares	26-34
Forfeiture Of Shares	35-43
Register Of Members	44-45
Record Dates	46
Transfer Of Shares	47-52
Transmission Of Shares	53-55
Untraceable Members	56
General Meetings	57-59
Notice Of General Meetings	60-61
Proceedings At General Meetings	62-66
Voting	67-78
Proxies	79-84
Corporations Acting By Representatives	85
No Action By Written Resolutions Of Members	86
Board Of Directors	87
Disqualification Of Directors	88
Executive Directors	89-90
Alternate Directors	91-94
Directors' Fees And Expenses	95-98
Directors' Interests	99-102
General Powers Of The Directors	103-108
Borrowing Powers	109-112
Proceedings Of The Directors	113-122
Audit Committee	123-125
Officers	126-129
Register of Directors and Officers	130
Minutes	131
Seal	132
Authentication Of Documents	133
Destruction Of Documents	134
Dividends And Other Payments	135-144
Reserves	145
Capitalisation	146-147
Subscription Rights Reserve	148
Accounting Records	149-153
Audit	154-159
Notices	160-162
Signatures	163
Winding Up	164-165
Indemnity	166
Financial Year End	167
Amendment To Memorandum and Articles of Association And Name of Company	168
Information	169

THE COMPANIES ACT (AS REVISED)
EXEMPTED COMPANY LIMITED BY SHARES

THE AMENDED AND RESTATED
ARTICLES OF ASSOCIATION

OF

Zhengye Biotechnology Holding Limited

(Conditionally adopted by way of a special resolution passed on July 21st 2023 and to become effective immediately prior to the completion of the initial public offering of the Company's ordinary shares with effect from [●])

TABLE A

1. The regulations in Table A in the Schedule to the Companies Act (As Revised) do not apply to the Company.

INTERPRETATION

2. (1) In these Articles, unless the context otherwise requires, the words standing in the first column of the following table shall bear the meaning set opposite them respectively in the second column.

<u>WORD</u>	<u>MEANING</u>
"Act"	The Companies Act, Cap. 22 (As Revised) of the Cayman Islands.
"Articles"	these Articles in their present form or as supplemented or amended or substituted from time to time.
"Audit Committee"	the audit committee of the Company formed by the Board pursuant to Article 123 hereof, or any successor audit committee.
"Auditor"	the independent auditor of the Company which shall be an internationally recognized firm of independent accountants.
"Board" or "Directors"	the board of directors of the Company or the directors present at a meeting of directors of the Company at which a quorum is present.
"capital"	the share capital from time to time of the Company.
"clear days"	in relation to the period of a notice, that period excluding the day when the notice is given or deemed to be given and the day for which it is given or on which it is to take effect.
"clearing house"	a clearing house recognised by the laws of the jurisdiction in which the shares of the Company (or depositary receipts therefor) are listed or quoted on a stock exchange or interdealer quotation system in such jurisdiction.

"Company"	Zhengye Biotechnology Holding Limited
"competent regulatory authority"	a competent regulatory authority in the territory where the shares of the Company (or depositary receipts therefor) are listed or quoted on a stock exchange or interdealer quotation system in such territory.
"debenture" and "debenture holder"	include debenture stock and debenture stockholder respectively.
"Designated Stock Exchange"	the stock exchange in the United States of America on which any shares are listed for trading.
"dollars" and "\$"	dollars, the legal currency of the United States of America.
"Exchange Act"	the Securities Exchange Act of 1934, as amended.
"head office"	such office of the Company as the Directors may from time to time determine to be the principal office of the Company.
"Independent Director"	a director who is an independent director as defined in the applicable rules and regulations of the Designated Stock Exchange.
"Member"	a duly registered holder from time to time of the shares in the capital of the Company.
"Memorandum of Association"	the memorandum of association of the Company, as amended from time to time.
"month"	a calendar month.
"Notice"	written notice unless otherwise specifically stated and as further defined in these Articles.
"Office"	the registered office of the Company for the time being.

“ordinary resolution”	a resolution shall be an ordinary resolution when it has been passed by a simple majority of votes cast by such Members as, being entitled so to do, vote in person or, in the case of any Member being a corporation, by its duly authorised representative or, where proxies are allowed, by proxy at a general meeting of which Notice has been duly given in accordance with Article 60;
“paid up”	paid up or credited as paid up.
“Register”	the principal register and where applicable, any branch register of Members of the Company to be maintained at such place within or outside the Cayman Islands as the Board shall determine from time to time.

2

“Registration Office”	in respect of any class of share capital such place as the Board may from time to time determine to keep a branch register of Members in respect of that class of share capital and where (except in cases where the Board otherwise directs) the transfers or other documents of title for such class of share capital are to be lodged for registration and are to be registered.
“SEC”	the United States Securities and Exchange Commission.
“Securities Act”	mean the U.S. Securities Act 1933 as amended, or any similar federal statute and the rules and regulations of the SEC thereunder as the same shall be in effect from time to time.
“Seal”	common seal or any one or more duplicate seals of the Company (including a securities seal) for use in the Cayman Islands or in any place outside the Cayman Islands.
“Secretary”	any person, firm or corporation appointed by the Board to perform any of the duties of secretary of the Company and includes any assistant, deputy, temporary or acting secretary.
“shares”	ordinary shares of par value US\$0.0001 each.
“special resolution”	<p>a resolution shall be a special resolution when it has been passed by a majority of not less than two-thirds of votes cast by such Members as, being entitled so to do, vote in person or, in the case of such Members as are corporations, by their respective duly authorised representative or, where proxies are allowed, by proxy at a general meeting of which Notice has been duly given in accordance with Article 60;</p> <p>a special resolution shall be effective for any purpose for which an ordinary resolution is expressed to be required under any provision of these Articles or the Statutes.</p>
“Statutes”	the Act and every other law of the Legislature of the Cayman Islands for the time being in force applying to or affecting the Company, its Memorandum of Association and/or these Articles.
“year”	a calendar year.

3

- (2) In these Articles, unless there be something within the subject or context inconsistent with such construction:
- (a) words importing the singular include the plural and vice versa;
 - (b) words importing a gender include both gender and the neuter;
 - (c) words importing persons include companies, associations and bodies of persons whether corporate or not;
 - (d) the words:
 - (i) “may” shall be construed as permissive;
 - (ii) “shall” or “will” shall be construed as imperative;
 - (e) expressions referring to writing shall, unless the contrary intention appears, be construed as including printing, lithography, email, facsimile, photography and other modes of representing words or figures in a visible form, and including where the representation takes the form of electronic display, or represented by any other substitute or format for storage or transmission for writing or partly one and partly another provided that both the mode of service of the relevant document or Notice and the Member’s election comply with all applicable Statutes, rules and regulations;
 - (f) any requirement as to delivery under the Articles include delivery in the form of an electronic record (as defined in the Electronic Transactions Act of the Cayman Islands) or an electronic communication;
 - (g) references to any law, ordinance, statute or statutory provision shall be interpreted as relating to any statutory modification or re-enactment thereof for the time being in force;
 - (h) save as aforesaid words and expressions defined in the Statutes shall bear the same meanings in these Articles if not inconsistent with the subject in the context;
 - (i) references to a document (including, but without limitation, a resolution in writing) being signed or executed include references to it being signed or executed under hand or under seal or by electronic communication or by electronic signature or by any other method and references to a Notice or document include a Notice or document recorded or stored in any digital, electronic, electrical, magnetic or other retrievable form or medium and information in visible form whether having physical substance or not;

- (j) Sections 8 and 19 of the Electronic Transaction Act of the Cayman Islands, as amended from time to time, shall not apply to these Articles to the extent it imposes obligations or requirements in addition to those set out in these Articles;
- (k) where a Member is a corporation, any reference in these Articles to a Member shall, where the context requires, refer to a duly authorised representative of such Member; and
- (l) references to “in the ordinary course of business” and comparable expressions mean the ordinary and usual course of business of the relevant party, consistent in all material respects (including nature and scope) with the prior practice of such party.

SHARE CAPITAL

3. (1) The share capital of the Company at the date on which these Articles come into effect shall be divided into ordinary shares of a par value of US\$0.0001 each.
- (2) Subject to the Act, the Company’s Memorandum and Articles of Association and, where applicable, the rules and regulations of the Designated Stock Exchange and/or any competent regulatory authority, the Company shall have the power to purchase or otherwise acquire its own shares and such power shall be exercisable by the Board in such manner, upon such terms and subject to such conditions as it in its absolute discretion thinks fit and any determination by the Board of the manner of purchase shall be deemed authorized by these Articles for purposes of the Act. Subject to the Act, the Company is hereby authorized to make payments in respect of a redemption or purchase of its own shares in any manner authorized by the Act, including out of its capital. The purchase of any share shall not oblige the Company to purchase any other share other than as may be required pursuant to applicable law and any other contractual obligations of the Company.
- (3) The Company is authorised to hold treasury shares in accordance with the Act and may designate as treasury shares any of its shares that it purchases or redeems, or any share surrendered to it subject to the rules and regulations of the Designated Stock Exchange and/or any competent regulatory authority. Shares held by the Company as treasury shares shall continue to be classified as treasury shares until such shares are either cancelled or transferred as the Board may determine on such terms and subject to such conditions as it in its absolute discretion thinks fits in accordance with the Act subject to the rules and regulations of the Designated Stock Exchange and/or any competent regulatory authority.
- (4) The Company may accept the surrender for no consideration of any fully paid share unless, as a result of such surrender, there would no longer be any issued shares of the Company other than shares held as treasury shares.
- (5) No share shall be issued to bearer.

ALTERATION OF CAPITAL

4. The Company may from time to time by ordinary resolution in accordance with the Act alter the conditions of its Memorandum of Association to:
- (a) increase its capital by such sum, to be divided into shares of such amounts, as the resolution shall prescribe;
 - (b) consolidate and divide all or any of its capital into shares of larger amount than its existing shares;
 - (c) without prejudice to the powers of the Board under Article 13, divide its shares into several classes and without prejudice to any special rights previously conferred on the holders of existing shares attach thereto respectively any preferential, deferred, qualified or special rights, privileges, conditions or such restrictions which in the absence of any such determination by the Company in general meeting, as the Directors may determine provided always that, for the avoidance of doubt, where a class of shares has been authorized by the Company no resolution of the Company in general meeting is required for the issuance of shares of that class and the Directors may issue shares of that class and determine such rights, privileges, conditions or restrictions attaching thereto as aforesaid, and further provided that where the Company issues shares which do not carry voting rights, the words “non-voting” shall appear in the designation of such shares and where the equity capital includes shares with different voting rights, the designation of each class of shares, other than those with the most favourable voting rights, must include the words “restricted voting” or “limited voting”;

- (d) sub-divide its shares, or any of them, into shares of smaller amount than is fixed by the Memorandum of Association (subject, nevertheless, to the Act), and may by such resolution determine that, as between the holders of the shares resulting from such sub-division, one or more of the shares may have any such preferred, deferred or other rights or be subject to any such restrictions as compared with the other or others as the Company has power to attach to unissued or new shares;
 - (e) cancel any shares which, at the date of the passing of the resolution, have not been taken, or agreed to be taken, by any person, and diminish the amount of its capital by the amount of the shares so cancelled or, in the case of shares, without par value, diminish the number of shares into which its capital is divided.
5. The Board may settle as it considers expedient any difficulty which arises in relation to any consolidation and division under the Article 4 and in particular but without prejudice to the generality of the foregoing may issue certificates in respect of fractions of shares or arrange for the sale of the shares representing fractions and the distribution of the net proceeds of sale (after deduction of the expenses of such sale) in due proportion amongst the Members who would have been entitled to the fractions, and for this purpose the Board may authorise any person to transfer the shares representing fractions to their purchaser or resolve that such net proceeds be paid to the Company for the Company’s benefit. Such purchaser will not be bound to see to the application of the purchase money nor will his title to the shares be affected by any irregularity or invalidity in the proceedings relating to the sale.
6. The Company may from time to time by special resolution, subject to any confirmation or consent required by the Act, reduce its share capital or any capital redemption reserve or other undistributable reserve in any manner permitted by law.
7. Except so far as otherwise provided by the conditions of issue, or by these Articles, any capital raised by the creation of new shares shall be treated as if it formed part of the original capital of the Company, and such shares shall be subject to the provisions contained in these Articles with reference to the payment of calls and instalments, transfer and transmission, forfeiture, lien, cancellation, surrender, voting and otherwise.

SHARE RIGHTS

8. Subject to the provisions of the Act, the rules and regulations of the Designated Stock Exchange and the Memorandum and Articles of Association and to any special rights conferred on the holders of any shares or class of shares, and without prejudice to Article 13 hereof, any share in the Company (whether forming part of the present capital or not) may be issued with or have attached thereto such rights or restrictions whether in regard to dividend, voting, return of capital or otherwise as the Board may determine, including without limitation on terms that they may be, or at the option of the Company or the holder are, liable to be redeemed on such terms and in such manner, including out of capital, as the Board may deem fit.

9. Subject to the Act, the rules and regulations of the Designated Stock Exchange and the Memorandum and Articles of Association, and to any special rights conferred on the holders of any shares or attaching to any class of shares, shares may be issued on the terms that may be or at the option of the Company or the holder are, liable to be redeemed on such terms and in such manner, including out of capital, as the Board may deem fit.

6

10. Subject to Article 13(1), the Memorandum of Association and any resolution of the Members to the contrary and without prejudice to any special rights conferred thereby on the holders of any other shares or class of shares, the share capital of the Company shall be divided into shares of a single class the holders of which shall, subject to these Articles:

- (a) be entitled to one vote per share;
- (b) be entitled to such dividends as the Board may from time to time declare;
- (c) in the event of a winding up or dissolution of the Company, whether voluntary or involuntary or for the purpose of a reorganisation or otherwise or upon any distribution of capital, be entitled to the surplus assets of the Company; and
- (d) generally, be entitled to enjoy all of the rights attaching to shares.

VARIATION OF RIGHTS

11. Subject to the Act and without prejudice to Article 8, all or any of the special rights for the time being attached to the shares or any class of shares may, unless otherwise provided by the terms of issue of the shares of that class, from time to time (whether or not the Company is being wound up) be varied, modified or abrogated with the sanction of a special resolution passed at a separate general meeting of the holders of the shares of that class. To every such separate general meeting all the provisions of these Articles relating to general meetings of the Company shall, *mutatis mutandis*, apply, but so that:

- (a) notwithstanding Article 59 which shall not apply to this Article 11, separate general meetings of the holders of a class or series of shares may be called only by (i) the Chairman of the Board, or (ii) a majority of the entire Board (unless otherwise specifically provided by the terms of issue of the shares of such class or series). Nothing in this Article 11 shall be deemed to give any Member or Members the right to call a class or series meeting;
- (b) the necessary quorum (whether at a separate general meeting or at its adjourned meeting) shall be a person or persons or (in the case of a Member being a corporation) its duly authorized representative together holding or representing by proxy not less than one-third in nominal value or par value of the issued shares of that class (but so that if at any adjourned meeting of such holders a quorum as above defined is not present, those Members who are present shall form a quorum (whatever the number of shares held by them));
- (c) every holder of shares of the class shall be entitled on a poll to one vote for every such share held by him; and
- (d) any holder of shares of the class present in person or by proxy or authorised representative may demand a poll.

12. The special rights conferred upon the holders of any shares or class of shares shall not, unless otherwise expressly provided in the rights attaching to or the terms of issue of such shares, be deemed to be varied, modified or abrogated by the creation or issue of further shares ranking *pari passu* therewith.

7

SHARES

13. (1) Subject to the Act, these Articles and, where applicable, the rules and regulations of the Designated Stock Exchange and without prejudice to any special rights or restrictions for the time being attached to any shares or any class of shares, the unissued shares of the Company (whether forming part of the original or any increased capital) shall be at the disposal of the Board, which may offer, allot, grant options over or otherwise dispose of them to such persons, at such times and for such consideration and upon such terms and conditions as the Board may in its absolute discretion determine but so that no shares shall be issued at a discount to their nominal value. In particular and without prejudice to the generality of the foregoing, the Board is hereby empowered to authorize by resolution or resolutions from time to time the issuance of one or more classes or series of preferred shares and to fix the designations, powers, preferences and relative, participating, optional and other rights, if any, and the qualifications, limitations and restrictions thereof, if any, including, without limitation, the number of shares constituting each such class or series, dividend rights, conversion rights, redemption privileges, voting powers, full or limited or no voting powers, and liquidation preferences, and to increase or decrease the size of any such class or series (but not below the number of shares of any class or series of preferred shares then outstanding) to the extent permitted by the Act. Without limiting the generality of the foregoing, the resolution or resolutions providing for the establishment of any class or series of preferred shares may, to the extent permitted by law, provide that such class or series shall be superior to, rank equally with or be junior to the preferred shares of any other class or series.

(2) Neither the Company nor the Board shall be obliged, when making or granting any allotment of, offer of, option over or disposal of shares, to make, or make available, any such allotment, offer, option or shares to Members or others with registered addresses in any particular territory or territories being a territory or territories where, in the absence of a registration statement or other special formalities, this would or might, in the opinion of the Board, be unlawful or impracticable. Members affected as a result of the foregoing sentence shall not be, or be deemed to be, a separate class of members for any purpose whatsoever. Except as otherwise expressly provided in the resolution or resolutions providing for the establishment of any class or series of preferred shares, no vote of the holders of preferred shares or ordinary shares shall be a prerequisite to the issuance of any shares of any class or series of the preferred shares authorized by and complying with the conditions of the Memorandum and Articles of Association.

(3) The Board may issue options, warrants or convertible securities or securities of similar nature conferring the right upon the holders thereof to subscribe for, purchase or receive any class of shares or securities in the capital of the Company on such terms as it may from time to time determine.

14. The Company may in connection with the issue of any shares exercise all powers of paying commission and brokerage conferred or permitted by the Act. Subject to the Act, the commission may be satisfied by the payment of cash or by the allotment of fully or partly paid shares or partly in one and partly in the other.

15. Except as required by law, no person shall be recognised by the Company as holding any share upon any trust and the Company shall not be bound by or required in any way to recognise (even when having notice thereof) any equitable, contingent, future or partial interest in any share or any fractional part of a share or (except only as otherwise provided by these Articles or by law) any other rights in respect of any share except an absolute right to the entirety thereof in the registered holder.

16. Subject to the Act and these Articles, the Board may at any time after the allotment of shares but before any person has been entered in the Register as the holder, recognise a renunciation thereof by the allottee in favour of some other person and may accord to any allottee of a share a right to effect such renunciation upon and subject to such terms and conditions as the Board considers fit to impose.

SHARE CERTIFICATES

17. Every share certificate shall be issued under the Seal or a facsimile thereof or with the Seal printed thereon and shall specify the number and class and distinguishing numbers (if any) of the shares to which it relates, and the amount paid up thereon and may otherwise be in such form as the Directors may from time to time determine. No certificate shall be issued representing shares of more than one class. The Board may by resolution determine, either generally or in any particular case or cases, that any signatures on any such certificates (or certificates in respect of other securities) need not be autographic but may be affixed to such certificates by some mechanical means or may be printed thereon.

18. (1) In the case of a share held jointly by several persons, the Company shall not be bound to issue more than one certificate therefor and delivery of a certificate to one of several joint holders shall be sufficient delivery to all such holders.

(2) Where a share stands in the names of two or more persons, the person first named in the Register shall as regards service of notices and, subject to the provisions of these Articles, all or any other matters connected with the Company, except the transfer of the shares, be deemed the sole holder thereof.

19. The Company is not obliged to issue a share certificate to a Member unless the Member requests it in writing from the Company. Every person whose name is entered, upon an allotment of shares, as a Member in the Register shall be entitled without payment, to receive one certificate for all such shares of any one class or several certificates each for one or more of such shares of such class upon payment for every certificate after the first of such reasonable out-of-pocket expenses as the Board from time to time determines.

20. Share certificates shall be issued within the relevant time limit as prescribed by the Act or as the Designated Stock Exchange may from time to time determine, whichever is the shorter, after allotment or, except in the case of a transfer which the Company is for the time being entitled to refuse to register and does not register, after lodgment of a transfer with the Company. Every share certificate of the Company shall bear legends required under the applicable laws, including the Securities Act.

21. (1) Upon every transfer of shares the certificate held by the transferor shall be given up to be cancelled, and shall forthwith be cancelled accordingly, and a new certificate shall be issued to the transferee in respect of the shares transferred to him at such fee as is provided in paragraph (2) of this Article 21. If any of the shares included in the certificate so given up shall be retained by the transferor a new certificate for the balance shall be issued to him at the aforesaid fee payable by the transferor to the Company in respect thereof.

(2) The fee referred to in paragraph (1) above shall be an amount not exceeding the relevant maximum amount as the Designated Stock Exchange may from time to time determine provided that the Board may at any time determine a lower amount for such fee.

22. If a share certificate shall be damaged or defaced or alleged to have been lost, stolen or destroyed a new certificate representing the same shares may be issued to the relevant Member upon request and on payment of such fee as the Board may determine and, subject to compliance with such terms (if any) as to evidence and indemnity and to payment of the costs and reasonable out-of-pocket expenses of the Company in investigating such evidence and preparing such indemnity as the Board may think fit and, in case of damage or defacement, on delivery of the old certificate to the Company provided always that where share warrants have been issued, no new share warrant shall be issued to replace one that has been lost unless the Board has determined that the original has been destroyed.

LIEN

23. The Company shall have a first and paramount lien on every share (not being a fully paid share) for all moneys (whether presently payable or not) called or payable at a fixed time in respect of that share. The Company shall also have a first and paramount lien on every share (not being a fully paid share) registered in the name of a Member (whether or not jointly with other Members) for all amounts of money presently payable by such Member or his estate to the Company whether the same shall have been incurred before or after notice to the Company of any equitable or other interest of any person other than such member, and whether the period for the payment or discharge of the same shall have actually become due or not, and notwithstanding that the same are joint debts or liabilities of such Member or his estate and any other person, whether a Member or not. The Company's lien on a share shall extend to all dividends or other moneys payable thereon or in respect thereof. The Board may at any time, generally or in any particular case, waive any lien that has arisen or declare any share exempt in whole or in part, from the provisions of this Article 23.

24. Subject to these Articles, the Company may sell in such manner as the Board determines any share on which the Company has a lien, but no sale shall be made unless some sum in respect of which the lien exists is presently payable, or the liability or engagement in respect of which such lien exists is liable to be presently fulfilled or discharged nor until the expiration of fourteen (14) clear days after a notice in writing, stating and demanding payment of the sum presently payable, or specifying the liability or engagement and demanding fulfilment or discharge thereof and giving notice of the intention to sell in default, has been served on the registered holder for the time being of the share or the person entitled thereto by reason of his death or bankruptcy.

25. The net proceeds of the sale shall be received by the Company and applied in or towards payment or discharge of the debt or liability in respect of which the lien exists, so far as the same is presently payable, and any residue shall (subject to a like lien for debts or liabilities not presently payable as existed upon the share prior to the sale) be paid to the person entitled to the share at the time of the sale. To give effect to any such sale the Board may authorise some person to transfer the shares sold to the purchaser thereof. The purchaser shall be registered as the holder of the shares so transferred and he shall not be bound to see to the application of the purchase money, nor shall his title to the shares be affected by any irregularity or invalidity in the proceedings relating to the sale.

CALLS ON SHARES

26. Subject to these Articles and to the terms of allotment, the Board may from time to time make calls upon the Members in respect of any moneys unpaid on their shares (whether on account of the nominal value of the shares or by way of premium), and each Member shall (subject to being given at least fourteen (14) clear days'

Notice specifying the time and place of payment) pay to the Company as required by such notice the amount called on his shares. A call may be extended, postponed or revoked in whole or in part as the Board determines but no Member shall be entitled to any such extension, postponement or revocation except as a matter of grace and favour.

27. A call shall be deemed to have been made at the time when the resolution of the Board authorising the call was passed and may be made payable either in one lump sum or by instalments.

10

28. A person upon whom a call is made shall remain liable for calls made upon him notwithstanding the subsequent transfer of the shares in respect of which the call was made. The joint holders of a share shall be jointly and severally liable to pay all calls and instalments due in respect thereof or other moneys due in respect thereof.

29. If a sum called in respect of a share is not paid before or on the day appointed for payment thereof, the person from whom the sum is due shall pay interest on the amount unpaid from the day appointed for payment thereof to the time of actual payment at such rate (not exceeding twenty per cent. (20%) per annum) as the Board may determine, but the Board may in its absolute discretion waive payment of such interest in whole or in part.

30. No Member shall be entitled to receive any dividend or bonus or to be present and vote (save as proxy for another Member) at any general meeting either personally or by proxy, or be reckoned in a quorum, or exercise any other privilege as a Member until all calls or instalments due by him to the Company, whether alone or jointly with any other person, together with interest and expenses (if any) shall have been paid.

31. On the trial or hearing of any action or other proceedings for the recovery of any money due for any call, it shall be sufficient to prove that the name of the Member sued is entered in the Register as the holder, or one of the holders, of the shares in respect of which such debt accrued, that the resolution making the call is duly recorded in the minute book, and that notice of such call was duly given to the Member sued, in pursuance of these Articles; and it shall not be necessary to prove the appointment of the Directors who made such call, nor any other matters whatsoever, but the proof of the matters aforesaid shall be conclusive evidence of the debt.

32. Any amount payable in respect of a share upon allotment or at any fixed date, whether in respect of nominal value or premium or as an instalment of a call, shall be deemed to be a call duly made and payable on the date fixed for payment and if it is not paid the provisions of these Articles shall apply as if that amount had become due and payable by virtue of a call duly made and notified.

33. On the issue of shares the Board may differentiate between the allottees or holders as to the amount of calls to be paid and the times of payment.

34. The Board may, if it thinks fit, receive from any Member willing to advance the same, and either in money or money's worth, all or any part of the moneys uncalled and unpaid or instalments payable upon any shares held by him and upon all or any of the moneys so advanced (until the same would, but for such advance, become presently payable) pay interest at such rate (if any) as the Board may decide. The Board may at any time repay the amount so advanced upon giving to such Member not less than one (1) month's Notice of its intention in that behalf, unless before the expiration of such notice the amount so advanced shall have been called up on the shares in respect of which it was advanced. Such payment in advance shall not entitle the holder of such share or shares to participate in respect thereof in a dividend subsequently declared.

11

FORFEITURE OF SHARES

35. (1) If a call remains unpaid after it has become due and payable the Board may give to the person from whom it is due not less than fourteen (14) clear days' Notice:

- (a) requiring payment of the amount unpaid together with any interest which may have accrued and which may still accrue up to the date of actual payment; and
- (b) stating that if the Notice is not complied with the shares on which the call was made will be liable to be forfeited.

(2) If the requirements of any such Notice are not complied with, any share in respect of which such Notice has been given may at any time thereafter, before payment of all calls and interest due in respect thereof has been made, be forfeited by a resolution of the Board to that effect, and such forfeiture shall include all dividends and bonuses declared in respect of the forfeited share but not actually paid before the forfeiture.

36. When any share has been forfeited, notice of the forfeiture shall be served upon the person who was before forfeiture the holder of the share. No forfeiture shall be invalidated by any omission or neglect to give such Notice.

37. The Board may accept the surrender of any share liable to be forfeited hereunder and, in such case, references in these Articles to forfeiture will include surrender.

38. Any share so forfeited shall be deemed the property of the Company and may be sold, re-allotted or otherwise disposed of to such person, upon such terms and in such manner as the Board determines, and at any time before a sale, re-allotment or disposition the forfeiture may be annulled by the Board on such terms as the Board determines.

39. A person whose shares have been forfeited shall cease to be a Member in respect of the forfeited shares but nevertheless shall remain liable to pay the Company all moneys which at the date of forfeiture were presently payable by him to the Company in respect of the shares, with (if the Board shall in its discretion so requires) interest thereon from the date of forfeiture until payment at such rate (not exceeding twenty per cent. (20%) per annum) as the Board shall determine. The Board may enforce payment thereof if it thinks fit, and without any deduction or allowance for the value of the forfeited shares, at the date of forfeiture, but his liability shall cease if and when the Company shall have received payment in full of all such moneys in respect of the shares. For the purposes of this Article 39 any sum which, by the terms of issue of a share, is payable thereon at a fixed time which is subsequent to the date of forfeiture, whether on account of the nominal value of the share or by way of premium, shall notwithstanding that time has not yet arrived be deemed to be payable at the date of forfeiture, and the same shall become due and payable immediately upon the forfeiture, but interest thereon shall only be payable in respect of any period between the said fixed time and the date of actual payment.

40. A declaration by a Director or the Secretary that a share has been forfeited on a specified date shall be conclusive evidence of the facts therein stated as against all persons claiming to be entitled to the share, and such declaration shall (subject to the execution of an instrument of transfer by the Company if necessary) constitute a good title to the share, and the person to whom the share is disposed of shall be registered as the holder of the share and shall not be bound to see to the application of the consideration (if any), nor shall his title to the share be affected by any irregularity in or invalidity of the proceedings in reference to the forfeiture, sale or disposal of the share. When any share shall have been forfeited, notice of the declaration shall be given to the Member in whose name it stood immediately prior to the forfeiture, and an entry of the forfeiture, with the date thereof, shall forthwith be made in the Register, but no forfeiture shall be in any manner invalidated by any omission or neglect to give such notice or make any such entry.

41. Notwithstanding any such forfeiture as aforesaid the Board may at any time, before any shares so forfeited shall have been sold, re-allotted or otherwise disposed of, permit the shares forfeited to be bought back upon the terms of payment of all calls and interest due upon and expenses incurred in respect of the share, and upon such further terms (if any) as it thinks fit.

42. The forfeiture of a share shall not prejudice the right of the Company to any call already made or instalment payable thereon.

43. The provisions of these Articles as to forfeiture shall apply in the case of non-payment of any sum which, by the terms of issue of a share, becomes payable at a fixed time, whether on account of the nominal value of the share or by way of premium, as if the same had been payable by virtue of a call duly made and notified.

REGISTER OF MEMBERS

44. (1) The Company shall keep in one or more books a Register of its Members and shall enter therein the following particulars, that is to say:

- (a) the name and address of each Member, the number and class of shares held by him and the amount paid or agreed to be considered as paid on such shares;
- (b) the date on which each person was entered in the Register; and
- (c) the date on which any person ceased to be a Member.

(2) The Company may keep an overseas or local or other branch register of Members resident in any place, and the Board may make and vary such regulations as it determines in respect of the keeping of any such register and maintaining a Registration Office in connection therewith.

45. The Register and branch register of Members, as the case may be, shall be open to inspection for such times and on such days as the Board shall determine by Members without charge or by any other person, upon a maximum payment of \$2.50 or such other sum specified by the Board, at the Office or Registration Office or such other place at which the Register is kept in accordance with the Act. The Register including any overseas or local or other branch register of Members may, after compliance with any notice requirements of the Designated Stock Exchange or by any electronic means in such manner as may be accepted by the Designated Stock Exchange to that effect, be closed for inspection at such times or for such periods not exceeding in the whole thirty (30) days in each year as the Board may determine and either generally or in respect of any class of shares.

RECORD DATES

46. For the purpose of determining the Members entitled to notice of or to vote at any general meeting, or any adjournment thereof, or entitled to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of shares or for the purpose of any other lawful action, the Board may fix, in advance, a date as the record date for any such determination of Members.

If the Board does not fix a record date for any general meeting, the record date for determining the Members entitled to a notice of or to vote at such meeting shall be at the close of business on the day next preceding the day on which notice is given, or, if in accordance with these Articles notice is waived, at the close of business on the day next preceding the day on which the meeting is held. The record date for determining the Members for any other purpose shall be at the close of business on the day on which the Board adopts the resolution relating thereto.

A determination of the Members of record entitled to notice of or to vote at a meeting of the Members shall apply to any adjournment of the meeting; provided, however, that the Board may fix a new record date for the adjourned meeting.

TRANSFER OF SHARES

47. (1) Subject to these Articles, any Member may transfer all or any of his shares by an instrument of transfer in the usual or common form or in a form prescribed by the Designated Stock Exchange or in any other form approved by the Board and may be under hand or, if the transferor or transferee is a clearing house or a central depository house or its nominee(s), by hand or by machine imprinted signature or by such other manner of execution as the Board may approve from time to time.

(2) Notwithstanding the provisions of subparagraph (1) above, for so long as any shares are listed on the Designated Stock Exchange, titles to such listed shares may be evidenced and transferred in accordance with the laws applicable to and the rules and regulations of the Designated Stock Exchange that are or shall be applicable to such listed shares. The register of members of the Company in respect of its listed shares (whether the Register or a branch register) may be kept by recording the particulars required by Section 40 of the Act in a form otherwise than legible if such recording otherwise complies with the laws applicable to and the rules and regulations of the Designated Stock Exchange that are or shall be applicable to such listed shares.

48. The instrument of transfer shall be executed by or on behalf of the transferor and the transferee provided that the Board may dispense with the execution of the instrument of transfer by the transferee in any case which it thinks fit in its discretion to do so. Without prejudice to Article 47, the Board may also resolve, either generally or in any particular case, upon request by either the transferor or transferee, to accept mechanically executed transfers. The transferor shall be deemed to remain the holder of the share until the name of the transferee is entered in the Register in respect thereof. Nothing in these Articles shall preclude the Board from recognising a renunciation of the allotment or provisional allotment of any share by the allottee in favour of some other person.

49. (1) The Board may, in its absolute discretion, and without giving any reason therefor, refuse to register a transfer of any share (not being a fully paid up share) to a person of whom it does not approve, or any share issued under any share incentive scheme for employees upon which a restriction on transfer imposed thereby still subsists, and it may also, without prejudice to the foregoing generality, refuse to register a transfer of any share to more than four joint holders or a transfer of any share (not being a fully paid up share) on which the Company has a lien.

(2) The Board in so far as permitted by any applicable law may, in its absolute discretion, at any time and from time to time transfer any share upon the Register to any branch register or any share on any branch register to the Register or any other branch register. In the event of any such transfer, the shareholder requesting such transfer shall bear the cost of effecting the transfer unless the Board otherwise determines.

(3) Unless the Board otherwise agrees (which agreement may be on such terms and subject to such conditions as the Board in its absolute discretion may from

time to time determine, and which agreement the Board shall, without giving any reason therefor, be entitled in its absolute discretion to give or withhold), no shares upon the Register shall be transferred to any branch register nor shall shares on any branch register be transferred to the Register or any other branch register and all transfers and other documents of title shall be lodged for registration, and registered, in the case of any shares on a branch register, at the relevant Registration Office, and, in the case of any shares on the Register, at the Office or such other place at which the Register is kept in accordance with the Act.

50. Without limiting the generality of the Article 49, the Board may decline to recognise any instrument of transfer unless:-

- (a) a fee of such maximum sum as the Designated Stock Exchange may determine to be payable or such lesser sum as the Board may from time to time require is paid to the Company in respect thereof;
- (b) the instrument of transfer is in respect of only one class of share;
- (c) the instrument of transfer is lodged at the Office or such other place at which the Register is kept in accordance with the Act or the Registration Office (as the case may be) accompanied by the relevant share certificate(s) and such other evidence as the Board may reasonably require to show the right of the transferor to make the transfer (and, if the instrument of transfer is executed by some other person on his behalf, the authority of that person so to do); and
- (d) if applicable, the instrument of transfer is duly and properly stamped.

51. If the Board refuses to register a transfer of any share, it shall, within two months after the date on which the transfer was lodged with the Company, send to each of the transferor and transferee notice of the refusal.

52. The registration of transfers of shares or of any class of shares may, after compliance with any notice requirement of the Designated Stock Exchange, be suspended at such times and for such periods (not exceeding in the whole thirty (30) days in any year) as the Board may determine. The period of thirty (30) days may be extended for a further period or periods not exceeding thirty (30) days in respect of any year if approved by the Members by ordinary resolution.

TRANSMISSION OF SHARES

53. If a Member dies, the survivor or survivors where the deceased was a joint holder, and his legal personal representatives where he was a sole or only surviving holder, will be the only persons recognised by the Company as having any title to his interest in the shares; but nothing in this Article will release the estate of a deceased Member (whether sole or joint) from any liability in respect of any share which had been solely or jointly held by him.

54. Any person becoming entitled to a share in consequence of the death or bankruptcy or winding-up of a Member may, upon such evidence as to his title being produced as may be required by the Board, elect either to become the holder of the share or to have some person nominated by him registered as the transferee thereof. If he elects to become the holder he shall notify the Company in writing either at the Registration Office or the Office, as the case may be, to that effect. If he elects to have another person registered he shall execute a transfer of the share in favour of that person. The provisions of these Articles relating to the transfer and registration of transfers of shares shall apply to such notice or transfer as aforesaid as if the death or bankruptcy of the Member had not occurred and the notice or transfer were a transfer signed by such Member.

55. A person becoming entitled to a share by reason of the death or bankruptcy or winding-up of a Member shall be entitled to the same dividends and other advantages to which he would be entitled if he were the registered holder of the share. However, the Board may, if it thinks fit, withhold the payment of any dividend payable or other advantages in respect of such share until such person shall become the registered holder of the share or shall have effectually transferred such share, but, subject to the requirements of Article 76(2) being met, such a person may vote at meetings.

UNTRACEABLE MEMBERS

56. (1) Without prejudice to the rights of the Company under paragraph (2) of this Article 56, the Company may cease sending cheques for dividend entitlements or dividend warrants by post if such cheques or warrants have been left uncashed on two consecutive occasions. However, the Company may exercise the power to cease sending cheques for dividend entitlements or dividend warrants after the first occasion on which such a cheque or warrant is returned undelivered.

(2) The Company shall have the power to sell, in such manner as the Board thinks fit, any shares of a Member who is untraceable, but no such sale shall be made unless:

- (a) all cheques or warrants in respect of dividends of the shares in question, being not less than three in total number, for any sum payable in cash to the holder of such shares in respect of them sent during the relevant period in the manner authorised by the Articles have remained uncashed;
- (b) so far as it is aware at the end of the relevant period, the Company has not at any time during the relevant period received any indication of the existence of the Member who is the holder of such shares or of a person entitled to such shares by death, bankruptcy or operation of law; and
- (c) the Company, if so required by the rules governing the listing of shares on the Designated Stock Exchange, has given notice to, and caused advertisement in newspapers to be made in accordance with the requirements of, the Designated Stock Exchange of its intention to sell such shares in the manner required by the Designated Stock Exchange, and a period of three (3) months or such shorter period as may be allowed by the Designated Stock Exchange has elapsed since the date of such advertisement.

For the purpose of the foregoing, the "relevant period" means the period commencing twelve (12) years before the date of publication of the advertisement referred to in paragraph (c) of this Article and ending at the expiry of the period referred to in that paragraph.

(3) To give effect to any such sale the Board may authorise some person to transfer the said shares and an instrument of transfer signed or otherwise executed by or on behalf of such person shall be as effective as if it had been executed by the registered holder or the person entitled by transmission to such shares, and the purchaser shall not be bound to see to the application of the purchase money nor shall his title to the shares be affected by any irregularity or invalidity in the proceedings relating to the sale. The net proceeds of the sale will belong to the Company and upon receipt by the Company of such net proceeds it shall become indebted to the former Member for an amount equal to such net proceeds. No trust shall be created in respect of such debt and no interest shall be payable in respect of it and the Company shall not be required to account for any money earned from the net proceeds which may be employed in the business of the Company or as it thinks fit. Any sale under this Article shall be valid and effective notwithstanding that the Member holding the shares sold is dead, bankrupt or otherwise under any legal disability or

GENERAL MEETINGS

57. The Company shall, if required by the Statute, in each year hold a general meeting as its annual general meeting, and shall specify the meeting as such in the notices calling it. An annual general meeting of the Company shall be held at such time and place as may be determined by the Board.

58. Each general meeting, other than an annual general meeting, shall be called an extraordinary general meeting. General meetings may be held at such times and in any location in the world as may be determined by the Board. Notwithstanding any provisions in these Articles, any general meeting or any class meeting may be held by means of such telephone, electronic or other communication facilities as to permit all persons participating in the meeting to communicate with each other, and participation in such a meeting shall constitute presence at such meeting. Unless otherwise determined by the Directors, the manner of convening and the proceedings at a general meeting set out in these Articles shall, *mutatis mutandis*, apply to a general meeting held wholly by or in-combination with electronic means.

59. A majority of the Board or the Chairman of the Board may call extraordinary general meetings, which extraordinary general meetings shall be held at such times and locations (as permitted hereby) as such person or persons shall determine. Any one or more Members holding not less than one-third of all votes attaching to the total issued and paid up share capital of the Company at the date of deposit of the requisition shall at all times have the right, by written requisition to the Board or the Secretary of the Company, to require an extraordinary general meeting to be called by the Board for the transaction of any business specified in such requisition; and such meeting shall be held within two (2) months after the deposit of such requisition. If within twenty one (21) days of such deposit the Board fails to proceed to convene such meeting the requisitionist(s) himself (themselves) may do so in the same manner, and all reasonable expenses incurred by the requisitionist(s) as a result of the failure of the Board shall be reimbursed to the requisitionist(s) by the Company.

NOTICE OF GENERAL MEETINGS

60. (1) An annual general meeting and any extraordinary general meeting may be called by not less than ten (10) clear days' Notice but a general meeting may be called by shorter notice, subject to the Act, if it is so agreed:

- (a) in the case of a meeting called as an annual general meeting, by all the Members entitled to attend and vote thereat; and
- (b) in the case of any other meeting, by a majority in number of the Members having the right to attend and vote at the meeting, being a majority together holding not less than ninety-five per cent. (95%) in nominal value of the issued shares giving that right.

(2) The notice shall specify the time and place of the meeting and, in case of special business, the general nature of the business. The notice convening an annual general meeting shall specify the meeting as such. Notice of every general meeting shall be given to all Members other than to such Members as, under the provisions of these Articles or the terms of issue of the shares they hold, are not entitled to receive such notices from the Company, to all persons entitled to a share in consequence of the death or bankruptcy or winding-up of a Member and to each of the Directors.

61. The accidental omission to give Notice of a meeting or (in cases where instruments of proxy are sent out with the Notice) to send such instrument of proxy to, or the non-receipt of such Notice or such instrument of proxy by, any person entitled to receive such Notice shall not invalidate any resolution passed or the proceedings at that meeting.

PROCEEDINGS AT GENERAL MEETINGS

62. (1) All business shall be deemed special that is transacted at an extraordinary general meeting, and also all business that is transacted at an annual general meeting, with the exception of:

- (a) the declaration and sanctioning of dividends;
- (b) consideration and adoption of the accounts and balance sheet and the reports of the Directors and Auditors and other documents required to be annexed to the balance sheet; and
- (c) the election of Directors.

(2) No business other than the appointment of a chairman of a meeting shall be transacted at any general meeting unless a quorum is present at the commencement of the business. At any general meeting of the Company, two (2) Members entitled to vote and present in person or by proxy or (in the case of a Member being a corporation) by its duly authorised representative representing not less than one-third in nominal value of the total issued voting shares in the Company throughout the meeting shall form a quorum for all purposes.

63. If within thirty (30) minutes (or such longer time not exceeding one hour as the chairman of the meeting may determine to wait) after the time appointed for the meeting a quorum is not present, the meeting shall stand adjourned to the same day in the next week at the same time and place or to such time and place as the Board may determine. If at such adjourned meeting a quorum is not present within half an hour from the time appointed for holding the meeting, the meeting shall be dissolved.

64. The Chairman of the Board shall preside as chairman at every general meeting. If at any meeting the chairman is not present within fifteen (15) minutes after the time appointed for holding the meeting, or is not willing to act as chairman, the Directors present shall choose one of their number to act, or if one Director only is present he shall preside as chairman if willing to act. If no Director is present, or if each of the Directors present declines to take the chair, or if the chairman chosen shall retire from the chair, the Members present in person or by its duly authorised representative or by proxy and entitled to vote shall elect one of their number to be chairman.

65. Prior to the holding of a general meeting, the Board may postpone, and at a general meeting, the chairman, may (without consent of the meeting) or shall at the direction of the meeting adjourn the meeting, from time to time and from place to place, but no business shall be transacted at any adjourned or postponed meeting other than the business which might lawfully have been transacted at the meeting had the adjournment or postponement not taken place. When a meeting is adjourned or postponed for fourteen (14) days or more, at least seven (7) clear days' notice of the adjourned or postponed meeting shall be given specifying the time and place of the adjourned or postponed meeting but it shall not be necessary to specify in such notice the nature of the business to be transacted at the adjourned or postponed meeting and the general nature of the business to be transacted. Save as aforesaid, it shall be unnecessary to give notice of an adjournment or postponement.

66. If an amendment is proposed to any resolution under consideration but is in good faith ruled out of order by the chairman of the meeting, the proceedings on the substantive resolution shall not be invalidated by any error in such ruling. In the case of a resolution duly proposed as a special resolution, no amendment thereto (other than a mere clerical amendment to correct a patent error) may in any event be considered or voted upon.

VOTING

67. Holders of ordinary shares have the right to receive notice of, attend, speak and vote at general meetings of the Company. Subject to any special rights or restrictions as to voting for the time being attached to any shares by or in accordance with these Articles, at any general meeting on a show of hands every Member present in person (or being a corporation, is present by a duly authorised representative), or by proxy shall have one vote and on a poll every Member present in person or by proxy or, in the case of a Member being a corporation, by its duly authorised representative shall have one vote for every fully paid share of which he is the holder but so that no amount paid up or credited as paid up on a share in advance of calls or instalments is treated for the foregoing purposes as paid up on the share. Notwithstanding anything contained in these Articles, where more than one proxy is appointed by a Member which is a clearing house or a central depository house (or its nominee(s)), each such proxy shall have one vote on a show of hands. A resolution put to the vote of a meeting shall be decided on a show of hands unless voting by way of a poll is required by the rules and regulations of the Designated Stock Exchange or (before or on the declaration of the result of the show of hands or on the withdrawal of any other demand for a poll) a poll is demanded:

- (a) by the chairman of such meeting; or
- (b) by at least three Members present in person or (in the case of a Member being a corporation) by its duly authorised representative or by proxy for the time being entitled to vote at the meeting; or
- (c) by a Member or Members present in person or (in the case of a Member being a corporation) by its duly authorised representative or by proxy and representing not less than one tenth of the total voting rights of all Members having the right to vote at the meeting; or
- (d) by a Member or Members present in person or (in the case of a Member being a corporation) by its duly authorised representative or by proxy and holding shares in the Company conferring a right to vote at the meeting being shares on which an aggregate sum has been paid up equal to not less than one tenth of the total sum paid up on all shares conferring that right.

A demand by a person as proxy for a Member or in the case of a Member being a corporation by its duly authorised representative shall be deemed to be the same as a demand by a Member. Votes (whether on a show of hands or by way of poll) may be cast by such means, electronic or otherwise, as the Directors or the chairman of the meeting may determine.

68. Unless a poll is duly demanded and the demand is not withdrawn, a declaration by the chairman that a resolution has been carried, or carried unanimously, or by a particular majority, or not carried by a particular majority, or lost, and an entry to that effect made in the minute book of the Company, shall be conclusive evidence of the facts without proof of the number or proportion of the votes recorded for or against the resolution.

69. If a poll is duly demanded the result of the poll shall be deemed to be the resolution of the meeting at which the poll was demanded. The Company shall only be required to disclose the voting figures on a poll if such disclosure is required by the rules and regulations of the Designated Stock Exchange.

70. A poll demanded on the election of a chairman, or on a question of adjournment, shall be taken forthwith. A poll demanded on any other question shall be taken in such manner (including the use of ballot or voting papers or tickets) and either forthwith or at such time (being not later than thirty (30) days after the date of the demand) and place as the chairman directs. It shall not be necessary (unless the chairman otherwise directs) for notice to be given of a poll not taken immediately.

71. The demand for a poll shall not prevent the continuance of a meeting or the transaction of any business other than the question on which the poll has been demanded, and, with the consent of the chairman, it may be withdrawn at any time before the close of the meeting or the taking of the poll, whichever is the earlier.

72. On a poll votes may be given either personally or by proxy.

73. A person entitled to more than one vote on a poll need not use all his votes or cast all the votes he uses in the same way.

74. All questions submitted to a meeting shall be decided by a simple majority of votes except where a greater majority is required by these Articles, by the Act or the rules and regulations of the Designated Stock Exchange. In the case of an equality of votes, whether on a show of hands or on a poll, the chairman of such meeting shall be entitled to a second or casting vote in addition to any other vote he may have.

75. Where there are joint holders of any share any one of such joint holders may vote, either in person or by proxy, in respect of such share as if he were solely entitled thereto, but if more than one of such joint holders be present at any meeting the vote of the senior holder who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders, and for this purpose seniority shall be determined by the order in which the names stand in the Register in respect of the joint holding. Several executors or administrators of a deceased Member in whose name any share stands shall for the purposes of this Article be deemed joint holders thereof.

76. (1) A Member who is a patient for any purpose relating to mental health or in respect of whom an order has been made by any court having jurisdiction for the protection or management of the affairs of persons incapable of managing their own affairs may vote, whether on a show of hands or on a poll, by his receiver, committee, *curator bonis* or other person in the nature of a receiver, committee or *curator bonis* appointed by such court, and such receiver, committee, *curator bonis* or other person may vote on a poll by proxy, and may otherwise act and be treated as if he were the registered holder of such shares for the purposes of general meetings, provided that such evidence as the Board may require of the authority of the person claiming to vote shall have been deposited at the Office, head office or Registration Office, as appropriate, not less than forty-eight (48) hours before the time appointed for holding the meeting, or adjourned meeting or poll, as the case may be.

(2) Any person entitled under Article 54 to be registered as the holder of any shares may vote at any general meeting in respect thereof in the same manner as if he were the registered holder of such shares, provided that forty-eight (48) hours at least before the time of the holding of the meeting or adjourned meeting, as the case may be, at which he proposes to vote, he shall satisfy the Board of his entitlement to such shares, or the Board shall have previously admitted his right to vote at such meeting in respect thereof.

77. No Member shall, unless the Board otherwise determines, be entitled to attend and vote and to be reckoned in a quorum at any general meeting unless he is duly registered and all calls or other sums presently payable by him in respect of shares in the Company have been paid.

78. If:

- (a) any objection shall be raised to the qualification of any voter; or
- (b) any votes have been counted which ought not to have been counted or which might have been rejected; or
- (c) any votes are not counted which ought to have been counted;

the objection or error shall not vitiate the decision of the meeting or adjourned meeting on any resolution unless the same is raised or pointed out at the meeting or, as the case may be, the adjourned meeting at which the vote objected to is given or tendered or at which the error occurs. Any objection or error shall be referred to the chairman of the meeting and shall only vitiate the decision of the meeting on any resolution if the chairman decides that the same may have affected the decision of the meeting. The decision of the chairman on such matters shall be final and conclusive.

PROXIES

79. Any Member entitled to attend and vote at a meeting of the Company shall be entitled to appoint another person as his proxy to attend and vote instead of him. A Member who is the holder of two or more shares may appoint more than one proxy to represent him and vote on his behalf at a general meeting of the Company or at a class meeting. A proxy need not be a Member. In addition, a proxy or proxies representing either a Member who is an individual or a Member which is a corporation shall be entitled to exercise the same powers on behalf of the Member which he or they represent as such Member could exercise.

80. The instrument appointing a proxy shall be in writing under the hand of the appointor or of his attorney duly authorised in writing or, if the appointor is a corporation, either under its seal or under the hand of an officer, attorney or other person authorised to sign the same. In the case of an instrument of proxy purporting to be signed on behalf of a corporation by an officer thereof it shall be assumed, unless the contrary appears, that such officer was duly authorised to sign such instrument of proxy on behalf of the corporation without further evidence of the facts.

81. Unless otherwise determined by the Board, the instrument appointing a proxy and (if required by the Board) the power of attorney or other authority (if any) under which it is signed, or a certified copy of such power or authority, shall be delivered to such place or one of such places (if any) as may be specified for that purpose in or by way of note to or in any document accompanying the notice convening the meeting (or, if no place is so specified at the Registration Office or the Office, as may be appropriate) not less than forty-eight (48) hours before the time appointed for holding the meeting or adjourned meeting at which the person named in the instrument proposes to vote or, in the case of a poll taken subsequently to the date of a meeting or adjourned meeting, not less than twenty-four (24) hours before the time appointed for the taking of the poll and in default the instrument of proxy shall not be treated as valid. No instrument appointing a proxy shall be valid after the expiration of twelve (12) months from the date named in it as the date of its execution, except at an adjourned meeting or on a poll demanded at a meeting or an adjourned meeting in cases where the meeting was originally held within twelve (12) months from such date. Delivery of an instrument appointing a proxy shall not preclude a Member from attending and voting in person at the meeting convened and in such event, the instrument appointing a proxy shall be deemed to be revoked.

82. Instruments of proxy shall be in any common form or in such other form as the Board may approve (provided that this shall not preclude the use of the two-way form) and the Board may, if it thinks fit, send out with the notice of any meeting forms of instrument of proxy for use at the meeting. The instrument of proxy shall be deemed to confer authority to demand or join in demanding a poll and to vote on any amendment of a resolution put to the meeting for which it is given as the proxy thinks fit. The instrument of proxy shall, unless the contrary is stated therein, be valid as well for any adjournment of the meeting as for the meeting to which it relates.

83. A vote given in accordance with the terms of an instrument of proxy shall be valid notwithstanding the previous death or insanity of the principal, or revocation of the instrument of proxy or of the authority under which it was executed, provided that no intimation in writing of such death, insanity or revocation shall have been received by the Company at the Office or the Registration Office (or such other place as may be specified for the delivery of instruments of proxy in the notice convening the meeting or other document sent therewith) two (2) hours at least before the commencement of the meeting or adjourned meeting, or the taking of the poll, at which the instrument of proxy is used.

84. Anything which under these Articles a Member may do by proxy he may likewise do by his duly appointed attorney and the provisions of these Articles relating to proxies and instruments appointing proxies shall apply *mutatis mutandis* in relation to any such attorney and the instrument under which such attorney is appointed.

CORPORATIONS ACTING BY REPRESENTATIVES

85. (1) Any corporation which is a Member may by resolution of its directors or other governing body authorise such person as it thinks fit to act as its representative at any meeting of the Company or at any meeting of any class of Members. The person so authorised shall be entitled to exercise the same powers on behalf of such corporation as the corporation could exercise if it were an individual Member and such corporation shall for the purposes of these Articles be deemed to be present in person at any such meeting if a person so authorised is present thereat.

(2) If a clearing house (or its nominee(s)) or a central depository entity (or its nominee(s)), being a corporation, is a Member, it may authorise such persons as it thinks fit to act as its representatives at any meeting of the Company or at any meeting of any class of Members provided that the authorisation shall specify the number and class of shares in respect of which each such representative is so authorised. Each person so authorised under the provisions of this Article shall be deemed to have been duly authorised without further evidence of the facts and be entitled to exercise the same rights and powers on behalf of the clearing house or a central depository entity (or its nominee(s)) as if such person was the registered holder of the shares of the Company held by the clearing house or a central depository entity (or its nominee(s)) including the right to vote individually on a show of hands.

(3) Any reference in these Articles to a duly authorised representative of a Member being a corporation shall mean a representative authorised under the provisions of this Article.

NO ACTION BY WRITTEN RESOLUTIONS OF MEMBERS

86. Any action required or permitted to be taken at any annual or extraordinary general meetings of the Company may be taken only upon the vote of the Members at an annual or extraordinary general meeting duly noticed and convened in accordance with these Articles and the Act and may not be taken by written resolution of Members without a meeting.

BOARD OF DIRECTORS

87. (1) Unless otherwise determined by the Company in general meeting, the number of Directors shall not be less than two (2). There shall be no maximum number of Directors unless otherwise determined from time to time by the Board. For so long as the shares are listed on the Designated Stock Exchange, the Directors shall include such number of Independent Directors as applicable law, rules or regulations or the Designated Stock Exchange require, unless the Board resolves to follow any available exceptions or exemptions. The Directors shall be elected or appointed in accordance with Article 87 and 88 and shall hold office until the expiration of his term or until their successors are elected or appointed.

(2) Subject to the Articles and the Act, the Company may by ordinary resolution elect any person to be a Director either to fill a casual vacancy or as an addition to the existing Board.

(3) The Directors shall have the power from time to time and at any time to appoint any person as a Director to fill a casual vacancy on the Board or as an addition to the existing Board subject to the Company's compliance with director nomination procedures required under the rules and regulations of the Designated Stock Exchange as long as shares are listed on the Designated Stock Exchange, unless the Board resolves to follow any available exceptions or exemptions.

(4) No Director shall be required to hold any shares of the Company by way of qualification and a Director who is not a Member shall be entitled to receive notice of and to attend and speak at any general meeting of the Company and of all classes of shares of the Company.

(5) Subject to any provision to the contrary in these Articles, a Director may be removed by way of an ordinary resolution of the Members at any time before the expiration of his period of office notwithstanding anything in these Articles or in any agreement between the Company and such Director (but without prejudice to any claim for damages under any such agreement).

(6) A vacancy on the Board created by the removal of a Director under the provisions of subparagraph (5) above may be filled by the election or appointment by ordinary resolution of the Members at the meeting at which such Director is removed or by the affirmative vote of a simple majority of the remaining Directors present and voting at a Board meeting.

(7) The Company may from time to time in general meeting by ordinary resolution increase or reduce the number of Directors but so that the number of Directors shall never be less than two (2).

87A. (1) Notwithstanding any other provisions in the Articles, at each annual general meeting one-third of the Directors for the time being (or, if their number is not a multiple of three (3), the number nearest to but not greater than one-third) shall retire from office by rotation provided that every Director shall be subject to retirement at an annual general meeting at least once every three years.

(2) A retiring Director shall be eligible for re-election by ordinary resolution of the members of the Company. The Directors to retire by rotation shall include (so far as necessary to ascertain the number of directors to retire by rotation) any Director who wishes to retire and not to offer himself for re-election. Any further Directors so to retire shall be those of the other Directors subject to retirement by rotation who have been longest in office since their last re-election or appointment and so that as between persons who became or were last re-elected Directors on the same day those to retire shall (unless they otherwise agree among themselves) be determined by lot.

(3) Unless otherwise provided by the rules of the Designated Stock Exchange, no person other than a Director retiring at the meeting shall, unless recommended by the Directors for election, be eligible for election as a Director at any general meeting.

DISQUALIFICATION OF DIRECTORS

88. The office of a Director shall be vacated if the Director:

- (1) resigns his office by notice in writing delivered to the Company at the Office or tendered at a meeting of the Board;
- (2) becomes of unsound mind or dies;
- (3) without special leave of absence from the Board, is absent from meetings of the Board for three consecutive meetings and the Board resolves that his office be vacated;
- (4) becomes bankrupt or has a receiving order made against him or suspends payment or compounds with his creditors;
- (5) is prohibited by law from being a Director; or
- (6) ceases to be a Director by virtue of any provision of the Statutes or is removed from office pursuant to these Articles.

EXECUTIVE DIRECTORS

89. The Board may from time to time appoint any one or more of its body to be a managing director, joint managing director or deputy managing director or to hold any other employment or executive office with the Company for such period (subject to their continuance as Directors) and upon such terms as the Board may determine and the Board may revoke or terminate any of such appointments. Any such revocation or termination as aforesaid shall be without prejudice to any claim for damages that such Director may have against the Company or the Company may have against such Director. A Director appointed to an office under this Article 91 shall be subject to the same provisions as to removal as the other Directors of the Company, and he shall (subject to the provisions of any contract between him and the Company) ipso facto and immediately cease to hold such office if he shall cease to hold the office of Director for any cause.

90. Notwithstanding Articles 95, 96, 97 and 98, an executive director appointed to an office under Article 89 hereof shall receive such remuneration (whether by way of salary, commission, participation in profits or otherwise or by all or any of those modes) and such other benefits (including pension and/or gratuity and/or other benefits on retirement) and allowances as the Board may from time to time determine, and either in addition to or in lieu of his remuneration as a Director.

ALTERNATE DIRECTORS

91. Any Director may at any time by Notice delivered to the Office or head office or at a meeting of the Directors appoint any person (including another Director) to be his alternate Director. Any person so appointed shall have all the rights and powers of the Director or Directors for whom such person is appointed in the alternative provided that such person shall not be counted more than once in determining whether or not a quorum is present. An alternate Director may be removed at any time by the body which appointed him and, subject thereto, the office of alternate Director shall continue until the happening of any event which, if he were a Director, would cause him to vacate such office or if his appointor ceases for any reason to be a Director. Any appointment or removal of an alternate Director shall be effected by Notice signed by the appointor and delivered to the Office or head office or tendered at a meeting of the Board. An alternate Director may also be a Director in his own right and may act as alternate to more than one Director. An alternate Director shall, if his appointor so requests, be entitled to receive notices of meetings of the Board or of committees of the Board to the same extent as, but in lieu of, the Director appointing him and shall be entitled to such extent to attend and vote as a Director at any such meeting at which the Director appointing him is not personally present and generally at such meeting to exercise and discharge all the functions, powers and duties of his appointor as a Director and for the purposes of the proceedings at such meeting the provisions of these Articles shall apply as if he were a Director save that as an alternate for more than one Director his voting rights shall be cumulative.

92. An alternate Director shall only be a Director for the purposes of the Act and shall only be subject to the provisions of the Act insofar as they relate to the duties and obligations of a Director when performing the functions of the Director for whom he is appointed in the alternative and shall alone be responsible to the Company for his acts and defaults and shall not be deemed to be the agent of or for the Director appointing him. An alternate Director shall be entitled to contract and be interested in and benefit from contracts or arrangements or transactions and to be repaid expenses and to be indemnified by the Company to the same extent *mutatis mutandis* as if he were a Director but he shall not be entitled to receive from the Company any fee in his capacity as an alternate Director except only such part, if any, of the remuneration otherwise payable to his appointor as such appointor may by Notice to the Company from time to time direct.

93. Every person acting as an alternate Director shall have one vote for each Director for whom he acts as alternate (in addition to his own vote if he is also a Director). If his appointor is for the time being absent from the People's Republic of China or otherwise not available or unable to act, the signature of an alternate Director to any resolution in writing of the Board or a committee of the Board of which his appointor is a member shall, unless the notice of his appointment provides to the contrary, be as effective as the signature of his appointor.

94. An alternate Director shall ipso facto cease to be an alternate Director if his appointor ceases for any reason to be a Director, however, such alternate Director or any other person may be re-appointed by the Directors to serve as an alternate Director PROVIDED always that, if at any meeting any Director retires but is re-elected at the same meeting, any appointment of such alternate Director pursuant to these Articles which was in force immediately before his retirement shall remain in force as though he had not retired.

25

DIRECTORS' FEES AND EXPENSES

95. The Directors shall receive such remuneration as the Board may from time to time determine. Each Director shall be entitled to be repaid or prepaid all traveling, hotel and incidental expenses reasonably incurred or expected to be incurred by him in attending meetings of the Board or committees of the board or general meetings or separate meetings of any class of shares or of debenture of the Company or otherwise in connection with the discharge of his duties as a Director.

96. Each Director shall be entitled to be repaid or prepaid all travelling, hotel and incidental expenses reasonably incurred or expected to be incurred by him in attending meetings of the Board or committees of the Board or general meetings or separate meetings of any class of shares or of debentures of the Company or otherwise in connection with the discharge of his duties as a Director.

97. Any Director who, by request, goes or resides abroad for any purpose of the Company or who performs services which in the opinion of the Board go beyond the ordinary duties of a Director may be paid such extra remuneration (whether by way of salary, commission, participation in profits or otherwise) as the Board may determine and such extra remuneration shall be in addition to or in substitution for any ordinary remuneration provided for by or pursuant to any other Article.

98. The Board shall determine any payment to any Director or past Director of the Company by way of compensation for loss of office, or as consideration for or in connection with his retirement from office (not being payment to which the Director is contractually entitled).

DIRECTORS' INTERESTS

99. A Director may:

- (a) hold any other office or place of profit with the Company (except that of Auditor) in conjunction with his office of Director for such period and upon such terms as the Board may determine. Any remuneration (whether by way of salary, commission, participation in profits or otherwise) paid to any Director in respect of any such other office or place of profit shall be in addition to any remuneration provided for by or pursuant to any other Article;
- (b) act by himself or his firm in a professional capacity for the Company (otherwise than as Auditor) and he or his firm may be remunerated for professional services as if he were not a Director;
- (c) continue to be or become a director, managing director, joint managing director, deputy managing director, executive director, manager or other officer or member of any other company promoted by the Company or in which the Company may be interested as a vendor, shareholder or otherwise and (unless otherwise agreed) no such Director shall be accountable for any remuneration, profits or other benefits received by him as a director, managing director, joint managing director, deputy managing director, executive director, manager or other officer or member of or from his interests in any such other company. Subject as otherwise provided by these Articles the Directors may exercise or cause to be exercised the voting powers conferred by the shares in any other company held or owned by the Company, or exercisable by them as Directors of such other company in such manner in all respects as they think fit (including the exercise thereof in favour of any resolution appointing themselves or any of them directors, managing directors, joint managing directors, deputy managing directors, executive directors, managers or other officers of such company) or voting or providing for the payment of remuneration to the director, managing director, joint managing director, deputy managing director, executive director, manager or other officers of such other company and any Director may vote in favour of the exercise of such voting rights in manner aforesaid notwithstanding that he may be, or about to be, appointed a director, managing director, joint managing director, deputy managing director, executive director, manager or other officer of such a company, and that as such he is or may become interested in the exercise of such voting rights in manner aforesaid.

26

Notwithstanding the foregoing, no Independent Director shall take any of the foregoing actions or any other action that would reasonably be likely to affect such Director's status as an Independent Director.

100. Subject to the Act and to these Articles, no Director or proposed or intending Director shall be disqualified by his office from contracting with the Company, either with regard to his tenure of any office or place of profit or as vendor, purchaser or in any other manner whatsoever, nor shall any such contract or any other contract or arrangement in which any Director is in any way interested be liable to be avoided, nor shall any Director so contracting or being so interested be liable to account to the Company or the Members for any remuneration, profit or other benefits realised by any such contract or arrangement by reason of such Director holding that office or of the fiduciary relationship thereby established provided that such Director shall disclose the nature of his interest in any contract or arrangement in which he is interested in accordance with Article 101 herein. An Independent Director is prohibited from entering into any transaction that would constitute a "related party transaction", as defined by the rules and regulations of the Designated Stock Exchange or under applicable laws, that could reasonably affect their status as an Independent Director.

101. A Director who to his knowledge is in any way, whether directly or indirectly, interested in a contract or arrangement or proposed contract or arrangement with the Company shall declare the nature of his interest at the meeting of the Board at which the question of entering into the contract or arrangement is first considered, if he knows his interest then exists, or in any other case at the first meeting of the Board after he knows that he is or has become so interested. For the purposes of this Article, a general Notice to the Board by a Director to the effect that:

- (a) he is a member or officer of a specified company or firm and is to be regarded as interested in any contract or arrangement which may after the date of the Notice be made with that company or firm; or
- (b) he is to be regarded as interested in any contract or arrangement which may after the date of the Notice be made with a specified person who is connected with him;

shall be deemed to be a sufficient declaration of interest under this Article in relation to any such contract or arrangement, provided that no such Notice shall be effective unless either it is given at a meeting of the Board or the Director takes reasonable steps to secure that it is brought up and read at the next Board meeting after it is given.

102. Following a declaration being made pursuant to the last preceding two Articles, subject to any separate requirement for Audit Committee approval under applicable law or the rules and regulations of the Designated Stock Exchange, and unless disqualified by the chairman of the relevant Board meeting, a Director may vote in respect of any contract or proposed contract or arrangement in which such Director is interested and may be counted in the quorum at such meeting.

GENERAL POWERS OF THE DIRECTORS

103. (1) The business of the Company shall be managed and conducted by the Board, which may pay all expenses incurred in forming and registering the Company and may exercise all powers of the Company (whether relating to the management of the business of the Company or otherwise) which are not by the Statutes or by these Articles required to be exercised by the Company in general meeting, subject nevertheless to the provisions of the Statutes and of these Articles and to such regulations being not inconsistent with such provisions, as may be prescribed by the Company in general meeting, but no regulations made by the Company in general meeting shall invalidate any prior act of the Board which would have been valid if such regulations had not been made. The general powers given by this Article shall not be limited or restricted by any special authority or power given to the Board by any other Article.

(2) Any person contracting or dealing with the Company in the ordinary course of business shall be entitled to rely on any written or oral contract or agreement or deed, document or instrument entered into or executed as the case may be by any one Director on behalf of the Company and the same shall be deemed to be validly entered into or executed by the Company as the case may be and shall, subject to any rule of law, be binding on the Company.

(3) Without prejudice to the general powers conferred by these Articles it is hereby expressly declared that the Board shall have the following powers:

- (a) to give to any person the right or option of requiring at a future date that an allotment shall be made to him of any share at par or at such premium as may be agreed;
- (b) to give to any Directors, officers or employees of the Company an interest in any particular business or transaction or participation in the profits thereof or in the general profits of the Company either in addition to or in substitution for a salary or other remuneration; and
- (c) to resolve that the Company be deregistered in the Cayman Islands and continued in a named jurisdiction outside the Cayman Islands subject to the provisions of the Act.

104. The Board may establish any regional or local boards or agencies for managing any of the affairs of the Company in any place, and may appoint any persons to be members of such local boards, or any managers or agents, and may fix their remuneration (either by way of salary or by commission or by conferring the right to participation in the profits of the Company or by a combination of two or more of these modes) and pay the working expenses of any staff employed by them upon the business of the Company. The Board may delegate to any regional or local board, manager or agent any of the powers, authorities and discretions vested in or exercisable by the Board (other than its powers to make calls and forfeit shares), with power to sub-delegate, and may authorise the members of any of them to fill any vacancies therein and to act notwithstanding vacancies. Any such appointment or delegation may be made upon such terms and subject to such conditions as the Board may think fit, and the Board may remove any person appointed as aforesaid, and may revoke or vary such delegation, but no person dealing in good faith and without notice of any such revocation or variation shall be affected thereby.

105. The Board may by power of attorney appoint any company, firm or person or any fluctuating body of persons, whether nominated directly or indirectly by the Board, to be the attorney or attorneys of the Company for such purposes and with such powers, authorities and discretions (not exceeding those vested in or exercisable by the Board under these Articles) and for such period and subject to such conditions as it may think fit, and any such power of attorney may contain such provisions for the protection and convenience of persons dealing with any such attorney as the Board may think fit, and may also authorise any such attorney to sub-delegate all or any of the powers, authorities and discretions vested in him. Such attorney or attorneys may, if so authorised under the Seal of the Company, execute any deed or instrument under their personal seal with the same effect as the affixation of the Company's Seal.

106. The Board may entrust to and confer upon a managing director, joint managing director, deputy managing director, an executive director or any Director any of the powers exercisable by it upon such terms and conditions and with such restrictions as it thinks fit, and either collaterally with, or to the exclusion of, its own powers, and may from time to time revoke or vary all or any of such powers but no person dealing in good faith and without notice of such revocation or variation shall be affected

thereby.

107. All cheques, promissory notes, drafts, bills of exchange and other instruments, whether negotiable or transferable or not, and all receipts for moneys paid to the Company shall be signed, drawn, accepted, endorsed or otherwise executed, as the case may be, in such manner as the Board shall from time to time by resolution determine. The Company's banking accounts shall be kept with such banker or bankers as the Board shall from time to time determine.

108. (1) The Board may establish or concur or join with other companies (being subsidiary companies of the Company or companies with which it is associated in business) in establishing and making contributions out of the Company's moneys to any schemes or funds for providing pensions, sickness or compassionate allowances, life assurance or other benefits for employees (which expression as used in this and the following paragraph shall include any Director or ex-Director who may hold or have held any executive office or any office of profit under the Company or any of its subsidiary companies) and ex-employees of the Company and their dependants or any class or classes of such person.

(2) The Board may pay, enter into agreements to pay or make grants of revocable or irrevocable pensions or other benefits to employees and ex-employees and their dependants, or to any of such persons, including pensions or benefits additional to those, if any, to which such employees or ex-employees or their dependants are or may become entitled under any such scheme or fund as mentioned in the last preceding paragraph. Any such pension or benefit may, as the Board considers desirable, be granted to an employee either before and in anticipation of or upon or at any time after his actual retirement, and may be subject or not subject to any terms or conditions as the Board may determine.

BORROWING POWERS

109. The Board may exercise all the powers of the Company to raise or borrow money and to mortgage or charge all or any part of the undertaking, property and assets (present and future) and uncalled capital of the Company and, subject to the Act, to issue debentures, bonds and other securities, whether outright or as collateral security for any debt, liability or obligation of the Company or of any third party.

110. Debentures, bonds and other securities may be made assignable free from any equities between the Company and the person to whom the same may be issued.

111. Any debentures, bonds or other securities may be issued at a discount (other than shares), premium or otherwise and with any special privileges as to redemption, surrender, drawings, allotment of shares, attending and voting at general meetings of the Company, appointment of Directors and otherwise.

112. (1) Where any uncalled capital of the Company is charged, all persons taking any subsequent charge thereon shall take the same subject to such prior charge, and shall not be entitled, by notice to the Members or otherwise, to obtain priority over such prior charge.

(2) The Board shall cause a proper register to be kept, in accordance with the provisions of the Act, of all charges specifically affecting the property of the Company and of any series of debentures issued by the Company and shall duly comply with the requirements of the Act in regard to the registration of charges and debentures therein specified and otherwise.

PROCEEDINGS OF THE DIRECTORS

113. The Board may meet for the despatch of business, adjourn and otherwise regulate its meetings as it considers appropriate. Questions arising at any meeting shall be determined by a majority of votes. In the case of any equality of votes the chairman of the meeting shall have an additional or casting vote.

114. A meeting of the Board may be convened by the Secretary on request of a Director or by any Director. The Secretary shall convene a meeting of the Board of which notice may be given in writing or by telephone or in such other manner as the Board may from time to time determine whenever he shall be required so to do by the president or chairman, as the case may be, or any Director.

115. (1) The quorum necessary for the transaction of the business of the Board may be fixed by the Board and, unless so fixed at any other number, shall be two (2) of the Board. An alternate Director shall be counted in a quorum in the case of the absence of a Director for whom he is the alternate provided that he shall not be counted more than once for the purpose of determining whether or not a quorum is present.

(2) Directors may participate in any meeting of the Board by means of a conference telephone or other communications equipment through which all persons participating in the meeting can communicate with each other simultaneously and instantaneously and, for the purpose of counting a quorum, such participation shall constitute presence at a meeting as if those participating were present in person.

(3) Any Director who ceases to be a Director at a Board meeting may continue to be present and to act as a Director and be counted in the quorum until the termination of such Board meeting if no other Director objects and if otherwise a quorum of Directors would not be present.

116. The continuing Directors or a sole continuing Director may act notwithstanding any vacancy in the Board but, if and so long as the number of Directors is reduced below the minimum number fixed by or in accordance with these Articles as the quorum, the continuing Directors or Director, notwithstanding that the number of Directors is below the number fixed by or in accordance with these Articles as the quorum or that there is only one continuing Director, may act for the purpose of filling vacancies in the Board or of summoning general meetings of the Company but not for any other purpose.

117. The Chairman of the Board shall be the chairman of all meetings of the Board. If the Chairman of the Board is not present at any meeting within five (5) minutes after the time appointed for holding the same, the Directors present may choose one of their number to be chairman of the meeting.

118. A meeting of the Board at which a quorum is present shall be competent to exercise all the powers, authorities and discretions for the time being vested in or exercisable by the Board.

119. (1) The Board may delegate any of its powers, authorities and discretions to committees (including, without limitation, the Audit Committee), consisting of such Director or Directors and other persons as it thinks fit, and they may, from time to time, revoke such delegation or revoke the appointment of and discharge any such committees either wholly or in part, and either as to persons or purposes. Any committee so formed shall, in the exercise of the powers, authorities and discretions so delegated, conform to any regulations which may be imposed on it by the Board.

(2) All acts done by any such committee in conformity with such regulations, and in fulfilment of the purposes for which it was appointed, but not otherwise, shall have like force and effect as if done by the Board, and the Board (or if the Board delegates such power, the committee) shall have power to remunerate the

members of any such committee, and charge such remuneration to the current expenses of the Company.

120. The meetings and proceedings of any committee consisting of two or more members shall be governed by the provisions contained in these Articles for regulating the meetings and proceedings of the Board so far as the same are applicable and are not superseded by any regulations imposed by the Board under the last preceding Article, indicating, without limitation, any committee charter adopted by the Board for purposes or in respect of any such committee.

121. A resolution in writing signed by all the Directors except such as are temporarily unable to act through ill-health or disability shall (provided that such number is sufficient to constitute a quorum and further provided that a copy of such resolution has been given or the contents thereof communicated to all the Directors for the time being entitled to receive notices of Board meetings in the same manner as notices of meetings are required to be given by these Articles) be as valid and effectual as if a resolution had been passed at a meeting of the Board duly convened and held. Such resolution may be contained in one document or in several documents in like form each signed by one or more of the Directors and for this purpose a facsimile signature of a Director shall be treated as valid.

122. All acts bona fide done by the Board or by any committee or by any person acting as a Director or members of a committee, shall, notwithstanding that it is afterwards discovered that there was some defect in the appointment of any member of the Board or such committee or person acting as aforesaid or that they or any of them were disqualified or had vacated office, be as valid as if every such person had been duly appointed and was qualified and had continued to be a Director or member of such committee.

AUDIT COMMITTEE

123. Without prejudice to the freedom of the Directors to establish any other committees, for so long as the shares of the Company (or depositary receipts therefor) are listed or quoted on the Designated Stock Exchange, the Board shall establish and maintain an Audit Committee as a committee of the Board, the composition and responsibilities of which shall comply with the rules and regulations of the Designated Stock Exchange and the rules and regulations of the SEC.

124. The Board shall adopt a formal written audit committee charter and review and assess the adequacy of the formal written charter on an annual basis.

125. For so long as the shares of the Company (or depositary receipts therefor) are listed or quoted on the Designated Stock Exchange, the Company shall conduct an appropriate review of all related party transactions on an ongoing basis and shall utilize the Audit Committee for the review and approval of potential conflicts of interest in accordance with the audit committee charter.

OFFICERS

126. (1) The officers of the Company shall consist of the Chairman of the Board, the Directors and Secretary and such additional officers (who may or may not be Directors) as the Board may from time to time determine, all of whom shall be deemed to be officers for the purposes of the Act and these Articles. In addition to the officers of the Company, the Board may also from time to time determine and appoint managers and delegate to the same such powers and duties as are prescribed by the Board.

(2) The Directors shall, as soon as may be after each appointment or election of Directors, elect amongst the Directors a chairman and if more than one Director is proposed for this office, the election to such office shall take place in such manner as the Directors may determine.

(3) The officers shall receive such remuneration as the Directors may from time to time determine.

127. (1) The Secretary and additional officers, if any, shall be appointed by the Board and shall hold office on such terms and for such period as the Board may determine. If thought fit, two or more persons may be appointed as joint Secretaries. The Board may also appoint from time to time on such terms as it thinks fit one or more assistant or deputy Secretaries.

(2) The Secretary shall attend all meetings of the Members and shall keep correct minutes of such meetings and enter the same in the proper books provided for the purpose. He shall perform such other duties as are prescribed by the Act or these Articles or as may be prescribed by the Board.

128. The officers of the Company shall have such powers and perform such duties in the management, business and affairs of the Company as may be delegated to them by the Directors from time to time.

129. A provision of the Act or of these Articles requiring or authorising a thing to be done by or to a Director and the Secretary shall not be satisfied by its being done by or to the same person acting both as Director and as or in place of the Secretary.

REGISTER OF DIRECTORS AND OFFICERS

130. The Company shall cause to be kept in one or more books at its Office a Register of Directors and Officers in which there shall be entered the full names and addresses of the Directors and Officers and such other particulars as required by the Act or as the Directors may determine. The Company shall send to the Registrar of Companies in the Cayman Islands a copy of such register, and shall from time to time notify to the said Registrar of any change that takes place in relation to such Directors and Officers as required by the Act.

MINUTES

131. (1) The Board shall cause minutes to be duly entered in books provided for the purpose:

- (a) of all elections and appointments of officers;
 - (b) of the names of the Directors present at each meeting of the Directors and of any committee of the Directors;
 - (c) of all resolutions and proceedings of each general meeting of the Members, meetings of the Board and meetings of committees of the Board and where there are managers, of all proceedings of meetings of the managers.
- (2) Minutes shall be kept by the Secretary at the Office.

SEAL

132. (1) The Company shall have one or more Seals, as the Board may determine. For the purpose of sealing documents creating or evidencing securities issued by the Company, the Company may have a securities seal which is a facsimile of the Seal of the Company with the addition of the word "Securities" on its face or in such other form as the Board may approve. The Board shall provide for the custody of each Seal and no Seal shall be used without the authority of the Board or of a committee of the Board authorised by the Board in that behalf. Subject as otherwise provided in these Articles, any instrument to which a Seal is affixed shall be signed autographically by one Director or by such other person (including a Director) or persons as the Board may appoint, either generally or in any particular case, save that as regards any certificates for shares or debentures or other securities of the Company the Board may by resolution determine that such signatures or either of them shall be dispensed with or affixed by some method or system of mechanical signature. Every instrument executed in manner provided by this Article 132 shall be deemed to be sealed and executed with the authority of the Board previously given.

(2) Where the Company has a Seal for use abroad, the Board may by writing under the Seal appoint any agent or committee abroad to be the duly authorised agent of the Company for the purpose of affixing and using such Seal and the Board may impose restrictions on the use thereof as may be thought fit. Wherever in these Articles reference is made to the Seal, the reference shall, when and so far as may be applicable, be deemed to include any such other Seal as aforesaid.

AUTHENTICATION OF DOCUMENTS

133. Any Director or the Secretary or any person appointed by the Board for the purpose may authenticate any documents affecting the constitution of the Company and any resolution passed by the Company or the Board or any committee, and any books, records, documents and accounts relating to the business of the Company, and to certify copies thereof or extracts therefrom as true copies or extracts, and if any books, records, documents or accounts are elsewhere than at the Office or the head office the local manager or other officer of the Company having the custody thereof shall be deemed to be a person so appointed by the Board. A document purporting to be a copy of a resolution, or an extract from the minutes of a meeting, of the Company or of the Board or any committee which is so certified shall be conclusive evidence in favour of all persons dealing with the Company upon the faith thereof that such resolution has been duly passed or, as the case may be, that such minutes or extract is a true and accurate record of proceedings at a duly constituted meeting.

DESTRUCTION OF DOCUMENTS

134. (1) The Company shall be entitled to destroy the following documents at the following times:

- (a) any share certificate which has been cancelled at any time after the expiry of one (1) year from the date of such cancellation;
- (b) any dividend mandate or any variation or cancellation thereof or any notification of change of name or address at any time after the expiry of two (2) years from the date such mandate variation cancellation or notification was recorded by the Company;
- (c) any instrument of transfer of shares which has been registered at any time after the expiry of seven (7) years from the date of registration;
- (d) any allotment letters after the expiry of seven (7) years from the date of issue thereof; and
- (e) copies of powers of attorney, grants of probate and letters of administration at any time after the expiry of seven (7) years after the account to which the relevant power of attorney, grant of probate or letters of administration related has been closed;

and it shall conclusively be presumed in favour of the Company that every entry in the Register purporting to be made on the basis of any such documents so destroyed was duly and properly made and every share certificate so destroyed was a valid certificate duly and properly cancelled and that every instrument of transfer so destroyed was a valid and effective instrument duly and properly registered and that every other document destroyed hereunder was a valid and effective document in accordance with the recorded particulars thereof in the books or records of the Company. Provided always that: (1) the foregoing provisions of this Article 134 shall apply only to the destruction of a document in good faith and without express notice to the Company that the preservation of such document was relevant to a claim; (2) nothing contained in this Article 134 shall be construed as imposing upon the Company any liability in respect of the destruction of any such document earlier than as aforesaid or in any case where the conditions of proviso (1) above are not fulfilled; and (3) references in this Article 134 to the destruction of any document include references to its disposal in any manner.

(2) Notwithstanding any provision contained in these Articles, the Directors may, if permitted by applicable law, authorise the destruction of documents set out in sub-paragraphs (a) to (e) of paragraph (1) of this Article 134 and any other documents in relation to share registration which have been microfilmed or electronically stored by the Company or by the share registrar on its behalf provided always that this Article shall apply only to the destruction of a document in good faith and without express notice to the Company and its share registrar that the preservation of such document was relevant to a claim.

DIVIDENDS AND OTHER PAYMENTS

135. Subject to the Act, the Board may from time to time declare dividends in any currency to be paid to the Members.

136. Dividends may be declared and paid out of the profits of the Company, realised or unrealised, or from any reserve set aside from profits which the Directors determine is no longer needed. The Board may also declare and pay dividends out of share premium account or any other fund or account which can be authorised for this purpose in accordance with the Act.

137. Except in so far as the rights attaching to, or the terms of issue of, any share otherwise provide:

- (a) all dividends shall be declared and paid according to the amounts paid up on the shares in respect of which the dividend is paid, but no amount paid up on a share in advance of calls shall be treated for the purposes of this Article as paid up on the share; and
- (b) all dividends shall be apportioned and paid pro rata according to the amounts paid up on the shares during any portion or portions of the period in respect of which the dividend is paid.

138. The Board may from time to time pay to the Members such interim dividends as appear to the Board to be justified by the profits of the Company and in particular (but without prejudice to the generality of the foregoing) if at any time the share capital of the Company is divided into different classes, the Board may pay such interim dividends in respect of those shares in the capital of the Company which confer on the holders thereof deferred or non-preferential rights as well as in respect of those

shares which confer on the holders thereof preferential rights with regard to dividend and provided that the Board acts bona fide the Board shall not incur any responsibility to the holders of shares conferring any preference for any damage that they may suffer by reason of the payment of an interim dividend on any shares having deferred or non-preferential rights and may also pay any fixed dividend which is payable on any shares of the Company half-yearly or on any other dates, whenever such profits, in the opinion of the Board, justifies such payment.

139. The Board may deduct from any dividend or other moneys payable to a Member by the Company on or in respect of any shares all sums of money (if any) presently payable by him to the Company on account of calls or otherwise.

140. No dividend or other moneys payable by the Company on or in respect of any share shall bear interest against the Company.

141. Any dividend, interest or other sum payable in cash to the holder of shares may be paid by cheque or warrant sent through the post addressed to the holder at his registered address or, in the case of joint holders, addressed to the holder whose name stands first in the Register in respect of the shares at his address as appearing in the Register or addressed to such person and at such address as the holder or joint holders may in writing direct. Every such cheque or warrant shall, unless the holder or joint holders otherwise direct, be made payable to the order of the holder or, in the case of joint holders, to the order of the holder whose name stands first on the Register in respect of such shares, and shall be sent at his or their risk and payment of the cheque or warrant by the bank on which it is drawn shall constitute a good discharge to the Company notwithstanding that it may subsequently appear that the same has been stolen or that any endorsement thereon has been forged. Any one of two or more joint holders may give effectual receipts for any dividends or other moneys payable or property distributable in respect of the shares held by such joint holders.

142. All dividends or bonuses unclaimed for one (1) year after having been declared may be invested or otherwise made use of by the Board for the benefit of the Company until claimed. Any dividend or bonuses unclaimed after a period of six (6) years from the date of declaration shall be forfeited and shall revert to the Company. The payment by the Board of any unclaimed dividend or other sums payable on or in respect of a share into a separate account shall not constitute the Company a trustee in respect thereof.

143. Whenever the Board has resolved that a dividend be paid or declared, the Board may further resolve that such dividend be satisfied wholly or in part by the distribution of specific assets of any kind and in particular of paid up shares, debentures or warrants to subscribe securities of the Company or any other company, or in any one or more of such ways, and where any difficulty arises in regard to the distribution the Board may settle the same as it thinks expedient, and in particular may issue certificates in respect of fractions of shares, disregard fractional entitlements or round the same up or down, and may fix the value for distribution of such specific assets, or any part thereof, and may determine that cash payments shall be made to any Members upon the basis of the value so fixed in order to adjust the rights of all parties, and may vest any such specific assets in trustees as may seem expedient to the Board and may appoint any person to sign any requisite instruments of transfer and other documents on behalf of the persons entitled to the dividend, and such appointment shall be effective and binding on the Members. The Board may resolve that no such assets shall be made available to Members with registered addresses in any particular territory or territories where, in the absence of a registration statement or other special formalities, such distribution of assets would or might, in the opinion of the Board, be unlawful or impracticable and in such event the only entitlement of the Members aforesaid shall be to receive cash payments as aforesaid. Members affected as a result of the foregoing sentence shall not be or be deemed to be a separate class of Members for any purpose whatsoever.

144. (1) Whenever the Board has resolved that a dividend be paid or declared on any class of the share capital of the Company, the Board may further resolve either:

- (a) that such dividend be satisfied wholly or in part in the form of an allotment of shares credited as fully paid up, provided that the Members entitled thereto will be entitled to elect to receive such dividend (or part thereof if the Board so determines) in cash in lieu of such allotment. In such case, the following provisions shall apply:
 - (i) the basis of any such allotment shall be determined by the Board;
 - (ii) the Board, after determining the basis of allotment, shall give not less than ten (10) days' Notice to the holders of the relevant shares of the right of election accorded to them and shall send with such notice forms of election and specify the procedure to be followed and the place at which and the latest date and time by which duly completed forms of election must be lodged in order to be effective;
 - (iii) the right of election may be exercised in respect of the whole or part of that portion of the dividend in respect of which the right of election has been accorded; and
 - (iv) the dividend (or that part of the dividend to be satisfied by the allotment of shares as aforesaid) shall not be payable in cash on shares in respect whereof the cash election has not been duly exercised ("the non-elected shares") and in satisfaction thereof shares of the relevant class shall be allotted credited as fully paid up to the holders of the non-elected shares on the basis of allotment determined as aforesaid and for such purpose the Board shall capitalise and apply out of any part of the undivided profits of the Company (including profits carried and standing to the credit of any reserves or other special account, share premium account, capital redemption reserve other than the Subscription Rights Reserve) as the Board may determine, such sum as may be required to pay up in full the appropriate number of shares of the relevant class for allotment and distribution to and amongst the holders of the non-elected shares on such basis; or

- (b) that the Members entitled to such dividend shall be entitled to elect to receive an allotment of shares credited as fully paid up in lieu of the whole or such part of the dividend as the Board may think fit. In such case, the following provisions shall apply:
 - (i) the basis of any such allotment shall be determined by the Board;
 - (ii) the Board, after determining the basis of allotment, shall give not less than ten (10) days' Notice to the holders of the relevant shares of the right of election accorded to them and shall send with such notice forms of election and specify the procedure to be followed and the place at which and the latest date and time by which duly completed forms of election must be lodged in order to be effective;
 - (iii) the right of election may be exercised in respect of the whole or part of that portion of the dividend in respect of which the right of election has been accorded; and

- (iv) the dividend (or that part of the dividend in respect of which a right of election has been accorded) shall not be payable in cash on shares in respect whereof the share election has been duly exercised (“the elected shares”) and in lieu thereof shares of the relevant class shall be allotted credited as fully paid up to the holders of the elected shares on the basis of allotment determined as aforesaid and for such purpose the Board shall capitalise and apply out of any part of the undivided profits of the Company (including profits carried and standing to the credit of any reserves or other special account, share premium account, capital redemption reserve other than the Subscription Rights Reserve) as the Board may determine, such sum as may be required to pay up in full the appropriate number of shares of the relevant class for allotment and distribution to and amongst the holders of the elected shares on such basis.
- (2) (a) The shares allotted pursuant to the provisions of paragraph (1) of this Article 144 shall rank *pari passu* in all respects with shares of the same class (if any) then in issue save only as regards participation in the relevant dividend or in any other distributions, bonuses or rights paid, made, declared or announced prior to or contemporaneously with the payment or declaration of the relevant dividend unless, contemporaneously with the announcement by the Board of their proposal to apply the provisions of sub-paragraph (a) or (b) of paragraph (2) of this Article 144 in relation to the relevant dividend or contemporaneously with their announcement of the distribution, bonus or rights in question, the Board shall specify that the shares to be allotted pursuant to the provisions of paragraph (1) of this Article shall rank for participation in such distribution, bonus or rights.
- (b) The Board may do all acts and things considered necessary or expedient to give effect to any capitalisation pursuant to the provisions of paragraph (1) of this Article 144, with full power to the Board to make such provisions as it thinks fit in the case of shares becoming distributable in fractions (including provisions whereby, in whole or in part, fractional entitlements are aggregated and sold and the net proceeds distributed to those entitled, or are disregarded or rounded up or down or whereby the benefit of fractional entitlements accrues to the Company rather than to the Members concerned). The Board may authorise any person to enter into on behalf of all Members interested, an agreement with the Company providing for such capitalisation and matters incidental thereto and any agreement made pursuant to such authority shall be effective and binding on all concerned.

(3) The Board may determine and resolve in respect of any one particular dividend of the Company that notwithstanding the provisions of paragraph (1) of this Article 144 a dividend may be satisfied wholly in the form of an allotment of shares credited as fully paid up without offering any right to shareholders to elect to receive such dividend in cash in lieu of such allotment.

(4) The Board may on any occasion determine that rights of election and the allotment of shares under paragraph (1) of this Article 144 shall not be made available or made to any shareholders with registered addresses in any territory where, in the absence of a registration statement or other special formalities, the circulation of an offer of such rights of election or the allotment of shares would or might, in the opinion of the Board, be unlawful or impracticable, and in such event the provisions aforesaid shall be read and construed subject to such determination. Members affected as a result of the foregoing sentence shall not be or be deemed to be a separate class of Members for any purpose whatsoever.

(5) Any resolution declaring a dividend on shares of any class by the Board, may specify that the same shall be payable or distributable to the persons registered as the holders of such shares at the close of business on a particular date, notwithstanding that it may be a date prior to that on which the resolution is passed, and thereupon the dividend shall be payable or distributable to them in accordance with their respective holdings so registered, but without prejudice to the rights *inter se* in respect of such dividend of transferors and transferees of any such shares. The provisions of this Article shall *mutatis mutandis* apply to bonuses, capitalisation issues, distributions of realised capital profits or offers or grants made by the Company to the Members.

RESERVES

145. (1) The Board shall establish an account to be called the share premium account and shall carry to the credit of such account from time to time a sum equal to the amount or value of the premium paid on the issue of any share in the Company. Unless otherwise provided by the provisions of these Articles, the Board may apply the share premium account in any manner permitted by the Act. The Company shall at all times comply with the provisions of the Act in relation to the share premium account.

(2) Before recommending any dividend, the Board may set aside out of the profits of the Company such sums as it determines as reserves which shall, at the discretion of the Board, be applicable for any purpose to which the profits of the Company may be properly applied and pending such application may, also at such discretion, either be employed in the business of the Company or be invested in such investments as the Board may from time to time think fit and so that it shall not be necessary to keep any investments constituting the reserve or reserves separate or distinct from any other investments of the Company. The Board may also without placing the same to reserve carry forward any profits which it may think prudent not to distribute.

CAPITALISATION

146. The Company may, upon the recommendation of the Board, at any time and from time to time pass an ordinary resolution to the effect that it is desirable to capitalise all or any part of any amount for the time being standing to the credit of any reserve or fund (including a share premium account and capital redemption reserve and the profit and loss account) whether or not the same is available for distribution and accordingly that such amount be set free for distribution among the Members or any class of Members who would be entitled thereto if it were distributed by way of dividend and in the same proportions, on the basis that the same is not paid in cash but is applied either in or towards paying up the amounts for the time being unpaid on any shares in the Company held by such Members respectively or in paying up in full unissued shares, debentures or other obligations of the Company, to be allotted and distributed credited as fully paid up among such Members, or partly in one way and partly in the other, and the Board shall give effect to such resolution provided that, for the purposes of this Article 146, a share premium account and any capital redemption reserve or fund representing unrealised profits, may be applied only in paying up in full unissued shares of the Company to be allotted to such Members credited as fully paid.

147. The Board may settle, as it considers appropriate, any difficulty arising in regard to any distribution and in particular may issue certificates in respect of fractions of shares or authorise any person to sell and transfer any fractions or may resolve that the distribution should be as nearly as may be practicable in the correct proportion but not exactly so or may ignore fractions altogether, and may determine that cash payments shall be made to any Members in order to adjust the rights of all parties, as may seem expedient to the Board. The Board may appoint any person to sign on behalf of the persons entitled to participate in the distribution any contract necessary or desirable for giving effect thereto and such appointment shall be effective and binding upon the Members.

SUBSCRIPTION RIGHTS RESERVE

148. The following provisions shall have effect to the extent that they are not prohibited by and are in compliance with the Act:

(1) If, so long as any of the rights attached to any warrants issued by the Company to subscribe for shares of the Company shall remain exercisable, the Company does any act or engages in any transaction which, as a result of any adjustments to the subscription price in accordance with the provisions of the conditions of the warrants, would reduce the subscription price to below the par value of a share, then the following provisions shall apply:

- (a) as from the date of such act or transaction the Company shall establish and thereafter (subject as provided in this Article 148) maintain in accordance with the provisions of this Article 148 a reserve (the "Subscription Rights Reserve") the amount of which shall at no time be less than the sum which for the time being would be required to be capitalised and applied in paying up in full the nominal amount of the additional shares required to be issued and allotted credited as fully paid pursuant to sub-paragraph (c) below on the exercise in full of all the subscription rights outstanding and shall apply the Subscription Rights Reserve in paying up such additional shares in full as and when the same are allotted;
- (b) the Subscription Rights Reserve shall not be used for any purpose other than that specified above unless all other reserves of the Company (other than share premium account) have been extinguished and will then only be used to make good losses of the Company if and so far as is required by law;

39

- (c) upon the exercise of all or any of the subscription rights represented by any warrant, the relevant subscription rights shall be exercisable in respect of a nominal amount of shares equal to the amount in cash which the holder of such warrant is required to pay on exercise of the subscription rights represented thereby (or, as the case may be the relevant portion thereof in the event of a partial exercise of the subscription rights) and, in addition, there shall be allotted in respect of such subscription rights to the exercising warrant holder, credited as fully paid, such additional nominal amount of shares as is equal to the difference between:
 - (i) the said amount in cash which the holder of such warrant is required to pay on exercise of the subscription rights represented thereby (or, as the case may be, the relevant portion thereof in the event of a partial exercise of the subscription rights); and
 - (ii) the nominal amount of shares in respect of which such subscription rights would have been exercisable having regard to the provisions of the conditions of the warrants, had it been possible for such subscription rights to represent the right to subscribe for shares at less than par and immediately upon such exercise so much of the sum standing to the credit of the Subscription Rights Reserve as is required to pay up in full such additional nominal amount of shares shall be capitalised and applied in paying up in full such additional nominal amount of shares which shall forthwith be allotted credited as fully paid to the exercising warrant holders; and
- (d) if, upon the exercise of the subscription rights represented by any warrant, the amount standing to the credit of the Subscription Rights Reserve is not sufficient to pay up in full such additional nominal amount of shares equal to such difference as aforesaid to which the exercising warrant holder is entitled, the Board shall apply any profits or reserves then or thereafter becoming available (including, to the extent permitted by law, share premium account) for such purpose until such additional nominal amount of shares is paid up and allotted as aforesaid and until then no dividend or other distribution shall be paid or made on the fully paid shares of the Company then in issue. Pending such payment and allotment, the exercising warrant holder shall be issued by the Company with a certificate evidencing his right to the allotment of such additional nominal amount of shares. The rights represented by any such certificate shall be in registered form and shall be transferable in whole or in part in units of one share in the like manner as the shares for the time being are transferable, and the Company shall make such arrangements in relation to the maintenance of a register therefor and other matters in relation thereto as the Board may think fit and adequate particulars thereof shall be made known to each relevant exercising warrant holder upon the issue of such certificate.

(2) Shares allotted pursuant to the provisions of this Article shall rank *pari passu* in all respects with the other shares allotted on the relevant exercise of the subscription rights represented by the warrant concerned. Notwithstanding anything contained in paragraph (1) of this Article, no fraction of any share shall be allotted on exercise of the subscription rights.

(3) The provision of this Article as to the establishment and maintenance of the Subscription Rights Reserve shall not be altered or added to in any way which would vary or abrogate, or which would have the effect of varying or abrogating the provisions for the benefit of any warrant holder or class of warrant holders under this Article without the sanction of a special resolution of such warrant holders or class of warrant holders.

(4) A certificate or report by the auditors for the time being of the Company as to whether or not the Subscription Rights Reserve is required to be established and maintained and if so the amount thereof so required to be established and maintained, as to the purposes for which the Subscription Rights Reserve has been used, as to the extent to which it has been used to make good losses of the Company, as to the additional nominal amount of shares required to be allotted to exercising warrant holders credited as fully paid, and as to any other matter concerning the Subscription Rights Reserve shall (in the absence of manifest error) be conclusive and binding upon the Company and all warrant holders and shareholders.

40

ACCOUNTING RECORDS

149. The Board shall cause true accounts to be kept of the sums of money received and expended by the Company, and the matters in respect of which such receipt and expenditure take place, and of the property, assets, credits and liabilities of the Company and of all other matters required by the Act or necessary to give a true and fair view of the Company's affairs and to explain its transactions.

150. The accounting records shall be kept at the Office or, at such other place or places as the Board decides and shall always be open to inspection by the Directors. No Member (other than a Director) shall have any right of inspecting any accounting record or book or document of the Company except as conferred by law or authorised by the Board or the Company in general meeting.

151. Subject to Article 152, a printed copy of the Directors' report, accompanied by the balance sheet and profit and loss account, including every document required by law to be annexed thereto, made up to the end of the applicable financial year and containing a summary of the assets and liabilities of the Company under convenient heads and a statement of income and expenditure, together with a copy of the Auditors' report, shall be sent to each person entitled thereto at least ten (10) days before the date of the general meeting and laid before the Company at the annual general meeting held in accordance with Article 57 provided that this Article shall not require a copy of those documents to be sent to any person whose address the Company is not aware of or to more than one of the joint holders of any shares or debentures.

152. Subject to due compliance with all applicable Statutes, rules and regulations, including, without limitation, the rules and regulations of the Designated Stock Exchange, and to obtaining all necessary consents, if any, required thereunder, the requirements of Article 151 shall be deemed satisfied in relation to any person by sending to the person in any manner not prohibited by the Statutes, a summarised financial statements derived from the Company's annual accounts and the directors' report which shall be in the form and containing the information required by applicable laws and regulations, provided that any person who is otherwise entitled to the annual financial statements of the Company and the directors' report thereon may, if he so requires by notice in writing served on the Company, demand that the

Company sends to him, in addition to a summarised financial statements, a complete printed copy of the Company's annual financial statement and the directors' report thereon.

153. The requirement to send to a person referred to in Article 151 the documents referred to in that article or a summary financial report in accordance with Article 152 shall be deemed satisfied where, in accordance with all applicable Statutes, rules and regulations, including, without limitation, the rules and regulations of the Designated Stock Exchange, the Company publishes copies of the documents referred to in Article 151 and, if applicable, a summary financial report complying with Article 152, by placing it on the Company's website or in any other manner (including by sending any form of electronic communication) permitted by Article 160.

AUDIT

154. Subject to applicable law and rules and regulations of the Designated Stock Exchange, the Board shall appoint an Auditor to audit the accounts of the Company and such auditor shall hold office until removed from office by a resolution of the Directors. Such auditor may be a Member but no Director or officer or employee of the Company shall, during his continuance in office, be eligible to act as an Auditor.

155. Subject to the Act the accounts of the Company shall be audited at least once in every year.

156. The remuneration of the Auditor shall be determined by the Audit Committee or, in the absence of such Audit Committee, by the Board.

157. The Board may remove the Auditor at any time before the expiration of his term of office and may by resolution appoint another Auditor in his stead.

158. The Auditor shall at all reasonable times have access to all books kept by the Company and to all accounts and vouchers relating thereto; and he may call on the Directors or officers of the Company for any information in their possession relating to the books or affairs of the Company.

159. The statement of income and expenditure and the balance sheet provided for by these Articles shall be examined by the Auditor and compared by him with the books, accounts and vouchers relating thereto; and he shall make a written report thereon stating whether such statement and balance sheet are drawn up so as to present fairly the financial position of the Company and the results of its operations for the period under review and, in case information shall have been called for from Directors or officers of the Company, whether the same has been furnished and has been satisfactory. The financial statements of the Company shall be audited by the Auditor in accordance with generally accepted auditing standards. The Auditor shall make a written report thereon in accordance with generally accepted auditing standards and the report of the Auditor shall be submitted to the Audit Committee. The generally accepted auditing standards referred to herein may be those of a country or jurisdiction other than the Cayman Islands. If so, the financial statements and the report of the Auditor should disclose this fact and name such country or jurisdiction.

NOTICES

160. Any Notice or document, whether or not, to be given or issued under these Articles from the Company to a Member shall be in writing or by cable, telex or facsimile transmission message or other form of electronic transmission or electronic communication and any such Notice and document may be served or delivered by the Company on or to any Member either (i) personally or (ii) by sending it through the post in a prepaid envelope addressed to such Member at his registered address as appearing in the Register or at any other address supplied by him to the Company for the purpose or (iii) by transmitting it to any such address or transmitting it to any telex or facsimile transmission number or electronic number or electronic address or website supplied by him to the Company for the giving of Notice or documents to him or which the person transmitting the notice or document reasonably and bona fide believes at the relevant time will result in the Notice or document being duly received by the Member or (iv) may also be served by advertisement in appropriate newspapers in accordance with the requirements of the Designated Stock Exchange or (v) to the extent permitted by all applicable Statutes, rules and regulations, including, without limitation, the rules and regulations of the Designated Stock Exchange, by placing it on the Company's website. In the case of joint holders of a share all notices shall be given to that one of the joint holders whose name stands first in the Register and notice so given shall be deemed a sufficient service on or delivery to all the joint holders.

161. Any Notice or other document:

- (a) if served or delivered by post, shall where appropriate be sent by airmail and shall be deemed to have been served or delivered on the day following that on which the envelope containing the same, properly prepaid and addressed, is put into the post; in proving such service or delivery it shall be sufficient to prove that the envelope or wrapper containing the notice or document was properly addressed and put into the post and a certificate in writing signed by the Secretary or other officer of the Company or other person appointed by the Board that the envelope or wrapper containing the Notice or other document was so addressed and put into the post shall be conclusive evidence thereof;
- (b) if sent by electronic communication, shall be deemed to be given on the day on which it is transmitted from the server of the Company or its agent. A Notice placed on the Company's website is deemed given by the Company to a Member on the day it is placed;
- (c) if served or delivered in any other manner contemplated by these Articles, shall be deemed to have been served or delivered at the time of personal service or delivery or, as the case may be, at the time of the relevant despatch or transmission or publication; and in proving such service or delivery a certificate in writing signed by the Secretary or other officer of the Company or other person appointed by the Board as to the act and time of such service, delivery, despatch or transmission or publication shall be conclusive evidence thereof; and
- (d) may be given to a Member in the English language or such other language as may be approved by the Directors, subject to due compliance with all applicable Statutes, rules and regulations.

162. (1) Any Notice or other document delivered or sent by post to or left at the registered address of any Member in pursuance of these Articles shall, notwithstanding that such Member is then dead or bankrupt or that any other event has occurred, and whether or not the Company has notice of the death or bankruptcy or other event, be deemed to have been duly served or delivered in respect of any share registered in the name of such Member as sole or joint holder unless his name shall, at the time of the service or delivery of the Notice or document, have been removed from the Register as the holder of the share, and such service or delivery shall for all purposes be deemed a sufficient service or delivery of such Notice or document on all persons interested (whether jointly with or as claiming through or under him) in the share.

(2) A Notice may be given by the Company to the person entitled to a share in consequence of the death, mental disorder or bankruptcy of a Member by sending it through the post in a prepaid letter, envelope or wrapper addressed to him by name, or by the title of representative of the deceased, or trustee of the bankrupt, or by any like description, at the address, if any, supplied for the purpose by the person claiming to be so entitled, or (until such an address has been so supplied) by giving the notice in any manner in which the same might have been given if the death, mental disorder or bankruptcy had not occurred.

(3) Any person who by operation of law, transfer or other means whatsoever shall become entitled to any share shall be bound by every Notice in respect of such share which prior to his name and address being entered on the Register shall have been duly given to the person from whom he derives his title to such share.

(4) Every Member or a person who is entitled to receive notice from the Company under the provisions of the Statutes or these Articles may register with the Company an electronic address to which notices can be served upon him.

SIGNATURES

163. For the purposes of these Articles, a cable or telex or facsimile or electronic transmission message purporting to come from a holder of shares or, as the case may be, a Director, or, in the case of a corporation which is a holder of shares from a director or the secretary thereof or a duly appointed attorney or duly authorised representative thereof for it and on its behalf, shall in the absence of express evidence to the contrary available to the person relying thereon at the relevant time be deemed to be a document or instrument in writing signed by such holder or Director in the terms in which it is received. The signature to any notice or document to be given by the Company may be written, printed or made electronically.

WINDING UP

164. (1) Subject to Article 164(2), the Board shall have power in the name and on behalf of the Company to present a petition to the court for the Company to be wound up.

(2) Unless otherwise provided by the Ac, a resolution that the Company be wound up by the court or be wound up voluntarily shall be a special resolution.

165. (1) Subject to any special rights, privileges or restrictions as to the distribution of available surplus assets on liquidation for the time being attached to any class or classes of shares (i) if the Company shall be wound up and the assets available for distribution amongst the Members shall be more than sufficient to repay the whole of the capital paid up at the commencement of the winding up, the excess shall be distributed *pari passu* amongst such members in proportion to the amount paid up on the shares held by them respectively and (ii) if the Company shall be wound up and the assets available for distribution amongst the Members as such shall be insufficient to repay the whole of the paid-up capital such assets shall be distributed so that, a nearly as may be, the losses shall be borne by the Members in proportion to the capital paid up, or which ought to have been paid up, at the commencement of the winding up on the shares held by them respectively.

(2) If the Company shall be wound up (whether the liquidation is voluntary or by the court) the liquidator may, with the authority of a special resolution and any other sanction required by the Act, divide among the Members in specie or kind the whole or any part of the assets of the Company and whether or not the assets shall consist of properties of one kind or shall consist of properties to be divided as aforesaid of different kinds, and may for such purpose set such value as he deems fair upon any one or more class or classes of property and may determine how such division shall be carried out as between the Members or different classes of Members. The liquidator may, with the like authority, vest any part of the assets in trustees upon such trusts for the benefit of the Members as the liquidator with the like authority shall think fit, and the liquidation of the Company may be closed and the Company dissolved, but so that no contributory shall be compelled to accept any shares or other property in respect of which there is a liability.

INDEMNITY

166. (1) Every Director (including for the purposes of this Article any alternate Director appointed pursuant to the provisions of these Articles), Secretary, or other officer for the time being and from time to time of the Company (but not including the Auditor) and the personal representatives of the same (each an "Indemnified Person") shall be indemnified and secured harmless out of the assets and profits of the Company from and against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such Indemnified Person, other than by reason of such Indemnified Person's own dishonesty, wilful default or fraud, in or about the conduct of the Company's business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such Indemnified Person in defending (whether successfully or otherwise) any civil proceedings concerning the Company or its affairs in any court whether in the Cayman Islands or elsewhere.

(2) Each Member agrees to waive any claim or right of action he might have, whether individually or by or in the right of the Company, against any Director on account of any action taken by such Director, or the failure of such Director to take any action in the performance of his duties with or for the Company; PROVIDED THAT such waiver shall not extend to any matter in respect of any fraud, willful default or dishonesty which may attach to such Director.

FINANCIAL YEAR

167. Unless otherwise determined by the Directors, the financial year of the Company shall end on the 31st day of December in each year.

AMENDMENT TO MEMORANDUM AND ARTICLES OF ASSOCIATION AND NAME OF COMPANY

168. No Article shall be rescinded, altered or amended and no new Article shall be made until the same has been approved by a special resolution of the Members. A special resolution shall be required to alter the provisions of the Memorandum of Association or to change the name of the Company.

INFORMATION

169. No Member shall be entitled to require discovery of or any information respecting any detail of the Company's trading or any matter which is or may be in the nature of a trade secret or secret process which may relate to the conduct of the business of the Company and which in the opinion of the Directors it will be inexpedient in the interests of the members of the Company to communicate to the public.

SHARE CERTIFICATE

Number of certificate

Number of shares

ZHENGYE BIOTECHNOLOGY HOLDING LIMITED

COMPANY NUMBER [NUMBER]

This is to certify that [Name] of [Address] is the registered holder of [Number] [Share Class] shares of [Value] each being [partly paid to the extent of [amount in words] [amount in numerals] per share]/[fully paid][and numbered [number]] in the above-named company, subject to the memorandum and articles of association of the company.

[Transfer date]

Director

Director/Secretary

EMPLOYMENT AGREEMENT

This EMPLOYMENT AGREEMENT (the "Agreement"), is entered into as of [], by and between **Zhengye Biotechnology Holding Limited**, a company incorporated and existing under the laws of Cayman Islands (the "Company"), and [], an individual (the "Executive"). The term "Company" as used herein with respect to all obligations of the Executive hereunder shall be deemed to include the Company and all of its direct or indirect parent companies, subsidiaries, affiliates, or subsidiaries or affiliates of its parent companies (collectively, the "Group").

RECITALS

The Company desires to employ the Executive and to assure itself of the services of the Executive during the term of Employment (as defined below).

The Executive desires to be employed by the Company during the term of Employment and upon the terms and conditions of this Agreement.

AGREEMENT

The parties hereto agree as follows:

1. POSITION

The Executive hereby accepts a position of [] of the Company (the "Employment").

2. TERM

Subject to the terms and conditions of this Agreement, the initial term of the Employment shall be [] years, commencing on [] (the "Effective Date"), unless terminated earlier pursuant to the terms of this Agreement. Upon expiration of the []-year term, the Employment shall be automatically extended for successive 1-year terms unless either party gives the other party hereto a 1-month prior written notice to terminate the Employment prior to the expiration of the then current term or unless terminated earlier pursuant to the terms of this Agreement.

3. PROBATION

There is no probationary period.

4. DUTIES AND RESPONSIBILITIES

The Executive's duties at the Company will include all jobs assigned by the Company's board of directors (the "Board").

The Executive shall devote all of his working time, attention and skills to the performance of his/her duties at the Company and shall faithfully and diligently serve the Company in accordance with this Agreement, the Memorandum and Articles of Association of the Company, as may be amended from time to time (the "Articles of Association"), and the guidelines, policies and procedures of the Company approved from time to time by the Board.

5. NO BREACH OF CONTRACT

The Executive shall use his/her best efforts to perform his/her duties hereunder. The Executive shall not, without prior consent of the Board, become an employee of any entity other than the Company and any subsidiary or affiliate of the Company, and shall not be concerned or interested in any business or entity that directly or indirectly competes with the Group (any such business or entity, a "Competitor"), provided that nothing in this clause shall preclude the Executive from holding shares or other securities of any Competitor that is listed on any securities exchange or recognized securities market anywhere, provided however, that the Executive shall notify the Company in writing prior to his/her obtaining a proposed interest in such shares or securities in a timely manner and with such details and particulars as the Company may reasonably require. The Company shall have the right to require the Executive to resign from any board or similar body which he/she may then serve if the Board reasonably determines, and notifies the Executive in writing, that the Executive's service on such board or body interferes with the effective discharge of the Executive's duties and responsibilities to the Company or that any business related to such service is then in competition with any business of the Company or any of its subsidiaries or affiliates.

The Executive hereby represents to the Company that: (i) the execution and delivery of this Agreement by the Executive and the performance by the Executive of the Executive's duties hereunder shall not constitute a breach of, or otherwise contravene, the terms of any other agreement or policy to which the Executive is a party or otherwise bound, except for agreements that are required to be entered into by and between the Executive and any member of the Group pursuant to applicable law of the jurisdiction where the Executive is based, if any; (ii) the Executive has no information (including, without limitation, confidential information and trade secrets) relating to any other person or entity which would prevent, or be violated by, the Executive entering into this Agreement or carrying out his/her duties hereunder; and (iii) the Executive is not bound by any confidentiality, trade secret or similar agreement (other than this) with any other person or entity except for other member(s) of the Group, as the case may be.

6. LOCATION

The Executive will be based in No.1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin City, Jilin Province, China, until both parties hereto agree to change otherwise. The Executive acknowledges that he/she may be required to travel from time to time in the course of performing his/her duties for the Company.

7. COMPENSATION AND BENEFITS

- (a) Compensation. The Executive's cash compensation (inclusive of any statutory social welfare reserves that the Company may be required to set aside for the Executive under applicable law) shall be provided by the Company in a separate schedule attached hereto ("Schedule A") or as specified in a separate agreement between the Executive and the Company's designated subsidiary or affiliated entity, subject to annual review and adjustment by the Company or the compensation committee of the Board. The cash compensation may be paid by the Company, a subsidiary or affiliated entity or a combination thereof, as designated by the Company from time to time.
- (b) Equity Incentives. To the extent the Company adopts and maintains a share incentive plan, the Executive will be eligible to participate in such plan pursuant to the terms thereof.
- (c) Benefits. The Executive is eligible for participation in any standard employee benefit plan of the Company that currently exists or may be adopted by the Company in the future, including, but not limited to, any retirement plan, life insurance plan, health insurance plan and travel/holiday plan.

8. TERMINATION OF THE AGREEMENT

- (a) By the Company. The Company may terminate the Employment for cause, at any time, without notice or remuneration, if the Executive (1) commits any serious or persistent breach or non-observance of the terms and conditions of the Employment; (2) is convicted of a criminal offence other than one which, in the opinion of the Board, does not affect the Executive's position as an employee of the Company, bearing in mind the nature of the Executive's duties and the capacity in which the Executive is employed; (3) willfully disobeys a lawful and reasonable order; (4) misconducts himself/herself and such conduct is inconsistent with the due and faithful discharge of the Executive's material duties hereunder; (5) is guilty of fraud or dishonesty; or (6) is habitually neglectful in his/her duties. The Company may terminate the Employment without cause at any time with a 1-month prior written notice to the Executive or by payment of 1 month's salary in lieu of notice.

2

- (b) By the Executive. The Executive may terminate the Employment at any time with a 1-month prior written notice to the Company. In addition, the Executive may resign prior to the expiration of the Agreement if such resignation or an alternative arrangement with respect to the Employment is approved by the Board.
- (c) Notice of Termination. Any termination of the Executive's Employment under this Agreement shall be communicated by written notice of termination from the terminating party to the other party in accordance with the provisions of Section 20 below. The notice of termination shall indicate the specific provision(s) of this Agreement relied upon in effecting the termination.

9. CONFIDENTIALITY AND NONDISCLOSURE

- (a) Confidentiality and Non-disclosure. The Executive hereby agrees at all times during the term of his/her Employment and after termination of the Executive's Employment under this Agreement, to hold in the strictest confidence, and not to use, except for the benefit of the Group, or to disclose to any person, corporation or other entity without written consent of the Company, any Confidential Information. The Executive understands that "Confidential Information" means any proprietary or confidential information of the Group, its affiliates, their clients, customers or partners, and the Group's licensors, including, without limitation, technical data, trade secrets, research and development information, product plans, services, customer lists and customers (including, but not limited to, customers of the Group on whom the Executive called or with whom the Executive became acquainted during the term of his/her Employment), supplier lists and suppliers, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, hardware configuration information, personnel information, marketing, finances, information about the suppliers, joint ventures, licensors, licensees, distributors, and other persons with whom the Group does business, information regarding the skills and compensation of other employees of the Group or other business information disclosed to the Executive by or obtained by the Executive from the Group, its affiliates, or their clients, customers, or partners, either directly or indirectly, in writing, orally or by drawings or observation of parts or equipment, if specifically indicated to be confidential or reasonably expected to be confidential. Notwithstanding the foregoing, Confidential Information shall not include information that is generally available and known to the public through no fault of the Executive.
- (b) Company Property. The Executive understands that all documents (including computer records, facsimile and e-mail) and materials created, received or transmitted in connection with his/her work or using the facilities of the Group are property of the Group and subject to inspection by the Group, at any time. Upon termination of the Executive's Employment with the Company (or at any other time when requested by the Company), the Executive will promptly deliver to the Company all documents and materials of any nature pertaining to his/her work with the Company and will provide prompt written certification of his compliance with this Agreement. Under no circumstances will the Executive have, following his/her termination, in his/her possession any property of the Group, or any documents or materials or copies thereof containing any Confidential Information.
- (c) Former Employer Information. The Executive agrees that he/she has not and will not, during the term of his/her employment, (i) improperly use or disclose any proprietary information or trade secrets of any former employer or other person or entity with which the Executive has an agreement or duty to keep in confidence, or (ii) bring into any premises of the Group any document or confidential or proprietary information belonging to such former employer, person or entity unless consented to in writing by such former employer, person or entity. The Executive will indemnify the Group and hold it harmless from and against all claims, liabilities, damages and expenses, including reasonable attorneys' fees and costs of suit, arising out of or in connection with any violation of the foregoing.

3

- (d) Third Party Information. The Executive recognizes that the Group may have received, and in the future may receive, from third parties confidential or proprietary information subject to a duty on the Group's part to maintain the confidentiality of such information and to use it only for certain limited purposes. The Executive agrees that the Executive owes the Group and such third parties, during the Executive's Employment by the Company and thereafter, a duty to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person or firm and to use it in a manner consistent with, and for the limited purposes permitted by, the Group's agreement with such third party.

This Section 9 shall survive the termination of this Agreement for any reason. In the event the Executive breaches this Section 9, the Company shall have right to seek remedies permissible under applicable law.

10. WITHHOLDING TAXES

Notwithstanding anything else herein to the contrary, the Company may withhold (or cause there to be withheld, as the case may be) from any amounts otherwise due or payable under or pursuant to this Agreement such national, provincial, local or any other income, employment, or other taxes as may be required to be withheld pursuant to any applicable law or regulation.

11. NOTIFICATION OF NEW EMPLOYER

In the event that the Executive leaves the employ of the Company, the Executive hereby grants consent to notification by the Company to his/her new employer about his/her rights and obligations under this Agreement.

12. ASSIGNMENT

This Agreement is personal in its nature and neither of the parties hereto shall, without the consent of the other, assign or transfer this Agreement or any rights or obligations hereunder; provided, however, that (i) the Company may assign or transfer this Agreement or any rights or obligations hereunder to any member of the Group without such consent, and (ii) in the event of a merger, consolidation, or transfer or sale of all or substantially all of the assets of the Company with or to any other individual(s) or entity, this Agreement shall, subject to the provisions hereof, be binding upon and inure to the benefit of such successor and

such successor shall discharge and perform all the promises, covenants, duties, and obligations of the Company hereunder.

13. SEVERABILITY

If any provision of this Agreement or the application thereof is held invalid, the invalidity shall not affect other provisions or applications of this Agreement which can be given effect without the invalid provisions or applications and to this end the provisions of this Agreement are declared to be severable.

14. ENTIRE AGREEMENT

This Agreement constitutes the entire agreement and understanding between the Executive and the Company regarding the terms of the Employment and supersedes all prior or contemporaneous oral or written agreements concerning such subject matter, other than any such agreement under any employment agreement entered into with a subsidiary of the Company at the request of the Company to the extent such agreement does not conflict with any of the provisions herein. The Executive acknowledges that he/she has not entered into this Agreement in reliance upon any representation, warranty or undertaking which is not set forth in this Agreement.

4

15. REPRESENTATIONS

The Executive hereby agrees to execute any proper oath or verify any proper document required to carry out the terms of this Agreement. The Executive hereby represents that the Executive's performance of all the terms of this Agreement will not breach any agreement to keep in confidence proprietary information acquired by the Executive in confidence or in trust prior to his/her Employment by the Company. The Executive has not entered into, and hereby agrees that he/she will not enter into, any oral or written agreement in conflict with this Section 15. The Executive represents that the Executive will consult his/her own consultants for tax advice and is not relying on the Company for any tax advice with respect to this Agreement or any provisions hereunder.

16. GOVERNING LAW

This Agreement shall be governed by and construed in accordance with the laws of the People's Republic of China, without regard to principles of conflict of laws.

17. ARBITRATION

Any dispute arising out of, in connection with or relating to, this Agreement shall be resolved through arbitration pursuant to this Section 17. The arbitration shall be conducted in Jilin City, Jilin Province, China in accordance with the rules of the Jilin Arbitration Commission in effect at the time of the arbitration. The award of the arbitration tribunal shall be final and binding upon the disputing parties, and any party may apply to a court of competent jurisdiction for enforcement of such award.

18. AMENDMENT

This Agreement may not be amended, modified or changed (in whole or in part), except by a formal, definitive written agreement expressly referring to this Agreement, which agreement is executed by both of the parties hereto.

19. WAIVER

Neither the failure nor any delay on the part of a party to exercise any right, remedy, power or privilege under this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power or privilege preclude any other or further exercise of the same or of any right, remedy, power or privilege, nor shall any waiver of any right, remedy, power or privilege with respect to any occurrence be construed as a waiver of such right, remedy, power or privilege with respect to any other occurrence. No waiver shall be effective unless it is in writing and is signed by the party asserted to have granted such waiver.

20. NOTICES

All notices, requests, demands and other communications required or permitted under this Agreement shall be in writing and shall be deemed to have been duly given and made if (i) sent by facsimile or email (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party), (ii) delivered by hand, (iii) otherwise delivered against receipt therefor, or (iv) sent by a recognized courier with next-day or second-day delivery to the last known address of the other party.

21. COUNTERPARTS

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original as against any party whose signature appears thereon, and all of which together shall constitute one and the same instrument. This Agreement shall become binding when one or more counterparts hereof, individually or taken together, shall bear the signatures of all of the parties reflected hereon as the signatories. Photographic copies of such signed counterparts may be used in lieu of the originals for any purpose.

22. NO INTERPRETATION AGAINST DRAFTER

Each party recognizes that this Agreement is a legally binding contract and acknowledges that such party has had the opportunity to consult with legal counsel of choice. In any construction of the terms of this Agreement, the same shall not be construed against either party on the basis of that party being the drafter of such terms. The Executive agrees and acknowledges that he/she has read and understands this Agreement, is entering into it freely and voluntarily, and has been advised to seek counsel prior to entering into this Agreement and has had ample opportunity to do so.

[Remainder of this page has been intentionally left blank.]

5

IN WITNESS WHEREOF, this Agreement has been executed as of the date first written above.

Zhengye Biotechnology Holding Limited

By: _____
Name: Songlin Song
Title: Chief Executive Officer

Executive

Signature: _____
Name: _____

[Signature Page to Employment Agreement]

6

Schedule A

Annual compensation is RMB [].

7

INDEMNIFICATION AGREEMENT

This Indemnification Agreement (this “Agreement”) is entered into as of [DATE] by and between Zhengye Biotechnology Holding Limited, a Cayman Islands company (the “Company”), and the undersigned, a director and/or an officer of the Company (“Indemnitee”), as applicable.

RECITALS

The Board of Directors of the Company (the “Board of Directors”) has determined that the inability to attract and retain highly competent persons to serve the Company is detrimental to the best interests of the Company and its shareholders and that it is reasonable and necessary for the Company to provide adequate protection to such persons against risks of claims and actions against them arising out of their services to the corporation.

AGREEMENT

In consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:

A. DEFINITIONS

The following terms shall have the meanings defined below:

Expenses shall include, without limitation, damages, judgments, fines, penalties, settlements and costs, attorneys’ fees and disbursements and costs of attachment or similar bond, investigations, and any other expenses paid or incurred in connection with investigating, defending, being a witness in, participating in (including on appeal), or preparing for any of the foregoing in, any Proceeding.

Indemnifiable Event means any event or occurrence that takes place either before or after the execution of this Agreement, related to the fact that Indemnitee is or was a director or an officer of the Company, or is or was serving at the request of the Company as a director or officer of another corporation, partnership, joint venture or other entity, or related to anything done or not done by Indemnitee in any such capacity, including, but not limited to neglect, breach of duty, error, misstatement, misleading statement or omission.

Participant means a person who is a party to, or witness or participant (including on appeal) in, a Proceeding.

Proceeding means any threatened, pending, or completed action, suit, arbitration or proceeding, or any inquiry, hearing or investigation, whether civil, criminal, administrative, investigative or other, including appeal, in which Indemnitee may be or may have been involved as a party or otherwise by reason of an Indemnifiable Event.

B. AGREEMENT TO INDEMNIFY

1. **General Agreement.** In the event Indemnitee was, is, or becomes a Participant in, or is threatened to be made a Participant in, a Proceeding, the Company shall indemnify the Indemnitee from and against any and all Expenses which Indemnitee incurs or becomes obligated to incur in connection with such Proceeding, to the fullest extent permitted by applicable law.

2. **Indemnification of Expenses of Successful Party.** Notwithstanding any other provision of this Agreement, to the extent that Indemnitee has been successful on the merits in defense of any Proceeding or in defense of any claim, issue or matter in such Proceeding, the Company shall indemnify Indemnitee against all Expenses incurred in connection with such Proceeding or such claim, issue or matter, as the case may be.

3. **Partial Indemnification.** If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for a portion of Expenses, but not for the total amount of Expenses, the Company shall indemnify the Indemnitee for the portion of such Expenses to which Indemnitee is entitled.

4. **No Employment Rights.** Nothing in this Agreement is intended to create in Indemnitee any right to continued employment with the Company.

5. **Contribution.** If the indemnification provided in this Agreement is unavailable and may not be paid to Indemnitee for any reason other than those set forth in Section B.4, then the Company shall contribute to the amount of Expenses paid in settlement actually and reasonably incurred and paid or payable by Indemnitee in such proportion as is appropriate to reflect (i) the relative benefits received by the Company on the one hand and by the Indemnitee on the other hand from the transaction or events from which such Proceeding arose, and (ii) the relative fault of the Company on the one hand and of the Indemnitee on the other hand in connection with the events which resulted in such Expenses, as well as any other relevant equitable considerations. The relative fault of the Company on the one hand and of the Indemnitee on the other hand shall be determined by reference to, among other things, the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent the circumstances resulting in such Expenses, judgments, fines or settlement amounts. The Company agrees that it would not be just and equitable if contribution pursuant to this Section B.5 were determined by pro rata allocation or any other method of allocation which does not take account of the foregoing equitable considerations.

C. INDEMNIFICATION PROCESS

1. **Notice and Cooperation by Indemnitee.** Indemnitee shall, as a condition precedent to his/her right to be indemnified under this Agreement, give the Company notice in writing as soon as practicable of any claim made against Indemnitee for which indemnification will or could be sought under this Agreement, provided that the delay of Indemnitee to give notice hereunder shall not prejudice any of Indemnitee’s rights hereunder, unless such delay results in the Company’s forfeiture of substantive rights or defenses. Notice to the Company shall be given in accordance with Section F.7 below. If, at the time of receipt of such notice, the Company has directors’ and officers’ liability insurance policies in effect, the Company shall give prompt notice to its insurers of the Proceeding relating to the notice. The Company shall thereafter take all necessary and desirable actions to cause such insurers to pay, on behalf of Indemnitee, all Expenses payable as a result of such Proceeding. In addition, Indemnitee shall give the Company such information and cooperation as the Company may reasonably request.

2. Indemnification Payment.

(a) **Advancement of Expenses.** Indemnitee may submit a written request with reasonable particulars to the Company requesting that the Company advance to Indemnitee all Expenses that may be reasonably incurred in advance by Indemnitee in connection with a Proceeding. The Company shall, within 10 business days of receiving such a written request by Indemnitee, advance all requested Expenses to Indemnitee. Any excess of the advanced Expenses over the actual Expenses will be repaid to the Company.

(b) **Reimbursement of Expenses.** To the extent Indemnitee has not requested any advanced payment of Expenses from the Company, Indemnitee shall be entitled to receive reimbursement for the Expenses incurred in connection with a Proceeding from the Company immediately after Indemnitee makes a written

request to the Company for reimbursement unless the Company refers the indemnification request to the Reviewing Party in compliance with Section C.2(c) below.

(c) Determination by the Reviewing Party. If the Company reasonably believes that it is not obligated under this Agreement to indemnify the Indemnitee, the Company shall, within 10 days after the Indemnitee's written request for an advancement or reimbursement of Expenses, notify the Indemnitee that the request for advancement of Expenses or reimbursement of Expenses will be submitted to the Reviewing Party (as hereinafter defined). The Reviewing Party shall make a determination on the request within 30 days after the Indemnitee's written request for an advancement or reimbursement of Expenses. Notwithstanding anything foregoing to the contrary, in the event the Reviewing Party informs the Company that Indemnitee is not entitled to indemnification in connection with a Proceeding under this Agreement or applicable law, the Company shall be entitled to be reimbursed by Indemnitee for all the Expenses previously advanced or otherwise paid to Indemnitee in connection with such Proceeding; provided, however, that Indemnitee may bring a suit to enforce his/her indemnification right in accordance with Section C.3 below.

3. Suit to Enforce Rights. Regardless of any action by the Reviewing Party, if Indemnitee has not received full indemnification within 30 days after making a written demand in accordance with Section C.2 above or 50 days if the Company submits a request for advancement or reimbursement to the Reviewing Party under Section C.2(c) above, Indemnitee shall have the right to enforce its indemnification rights under this Agreement by commencing litigation in any court of competent jurisdiction seeking a determination by the court or challenging any determination by the Reviewing Party or any aspect of this Agreement. Any determination by the Reviewing Party not challenged by Indemnitee and any judgment entered by the court shall be binding on the Company and Indemnitee.

4. Assumption of Defense. In the event the Company is obligated under this Agreement to advance or bear any Expenses for any Proceeding against Indemnitee, the Company shall be entitled to assume the defense of such Proceeding, with counsel approved by Indemnitee, upon delivery to Indemnitee of written notice of its election to do so. After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee under this Agreement for any fees of counsel subsequently incurred by Indemnitee with respect to the same Proceeding, unless (i) the employment of counsel by Indemnitee has been previously authorized by the Company, (ii) Indemnitee shall have reasonably concluded, based on written advice of counsel, that there may be a conflict of interest of such counsel retained by the Company between the Company and Indemnitee in the conduct of any such defense, or (iii) the Company ceases or terminates the employment of such counsel with respect to the defense of such Proceeding, in any of which events the fees and expenses of Indemnitee's counsel shall be at the expense of the Company. At all times, Indemnitee shall have the right to employ counsel in any Proceeding at Indemnitee's expense.

2

5. Defense to Indemnification, Burden of Proof and Presumptions. It shall be a defense to any action brought by Indemnitee against the Company to enforce this Agreement that it is not permissible under this Agreement or applicable law for the Company to indemnify the Indemnitee for the amount claimed. In connection with any such action or any determination by the Reviewing Party or otherwise as to whether Indemnitee is entitled to be indemnified under this Agreement, the burden of proving such a defense or determination shall be on the Company.

6. No Settlement without Consent. Neither party to this Agreement shall settle any Proceeding in any manner that would impose any damage, loss, penalty or limitation on Indemnitee without the other party's written consent. Neither the Company nor Indemnitee shall unreasonably withhold its consent to any proposed settlement.

7. Company Participation. Subject to Section B.5, the Company shall not be liable to indemnify the Indemnitee under this Agreement with regard to any judicial action if the Company was not given a reasonable and timely opportunity, at its expense, to participate in the defense, conduct and/or settlement of such action.

8. Reviewing Party.

(a) For purposes of this Agreement, the Reviewing Party with respect to each indemnification request of Indemnitee that is referred by the Company pursuant to Section C.2(c) above shall be (A) the Board of Directors by a majority vote of a quorum consisting of Disinterested Directors (as hereinafter defined), or (B) if a quorum of the Board of Directors consisting of Disinterested Directors is not obtainable or, even if obtainable, said Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board of Directors, a copy of which shall be delivered to Indemnitee. If the Reviewing Party determines that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within 10 days after such determination. Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee's entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any Independent Counsel or member of the Board of Directors shall act reasonably and in good faith in making a determination under this Agreement of the Indemnitee's entitlement to indemnification. Any reasonable costs or expenses (including reasonable attorneys' fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee's entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. "Disinterested Director" means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.

(b) If the determination of entitlement to indemnification is to be made by Independent Counsel, the Independent Counsel shall be selected as provided in this Section C.8(b). The Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board of Directors, in which event the proceeding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may be, may, within 10 days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of "Independent Counsel" as defined in Section C.8(d) of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If a written objection is made and substantiated, the Independent Counsel selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit. If, within 20 days after submission by Indemnitee of a written request for indemnification, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition a court of competent jurisdiction for resolution of any objection which shall have been made by the Company or Indemnitee to the other's selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel. The Company shall pay any and all reasonable fees and expenses of Independent Counsel incurred by such Independent Counsel in connection with acting under this Agreement, and the Company shall pay all reasonable fees and expenses incident to the procedures of this Section C.8(b), regardless of the manner in which such Independent Counsel was selected or appointed.

3

(c) In making a determination with respect to entitlement to indemnification hereunder, the Reviewing Party shall presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with this Agreement, and the Company shall have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that

presumption. The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement (with or without court approval), conviction, or upon a plea of *nolo contendere* or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he/she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his/her conduct was unlawful. For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee's action is based on the records or books of account of the Company and any other corporation, partnership, joint venture or other entity of which Indemnitee is or was serving at the written request of the Company as a director, officer, employee, agent or fiduciary, including financial statements, or on information supplied to Indemnitee by the officers and directors of the Company or such other corporation, partnership, joint venture or other entity in the course of their duties, or on the advice of legal counsel for the Company or such other corporation, partnership, joint venture or other entity or on information or records given or reports made to the Company or such other corporation, partnership, joint venture or other entity by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Company or such other corporation, partnership, joint venture or other entity. In addition, the knowledge and/or actions, or failure to act, of any director, officer, agent or employee of the Company or such other corporation, partnership, joint venture or other entity shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. The provisions of this Section C.8(c) shall not be deemed to be exclusive or to limit in any way the other circumstances in which the Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement.

(d) "Independent Counsel" means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term "Independent Counsel" shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee's rights under this Agreement. The Company agrees to pay the reasonable fees of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.

D. DIRECTOR AND OFFICER LIABILITY INSURANCE

1. Good Faith Determination. The Company shall from time to time make the good faith determination whether or not it is practicable for the Company to obtain and maintain a policy or policies of insurance with reputable insurance companies providing the officers and directors of the Company with coverage for losses incurred in connection with their services to the Company or to ensure the Company's performance of its indemnification obligations under this Agreement.

2. Coverage of Indemnitee. To the extent the Company maintains an insurance policy or policies providing directors' and officers' liability insurance, Indemnitee shall be covered by such policy or policies, in accordance with its or their terms, to the maximum extent of the coverage available for any of the Company's directors or officers.

3. No Obligation. Notwithstanding the foregoing, the Company shall have no obligation to obtain or maintain any director and officer insurance policy if the Company determines in good faith that such insurance is not reasonably available in the case that (i) premium costs for such insurance are disproportionate to the amount of coverage provided, or (ii) the coverage provided by such insurance is limited by exclusions so as to provide an insufficient benefit.

E. NON-EXCLUSIVITY; U.S. FEDERAL PREEMPTION; TERM

1. Non-Exclusivity. The indemnification provided by this Agreement shall not be deemed exclusive of any rights to which Indemnitee may be entitled under the Company's current memorandum and articles of association, as may be amended from time to time, applicable law or any written agreement between Indemnitee and the Company (including its subsidiaries and affiliates). The indemnification provided under this Agreement shall continue to be available to Indemnitee for any action taken or not taken while serving in an indemnified capacity even though he/she may have ceased to serve in any such capacity at the time of any Proceeding.

2. U.S. Federal Preemption. Notwithstanding the foregoing, both the Company and Indemnitee acknowledge that in certain instances, U.S. federal law or public policy may override applicable law and prohibit the Company from indemnifying its directors and officers under this Agreement or otherwise. Such instances include, but are not limited to, the prohibition by the U.S. Securities and Exchange Commission (the "SEC") on indemnification for liabilities arising under certain U.S. federal securities laws. Indemnitee understands and acknowledges that the Company has undertaken or may be required in the future to undertake with the SEC an obligation to submit the question of indemnification to a court in certain circumstances for a determination of the Company's right under public policy to indemnify Indemnitee.

3. Duration of Agreement. All agreements and obligations of the Company contained herein shall continue during the period Indemnitee is an officer and/or a director of the Company (or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise) and shall continue thereafter so long as Indemnitee shall be subject to any Proceeding by reason of his/her former or current capacity at the Company, whether or not he/she is acting or serving in any such capacity at the time any Expense is incurred for which indemnification can be provided under this Agreement. This Agreement shall continue in effect regardless of whether Indemnitee continues to serve as an officer and/or a director of the Company or any other enterprise at the Company's request.

F. MISCELLANEOUS

1. Amendment of this Agreement. No supplement, modification, or amendment of this Agreement shall be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall operate as a waiver of any other provisions (whether or not similar), nor shall such waiver constitute a continuing waiver. Except as specifically provided in this Agreement, no failure to exercise or any delay in exercising any right or remedy shall constitute a waiver.

2. Subrogation. In the event of payment to Indemnitee by the Company under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and shall do everything that may be necessary to secure such rights, including the execution of such documents necessary to enable the Company to bring suit to enforce such rights.

3. Assignment; Binding Effect. Neither this Agreement nor any of the rights or obligations hereunder may be assigned by either party hereto without the prior written consent of the other party; except that the Company may, without such consent, assign all such rights and obligations to a successor in interest to the Company which assumes all obligations of the Company under this Agreement. Notwithstanding the foregoing, this Agreement shall be binding upon and inure to the benefit of and be enforceable by and against the parties hereto and the Company's successors (including any direct or indirect successor by purchase, merger, consolidation, or otherwise to all or substantially all of the business and/or assets of the Company) and assigns, as well as Indemnitee's spouses, heirs, and personal and legal representatives.

4. Severability and Construction. Nothing in this Agreement is intended to require or shall be construed as requiring the Company to do or fail to do any act in violation of applicable law. The Company's inability, pursuant to a court order, to perform its obligations under this Agreement shall not constitute a breach of this Agreement. In addition, if any portion of this Agreement shall be held by a court of competent jurisdiction to be invalid, void, or otherwise unenforceable, the remaining provisions shall remain enforceable to the fullest extent permitted by applicable law. The parties hereto acknowledge that they each have opportunities to have their respective counsels review this Agreement. Accordingly, this Agreement shall be deemed to be the product of both of the parties hereto, and no ambiguity shall be

construed in favor of or against either of the parties hereto.

5. Counterparts. This Agreement may be executed in two counterparts, both of which taken together shall constitute one instrument.

6. Governing Law. This agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of New York, without giving effect to conflicts of law provisions thereof.

7. Notices. All notices, demands, and other communications required or permitted under this Agreement shall be made in writing and shall be deemed to have been duly given if delivered by hand, against receipt, or mailed via postage prepaid, certified or registered mail, return receipt requested, and addressed to the Company at:

Zhengye Biotechnology Holding Limited

Attention: Chief Executive Officer

and to Indemnitee at his/her address last known to the Company.

8. Entire Agreement. This Agreement constitutes the entire agreement and supersedes all prior agreements and understandings, both written and oral, between the parties with respect to the subject matter hereof.

(Signature page follows)

IN WITNESS WHEREOF, the parties hereto execute this Agreement as of the date first written above.

Zhengye Biotechnology Holding Limited

By: _____
Name:
Title:

Indemnitee

Signature:
Name:

[Signature Page to Indemnification Agreement]

Zhengye Biotechnology Holding Limited
No.1 Lianmeng Road, Jilin Economic & Technical Development Zone
Jilin City, Jilin Province, China

[Date]

[Name]
[Address]

Re: Director Offer Letter

Dear :

Zhengye Biotechnology Holding Limited, a Cayman Islands company (the "Company") is pleased to offer you a position as a member of the Company's Board of Directors (the "Board"). We are very impressed with your credentials, and we look forward to your future success in this role.

Zhengye Biotechnology Holding Limited 一家开曼群岛公司 ("公司") 很荣幸为您提供公司董事会 (以下简称"董事会") 成员的职业。您的资历给我们留下了非常深刻的印象, 我们期待着您在这个职位上取得成功。

This letter shall constitute an agreement ("Agreement") between you and the Company and contains all the terms and conditions relating to the services you are to provide.

本函应构成您与本公司之间的协议 ("协议"), 并包含与您将提供的服务相关的所有条款和条件。

1. **Term.** This Agreement shall have an initial term of 2 years, beginning on the effective date of the registration statement in connection with the Company's initial public offering of its ordinary shares. Your term as director shall continue subject to the provisions in Section 7 below or until your successor is duly elected and qualified. The position shall be up for re-election every 2 years at the Company's annual general meeting and upon re-election, the terms and provisions of this Agreement shall remain in full force and effect.

1. 期限。本协议的初始期限为2年, 自首次公开发行相关的登记声明生效之日起生效。根据下文第 7 节的规定, 您的董事任期应继续有效, 或直到您的继任者被正式选出并具备资格为止。该职位应在每2年的公司年度股东大会上进行重新选举, 并且在再次当选后, 本协议的条款和规定应保持完全有效。

2. **Services.** You shall render services as a member of the Board in accordance with high professional and ethical standards and in accordance with all applicable laws and rules and regulations pertaining to your performance hereunder. You shall be required to attend all meetings of the Board called from time to time either in-person or by telephone. Should you be elected to serve on a committee of the Board, you shall be required to attend such number of meetings of such committee as required by its members pursuant to the charter of such committee or as may be called from time to time. The services described in this Section 2 shall hereinafter be referred to as your "Duties."

2. 服务。作为董事会成员, 您应按照高级专业和道德标准以及与您在本协议项下履行职责相关的所有适用法律法规提供服务。您必须亲自或通过电话参加董事会的所有会议。您将当选为董事会某一委员会的成员, 您须出席该委员会根据该委员会章程所规定的次数或不时召开的会议。本第 2 条所述的服务在下文中称为"职责"

3. **Services for Others.** You shall be free to represent or perform services for other persons during the term of this Agreement. You agree, however, that you do not presently perform and do not intend to perform, during the term of this Agreement, similar Duties, consulting, or other services for companies whose businesses are or would be, in any way, competitive with the Company (except for companies previously disclosed by you to the Company in writing). Should you propose to perform similar duties, consulting with, or other services for any such company, you agree to notify the Company in writing in advance (specifying the name of the organization for whom you propose to perform such services) and to provide information to the Company sufficient to allow it to determine if the performance of such services would conflict with areas of interest to the Company.

4. 为他人提供的服务。在本协议有效期内, 您有权代表或为其他人提供服务。但是, 您同意, 在本协议有效期内, 您目前没有也不打算为现有或潜在业务、以任何方式与公司有竞争关系的公司履行或提供类似的职责、咨询或其他服务 (但您事先向公司书面披露的除外)。如果您提议为任何此类公司履行类似的职责、咨询或其他服务, 您同意提前以书面形式通知本公司 (指明您拟为其提供此类服务的组织的名称), 并向本公司提供足够的信息, 以使本公司能够评估该等服务的履行是否会与本公司的利益相冲突。

5. **Compensation.**

4. 报酬/津贴

4.1. **Cash.** Commencing on the Appointment Date, and upon each anniversary thereof that you remain a director, you shall receive cash compensation/allowance of USD360,000 or an equivalent amount in RMB for each calendar year of service under this Agreement on a pro-rated basis. Cash compensation/allowance are disbursed on a monthly basis. In cases where payment is made in RMB, the exchange rate is determined according to the Bank of China's conversion rate from RMB to USD as of the last day of the preceding month. Notwithstanding the foregoing to the contrary, all fees are subject to approval and/or change, as deemed appropriate by the Compensation Committee of the Board. You shall be reimbursed for reasonable expenses documented and incurred by you in connection with the performance of your Duties (including travel expenses for meetings you attend in- person).

4.1. 现金。从任命日期开始, 以及您担任董事的每一周年, 您应按比例在本协议项下服务的每一自然年获得3.6万美元的现金报酬/津贴或等额的人民币, 现金报酬/津贴按月发放, 如果发放人民币, 汇率按照人民币对美元上月最后一日中行折算价汇率值来折算。尽管有上述相反的规定, 所有费用均须经董事会薪酬委员会批准和/或作出适当的变更。您因履行职责而发生的合理费用 (包括现场出席会议的差旅费) 应得到报销。

4.2. **Service on Board Committee(s).** Should you be named to a committee of the Board, the Compensation Committee of the Board will determine any additional compensation, if any, for serving on such committee. However, the Company currently does not plan to provide any additional compensation to members of Committees of the Board.

4.2. 在董事会委员会任职。如果你被任命为董事会委员会的成员, 董事会薪酬委员会将决定在该委员会任职的任何额外报酬 (如有)。但是, 本公司目前不打算向董事会各委员会的成员提供任何额外的薪酬。

5. No Assignment. Because of the personal nature of the services to be rendered by you, this Agreement may not be assigned by you without the prior written consent of the Company.

5. 不得转让。由于您所提供服务的特殊属性，未经本公司事先书面同意，您不得转让本协议。

6. Confidential Information; Non-Disclosure. In consideration of your access to the premises of the Company and/or you access to certain Confidential Information of the Company, in connection with your business relationship with the Company, you hereby represent and agree as follows:

6. 保密信息；保密。考虑到您进入本公司的经营场所和/或您接触到本公司的某些保密信息，就您与本公司的业务关系而言，您特此声明并同意如下：

6.1. Definition. For purposes of this Agreement, the term “Confidential Information” means:

6.1. 定义。在本协议中，“保密信息”一词是指：

a. Any information that the Company possesses that has been created, discovered, or developed by or for the Company, and that has or could have commercial value or utility in the business in which the Company is engaged; or

a、公司拥有的、由公司创建、发现或开发的、在公司从事的业务中具有或可能具有商业价值或效用的任何信息；或

b. Any information that is related to the business of the Company and is generally not known by non-Company personnel.

b、与公司业务有关的、非公司人员一般不知道的任何信息。

c. By way of illustration, but not limitation, Confidential Information includes trade secrets and any information concerning products, processes, formulas, designs, inventions (whether or not patentable or registrable under copyright or similar laws, and whether or not reduced to practice), discoveries, concepts, ideas, improvements, techniques, methods, research, development and test results, specifications, data, know-how, software, formats, marketing plans, and analyses, business plans and analyses, strategies, forecasts, customer and supplier identities, characteristics, and agreements.

c、作为说明，但不限于，机密信息包括商业秘密和与产品、工艺、配方、设计、发明（无论是否根据版权法或类似法律可申请专利或注册，也不论是否被简化为实践）、发现、概念、想法、改进、技术、方法、研究、开发和测试结果、规范、数据、专有技术、软件、格式、营销计划和分析、商业计划和分析、战略、预测、客户和供应商身份、特征和协议。

6.2. Exclusions. Notwithstanding the foregoing, the term Confidential Information shall not include:

6.2. 例外条款。尽管有上述规定，保密信息一词不应包括：

a. Any information that becomes generally available to the public, other than as a result of a breach of the confidentiality portions of this Agreement, or any other agreement requiring confidentiality between the Company and you;

a、除因违反本协议的保密条款或本公司与您之间要求保密的任何其他协议外，公众可获得的任何信息；

and
b. Information received from a third party in rightful possession of such information who is not restricted from disclosing such information;

b、从合法拥有该等信息的第三方收到的信息，该第三方不受披露该等信息的限制；以及

c. Information known by you prior to receipt of such information from the Company, which prior knowledge can be documented.

c、您在收到本公司提供的此类信息之前知道的信息，这些信息可以记录在案。

6.3. Documents. You agree that, without the express prior written consent of the Company, you will not remove from the Company’s premises, any notes, formulas, programs, data, records, machines, or any other documents or items that in any manner contain or constitute Confidential Information, nor will you make reproductions or copies of same. In the event you receive any such documents or items by personal delivery from any duly designated or authorized personnel of the Company, you shall be deemed to have received the express written consent of the Company. In the event that you receive any such documents or items, other than through personal delivery as described in the preceding sentence, you agree to inform the Company promptly of your possession of such documents or items. You shall promptly return any such documents or items, along with any reproductions or copies to the Company upon the Company’s demand, upon termination of this Agreement, or upon your termination or resignation, as provided in Section 7 herein.

6.3. 文件。您同意，未经本公司事先明确书面同意，您不得将任何注释、公式、程序、数据、记录、机器或以任何方式，将包含或构成机密信息的任何其他文件或项目从公司的经营场所移走，你也禁止对此类文件进行复制。如果您从本公司任何正式指定或授权的人员处收到任何此类文件或项目，您应被视为已收到本公司的明确书面同意。如果您收到任何此类文件或项目，而不是通过前句所述的亲自递送，您同意立即通知公司您拥有这些文件或项目。您应立即归还任何此类文件或项目，根据本协议第 7 条的规定，在本协议终止时，或在您终止或辞职时，随本公司要求向本公司提供任何复制品或副本。

6.4. No Disclosure. You agree that you will hold in trust and confidence all Confidential Information and will not disclose to others, directly or indirectly, any Confidential Information or anything relating to such information without the prior written consent of the Company, except as maybe necessary in the course of your business relationship with the Company. You further agree that you will not use any Confidential Information without the prior written consent of the Company, except as may be necessary in the course of your business relationship with the Company, and that the provisions of this Section 6.4 shall survive termination of this Agreement.

6.4. 不披露。您同意，您将对所有机密信息进行托管和保密，未经本公司事先书面同意，您不会直接或间接向他人披露任何机密信息或与此类信息相关的任何内容，除非在你与公司的业务关系中有必要。您进一步同意，未经本公司事先书面同意，您不会使用任何保密信息，除非在您与本公司的业务关系过程中有必要，本第 6.4 条的规定在本协议终止后仍然有效。

7. **Termination and Resignation.** Your membership on the Company's Board may be terminated for any or no reason or you may also terminate your membership on the Board for any or no reason except as provided in the Company's Memorandum and Articles of Association, as amended from time to time. Upon the effective date of the termination or resignation, your right to compensation hereunder will terminate.

7. 终止和辞职。您在公司董事会的成员资格可能会因任何原因或无原因而终止，或者您也可以出于任何原因或无原因终止您在董事会的成员资格，除非公司的组织大纲和公司章程细则（经不时修订）另有规定。在终止或辞职生效之日起，您在本协议项下获得补偿的权利将终止，但公司有义务根据您已经获得的补偿，向您支付任何现金补偿（或公司普通股的同价值）（如适用），并补偿您在该等终止或辞职生效之日因履行职责而产生的批准费用。

8. **Independent Contractor.** You understand, acknowledge and agree that your relationship with the Company is that of an independent contractor and nothing in this Agreement is intended to or should be construed to create a relationship other than that of independent contractor. Nothing in this Agreement shall be construed as a contract of employment/engagement between you and the Company or as a commitment on the part of the Company to retain you in any capacity, for any period of time or under any specific terms or conditions, or to continue your service to the Company beyond any period.

8. 独立签约人。您理解、承认并同意，您与本公司的关系是独立签约人的关系，本协议中的任何内容均无意或不应被解释为与独立签约人的关系以外的关系。本协议中的任何内容均不得解释为您与本公司之间的雇佣/聘用合同，也不得解释为本公司承诺以任何身份在任何时间段内或在任何特定条款或条件下保留您，或在任何期限后继续为本公司服务。

9. **Governing Law; Consent to Jurisdiction.** Any dispute, controversy, difference or claim arising out of or relating to this contract, including the existence, validity, interpretation, performance, breach or termination thereof or any dispute regarding non-contractual obligations arising out of or relating to it shall be referred to and finally resolved by [arbitration administered by the Jilin Arbitration Commission when the Notice of Arbitration is submitted, and the decision rendered is final. The law of this arbitration clause shall be PRC law. The seat of arbitration shall be Jilin City, Jilin Province. The arbitration proceedings shall be conducted in Chinese.]

9. 管辖法律；同意管辖权。由本合同引起或与本合同有关的任何争议、争议、分歧或索赔，包括存在、有效性、解释、履行，违反或终止其或与之有关的非合同义务的任何争议，[应在提交仲裁通知时，由吉林仲裁委员会进行仲裁，仲裁为终本的。本仲裁条款的法律为中国法律。仲裁的地点是中国吉林省吉林市。仲裁程序应以中文进行。]

10. **Entire Agreement; Amendment; Waiver; Counterparts.** This Agreement expresses the entire understanding with respect to the subject matter hereof and supersedes and terminates any prior oral or written agreements with respect to the subject matter hereof. Any term of this Agreement may be amended and observance of any term of this Agreement may be waived only with the written consent of the parties hereto. Waiver of any term or condition of this Agreement by any party shall not be construed as a waiver of any subsequent breach or failure of the same term or condition or waiver of any other term or condition of this Agreement. The failure of any party at any time to require performance by any other party of any provision of this Agreement shall not affect the right of any such party to require future performance of such provision or any other provision of this Agreement. This Agreement may be executed in separate counterparts each of which will be an original and all of which taken together will constitute one and the same agreement, and may be executed using facsimiles of signatures, and a facsimile of a signature shall be deemed to be the same, and equally enforceable, as an original of such signature.

10. 完整协议；修订；弃权；副本。本协议表达了对本协议标的的完整理解，并取代和终止先前与本协议标的有关的任何口头或书面协议。只有经双方书面同意，才能修改本协议的任何条款，并放弃遵守本协议的任何条款。任何一方放弃本协议的任何条款或条件，不得解释为对任何后续违反或未能遵守同一条款或条件或放弃本协议任何其他条款或条件的弃权。任何一方在任何时候未能要求任何其他方履行本协议的任何条款，不得影响任何该方要求未来履行该条款或本协议任何其他条款的权利。本协议可单独签署，每份副本均为原件，所有副本共同构成同一协议，并可使用签名传真件签署，签名的传真件应视为与该签名原件相同且具有同等效力。

This Agreement has been executed and delivered by the undersigned and is made effective as of the date set first set forth above.

本协议已由下述签字人签署并交付，并于上述日期生效。

Sincerely,

Zhengye Biotechnology Holding Limited

By: _____

Name: Zhenfa Han

Title: Chairman of the board

Agreed to and accepted:

[Director Name]

Jilin Zhengye Biological Products Co., Ltd

VETERINARY VACCINES SALES CONTRACTParty A (the Seller): Jilin Zhengye Biological Products Co., Ltd

Unified Social Credit Code: 91220000124494874F

Address: No.1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin Province

Sales Supervisor: _____, ID Number: _____, Tel: _____

Party B (the Buyer): _____ (Enterprise Category: _____)

Veterinary Drug Business License Number: _____

Unified Social Credit Code: _____

Address: _____

Legal Representative: _____, ID Number: _____, Tel: _____

Contact Person: _____, ID number: _____, Tel: _____

Based on the principles of fairness, impartiality, mutual benefit, honesty, and trustworthiness, and in accordance with laws and regulations such as *the Civil Code of the People's Republic of China, the Regulations on the Administration of Veterinary Drugs, and the Measures for the Operation and Management of Veterinary Biological Products*, the contract (hereinafter referred to as "the Contract") is entered into between Party A and Party B concerned on the basis of equality and mutual benefit to develop business on terms and conditions mutually agreed upon as follows.

Article 1 Contents of Collaboration

- 1.1 After mutual consultation and agreement, Party B agrees to purchase vaccines produced by Party A for epidemic prevention purposes in its branch/subsidiary farms (see Annex 1 for the list of branch/subsidiary farms of Party B). The specific types and prices of vaccines to be purchased are shown in Annex 2. The list of newly added branch/subsidiary breeding farms or newly added vaccine varieties and prices of Party B shall be subject to a supplementary agreement signed by both parties.

1

- 1.2 Party B shall lawfully use the animal biological products produced by Party A within the agreed breeding farm. Without the written consent of Party A, Party B shall not transfer, sell or gift the veterinary biological products supplied by Party A to any third party outside the list in Annex 1.
- 1.3 Party B shall purchase veterinary vaccines from Party A from [date] to [date] (specific types and prices of vaccines to be purchased are shown in Annex 2), with a provisional purchase amount of approximately _____ RMB (in 10,000 yuan). The amounts involved in this Contract and the annexes are all inclusive of taxes. When Party A discovers that the cumulative supply amount exceeds the agreed amount in the Contract, it shall contact Party B to sign a supplementary agreement. Otherwise, if the purchase order exceeds the agreed amount in this clause, Party A may refuse to ship and shall not be liable for breach of contract.

Article 2 Term

- 2.1 This Contract is valid for the same period as the one in Article 1.3. If the term expires but there is still an unfulfilled transaction between the two parties, the term shall remain valid until the completion of the transaction by both parties.
- 2.2 One month before the Contract expires, both parties shall negotiate and determine whether to renew the Contract based on the actual situation. After reaching an agreement through consultation, both parties shall sign a new contract.

Article 3 Quality Standard

- 3.1 The products supplied by Party A shall comply with the quality standards, labeling standards, and promotional materials promised by Party A, as well as the national quality standards for animal medicine vaccines and relevant regulations.
- 3.2 Party A is responsible for the quality of the product during its shelf life and guarantees that the provided products do not contain pollutants, harmful substances, or prohibited substances according to national regulations.
- 3.3 If there is a dispute between Party A and Party B regarding product quality issues, both parties shall jointly entrust a third-party national authoritative testing agency to conduct inspections. If the inspection results do not meet the quality standards stipulated in the contract, Party A shall bear the relevant testing costs and any losses caused to Party B. If the inspection results meet the quality standards stipulated in the contract, the relevant testing costs shall be borne by Party B.
- 3.4 Party A guarantees that the validity period of the vaccine upon arrival must be at least 6 months, or the remaining validity period shall not be less than 50% of the product's validity period. The principle for each arrival batch is one batch, with a maximum of two batches.
- 3.5 The packaging standard requirements for the product: The packaging can ensure that the supplied product can be transported and unloaded properly. For the sake of biosafety, the outer packaging must be covered with film. Otherwise, Party B has the right to refuse, and the packaging cost shall be borne by Party A.

2

Article 4 Ordering, Payment, Delivery, and Inspection

- 4.1 Ordering Method and Ordering Confirmation: Party B must fill in the *Zhengye Biological Vaccine Product Purchase and Sales Order Sheet* (see Annex 3) and stamp it with the corporate seal or the contract special seal, and send it to Party A by email. Party A will review it and stamp it before returning it to Party B. the document shown in Annex 3 can only take effect after both parties jointly sign and seal it.
- 4.2 Ordering requirements: When filling the document shown in Annex 3, Party B shall be informed that the minimum order amount for a single order shall not be less than 20,000 yuan for swine vaccines and 10,000 yuan for other vaccines. Meanwhile, the quantity of a single order by Party B shall not be lower than the minimum packaging quantity of that product. Otherwise, Party A has the right to refuse to stamp the official seal on Annex 3, and any losses resulting from this shall be borne independently by Party B. In special circumstances, the agreement reached by both parties through consultation shall prevail.
- 4.3 Payment: By credit sales. Party A agrees to grant Party B a period not exceeding _____ days for the payment, and both parties agree to comply with the following requirements.
- 4.3.1 Reconciliation requirements: The designated personnel of both parties must reconcile the goods and accounts payable of the previous month at the beginning of each month, verify the specific specifications, quantities, and payment amount of the received goods, and reconcile them in writing, and deliver them via email or express delivery. Unless otherwise agreed by both parties, if Party B fails to reconcile accounts with Party A within the aforementioned period, it shall be deemed that Party B approves Party A's bill, and Party B shall pay the price according to Party A's bill. After the reconciliation is correct, Party A shall issue relevant sales electronic invoices to Party B and send them to Party B's designated email address.
- 4.3.2 Settlement and Payment Requirements:
- A. Party B shall complete the payment to Party A within _____ working days after receiving the invoice from Party A.
- B. Other settlement of payment: _____ After consultation between both parties, settlement and payment shall be made in accordance with Point ____ (A/B).

3

- 4.3.3 If Party A fails to receive the due accounts payable from Party B on time, Party A has the right to stop shipping to Party B and reserves the right to recover relevant losses from Party B. Party B shall be liable for breach of contract.
- 4.4 Payment: Bank transfer. Both parties confirm that under no circumstances shall Party B pay the payment due to Party A to any individual employee of Party A (including but not limited to cash, remittance, etc.), otherwise Party B shall bear full responsibility for any consequences caused.

Party A designates the corporate payment account as follows (any changes to the account are subject to Party A's written notice with corporate seal):

Bank of Deposit	Bank Account Name	Bank Account Number
Jilin Hadawan Branch of China Construction Bank	Jilin Zhengye Biological Products Co., Ltd	22001616338059668888

4.5 Delivery

4.5.1 After signing the document shown in Annex 3 in accordance with Article 4.1, Party A shall deliver the products to the designated location of Point ____ (A/B) through a third-party logistics provider and inform Party B as soon as possible to pick up or receive the goods at the designated location. Party B shall receive the products in a timely manner within [3] hours after the products arrive at the agreed location. Any responsibility or loss caused by Party B's delay in receiving/picking up the goods shall be borne entirely by Party B.

A. If Party B is located in a county-level area or an urban area, Party A shall deliver the goods to Party B whose address is number _____, _____ street/road, _____ county, _____ city, _____ province through a third-party logistics provider.

B. If Party B is located in an area below the county level or in a remote area, Party A shall deliver the goods to the pickup location of the city at or above the county level as stipulated in this Contract through a third-party logistics provider. Both parties agree that the pickup location of Party B shall be at number _____, _____ street/road, _____ county, _____ city, _____ province (the location must be the city at or above the county level where Party B is located).

4.5.2 The contact person for Party B to receive/pick up the goods is _____, with the contact information of _____.

4.5.3 If the delivery address or contact person or contact information of Party B changes, Party B shall notify Party A in writing or by email before Party A ships the goods. Otherwise, all losses caused shall be borne by Party B.

4.5.4 The freight and transportation responsibility (including but not limited to related transportation costs, insurance, storage, and the risk of product loss and damage) from the factory of Party A to the agreed location for Party B to pick up the goods shall be borne by Party A. The freight and transportation responsibility (including but not limited to related transportation costs, insurance, storage, and the risk of product loss and damage) incurred by Party B to pick up the goods at the agreed location shall be borne by Party B.

4.5.5 The delivery deadline agreed upon by both parties shall be subject to Annex 3.

4

4.6 Inspection: Upon receipt of the goods, Party B shall immediately conduct an inspection to verify whether the name, specifications, quantity, etc. of the goods match. After confirming that there are no errors, Party B shall sign and confirm in the *Delivery Sheet* [at the column of "Customer Receipt Confirmation"]. If the delivered product does not match the *Delivery Sheet*, or if there is any shortage or damage to the products, it should be immediately photographed for evidence, and detailed on the delivery receipt. Within two working days from the date of receipt, the *Delivery Sheet* should be reported to Party A by fax or email for any shortage or damage, and Party A will take corresponding measures. If Party B fails to sign detailed opinions and notify Party A within the above-mentioned period, it shall be deemed that the goods received by Party B are intact and undamaged, and Party B shall not make any demands on Party A regarding this batch of goods.

4.7 Due to the special feature of biological products and regulatory requirements from government departments, goods that have no quality issues after shipment will not be returned. If there is a quality problem during the shelf life, and it is confirmed by Party A that it is a quality problem, it can be returned. The return process shall be handled in accordance with Party A's relevant requirements. Goods that exceed their shelf life will not be returned or exchanged.

Article 5 Liabilities for Breach of Contract

5.1 Either party to this Contract who violates or fails to fulfill any of its representations, warranties, commitments, obligations, or responsibilities under this Contract on time shall constitute a breach of contract, and shall compensate the complying party for any losses caused. Unless otherwise agreed in this contract, the non-breaching party has the right to demand that the breaching party rectify the breach within [7] days. If the breaching party fails to rectify or if the purpose of this Contract cannot be achieved due to the breaching party's breach, the aggrieved party has the right to terminate this Contract, and the breaching party shall compensate for any losses caused to the aggrieved party as a result.

5.2 Party A's Liabilities for Breach of Contract

5.2.1 Except for force majeure, Party A shall pay a penalty equivalent to 0.5% of the delayed delivery value for each day of delay in delivery. If Party A delays delivery for 3 days, or if the quality of the products provided is unqualified and cannot be replaced as requested by Party B, Party B has the right to unilaterally terminate the Contract. However, for the payment generated by the performance of the Contract by both parties before the termination of the Contract, Party B shall settle it with Party A within the time limit specified by Party A. Otherwise, Party B shall pay Party A a penalty of 0.05% of the outstanding payment for each day of delay.

5

5.2.2 Party A shall ensure that it has the necessary qualifications and all licenses to sell the products, the source of the supplied products is legal, the procedures are compliant, and the sale will not infringe upon the legitimate rights and interests of any third party. If Party A violates this commitment and causes economic losses to Party B, Party A shall be liable for compensation.

5.2.3 The quality responsibility of Party A shall be executed in accordance with the provisions of Article 3 of this Contract. If Party A violates this commitment and causes economic losses to Party B, Party A shall be liable for compensation.

5.3 Party B's Liabilities for Breach of Contract

5.3.1 If Party B, without the written consent of Party A, flows Party A's products used by Party B's branch/subsidiary breeding farms as stipulated in this Contract into other areas or other breeding farms outside the list in Annex 1, causing losses to Party A or other customers of Party A; or without written permission from Party A, Party B engages in or assists, or collaborates with a third party to sell Party A's veterinary biological products in any form on online platforms. If such an event occurs, Party B shall pay Party A a penalty of 5,000 yuan per occurrence. If such an event occurs for the second time, Party A has the right to terminate this Contract and not return all the fees already paid by Party B. At the same time, Party B shall pay Party A a penalty of [1] % of the provisional purchase price under this Contract. If the penalty is not sufficient to compensate for Party A's losses, Party B shall make up for it.

5.3.2 If Party B (including its branches/subsidiaries) fails to pay the payable amount to Party A on time, Party B shall pay a penalty equivalent to 0.05% of the delayed payment amount to Party A for each day of delay in payment. If the payment is delayed for more than 30 days or if there are 3 instances of delayed payment during the cooperation period, Party A has the right to terminate this Contract and not return all the fees already paid by Party B. At the same time, Party B shall pay Party A a penalty of [1] % of the provisional purchase price under this Contract. If the penalty is not sufficient to compensate for Party A's losses, Party B shall make up for it.

5.4 "Losses" stipulated in this Contract refer to all losses caused to the complying party due to breach of contract, as well as all expenses incurred in claims or litigation, including but not limited to litigation fees, preservation fees, investigation fees, travel expenses, evaluation fees, appraisal fees, lawyer fees, etc. incurred in handling the dispute.

Article 6 Anti-Corruption Provisions

6.1 Party A prohibits Party A from providing personal convenience, bribery, or engaging in abnormal business banquets to Party B's employees in any way. If Party A engages in any abnormal economic activities such as private dining, providing personal convenience to Party B's employees, bribery, etc. during the performance of the Contract, once verified by Party B, Party A shall be punished for violating personnel at a rate of 1,000 yuan per person, and Party B has the right to unilaterally terminate the Contract. However, for the payment generated by the performance of the Contract by both parties before the termination of the Contract, Party B shall settle it with Party A within the time limit specified by Party A. Otherwise, Party B shall bear the liability for breach of contract in accordance with Article 5. 3.2 of this Contract. If Party A states the facts to Party B afterwards, or if Party A has evidence to show that the above behavior is an unavoidable act of pressure exerted by Party B's employees, Party B may retain the cooperative relationship or be exempted from relevant penalties after confirmation.

6

6.2 Party B states that it is prohibited for Party B to express or imply in any way that Party A invites them to eat, drink, accept gifts or other personal conveniences or benefits provided by Party A. If the employees of Party B explicitly or implicitly request banquets, receptions, or requests for gifts, gifts, vouchers, or other benefits, or intentionally create difficulties, Party A may report to the supervisory department of Party B. The specific reporting channels are as follows. Reporting hotline: _____. During the cooperation period, if there are a total of [3] occurrences of the behavior, or if Party A reports but Party B does not respond, Party A has the right to terminate this Contract and not refund all fees already paid by Party B.

Article 7 Notification and Mailing

7.1 The sales person in charge of Party A, as is shown on the cover of this Contract, and the contact person of Party B shall be responsible for delivering and receiving relevant business materials and legal documents on behalf of their parties, including notices of contract termination, and receiving relevant legal documents served by the court in case of disputes. The mailing addresses of both parties are shown on the cover of this Contract.

7.2 Either party must notify the other party in writing of any changes in the authorized signatory or the contact information, mailing address, or other information of the authorized signatory three days in advance. Otherwise, the other party shall bear the adverse legal consequences of inability to deliver.

7.3 Commercial materials, evidence materials, legal documents, and other materials related to the performance of this Contract shall become effective upon the signature of each authorized signatory. If the authorized signatory refuses to sign, they may be detained and delivered, with equal legal effect.

Article 8 Force Majeure

If the Contract cannot be performed due to war, fire, flood, rainstorm, blizzard,

earthquake, major epidemic, major strike, or other force majeure, neither party shall hold the other party accountable. But it is necessary to notify the other party and take corresponding remedial measures to reduce the occurrence of losses. After the above reasons are eliminated, the performance of this Contract should be resumed as soon as possible, and the handling of losses caused by force majeure should be negotiated, or the Contract should be terminated through negotiation based on the actual situation.

Article 9 Amendment and Termination of Contract

- 9.1 This Contract may be amended or terminated by mutual agreement between both parties.
- 9.2 When one party unilaterally requests to terminate the Contract, the party must notify the other party 30 days in advance and negotiate the termination of the Contract.

Article 10 Miscellaneous

- 10.1 This Contract is in _____, with Party A in possession of _____ copy/copies and Party B in possession of _____ copy/copies, and has the same legal effect.
- 10.2 The Annex to this Contract is an integral part of the Contract and have the same legal effect as this Contract.
- 10.3 Party A shall provide Party B with the supplier registration information: business license, organization code certificate, tax registration certificate, account opening permit, company profile, and stamped with the official seal.
- 10.4 This Contract may apply to the branches/subsidiaries of Party B within the scope of consolidated financial statements. The actual procurement shall be based on the business license of Party B's branches/subsidiaries listed in Annex 1 of this Contract and reported to Party A by Party B after the Contract is signed. The invoice and settlement shall be based on the actual order entity signed. If there is an increase in the list of branch/subsidiary companies of Party B, Party B shall notify Party A in writing and provide Party B with the business license of the added branch/subsidiary companies. Otherwise, Party A has the right to refuse to ship and shall not be deemed as a breach of contract by Party A. If there is a reduction in the directory of branch/subsidiary of Party B, Party B shall notify Party A in writing and settle the payment owed by the branch/subsidiary to Party A within one week of the notification. If Party B fails to notify Party A in writing in a timely manner, resulting in the shipment, or if Party B's branch/subsidiary fails to settle the payment owed by the branch/subsidiary to Party A within one week, Party A has the right to refuse to deliver or even terminate this Contract, which shall not be deemed as a breach of contract by Party A. Party B shall bear the cost and liabilities for breach of contract.

Article 11 Supplementary Provisions

- 11.1 Any disputes arising from the performance of this Contract shall be resolved through consultation between both parties. If consultation fails, the plaintiff may file a lawsuit with the People's Court located in the plaintiff's location.
- 11.2 Both parties may sign a supplementary contract for any other matters not covered, which is an integral part of this Contract and has equal legal effect.
- 11.3 This Contract shall come into effect from the date of signature and seal by both parties.
- 11.4 Both parties voluntarily sign this Contract for mutual compliance.

Annex 1: List of Party B's Subsidiaries/Branches

Annex 2: Catalogue of Vaccines and Price

Party A: Jilin Zhengye Biological Products Co., Ltd

(Seal)

Authorized Representative(signature):

Date:

Party B:

(Seal)

Person in Charge (signature):

Date:

Annex 2: Catalogue of Vaccines and Price

Annex 3: Vaccines Ordering Sheet

Jilin Zhengye Biological Products Co., Ltd;

The Supplier: Jilin Zhengye Biological Products Co., Ltd

Address: No.1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin Province

Tel: 0432-

Fax: 0432-63451800

Email:

Contact Person:

Mobile:

The Purchaser: _____

Address: _____

SUPPLYING CONTRACT

Contract number : ZYC

The Buyer (Party A) : Jilin Zhengye Biological Products Co., Ltd

Unified Social Credit Code:

Signed in : Jilin City

The Seller (Party B) :

Signed on :

Unified Social Credit Code:

According to the provisions of the *Contract Law of the People's Republic of China*, based on the principles of equality, mutual benefit, good faith, and good faith, the Buyer and the Seller have reached the following terms and conditions through friendly consultation regarding the purchase and sale of the following materials for mutual compliance.

1. Product Name, Specifications, Unit Price, Quality Requirement and Delivery Time and Amount

Number	Product Name	Specification	Unit Price (yuan/ml)	Quality Requirement	Delivery time and amount	Notes
1						
2						
3						
4						
5						
Total	Amount: yuan					

2. Requirements of Quality and Packing

- 2.1 The quality requirements of this Contract are as follows: to comply with the quality requirements in Article 1, and to comply with national and industry standards (whichever is higher) for the remaining unclear parts.
- 2.2 Packing: cardboard box packaging, packing materials are not recyclable. The Seller shall provide packing that guarantees the safety and undamaged condition of the product. The Seller shall be responsible for any damage or loss of goods caused by packing issues.

3. Delivery and Shipping

- 3.1 The Seller shall deliver the goods to the warehouse personnel designated by the Buyer and provide a delivery note stamped with the Seller's official seal, which shall be inspected and signed for by the warehouse personnel designated by the Buyer.

The Seller must provide the following documents with the goods, including but not limited to a delivery list stamped with an official seal (or delivery special seal) (i.e. the product name, specifications, and quantity in the delivery list must be consistent with the contract), and product inspection report (or product qualification certificate).

- 3.2 Shipping: Automobile, railway, and aviation are all available for shipping, ensuring the quality of goods during the logistics process. Before the Seller delivers the goods to the Buyer's designated delivery location, all risks shall be borne by the Seller, and the Seller shall bear transportation, loading and unloading, and any resulting costs.
- 3.3 Delivery location and receiving party : Jilin Zhengye Biological Products Co., Ltd

4. Inspection and Objection:

- 4.1 Acceptance time: within 30 days from the date of receipt of the goods.

- 4.2 Acceptance standards: comply with the quality requirements in the table of Article 1 or the national or industry standards.
- 4.3 If Party A finds that the variety, model, specification, quantity, and quality of the product do not meet the regulations during acceptance, Party A shall raise a written objection to Party B within 7 working days.
- 4.4 After receiving written objections from Party A, Party B shall be responsible for handling them within ten days (unless otherwise specified or agreed upon by the parties).

5. Payment Term:

- 5.1 Payment: Payment for the goods shall be made by wire transfer or acceptance draft. Party A shall settle the payment within 90 working days after confirming that there are no objections to the quantity and quality, and Party B shall provide a value-added tax invoice recognized by Party A.
- 5.2 Payment Time: (Note: The Seller needs to issue a full value-added tax special invoice before making the payment. If the Seller fails to issue or issues an unqualified invoice, the Buyer has the right to delay payment of the corresponding amount until the Seller issues a qualified invoice.)

6. Email and Contact of Party A and Party B

Seller's contact person:	Name:	Tel:	WeChat:
	Email :		Mailing address:
Buyer's contact person:	Name:	Tel:	WeChat:

Email :

Mailing address:

7. Responsibilities of Party A and Party B

- 7.1 Should the variety, model, specification, quantity, and quality of the products delivered by Party B do not comply with the provisions of the contract, the price shall be based on the quality with the condition that Party A agrees to use them. Should Party A be unable to utilize it, Party B shall be responsible for replacing it according to the specific situation of the product and bear the responsibility of exchanging or returning it.
- 7.2 Should Party B fail to deliver the goods on time, Party B shall negotiate with Party A before shipment. Should Party A still need the goods, Party B shall make up for it as needed. Should Party A no longer need the goods, Party B shall be notified within seven days after receiving notice from Party B to complete the procedures for terminating the contract.
- 7.3 Should the products of Party B comply with the contract provisions but Party A refuses to accept the goods in violation of the contract provisions, Party A shall bear all losses caused thereby.

8. Liabilities for Breach of Contract

Either party in the Contract must notify the other party at least 7 days in advance to cancel the Contract, otherwise they shall bear all losses caused to the other party as a result.

9. Force Majeure

Either party shall not be held responsible for failure or delay to perform all or any part of this agreement due to force majeure events such as earthquakes, floods and riots that could not be predicted by the relative party. The party affected by the event of force majeure shall inform the other party as soon as possible and thereafter take measures to prevent the expansion of losses, and provide a certificate of the event issued by government agencies or corresponding departments within 15 days after its occurrence. Both parties may negotiate to terminate the Contract or other related matters.

10. Settlement of Dispute

Any disputes arising from the performance of this Contract or related to this contract shall be resolved through friendly consultation between both parties. If consultation fails, the people's court in the place where the contract is signed shall have jurisdiction in accordance with the law. The litigation costs, investigation fees, lawyer fees, and travel expenses incurred due to litigation shall be borne by the losing party.

2

11. Integrity Agreement

- 11.1 If the Buyer and its staff receive gifts, valuable items, securities, or other benefits directly or indirectly gifted by the Seller's staff, they shall be subject to party and political disciplinary sanctions in accordance with their management authority and relevant laws, regulations, and provisions. If they are suspected of committing a crime, they shall be transferred to judicial authorities for processing.
- 11.2 The Seller and other staff members who directly or indirectly give gifts, valuable items or securities to the Buyer's staff members in the name of the company or individual, or use other means to provide improper benefits in a disguised manner, shall be fined 10 times the amount involved by the Seller for each occurrence. The penalty shall be deducted from the contract payment due in the current period. If losses are caused to the Buyer's engineering (production), the Seller shall provide full compensation. If the circumstances are serious, in addition to imposing a penalty of 10 times the amount involved by the Seller, a penalty of 20% to 30% of the contract price shall also be imposed on the Seller. If the circumstances are particularly serious, the Buyer has the right to terminate its procurement contract and impose a penalty of not being allowed to enter the Buyer's material procurement project for one to two years. The losses and all expenses incurred by the Buyer as a result shall be borne by the Seller and deducted from the settlement payment of the material procurement contract.

12. Effectiveness and Miscellaneous

- 12.1 Any written notice shall be deemed delivered to the other party upon being notified in writing to the communication address, email or fax specified in this contract. If one party's contact information changes, they should notify the other party in writing in a timely manner. Otherwise, if the original contact information is used, it will be deemed as valid delivery.
- 12.2 If the signed contract or order is reached by fax or scanning, it will be deemed as a valid contract. The main text of this contract shall be based on printed text, and any handwritten or altered text shall be invalid.
- 12.3 If the order is signed by fax or scanning, the Seller must confirm and return it to the Buyer before the time agreed upon by both parties. If the Seller confirms that the return is overdue, it must be approved by the Buyer before it becomes effective. Otherwise, the original order will become invalid.
- 12.4 Any modifications, supplements, and changes to the contract terms shall be made in writing. On the basis of mutual agreement between the Buyer and Seller, a written agreement shall be signed and stamped by authorized representatives of both parties. The modified, supplemented, or modified documents confirmed by the signatures and seals of both parties are an effective part of the Contract and have the same legal effect as the Contract.
- 12.5 Miscellaneous: Before the first transaction, the Seller shall provide the Buyer with the company's business license stamped with the official seal, tax registration certificate, and the legal representative's authorization letter as a backup. Long term suppliers should proactively provide the Buyer with updated documents or annual inspections for their record keeping. When changing the signing representative, a power of attorney for that representative should be provided.
- 12.6 This Contract shall come into effect from the date of being stamped by both parties. Two copies shall be made, with each party holding one copy and having equal legal effect. The validity period of the contract is from [] (date) to [] (date).

Party A

Name (seal): Jilin Zhengye Biological Products Co., Ltd

Authorized Representative:

Address: No.1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin Province

Tel: 0432-63047105

Party B

Name (seal):

Authorized Representative:

Address:

Tel:

Fax: 0432-63056300

Fax:

Bank of deposit: Jilin Hadawan Branch of China Construction Bank

Bank of deposit:

Bank account number:
2200161633805966888

Bank account number:

Jilin Zhengye Biological Products Co., Ltd

DISTRIBUTION CONTRACT FOR VETERINARY VACCINES IN 2023

Party A (the Manufacturer): Jilin Zhengye Biological Products Co., Ltd

Unified Social Credit Code: 91220000124494874F

Address: No.1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin Province

Sales Supervisor: _____, ID Number: _____, Tel: _____

Party B (the Distributor): _____ (Enterprise Category: _____)

Veterinary Drug Business License Number: _____

Unified Social Credit Code: _____

Address: _____

Legal Representative: _____, ID Number: _____, Tel: _____

Contact Person: _____, ID number: _____, Tel: _____

The parties are willing to leverage their strengths and work together to provide healthy breeding services. They will work together to develop and deliver value in the market of veterinary biological products, to unleash and meet the needs of customers, to improve production efficiency for customers, and to increase the penetration rates of their products. Party A should encourage and support Party B to pursue excellence and become a leader in the local market. Based on the principles of fairness, impartiality, mutual benefit, honesty, and trustworthiness, and in accordance with laws and regulations such as *the Civil Code of the People's Republic of China, the Regulations on the Administration of Veterinary Drugs, and the Measures for the Operation and Management of Veterinary Biological Products*, the contract (hereinafter referred to as "the Contract") is entered into between the parties concerned on the basis of equality and mutual benefit to develop business on terms and conditions mutually agreed upon as follows.

Article 1 Distribution Territory and Variety:

- 1.1 Party B shall meet the business conditions and requirements stipulated in the *Management Measures for the Operation of Veterinary Biological Products*, and strictly abide by the regulations for the storage, transportation, and distribution of veterinary biological products.

1

- 1.2 After both parties have reached an agreement on the business development goals and action strategies for the designated distribution territory, Party A agrees to authorize Party B to distribute veterinary biological products produced by Party A that meet national standards of breeding for the non-group enterprises of breeding in _____. The product variety and sales price system can be found in the *Zhengye Biological Veterinary Biological Products Distribution Catalog and Price List* in Annex 1, and the newly-added product variety shall be subject to the supplementary list signed by both parties.
- 1.3 Party B shall lawfully distribute the veterinary biological products produced by Party A within the agreed distribution territory, and shall not sell, transfer, or distribute any veterinary biological products produced by the Party A beyond the agreed territory or variety.
- 1.4 "Group enterprises of breeding" refer to the enterprises with a stock of over 10,000 sows, over 100,000 sets of breeding poultry, over 500,000 poultry that produce eggs, over 10 million poultry that produce meat, and over 10,000 beef cattle (sheep). Enterprises that do not have such scales are referred to as "non-group enterprises of breeding". The group enterprises of breeding shall be directly developed by Party A. If Party B is willing to assist Party A to become a group enterprise of breeding, both parties shall negotiate and agree on specific cooperation methods before signing a separate agreement.
- 1.5 Party A has the right to adjust the supply price of the products based on changes in production costs and other reasons, but needs to notify Party B in writing at least one month in advance.
- 1.6 Within 5 days from the date of signing this Contract, Party B shall provide Party A with a copy of the *Veterinary Drug Business License* held by Party B for filing.
- 1.7 During the validity period of this Contract, if there is any change in the content stated on the *Veterinary Drug Business License* held by Party B or if the *Veterinary Drug Business License* involves extension matters, Party B shall provide Party A with the information of the *Veterinary Drug Business License* held by Party B within 5 days from the date of obtaining the new one.
- 1.8 During the validity period of this contract, if the *Veterinary Drug Business License* held by Party B is revoked by relevant departments in accordance with the law or fails to be extended in a timely manner after expiration, Party B shall notify Party A in writing within 5 days from the date of relevant matters. From the date of the written notice reaching Party A, the cooperation relationship between Party A and Party B shall terminate automatically.

2

Article 2 Term of Contract

- 2.1 This Contract is valid from January 1, 2023 to December 31, 2023.
- 2.2 One month before the expiration of the contract period, both parties shall negotiate and determine whether to renew the distribution contract for animal biological products for the next year based on the actual situation. Under the condition of achieving the annual distribution target stipulated in this Contract, Party B has the priority right to renew the contract.

Article 3 Ordering, Payment, Delivery, and Inspection

- 3.1 Order Method and Order Confirmation:
 - 3.1.1 Online ordering for using “U-ordering”: Party B shall choose the product name, quantity, logistics method, etc. according to their own needs on the “U-ordering”.
 - 3.1.2 Offline ordering for not using “U-ordering”: Party B must complete the *Product Purchase and Sales Contract* (see Annex 2) for each order, stamp it with an official seal, and send it to Party A’s business department in writing by fax or email. After the business team of Party A reviews and accepts the *Product Purchase and Sales Contract*, Party B shall be notified of payment through communication via telephone, SMS, or WeChat.
- 3.2 Ordering requirements: Party B shall not place a single order whose total price is lower than the minimum order amount (i.e. the minimum order amount for pig vaccines shall be 20,000 yuan, and other vaccines shall not be 10,000 yuan), and the order quantity of a single product shall not be lower than the minimum packing quantity. Otherwise, Party B shall bear the shipping cost of this batch of goods on its own.
- 3.3 Payment: Payment should be made in advance before delivery. Party B must remit the full amount of the payment to the designated receiving account of Party A listed below before shipment, and arrange shipment after Party A’s finance department verifies that the payment is correct. Both parties confirm that under no circumstances shall Party B pay the payment due to Party A to any individual employee of Party A (including but not limited to cash, remittance, etc.), otherwise Party B shall bear full responsibility for any consequences caused.

Party A designates the corporate payment account as follows (any changes to the account are subject to Party A’s written notice with corporate seal):

Bank of Deposit	Bank Account Name	Bank Account Number
Jilin Hadawan Branch of China Construction Bank	Jilin Zhengye Biological Products Co., Ltd	2200161633805966888

- 3.4 Delivery
 - 3.4.1 After Party A’s finance department confirms that full payment has been received from Party B, Party A shall deliver the goods to the agreed location of _____ (A /B) through a third-party logistics provider and promptly notify Party B to pick up or receive the goods at the agreed location. Party B shall receive the goods in a timely manner within [] hours after the goods arrive at the agreed location. Any responsibility or loss caused by Party B’s delay in receiving/picking up the goods shall be borne entirely by Party B.

- A. If Party B is located in a county-level area or an urban area, Party A shall deliver the goods to Party B whose address is number _____, _____ street/road, _____ county, _____ city, _____ province through a third-party logistics provider.
- B. If Party B is located in an area below the county level or in a remote area, Party A shall deliver the goods to the pickup location of the city at or above the county level as stipulated in this Contract through a third-party logistics provider. Both parties agree that the pickup location of Party B shall be at number _____, _____ street/road, _____ county, _____ city, _____ province (the location must be the city at or above the county level where Party B is located).
- 3.4.2 The contact person for Party B to receive/pick up the goods is _____, with the contact information of _____.
- 3.4.3 If the delivery address or contact person or contact information of Party B changes, Party B shall notify Party A in writing or by email before Party A ships the goods. Otherwise, all losses caused shall be borne by Party B.
- 3.4.4 The freight and transportation responsibility from the factory of Party A to the agreed pick-up/delivery location of Party B shall be borne by Party A, while the freight and transportation responsibility incurred by Party B when picking up the goods at the agreed location shall be borne by Party B.
- 3.5 Inspection: Upon receipt of the goods, Party B shall immediately conduct an inspection to verify whether the name, specifications, quantity, etc. of the goods match. After confirming that there are no errors, Party B shall sign and confirm in the *Delivery Sheet* [at the column of “Customer Receipt Confirmation”], or click to confirm receipt through the “U-ordering” online platform; If the delivered product does not match the *Delivery Sheet*, or if there is any shortage or damage to the products, it should be immediately photographed for evidence, and detailed on the delivery receipt. Within two working days from the date of receipt, the *Delivery Sheet* should be reported to Party A by fax or email for any shortage or damage, and Party A will take corresponding measures. If Party B fails to sign detailed opinions and notify Party A within the above-mentioned period, it shall be deemed that the goods received by Party B are intact and undamaged, and Party B shall not make any demands on Party A regarding this batch of goods. The date of the above notice shall be postponed in case of statutory holidays.
- 3.6 Due to the special feature of biological products and regulatory requirements from government departments, goods that have no quality issues after shipment will not be returned. If there is a quality problem during the shelf life, and it is confirmed by Party A that it is a quality problem, it can be returned. The return process shall be handled in accordance with Party A’s relevant requirements. Goods that exceed their shelf life will not be returned or exchanged.

Article 4 Distribution Targets and Assessment

- 4.1 The total amount (calculated based on the amount purchased by Party B from Party A) for the distribution of Party A’s veterinary biological products by Party B during the term of this Contract is _____ RMB yuan.
- 4.2 The quarterly distribution plan of Party B (calculated based on the purchase amount from Party A) is as follows:

Quarter	Q1	Q2	Q3	Q4	Total
Plan (in 10,000 RMB)					

In particular, the minimum monthly distribution amount shall not be less than 6% of the annual distribution target.

Article 5 Distribution Support

- 5.1 The regional sales team of Party A shall assist Party B in jointly developing large-scale breeding farms or secondary distributors. Party B shall regularly provide target customer information to Party A's sales team and provide support to Party A's personnel. Both parties shall hold a monthly market development analysis meeting and submit the *Monthly Market Development Meeting Minutes* to Party A's technical and marketing department by email for filing.
- 5.2 In order to help Party B better explore the market and solve problems in the breeding farm, Party A will provide different forms of professional technical service support to Party B and its important target customers, and periodically provide support such as promotion, lectures, and company visits to Party B. The specific form, time, and cost sharing method of support shall be separately discussed by both parties according to business development needs, and shall be implemented after approval by the person in charge of Party A.

Article 6 Liability for Distribution Breach of Contract

- 6.1 If any one or more of the following behaviors occur during the distribution process of Party B, it shall constitute a breach of contract and Party B shall bear the liability for breach of contract in accordance with the law.
- 6.1.1 Party B, without the written consent of Party A, sells products from the first party across regions on its own or causes losses to Party A and other customers due to counterfeit goods flowing into other regions.
- 6.1.2 If Party B sells to the breeding farm at a price lower than the terminal price specified in Annex 1 of this Contract.
- 6.1.3 Without written permission from Party A, Party B engages in, assists, or collaborates with a third party to sell Party A's veterinary biological products in any form on online platforms.
- 6.1.4 Party B sells counterfeit biological products produced by Party A or expired biological products; or if Party B abuses or applies Party A's trademark identification and labels.
- 6.1.5 Party B does not meet the operating conditions and requirements stipulated in the *Management Measures for the Operation of Veterinary Biological Products*; or if Party B does not store drugs according to the labels and instructions of veterinary biological products.
- 6.1.6 If Party B violates industry laws and regulations by promoting information that does not match the content of Party A's product manual without authorization, causing losses to Party A or a third party, Party A or a third party reserves the right to pursue legal action.

- 6.1.7 Engaging in other illegal and irregular behaviors or engaging in other behaviors that infringe upon the interests of Party A.

Should Party B violate any one or more of these provisions, Party B shall pay Party A the penalty of 5% of the total value of the goods. Should the liquidated damages be insufficient to compensate for the losses suffered by Party A, Party B shall also compensate for the part of the liquidated damages that is insufficient to compensate for the losses. Should the breach of contract by Party B be serious, Party A has the right to stop supplying goods to Party B and to terminate this Contract. Should Party B be found to have violated Article 5.1.1, Party B should pay a penalty of 5% of the annual distribution target amount to Party A and demand the recovery of all counterfeit products for the first time and cancel the annual gift reward. Should the Distributor be found to be tampering with goods for the second time, the Agency/Distributor qualification will be directly cancelled.

- 6.2 After the expiration of the term of this Contract and the voluntary termination by mutual agreement, both parties shall not have the right to claim compensation from the other party.

Article 7 Notification and Mailing

- 7.1 The sales person in charge of Party A, as is shown on the cover of this Contract, and the contact person of Party B shall be responsible for delivering and receiving relevant business materials and legal documents on behalf of their parties, including notices of contract termination, and receiving relevant legal documents served by the court in case of disputes. The mailing addresses of both parties are shown on the cover of this Contract.
- 7.2 One party must notify the other party in writing of any changes in the authorized signatory or the contact information, mailing address, or other information of the authorized signatory. Otherwise, the other party shall bear the adverse legal consequences of inability to deliver.
- 7.3 Commercial materials, evidence materials, legal documents, and other materials related to the performance of this Contract shall become effective upon the signature of each authorized signatory. If the authorized signatory refuses to sign, they may be detained and delivered, with equal legal effect.

Article 8 Force Majeure

If the Contract cannot be performed due to war, fire, flood, rainstorm, blizzard, earthquake, major epidemic, major strike, or other force majeure, neither party shall hold the other party accountable. But it is necessary to notify the other party and take corresponding remedial measures to reduce the occurrence of losses. After the above reasons are eliminated, the performance of this Contract should be resumed as soon as possible, and the handling of losses caused by force majeure should be negotiated, or the Contract should be terminated through negotiation based on the actual situation.

Article 9 Amendment and Termination of Contract

- 9.1 This Contract may be amended or terminated by mutual agreement between both parties.
- 9.2 When either party unilaterally requests to terminate the Contract, the party must notify the other party 30 days in advance and negotiate the termination of the Contract.

Article 10 Supplementary Provisions

- 10.1 This Contract is made in duplicate, with each party holding one copy which has equal legal effect.

10.2 Any disputes arising from the performance of this Contract shall be resolved through consultation between both parties. If no agreement can be reached through consultation, the People's Court located in the place where Party A is located shall have jurisdiction.

10.3 Both parties may sign a supplementary contract for any other matters not covered, which is an integral part of this Contract and has equal legal effect.

10.4 This Contract shall come into effect from the date of signature and seal by both parties.

Both parties voluntarily sign and abide by this Contract.

Annex 1: Veterinary Biological Product Catalogue and Price List of Jilin Zhengye Biological Products Co., Ltd;

Annex 2: Purchase and Sales Contract of Jilin Zhengye Biological Products Co., Ltd;

Party A: Jilin Zhengye Biological Products Co., Ltd

(Seal)

Sales Manager (signature):

Date:

Party B:

(Seal)

Person in Charge (signature):

Date:

7

**Annex 1: Veterinary Biological Product Catalogue and Price List of
Jilin Zhengye Biological Products Co., Ltd;**

Product Name	Specification	Packing (bottles/box)	Unit	Primary Price	Secondary Price	Terminal Price
Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, live (Strain huadu + Strain CV777+Strain NX)	1 for 10	500	bottle	¥ 60.00	¥ 85.00	¥ 200.00
	1 for 5	500	bottle	¥ 30.00	¥ 42.50	¥ 100.00
	1 for 2	500	bottle	¥ 12.00	¥ 17.00	¥ 40.00
Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine , Inactivated	40 ml	150	bottle	¥ 28.00	¥ 35.00	¥ 65.00
	100 ml	80	bottle	¥ 65.00	¥ 85.00	¥ 150.00
Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine G , Inactivated	40 ml	150	bottle	¥ 40.00	¥ 70.00	¥ 120.00
	100 ml	80	bottle	¥ 100.00	¥ 150.00	¥ 260.00
Porcine Cirovirus Type 2 Vaccine, Inactivated (Strain SH)	20 ml	300	bottle	¥ 35.00	¥ 60.00	¥ 120.00
	100 ml	80	bottle	¥ 150.00	¥ 280.00	¥ 560.00
Swine Pseudorabies Vaccine G, Live	1 for 20	600	bottle	¥ 32.00	¥ 52.00	¥ 80.00
	1 for 50	600	bottle	¥ 75.00	¥ 125.00	¥ 200.00

8

Swine Pseudorabies Vaccine, Live	1 for 10	600	bottle	¥ 7.50	¥ 10.00	¥ 15.00
	1 for 20	600	bottle	¥ 14.00	¥ 18.00	¥ 28.00
Swine Fever Vaccine, Live (Tissue Origin)	1 for 10	600	bottle	¥ 5.00	¥ 6.50	¥ 15.00
	1 for 20	600	bottle	¥ 8.00	¥ 12.00	¥ 28.00
Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live (Strain HuN4-F112)	1 for 10	500	bottle	¥ 30.00	¥ 45.00	¥ 60.00
	1 for 20	500	bottle	¥ 50.00	¥ 70.00	¥ 100.00
Clostridium perfringens Bivalent Vaccine for Piglets, Inactivate (Type A and C)	1 for 10	300	bottle	¥ 35.00	¥ 55.00	¥ 80.00
Swine Parvovirus Vaccine, Inactivated (Strain CP-99)	4 ml	500	bottle	¥ 2.50	¥ 3.00	¥ 5.00
	20 ml	300	bottle	¥ 10.00	¥ 60.00	¥ 80.00
Swine Pasteurella multocida Vaccine , Live (Strain 679-230)	1 for 50	1000	bottle	¥ 3.50	¥ 4.00	¥ 7.00
Paratyphus Vaccine for Piglets , Live	1 for 20	1000	bottle	¥ 3.00	¥ 4.00	¥ 7.00

9

Swine Erysipelas Vaccine	1 for 50	500	bottle	¥ 5.00	¥ 7.00	¥ 12.00
Mycoplasma Hyopneumoniae Vaccine , Live (Strain RM48)	1 for 10	600	bottle	¥ 30.00	¥ 50.00	¥ 80.00
	1 for 20	600	bottle	¥ 60.00	¥ 100.00	¥ 160.00
Notes	<p>1. This table is an essential component of the distribution contract signed by both parties, and it shall be valid from the effective date of the distribution contract signed by both parties, until the termination of the distribution contract or further notice from Party A. Party A reserves the right to adjust the prices of various items in this table, but must notify Party B in writing one month in advance.</p> <p>2. The “terminal price” refers to the sales price of veterinary biological products sold by Party B to the end customer, and Party B shall not sell them at a price lower than the terminal price.</p> <p>3. In special circumstances where it is necessary to adjust the terminal price (price reduction or price increase) for sales, Party B must apply in writing to Party A. After obtaining Party A’s written consent, Party B can sell at the new terminal price.</p> <p>4. If Party B violates the above requirements, in accordance with Article 5 of the Distribution Contract signed by both parties, Party B shall bear the liability for breach of contract, and Party A has the right to take corresponding punishment measures.</p>					

Supplementary Agreement: Distribution Assessment and Rewards

1. If Party B fails to achieve the minimum monthly distribution amount specified in the preceding Contract for three consecutive months during the term of the Contract, or the distribution amount for two consecutive quarters is lower than 70% of the quarterly target specified in the preceding Contract, or the annual distribution amount is lower than 70% of the annual target specified in the preceding Contract, Party A has the right to unilaterally terminate the Contract. Party A shall notify Party B of the termination of the contract in the form of a *Termination Notice*, which shall take effect immediately upon delivery to Party B. Upon then, the termination procedure of this Contract shall be completed, and both parties shall handle other related matters in accordance with the law.

2. During the term of the Contract (i.e. the deadline for annual distribution target assessment is December 25th of the year), after confirmation by Party A, if Party B achieves the distribution target as stipulated in this Contract, Party A will reward Party B in the form of standard rebates and gifts of similar products as stipulated in this Contract. The reward will be redeemed when Party B purchases the following year. If Party B returns or refunds after the reward is redeemed, Party A shall recalculate the actual sales return amount and reward amount completed by Party B based on the return or refund, and deduct the equivalent amount of the reward already redeemed before refunding.

3. Annual distribution reward standard: If the distribution return amount of Party B in 2023 reaches the annual distribution target, Party A shall give Party B a return reward at the ratio of 5% of the distribution return amount in 2023.

4. This Supplementary Agreement shall come into effect at the same time as the Distribution Contract and shall have the same legal effect.

Notes:

- ① The products returned under the contract are company rewards and will not be accumulated in the next year's distribution amount, and will not be counted as rebates.
- ② If the distribution target is not achieved 100% but more than 80% is achieved, a rebate will be calculated based on **80%** of the completion amount.
- ③ If the actual distribution rebate amount is lower than 80% of the distribution target, no annual rebate will be given.
- ④ Any of the above rewards can only be implemented if Party B has no outstanding debts.
- ⑤ Those who terminate this Contract during the term of the Contract shall not be entitled to this reward policy.

Party A: Jilin Zhengye Biological Products Co., Ltd

(Seal)

Sales Manager (signature):

Date:

Party B:

(Seal)

Person in Charge (signature):

Date:

Annex 2: Purchase and Sales Contract

Jilin Zhengye Biological Products Co., Ltd;

The Supplier: Jilin Zhengye Biological Products Co., Ltd

Address: No.1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin Province
Tel: 0432-
Fax: 0432-63451800
Email:
Contact Person:
Mobile:

The Purchaser: _____
Address: _____
Tel: _____
Fax: _____
Email: _____
Contact Person: _____
Mobile: _____

1. Both parties have agreed through consultation that the supplier shall sell the following products to the purchaser in accordance with the following terms:

Product name	Specifications	Packing	Amount (unit: bottle)	Value	Notes
Total					

2. Quality requirements: National standards for relevant products or internal control standards of supplier enterprises.

3. Payment: Payment in advance before delivery.

4. Delivery terms: As agreed in the distribution contract between both parties.

5. Delivery time: The supplier shall send out the goods within three working days after receiving the buyer's order and full payment, and notify the buyer of the estimated time when the goods will arrive at the above-mentioned delivery location.

6. Delivery terms, freight burden, and acceptance method: In accordance with the provisions of the distribution contract between both parties.

7. Invoice: [] Ordinary Invoice for Value-added Tax; [] Special Invoice for Value-added Tax.

8. Miscellaneous

9. Notes: This order is an ancillary part of the Distribution Contract signed between the Supplier and the Purchaser, and the Supplier and Purchaser are bound by the Distribution Contract already signed by both parties regarding the purchase and sales matters under this order.

The Supplier: Jilin Zhengye Biological Products Co., Ltd
Bank of Deposit: Jilin Hadawan Branch of China Construction Bank
Bank Account Number: 22001616338059668888
Tax Number: 91220000124494874F
Person in Charge:
Seal:
Date:

The Purchaser:
Bank of Deposit:
Bank Account Number:
Tax Number:
Person in Charge:
Seal:
Date:

Contract Number:

**TECHNOLOGY TRANSFER
(TECHNICAL SECRET) CONTRACT**

Project Name: _____

Party A: _____

Party B: _____

Signed on: _____

Signed at: _____

Term of Validity: _____

Printed by the Ministry of Science and Technology of the People's Republic of China

Instructions of Filling this Contract

- I. The Contract is used by contractual parties by reference to the technology development (entrustment) model contract printed by Ministry of Science and Technology of the People's Republic of China, and the technology contracts recommended by various recognized technology contract registration institutions.
- II. The Contract is applicable to the technology development contracts in which one party entrusts the other party to research and develop new technologies, new products, new crafts or new materials and its systems.
- III. Any matter not covered by the Contract may be agreed by parties concerned on an attached sheet, which constitutes an inseparable part of the Contract.
- IV. As for the terms and conditions which are not needed to be filled in this Contract agreed upon by the parties, they should be indicated with the word such as N.A.

**TECHNOLOGY TRANSFER
(TECHNICAL SECRET) CONTRACT**

Transferee (Party A): _____

Address: _____

Legal Representative: _____

Project Contact Person: _____

Contact Information : _____

Mailing Address: _____

Tel: _____ Fax Number: _____

Email: _____

Transferer (Party B): _____

Address: _____

Legal Representative: _____

Project Contact Person: _____

Contact Information : _____

Mailing Address: _____

Tel: _____ Fax Number: _____

Email: _____

WHEREAS, Party B intends to transfer to Party A _____ (the right of use/ transferable right) of the technical secret of the project of _____, and Party A shall obtain the transfer and pay the fund.

NOW, THEREFORE, in consideration of the mutual covenants contained herein and in accordance with the provisions of the Contract Law of the People's Republic of China, both parties agree as follows:

Article 1 The content of the technical secret transferred by Party B to Party A is as follows:

1. The Content of the Technical Secret: _____

_____.

2. Technical Indicators and Parameters: _____

_____.

3. Industrialization Development of the Technical Secret: _____

_____.

Article 2 Party B shall submit the following technical materials to Party A to ensure the transfer of the underlying technical secret:

1. _____;
2. _____;
3. _____;
4. _____.

Article 3 Party B agrees to submit technical documents according to the arrangement as follows:

1. Submission Time: _____;
2. Submission Location: _____;
3. Submission Method: _____.

Article 4 The conditions for Party B to implement or license this technical secret before the effectiveness of this Contract are as follows:

1. Party B's Implementation of the Technical Secret (i.e., implementation time, location, method, and scale):
_____.
2. Status (i.e., time, location, method, and scale) of Party B's Transfer of the Technical Secret to Others:
_____.

Article 5 Party A shall implement this technical secret in the following scope, method, and period:

1. Implementation Scope: _____.
2. Implementation Method: _____.
3. Implementation Period: _____.

Article 6 Party B guarantees the practicality and reliability of this technical secret, and guarantees that this technical secret does not infringe on the legitimate rights of any third party. If a third party accuses Party A of infringing on technical secret and is awarded compensation by Party A, Party B shall _____.

Article 7 In performing the Contract, if the technical secret has already been disclosed by others (except for those disclosed through patent rights), one party shall notify the other party to terminate the Contract within _____ days. If the other party fails to notify within the time limit and causes losses to the other party, the other party shall be entitled to demand compensation as follows: _____.

Article 8 Both parties agree that the confidentiality obligations to be observed in the performance of this Contract are as follows:

Party A:

1. Confidential (including technical and business information): _____.
2. Scope of individuals involving confidential: _____.
3. Term of confidentiality: _____.
4. Liabilities for disclosure of confidential: _____.

Party B:

1. Confidential (including technical and business information): _____.
2. Scope of individuals involving confidential: _____.
3. Term of confidentiality period: _____.

4. Liabilities for disclosure of confidential: _____
_____.

Article 9 During the validity period of this Contract, Party B shall be entitled to apply for a patent for this technical secret, and Party A shall be entitled to continue using it in accordance with this Contract.

Article 10 In order to ensure the effective implementation of this technical secret by Party A, Party B shall provide the following technical services and guidance to Party A:

1. Content of technical services and guidance: _____
_____.

2. Method of technical service and guidance: _____
_____.

5

Article 11 Party A shall pay the technical secret usage fund to Party B based on the following schedule:

1. The total amount of technical secret usage fund shall be _____. Technical service and guidance funds shall be _____.

2. The technical secret usage fund offered by Party A is paid by _____ (lump sum / installments/ commission) to Party B.

The specific payment method and terms are as follows:

(1) _____

(2) _____

(3) _____

The bank of deposit, bank address and account number of Party B are as follows:

Bank of Deposit _____

Bank Address _____

Account number _____

3. Both parties agree that if Party A pays Party B a licensing fee based on the benefits generated from implementing the technology secret, Party B has the right to inspect the relevant accounting records of Party A by _____.

Article 12 Both parties confirm that Party B authorizes Party A to implement the technical secret, provide technical services, and provide technical guidance in accordance with the following standards and methods for acceptance.

1. _____;

2. _____;

3. _____.

Article 13 Party A shall implement the technical secret within _____ days upon the Effective Date of this Contract; Party A shall inform Party B with appropriate explanation and gain recognition from Party B in the event of failure to implement on schedule. Party B shall be entitled to ask Party A for liquidated damages or indemnification provided that Party A fails to implement the technical secret _____ days overdue.

6

Article 14 Both parties agree that during the performance of this Contract, neither party shall restrict the other party's technological competition and development in the following ways.

1. _____;

2. _____;

3. _____.

Article 15 Both parties confirm that

1. Party A shall not be entitled to use the technical secret transferred by Party B for subsequent improvement. The new technological achievements with substantive or creative technological progress characteristics resulting from this shall belong to _____ (Party A/ both parties). The distribution the relevant interest is as follows:

_____.

2. Party B shall be entitled to make subsequent improvements to the technical secret transferred to Party A. The new technological achievements with substantive or creative technological progress characteristics resulting from this shall belong to _____ (Party A/ both parties). The distribution the relevant interest is as follows:

_____.

Article 16 Any amendments to the Contract shall be negotiated and agreed by both parties and confirmed in written form. A party may submit a request to the other party to change the rights and obligations under the Contract, and the other party shall reply within ____ days in the event of any of the following situation. Failure of reply shall be deemed as consent.

1. _____;
2. _____;
3. _____;
4. _____.

Article 17 Both parties agree with the following liability for default.

1. Where Party _____ violates Article _____ hereunder, Party _____ shall _____ (by calculating the damages for breach of contract or by the amount of compensation for losses).
2. Where Party _____ violates Article _____ hereunder, Party _____ shall _____ (by calculating the damages for breach of contract or by the amount of compensation for losses).
3. Where Party _____ violates Article _____ hereunder, Party _____ shall _____ (by calculating the damages for breach of contract or by the amount of compensation for losses).
4. Where Party _____ violates Article _____ hereunder, Party _____ shall _____ (by calculating the damages for breach of contract or by the amount of compensation for losses).

7

Article 18 As confirmed by both parties, within the validity of this Contract, Party A designates _____ as Party A's project contact person, and Party B designates _____ as Party B's project contact person. Project contact persons shall undertake the following responsibilities:

1. _____
2. _____
3. _____

Where a party changes its contact, such party shall give a written notice to the other party on a timely basis. Where the performance of the Contract is affected, or losses are incurred due to the failure of timely notice, such party shall assume the liabilities thereon.

Article 19 The Parties recognize that one party may terminate the Contract by noticing the other party in the event of the followings:

- 1 . Force majeure and technological risks;
2. _____
3. _____

Article 20 Any disputes incurred in connection with the performance of the Contract shall be resolved through mutual negotiation and coordination. Any dispute which cannot be resolved through mutual negotiation and coordination shall be handled in accordance with Point _____:

1. Submit to _____ Arbitration Commission for arbitration;
2. Lodge a proceeding with the People's Court.

Article 21 The Parties agree that the definitions and interpretations of the relevant terms and technical terms involved in this Contract and exhibits are as follows.

1. _____
2. _____
3. _____
4. _____
5. _____

8

Article 22 The following technical documents related to the performance of this Contract shall not form an integral part of this Contract after confirmation by both parties.

- 1 . Technical background information: _____
- 2 . Feasibility study report: _____
- 3 . Technical evaluation report: _____
- 4 . Technical standards and specifications: _____

5 . Original design and process documents: _____

6 . Miscellaneous: _____

Article 23 The Parties agree that other relevant matters of this Contract are _____

_____.

Article 24 This Contract is made in _____ original copies, with equal legal effect.

Article 25 The Contract shall be effective upon the signature and seal of the Parties.

Party A: _____ (seal)
Legal representative/entrusted agent: (signature)
Date:

Party B: _____ (seal)
Legal representative/entrusted agent: (signature)
Date:

Paste the tax receipt at:

(This page is filled in by the Technology Contract Registration Organization)

Contract registration number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

1. Applicant for registration: _____

2. Registration materials:

(1) _____

(2) _____

(3) _____

3. Contract type: _____

4. Contract transaction amount: _____

5. Technical transaction volume: _____

Technology Contract Registration Organization (seal)

Processed by: _____
Date:

Contract Number: _____

**TECHNOLOGY DEVELOPMENT (COOPERATION)
CONTRACT**

Project Name: _____

Party A: _____

Party B: _____

Party C: _____

Signed on: _____

Signed at: _____

Term of Validity: _____

Printed by the Ministry of Science and Technology of the People's Republic of China

Instructions of Filling this Contract

- I. The Contract is used by contractual parties by reference to the technology development (entrustment) model contract printed by Ministry of Science and Technology of the People's Republic of China, and the technology contracts recommended by various recognized technology contract registration institutions.
- II. The Contract is applicable to the technology development contracts in which one party entrusts the other party to research and develop new technologies, new products, new crafts or new materials and its systems.
- III. Any matter not covered by the Contract may be agreed by parties concerned on an attached sheet, which constitutes an inseparable part of the Contract.
- IV. As for the terms and conditions which are not needed to be filled in this Contract agreed upon by the parties, they should be indicated with the word such as N.A.

TECHNOLOGY DEVELOPMENT (COOPERATION) CONTRACT

Party A: _____

Address: _____

Legal Representative: _____

Project Contact Person: _____

Contact Information : _____

Mailing Address: _____

Tel: _____ Fax Number: _____

Email: _____

Party B: _____

Address: _____

Legal Representative: _____

Project Contact Person: _____

Contact Information : _____

Mailing Address: _____

Tel: _____ Fax Number: _____

Email: _____

Party C: _____

Address: _____

Legal Representative: _____

Project Contact Person: _____

Contact Information : _____

Mailing Address: _____

Tel: _____ Fax Number: _____

Email: _____

WHEREAS, all the parties involved in this Contract shall jointly participate in the research and development of the project of _____. NOW, THEREFORE, in consideration of the mutual covenants contained herein and in accordance with the provisions of the Contract Law of the People's Republic of China, all the parties agree as follows:

Article 1 The requirements for the collaborative research and development project under this Contract are as follows.

1 . Technology objectives: _____

_____.

2 . Technology contents: _____

_____.

3 . Technology methods and roadmap: _____

_____.

Article 2 All the parties to this Contract shall undertake the following tasks in the research and development project.

Party A

1 . Research and Development Contents: _____
_____.

2 . Work Schedule: _____
_____.

3. Research and Development Period: _____.

4. Research and Development Location: _____.

Party B

1 . Research and Development Contents: _____
_____.

2 . Work Schedule: _____
_____.

3. Research and Development Period: _____.

4. Research and Development Location: _____.

Party C

1 . Research and Development Contents: _____
_____.

2 . Work Schedule: _____
_____.

3. Research and Development Period: _____.

4. Research and Development Location: _____.

Article 3 To ensure the full performance of this contract, all the parties to this Contract have decided to organize, manage, and coordinate the research and development work in the following ways: _____

_____.

Article 4 All the parties to this Contract have agreed to provide the following technology information and conditions for the research and development work of this Contract project:

Party A: _____

_____.

Party B: _____

_____.

Party C: _____

_____.

After the completion of this Contract, the aforementioned data and conditions shall be processed in the following manner: _____
_____.

Article 5 All the parties to this Contract agree to provide or pay for the research and development funds and other investments of this contract project in the following manner.

Party A

- 1. Offering or payment method: _____
- 2. The amount paid or converted into the technology investment: _____
- 3. Term of using the fund: _____

Party B

- 1. Offering or payment method: _____
- 2. The amount paid or converted into the technology investment: _____
- 3. Term of using the fund: _____

Party C

- 1. Offering or payment method: _____
- 2. The amount paid or converted into the technology investment: _____
- 3. Term of using the fund: _____

Article 6 The cooperating party which provides technology as an investment shall ensure the technology it provided fail to infringe upon the legitimate rights and interests of any third party. In the event that a third party alleges a cooperating party or parties have infringed by implementing the technology, the party providing the technology shall act as follows: _____

Article 7 Any amendments to the Contract shall be negotiated and agreed by all the parties and confirmed in written form. A party may submit a request to the other parties to change the rights and obligations under the Contract, and the other parties shall reply within _____ days in the event of any of the following situation. Failure of reply shall be deemed as consent:

- 1 . _____ ;
- 2 . _____ ;
- 3 . _____ ;
- 4 . _____ ..

Article 8 Without the consent of other cooperating parties, one or more parties shall not transfer part or all of the research and development work of this Contract project to a third party. Nevertheless, in any of the following circumstances, one or more cooperating parties may transfer part or all of the research and development work of this Contract project to a third party without the consent of other cooperating parties:

- 1 . _____ ;
- 2 . _____ ;
- 3 . _____ .

The specific contents that can be transferred by one or more cooperating parties include: _____

Article 9 In the performance of this contract, for losses to either party or all the parties involved in a failure or partial failure resulting from insurmountable technical difficulties, the liability for risks should be agreed upon by all the parties of this Contract as follows:

- 1 . _____ ;
- 2 . _____ ;
- 3 . _____ .

As confirmed by all the parties, the technical risks in this Contract should be identified in the manner of _____. The basic content of technical risks identification should include but not limited to the existence, scope, degree, and losses of risks. The basic conditions for the identification of technical risks are as follows.

1. The project in this Contract is sufficiently difficult under the current state of art;
2. Party B has no fault subjectively and the failure of the research and development is identified as reasonable.

When one party discovers technical risks that may lead to research and development failure or partial failure, the party shall notify other parties within _____ days and take appropriate measures to reduce losses. Where the party fails in making the notice or taking appropriate measures and thus enlarging the losses, the party shall be liable for the enlarged losses.

Article 10 In the performance of this Contract, if the technology of the research and development project has been made public by others (including by the form of patent), one party or parties should notify other party or parties to rescind the Contract within _____ days. Where one party fails to make the notice, thus causing losses to the other party or parties, the other party or parties has the rights to claim for compensation.

Article 11 The Parties confirmed to undertake the following obligation of confidentiality for the performance of the Contract as follows.

Party A

1. Confidential contents (including technical information and business information): _____
2. Scope of individuals involving confidential: _____
3. Term of confidentiality period: _____
4. Liabilities for disclosure of confidential: _____

Party B

1. Confidential contents (including technical information and business information): _____
2. Scope of individuals involving confidential: _____
3. Term of confidentiality period: _____
4. Liabilities for disclosure of confidential: _____

Party C

1. Confidential contents (including technical information and business information): _____
2. Scope of individuals involving confidential: _____
3. Term of confidentiality period: _____
4. Liabilities for disclosure of confidential: _____

Article 12 The Parties should deliver the research and development achievements in the following manners.

Party A

1. The forms and numbers of research and development achievements to be delivered: _____
2. Date and venue for research and development achievements delivery: _____

Party B

1. The forms and numbers of research and development achievements to be delivered: _____
2. Date and venue for research and development achievements delivery: _____

Party C

1. The forms and numbers of research and development achievements to be delivered:

_____.

2. Date and venue for research and development achievements delivery:

_____.

Article 13 The Parties agree with the following standards and methods of inspection and acceptance of the research and development achievements delivered by one of the Parties.

Party A: _____

_____.

Party B: _____

_____.

Party C: _____

_____.

Article 14 The Parties agree with the following standards and methods of inspection and acceptance of the final research and development achievements stipulated in this Contract: _____

_____.

Article 15 As confirmed by all the Parties, the ownership of the research and development achievements and the intellectual property rights arising from different stages of the performance of this Contract shall be dealt with in the _____ of the following manners.

1. _____ (Party A/Party B/Party C/ all the Parties) has/have the right to apply for the patent.

The use of the patent and the distribution mode of the relevant interest are as follows:

_____.

2. In the manner of the technical secrets. The ownership of the right to use or to transfer the research and development achievements and from which the interest derived shall be dealt with according to the following agreement.

(1) The right to use the technical secrets: _____;

(2) The right to transfer the technical secrets: _____;

(3) Distribution of relevant interest: _____.

Special provisions on the ownership of the technical achievements and related intellectual property rights arising from different stages of the performance of this Contract and independently completed by the cooperating parties are agreed by the Parties as follows:

_____.

Article 16 As confirmed by all the Parties, the ownership of the final research and development achievements and the intellectual property rights arising from the performance of this Contract shall be dealt with in the _____ of the following manners.

1. _____ (Party A/Party B/Party C/ all the Parties) has/have the right to apply for the patent.

The use of the patent and the distribution mode of the relevant interest are as follows:

_____.

2. In the manner of the technical secrets. The ownership of the right to use or to transfer the research and development achievements and from which the interest derived shall be dealt with according to the following agreement.

(1) The right to use the technical secrets: _____;

(2) The right to transfer the technical secrets: _____;

(3) Distribution of relevant interest: _____.

Special provisions on the ownership of the final technical achievements and related intellectual property rights arising from the performance of this Contract are agreed by the Parties as follows: _____

_____.

Article 17 Individuals from any of the Parties who have accomplished a technological achievement in the Contract shall have the right to be named as such in the

documents related to the technological achievement and the right to receive certificates of honor and awards.

The Parties should determine the list of individuals who are responsible for completing the final research results through consultation. The individuals have the right to be named as such in the documents related to the technological achievement and the right to receive certificates of honor and awards.

Article 18 The research and development equipment, facilities, and materials etc. that were purchased by one party or parties with the stipulated fund belong to _____ (Party A/Party B/Party C/ the Parties).

Article 19 As confirmed by all the parties, where one party or parties violate(s) the provisions of this Contract, thus causing standstill, delay or failure of the research and development of the project, the party shall be liable for the breach of the Contract according to the following agreement:

Party A:

1. If Party A violates Article ____ of this Contract, the party should _____ (by calculating the damages for breach of contract or by the amount of compensation for losses).
2. If Party A violates Article ____ of this Contract, the party should _____ (by calculating the damages for breach of contract or by the amount of compensation for losses).
3. If Party A violates Article ____ of this Contract, the party should _____ (by calculating the damages for breach of contract or by the amount of compensation for losses).

Party B:

1. If Party B violates Article ____ of this Contract, the party should _____ (by calculating the damages for breach of contract or by the amount of compensation for losses).
2. If Party B violates Article ____ of this Contract, the party should _____ (by calculating the damages for breach of contract or by the amount of compensation for losses).
3. If Party B violates Article ____ of this Contract, the party should _____ (by calculating the damages for breach of contract or by the amount of compensation for losses).

11

Party C:

1. If Party C violates Article ____ of this Contract, the party should _____ (by calculating the damages for breach of contract or by the amount of compensation for losses).
2. If Party C violates Article ____ of this Contract, the party should _____ (by calculating the damages for breach of contract or by the amount of compensation for losses).
3. If Party C violates Article ____ of this Contract, the party should _____ (by calculating the damages for breach of contract or by the amount of compensation for losses).

Article 20 As confirmed by all the parties, any party has the right to make follow-up improvements to the technological achievements as stipulated in the Contract. The new technological achievements with substantial or creative technological progress derived from the follow-up improvements belong to _____ (Party A/Party B/Party C/ the Parties). Distribution of relevant interest is as follows: _____

Article 21 As confirmed by all the parties, within the validity of this Contract, Party A designates _____ as Party A's project contact person, Party B designates _____ as Party B's project contact person, and Party C designates _____ as Party C's project contact person. Project contact persons shall undertake the following responsibilities.

- 1 . _____
- 2 . _____
- 3 . _____

Where a party changes its contact, such party shall give a written notice to the other party on a timely basis. Where the performance of the Contract is affected, or losses are incurred due to the failure of timely notice, such party shall assume the liabilities thereon.

Article 22 All the parties recognize that one party may terminate the Contract by noticing the other parties in the event of the followings.

- 1 . Force majeure and technological risks;
- 2 . _____
- 3 . _____

12

Article 23 Any disputes incurred in connection with the performance of the Contract shall be resolved through mutual negotiation and coordination. Any dispute which cannot be resolved through mutual negotiation and coordination shall be handled in accordance with Point _____.

1. Submit to _____ Arbitration Commission for arbitration;

2. Lodge a proceeding with the People's Court.

Article 24 All the parties agree that the definitions and interpretations of the relevant terms and technical terms involved in this Contract and exhibits are as follows.

- 1 . _____
- 2 . _____
- 3 . _____
- 4 . _____
- 5 . _____

Article 25 The following technical documents related to the performance of this Contract shall not form an integral part of this Contract after confirmation by all the parties.

- 1 . Technical background information: _____
- 2 . Feasibility study report: _____
- 3 . Technical evaluation report: _____
- 4 . Technical standards and specifications: _____
- 5 . Original design and process documents: _____
- 6 . Miscellaneous: _____

Article 26 All the parties agree that other relevant matters of this Contract are: _____

_____.

Article 27 This Contract is made in _____ original copies, with equal legal effect.

Article 28 The Contract shall be effective upon the signature and seal of all the parties.

Party A: _____ (seal)
Legal representative/entrusted agent: (signature)
Date: _____

Party B: _____ (seal)
Legal representative/entrusted agent: (signature)
Date: _____

Party C: _____ (seal)
Legal representative/entrusted agent: (signature)
Date: _____

Paste the tax receipt at:

(This page is filled in by the Technology Contract Registration Organization)

Contract registration number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

- 1. Applicant for registration: _____
- 2. Registration materials:
 - (1) _____
 - (2) _____
 - (3) _____
- 3. Contract type: _____
- 4. Contract transaction amount: _____
- 5. Technical transaction volume: _____

Processed by: _____
Date: _____

Contract Number:

--	--	--	--	--	--	--	--	--

TECHNOLOGY DEVELOPMENT CONTRACT

(Version 2003)

Project Name: Manufacturing Technology Development of Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P)

Entrusting Party (Party A): Jilin Zhengye Biological Products Co., Ltd

Research Development Party (Party B): Shanghai Veterinary Research Institute of the Chinese Academy of Agricultural Sciences

Signing on April 22, 2015

Signed in Minhang District (County), Shanghai, China

Term : April 22, 2015 to April 21, 2020

Printed by Shanghai Scientific and Technological Committee, and
Shanghai Administration of Industry and Commerce

WHEREAS, Party A and Party B intend to conduct technology development for the project Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P)

NOW, THEREFORE, in consideration of the mutual covenants contained herein and in accordance with the provisions of the Contract Law of the People's Republic of China, both parties agree as follows:

Article 1 The content, form, and requirements of the underlying technology:

Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P) can be used for the prevention of duck Tambusu virus disease. FX2010-180P strain of the vaccine cannot infect susceptible ducks through the nasal cavity or spread horizontally between ducks. It is artificially passed through susceptible ducks and does not undergo virulence reversion. The safety of the virus strain is good. Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P) is administered to ducks of different ages (healthy Tambusu virus susceptible ducks) at one time, Antibodies can be detected on the 4th day after immunization, and on the 14th day after immunization, the E1ISA antibody of duck Tambous virus reaches 1:20 or above, and the antibody can be maintained at 1:20 or above for more than 6 months. On the 14th day or 6 months after immunization, the protective rate of the vaccinated ducks reached 100%. After single dose, repeated single dose, and high-dose vaccination of susceptible ducks, the growth and production performance of the experimental ducks were normal, and there were no adverse reactions. In summary, Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P) has good safety for ducklings and laying ducks, and has a good preventive effect on duck Tambous virus disease.

1. The current completion stage:

The project team has completed the research work in the laboratory stage and intermediate trial production stage, and have obtained clinical trial approval from the Ministry of Agriculture. The project team is currently conducting clinical trials at the approved experimental sites.

2. Technical development content and requirements

(1) Carry out and complete clinical trials, material organization, and data processing of Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P);

(2) Draft an application for the Registration Certificates of New Veterinary Drugs for Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P) and apply for the Registration Certificates of New Veterinary Drugs.

Article 2 Technical indicators and parameters to be achieved:

1. Complete clinical trials of Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P);

2. Draft an application for the Registration Certificates of New Veterinary Drugs for Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P) and apply for the Registration Certificates of New Veterinary Drugs.

Article 3 Research and development plan:

Party A:

1. Participate in clinical trials of Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P) and assist in material organization and data processing;

2. Participate in drafting the application for the Registration Certificates of New Veterinary Drugs for Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P)

and assisted Party B in applying for the Registration Certificates of New Veterinary Drugs.

Party B:

1. Preside over the clinical trial of Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P) and organize materials and process data;
2. Draft an application for the Registration Certificates of New Veterinary Drugs for Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P) and apply for the Registration Certificates of New Veterinary Drugs.

Article 4 Research and development funds, remuneration, and payment or settlement methods:

1. Research and development funds refer to the costs required to complete the research and development work of this project, while compensation refers to the usage fees for the development results of this project and the research subsidies for research and development personnel.

Research and development funds and compensation for this project: 5% commission and six million yuan of sales revenue (including funds of _____ yuan, 5% commission and six million yuan of compensation sales revenue)

2. Payment method for funds and remuneration (using the following④ and ⑤ method):

- ① Total payment at once: RMB _____ yuan, time: _____
- ② Installment payment: RMB _____ yuan, time: _____
RMB _____ yuan, time: _____
- ③ Commission based on profit %, term: _____
- ④ 5% commission on sales, with a period of five years from the start of production.
- ⑤ Other methods:

(1) The sales commission shall be calculated according to ④;

(2) The other development funds and remuneration have been paid when the strategic cooperation framework agreement was signed and fulfilled by both parties in 2008.

Article 5 Property ownership of equipment, devices, and materials purchased with research and development funds shall belong to:

Party B.

Article 6 Term, location, and method of performance:

This contract shall be performed in Shanghai (location) from April 22nd, 2015 to April 21st, 2020.

The performance method of this Contract:

Party B shall provide to Party A: 1. Seed virus strain: FX2010 strain, and FX2010-180P strain; 2. The manufacturing and testing trial procedures (draft), quality standards (draft), and operating procedures for each inspection item of the live vaccine for Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P), as well as a sample manual and inner packaging label, research data on virus species used in production and testing, research data on production technology, and product quality research data. Both Party A and Party B jointly apply for the Registration Certificates of New Veterinary Drugs for the Duck Tembusu Viral Disease Vaccine, Live (Strain FX2010-180P).

Article 7 Confidentiality of technical intelligence and information:

The ownership of this technical secret belongs to Party B, and Party A shall be entitled to use the technology. The technical secrets of the water project cover all the technical content of the research and development of the live vaccine for duck Tambous virus disease (FX2010-180P strain). Party A shall keep the technical secrets confidential and shall not transfer the involved virus species and their production technology (including investing in the technology) or give them to other enterprises, units, and individuals. The confidentiality period is permanent.

Article 8 Content of technical collaboration and guidance:

During the production phase of Party A, Party B shall cooperate with Party A to solve technical problems; to utilize the scientific research conditions of Party B to train 1-2 technical personnel for Party A, so that Party A can carry out subsequent production work and guide Party A to produce 3 batches of qualified products. If the production conditions of Party A result in the inability to produce qualified products, the responsibility shall be borne by Party A. If Party B is unable to produce qualified products due to reasons such as poisoning or technology, the responsibility shall be borne by Party B.

Article 9 Liabilities of Risks:

During the performance of this Contract, where there are technical difficulties resulting in partial or complete failure of research and development, the risk responsibility shall be borne by Party A

As agreed, Party A shall bear 100% of the risk liability.

Party B shall bear 0%.

Article 10 Intellectual Property of Technical Achievements:

1. Patent Application Right:

The intellectual property rights generated from the development of this technology belong to Party B.

2. The right to use and transfer technical secrets:

The ownership of this technical secret belongs to Party B, and Party A is entitled to use it, which is limited to Party A's own production and sales; without the consent of Party B, Party A shall not transfer or disclose any technical secrets of this research and development to any third party, nor shall it use this technology for secondary development.

Article 11 Acceptance Standards and Methods:

The technical achievements completed by the research and development institute have met the technical indicators listed in Article 2 of this contract according to the standards of _____, and are accepted through in kind, written, and electronic material delivery. Party A shall issue a technical project acceptance certificate.

Article 12 Calculation method for liquidated damages or liability for default

In case of violation of the provisions of this contract, the defaulting party shall bear the liability for breach of contract in accordance with the relevant provisions of the Contract Law of the People's Republic of China.

1. Where Party A violates the provisions of Article 4, 7, and 10 of this Contract, Party A shall bear the following liability for breach of contract:

(1) Where Party A violates Article 4 of this contract, Party A shall bear the liability for breach of contract. Party B has the right to terminate this contract, and Party A shall pay Party B 50% (three million yuan) of the total transfer fee as a penalty.

(2) Where Party A violates Article 7 of this contract, Party A shall bear the liability for breach of contract, and Party B has the right to demand compensation from Party A.

(3) Where Party A violates Article 10 of this contract, Party A shall bear the liability for breach of contract, and Party B has the right to demand compensation from Party A.

2. Where Party B violates the provisions of Articles 6 and 8 of this Contract, Party B shall bear the following liability for breach of contract:

(1) Where Party B violates the provisions of Article 6 of this contract, Party B shall bear the liability for breach of contract. Party A has the right to terminate this contract, and Party A has the right to demand compensation for losses from Party B.

(2) Where Party B violates the provisions of Article 8 of this contract, Party B shall bear the liability for breach of contract, and Party A has the right to demand Party B to compensate for the losses.

3. Miscellaneous:

N.A.

Article 13 Resolution of Contract Disputes

Any disputes incurred in connection with the performance of the Contract shall be resolved through mutual negotiation and coordination. Any dispute which cannot be resolved through mutual negotiation and coordination shall be handled in accordance with Point 1:

1. Submit to Shanghai Arbitration Commission for arbitration;

2. Bring a lawsuit to the People's Court and agree on the jurisdiction of ____ People's Court.

① Place of residence of the defendant ② Place of contract performance ③ Place of contract signing ④ Plaintiff's domicile ⑤ Location of the subject matter

Article 14 Interpretation of Terms and Terminology

N.A.

Article 15 Miscellaneous

N.A.

Please fill in the clauses marked with ※ in this contract according to the filling instructions.

	Name	Jilin Zhengye Biological Products Co., Ltd. (signature and seal)
	Legal representative	Han Zhenfa (signature and seal)

Entrusted by (Party A)				Special Seal for Technical Contract or Official Seal April 22nd, 2015	
	Entrusted agent	signature and seal)			
	Contact (handling) person	He Youyu	(signature and seal)		
	Residence (Mailing Address)	No.1 Zhengye Street, Jilin Economic and Technological Development Zone, Jilin Province	Postal Code		
	TEL				
	Bank of deposit	China Construction Bank Jilin Hadawan Branch			
Account number	22001616338059668888				
Research and development person (Party B)	Name	Shanghai Institute of Veterinary Medicine, Chinese Academy of Agricultural Sciences (signature and seal)		Special Seal for Technical Contract or Official Seal April 22nd, 2015	
	Legal representative	Tong Guangzhi (signature and seal)			
	Entrusted agent	(signature)			
	Contact (handling) person	Zhou Jie (signature)			
	Residence (Mailing Address)	518 Ziyue Road, Minhang District, Shanghai	Postal Code		
	Tel	021-34293140			
Bank of deposit	Agricultural Bank of China Shanghai Zizhu Science Park Branch				
Account number	03441500040007695				
Intermediary	Name			Special Seal for Technical Contract or Official Seal Date	
	Legal representative				
	Entrusted agent				
	Contact (handling) person				
	Residence (Mailing Address)				
	Tel				
	Bank of deposit				
	Account number				

Instruction of Filling the Form
(Stamp duty can be applied)

1. The filling method for "Contract Registration Number":

The contract registration number shall be filled in by each contract registration office.

2. A technology development contract refers to a contract signed between the parties for the research and development of new technologies, new products, new processes, new materials, and their systems. Technology development contracts include commissioned development contracts and cooperative development contracts.

3. Projects within the plan should fill in the plans of the State Council ministries, provinces, Baizhi regions, municipalities directly under the central government, cities specifically designated in the plan, prefectures, and cities (counties). Projects that do not belong to the above plans should be indicated by (/) in this column.

4. The content and form of the target technology:

This includes the technical and economic indicators that the development project should achieve, the development purpose, the scope and benefits of use, the submission method and quantity of results. The submission of development results can take the following forms:

- (1) Product design, process procedures, material formulas, and other technical documents such as drawings, papers, and reports;
- (2) Disk, tape, computer software;
- (3) New animal or plant varieties and microbial strains; and
- (4) Samples and prototypes.

5. Research and development plan:

This includes the progress of each party's facility development project, the technical issues to be solved at each stage, the goals to be achieved, and the deadline for completion.

6. Confidentiality of technical intelligence and information:

This includes the content, deadline, and responsibilities for the confidentiality of information and data from all parties involved, as well as the disclosure of technical secrets. Both parties may agree that this clause shall remain valid regardless of whether this contract is modified, terminated, or terminated.

7. Resolution of contract disputes:

The Arbitration Law of the People's Republic of China stipulates a system of arbitration or trial, in which the parties to the contract waive their right to file a lawsuit with the court if they only choose arbitration; If the parties to the contract choose to file a lawsuit, that is, waive the arbitration, the parties to the contract should agree on the method of resolving the contract dispute.

8. Miscellaneous:

If the contract is signed through the introduction of an intermediary institution, the intermediary contract should be included as an attachment to this contract. If both parties agree to mortgage and guarantee the deposit property, copies of the deposit payment, property mortgage and guarantee procedures should be included as an attachment to this contract.

9. If the agent is entrusted to sign this contract, a certificate should be issued and displayed.

10. In this contract, any clause that the parties agree not to fill in shall be indicated by (/) in the blank space provided.

11. Five original copies of this contract.

The registration authority reviews the registration column:

Technical Contract Registration Authority (Special Seal)

Processed by : (signature)

Date

Memorandum

On September 9th, 2008, Shanghai Veterinary Research Institute of the Chinese Academy of Agricultural Sciences (hereinafter referred to as "Shanghai Veterinary Research Institute") signed a strategic cooperation framework agreement with Jilin Zhengye Biological Products Co., Ltd (hereinafter referred to as "Zhengye Biological"), with a cooperation period of ten years. On March 1, 2011, the two sides signed a supplementary agreement on the basis of the strategic cooperation framework agreement. On September 9, 2018, the cooperation period between the two parties came to an end. Regarding how to end the cooperation and whether to continue the cooperation after the end of the cooperation, members of the new leadership team of Zhengye Biological and the main person in charge of the Shanghai Veterinary Research Institute negotiated on April 3, 2018 at the Shanghai Veterinary Research Institute.

Participants in the negotiation:

Shanghai Veterinary Research Institute: Director Tong Guangzhi, Secretary Ma Zhiyong, Deputy Director Ding Dian, Deputy Director Chen Hongjun

Zhengye Biological: Chairman Shao Yu, General Manager Song Songlin, Deputy General Manager He Yuyou, and Assistant General Manager Lianwei

Date: April 3rd, 2018

Location: Conference Room A211, Shanghai Veterinary Research Institute

Negotiation content:

As the cooperation agreement between the two parties is coming to an end, the new leadership team of Zhengye Biological wishes to continue cooperation with Shanghai Veterinary Research Institute.

Shanghai Veterinary Research Institute believes that the cooperation with Zhengye Biological has been pleasant for both parties over the past decade. At the same time, Shanghai Veterinary Research Institute guarantees that the five vaccines that have been approved for clinical trials before the end of the cooperation period but have not yet obtained the Registration Certificate of New Veterinary Drugs will still comply with the requirements of the cooperation agreement after the end of the cooperation period and transferred to Shanghai Veterinary Research Institute (Zhengye Biological has provided strategic funds to Shanghai Veterinary Research Institute and will pay 5% of the annual sales revenue within five years after obtaining the veterinary drug product approval number for production, without paying any other fees). These five vaccines are as follows: Duck Tembusu Viral Disease Vaccine, Live; Swine Pseudorabies Vaccine, Inactivated (Strain JS-2012- Δ gI/gE); Swine Pseudorabies Vaccine of Double Gene Deletion Attenuated Strain JS-2012- Δ gI/Ge; Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Genetically Engineered Live Vaccine (Strain rHN-NP49); and Trivalent Inactivated Vaccine for Riemerella Anatipestifer.

Both parties agree to use Zhengye Biological's cell line and suspension process to jointly develop the Swine Pseudorabies Vaccine, Inactivated (Strain JS-2012- Δ gI/gE) (suspension culture) and apply for the new veterinary drug certificate after obtaining the Registration Certificate of New Veterinary Drugs for Swine Pseudorabies Vaccine, Inactivated (Strain JS-2012- Δ gI/Ge). Both parties jointly own intellectual property rights of the vaccine. If the production is transferred to a third party, the transfer proceeds shall be negotiated and distributed by both parties (the specific cooperation plan shall be separately agreed upon).

Regarding the matter of continuing cooperation, based on the good foundation of the past decade, Shanghai Veterinary Research Institute has expressed its willingness to continue cooperation with Zhengye Biological, but it is recommended to adopt one of the following three ways of cooperation:

1) Zhengye Biological does not need to provide fixed financial support to Shanghai Veterinary Research Institute. If interested in the vaccines independently developed by Shanghai Veterinary Research Institute, Zhengye Biological can receive priority to transfer with payment which shall be negotiated by the two sides; 2) Zhengye Biological can provide a small amount of fixed funding support to Shanghai Veterinary Research Institute every year. If interested in the vaccines independently developed by the second party, Zhengye Biological can receive priority paid transfer which shall be negotiated by the two sides; or 3) On the basis of the willingness to continue cooperation, Zhengye Biological will continue to provide an annual financial support. Shanghai Veterinary Research Institute's independently developed vaccine products can be transferred to Zhengye Biological with priority discounts and compensation.

The two sides exchanged ideas on the intention to jointly build a research and development center and invest in Zhengye Biological by Shanghai Veterinary Research Institute. The specific cooperation matters need to be further negotiated.

Zhengye Biological expresses its gratitude for the support of Shanghai Veterinary Research Institute and looks forward to further comprehensive and in-depth cooperation between the two sides in the future.

This Memorandum has the same legal effect as the Strategic Agreement and Supplementary Agreement previously signed by both parties regarding matters agreed upon by them.

This Memorandum is in duplicate, with each party holding one copy.

Shanghai Institute of Veterinary Medicine, Chinese Academy of Agricultural Sciences

(Signature and seal)

Jilin Zhengye Biological Products Co., Ltd
(Signature and seal)

April 3rd, 2018

Contract Number:

TECHNOLOGY LISENSING (TECHICAL SECRETS) AGREEMENT

Project Name: Technology Transfer of the Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, live (Strain huadu+Strain CV777+Strain NX)

Transferee (Party A): Jilin Zhengye Biological Products Co., Ltd

Transferer (Party B): Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences

Signing on April 5th, 2012

Signed in Harbin, China

Term : April 5th, 2012 to April 5th, 2032

Printed by the Ministry of Science and Technology of the People's Republic of China

1 / 17

Instruction

I. The Contract is used by contractual parties by reference to the technology development (entrustment) model contract printed by Ministry of Science and Technology of the People's Republic of China, and the technology contracts recommended by various recognized technology contract registration institutions.

II. The Contract is applied for the technology development Contracts in which one party entrusts the other party to research and develop new technologies, products, crafts or new materials and its systems.

III. If there are several representatives in either party, Party A or Party B could be respectively listed as common entrusting party or common entrusted party in the "Entrusting Party" or "Entrusted Party" provisions (new page) according to their own relations in the Contract.

IV. Any matter not covered by the Contract may be agreed by parties concerned on an attached sheet, which constitutes an inseparable part of the Contract.

V. As for the terms and conditions which are not needed to be filled in this Contract agreed upon by the parties, they should be indicated with the word such as N.A.

2 / 17

TECHNOLOGY TRANSFER (TECHNICAL SECRETS) CONTRACT

Transferee (Party A): Jilin Zhengye Biological Products Co., Ltd

Address : No. 1 Lianmeng Street, Jilin Economic and Technological Development Zone, Jilin Province

Legal Representative : Han Zhenfa

Project Contact Persson : Lian Wei

Contact Information : 13944229513

Mailing address : Lianmeng Street, Jilin Economic and Technological Development Zone, Jilin Province

Tel : 0432-63047108

Fax number : 0432-63056300

Email : 5196602@qq.com

Transferer (Party B): Harbin Veterinary Research Institute

Address : No. 427 Maduan Street, Nangang District, Harbin City

Legal Representative : Kong Jiagang

Project Contact Person : Feng Li

Contact Information : 18946066048

Mailing address : No. 427 Maduan Street, Nangang District, Harbin City

Tel : 18946066048

Fax number : 0451-51997166

Email : fengli_h@163.com

WHEREAS, Party B intends to transfer to Party A the right of use of the technical secret of the production process of the Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, live (Strain huadu+Strain CV777+Strain NX), and Party A shall obtain the transfer and pay the fund.

NOW, THEREFORE, in consideration of the mutual covenants contained herein and in accordance with the provisions of the Contract Law of the People's Republic of China, both parties agree as follows:

Article 1 The content of the technical secret transferred by Party B to Party A is as follows:

1. The Content of the Technical Secret: the seed virus and production process of the Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, live (Strain huadu+Strain CV777+Strain NX).
2. Technical Indicators and Parameters: The Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, live (Strain huadu+Strain CV777+Strain NX) is used to prevent infection of porcine infectious gastroenteritis virus, porcine epidemic diarrhea virus, and porcine rotavirus (G5 type). The three strains of weak virus Huadu strain, weak virus CV777 strain, and NX strain are all isolated and cultivated by Party B in response to the epidemic situation of porcine viral diarrhea in China, and Party B fully owns the intellectual property rights. The vaccine is administered at the Houhai acupuncture point, which is safe and effective, with a total immune protection rate of over 85%. The immune duration is 6 months, and the passive immune duration of piglets lasts until 7 days after weaning. It is stored below -20 °C and has a validity period of 24 months.
3. Industrialization Development of the Technical Secret: The research result can be applied to manufacturing for the manufacturing process is well-developed and the overall vaccine efficacy is over 85%, reaching the advanced level at home and abroad.

Article 2 Party B shall submit the following technical materials to Party A to ensure the transfer of the underlying technical secret:

1. The Parties jointly apply for the Registration Certificate of New Veterinary Drugs of the Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, live (Strain huadu+Strain CV777+Strain NX), but Party A is the exclusive holder of the Registration Certificate of New Veterinary Drugs and guarantee not to transfer the certificate again.
2. On the premise of obtaining the Registration Certificate of New Veterinary Drugs, Party B shall transfer the seed virus and production process of the Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, live (Strain huadu+Strain CV777+Strain NX) to Party A.

Article 3 Party B agrees to submit technical documents according to the arrangement as follows:

1. Submission Time: Party B shall submit the Registration Certificate of New Veterinary Drugs of the Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, live (Strain huadu+Strain CV777+Strain NX) to Party A within 30 business days upon the effectiveness of the Contract.
2. Submission Location: Harbin, China
3. Submission Method: Party A shall assign a delegate to collect the documents.

Article 4 The conditions for Party B to implement or license this technical secret before the effectiveness of this Contract are as follows:

1. Party B's Implementation of the Technical Secret (i.e., implementation time, location, method, and scale):

Party B signed a Technology Development (Cooperation) Contract with Harbin Weike Biotechnology Development Co., Ltd. and Shanghai Hile Biopharmaceutical Co., Ltd. on November 30, 2010.

2. Status (i.e., time, location, method, and scale) of Party B's Transfer of the Technical Secret to Others N.A during the monitoring period.

Article 5 Party A shall implement this technical secret in the following scope, manner, and period:

1. Implementation scope: Production shall be carried out by Party A or by a production enterprise with controlling rights of Party A. Party B shall have the ownership of the technical achievements and all intellectual property rights transferred under this Contract. Party A shall be only entitled to use the technology to produce and sell the products of this project during the implementation period after paying the usage fund as agreed in this Contract. Party A shall not transfer or cooperate in the virus seeds and production of the Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, live (Strain huadu+Strain CV777+Strain NX) to a third party. Party A shall not apply the underlying technical secret to improve the R&D and production process of other new products.
2. Implementation Method: production and sales.

3. Implementation Period: From April 5, 2012 to April 5, 2032. If Party A wishes to continue using this technology secret to produce products after the expiration of the Contract, Party A shall obtain the consent of Party B and comply with Article 11 of this Contract that reads "Party B shall be given a sales commission of 5% of the sales revenue every year, and settlement shall be made before December 10 every year". If there are no force majeure factors, Party B shall agree to renew the Contract in principle.

Article 6 Party B guarantees the practicality and reliability of this technical secret, and guarantees that this technical secret does not infringe on the legitimate rights of any third party. If a third party accuses Party A of infringing on technical secret and is awarded compensation by Party A, Party B shall bear the compensation responsibility. If a third party maliciously infringes, Party B shall not be liable.

Article 7 In performing the Contract, if the technical secret has already been disclosed by others (except for those disclosed through patent rights), one party shall notify the other party to terminate the Contract within ten days. If the other party fails to notify within the time limit and causes losses to the other party, the other party shall be entitled to demand compensation. In performing the Contract, Party B shall be entitled to transfer the technology stipulated in the Contract to a third party, but shall bear the obligation of confidentiality.

Article 8 Both parties agree that the confidentiality obligations to be observed in the performance of this Contract are as follows:

Party A:

1. Confidential (including technical and business information):The seed virus and production process of the Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, live (Strain huadu+Strain CV777+Strain NX); and all information and data of both parties during the transfer period and cooperation process.

7 / 17

2. Scope of individuals involving confidential: Members of the project team who have access to the underlying technology and information.

3. Term of Confidentiality period: Permanent

4. Liabilities for disclosure of confidential: Party A shall pay Party B liquidated damages of 10 million RMB for breach of contract; Party A shall not be entitled to refund the technology transfer fund paid by Party B; and Party A shall assume the economic losses suffered by Party B due to the disclosure of confidential.

Party B:

1. Confidential (including technical and business information):All relevant information and data archives of both parties during the transfer period and cooperation process.

2. Scope of individuals involving confidential: Members of the project team who have access to the underlying technology and information.

3. Term of Confidentiality period: Permanent

4. Liabilities for disclosure of confidential: Party B shall pay Party A liquidated damages of 10 million RMB for breach of contract.

Article 9 During the validity period of this Contract, Party B shall be entitled to apply for a patent for this technical secret, and Party A shall be entitled to continue using it in accordance with this Contract.

8 / 17

Article 10 In order to ensure the effective implementation of this technical secret by Party A, Party B shall provide the following technical services and guidance to Party A:

1. Content of technical services and guidance: N.A.

2. Method of technical service and guidance: N.A.

Article 11 Party A shall pay the technical secret usage fund to Party B based on the following schedule:

1. The total amount of technical secret usage fund shall be RMB 56 million; Party A shall also pay a commission of 5% of the sales revenue of the product to Party B every year after the product is produced and sold.

Technical service and guidance funds shall be N.A.

2. The technical secret usage fund has been paid by Party A to Party B in the early stage, which is RMB 2 million. The remaining RMB 54 million shall be paid to Party B in installments.

The specific payment method and terms are as follows:

(1) In the first installment, which is by December 10, 2014, Party A shall pay technology transfer and usage fund of RMB twenty-one million six hundred thousand to Party B.

(2) In the second installment, which is by October 20th, 2015, Party A shall pay a technology transfer and usage fund of RMB sixteen million two hundred thousand to Party B.

9 / 17

(3) In the third installment, which is by October 20th, 2016, Party A shall pay the remaining amount of technology transfer and usage fund of RMB sixteen million two hundred thousand to Party B.

(4) Starting from the date of production and sales, Party A shall pay Party B a lump sum of 5% of the sales amount annually by December 1st annually. Party B shall

be entitled to inspect the relevant accounting records of the first party through auditing. Party A shall be responsible for keeping relevant documents and accounts for Party B's reference. This clause shall not terminate upon the expiration of the term of this Contract.

(5) Party B may terminate the Contract and call back the virus seed and production process provided that Party A fails to pay the transfer fund hereunder. Party A shall no longer be entitled to produce and sell the Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, live (Strain huadu+Strain CV777+Strain NX).

(6) Party A shall assume all the liabilities for any adverse consequences caused by the failure of the Party A's funds to be provided in a timely manner. Party B shall not refund RMB 2 million out of the first installment to Party A provided that the Registration Certificate of New Veterinary Drugs cannot be obtained due to subjective factors not caused by Party B or changes in national policies of. However, Party A shall be entitled to refuse to pay the unpaid technology transfer and use fund, and the Contract shall be terminated.

The bank name, address, and account of Party B:

Bank of Deposit: Harbin Bank Technology Branch

Bank Address: No. 23 Tianshun Street, Nangang District, Harbin City

Account number: 8840 1030 5809 016

10 / 17

Article 12 Both parties confirm that Party B authorizes Party A to implement the technical secret, provide technical services, and provide technical guidance in accordance with the following standards and methods for acceptance:

1. N.A.

2. N.A.

3. N.A.

Article 13 Party A shall implement the technical secret within N.A. days upon the Effective Date of this Contract; Party A shall inform Party B with appropriate explanation and gain recognition from Party B in the event of failure to implement on schedule. Party B shall be entitled to ask Party A for liquidated damages or indemnification provided that Party A fails to implement the technical secret N.A. days overdue.

Article 14 Both parties agree that during the performance of this Contract, neither party shall restrict the other party's technological competition and development in the following ways:

1. N.A.

2. N.A.

3. N.A.

11 / 17

Article 15 Both parties confirm that:

1. Party A shall not be entitled to use the technical secret transferred by Party B for subsequent improvement.

2. Party B shall be entitled to make subsequent improvements to the technical secret transferred to Party A. The new technological achievements with substantive or creative technological progress characteristics resulting from this shall belong to Party B.

Article 16 Any amendments to the Contract shall be negotiated and agreed by both parties and confirmed in written. A party may submit a request to the other party to change the rights and obligations under the Contract, and the other party shall reply within N.A. days in the event of any of the following situation. Failure of reply shall be deemed as consent:

1. N.A.

2. N.A.

3. N.A.

4. N.A.

Article 17 Both parties agree with the following liability for default:

1. Where Party A violates Article 8 hereunder, Party A shall pay liquidated damages in the amount of 10 million RMB; Party A has no right to recover the technology transfer fund already paid to Party B; and Party B will hold Party A responsible for disclosing technical secret and compensating for actual losses.

12 / 17

2. Where Party A violates Article 5 hereunder, Party A shall pay liquidated damages in the amount of 10 million RMB; and Party B will hold Party A responsible for disclosing technical secret and compensating for actual losses.

3. Where Party A violates Article 11 hereunder, Party A shall pay liquidated damages in the amount of 10 million RMB; and Party B will hold Party A responsible for disclosing technical secret and compensating for actual losses.

4. Where Party B violates Article 2 hereunder, Party B shall pay liquidated damages in the amount of 10 million RMB; and Party B shall return all the technology transfer fund paid to Party A.

Article 18 Both parties agree that during the validity period of this Contract, Party A shall designate Lian Wei as the project contact person of Party A, and Party B shall designate Feng Li as the project contact person of Party B. The project contact person bears the following responsibilities:

1. Record the contact matters between both parties;
2. N.A.;
3. N.A.

Where a party changes its contact, such party shall give a written notice to the other party on a timely basis. Where the performance of the Contract is affected, or losses are incurred due to the failure of timely notice, such party shall assume the liabilities thereon.

13 / 17

Article 19 Both parties recognize that one party may terminate the Contract by noticing the other party in the event of the followings:

1. Force majeure: When force majeure factors defined by law and national policies, documents, standards, and other national actions result in the inability or partial inability to perform this Contract, this Contract may be terminated
2. When both parties agree to terminate this Contract through consultation, this Contract may be terminated.

Article 20 Any disputes incurred in connection with the performance of the Contract shall be resolved through mutual negotiation and coordination. Any dispute which cannot be resolved through mutual negotiation and coordination shall be handled in accordance with Point 1:

1. Submit to Harbin Arbitration Commission for arbitration;
2. Lodge a proceeding with the People's Court.

Article 21 Both parties agree that the definitions and interpretations of the relevant terms and technical terms involved in this Contract and exhibits are as follows:

N.A.

Article 22 The following technical documents related to the performance of this Contract shall not form an integral part of this Contract after confirmation by both parties:

1. Technical background information: N.A.;

14 / 17

2. Feasibility study report: N.A.;
3. Technical evaluation report: N.A.;
4. Technical standards and specifications: N.A.;
5. Original design and process documents: N.A.;
6. Miscellaneous: N.A.;

Article 23 Both parties agree that other relevant matters of this Contract are:

1. Party A shall coordinate the approval of the national veterinary regulatory department for this work and ensure that Party A meets the conditions for producing the vaccine using the transferred technology.

2. Party A shall be responsible for the quality of the products produced by the transfer project and the legal consequences arising therefrom.

3. If this Contract is terminated, Party B shall take back the seed and production process of the Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, live (Strain huadu+Strain CV777+Strain NX), and Party A shall no longer be entitled to produce the Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, live (Strain huadu+Strain CV777+Strain NX).

15 / 17

4. After the expiration of this Contract, where Party A applies to renew the Contract with the same content, Party B shall agree that Party A will no longer pay Party B a technology transfer and usage fund (i.e., five to six million yuan), but an annual commission of 5% of the sales revenue of the product; where Party A no longer renews this Contract, this Contract will be terminated. Party B shall take back the seed and production process of the Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, live (Strain huadu+Strain CV777+Strain NX). Party A shall no longer have the right to produce the Swine Transmissible Gastroenteritis, Porcine Epidemic Diarrhea and Porcine Rotavirus (G5 type) Vaccine, live (Strain huadu+Strain CV777+Strain NX).

Article 24 This Contract is made in eight original copies, with four copies each for Party A and Party B, with equal legal effect.

Article 25 The Contract shall be effective upon the signature and seal of both parties.

Party A: _____ (seal)

Legal representative/entrusted agent: (signature)

Date

Party B: _____ (seal)

Legal representative/entrusted agent: (signature)

Date

Paste the tax receipt at:

(This page is filled in by the technical contract registration agency)

Contract registration number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

1. Applicant for registration:

2. Registration materials:

(1)

(2)

(3)

3. Contract type:

4. Contract transaction amount:

5. Technical transaction volume:

Technology Contract Registration Organization (seal)

Processed by: _____

Date

Contract Number:

**TECHNOLOGY LISING (TECHICAL SECRETS)
AGREEMENT**

Project Name: Technology Transfer of the Reassortant Newcastle Disease Virus and Avian Influenza Virus (H9 Subtype) Vaccine, Inactivated (Strain aSG10+Strain G)

Transferee (Party A): Jilin Zhengye Biological Products Co., Ltd

Transferer (Party B): China Agricultural University

Transferer (Party C): China Institute of Veterinary Drug Control

Signed in Beijing, China

Term: July 2018 to July 2032

Printed by the Ministry of Science and Technology of the People's Republic of China

1 / 19

Instruction

- I. The contract is used by contractual parties by reference to the technology development (entrustment) model contract printed by Ministry of Science and Technology of the People's Republic of China, and the technology contracts recommended by various recognized technology contract registration institutions.
- II. The contract is applied for the technology development contracts in which one party entrusts the other party to research and develop new technologies, products, crafts or new materials and its systems.
- III. If there are several representatives in either party, Party A or Party B could be respectively listed as common entrusting party or common entrusted party in the "Entrusting Party" or "Entrusted Party" provisions (new page) according to their own relations in the contract.
- IV. Any matter not covered by the Contract may be agreed by parties concerned on an attached sheet, which constitutes an inseparable part of the Contract.
- V. As for the terms and conditions which are not needed to be filled in this contract agreed upon by the parties, they should be indicated with the word such as N.A.

2 / 19

TECHNOLOGY TRANSFER (TECHNICAL SECRETS) CONTRACT

Transferee (Party A): Jilin Zhengye Biological Products Co., Ltd

Address : Jilin City, Jilin Province, China

Legal Representative: Han Zhenfa

Project Contact Person: He Yuyou

Contact Information

Mailing address: No. 1, Lianmeng Street, Jilin Economic and Technological Development Zone, Jilin Province

Tel: 0432-63047118 Fax: 0432-63056300

Email: 754689439@qq.com Postal Code: 132101

Transferer (Party B): China Agricultural University

Address: No. 2, Yuanmingyuan West Road, Haidian District, Beijing

Legal Representative: Sun Qixin

Project Contact Person: Zhang Guozhong

Contact Information

Mailing address: School of Animal Medicine, China Agricultural University, No. 2, Yuanmingyuan West Road, Haidian District, Beijing

Tel: 010-62733660 Fax: 010-62732984

Email: zhanggz@cau.edu.cn Postal code: 100193

Transferer (Party C): China Veterinary Drug Administration

Address: No. 8 Zhongguancun South Street, Haidian District, Beijing

Legal Representative: Li Ming

Project Contact Person: Liu Yebing

3 / 19

Contact information

Mailing Address: No. 8 Zhongguancun South Street, Haidian District, Beijing

Tel: 010-62103542 Fax: 010-62103539

Email: zjskjc@163.com Postal code: 100081

WHEREAS, Party B and Party C intend to license Party A the right of use of the technical secret of the production process of Reassortant Newcastle Disease Virus and Avian Influenza Virus (H9 Subtype) Vaccine, Inactivated (Strain aSG10+Strain G), and Party A shall obtain the transfer and pay the fund.

NOW, THEREFORE, in consideration of the mutual covenants contained herein and in accordance with the provisions of the Contract Law of the People's Republic of China, the three parties agree as follows:

Article 1 The technical secrets licensed by Party B and Party C to Party A are as follows:

1. Scope of Technical Secrets: This strain is inoculated with susceptible chicken embryos using the gene VII strain of Newcastle disease virus aSG10 and H9N2 subtype of avian influenza virus G strains respectively. The infected embryo fluid is harvested, concentrated, inactivated with formaldehyde solution, and emulsified with adjuvant. The vaccine is used to prevent Newcastle disease and H9 subtype avian influenza. The main content of this technical secret is the production process, production and testing of recombinant Newcastle disease virus and avian influenza (H9 subtype) inactivated vaccine, as well as related formulas.

4 / 19

2. Technical Indicators and Parameters: (1) Characteristics of strain aSG10 virus: The virus content per 0.1ml should be ≥ 108.5 EID₅₀, and the agglutination value to chicken red blood cells should not be less than 1:256 (micro method); the pathogenicity index of intracerebral vaccination should be ≤ 0.4 ; 1-day old SPF chickens should not experience death or any clinical symptoms of Newcastle disease after vaccination. (2) Characteristics of G strain virus species: The virus content should be ≥ 108.5 EID₅₀ per 0.1ml; The agglutination value of chicken red blood cells should not be less than 1:256 (micro method); SPF chickens do not exhibit clinical symptoms related to avian influenza after vaccination. (3) Vaccine production process: After inoculating susceptible chicken embryos aged 9-11 days, strain aSG10 was cultured for 96 hours. The infected chicken embryo solution was collected and concentrated twice. After inactivation with a 0.1% formaldehyde solution, its agglutination value to chicken red blood cells should not be less than 1:512 (micro method); After inoculated with susceptible chicken embryos aged 9-11 days, strain G was cultured for 72 hours. The infected chicken embryo solution was concentrated twice and inactivated with 0.2% formaldehyde solution. Its agglutination value to chicken red blood cells should not be less than 1:512 (micro method); The inactivated aSG10 strain and G strain were mixed in equal amounts to prepare a water phase vaccine. The water phase and oil phase were prepared in a ratio of 1:2. SPF chickens aged 3-5 weeks were immunized with 20 μ L vaccine. The geometric mean of HI antibody titers against the aSG10 strain antigen in the immunized group should be $\geq 1:64$. After the virus was attacked, the vaccinated chickens were judged to be protected against disease, death, and negative virus isolation. At least 7 chickens in the immunized group should be protected; SPF chickens aged 3-5 weeks were immunized with 0.25mL vaccine, and the geometric mean of HI antibody titers against G strain antigen in the immunized group should be $\geq 1:128$. After challenge, at least 90% of the immunized group chickens should be negative for virus isolation.

3. The Degree of Industrial Development of this Technical Secret: The technical secret provided by Party B and Party C to Party A can be industrialized for production.

5 / 19

Article 2 Party B and Party C shall submit the following technical materials to Party A to ensure the transfer of the underlying technical secret:

1. Two attenuated strains of chicken Newcastle disease virus aSG10, 1ml/strain.

2. Two strains of H9 subtype avian influenza G strain, 1ml/strain.

3. Manufacturing and Inspection Procedures (paper version) for Reassortant Newcastle Disease Virus and Avian Influenza Virus (H9 Subtype) Vaccine, Inactivated (Strain aSG10+Strain G).

4. Quality standards and User Manual (paper version) for Reassortant Newcastle Disease Virus and Avian Influenza Virus (H9 Subtype) Vaccine, Inactivated (Strain aSG10+Strain G).

5. Quality standards and testing techniques for raw and auxiliary materials (paper version).

Article 3 Party B and Party C agree to submit technical documents according to the arrangement as follows:

1. Submission Time: Within 15 working days after obtaining Registration Certificate of New Veterinary Drugs and Party A completes the payment to Party B and Party C.

6 / 19

2 Submission Location: China Agricultural University

3 Submission Method: Three parties assign delegates to sign on site to confirm handover.

Article 4 The conditions for Party B and Party C to implement or license this technical secret before the effectiveness of this contract are as follows:

1. The implementation of this technical secret by Party B and Party C (time, location, method, and scale):During the research period of the technical secrets of this project, Party B and Party C have implemented the technical secrets of this project under the controlled conditions of Party B, Party C, and designated pilot units. At the same time, Party A acknowledges the status of the technical secrets implemented by Party B and Party C in this project.

2. The status (time, location, method, and scale) of Party B and Party C's licensing of this technical secret to others:The technical secret of this project is the independent intellectual property technology of Party B and Party C. Party B and Party C shall simultaneously license the use of this technical secret to other enterprises, and the second party and the third party shall continue to have the right to license to other enterprises. Party A acknowledges the status of the second party and the third party's license of this technical secret and the right to continue licensing.

7 / 19

Article 5 Party A shall implement this technical secret in the following scope, manner, and period:

1. Implementation scope: Production shall only be carried out within the scope of Party A or one of its holding factories.

2. Implementation method: Party B and Party C are responsible for guiding Party A's implementation, with Party B responsible for technical guidance and training, and Party C responsible for technical consulting. Party A only has the right to produce and the right to sell corresponding products, and has no other rights. During the product monitoring period, Party A shall collect data on the efficacy and adverse reactions of the new veterinary drug, and submit a monitoring summary report to the Veterinary Drug Evaluation Center of the Ministry of Agriculture every year until the end of the monitoring period. The report content shall be true, complete, and accurate.

3. Implementation period: 20 years. Where Party A needs to continue using this vaccine technology after the expiration of the contract, Party A, Party B, and Party C shall sign a separate contract, and the transfer price shall be negotiated separately.

Article 6 Party B and Party C guarantee the practicality and reliability of this technical secret, and guarantees that this technical secret does not infringe on the legitimate rights of any third party. If a third party accuses Party A of infringing on technical secret and is awarded compensation by Party A, Party B and Party C shall assist Party A in safeguarding their rights.

8 / 19

Article 7 The three parties agree that the confidentiality obligations to be observed in the performance of this contract are as follows:

Party A:

1. Confidential (including technical and business information):Relevant technical secrets provided by Party B and Party C to Party A for the performance of this contract.

2. Scope of individuals involving confidential: All personnel of Party A involved in this work.

3. Term of Confidentiality period: Permanent

4. Liabilities for disclosure of confidential: Party A shall bear the following liabilities for disclosure off confidential that causes economic losses to Party B and Party C: (1) Party B and Party C shall be entitled to terminate this contract; (2) All fees already paid by Party A shall not be refunded by Party B and Party C. (3) Party A shall pay Party B and Party C liquidated damages equal to three times the total usage fund hereunder.

Party B and Party C:

1. Confidential (including technical and business information):Party A's relevant technical and trade secrets that Party B and Party C obtain due to the performance of this contract.

9 / 19

2. Scope of individuals involving confidential: All personnel of Party B and Party C involved in this work.

3. Term of Confidentiality period: Permanent

4. Liabilities for disclosure of confidential: Party A shall be entitled to demand that Party B and Party C bear the direct economic losses caused thereby, and the limit shall be the actual amount of usage fund paid by Party A to Party B and Party C.

Article 8 During the validity period of this Contract, Party B and Party C shall be entitled to apply for a patent for this technical secret, and Party A shall be entitled to continue using it in accordance with this contract.

Article 9 In order to ensure the effective implementation of this technical secret by Party A, Party B and Party C shall provide the following technical services and guidance to Party A:

1. Content of Technical Services and Guidance: (1) Party B and both parties are responsible for actively cooperating with Party A in product production. (2) The second party and both parties shall assign relevant personnel to be responsible for the technical guidance work of the first party and provide technical support to the first party.

2. Method of Technical Service and Guidance: According to the requirements of Party A, Party B provides on-site technical guidance and training to Party A, while Party C provides technical consultation. However, Party A shall be responsible for providing Party B and Party C with all conditions related to the licensing of

technology use rights, such as product technology use, trial production, and technical training, and shall bear the relevant expenses (which refer to the accommodation and transportation expenses of Party B and Party C's personnel engaged in technical services to Party A, as well as the expenses related to product trial production and other work)

10 / 19

Article 10 Party A shall pay the technical secret usage fund to Party B and Party C based on the following schedule:

1. The total amount of technical secret usage fund shall be RMB six million (¥6,000,000.00).
2. The technical secret usage fund shall be paid by Party A in installments to Party B and C, including three million three hundred thousand yuan (¥3,300,000.00) to Party B's designated bank account and two million seven hundred thousand yuan (¥2,700,000.00) to Party C.

The specific payment method and terms are as follows:

① Within twenty working days after the effective date of this contract, Party A shall pay Party B and Party C a technology usage fund of RMB two million (¥2,000,000.00), of which Party A shall pay Party B a technology usage fund of RMB one million and one hundred thousand (¥1,100,000.00), and Party C shall pay Party C a technology usage fund of RMB nine hundred thousand (¥900,000.00).

② Within twenty working days after obtaining the new veterinary drug registration certificate (as announced by the Ministry of Agriculture), Party A shall pay a technology usage fund of RMB four million (¥4,000,000.00) to Party B and both parties, of which Party A shall pay a technology usage fee of RMB two million two hundred thousand (¥2,200,000.00) to Party B and RMB one million eight hundred thousand (¥1,800,000.00) to Party C.

11 / 19

The bank name, address, and account of Party B:

Bank of Deposit: China Construction Bank Shangdi Branch

Account Name: China Agricultural University

Account number: 11001045300053003131-0002

The bank name, address, and account of Party C:

Bank of Deposit: Bank of Communications Beijing Academy of Agricultural Sciences Branch

Account name: China Veterinary Drug Administration

Account number: 110060435018010043864

Article 11 The three parties confirm that Party B and Party C authorize Party A to implement this technical secret, provide technical services and guidance to Party A, and conduct acceptance according to the following standards and methods (except for cases where the following goals cannot be achieved due to Party A's reasons):

1. Party B and Party C shall guide Party A to produce according to relevant process standards, etc.
2. The vaccine transferred by Party A meets the production regulations and technical standards.

12 / 19

Article 12 Party A shall start implementing this technical secret within one year after obtaining the new veterinary drug registration certificate; If it is not implemented within the specified time limit, Party B and Party C shall be notified in a timely manner and given a legitimate explanation, with the approval of Party B. If Party A is one year overdue in implementing the technical secret and gives no legitimate explanation, which affects the technology transfer and losses of Party B and Party C, Party B and Party C shall be entitled to demand Party A to pay liquidated damages or compensate for the losses.

Article 13 The three parties confirm that:

1. Party A shall only be entitled to sign the name of the unit for the new veterinary drug registration certificate of the recombinant Newcastle disease virus and avian influenza (H9 subtype) inactivated vaccine, as well as the right to produce and sell the vaccine; If Party A needs to use the technology transferred by Party B and Party C for subsequent improvements, Party A shall obtain the consent of Party B and Party C.

2. Party A shall not use the seed virus and related technologies involved in this technology for the research and development of other products.

3. Party B and Party C shall be entitled to make subsequent improvements to the technical secrets transferred to Party A. The new technological achievements with substantive or creative technological progress characteristics resulting from this shall belong to the improvement party between Party B and Party C. The specific distribution method for relevant benefits is as follows: in accordance to the consultation between Party B and Party C.

13 / 19

Article 14 Any amendments to the Contract shall be negotiated and agreed by both parties and confirmed in written. A party may submit a request to the other party to

change the rights and obligations under the Contract, and the other party shall reply within ten days in the event of any of the following situation. Failure of reply shall be deemed as consent:

1. Where either party fails to perform its obligations under this contract due to force majeure, it shall be exempted from breach of contract liability, but shall promptly notify the other two parties and provide a certificate of inability to perform the contract due to force majeure within thirty days.
2. Where either party fails to fulfill its obligations under this contract due to changes in veterinary drug laws, regulations, or policies, it shall be exempted from breach of contract liability, but shall promptly notify the other two parties and provide proof of inability to fulfill the contract within thirty days.
3. Where this contract cannot be fulfilled due to factors such as production conditions of Party A, Party A may propose to modify the contract, but Party A shall compensate for all losses caused to Party B and Party C.

Article 15 The three parties agree with the following liability for default:

1. Where Party A violates Article 10 hereunder, Party A shall be liable for breach of contract. When the overdue time does not exceed one month, in addition to paying the usage fee to Party B and Party C, Party A shall pay 0.5% of the payable amount as a late fee to Party B and Party C for each day of delay. If the overdue time exceeds one month, Party B and the West may negotiate and notify Party A to terminate this contract. The fees already paid by Party A shall not be refunded.

14 / 19

2. Where Party A violates Article 7 hereunder, Party A shall bear the liability for breach of contract. Party A shall pay liquidated damages of three times the total usage fee as stipulated in this contract to Party B and Party C.
3. Where Party A violates other provisions of this contract, Party A shall bear the liability for breach of contract, and shall pay Party B and Party C liquidated damages of three times the total usage fee as stipulated in this contract, and immediately stop the infringement.
4. Where Party B and Party C violates Article 7 hereunder, the disclosing party shall bear the liability for breach of contract. Party A has the right to demand that the disclosing party bear all economic losses caused thereby, and the compensation amount shall be limited to the fees already paid by Party A at that time.

Article 16 The three parties agree that during the validity period of this contract, Party A shall designate He Youyu as the project contact person of Party A, Party B shall designate Zhang Guozhong as the project contact person of Party B, and Party C shall designate Guo Ye as the project contact person of Party C. The project contact person bears the following responsibilities:

1. The contact persons of the three parties are responsible for negotiating technical guidance related matters;
2. The contact person of Party A is responsible for arranging and coordinating relevant matters of Party A;

15 / 19

3. The contact person of Party B is responsible for arranging and coordinating relevant matters of Party B;
4. The contact person of Party C is responsible for arranging and coordinating relevant matters of Party C.

Where a party changes its contact, such party shall give a written notice to the other two parties on a timely basis. Where the performance of the Contract is affected, or losses are incurred due to the failure of timely notice, such party shall assume the liabilities thereon.

Article 17 The three parties recognize that one party may terminate the Contract by noticing the other party in the event of the followings:

1. Force majeure;
2. Laws, regulations, or other normative documents related to veterinary drug management issued by the state or government regulatory authorities that fundamentally prevent the performance of this agreement;
3. Other situations determined by consensus among the three parties.

16 / 19

Article 18 Any disputes incurred in connection with the performance of the Contract shall be resolved through mutual negotiation and coordination. Any dispute which cannot be resolved through mutual negotiation and coordination shall be handled in accordance with Point 1:

1. Submit to Beijing Arbitration Commission for arbitration;
2. Lodge a proceeding with the People's Court.

Article 19 The three parties agree that the definitions and interpretations of the relevant terms and technical terms involved in this contract and exhibits are as follows:

N.A.

Article 20 The following technical documents related to the performance of this contract shall not form an integral part of this Contract after confirmation by the three parties:

1. Technical background information: N.A.;
2. Feasibility study report: N.A.;

- 3. Technical evaluation report: N.A.
- 4. Technical standards and specifications: N.A.
- 5. Original design and process documents: N.A.
- 6. Miscellaneous: N.A.

Article 21 The three parties agree that other relevant matters of this contract are: if the technical achievements of this project do not ultimately obtain a new veterinary drug certificate, Party B and Party C will refund all payments made by Party A without interest, but will no longer bear any other responsibilities. Any matters not covered in this contract shall be separately agreed upon.

Article 22 This contract is made in 9 copies, with each party holding 3 copies and having equal legal effect.

Article 23 The Contract shall be effective upon the signature and seal of the three parties.

Party A: _____ (Seal)

Legal representative/entrusted agent: (signature)

Date

Party B: _____ (Seal)

Legal representative/entrusted agent: (signature)

Date

Party C: _____ (Seal)

Legal representative/entrusted agent: (signature)

Date

Paste the tax receipt at:

(This page is filled in by the technical contract registration agency)

Contract registration number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

- 1. Applicant for registration:
- 2. Registration materials:
 - (1)
 - (2)
 - (3)
- 3. Contract type:
- 4. Contract transaction amount:
- 5. Technical transaction volume:

Technology contract registration organization (seal)

Processed by: _____

Date

COOPERATION AGREEMENT

This Cooperation Agreement (“Agreement”) is entered into on _____ by and between:

Jilin University, hereinafter referred to as “Party A”, and

Jilin Zhengye Biological Products Co., Ltd hereinafter referred to as “Party B”,

Collectively referred to as the “Parties”.

WHEREAS, the Parties wish to collaborate on the research project named [The Development and Efficacy Evaluation of the Porcine Hemagglutinating Encephalomyelitis Virus DNA Vaccine].

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties agree to jointly apply for the 2021 Annual Funding of Key Research and Development Projects sponsored by Jilin Provincial Department of Science and Technology. Party A guarantees to conduct the core technology development project whereas Party B guarantees to provide supporting technical services to develop the Porcine Hemagglutinating Encephalomyelitis Virus DNA Vaccine and to evaluate the immune efficacy.

Party A shall design and manufacture the DNA vaccines against porcine hemagglutinating encephalomyelitis virus and test the vaccine safety, immunogenicity, and efficacy. Party B shall provide animal testing sites, conduct daily standardized breeding and management of experimental animals, assist Party A in vaccination and sample collection, and handle harmless treatment of experimental animals. During the project execution period, the Parties shall strictly fulfill the above responsibilities.

IN WITNESS WHEREOF, the Parties agree with the above plan of the project description and the funding allocation and hereto have signed this Agreement.

Party A: Jilin University (seal)

By _____

Research Project Leader of Party A

Date _____

Party B: Jilin Zhengye Biological Products Co., Ltd (seal)

By _____

Research Project Member of Party B

Date _____

COOPERATION AGREEMENT OF JOINT RESEARCH PROJECT

This Cooperation Agreement ("Agreement") is entered into on September 18, 2020, by and between:

Jilin University, hereinafter referred to as "Party A", and

Jilin Zhengye Biological Products Co., Ltd hereinafter referred to as "Party B",

Collectively referred to as the "Parties".

WHEREAS, the Parties wish to collaborate on the research project named [The Key Technique Study for the Development of the Live Gene-deletion-attenuated Vaccine against Ovine and Caprine Ecthyma (Orf)].

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties agree to jointly apply for the 2021 Annual Funding for Key Research and Development Projects in the agricultural field sponsored by Jilin Provincial Department of Science and Technology, with the project named [The Key Technique Study for the Development of the Live Gene-deletion-attenuated Vaccine against Ovine and Caprine Ecthyma (Orf)] hosted by Party A and joined by Party B. The Parties guarantee to organize and implement the research tasks and live up to the requirements during the project execution cycle, to allocate the funding reasonably according to regulations, and to ensure the completion of the research on schedule.

Party A shall rescue, identify, and purify attenuated vaccine strains that lack the main virulence genes of ORFV; screen candidate vaccine strains for Orf; evaluate the biological safety and immune protection effect of Orf candidate vaccine strains; and conduct laboratory research, such as immunity optimization research.

Party B shall optimize the cell culture and freezing process of candidate vaccines; provide animal testing sites, standardize the breeding and management of experimental animals; assist Party A in vaccination and sample collection, and handle the harmless treatment of experimental animals.

Party A shall obtain 90% of the government funding and Party B shall obtain 10% of the government funding once their application is approved.

IN WITNESS WHEREOF, the Parties agree with the above plan of the project description and the funding allocation and hereto have signed this Agreement.

Party A: Jilin University (seal)

By _____

Research Project Leader

Date

Party B: Jilin Zhengye Biological Products Co., Ltd (seal)

By _____

Research Project Member

Date

COOPERATION AGREEMENT OF JOINT RESEARCH PROJECT

This Cooperation Agreement of Joint Research Project (“Agreement”) is entered into on September 19, 2020, by and between:

Jilin Agricultural Science and Technology University, a university located at No. 77 Hanlin Road, Economic and Technological Development Zone, Jilin City to host the research project with the project contact person Yin Baishuang whose phone number is 15144254601, hereinafter referred to as “Party A”, and

Jilin Zhengye Biological Products Co., Ltd a company located at No. 8 Hanlin Road, Economic and Technological Development Zone, Jilin City to support the research project with the project contact person Wang Congyu whose phone number is 13843241346, hereinafter referred to as “Party B”,

Collectively referred to as the “Parties”.

WHEREAS, the Parties wish to collaborate on the research project named [The Development and Efficacy Evaluation of Jilin-region-specific High Efficiency Inactivated PED Vaccine].

NOW, THEREFORE, in consideration of the mutual covenants contained herein and in accordance with the provisions of the Contract Law of the People’s Republic of China, the Parties agree as follows:

1. Project Description:

1.1 Project Application and Funding: The Parties have reached the following agreement regarding their joint application of a research project. Party A and Party B shall jointly apply for the 2021 Annual Funding for Key Research and Development Projects sponsored by Jilin Province Science and Technology Development Initiative, and the project name is [The Development and Efficacy Evaluation of Jilin-region-specific High Efficiency Inactivated PED Vaccine]. Party A shall be the host to conduct the research and Party B shall be the supporting partner. The Parties jointly apply for 500,000 RMB government funding for scientific research offered by the Jilin Provincial Department of Science and Technology, and Party B agrees to provide funding in the amount of 300,000 RMB for the project.

1.2 Technical Contents of the Project: The Project aims to establish a PEDV positive sample library in different pig breeding concentration areas in Jilin region; to isolate and identify the genotype of PEDV epidemic strains in Jilin region, and verify the pathogenicity of PEDV epidemic strains; to develop a highly efficient and specific PEDV cocktail inactivated vaccine for Jilin region, evaluate the immune protection effect of the vaccine, and develop laboratory samples for Jilin-region-specific high efficiency PEDV vaccine. The Project will provide technical support for the subsequent development of Chinese homegrown vaccines and new biological products manufactured by the supporting company, thereby promoting the sustainable and healthy development of the pig industry in Jilin Province.

1.3 Technical Methods of the Project: (1) PEDV isolation and fluorescence real-time quantitative PCR identification techniques adopted by 5 breeding farms in Jilin region; (2) cell culture and pathogenicity identification techniques for PEDV epidemic strains; (3) identification of plaque clone purification and optimization of proliferation culture conditions for PEDV strains; (4) manufacturing technique of PEDV cocktail inactivated vaccine; and (5) evaluation technique for immune protection effect of PEDV cocktail inactivated vaccine.

2. Research Team:

2.1 Party A shall design and implement the project named [The Development and Efficacy Evaluation of Jilin-region-specific High Efficiency Inactivated PED Vaccine], conduct PEDV flow control and isolation and identification in Jilin region, and launch laboratory research on the formation of PED cocktail inactivated vaccine.

2.2 Party B shall conduct immune effect evaluation and pilot study of the project named [The Development and Efficacy Evaluation of Jilin-region-specific High Efficiency Inactivated PED Vaccine], and provide experimental resources as necessary to carry out experiments on animals.

3. Allocation of the funding

After receiving the government funding from the Jilin Provincial Department of Science and Technology, Party A shall obtain 80% of the funding and Party B shall obtain 20% of the funding. The government funding and the funding offered by Party B shall be fully invested on the research and development of the project. Party B shall set up a ledger and spend the funding exclusively on the research project.

4. Intellectual Property:

4.1 The ownership of the theoretical achievements based on the research conducted by either of the Parties, such as the publication of papers and monographs, is governed by the party that conducts the research, whereas the applied technological achievements, such as patents and the property rights of the products manufactured in accordance of the research, is also governed by the party that conducts the research.

4.2 The ownership of the scientific and technological achievements of the Project is jointly governed by the Parties. The Parties can jointly apply for the registration of new veterinary drugs and distribute intellectual property rights and the conversion benefits of scientific and technological achievements at a ratio of 50% to 50%. Party B shall claim priority in manufacturing products developed from the research.

5. Risks and Termination:

5.1 This Agreement shall commence on the Effective Date and continue until the completion of the Project, unless terminated earlier as provided herein. This Agreement is valid only for the application of the project.

5.2 Either Party may terminate this Agreement with written notice to the other Party in the event of a material breach of its obligations hereunder. In case of force majeure, both parties shall bear the losses separately.

If the funding application of the project is not approved, this Agreement will automatically be invalidated. This Agreement is made executed in two original counterparts each of which shall have equal effect in law. Each Party shall keep one copy of the original Agreement.

IN WITNESS WHEREOF, the Parties agree with the above plan of the project description and hereto have signed this Agreement.

Party A: Jilin Agricultural Science and Technology University
(seal)

By _____

Legal Person/Manager of Party A

Date

Party B: Jilin Zhengye Biological Products Co., Ltd (seal)

By _____

Legal Person/Manager of Party B

Date

COOPERATION AGREEMENT

This Cooperation Agreement ("Agreement") is entered into on October 14, 2021, by and between:

Jilin University, hereinafter referred to as "Party A", and

Jilin Zhengye Biological Products Co., Ltd hereinafter referred to as "Party B",

Collectively referred to as the "Parties".

WHEREAS, the Parties wish to collaborate on the research project named [Establishing the OFTu Immortalized Cell Line and its Application in Developing Ovine and Caprine Poxvirus Vaccine].

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties agree to jointly apply for the 2022 Annual Funding of Key Research and Development Projects in the agricultural field sponsored by Jilin Provincial Department of Science and Technology with the project named [Establishing the OFTu Immortalized Cell Line and its Application in Developing Ovine and Caprine Poxvirus Vaccine] with Party A as the project leader and Party B as the project member. The Parties guarantee to participate in the project according to the research tasks stated in the funding application form, organize project implementation, use the funding reasonably according to regulations, and ensure the completion on schedule.

Party A shall construct an immortalized cell line of sheep nasal oracle bone cells (OFTu) and evaluate the proliferation ability of OFTu cell line; carry out the chromosomal karyotype analysis and evaluation of potential tumorigenic ability of OFTu cell line; and evaluate the amplification ability of sheep derived poxvirus in OFTu cell line.

Party B shall optimize the large-scale cultivation and inheritance process of OFTu cell line; and assist Party A in conducting amplification testing of the smallpox virus vaccine strain.

IN WITNESS WHEREOF, the Parties agree with the above plan of the project description and hereto have signed this Agreement.

Party A: Jilin University (seal)

By _____

Research Project Leader of Party A

Date

Jilin Zhengye Biological Products Co., Ltd (seal)

By _____

Research Project Member of Party B

Date

COOPERATION AGREEMENT

This Cooperation Agreement ("Agreement") is entered into on October 14, 2021 by and among:

Jilin University, hereinafter referred to as "Party A",

Health Commission of Jilin Province (or Jilin Provincial Institute of Public Health), hereinafter referred to as "Party B", and

Jilin Zhengye Biological Products Co., Ltd hereinafter referred to as "Party C",

Collectively referred to as the "Parties".

WHEREAS, the Parties wish to collaborate on the research project named [The Development of ASFV-PRV Nucleic Acid rapid Co-test Kit and its Application in the Quarantine of Cold-chain Pork].

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties shall jointly apply for the 2022 Annual Funding for Key Research and Development Projects in the field of social development sponsored by Jilin Province Science and Technology Initiative with the project named [The Development of ASFV-PRV Nucleic Acid rapid Co-test Kit and its Application in the Quarantine of Cold-chain Pork] with Party A and the project leader and Party B and Party C as the project participants. The Parties guarantee to participate in the project according to the research tasks stated in the project application form, organize project implementation, use the funding reasonably according to regulations, and ensure the completion on schedule.

Party A shall establish a multiplex fluorescence quantitative PCR test method to detect ASFV, PRV wild-type strains, and vaccine strains; obtain ASFV-PRV nucleic acid synchronous rapid detection kit; compose a food safety quarantine report of ASFV and PRV in cold-chain pork in Jilin Province.

Party B shall provide a P3 biosafety laboratory for virus nucleic acid extraction and PCR amplification; assist Party A in the collection of samples and handle the harmless treatment of experiment materials.

Party C shall assemble the test kits and work on the marketing promoting; assist Party A to collect samples and quarantine food safety against ASFV and PRV of cold-chain pork in Jilin Province.

IN WITNESS WHEREOF, the Parties agree with the above plan of the project description and hereto have signed this Agreement.

Party A: Jilin University (seal)

By _____

Research Project Leader of Party A

Date

Party B: Health Commission of Jilin Province
(or Jilin Provincial Institute of Public Health) (seal)

By _____

Research Project Member of Party B

Date

Party C: Jilin Zhengye Biological Products Co., Ltd (seal)

By _____

Research Project Member of Party C

Date

COOPERATION AGREEMENT OF JOINT RESEARCH PROJECT

This Cooperation Agreement of Joint Research Project (“Agreement”) is entered into on September 19, 2020, by and between:

Jilin Agricultural University, a university located at No. 2888 Xincheng Street, Changchun City to host the research project, hereinafter referred to as “Party A”, and

Jilin Zhengye Biological Products Co., Ltd a company located at No. 8 Hanlin Road, Economic and Technological Development Zone, Jilin City to support the research project, hereinafter referred to as “Party B”,

Collectively referred to as the “Parties”.

WHEREAS, the Parties wish to collaborate on the research project named [The Development of Fish Enteritis Gene-deletion-attenuated Live Vaccine].

NOW, THEREFORE, in consideration of the mutual covenants contained herein and in accordance with the provisions of the Contract Law of the People’s Republic of China, the Parties agree as follows:

1. Project Description:

1.1 The Parties agree to jointly apply for the government funding for the research project named [The Development of Fish Enteritis Gene-deletion-attenuated Live Vaccine].

1.2 Division of the Tasks:

Party A shall take the following tasks as to report, implement, and summarize the project as the host of the research of “construction and immune effect evaluation of live attenuated vaccine strains caused by bacterial enteritis gene deletion in fish, and screening of frozen protective agents for live attenuated vaccine strains caused by bacterial enteritis gene deletion in fish”.

Party B shall take the following tasks as to “optimize the process related to the attenuated live vaccine caused by gene deletion in fish bacterial enteritis in the project”.

2. Allocation of the Funding

2.1 After receiving funding for the project, Party A shall allocate an amount of 50,000 RMB to Party B. The payment shall be made in accordance with Point 1 described as follows:

- (1) After the project funding are received, Party A shall make a one-time payment to Party A;
- (2) If the project funding is granted on an installment plan, Party A shall pay Party B within 30 days upon receipt of each installment.

3. Miscellaneous

3.1 If the funding application is approved, the validity period of this Agreement will be automatically extended until the project is completed and assessed. If the funding application is not approved, this Agreement will automatically terminate.

3.2 This Agreement is executed in two original counterparts each of which shall have equal effect in law. Each Party shall keep one copy of the original Agreement.

3.3 Without the permission of the other party, neither Party A nor Party B shall disclose the content of this Agreement, as well as relevant technical information, materials, etc., to any third party. The confidentiality period is 3 years.

3.4 Any disputes arising from the performance of this contract between the cooperating parties shall be resolved through consultation and mediation. Any dispute which cannot be resolved through mutual negotiation and coordination shall be handled in accordance with Point 2:

- (1) Submit to the _____ Arbitration Commission for arbitration.
- (2) Bring a lawsuit to the People’s Court in accordance with the law.

3.5 The Parties hereto may enter into written supplemental agreements in relation to the matters not mentioned herein through negotiation. Supplemental agreements shall have equal legal effect of this Agreement.

3.6 Any exhibits, memorandum, and other documents related to this Agreement shall have the same legal effect as this Agreement.

Party A: Jilin Agricultural University (seal)

By _____
Legal Person/Manager

Date

Party B: Jilin Zhengye Biological Products Co., Ltd (seal)

By _____
Legal Person/Manager

Exhibit: Proof of the Self-raised Funding

Proof of the Self-raised Funding for Research Project for the Provincial Department of Science and Technology

It is to certify that Jilin Zhengye Biological Products Co., Ltd (“Company”) and Professor Zhang Lei from Jilin Agricultural University jointly apply for the 2022 Annual Project sponsored by Jilin Provincial Department of Science and Technology with the project [The Development of Fish Enteritis Gene-deletion-attenuated Live Vaccine] with a self-raised funding of 250,000 RMB fully provided by the Company as R&D investment fund. The Company agrees to set up a separate account for the self-raised funding and use the funding exclusively for the project.

The self-raised funding is used mainly for material expenses and labor cost.

By _____
Project Leader

Jilin Zhengye Biological Products Co., Ltd (corporate seal)

By _____
Legal Person/Manager

Date

COOPERATION AGREEMENT

This Cooperation Agreement ("Agreement") is entered into on September 13, 2022 by and between:

Jilin University, hereinafter referred to as "Party A", and

Jilin Zhengye Biological Products Co., Ltd hereinafter referred to as "Party B",

Collectively referred to as the "Parties".

WHEREAS, the Parties wish to collaborate on the research project named [The Development of Ovine and Caprine Contagious Pustular Virus mRNA Vaccine Based on Lipid Nanoparticle Technology].

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties shall jointly apply for the 2023 Annual Funding for Key Research and Development Projects in the field of agriculture sponsored by Jilin Provincial Department of Science and Technology with the project named [The Development of Ovine and Caprine Contagious Pustular Virus mRNA Vaccine Based on Lipid Nanoparticle Technology], with Party A as project leader and Party B as the project participant. The Parties guarantee to participate in the project according to the research tasks stated in the project application form, organize project implementation, use the funding reasonably according to regulations, and ensure the completion on schedule.

Party A shall conduct overall design of the project; screen the main immunogenic proteins of sheep infectious pus virus; carry out antigen sequence design; make mRNA preparation; make preparation of mRNA lipid nanoparticles; and evaluate the safety and efficacy of vaccine particles.

Party B shall optimize the preparation, purification, and other processes of the sheep infectious pus virus mRNA vaccine stock solution; provide animal testing sites, conduct daily standardized breeding and management of experimental animals, assist Party A in vaccination and sample collection, and handle harmless treatment of experimental animals.

IN WITNESS WHEREOF, the Parties agree with the above plan of the project description and hereto have signed this Agreement.

Party A: Jilin University (seal)

By _____
Research Project Leader from Party A

Date

Jilin Zhengye Biological Products Co., Ltd (seal)

By _____
Research Project Member from Party B

Date

COOPERATION AGREEMENT

This Cooperation Agreement ("Agreement") is entered into on ____ by and among:

Jilin University, hereinafter referred to as "Party A",

Health Commission of Jilin Province (or Jilin Provincial Institute of Public Health), hereinafter referred to as "Party B", and

Jilin Zhengye Biological Products Co., Ltd hereinafter referred to as "Party C",

Collectively referred to as the "Parties".

WHEREAS, the Parties wish to collaborate on the research project named [The Development of Combined VSV-SVV Nucleic Acid Rapid Test Kit and its Application in the Quarantine of Cold-chain Pork].

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties shall jointly apply for the 2023 Annual Funding for Key Research and Development Projects in the field of social development sponsored by Jilin Province Science and Technology Initiative with the project named [The Development of Combined VSV-SVV Nucleic Acid Rapid Test Kit and its Application in the Quarantine of Cold-chain Pork], with Party A as the project leader and Party B and Party C as the project members. The Parties guarantee to participate in the project according to the research tasks stated in the project application form, organize project implementation, use the funding reasonably according to regulations, and ensure the completion on schedule.

Party A shall carry out the overall design of the experimental project; establish a dual fluorescence quantitative PCR nucleic acid test method for detecting water induced stomatitis (VSV) and Seneca valley disease (SVV); assemble the combined VSV-SVV nucleic acid rapid test kit and evaluate its application; and compose a food safety quarantine report of VSV and SVV in cold-chain pork in Jilin Province.

Party B shall provide a P3 biosafety laboratory for virus nucleic acid extraction and PCR amplification, and assist Party A in sample collection and harmless treatment of the experiment materials.

Party C shall assemble the test kits and work on the marketing promoting; assist Party A to collect samples and quarantine food safety against VSV and SVV of cold-chain pork in Jilin Province.

IN WITNESS WHEREOF, the Parties agree with the above plan of the project description and hereto have signed this Agreement.

Party A: Jilin University (seal)

By _____
Research Project Leader of Party A

Date

Party B: Health Commission of Jilin Province
(or Jilin Provincial Institute of Public Health) (seal)

By _____
Research Project Member of Party B

Date

Party C: Jilin Zhengye Biological Products Co., Ltd (seal)

By _____
Research Project Member of Party C

Date

COOPERATION AGREEMENT

This Cooperation Agreement ("Agreement") is entered into on September 16, 2022 by and between:

Jilin University, hereinafter referred to as "Party A", and

Jilin Zhengye Biological Products Co., Ltd hereinafter referred to as "Party B",

Collectively referred to as the "Parties".

WHEREAS, the Parties wish to collaborate on the research project named [The Study of Rapid Visual Nucleic Acid Test of Various SARS-CoV-2 Mutants].

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties shall jointly apply for the 2023 Annual Funding for Key Research and Development Projects in the field of social development sponsored by Jilin Province Science and Technology Initiative with the project named [The Study of Rapid Visual Nucleic Acid Test of Various SARS-CoV-2 Mutants] with Party A as the project leader and Party B as the project member. The Parties guarantee to participate in the project according to the research tasks stated in the project application form, organize project implementation, use the funding reasonably according to regulations, and ensure the completion on schedule.

Party A shall design the project; prepare organic luminescent material labeled probes; optimize isothermal amplification conditions; and evaluate the sensitivity and the clinical sample of SARS-CoV-2 rapid nucleic acid visualization detection method.

Party B shall compare and analyze the complete gene sequences of multiple variants of SARS-CoV-2; design the primers and probes; and evaluate the specificity of SARS-CoV-2 rapid nucleic acid visualization detection method.

IN WITNESS WHEREOF, the Parties agree with the above plan of the project description and hereto have signed this Agreement.

Party A: Jilin University (seal)

By _____
Research Project Leader of Party A

Date

Party B: Jilin Zhengye Biological Products Co., Ltd (seal)

By _____
Research Project Member of Party B

Date

Exhibit: Proof of the Self-raised Funding

Proof of the Self-raised Funding for Research Project for the Provincial Department of Science and Technology

It is to certify that Jilin Zhengye Biological Products Co., Ltd ("Company") and Ci Xinxin from Jilin Agricultural University jointly apply for the 2023 Annual Project sponsored by Jilin Provincial Department of Science and Technology with the project [The Study of Rapid Visual Nucleic Acid Test of Various SARS-CoV-2 Mutants] with a self-raised funding of 260,000 RMB fully provided by the Company as R&D investment fund. The Company agrees to set up a separate account for the self-raised funding and use the fund exclusively for the project.

The Self-raised funding is used mainly for material expenses and labor cost.

By _____
Project Leader

Jilin Zhengye Biological Products Co., Ltd (seal)

By _____
Legal Person/Manager

Date

COOPERATION AGREEMENT OF JOINT RESEARCH PROJECT

This Cooperation Agreement ("Agreement") is entered into on September 13, 2022 by and between:

Jilin Agricultural University, hereinafter referred to as "Party A", and

Jilin Zhengye Biological Products Co., Ltd hereinafter referred to as "Party B",

Collectively referred to as the "Parties".

WHEREAS, the Parties wish to collaborate on the research project named [The Development of Animal Microecological Vaccine for the Biological Control of African Swine Fever].

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties agree to jointly apply for the 2023 Annual Funding for Key Research and Development Projects sponsored by Jilin Science and Technology Initiative with the project named [The Development of Animal Microecological Vaccine for the Biological Control of African Swine Fever].

1. Devision of the Tasks

Party A shall take the following tasks of project application, implementation, and summary; identification of strains; development of a composite lactobacillus vaccine; biosafety intermediate test report; and biosafety intermediate test.

Party B shall take the task of product inspection.

2. Allocation of the Funding:

After the project funding is approved, Party A shall obtain 90% of the funding offered by the government, while Party B shall obtain 10%. The Parties shall set up an account for the exclusive use of the funding in the scientific research.

3. Ownership of Intellectual Property Rights

During the research project, the ownership of the research results and related intellectual property rights based on the research conducted by either of the Parties is governed by the Party that conducts the research. However, Party A shall be entitled to use the project information of Party B for non-commercial purposes (such as in the compiling of government meeting presentations, reports, documents and referring to the statistical data, etc.), and the Parties shall share intellectual property rights during the project execution period.

4. Cooperation Term

The term of the agreement is the project implementation cycle, and the agreement shall be invalidated upon completion of the project. If the project application is not approved, this agreement will be automatically invalidated.

5. This Agreement is executed in four original counterparts each of which shall have equal effect in law. Each Party shall keep two copies of the original Agreement. The Parties hereto may enter into written supplemental agreements in relation to the matters not mentioned herein through negotiation. Supplemental agreements shall have equal legal effect of this Agreement.

Party A: Jilin Agricultural University (seal)

By _____

Research Project Leader from Party A

Date

Party B: Jilin Zhengye Biological Products Co., Ltd (seal)

By _____

Research Project Member from Party B

Date

COOPERATION AGREEMENT OF JOINT RESEARCH PROJECT

This Cooperation Agreement of Joint Research Project (“Agreement”) is entered into on September 13, 2022 by and among:

Jilin Agricultural University, a university located at 2888 Xincheng Street, Changchun City to host the research project, hereinafter referred to as “Party A”,

Jilin Zhengye Biological Products Co., Ltd a company located at No. 8 Hanlin Road, Economic and Technological Development Zone, Jilin City to support the research project, hereinafter referred to as “Party B”, and

Jilin Provincial Center for Animal Disease Prevention and Control an organization located at No. 4510 Xi’an Road, Changchun City to support the research project, hereinafter referred to as “Party C”,

Collectively referred to as the “Parties”.

WHEREAS, the Parties wish to collaborate on the research project named [The Development and Application of Rapid Visual Test Technology for Key Viral Diseases in Goslings].

NOW, THEREFORE, in consideration of the mutual covenants contained herein and in accordance with the provisions of the Contract Law of the People’s Republic of China, the Parties agree as follows:

1. Project Description:

1.1 The Parties agree to jointly apply for the government funding for the research project named [The Development and Application of Rapid Visual Test Technology for Key Viral Diseases in Goslings].

1.2 Division of the Tasks:

Party A shall take the tasks of project application, implementation, and summary as the host of the project and undertake the research of “the establishment of fluorescence quantitative PCR detection method and visualization detection method for common viral diseases in goslings” in the project.

Party B shall take the tasks of “marketing promotion of the detection method” etc.

Party C shall take the tasks of “quality and standard inspection of the detection method” etc.

2. Allocation of the Funding

2.1 After receiving funding for the project, Party A shall allocate an amount of 50,000 RMB to Party B. The payment shall be made in accordance with Point 2 described as follows:

- (1) After the project funding are received, Party A shall make a one-time payment to Party A within ____ days upon the receipt;
- (2) If the project funding is granted on an installment plan, Party A shall pay Party B within 30 days upon receipt of each installment.

2.2 Party B shall offer 250,000 RMB for project research, accounting for 30.1% of the total project budget. The funding is for the completion of the research tasks specified in the project plan.

3. Miscellaneous

3.1 If the funding application is approved, the validity period of this Agreement will be automatically extended until the project is completed and assessed. If the funding application is not approved, this Agreement will automatically be terminated.

3.2 This Agreement is executed in three original counterparts each of which shall have equal effect in law. Each Party shall keep one copy of the original Agreement.

3.3 Without the permission of the other party, neither Party A, Party B nor Party C shall disclose the content of this Agreement, as well as relevant technical information, materials, etc., to any third party. The confidentiality period is 3 years.

3.4 Any disputes arising from the performance of this contract between the cooperating parties shall be resolved through consultation and mediation. Any dispute which cannot be resolved through mutual negotiation and coordination shall be handled in accordance with Point 2:

- (1) Submit to the Arbitration Commission for arbitration.
- (2) Bring a lawsuit to the people’s court in accordance with the law.

3.5 The Parties shall strictly follow the relevant regulations of Jilin Provincial Science and Technology Research Management Plan to execute the project budget, to ensure that the research tasks specified in the project plan are completed on time and live up to the assessment standard. If the research and development progress of Party A and Party C is delayed, Party A is entitled to urge Party B and Party C to accelerate the progress.

3.6 The Parties shall cooperate with professional institutions in the process management and assessment. Party A shall coordinate the project execution by holding seminars and meetings whereas Party B and Party C shall submit annual technical reports, final technical reports, and feature technical reports within the time specified by the management team.

3.7 The Parties hereto may enter into written supplemental agreements in relation to the matters not mentioned herein through negotiation. Supplemental agreements shall have equal legal effect of this Agreement.

3.8 Any exhibits, attachment, and other documents related to this Agreement shall have the same legal effect as this Agreement.

Party A: Jilin Agricultural University (seal)

By _____

Legal Person/Manager

Date

Party B: Jilin Zhengye Biological Products Co., Ltd (seal)

By _____

Legal Person/Manager

Date

Party C: Jilin Provincial Center for Animal Disease
Prevention and Control (seal)

By _____

Legal Person/Manager

Date

COOPERATION AGREEMENT

This Cooperation Agreement ("Agreement") is entered into on September 19, 2022 by and between:

Jilin Academy of Agricultural Sciences, hereinafter referred to as "Party A", and

Jilin Zhengye Biological Products Co., Ltd hereinafter referred to as "Party B",

Collectively referred to as the "Parties".

WHEREAS, the Parties wish to collaborate on the research project named [The Development and Application of Fluorescent ERA Rapid Thermostatic Diagnostic Technology for Key Viral Diarrhea Diseases in Pigs].

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties shall jointly apply for the 2023 Annual Funding for Key Research and Development Projects in the field of agriculture sponsored by Jilin Provincial Department of Science and Technology with the project named [The Development and Application of Fluorescent ERA Rapid Thermostatic Diagnostic Technology for Key Viral Diarrhea Diseases in Pigs], with Party A as project leader and Party B as the project participant. The Parties guarantee to participate in the project according to the research tasks stated in the project application form, organize project implementation, use the funding reasonably according to regulations, and ensure the completion on schedule.

Party A shall explore the conventional diagnostic markers for the same pathogen and specific diagnostic markers for different pathogens, manufacture homogeneous and stable nucleic acid reference materials; design primers and exo probes for the diagnostic markers of pathogens, optimize primers, reaction systems, and reaction conditions, evaluate the specificity, sensitivity, stability, and accuracy, and set up a fluorescence ERA constant temperature detection method to implement on-site rapid detection within 15-20 minutes; conduct a background investigation on four types of porcine viral diarrhea pathogens in Jilin Province; and complete the trial production of rapid diagnostic reagents and promote grassroots technology.

Party B shall provide access to the Jilin Province Animal Vaccine Engineering Research Center, build a research and development team to establish a constant temperature testing method, and offer the current vaccine strains and samples from the pig farms in Jilin Province.

The Parties agree that the ownership of the Fluorescent ERA Rapid Thermostatic Diagnostic Technology for Key Viral Diarrhea Diseases in Pigs in this project belongs to Party A, and the economic benefits generated thereby belong to Party A. The new technologies, products, patents, and other achievements obtained in this project research belong to Party A, and shall be transferred to Party B with priority.

The Parties agree to apply for government funding for science and technology research of 500,000 RMB for the project, and Party B shall offer an amount of 250,000 RMB for the project. The plan is to allocate 80% of the government funding to Party A and 20% to Party B.

IN WITNESS WHEREOF, the Parties agree with the above plan of the project description and funding allocation and hereto have signed this Agreement.

Party A: Jilin Academy of Agricultural Sciences (seal)

By _____

Research Project Leader from Party A

Date

Jilin Zhengye Biological Products Co., Ltd (seal)

By _____

Research Project Member from Party B

Date

COOPERATION AGREEMENT OF JOINT RESEARCH PROJECT

This Cooperation Agreement of Joint Research Project (“Agreement”) is entered into on September 20, 2022 by and between:

Jilin Institute of Animal Husbandry and Veterinary Medicine, hereinafter referred to as “Party A”, and

Jilin Zhengye Biological Products Co., Ltd hereinafter referred to as “Party B”,

Collectively referred to as the “Parties”.

WHEREAS, the Parties wish to collaborate on the research project named [The Preparation Process Study of Immunoglobulin Y against Rotavirus Disease in Herbivorous Animals and its Prophylactic Application].

NOW, THEREFORE, in consideration of the mutual covenants contained herein and in accordance with the provisions of the Contract Law of the People’s Republic of China, the Parties agree as follows:

1. Project Description:

The Parties agree to jointly apply for the 2023 annual funding for the field of effective agriculture and key manufacturing technology of green production sponsored by Jilin Province Science and Technology Initiative with the project named [The Preparation Process Study of Immunoglobulin Y against Rotavirus Disease in Herbivorous Animals and its Prophylactic Application]. The Parties guarantee to complete the tasks and fulfill the goals through complementary advantages, collaborative efforts, and a combination of the strengths from industry, academia, and research.

2. Division of the Tasks:

2.1 Party A shall serve as the project leader to organize and implement the research by taking the following tasks:

- (1) Perform molecular genetic analysis on rotavirus isolates from different hosts to obtain the optimal antigenic epitopes;
- (2) Construct a multi-antigen epitope tandem expression vector based on a rod-shaped virus multi-gene expression system to prepare specific antigens; and
- (3) Optimize the immune program, improve the production efficiency of IgY antibodies, and compare the biological activity of antibodies obtained by different purification methods.

2.2 Party B shall serve as the project supporting member and take the tasks of improving the production processes of IgY drying, coating, etc., evaluating the clinical prevention and control effects, and conducting demonstration and promotion on breeding farms.

3. Allocation of the Funding

The project is budgeted at 800,000 RMB, of which 70% is from the Jilin Provincial Science and Technology Innovation Research Funding and 30% is offered by Party B. The actual amount of funding is subject to the approval of the application. The approved funding shall be allocated by both parties in a ratio of 4:1, and the use of funding shall be strictly in accordance with the 2023 Project Fund Management Measures of Jilin Provincial Science and Technology Development Plan.

4. Intellectual Property

The Parties agree that the ownership of the project [The Preparation Process Study of Immunoglobulin Y against Rotavirus Disease in Herbivorous Animals and its Prophylactic Application] belongs to Party A, and the economic benefits generated thereby belong to Party A; the new technologies, products, patents, and other achievements obtained from the project belong to Party A whereas Party B has the right of authorship for the patented achievements.

5. Term and Termination:

5.1 This Agreement shall commence on the Effective Date.

5.2 The Parties agree that in the process of executing the agreement, if force majeure or technical risks occur that prevent the agreement from continuing to be performed, the other party shall be notified in a timely manner to minimize losses and jointly negotiate changes or termination of the Agreement.

5.3 Either Party may change and terminate this Agreement with written notice to the other Party 60 working days in advance.

6. Miscellaneous

6.1 If the funding for this project is approved, the validity period of this Agreement will be automatically extended until the project is completed and assessed. If the funding for this project is not approved, this Agreement will automatically terminate.

6.2 This Agreement is made executed in four original counterparts each of which shall have equal effect in law. Each Party shall keep two copies of the original Agreement.

6.3 Without permission, both parties and their relevant personnel shall not disclose the content of the agreement, as well as relevant technical information, materials, etc. to others.

6.4 The Parties hereto may enter into written supplemental agreements in relation to the matters not mentioned herein through negotiation. Supplemental agreements shall have equal legal effect of this Agreement.

7. The exhibits, memorandums, and other documents related to this Agreement have the same legal effect as this Agreement.

Party A: Jilin Institute of Animal Husbandry and Veterinary
Medicine (seal)

By _____

Research Project Leader of Party A

Date

Party B: Jilin Zhengye Biological Products Co., Ltd (seal)

By _____

Research Project Member of Party B

Date

List of Subsidiaries

Subsidiaries	Place of Incorporation
VVAX Skyline Holdings Limited	The British Virgin Islands
Windsor Holdings Co., Ltd.	Cayman Islands
Peg Biotechnology (HK) Holding Limited	Hong Kong
Hainan Senhan Biotechnology Co., Ltd.	China
Jilin Zhengye Biological Products Co., Ltd.	China



WWC, P.C. CERTIFIED PUBLIC ACCOUNTANTS

Consent of Independent Registered Public Accounting Firm

We hereby consent to the incorporation of our report dated August 4, 2023, except for the reclassification discussed in Note 2 as to which the date is November 17, 2023 in the Registration Statement on Form F-1, under the Securities Act of 1933, with respect to the consolidated balance sheets of Zhengye Biotechnology Holding Limited and its subsidiaries (the "Company") as of December 31, 2022 and 2021, and the related consolidated statements of income and comprehensive income, shareholders' equity, and cash flows for each of the years in the two-year period ended December 31, 2022, and the related notes included herein.

We also consent to the reference to us under the heading "Experts" in such Registration Statement.

San Mateo, California
January 8, 2024

WWC, P.C.

WWC, P.C.
Certified Public Accountants
PCAOB ID: 1171

**CODE OF BUSINESS CONDUCT AND ETHICS OF
ZHENGYE BIOTECHNOLOGY HOLDING LIMITED**

INTRODUCTION

Purpose

This Code of Business Conduct and Ethics (this “Code”) contains general guidelines for the conduct of business of Zhengye Biotechnology Holding Limited, a Cayman Islands company (the “Company”), consistent with the highest standards of business ethics. To the extent where this Code requires a higher standard than required by commercial practice or applicable laws, rules or regulations, we shall adhere to these higher standards.

This Code applies to all the directors, officers, and employees of the Company and its subsidiaries (which, unless the context otherwise requires, are collectively referred to as the “Company” in this Code). We refer to all persons covered by this Code as “Company employees” or simply “employees.” We also refer our chief executive officer and our chief financial officer as our “principal financial officers.”

Seeking Help and Information

This Code is not intended to be a comprehensive rulebook and cannot address every situation that you may face. If you feel uncomfortable about a situation or if you have any doubts whether it is consistent with the Company’s ethical standards, do seek help. We encourage you to first contact your supervisor for help. If your supervisor cannot answer your question or resolve your problem, or if you do not feel comfortable contacting your supervisor, you may contact the Compliance Officer of the Company, who shall be a person appointed by the Board of Directors of the Company. [●] has been appointed by the Board of Directors of the Company as the Compliance Officer of the Company. The Company will notify you if there is a change in the appointment of the Compliance Officer. You may remain anonymous and will not be required to reveal your identity in your communication to the Company.

Reporting Violations of the Code

All employees have a duty to report any known or suspected violation of this Code, including any violation of the laws, rules, regulations or policies that apply to the Company. If you know of or suspect a violation of this Code, immediately report the conduct to your supervisor. Your supervisor will contact the Compliance Officer, who will work with you and your supervisor to investigate the matter. If you do not feel comfortable reporting the matter to your supervisor or you do not get a satisfactory response, you may contact the Compliance Officer directly. Employees making a report need not leave their name or other personal information and reasonable efforts will be used to conduct the investigation that follows from the report in a manner that protects the confidentiality and anonymity of the employee submitting the report. All reports of known or suspected violations of the law or this Code will be handled sensitively and with discretion. Your supervisor, the Compliance Officer and the Company will protect your confidentiality to the extent possible, consistent with law and the Company’s need to investigate your report.

It is the Company’s policy that any employee who violates this Code will be subject to appropriate discipline, which may include termination of employment. This determination will be based upon the facts and circumstances of each situation. An employee accused of violating this Code will be given an opportunity to present his or her version of the events at issue prior to any determination of appropriate discipline. Employees who violate the law or this Code may expose themselves to substantial civil damages, criminal fines and prison terms. The Company may also face substantial fines and penalties, and many incur damage to its reputation and standing in the community. Your conduct as a representative of the Company, if it does not comply with the law or with this Code, can result in serious consequences for both you and the Company.

Policy Against Retaliation

The Company prohibits retaliation against an employee who, in good faith, seeks help or reports known or suspected violations. Any reprisal or retaliation against an employee because such employee, in good faith, sought help or filed a report will be subject to disciplinary action, including potential termination of employment.

Waivers of the Code

Waivers of this Code for employees may be granted only by an executive officer of the Company. Any waiver of this Code for our directors, executive officers or other principal financial officers may be granted only by our Board of Directors or the appropriate committee of our Board of Directors and will be disclosed to the public as required by law or the rules of Nasdaq.

CONFLICTS OF INTEREST

Identifying Potential Conflicts of Interest

A conflict of interest may occur when an employee’s private interest interferes, or appears to interfere, with the interests of the Company as a whole. You should avoid any private interest that influences your ability to act in the interests of the Company or that makes it difficult to perform your work objectively and effectively.

Identifying potential conflicts of interest may not always be clear-cut. The following situations are examples of conflicts of interest:

- Outside Employment. No employee should be employed by, serve as a director of, or provide any services not in his or her capacity as a Company’s employee to a company that is a material customer, supplier, or competitor of the Company.
- Improper Personal Benefits. No employee should obtain any material (as to him or her) personal benefits or favors because of his or her position in the Company. Please see “Gifts and Entertainment” below for additional guidelines in this area.
- Financial Interests. No employee should have a significant financial interest (ownership or otherwise) in any company that is a material customer, supplier or competitor of the Company. A “significant financial interest” means (i) ownership of greater than 1% of the equity of a material customer, supplier or competitor or (ii) an investment in a material customer, supplier or competitor that represents more than 5% of the total assets of the employee.
- Loans or Other Financial Transactions. No employee should obtain loans or guarantees of personal obligations from, or enter into any other personal financial transaction with, any company that is a material customer, supplier or competitor of the Company. This guideline does not prohibit arms-length transactions with banks, brokerage firms or other financial institutions.
- Service on Boards and Committees. No employee should serve on a board of directors or trustees or on a committee of any entity (whether profit or not-for-profit) whose interests would reasonably be expected to be in conflict with those of the Company.

- **Actions of Family Members.** The actions of family members outside the workplace may also give rise to the conflicts of interest described above because they may influence an employee's objectivity in the making of decisions on behalf of the Company. For the purposes of this Code, "family members" include your spouse or life-partner, brothers, sisters and parents, in-laws and children, whether such relationships are by blood or adoption.

For the purposes of this Code, a company is considered to be a "material" customer if that company has made payments to the Company in the past year in excess of US\$100,000 or 10% of the customer's gross revenues, whichever is greater. A company is considered as a "material" supplier if that company has received payments from the Company in the past year in excess of US\$100,000 or 10% of the supplier's gross revenues, whichever is greater. A company is considered as a "material" competitor if that company competes in the Company's line of business and has annual gross revenues from such line of business in excess of US\$500,000. If you are uncertain whether a particular company is a material customer, supplier or competitor, please contact the Compliance Officer for assistance.

Disclosure of Conflicts of Interest

The Company requires employees to disclose any situations that would reasonably be expected to give rise to a conflict of interest. If you suspect that you have a conflict of interest, or something that others could reasonably perceive as a conflict of interest, you must report it to your supervisor or the Compliance Officer. Your supervisor and the Compliance Officer will work with you to determine whether you have a conflict of interest and, if so, how best to address it. Although conflicts of interest are not automatically prohibited, they are not desirable and may only be waived as described in "Waivers of the Code" above.

CORPORATE OPPORTUNITIES

As an employee of the Company, you have an obligation to advance the Company's interests when the opportunity to do so arises. If you discover or are presented with a business opportunity through the use of corporate property, information, or because of your position in the Company, you should first present the business opportunity to the Company before pursuing the opportunity in your individual capacity. No employee may use corporate property, information, or his or her position in the Company for personal gain or in a manner that may compete with the Company.

You should disclose to your supervisor the terms and conditions of each business opportunity covered under this Code that you wish to pursue. Your supervisor will contact the Compliance Officer and the appropriate management personnel to determine whether the Company wishes to pursue the business opportunity. If the Company waives its right to pursue the business opportunity, you may pursue the business opportunity on the same terms and conditions as originally proposed and consistent with the other ethical guidelines set forth in this Code.

Confidential Information and Company's Property

Employees have access to a variety of confidential information while being employed at the Company. Confidential information includes all non-public information that might be of use to competitors, or, if disclosed, harmful to the Company or its customers. Each employee has a duty to respect and safeguard the confidentiality of the Company's information and the information of our suppliers and customers, except when disclosure is authorized or legally mandated. In addition, you must refrain from using any confidential information from any previous employment if, in doing so, you could reasonably be expected to breach your duty of confidentiality to your former employers. An employee's obligation to protect confidential information continues after he or she leaves the Company. Unauthorized disclosure of confidential information could cause competitive harm to the Company and/or its customers and could result in legal liability to you and the Company.

Employees also have a duty to protect the Company's intellectual property and other business assets. The intellectual property, business systems and the security of the Company are critical to the Company's business.

Any questions or concerns on whether the disclosure of Company information is legally mandated should be promptly referred to the Compliance Officer.

Safeguarding Confidential Information and Company's Property

Care must be taken to safeguard and protect confidential information and the Company's property. Accordingly, the following measures should be adhered to:

- The Company's employees should conduct their business and social activities so as not to risk inadvertent disclosure of confidential information. For example, when not in use, confidential information should be securely stored. Besides, review of confidential documents or discussion of confidential subjects in public places (e.g., airplanes, trains, taxis, buses, etc.) should not be conducted so as to prevent being overheard or accessed by unauthorized persons.
- When in the Company's offices, confidential matters should not be discussed within hearing range of visitors or others not working on such matters.
- Confidential matters should not be discussed with other employees not working on such matters or with friends or relatives, including those living in the same household as a Company's employee.
- The Company's employees are only to access, use, and disclose confidential information that is necessary for them to perform their duties. They are not to disclose confidential information to other employees or contractors at the Company unless it is necessary for those employees or contractors to have such confidential information in the course of their duties.
- The Company's files, personal computers, networks, software, internet access, internet browser programs, emails, voice mails, and other business equipment (e.g., desks and cabinets) and resources are provided for business use, and they are the exclusive property of the Company. Misuse of such Company's property is not tolerable.

COMPETITION AND FAIR DEALING

All employees are obligated to deal fairly with fellow employees and with the Company's customers, suppliers and competitors. Employees should not take unfair advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of material facts, or any other unfair-dealing practice.

Relationships with Customers

Our business success depends upon our ability to foster lasting customer relationships. The Company is committed to dealing with customers fairly, honestly, and with integrity. Specifically, you should keep the following guidelines in mind when dealing with customers:

- Information we supply to customers should be accurate and complete to the best of our knowledge. Employees should not deliberately misrepresent information to customers.
- Employees should not refuse to sell, service, or maintain products the Company has produced simply because a customer is buying products from another supplier.
- Customer entertainment should not exceed the reasonable and customary business practice of the Company. Employees should not provide entertainment or other benefits that could be viewed as an inducement to or a reward for customer's purchase decisions. Please see "Gifts and Entertainment" below for additional guidelines in this area.

Relationships with Suppliers

The Company deals fairly and honestly with its suppliers. This means that our relationships with suppliers are based on price, quality, service, and reputation, among other factors. Employees dealing with suppliers should carefully guard their objectivity. Specifically, no employee should accept or solicit any personal benefit from a supplier or potential supplier that might compromise, or appear to compromise, their objective assessment of the supplier's products and prices. Employees can give or accept promotional items of nominal value or moderately scaled entertainment within the limits of reasonable and customary business practice of the Company. Please see "Gifts and Entertainment" below for additional guidelines in this area.

Relationships with Competitors

The Company is committed to free and open competition in the marketplace. Employees should avoid actions that would be contrary to laws governing competitive practices in the marketplace, including antitrust laws. Such actions include misappropriation and/or misuse of a competitor's confidential information or making false statements about the competitor's business and business practices.

PROTECTION AND USE OF COMPANY'S ASSETS

Employees should protect the Company's assets and ensure their efficient use for legitimate business purposes only. Theft, carelessness and waste have a direct impact on the Company's profitability. The use of Company funds or assets, whether or not for personal gain, for any unlawful or improper purpose is prohibited.

To ensure the protection and proper use of the Company's assets, each employee should:

- exercise reasonable care to prevent theft, damage or misuse of Company's property;
- report the actual or suspected theft, damage or misuse of Company's property to a supervisor;

- use the Company's telephone system, other electronic communication services, written materials and other property primarily for business-related purposes;
- safeguard all electronic programs, data, communications and written materials from inadvertent access by others; and
- use Company's property only for legitimate business purposes, as authorized in connection with your job responsibilities.

Employees should be aware that Company's property includes all data and communications transmitted or received to or by, or contained in, the Company's electronic or telephonic systems, as well as all written communications. Employees and other users of Company's property should have no expectation of privacy with respect to these communications and data. To the extent permitted by law, the Company has the ability, and reserves the right, to monitor all electronic and telephonic communication. These communications may also be subject to disclosure to law enforcement or government officials.

GIFTS AND ENTERTAINMENT

The act of giving and receiving of gifts is a common business practice. Appropriate business gifts and entertainment are welcome courtesies designed to build relationships and understanding among business partners. However, gifts and entertainment should not compromise, or appear to compromise, your ability to make objective and fair business decisions.

It is your responsibility to use good judgment in this area. As a general rule, you may give or receive gifts or entertainment to or from customers or suppliers only if the gift or entertainment would not be viewed as an inducement to or reward for any particular business decision. All gifts and entertainment expenses should be properly accounted for on expense reports. The following specific examples may be helpful:

- Meals and Entertainment. You may occasionally accept or give meals, refreshments or other entertainment if:
 - The items are of reasonable value;
 - The purpose of the meeting or attendance at the event is business related; and
 - The expenses would be paid by the Company as a reasonable business expense if not paid for by another party.

Entertainment of reasonable value may include food and tickets for sporting and cultural events if they are generally offered to other customers, suppliers or vendors.

- Advertising and Promotional Materials. You may occasionally accept or give advertising or promotional materials of nominal value.
- Personal Gifts. You may accept or give personal gifts of reasonable value that are related to recognized special occasions, such as a graduation, promotion, new job, wedding, retirement or a holiday. A gift is also acceptable if it is based on a family or personal relationship and unrelated to the business involved between the individuals.
- Gifts Rewarding Service or Accomplishment. You may accept a gift from a civic, charitable or religious organization specifically related to your service or accomplishment.

You must be particularly careful that gifts and entertainment are not construed as bribes, kickbacks, or other improper payments. See "The Foreign Corrupt Practices Act" below for a more detailed discussion of our policies on giving or receiving gifts related to business transactions.

You should make every effort to refuse or return a gift that is beyond these permissible guidelines. If it would be inappropriate to refuse a gift or you are unable to

return a gift, you should promptly report the gift to your supervisor. Your supervisor will bring the gift to the attention of the Compliance Officer, who may require you to donate the gift to an appropriate community organization. If you have any questions on whether it is permissible to accept a gift or something else of value, contact your supervisor or the Compliance Officer for additional guidance.

COMPANY RECORDS

Accurate and reliable records are crucial to our business. Our records are the basis of our earnings statements, financial reports and other disclosures to the public and guide our business decision-making and strategic planning. Company records include booking information, payroll, timecards, travel and expense reports, e-mails, accounting and financial data, measurement and performance records, electronic data files and all other records maintained in the ordinary course of our business.

All Company records must be complete, accurate and reliable in all material respects. Undisclosed or unrecorded funds, payments or receipts are inconsistent with our business practices and are prohibited. You are responsible for understanding and complying with our record-keeping policy. Ask your supervisor if you have any questions.

ACCURACY OF FINANCIAL REPORTS AND OTHER PUBLIC COMMUNICATIONS

As a public company we are subject to various securities laws, regulations and reporting obligations. These laws, regulations and obligations and our policies require the disclosure of accurate and complete information regarding the Company's business, financial condition and results of operations. Inaccurate, incomplete or untimely reporting will not be tolerated and can severely damage the Company's reputation and integrity, and result in legal liability.

It is essential that the Company's financial records, including all filings with the Securities and Exchange Commission ("SEC") be accurate and timely. Accordingly, in addition to adhering to the conflict of interest policy and other policies and guidelines under this Code, the principal financial officers and other senior financial officers must take special care to exhibit integrity at all times and to instill this value within their organizations. In particular, these senior officers must ensure their conduct is honest and ethical that they abide by all public disclosure requirements by providing full, fair, accurate, timely and understandable disclosures, and that they comply with all other applicable laws and regulations. These financial officers must also understand and strictly comply with generally accepted accounting principles in the U.S. and all standards, laws and regulations for accounting and financial reporting of transactions, estimates and forecasts.

In addition, U.S. federal securities law requires the Company to maintain proper internal books and records and to devise and maintain an adequate system of internal accounting controls. The SEC has supplemented the statutory requirements by adopting rules that prohibit (1) any person from falsifying records or accounts subject to the above requirements and (2) officers or directors from making any materially false, misleading, or incomplete statement to an accountant in connection with an audit or any filing with the SEC. These provisions reflect the SEC's intent to discourage officers, directors, and other persons with access to the Company's books and records from taking action that might result in the communication of materially misleading financial information to the investing public.

COMPLIANCE WITH LAWS AND REGULATIONS

Each employee has an obligation to comply with all laws, rules and regulations applicable to the Company's operations. These include, without limitation, laws covering bribery and kickbacks, copyrights, trademarks and trade secrets, information privacy, insider trading, illegal political contributions, antitrust prohibitions, foreign corrupt practices, offering or receiving gratuities, environmental hazards, employment discrimination or harassment, occupational health and safety, false or misleading financial information or misuse of corporate assets. You are expected to understand and comply with all laws, rules and regulations that apply to your job position. If any doubt exists about whether a course of action is lawful, you should seek advice from your supervisor or the Compliance Officer.

COMPLIANCE WITH INSIDER TRADING LAWS

The Company has an insider trading policy, which may be obtained from the Compliance Officer. The following is a summary of some of the general principles relevant to insider trading, and should be read in conjunction with the aforementioned specific policy.

Company employees are prohibited from trading in shares or other securities of the Company while in possession of material, non-public information about the Company. In addition, Company employees are prohibited from recommending, "tipping" or suggesting that anyone else buy or sell shares or other securities of the Company on the basis of material, non-public information. Company employees who obtain material non-public information about another company in the course of their employment are prohibited from trading in shares or securities of the other company while in possession of such information or "tipping" others to trade on the basis of such information. Violation of insider trading laws can result in severe fines and criminal penalties, as well as disciplinary action by the Company, up to and including termination of employment.

Information is "non-public" if it has not been made generally available to the public by means of a press release or other means of widespread distribution. Information is "material" if a reasonable investor would consider it important in a decision to buy, hold or sell stock or other securities. As a rule of thumb, any information that would affect the value of stock or other securities should be considered material. Examples of information that is generally considered "material" include:

- Financial results or forecasts, or any information that indicates the Company's financial results may exceed or fall short of forecasts or expectations;
- Important new products or services;
- Pending or contemplated acquisitions or dispositions, including mergers, tender offers or joint venture proposals;
- Possible management changes or changes of control;
- Pending or contemplated public or private sales of debt or equity securities;
- Acquisition or loss of a significant customer or contract;
- Significant write-offs;
- Initiation or settlement of significant litigation; and
- Changes in the Company's auditors or a notification from its auditors that the Company may no longer rely on the auditor's report.

The laws against insider trading are specific and complex. Any questions about information you may possess or about any dealings you have had in the Company's securities should be promptly brought to the attention of the Compliance Officer.

PUBLIC COMMUNICATIONS AND PREVENTION OF SELECTIVE DISCLOSURE

Public Communications Generally

The Company places a high value on its credibility and reputation in the community. What is written or said about the Company in the news media and investment community directly impacts our reputation, positively or negatively. Our policy is to provide timely, accurate and complete information in response to public requests (media, analysts, etc.), consistent with our obligations to maintain the confidentiality of competitive and proprietary information and to prevent selective disclosure of market-sensitive financial data. To ensure compliance with this policy, all news media or other public requests for information regarding the Company should be directed to the Company's Investor Relations Department. The Investor Relations Department will work with you and the appropriate personnel to evaluate and coordinate a response to the request.

7

Prevention of Selective Disclosure

Preventing selective disclosure is necessary to comply with United States securities laws and to preserve the reputation and integrity of the Company as well as that of all persons affiliated with it. "Selective disclosure" occurs when any person provides potentially market-moving information to selected persons before the news is available to the investing public generally. Selective disclosure is a crime under United States law and the penalties for violating the law are severe.

The following guidelines have been established to avoid improper selective disclosure. Every employee is required to follow these procedures:

- All contact by the Company with investment analysts, the press and/or members of the media shall be made through the chief executive officer, chief financial officer or persons designated by them (collectively, the "Media Contacts").
- Other than the Media Contacts, no officer, director or employee shall provide any information regarding the Company or its business to any investment analyst or member of the press or media.
- All inquiries from third parties, such as industry analysts or members of the media, about the Company or its business should be directed to a Media Contact. All presentations to the investment community regarding the Company will be made by us under the direction of a Media Contact.
- Other than the Media Contacts, any employee who is asked a question regarding the Company or its business by a member of the press or media shall respond with "No comment" and forward the inquiry to a Media Contact.

These procedures do not apply to the routine process of making previously released information regarding the Company available upon inquiries made by investors, investment analysts and members of the media.

Please contact the Compliance Officer if you have any questions about the scope or application of the Company's policies regarding selective disclosure.

THE FOREIGN CORRUPT PRACTICES ACT

Foreign Corrupt Practices Act

The Foreign Corrupt Practices Act of 1977 (the "FCPA") prohibits the Company and its employees and agents from offering or giving money or any other item of value to win or retain business or to influence any act or decision of any governmental official, political party, candidate for political office or official of a public international organization. Stated more concisely, the FCPA prohibits the payment of bribes, kickbacks or other inducements to foreign officials. This prohibition also extends to payments to a sales representative or agent if there is a reason to believe that the payment will be used indirectly for a prohibited payment to foreign officials. Violation of the FCPA is a crime that can result in severe fines and criminal penalties, as well as disciplinary action by the Company, up to and including termination of employment.

Certain small facilitation payments to foreign officials may be permissible under the FCPA if customary in the country or locality and intended to secure routine governmental action. Governmental action is "routine" if it is ordinarily and commonly performed by a foreign official and does not involve the exercise of discretion. For instance, "routine" functions would include setting up a telephone line or expediting a shipment through customs. To ensure legal compliance, all facilitation payments must receive prior written approval from the Compliance Officer and must be clearly and accurately reported as a business expense.

ENVIRONMENT, HEALTH AND SAFETY

The Company is committed to providing a safe and healthy working environment for its employees and avoiding adverse impact and injury to the environment and the communities in which we do business. Company's employees must comply with all applicable environmental, health and safety laws, regulations and Company's standards. It is your responsibility to understand and comply with the laws, regulations and policies that are relevant to your job. Failure to comply with environmental, health and safety laws and regulations can result in civil and criminal liability against you and the Company, as well as disciplinary action by the Company, up to and including termination of employment. You should contact the Compliance Officer if you have any questions about the laws, regulations and policies that apply to you.

8

Environment

All Company's employees should strive to conserve resources and reduce waste and emissions through recycling and other energy conservation measures. You have a responsibility to promptly report any known or suspected violations of environmental laws or any events that may result in a discharge or emission of hazardous materials. Employees whose jobs involve manufacturing have a special responsibility to safeguard the environment. Such employees should be particularly alert to the storage, disposal and transportation of waste, and handling of toxic materials and emissions into the land, water or air.

Health and Safety

The Company is committed not only to complying with all relevant health and safety laws, but also to conducting business in a manner that protects the safety of its

employees. All employees are required to comply with all applicable health and safety laws, regulations and policies relevant to their jobs. If you have a concern about unsafe conditions or tasks that present a risk of injury to you, please report these concerns immediately to your supervisor or the Human Resources Department.

EMPLOYMENT PRACTICES

The Company pursues fair employment practices in every aspect of its business. The following is intended to be a summary of our employment policies and procedures. Copies of our detailed policies are available from the Human Resources Department. Company employees must comply with all applicable labor and employment laws, including anti-discrimination laws and laws related to freedom of association, privacy and collective bargaining. It is your responsibility to understand and comply with the laws, regulations and policies that are relevant to your job. Failure to comply with labor and employment laws can result in civil and criminal liability against you and the Company, as well as disciplinary action by the Company, up to and including termination of employment. You should contact the Compliance Officer or the Human Resources Department if you have any questions about the laws, regulations and policies that apply to you.

Harassment and Discrimination

The Company is committed to providing equal opportunity and fair treatment to all individuals on the basis of merit, without discrimination because of race, color, religion, national origin, gender (including pregnancy), sexual orientation, age, disability, veteran status or other characteristic protected by law. The Company prohibits harassment in any form, whether physical or verbal and whether committed by supervisors, non-supervisory personnel or non-employees. Harassment may include, but is not limited to, offensive sexual flirtations, unwanted sexual advances or propositions, verbal abuse, sexually or racially degrading words, or the display in the workplace of sexually suggestive objects or pictures.

If you have any complaints about discrimination or harassment, report such conduct to your supervisor or the Human Resources Department. All complaints will be treated with sensitivity and discretion. Your supervisor, the Human Resources Department and the Company will protect your confidentiality to the extent possible, consistent with law and the Company's need to investigate your concern. Where our investigation uncovers harassment or discrimination, we will take prompt corrective action, which may include disciplinary action by the Company, up to and including, termination of employment. The Company strictly prohibits retaliation against an employee who, in good faith, files a complaint.

Any member of management who has reason to believe that an employee has been the victim of harassment or discrimination or who receives a report of alleged harassment or discrimination is required to report it to the Human Resources Department immediately.

CONCLUSION

This Code of Business Conduct and Ethics contains general guidelines for conducting the business of the Company consistent with the highest standards of business ethics. If you have any questions about these guidelines, please contact your supervisor or the Compliance Officer. We expect all Company employees to adhere to these standards.

This Code of Business Conduct and Ethics, as applied to the Company's principal financial officers, shall be the Company's "code of ethics" within the meaning of Section 406 of the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder.

This Code and the matters contained herein are neither a contract of employment nor a guarantee of continuing Company policy. We reserve the right to amend, supplement or discontinue this Code and the matters addressed herein, without prior notice, at any time.

**AUDIT COMMITTEE CHARTER
OF
ZHENGYE BIOTECHNOLOGY HOLDING LIMITED**

This Audit Committee Charter (the “Charter”) was adopted by the Board of Directors (the “Board”) of Zhengye Biotechnology Holding Limited, a Cayman Islands exempted company (the “Company”), on [●], 2023, and shall become effective upon the effectiveness of the Company’s registration statement on Form F-1 relating to the Company’s initial public offering.

I. Purpose

The purpose of the Audit Committee (the “Committee”) is to oversee the accounting and financial reporting processes of the Company and the audits of the financial statements of the Company. The Committee assists the Board with its oversight responsibilities regarding: (i) the integrity of the Company’s financial statements; (ii) the Company’s compliance with legal and regulatory requirements; (iii) the independent auditor’s qualifications and independence; and (iv) the performance of the Company’s internal audit function and independent auditor. The Committee shall prepare the report required by the rules of the Securities and Exchange Commission (the “SEC”) to be included in the Company’s annual report on Form 20-F.

In addition to the powers and responsibilities expressly delegated to the Committee in this Charter, the Committee may exercise any other powers and carry out any other responsibilities delegated to it by the Board from time to time consistent with the Company’s Memorandum and Articles of Association, as amended from time to time (the “Articles”). The powers and responsibilities delegated by the Board to the Committee in this Charter or otherwise shall be exercised and carried out by the Committee as it deems appropriate without requirement of Board approval, and any decision made by the Committee (including any decision to exercise or refrain from exercising any of the powers delegated to the Committee hereunder) shall be at the Committee’s sole discretion. While acting within the scope of the powers and responsibilities delegated to it, the Committee shall have and may exercise all the powers and authority of the Board. To the fullest extent permitted by law, the Committee shall have the power to determine which matters are within the scope of the powers and responsibilities delegated to it.

Notwithstanding the foregoing, the Committee’s responsibilities are limited to oversight. Although the Committee has the responsibilities set forth in this Charter, it is not the responsibility of the Committee to plan or conduct audits or to determine that the Company’s financial statements and disclosure are complete and accurate and are in accordance with generally accepted accounting principles and applicable laws, rules and regulations. These are the responsibilities of the Company’s management (“Management”) and the independent auditor.

Furthermore, auditing literature, particularly Statement of Accounting Standards No. 71, defines the term “review” to include a particular set of required procedures to be undertaken by independent auditors. The members of the Committee are not independent auditors, and the term “review” as used in this Charter is not intended to have that meaning and should not be interpreted to suggest that the Committee members can or should follow the procedures required of auditors performing reviews of financial statements.

II. Membership

The Committee shall consist of at least three members of the Board, as determined by the Board. Each Committee member shall be financially literate as determined by the Board in its business judgment or must become financially literate within a reasonable period of time after his or her appointment to the Committee. Members of the Committee must (i) not have participated in the preparation of the financial statements of the Company or any current subsidiary of the Company at any time during the past three years; and (ii) be able to read and understand fundamental financial statements, including a company’s balance sheet, income statement, and cash flow statement. Members of the Committee are not required to be engaged in the accounting and auditing profession and, consequently, some members may not be expert in financial matters, or in matters involving auditing or accounting. However, at least one member of the Committee must have accounting or related financial management expertise as determined by the Board in its business judgment. In addition, at least one member of the Committee shall be an “audit committee financial expert” within the definition adopted by the SEC or shall possess financial sophistication within the meaning of the Nasdaq Listing Rules, or the Company shall disclose in its annual report on Form 20-F required pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the reasons why at least one member of the Committee is not an “audit committee financial expert.”

At least a majority of the members of the Committee shall be independent within the meaning of Section 5605(a)(2) of the Nasdaq Listing Rules and will satisfy the independence requirements of Rule 10A-3(b)(1) under the Exchange Act within the 90-day period after the effectiveness of the Company’s registration statement on Form F-1 relating to the Company’s initial public offering (the “Effective Time”). All Committee members must satisfy the independence requirements of Rule 10A-3(b)(1) under the Exchange Act beginning from the first anniversary of the Effective Time. No Committee member may simultaneously serve on the audit committee of more than two other public companies, unless the Board determines that such simultaneous service would not impair the ability of such member to effectively serve on the Committee and such determination is disclosed in the Company’s annual report on Form 20-F.

The members of the Committee, including the chairperson (the “Chair”) of the Committee, shall be appointed by the Board. Committee members may be removed from the Committee, with or without cause, by the Board.

III. Meetings and Procedures

The Chair (or in his or her absence, a member designated by the Chair) shall preside at each meeting of the Committee and set the agendas for Committee meetings. The Committee shall have the authority to establish its own rules and procedures for notice and conduct of its meetings so long as they are not inconsistent with any provisions of the Articles that are applicable to the Committee.

The Committee shall meet at least once during each fiscal quarter and more frequently as the Committee deems desirable. Except as required by law, all matters shall be approved by a simple majority of all the Committee members.

The Committee shall meet separately and periodically with Management, with the internal auditor, and with the independent auditor. Any meeting of the Committee may be conducted in person or via telephone conference or similar communications equipment where every meeting participant can hear each other.

All non-Management directors that are not members of the Committee may attend and observe meetings of the Committee, but shall not participate in any discussion or deliberation unless invited to do so by the Committee, and in any event shall not be entitled to vote. The Committee may, at its discretion, include in its meetings members of the Company’s Management, representatives of the independent auditor, the internal auditor, and any other financial personnel employed or retained by the Company or any other persons whose presence the Committee believes to be necessary or appropriate. Notwithstanding the foregoing, the Committee may also exclude from its meetings any persons it deems appropriate, including, but not limited to, any non-Management director that is not a member of the Committee.

The Committee may retain any independent counsel, experts, or advisors (accounting, financial, or otherwise) that the Committee believes to be necessary or appropriate. The Committee may also utilize the services of the Company’s regular legal counsel or other advisors to the Company. The Company shall provide for appropriate funding, as determined by the Committee, for payment of compensation to the independent auditor for the purpose of rendering or issuing an audit report or performing other audit, review, or attestation services, for payment of compensation to any counsel, experts, or advisors employed by the Committee and for ordinary

administrative expenses of the Committee that are necessary or appropriate in carrying out its duties.

The Committee may conduct or authorize investigations into any matters within the scope of the powers and responsibilities delegated to the Committee.

IV. Powers and Responsibilities

1. *Appointment and Oversight.* The Committee shall be directly responsible for the appointment, compensation, retention, removal and oversight of the work of the independent auditor (including resolution of any disagreements between Management and the independent auditor regarding financial reporting) for the purpose of preparing or issuing an audit report or related work or performing other audit, review, or attestation services for the Company, and the independent auditor shall report directly to the Committee.

2. *Pre-Approval of Services.* Before the independent auditor is engaged by the Company or its subsidiaries to render audit or non-audit services, the Committee shall pre-approve the engagement. Committee pre-approval of audit and non-audit services will not be required if the engagement for the services is entered into pursuant to pre-approval policies and procedures established by the Committee regarding the Company's engagement of the independent auditor, provided that the policies and procedures are detailed as to the particular service, the Committee is informed of each service provided and such policies and procedures do not include delegation of the Committee's responsibilities under the Exchange Act to the Management. The Committee may delegate to one or more designated members of the Committee the authority to grant pre-approvals, provided that such pre-approvals are presented to the Committee at a subsequent meeting. If the Committee elects to establish pre-approval policies and procedures regarding non-audit services, the Committee must be informed of each non-audit service provided by the independent auditor. Committee pre-approval of non-audit services (other than review and attestation services) also will not be required if such services fall within available exceptions established by the SEC.

2

3. *Independence of Independent Auditor.* The Committee shall, at least annually, review the independence and quality control procedures of the independent auditor and the experience and qualifications of the independent auditor's senior personnel that are providing audit services to the Company. In conducting its review:

(i) The Committee shall obtain and review a report prepared by the independent auditor describing (a) the auditing firm's internal quality-control procedures, and (b) any material issues raised by the most recent internal quality-control review, or peer review, of the auditing firm, or by any inquiry or investigation by governmental or professional authorities, within the preceding five years, respecting one or more independent audits carried out by the auditing firm, and any steps taken to deal with any such issues;

(ii) The Committee shall ensure that the independent auditor prepare and deliver, at least annually, a written statement delineating all relationships between the independent auditor and the Company. The Committee shall actively engage in a dialogue with the independent auditor with respect to any disclosed relationships or services that, in the view of the Committee, may impact the objectivity and independence of the independent auditor. If the Committee determines that further inquiry is advisable, the Committee shall take appropriate action in response to the independent auditor's report to satisfy itself of the auditor's independence;

(iii) The Committee shall confirm with the independent auditor that the independent auditor is in compliance with the partner rotation requirements established by the SEC; and

(iv) The Committee shall, if applicable, consider whether the independent auditor's provision of any permitted information technology service or other non-audit service to the Company is compatible with maintaining the independence of the independent auditor.

4. Meetings with Management, the Independent Auditor, and the Internal Auditor.

(i) The Committee shall meet with Management, the independent auditor, and the internal auditor in connection with each annual audit to discuss the scope of the audit, the procedures to be followed, and the staffing of the audit.

(ii) The Committee shall review and discuss with Management and the independent auditor any material off-balance sheet transactions, arrangements, obligations (including contingent obligations), and other relationships of the Company with unconsolidated entities of which the Committee is made aware that do not appear on the financial statements of the Company and that may have a material current or future effect on the Company's financial condition, results of operations, liquidity, capital expenditures, capital resources, or significant components of revenues or expenses.

(iii) The Committee shall review and discuss the annual audited financial statements with Management and the independent auditor, including the Company's disclosures under "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in the Company's annual report on Form 20-F.

5. Separate Meetings with the Independent Auditor.

(i) The Committee shall review with the independent auditor any problems or difficulties the independent auditor may have encountered during the course of the audit work, including any restrictions on the scope of activities or access to required information or any significant disagreements with Management and Management's responses to such matters.

(ii) The Committee shall discuss with the independent auditor the report that such auditor is required to make to the Committee regarding: (a) all critical accounting policies and practices to be used; (b) all alternative treatments within U.S. GAAP for policies and practices related to material items that have been discussed among Management and the independent auditor, including the ramifications of the use of such alternative disclosures and treatments, and the treatment preferred by the independent auditor; and (c) all other material written communications between the independent auditor and Management, such as any Management letter, Management representation letter, reports on observations and recommendations on internal controls, independent auditor's engagement letter, independent auditor's independence letter, schedule of unadjusted audit differences and a listing of adjustments and reclassifications not recorded, if any.

(iii) The Committee shall discuss with the independent auditor the matters required to be discussed by Statement on Auditing Standards No. 61, "Communication with Audit Committees," as then in effect.

3

6. *Recommendation to Include Financial Statements in Annual Report.* The Committee shall, based on the review and discussions in paragraphs 4(iii) and 5(iii) above, and based on the disclosures received from the independent auditor regarding its independence and discussions with the auditor regarding such independence pursuant to subparagraph 3(ii) above, determine whether to recommend to the Board that the audited financial statements be included in the Company's annual report on Form 20-F for the fiscal year subject to the audit.

7. The Committee shall discuss with Management and the independent auditor the Company's earnings press releases (with particular focus on any "pro forma" or "adjusted" non-GAAP information), as well as financial information and earnings guidance provided to analysts and rating agencies. The Committee's discussion in this regard may be general in nature (i.e., discussion of the types of information to be disclosed and the type of presentation to be made) and need not take place in advance of each earnings release or each instance in which the Company may provide earnings guidance.

8. The Committee shall review all related party transactions by the Company (including any of its subsidiaries and consolidated affiliates) on an ongoing basis and all such transactions must be approved by the Committee in advance. All related party transactions should be disclosed in accordance with applicable legal and regulatory requirements. The Committee recognizes that there are situations where the Company may have to obtain products or services of a nature, quantity or quality, or on other terms, that are not readily available from alternative sources or when the Company provides products or services to related persons on an arm's length basis on terms comparable to those provided to unrelated third parties.

a. The Committee shall consider all of the relevant facts and circumstances available to the Committee, including (if applicable), but not limited to:

- The benefits to the Company;
- The impact on a director's independence in the event the related person is a director, an immediate family member of a director or an entity in which a director is a principal, member, partner, shareholder or executive officer;
- The availability of other sources for comparable products or services;
- The terms of the transaction; and
- The terms available to unrelated third parties and employees generally.

b. No member of the Committee shall participate in any review, consideration or approval of any related party transactions with respect to which such member or any of his or her immediate family members is the related person. The Board shall approve only those related party transactions that are in, or are not inconsistent with, the best interests of the Company and its shareholders, as the Committee determines in good faith.

9. The Committee shall discuss with Management and the independent auditor any correspondence from or with regulators or governmental agencies, any employee complaints or any published reports that raise material issues regarding the Company's financial statements, financial reporting process, accounting policies, or internal audit function.

10. The Committee shall discuss with the Company's internal or outside counsel any legal matters brought to the Committee's attention that could reasonably be expected to have a material impact on the Company's financial statements.

11. The Committee shall request assurances from Management, the independent auditor, and the Company's internal auditors that the Company's subsidiaries and affiliated entities, if any, are operated in conformity with applicable legal requirements, including disclosure of related party transactions.

12. The Committee shall discuss with Management the Company's policies with respect to risk assessment and risk management. The Committee shall discuss with Management the Company's significant financial risk exposures and the actions Management has taken to limit, monitor or control such exposures.

4

13. The Committee shall monitor the compliance with the Company's code of business conduct and ethics, including reviewing the adequacy and effectiveness of the Company's procedures to ensure proper compliance.

14. The Committee shall review the adequacy and effectiveness of the Company's accounting and internal control policies and procedures and any steps taken to monitor and control major financial risk exposures.

15. The Committee shall review and concur with Management on the need for an internal audit department and on the appointment, replacement, reassignment, or dismissal of an internal audit department senior manager or director. The Committee shall also review any internal reports to Management (or summaries thereof) prepared by the internal audit department, as well as Management's response.

16. The Committee shall set clear hiring policies for employees or former employees of the Company's independent auditor.

17. The Committee shall establish procedures for the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters. The Committee shall also establish procedures for the confidential and anonymous submission by employees regarding questionable accounting or auditing matters.

18. The Committee shall provide the Company with the report of the Committee with respect to the audited financial statements required by Item 306 of Reg. S-K, for inclusion in each of the Company's annual reports filed on Form 20-F.

19. The Committee, through its Chair, shall report regularly to, and review with, the Board any issues that arise with respect to the quality or integrity of the Company's financial statements, the Company's compliance with legal or regulatory requirements, the performance and independence of the Company's independent auditor, the performance of the Company's internal audit function or any other matter the Committee determines is necessary or advisable to report to the Board.

20. The Committee shall at least annually perform an evaluation of the performance of the Committee and its members, including a review of the Committee's compliance with this Charter.

21. The Committee shall at least annually review and reassess this Charter and submit any recommended changes to the Board for its consideration.

V. Delegation of Duties

In fulfilling its responsibilities, the Committee shall be entitled to delegate any or all of its responsibilities to a subcommittee of the Committee to the extent permitted by, or consistent with provisions of, the Articles and applicable laws and regulations and rules of the markets in which the Company's securities then trade.

5

**COMPENSATION COMMITTEE CHARTER
OF
ZHENGYE BIOTECHNOLOGY HOLDING LIMITED**

This Compensation Committee Charter (the “Charter”) was adopted by the Board of Directors (the “Board”) of Zhengye Biotechnology Holding Limited, a Cayman Islands exempted company (the “Company”), on [●], 2023, and shall become effective upon the effectiveness of the Company’s registration statement on Form F-1 relating to the Company’s initial public offering.

I. Purpose

The purpose of the Compensation Committee (the “Committee”) is (i) to assist the Board in discharging the Board’s responsibilities relating to compensation of the Company’s executives, including reviewing and evaluating and, if necessary, revising the compensation plans, policies, and programs of the Company adopted by management, and (ii) to review and approve the disclosure of executive compensation for inclusion in the Company’s annual report on Form 20-F filed with the U.S. Securities and Exchange Commission’s (the “SEC”) in accordance with applicable rules and regulations. The Committee shall ensure that compensation programs are designed to encourage high performance, promote accountability, and assure that employee interests are aligned with the interests of the Company’s shareholders.

In addition to the powers and responsibilities expressly delegated to the Committee in this Charter, the Committee may exercise any other powers and carry out any other responsibilities delegated to it by the Board from time to time consistent with the Company’s Memorandum and Articles of Association, as amended from time to time (the “Articles”). The powers and responsibilities delegated by the Board to the Committee in this Charter or otherwise shall be exercised and carried out by the Committee as it deems appropriate without the requirement of Board approval, and any decision made by the Committee (including any decision to exercise or refrain from exercising any of the powers and responsibilities delegated to the Committee hereunder) shall be at the Committee’s sole discretion. While acting within the scope of the powers and responsibilities delegated to it, the Committee shall have and may exercise all the powers and authority of the Board. To the fullest extent permitted by law, the Committee shall have the power to determine which matters are within the scope of the powers and responsibilities delegated to it.

II. Membership

The Committee shall be composed of three or more directors, as determined by the Board, none of whom shall be an employee of the Company and each of whom (i) shall satisfy the “independence” requirements of Section 5605(a)(2) of the Nasdaq Listing Rules and Rule 10C-1 under the Securities Exchange Act, (ii) shall be a “non-employee director” within the meaning of Rule 16b3 of the Securities Exchange Act of 1934, as amended, (iii) shall be an “outside director” under the regulations promulgated under Section 162(m) of the Internal Revenue Code of 1986, as amended, and (iv) shall have experience, in the business judgment of the Board, that would be helpful in addressing the matters delegated to the Committee, and shall not accept directly or indirectly any consulting, advisory, or other compensatory fees (the “Compensatory Fees”) from the Company or any subsidiary thereof. For the purpose of this paragraph, the Compensatory Fees do not include: (i) fees received as a member of the Committee, the Board, or any other Board committee; or (ii) the receipt of fixed amounts of compensation under a retirement plan (including deferred compensation) for prior service with the Company (provided that such compensation is not contingent in any way on continued service).

In determining whether a director is eligible to serve on the Committee, the Board shall consider all factors specifically relevant to determining whether a director has a relationship to the Company which is material to such director’s ability to be independent from management in connection with the duties of a Committee member, including but not limited to, whether the director is affiliated with the Company, any subsidiary of the Company, or any affiliate of a subsidiary of the Company.

At least a majority of the members of the Committee shall satisfy the independence requirements of the Nasdaq Listing Rules within the 90-day period after the effectiveness of the Company’s registration statement on Form F-1 relating to the Company’s initial public offering (the “Effective Time”), and all of the members of the Committee shall satisfy the independence requirements of the Nasdaq Listing Rules beginning from the first anniversary of the Effective Time.

The members of the Committee, including the chairperson of the Committee (the “Chair”), shall be appointed by the Board on the recommendation of the Nomination and Corporate Governance Committee. Committee members may be removed from the Committee, with or without cause, by the Board. If one Committee member ceases to be independent in accordance with the requirements of Rule 10C-1 due to circumstances beyond the member’s reasonable control, that person, with notice by the Company to Nasdaq or the applicable national security association, may remain a compensation committee member of the Company until the earlier of its next annual shareholders meeting or one year from the occurrence of the event that caused the member to be no longer independent.

III. Meetings and Procedures

The Chair (or in his or her absence, a member designated by the Chair) shall preside at each meeting of the Committee and set the agendas for Committee meetings. The Committee shall have the authority to establish its own rules and procedures for notice and conduct of its meetings so long as they are not inconsistent with any provisions of the Articles that are applicable to the Committee.

The Committee shall meet on a regularly scheduled basis at least once per year and more frequently as and when the Committee deems necessary or desirable. A meeting of the Committee may be conducted in person or via telephone conference where every meeting participant can hear each other. Except as required by law, all matters shall be approved by a simple majority of all the Committee members.

All non-management directors who are not members of the Committee may attend and observe meetings of the Committee, but shall not participate in any discussion or deliberation unless invited to do so by the Committee, and in any event shall not be entitled to vote. The Committee may, at its discretion, include in its meetings members of the Company’s management or any other person whose presence the Committee believes to be necessary or appropriate. Notwithstanding the foregoing, the chief executive officer may not be present during voting or deliberations concerning his or her compensation, and the Committee may exclude from its meetings any persons it deems appropriate, including but not limited to any non-management director who is not a member of the Committee.

The Chair shall report to the Board regarding the activities of the Committee at appropriate times and as otherwise requested by the Chairman of the Board.

IV. Duties and Responsibilities

1. The Committee shall, at least annually, review and approve the compensation of the chief executive officer. In determining the long-term incentive component of the chief executive officer’s compensation, the Committee shall consider the Company’s performance, the value of similar incentive awards to chief executive officers at comparable companies, and the awards given to the chief executive officer in past years. The Committee shall have sole authority to determine the chief executive officer’s compensation.

2. The Committee shall, with respect to executive officers other than the chief executive officer, make recommendations to the Board concerning compensation, incentive compensation plans, and equity-based plans.

3. The Committee shall annually review all annual bonuses, long-term incentive compensation, stock options, employee pension, and welfare benefit plans (including *employee stock purchase plans, long-term incentive plans, management incentive plans and others*), and with respect to each plan shall have responsibility

for:

(i) setting performance targets under all annual bonuses and long-term incentive compensation plans as appropriate;

(ii) certifying that any and all performance targets used for any performance-based equity compensation plans have been met before payment of any executive bonus or compensation or exercise of any executive award granted under any such plan(s);

2

(iii) approving all amendments to, and terminations of, all compensation plans and any awards under such plans;

(iv) granting any awards under any performance-based annual bonus, long-term incentive compensation and equity compensation plans to executive officers or current employees with the potential to become the chief executive officer or an executive officer, including stock options and other equity rights (e.g., restricted stock, stock purchase rights);

(v) approving which executive officers are entitled to awards under the Company's stock option plan(s);

(vi) repurchasing securities from terminated employees; and

(vii) conducting an annual review of all compensation plans, including reviewing each plan's administrative costs, reviewing current plan features relative to any proposed new features, and assessing the performance of the plan's internal and external administrators if any duties have been delegated.

4. The Committee may, in its sole discretion, retain or receive the advice from the Company's regular legal counsel, other independent counsel, compensation and benefits consultants, and other experts or advisors (the "Compensation Advisors") that the Committee believes to be desirable or appropriate. The Committee is not bound by the advice or recommendations of the Compensation Advisors and shall exercise its own judgment in fulfilling its responsibilities.

5. The Committee shall be directly responsible for the appointment, compensation, and oversight of the work of the Compensation Advisors.

6. The Company shall provide for appropriate funding, as determined by the Committee, for payment of compensation to the Compensation Advisors.

7. The Committee shall select, or receive advice from the Compensation Advisors, other than in-house legal counsel, after taking into consideration the following factors:

(i) the provision of other services to the Company by the person that employs the Compensation Advisors;

(ii) the amount of fees received from the Company by the person that employs the Compensation Advisors, as a percentage of the total revenue of the person that employs such Compensation Advisors;

(iii) the policies and procedures of the person that employs the Compensation Advisors that are designed to prevent conflicts of interest;

(iv) any business or personal relationship of the Compensation Advisors with a member of the Committee;

(v) any stock of the Company owned by the Compensation Advisors; and

(vi) any business or personal relationship of the Compensation Advisor or the person employing the Compensation Advisors with an executive officer of the Company.

8. The Committee shall conduct the independence assessment outlined in this Charter with respect to any Compensation Advisors, other than in-house legal counsel. Nevertheless, the Committee may select, or receive advice from, any Compensation Advisors, including ones that are not independent, after considering factors 7(i) through 7(vi) outlined above.

9. For purposes of this Charter, the Committee is not required to conduct an independence assessment for any Compensation Advisors that act in a role limited to the following activities for which no public disclosure is required: (a) consulting on any broad-based plan that does not discriminate in scope, terms, or operation, in favor of any executive officers or directors of the Company, and that is available generally to all salaried employees; or (b) providing information that either is not customized for a particular issuer or that is customized based on parameters that are not developed by such Compensation Advisors, and about which such Compensation Advisors does not provide advice.

3

10. The Committee shall establish and periodically review policies concerning prerequisite benefits.

11. The Committee shall periodically review the Company's policies with respect to change of control or "parachute" payments, if any.

12. The Committee shall manage and review executive officer and director indemnification and insurance matters.

13. The Committee shall manage and review any employee loans in an amount equal to or greater than US\$60,000.

14. The Committee shall prepare and approve the disclosure of executive compensation for inclusion in the Company's annual report on Form 20-F.

15. The Committee shall on an annual basis evaluate its own performance, including its compliance with this Charter, and provide any written material with respect to such evaluation to the Board, including any recommendations for changes in procedures or policies governing the Committee. The Committee shall conduct such evaluation and review in such manner as it deems appropriate.

16. The Committee shall periodically report to the Board its findings and actions.

17. The Committee shall review and reassess this Charter at least annually and submit any recommended changes to the Board for its consideration.

V. Delegation of Duties

In fulfilling its responsibilities, the Committee shall be entitled to delegate any or all of its responsibilities to a subcommittee of the Committee, to the extent consistent with the Articles and applicable law and rules of the markets in which the Company's securities then trade.

**NOMINATING AND CORPORATE GOVERNANCE COMMITTEE CHARTER
OF
ZHENGYE BIOTECHNOLOGY HOLDING LIMITED**

This Nominating and Corporate Governance Committee Charter (the “Charter”) was adopted by the Board of Directors (the “Board”) of Zhengye Biotechnology Holding Limited, a Cayman Islands exempted company (the “Company”), on [●], 2023, and shall become effective upon the effectiveness of the Company’s registration statement on Form F-1 relating to the Company’s initial public offering.

I. Purpose

The purpose of the Nominating and Corporate Governance Committee (the “Committee”) is to assist the Board in discharging the Board’s responsibilities regarding:

1. identification and recommendation of qualified director nominees to be elected at the next annual meeting of shareholders (or special meeting of shareholders at which directors are to be elected);
2. identification and recommendation of qualified candidates to fill any vacancies on the Board;
3. annual review of the composition of the Board in light of the characteristics of independence, qualification, experience and availability of the Board members;
4. oversight of the evaluation of the Board; and
5. monitoring of compliance with the Company’s code of business conduct and ethics, including reviewing the adequacy and effectiveness of the Company’s internal rules and procedures to ensure compliance with applicable laws and regulations.

In addition to the powers and responsibilities expressly delegated to the Committee in this Charter, the Committee may exercise any other powers and carry out any other responsibilities delegated to it by the Board from time to time consistent with the Company’s Memorandum and Articles of Association, as amended from time to time (the “Articles”). The powers and responsibilities delegated by the Board to the Committee in this Charter or otherwise may be exercised and carried out by the Committee as it deems appropriate without Board approval, and any decision made by the Committee (including any decision to exercise or refrain from exercising any of the powers delegated to the Committee hereunder) shall be at the Committee’s sole discretion. While acting within the scope of the powers and responsibilities delegated to it, the Committee has and may exercise all the powers and authority of the Board. To the fullest extent permitted by law, the Committee shall have the power to determine which matters are within the scope of the powers and responsibilities delegated to it.

II. Membership

The Committee shall be comprised of three or more members of the Board, as determined by the Board, each of whom has experience, in the business judgment of the Board, that would be helpful in addressing the matters delegated to the Committee. In addition, at least a majority of the members of the Committee shall satisfy the independence requirements of Section 5605(a)(2) of the Nasdaq Listing Rules within the 90-day period after the effectiveness of the Company’s registration statement on Form F-1 relating to the Company’s initial public offering (the “Effective Time”), and all of the members of the Committee shall satisfy the independence requirements of Section 5605(a)(2) of the Nasdaq Listing Rules beginning from the first anniversary of the Effective Time.

The members of the Committee, including the chairperson of the Committee (the “Chair”), shall be appointed by the Board. Committee members may be removed from the Committee, with or without cause, by the Board. Any action duly taken by the Committee shall be valid and effective, whether or not the members of the Committee at the time of such action are later determined not to have satisfied the requirements for membership provided herein.

1

III. Meetings and Procedures

The Chair (or in his or her absence, a member designated by the Chair) shall preside at each meeting of the Committee and set the agendas for Committee meetings. The Committee shall have the authority to establish its own rules and procedures for notice and conduct of its meetings so long as they are not inconsistent with any provisions of the Articles that are applicable to the Committee.

The Committee shall meet on a regularly scheduled basis, at least twice per year and more frequently as and when the Committee deems necessary or desirable. A meeting of the Committee may be conducted in person or via telephone conference where every meeting participant can hear each other. Except as required by law, all matters shall be approved by a simple majority of all the Committee members.

All non-management directors who are not members of the Committee may attend and observe meetings of the Committee, but shall not participate in any discussion or deliberation unless invited to do so by the Committee, and in any event shall not be entitled to vote. The Committee may, at its discretion, include in its meetings members of the Company’s management, or any other person whose presence the Committee believes to be desirable and appropriate. Notwithstanding the foregoing, the Committee may exclude from its meetings any persons, including any non-management director, who is not a member of the Committee.

The Committee may retain any independent counsel, experts or advisors that the Committee believes to be desirable and appropriate. The Committee may also use the services of the Company’s regular legal counsel or other advisors to the Company. The Company shall provide for appropriate funding, as determined by the Committee, for payment of compensation to any such persons employed by the Committee and for ordinary administrative expenses of the Committee that are necessary or appropriate in carrying out its duties. The Committee shall have sole authority to retain and terminate any search firm to be used to identify director candidates, including sole authority to approve such search firm’s fees and other retention terms.

The Chair shall report to the Board regarding the activities of the Committee at appropriate times and as otherwise requested by the Chairman of the Board.

2

IV. Duties and Responsibilities

1. (a) At an appropriate time prior to each annual meeting of shareholders at which directors are to be elected or reelected, the Committee shall recommend to the Board for nomination by the Board such candidates as the Committee, in the exercise of its judgment, has found to be well qualified and willing and available to serve.

(b) At an appropriate time after a vacancy arises on the Board or a director advises the Board of his or her intention to resign, the Committee shall recommend to the Board for appointment by the Board to fill such vacancy, such candidate as the Committee, in the exercise of its judgment, has found to be well qualified and willing and available to serve.

2. The Committee shall annually review the performance of each incumbent director and shall consider the results of such evaluation when determining whether or not to recommend the nomination of such director for an additional term.

3. The Committee shall oversee the Board in the Board's annual review of its own performance and the performance of management, and will make appropriate recommendations to improve performance.

4. The Committee shall consider, prepare and recommend to the Board such policies and procedures with respect to corporate governance matters as may be required or required to be disclosed pursuant to any rules promulgated by the Securities and Exchange Commission or otherwise considered to be desirable and appropriate in the discretion of the Committee.

5. The Committee shall evaluate its own performance on an annual basis, including its compliance with this Charter, and provide the Board with any recommendations for changes in procedures or policies governing the Committee. The Committee shall conduct such evaluation and review in such manner as it deems appropriate.

6. The Committee shall periodically report to the Board on its findings and actions.

7. The Committee shall review and reassess this Charter at least annually and submit any recommended changes to the Board for its consideration.

V. Delegation of Duties

In fulfilling its responsibilities, the Committee shall be entitled to delegate any or all of its responsibilities to a subcommittee of the Committee, to the extent consistent with the Articles and applicable law and rules of the markets in which the Company's securities then trade.

Filing Fee Table

F-1

(Form Type)

Zhengye Biotechnology Holding Limited
(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

	<u>Security Type</u>	<u>Security Class Title</u>	<u>Fee Calculation or Carry Forward Rule</u>	<u>Amount Registered</u>	<u>Proposed Maximum Offering Price Per Unit</u>	<u>Proposed Maximum Aggregate Offering Price⁽¹⁾</u>	<u>Fee Rate</u>	<u>Amount of Registration Fee⁽²⁾</u>
Fees to Be Paid	Equity	Ordinary shares, par value \$0.0001 per share ⁽³⁾	Rule 457(o)		\$	\$20,000,000	0.00014760	\$ 2,952
		Total Offering Amounts				\$		\$
		Total Fees Previously Paid						\$ 0
		Total Fee Offset						\$ 0
		Net Fee Due						<u>\$ 2,952</u>

(1) Estimated solely for the purpose of determining the amount of registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended. Includes ordinary shares that may be purchased by US Tiger Securities, Inc., the underwriter, pursuant to its option to purchase additional ordinary shares to cover over-allotment, if any.

(2) Calculated pursuant to Rule 457(o) under the Securities Act, based on an estimate of the proposed maximum aggregate offering price.

(3) In accordance with Rule 416, the Registrant is also registering an indeterminate number of additional ordinary shares that shall be issuable after the date hereof as a result of share splits, share dividends, or similar transactions.

